<SEC-DOCUMENT>0001193125-25-064163.txt : 20250326
<SEC-HEADER>0001193125-25-064163.hdr.sgml : 20250326
<ACCEPTANCE-DATETIME>20250326170936
ACCESSION NUMBER:		0001193125-25-064163
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		95
FILED AS OF DATE:		20250326
DATE AS OF CHANGE:		20250326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tectonic Therapeutic, Inc.
		CENTRAL INDEX KEY:			0001681087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				810710585
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286133
		FILM NUMBER:		25774229

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 210
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(339) 666-3320

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 210
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVROBIO, Inc.
		DATE OF NAME CHANGE:	20180131

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AvroBio, Inc.
		DATE OF NAME CHANGE:	20160729
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d863285ds1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:tecx="http://www.aw.com/20241231" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;">
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2024To12_31_2024" id="ixv-19785">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2024To12_31_2024" id="ixv-19786">0001681087</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden136075533" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">MA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden136075532" contextRef="P01_01_2024To12_31_2024">MA</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tecx-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_20_2024To06_20_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-20</xbrli:startDate> <xbrli:endDate>2024-06-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_19_2020"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-19</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2025To02_28_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-01</xbrli:startDate> <xbrli:endDate>2025-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndPre-ClinicalExpensesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ResearchAndPre-ClinicalExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ClinicalAndDevelopmentExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ClinicalAndDevelopmentExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ChemistryManufacturingAndControlExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:MemberOfTheScientificAdvisoryBoardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AvrobioMemberTECXTypeOfCommonStockAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="tecx:TypeOfCommonStockAxis">tecx:AvrobioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_UnrestrictedCommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:UnrestrictedCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_UndesignatedPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:UndesignatedPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:AvrobioIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandNineteenAndTwoThousandTwentyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CvrAgreementMemberTECXAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:CvrAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AvrobioMemberTECXAgreementAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:AvrobioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ExpirationThrough2040MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tecx:ExpirationThrough2040Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ExpirationThrough2040MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tecx:ExpirationThrough2040Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ExpirationThrough2035MemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tecx:ExpirationThrough2035Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SimpleAgreementsForFutureEquityMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndPre-ClinicalExpensesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ResearchAndPre-ClinicalExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ClinicalAndDevelopmentExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ClinicalAndDevelopmentExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ChemistryManufacturingAndControlExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:MemberOfTheScientificAdvisoryBoardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_HarvardAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RestrictedCommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:RestrictedCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_UnrestrictedCommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:UnrestrictedCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SimpleAgreementForFutureEquityMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tecx:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdvisoryServicesAgreementMemberusgaapRelatedPartyTransactionAxis_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:AdvisoryServicesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:MemberOfTheScientificAdvisoryBoardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdimabAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:AdimabAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FederalMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tecx:FederalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">us-gaap:RetirementPlanNameOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_HarvardAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandNineteenAndTwoThousandTwentyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AtTheMarketFacilityMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tecx:AtTheMarketFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SimpleAgreementForFutureEquityMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tecx:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AdvisoryServicesAgreementMemberusgaapRelatedPartyTransactionAxis_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:AdvisoryServicesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:MemberOfTheScientificAdvisoryBoardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AdimabAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:AdimabAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">us-gaap:RetirementPlanNameOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tecx:AvroAvrobioCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandNineteenAndTwoThousandTwentyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_FederalMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tecx:FederalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:AvrobioIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AvorbioCommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:AvorbioCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AvorbioCommonStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberTECXAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:AvorbioCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_30_2024To01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-30</xbrli:startDate> <xbrli:endDate>2024-01-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-01-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2025To02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-01</xbrli:startDate> <xbrli:endDate>2025-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2025To02_28_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-01</xbrli:startDate> <xbrli:endDate>2025-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_20_2024To06_20_2024_SubscriptionAgreementMemberTECXAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-20</xbrli:startDate> <xbrli:endDate>2024-06-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_20_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_20_2024_SubscriptionAgreementMemberTECXAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tecx:OperatingLeaseForOfficeAndLaboratorySpacesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_10_2022To02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-10</xbrli:startDate> <xbrli:endDate>2022-02-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_FundInvestorsMembersrtTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tecx:FundInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_IndividualInvestorsMembersrtTitleOfIndividualAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tecx:IndividualInvestorsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_19_2020To11_19_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tecx:OperatingLeaseForOfficeAndLaboratorySpacesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-19</xbrli:startDate> <xbrli:endDate>2020-11-19</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandNineteenAndTwoThousandTwentyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft"> <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month"> <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Segment"> <xbrli:measure>tecx:Segment</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">As filed with the Securities and Exchange Commission on March&#160;26, 2025 </div></div></div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Registration No.&#160;333-&#8194;&#8194;&#8194;&#8194;&#8194; </div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 2pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">Washington, D.C. 20549 </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2024To12_31_2024" id="ixv-21189">S-1</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">REGISTRATION STATEMENT </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2024To12_31_2024" id="ixv-21190">Tectonic Therapeutic, Inc.</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 34%;"/>
<td style="vertical-align: bottom;"/>
<td style="width: 32%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 32%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="text-align: center; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:stateprovnameen" id="ixv-21191">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2024To12_31_2024" id="ixv-21192">2836</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2024To12_31_2024" id="ixv-21193">81-0710585</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(State or other jurisdiction of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Primary Standard Industrial</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Classification Code No.)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(I.R.S. Employer</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Identification Number)</div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To12_31_2024" id="ixv-21194">490 Arsenal Way</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2024To12_31_2024" id="ixv-21195">Suite 210</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To12_31_2024" id="ixv-21196">Watertown</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden136075532;display:inline;">MA</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To12_31_2024" id="ixv-21197">02472</ix:nonNumeric> (<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To12_31_2024" id="ixv-21198">339</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To12_31_2024" id="ixv-21199">666-3320</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">(I.R.S. Employer </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Identification Number) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-21200">Daniel Lochner</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Chief Financial Officer</div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-21201">490 Arsenal Way</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-21202">Suite 210</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-21203">Watertown</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden136075533;display:inline;">MA</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-21204">02472</ix:nonNumeric> (<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-21205">339</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-21206">666-3320</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Divakar S. Gupta </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Brandon Fenn </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Minkyu Park </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Cooley LLP </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">55 Hudson Yards</div></div> </div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">New York, New York 10001 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(212) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">479-6000</div> </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Approximate Date of Commencement of Proposed Sale to the Public: </div></div>From time to time after the effective date of this registration statement. </div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#8194;&#9746; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 9pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 15%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 62%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 18%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 2%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:entityfilercategoryen" id="ixv-234"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:boolballotbox" id="ixv-21207">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:boolballotbox" id="ixv-21208">&#9744;</ix:nonNumeric></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div style="position:relative; overflow:visible; width:628pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt)"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. Neither we nor the selling securityholders may sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p></div><div style="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt)"> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED March&#160;26, 2025 </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g863285g02v02.jpg" alt="LOGO" style="width:1.50248in;height:0.396428in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 3,689,465 Shares of Common Stock </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the proposed offer and resale or other disposition from time to time by the selling stockholders identified in this prospectus of up to an aggregate of 3,689,465 shares of common stock, par value $0.0001 per share, of Tectonic Therapeutic, Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the resale of the shares of common stock pursuant to the selling stockholders&#8217; registration rights under the Securities Purchase Agreement among us and the selling stockholders. Our registration of the resale of the shares of common stock covered by this prospectus does not mean that the selling stockholders will offer or sell all or any of the shares of common stock. The selling stockholders may offer, sell or distribute all or a portion of their shares of common stock from time to time directly or indirectly through one or more underwriters, broker-dealers or agents, and in one or more public or private transactions, which may involve crosses or block transactions. The shares of common stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. See the section entitled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; for more information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from any sale of common stock by the selling stockholders pursuant to this prospectus. We have agreed to bear the expenses in connection with the registration of the resale of the shares of common stock to be offered by this prospectus by the selling stockholders except for any underwriting discounts and commissions or transfer taxes relating to the sale of common stock, which will be borne by the selling stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;TECX.&#8221; On March&#160;25, 2025, the closing price for our common stock, as reported on Nasdaq, was $21.22 per share. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman;font-weight:bold">See the section entitled &#8220;<a href="#toc863285_4">Risk Factors</a>&#8221; beginning on page 9 of this prospectus to read about factors you should consider before buying our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is&#8195;&#8195;, 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:120pt; font-family:Times New Roman">&#8195; </p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div> <p style="clear:both; font-size:1pt; height:0">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:96%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_1">ABOUT THIS PROSPECTUS .</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS .</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_4">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_5">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_6">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY .</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_7">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_8">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_9">MANAGEMENT .</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_10">EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_11">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_12">PRINCIPAL SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_13">SELLING STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_14">DESCRIPTION OF CAPITAL STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_15">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS TO <span style="white-space:nowrap">NON-U.S.</span> HOLDERS OF OUR COMMON STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_16">PLAN OF DISTRIBUTION .</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_17">LEGAL MATTERS .</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_18">EXPERTS .</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_20">WHERE YOU CAN FIND MORE INFORMATION .</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc863285_21">INDEX TO FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">You should rely only on the information provided in this prospectus, as well as the information incorporated by reference to exhibits to the registration statement of which this prospectus forms a part and any applicable prospectus supplement or amendment. Neither we nor the selling stockholders have authorized anyone to provide you with different information. Neither we nor the selling stockholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents filed as exhibits to the registration statement of which this prospectus forms a part, our business, financial condition, results of operations and prospects may have changed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by the selling stockholders identified in this prospectus under the caption &#8220;Selling Stockholders,&#8221; from time to time, of up to an aggregate of 3,689,465 shares of common stock. We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the selling stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor the selling stockholders, have authorized anyone to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where it is lawful to do so. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any shares other than the registered shares to which it relates, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy shares in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or shares are sold on a later date. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus may involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; contained in this prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement may add to, update or change the information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplement together with additional information described below under the heading &#8220;Where You Can Find Additional Information&#8221; or incorporated by reference herein as described under the heading &#8220;Incorporation of Certain Information by Reference.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer, collectively to Tectonic Therapeutic, Inc., a Delaware corporation, and its consolidated subsidiaries (including Tectonic Operating Company, Inc., previously Tectonic Therapeutic, Inc., referred to as &#8220;Legacy Tectonic&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use various trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the <sup style="font-size:75%; vertical-align:top">&#174;</sup> and <sup style="font-size:75%; vertical-align:top">&#8482;</sup> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains and/or incorporates by reference statements that are not historical facts and are considered forward-looking within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions or negative of these terms may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our strategies, prospects, plans, expectations or objectives of management for our future operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our progress, scope or timing of the development of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our expectations surrounding the potential safety, efficacy, and regulatory and clinical progress of TX45, TX2100 and any other product candidates, and our anticipated milestones and timing therefor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the benefits that may be derived from any of our future products, if approved, or the commercial or market opportunity with respect to any of our future products, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to protect our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our anticipated operations, financial position, ability to raise capital to fund our operations, revenues, costs or expenses; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the statements regarding our future economic conditions or performance, statements of belief and any statement of assumptions underlying any of the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available to us at the time of this prospectus or the documents incorporated by reference herein and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties, and other factors. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward- looking statements, including those set forth in this prospectus in the section entitled &#8220;Risk Factors&#8221; and in our periodic filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Our SEC filings are available publicly on the SEC&#8217;s website at www.sec.gov. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Additional cautionary statements or discussions of risks and uncertainties that could affect our results or the achievement of the expectations described in forward-looking statements may also be contained in any accompanying prospectus supplement. Should one or more of the risks or uncertainties described in this prospectus, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and any accompanying prospectus supplement if any, completely and with the understanding that our actual future results, levels of activity and performance as well as other events and circumstances may be materially different from what we expect. Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this prospectus. We qualify all of our forward-looking statements by these cautionary statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_3">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (&#8220;GPCRs&#8221;). The discovery of biologics that can modulate GPCRs has historically been quite challenging. We have developed a proprietary technology platform called GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup>, with the aim of addressing these challenges and to enable the discovery and development of GPCR-targeted biologic medicines that can modify the course of disease. We focus on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GPCRs are receptor molecules found on the surface of cells that act as sensors for various extracellular stimuli to enable communication between cells and their environment. These molecules regulate diverse aspects of human biology including blood pressure, glucose metabolism, transmission between neurons and immune surveillance. There are over 800 human genes encoding GPCRs, underscoring the extent to which human biology has relied on this molecular system for physiological control. The breadth of effects controlled by GPCRs is illustrated by the fact that greater than 30% of all approved drugs address targets in this class. The vast majority of these drugs, however, are small molecules, and their targets have been largely confined to a few GPCR subfamilies, many of which have a natural ligand that is also a small molecule. We believe there are many situations where biologics could present advantages over small molecules for this class of targets. For instance, when targeting a single member of a highly related family of GPCRs, the selectivity profile achievable with an antibody may be preferable to that of a small molecule in order to optimize the therapeutic efficacy and safety for the patient. Conversely, when multi-modal action is needed to achieve a desired physiological effect, proteins engineered for bispecific function allow for dual target engagement, unlike small molecules that are generally optimized for action on a single target. We are focused on developing biologics to address GPCRs with the goal of capturing such opportunities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It has been historically difficult to discover therapeutic proteins and antibodies that bind to and modulate the activity of GPCRs because of the low endogenous level of expression of many GPCRs, complex biochemistry and their inherent instability when removed from their natural environment in, the cell membrane. To unlock the potential for biologic therapeutics to broaden the clinical utility of GPCRs, we use our proprietary GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup><sup style="font-size:75%; vertical-align:top"> </sup>technology platform in an attempt to overcome the known challenges of GPCR-targeted drug discovery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial components of the platform, its first generation yeast library design and initial yeast selection protocols, were developed at the Harvard Medical School. However, over the last few years we have improved and modified all aspects of the platform including second and third generation library designs, optimized GPCR engineering strategies and yeast selection protocols better suited to GPCR antibody discovery. These modifications have resulted in selection campaigns that have a higher success rate with molecules that have higher affinity and potency and better biophysical properties compared to hits identified from initial antibody selection campaigns. The GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup> platform includes components aimed at optimizing the expression, purification, and stabilization of GPCRs and pairs these advances with our protein engineering and structural biology capabilities. While the current libraries, receptor engineering and selection strategies are producing GPCR-targeted antibodies, we continue to evolve and modify aspects of the platform, which we believe will lead to even better results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead asset TX000045, referred to as TX45, is an <span style="white-space:nowrap">Fc-relaxin</span> fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, relaxin. Relaxin is an endogenous protein that is expressed at low levels in both men and women. In normal human physiology, relaxin is upregulated during pregnancy where it exerts vasodilatory effects, reduces systemic and pulmonary vascular resistance and increases cardiac output to </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accommodate the increased demand for oxygen and nutrients from the developing fetus. Relaxin also exerts anti-fibrotic effects on pelvic ligaments to facilitate delivery of the baby. Scientists have hypothesized that these unique dual aspects of relaxin biology may offer therapeutic potential in the treatment of cardiovascular disease. Unfortunately, the development of a viable therapeutic targeting relaxin has been challenging, primarily because of relaxin&#8217;s very short half-life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe TX45&#8217;s pharmacological profile, which is the direct result of applying our protein engineering capabilities, has the potential to overcome the limitations that have impeded previous attempts to develop relaxin as a therapeutic protein. We have identified Group 2 pulmonary hypertension (&#8220;PH&#8221;) in the setting of heart failure with preserved ejection Fraction (&#8220;HFpEF&#8221;) referred to as <span style="white-space:nowrap">PH-HFpEF,</span> as the initial disease in which to interrogate the therapeutic potential of relaxin. We hypothesize that treatment with relaxin could improve hemodynamics through effects on pulmonary and systemic vasodilation, cardiac diastolic dysfunction and potential remodeling in both the pulmonary vessels and the heart which could translate into a clinically meaningful improvement in exercise capacity in these patients. Clinical trials are ongoing to confirm this hypothesis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second program, TX2100, is aimed at the discovery and development of a GPCR targeting biotherapeutic as a potential treatment for Hereditary Hemorrhagic Telangiectasia (&#8220;HHT&#8221;), the second-most common genetic bleeding disorder. In HHT, abnormal blood vessel formations result in telangiectasias and arterio-venous malformations or &#8220;AVMs.&#8221; These abnormal vessels are prone to spontaneous and severe bleeding that can be life-threatening. There are no currently approved therapies to treat HHT. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In HHT patients, mutations have been identified in BMP9, BMP10, Endoglin, ALK1 and SMAD4 proteins, all of which are members of a common signaling pathway. Preclinically, <span style="white-space:nowrap">knock-out</span> or inhibition of pathway members leads to increased expression of factors that drive angiogenesis and abnormal blood vessel formation that phenocopy the clinical situation. The GPCR target for our HHT program is a receptor for an angiogenic factor known to be upregulated in HHT animal models. By blocking the signaling of this receptor, we anticipate the potential for decreased bleeding resulting from the abnormal angiogenesis seen in HHT. We selected TX2100 as a development candidate. TX2100 is a <span style="white-space:nowrap">VHH-Fc</span> fusion antagonist to an undisclosed GPCR target (&#8220;GPCR3&#8221;). We intend to start IND enabling toxicology studies in the second quarter of 2025 and expect to initiate a Phase 1 clinical trial for TX2100 in the fourth quarter of 2025 or the first quarter of 2026, subject to the results of <span style="white-space:nowrap">IND-enabling</span> studies. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Pipeline </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes key information about our development programs and other pipeline programs: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g863285g09v09.jpg" alt="LOGO" style="width:6.26667in;height:3.36425in"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Private Placement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Securities Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;3, 2025, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain accredited investors (the &#8220;selling stockholders&#8221;), pursuant to which we issued and sold 3,689,465 shares (the &#8220;Shares&#8221;) of our common stock, $0.0001 par value per share, at a price of $50.00 per Share to certain institutional accredited investors and $54.14 per Share to individual accredited investors that are either an officer or director of the Company (the &#8220;Private Placement&#8221;). Our total gross proceeds from the sale of the Shares in the Private Placement were approximately $185.0&#160;million. The closing of the Private Placement occurred on February&#160;5, 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Registration Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Private Placement, we entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the selling stockholders, pursuant to which we agreed to register the Shares for resale. Under the Registration Rights Agreement, we agreed, among other things, to prepare and file with the SEC a registration statement on <span style="white-space:nowrap">Form&#160;S-1&#160;to</span> register for resale the Shares within 54 calendar days of the closing of the Private Placement, and to use reasonable best efforts to have the registration statement declared effective at the earliest possible date, but in any event no later than the earlier of (a)&#160;the 90th calendar day following the initial filing date or (b)&#160;the fifth business day after the date we are notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be &#8220;reviewed&#8221; or will not be subject to further review. We also agreed to use reasonable best efforts to keep such registration statement effective until the earlier of the date the Shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction. We agreed to be responsible for all fees and expenses incurred in connection with the registration of the Shares. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Associated with Our Business </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in the section entitled &#8220;Risk Factors,&#8221; following this prospectus summary. These risks include the following, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a limited operating history, have incurred net losses in every year since our inception, and expect to continue to incur net losses in the future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will need substantial additional funding in order to complete the development and commence commercialization of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, reduce or eliminate certain of our product development or research operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have limited experience in therapeutic discovery and development and our GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup> platform may never result in the regulatory approval of a product candidate. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">All of our product candidates are in discovery, preclinical or early clinical development. Clinical trials are difficult to design and implement, and they involve a lengthy and expensive process with uncertain outcomes. We may experience delays in completing, or ultimately be unable to complete, the development and commercialization of TX45 or any future product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our clinical trials may fail to demonstrate substantial evidence of the safety, efficacy, purity and potency of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture TX45 and any other product candidates, and we may rely on third parties to produce and process our products, if approved. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of our common stock is expected to be volatile, and the market price of the common stock may drop. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is located at 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472, and our telephone number is (339) <span style="white-space:nowrap">666-3320.</span> Our website address is www.tectonictx.com. We do not incorporate the information on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. Our common stock is listed on Nasdaq under the symbol &#8220;TECX.&#8221; </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Implications of Being a Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of the common stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $250.0&#160;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of the common stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700.0&#160;million measured on the last business day of our second fiscal quarter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the information in this prospectus and that we provide to our investors in the future may be different than what you might receive from other public reporting companies. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE OFFERING </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </p></td>
<td>Tectonic Therapeutic, Inc. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Offered by the Selling Stockholders </p></td>
<td>Up to an aggregate of 3,689,465 shares of common stock. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Outstanding </p></td>
<td>18,662,672 shares of common stock as of February&#160;28, 2025. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </p></td>
<td>All of the shares of common stock offered by the selling stockholders pursuant to this prospectus will be sold by the selling stockholders for their respective accounts. We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Symbol </p></td>
<td>TECX. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering Price </p></td>
<td>The selling stockholders will offer the shares of common stock offered by this prospectus at the prevailing market prices or at privately negotiated prices. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </p></td>
<td>You should read the &#8220;Risk Factors&#8221; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information concerning the offering, see &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; beginning on page 148. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of issued and outstanding shares of common stock as of February&#160;28, 2025 excludes the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,795,648 shares of common stock issuable upon the exercise of outstanding stock options at a weighted average exercise price of $19.10 under our 2019 and 2024 Equity Incentive Plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">31,891 shares of common stock issuable upon the exercise of outstanding options at a weighted average exercise price of $40.80 under the AVROBIO, Inc. 2018 Equity Incentive Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">180,487 shares of common stock issuable upon the settlement of outstanding restricted stock units; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,245,659 shares of common stock reserved for future issuance under our 2024 Equity Incentive Plan; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">295,906 shares of common stock reserved for future issuance under our 2024 Employee Stock Purchase Plan. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_4">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves risks. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under &#8220;Cautionary Note Regarding Forward-Looking Statements,&#8221; you should carefully consider the specific risks set forth herein. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. When determining whether to invest, you should also refer to the other information contained in this prospectus, including our financial statements and the related notes thereto, and the other financial information concerning us included elsewhere in this prospectus. Additionally, the risks and uncertainties described in this prospectus or any prospectus supplement are not the only risks and uncertainties that we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may become material and adversely affect our business. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Position and Cash Needs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a limited operating history and have incurred net losses in every year since our inception. We expect to continue to incur net losses in the future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company with a limited operating history. Since our inception in 2019, we have invested most of our resources in organizing and staffing our company, developing our technology and product candidates, building our intellectual property portfolio, conducting business planning, raising capital and providing general and administrative support for these operations. We also completed a reverse merger with AVROBIO, Inc. in June 2024 and have been operating under this structure for only a short time (for additional information concerning the merger, see &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; beginning on page 71). Consequently, we have no meaningful operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing drug products. We continue to incur significant research and clinical development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. For the years ended December&#160;31, 2024 and 2023, we reported a net loss of $58.0&#160;million and $42.8&#160;million, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $148.6&#160;million. We expect to continue to incur significant losses for the foreseeable future, and expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our lead product candidate, TX45, along with any future product candidates we may develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our expenses will increase substantially if, and as, we: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continue the research and development of our clinical- and preclinical-stage product candidates and discovery-stage programs, including the continued development of our lead product candidate TX45; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increase the amount of research and development activities to identify and develop product candidates using our proprietary discovery approach; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make milestone, royalty or other payments under <span style="white-space:nowrap">in-license</span> or collaboration agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain, expand and protect our intellectual property portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">invest in or <span style="white-space:nowrap">in-license</span> other technologies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, manufacturing challenges, safety issues or other regulatory challenges. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we, our collaborators and any potential future collaborators must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, producing biologics with contract manufacturing development organizations (&#8220;CDMOs&#8221;) in the United States and in other countries, obtaining marketing approval for product candidates, manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need substantial additional funding in order to complete the development and commence commercialization of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, reduce or eliminate certain of our product development or research operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have financed our operations primarily through the sale and issuance of common stock, convertible preferred stock, convertible promissory notes and the issuance of SAFEs. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue our Phase 1b and Phase 2 clinical trials of TX45, pursue manufacturing activities for our HHT product candidate, TX2100, and initiate health authority and/or IND enabling safety studies and continue to research, develop and initiate clinical trials of any other future product candidates. In addition, if we successfully complete development through Phase 3 and obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our product development programs or any future commercialization efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, we had $141.2&#160;million in cash and cash equivalents. Although we believe that our available cash and cash equivalents will be sufficient to fund our planned operations for at least 12 months following the date of our consolidated financial statements included in this prospectus, this belief is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future capital requirements for TX45 or our preclinical programs will depend on many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the progress, timing and completion of preclinical studies and clinical trials for our current or any future product candidates, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to disease outbreaks, epidemics and pandemics or other causes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of milestone and royalty payments we are required to make or are eligible to receive under our license agreements with Harvard and other license agreements, as applicable; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of potential new product candidates we identify and decide to develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the need for additional or expanded <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials beyond those that we plan to conduct with respect to our current and future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs involved in growing the organization to the size needed to allow for the research, development and potential commercialization of our current or any future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs involved in filing patent applications, maintaining and enforcing patents or defending against infringement or other claims raised by third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the maintenance of our existing license and collaboration agreements and the entry into new license and collaboration agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing technological and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of completion of commercial-scale outsourced manufacturing activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our product candidates, if approved; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market acceptance of any approved product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt or royalty financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. Market volatility resulting from geopolitical and economic instability, including the conflicts between Russia and Ukraine and in the Middle East or other factors could also adversely impact our ability to access capital as and when needed. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or product candidates or we may be unable to take advantage of future business opportunities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital will cause dilution to our stockholders, and may restrict our operations, or require us to relinquish rights to our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity, debt or royalty financings, third-party funding, marketing, and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our current stockholders will be diluted, and the terms of these securities may include liquidation or other preferences. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional capital through future collaborations, strategic alliances, or third-party licensing arrangements, we may have to relinquish certain valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our clinical development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have limited experience in therapeutic discovery and development and our GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup><sup style="font-size:75%; vertical-align:top"> </sup>platform may never result in the regulatory approval of a product candidate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the prior experience of individuals on our management team in drug discovery and development, we are still a relatively young organization that has not yet completed the full cycle of activities from discovery through regulatory approval for any of our portfolio projects. Our GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup> discovery platform has been the focus of technology development efforts over the last four years and is in the early stages of being applied to novel therapeutic target opportunities. There is no guarantee the platform&#8217;s capabilities or its application to targets of interest will lead to therapeutic product candidates that can be successfully developed through different stages of clinical trials and registered for marketing as therapeutic drugs in the United States or any other territory. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are very early in our development efforts. If we are unable to advance TX45 or any of our other product candidates through clinical development, obtain regulatory approval and ultimately commercialize TX45 or any of our other product candidates, or experience significant delays in doing so, our business will be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no products approved for sale and our lead product candidate, TX45, will require clinical development, regulatory review and approval in each jurisdiction in which we intend to market it, access to sufficient commercial manufacturing capacity, and significant sales and marketing efforts before we can generate any revenue from product sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. We are early in our product candidate development efforts, as TX45 is still in a Phase 1b clinical trial and recently initiated a Phase 2 clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate product revenues, which we do not expect will occur in the foreseeable future, if ever, will depend heavily on the successful development and eventual commercialization of TX45, TX2100, and any future product candidates we develop, which may never occur. TX45 and any future product candidates we develop will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other jurisdictions for specific indications for use, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales. The success of our current and future product candidates will depend on several factors, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful and timely completion of preclinical studies and clinical trials for which the FDA, or any comparable foreign regulatory authority agree with the design, endpoints or implementation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">receiving regulatory approvals or authorizations for conducting our planned clinical trials or future clinical trials; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiation and successful patient enrollment in, and completion of, additional clinical trials on a timely basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate is safe, pure, and potent for its targeted indications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">timely receipt of marketing approvals for our product candidates from applicable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and scaling up, either alone or with third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining and maintaining patent and proprietary information protection or regulatory exclusivity for our product candidates, both in the United States and internationally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully scaling a sales and marketing organization and launching commercial sales of our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance of our product candidates&#8217; benefits and uses, if approved, by patients, the medical community and third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintaining a continued acceptable safety profile of our product candidates following approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effectively competing with companies developing and commercializing other therapies in the indications which our product candidates target; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enforcing and defending intellectual property rights and claims. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize TX45 or any future product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for our current and future product candidates, we may not be able to continue our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">All of our product candidates are in discovery, preclinical or Phase 1 and Phase 2 clinical trials. Clinical trials are difficult to design and implement, and they involve a lengthy and expensive process with uncertain outcomes. We may experience delays in completing, or ultimately be unable to complete, the development and commercialization of TX45 or any future product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. We cannot guarantee that any of our ongoing and planned clinical trials will be conducted as planned or completed on schedule, if at all. Moreover, even if these trials are initiated or conducted on a timely basis, issues may arise that could result in the suspension or termination of such clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have completed only one clinical trial (Phase 1a trial in normal healthy volunteer with TX45) required for the approval of any of our product candidates. Enrollment in Part A of our TX45 Phase1b trial in patients with Group 2 PH and HFpEF is complete and we are currently conducting a Part B trial in Group 2 PH patients with HFrEF. We are enrolling a TX45 Phase 2 clinical trial in Group 2 PH patients with HFpEF, and we may experience delays in our ongoing clinical trials or preclinical studies. Additionally, we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time, have sufficient drug </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supply for our product candidates on a timely basis or be completed on schedule, if at all. Furthermore, our product candidate TX2100 is still in preclinical studies and the full results of such studies are not yet known. A failure of one or more clinical trials can occur at any stage of testing, and our ongoing and future clinical trials may not be successful. We also may experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize TX45 or any future product candidates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in or failure to obtain regulatory authorizations to commence a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching a consensus with regulatory agencies as to the design or implementation of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in or failure to obtain institutional review board (&#8220;IRB&#8221;) approval at each site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in or failure to recruit a sufficient number of suitable patients to participate in a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to have patients complete a trial or return for post-treatment <span style="white-space:nowrap">follow-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical sites deviating from trial protocol or dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in adding new clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to manufacture sufficient quantities of our product candidates for use in clinical trials in a timely manner; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, such as complications with pharmacokinetic behaviors, or safety or tolerability concerns that could cause us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to perform clinical trials in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practices (&#8220;GCP&#8221;) requirements, or regulatory guidelines in other countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements, policies and guidelines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of our third-party research contractors to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in establishing the appropriate dosage levels in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the quality or stability of our product candidates falling below acceptable standards; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business interruptions resulting from natural disasters, political, geopolitical and economic instability, including political unrest or unstable economic conditions in China, the war between Russia and Ukraine, the conflict in the Middle East, terrorism, political turmoil, disease outbreaks, epidemics and pandemics. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or comparable foreign regulatory authorities, or recommended for suspension or termination by the Data Safety Monitoring Board for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any period during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our clinical trials may fail to demonstrate substantial evidence of the safety, efficacy, purity and potency of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory approvals to market and sell any of our product candidates, including TX45 and any other future product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our biologic products, including TX45, are safe and effective for use in each targeted indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications, patient population and regulatory agency. Prior to obtaining approval to commercialize TX45 and any future product candidates in the United States or abroad, we, our collaborators or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses or may not provide a sufficient risk-benefit ratio, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do or find a risk-benefit ratio for a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposed indication acceptable, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities will view our product candidates as having efficacy even if positive results are observed in clinical trials. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, approval of TX45 and any future product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit our commercial potential. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later-stage trials. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of nonclinical, preclinical and early-stage clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Furthermore, there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA approval. Any such setbacks in our clinical development could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates may be associated with serious adverse, undesirable or unacceptable side effects or other properties or safety risks, which may delay or halt their clinical development, or prevent marketing approval. If such side effects are identified during the development of our product candidates or following approval, we may suspend or abandon our development of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. While our lead product candidate, TX45, has been generally well tolerated in its preclinical studies, the Phase 1a healthy volunteer trial and our Phase 1b study in patients with Group 2 PH to date, the results from future preclinical studies and clinical trials, including of our other product candidates, may identify safety concerns or other undesirable properties of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of our ongoing Phase 1b clinical trial of TX45, the recently initiated Phase 2 clinical trial of TX45, and future clinical trials of these and other product candidates may show that our product candidates cause undesirable or unacceptable side effects or even death. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, if our product candidates are associated with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, adverse developments in clinical trials of pharmaceutical and biopharmaceutical products conducted by others may cause the FDA or other regulatory oversight bodies to suspend or terminate our clinical trials or to change the requirements for approval of any of our product candidates. For example, immunogenicity is a concern for all protein therapeutics in human clinical trials, and immunogenic reactions in patients in our trials may lead to adverse effects and/or impact exposure, which in turn may lead to protocol amendments, clinical holds, or other actions that delay or significantly impact the prospects for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any of our product candidates receive marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may withdraw approvals of such product and require us to take such approved product off the market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) plan to ensure that the benefits of the product outweigh its risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be subject to limitations on how we may promote the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of the product may decrease significantly; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be subject to litigation or product liability claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reputation may suffer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our product candidates, if approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with, or otherwise adversely affect, clinical trials of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timely completion of our clinical trials in accordance with our protocols depends, among other things, on our ability to recruit a sufficient number of eligible patients to participate and remain in the trial until its conclusion. Patients may be unwilling to participate in our clinical trials because of negative publicity from adverse events related to novel therapeutic approaches, competitive clinical trials for similar patient populations, the existence of current treatments or for other reasons. Any delays related to patient enrollment could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether. We may not be able to identify, recruit and enroll a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sufficient number of patients, or those with the required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by many factors, including the: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">location of trial sites in Moldova and Georgia for the Phase 1b trial and Phase II with its proximity to the conflict between Russia and the Ukraine; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining, or the inability to obtain, required approvals from IRBs and ethics committees or other governing entities at clinical trial sites selected for participation in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement on acceptable terms with clinical trial sites on clinical budgets and/or clinical trial agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">deviations from the trial protocol by clinical trial sites and investigators, or failures to conduct the trial in accordance with regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">size and nature of the patient population and process for identifying patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">proximity and availability of clinical trial sites for prospective patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">eligibility and exclusion criteria for the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">design of the clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">safety profile, to date, of the product candidate under study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">perceived risks and benefits of the product candidate under study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">perceived risks and benefits of our approach; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval of competing product candidates currently under investigation for the treatment of similar diseases or conditions, or competing clinical trials for similar product candidates or targeting patient populations meeting our patient eligibility criteria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">severity of the disease under investigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">degree of progression of the patient&#8217;s disease at the time of enrollment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to obtain and maintain patient consent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risk that enrolled patients will drop out before completion of the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patient referral practices of physicians; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to adequately monitor patients during and after treatment. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim, topline or preliminary data from our clinical trials. Preliminary and interim data from our clinical trials may change as more patient data become available. Preliminary or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interim data from our clinical trials are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available and we issue our final clinical trial report. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, topline and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, if any, and the company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, if any, product candidate or our business. If the preliminary and interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before we can commence clinical trials for any product candidate, we must complete extensive preclinical studies that support any future Investigational New Drug (&#8220;IND&#8221;) applications in the United States, or similar applications in other jurisdictions. In July 2024, we received clearance from the FDA for our IND application for our TX45 program. Conducting preclinical testing is a lengthy, time-consuming and expensive process and delays associated with product candidates for which we are directly conducting preclinical testing and studies may cause us to incur additional operating expenses. While we are currently conducting a Phase 1b and the recently initiated Phase 2 clinical trials for TX45, including some trials which may be outside of the United States, we cannot be certain of the timely completion or outcome of our preclinical testing and studies for our other product candidates and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and foreign clinical trials will ultimately support the further development of our other product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or comparable foreign regulatory authorities allowing clinical trials to begin. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, laws or regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe, pure and potent for its proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the population studied may not be sufficiently broad or representative to assure safety or efficacy in the population for which we seek approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the results of clinical trials may not meet the level of clinical significance required by the FDA or comparable foreign regulatory authorities for approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may require additional preclinical studies or clinical trials beyond those that we currently anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a Biologics License Application (&#8220;BLA&#8221;) as applicable, to the FDA or other submission or to obtain regulatory approval in the United States or elsewhere; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA or any comparable foreign regulatory authorities or the laws they enforce may significantly change in a manner rendering our clinical data insufficient for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, financial condition and results of operations. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, if any, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The FDA and any comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are presently conducting clinical development in the United States, Eastern Europe, the European Union, Australia, and New Zealand and will likely choose to conduct additional international clinical trials in the future. The acceptance of study data by the FDA or any comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions or may not be accepted at all. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice, (ii)&#160;the trials are performed by clinical investigators of recognized competence and pursuant to compliance with current GCP requirements and (iii)&#160;the FDA is able to validate the data through an <span style="white-space:nowrap">on-site</span> inspection or other appropriate mean. Additionally, the FDA&#8217;s clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any applicable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we receive regulatory approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with such product candidate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with CGMPs and GCP requirements for any clinical trials that we conduct post-approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to CGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with CGMP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient <span style="white-space:nowrap">follow-up,</span> a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention or refusal to permit the import or export of our product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses and a company that is found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses may be subject to significant liability including, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such <span style="white-space:nowrap">off-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of <span style="white-space:nowrap">off-label</span> use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of <span style="white-space:nowrap">off-label</span> use and has enjoined companies from engaging in <span style="white-space:nowrap">off-label</span> promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of a BLA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If approved, our investigational products may face competition from biosimilars approved through an abbreviated regulatory pathway. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing TX45 initially for the treatment of Group 2 Pulmonary Hypertension (&#8220;PH&#8221;) in HFpEF, which we anticipate will be regulated as a biological product. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;) includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <span style="white-space:nowrap">FDA-licensed</span> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the <span style="white-space:nowrap">12-year</span> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <span style="white-space:nowrap">non-biological</span> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of biotechnology products. Currently, we have no products that have been approved for commercial sale; however, the current and future use of product candidates by us and our collaborators in clinical trials, and the potential sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients who use the product, healthcare providers, pharmaceutical companies, our collaborators or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a product, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. Regardless of the merits or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our products due to negative public perception; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants or difficulties in recruiting new trial participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiation of investigations by regulators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs to defend or settle the related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a diversion of management&#8217;s time and our resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to trial participants or patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product recalls, withdrawals or labeling, marketing or promotional restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenues from product sales; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize any of our product candidates, if approved. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe we maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential product candidates. These decisions may prove to have been wrong and may adversely affect our ability to develop our own programs, our attractiveness as a commercial partner and may ultimately have an impact on our commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular proprietary molecules in our library, product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the biotechnology industry, in particular for our lead product candidate, TX45, TX2100, our business, financial condition and results of operations could be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may seek orphan drug designation for product candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our business strategy, we may seek orphan drug designation for any product candidates we develop, and we may be unsuccessful. While we have not made a determination on whether we intend to seek orphan drug designation for any of our product candidates at this time, we may do so in the future. Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act in the United States, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards certain clinical trial costs, tax advantages and <span style="white-space:nowrap">user-fee</span> waivers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in the United States, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same indication for seven years, except in limited circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect the product candidate from competition because different therapies can be approved for the same condition and the same therapies can be approved for different conditions but used <span style="white-space:nowrap">off-label.</span> Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for applicable indications for our current and any future product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Commercialization of Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are successful in obtaining marketing approval from applicable regulatory authorities for TX45 or any other product candidate, our ability to generate revenues from any such products will depend on our success in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launching commercial sales of such products, whether alone or in collaboration with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">receiving approved labels with claims that are necessary or desirable for successful marketing, and that do not contain safety or other limitations that would impede our ability to market such products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">creating market demand for such products through marketing, sales and promotion activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">hiring, training, and deploying a sales force or contracting with third parties to commercialize such products in the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">creating strategic collaborations with, or offering licenses to, third parties to promote and sell such products in foreign markets where we receive marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing such products (i)&#160;in sufficient quantities, (ii)&#160;at acceptable quality and cost and (iii)&#160;in a presentation that is practical and compatible with the intended clinical use to meet commercial demand at launch and thereafter; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintaining patent and trade secret protection and regulatory exclusivity for such products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">achieving market acceptance of such products by patients, the medical community, and third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">achieving coverage and adequate reimbursement from third-party payors for such products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patients&#8217; willingness to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> in the absence of such coverage and adequate reimbursement from third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effectively competing with other therapies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintaining a continued acceptable safety profile of such products following launch. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects will be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to <span style="white-space:nowrap">in-license</span> novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compete in the segments of the biotechnology, pharmaceutical and other related industries that develop and market therapies for the treatment of Group 2 PH with HFpEF and Hereditary Hemorrhagic Telangiectasia (&#8220;HHT&#8221;) disorders. Although there are no other companies who have commercialized therapies for the same therapeutic areas that our product candidates target, there are many other companies, including large biotechnology and pharmaceutical companies, that are developing therapies for the same therapeutic areas. For example, AstraZeneca and Tenax Therapeutics for the treatment of Group 2 PH and Diagonal Therapeutics and Vaderis Therapeutics for the treatment of HHT. In addition, in January 2025, Eli Lilly terminated its Phase 2 trial of volenrelaxin, which has affected investor perception of relaxin product candidates in general. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will continue to face intense and increasing competition as new treatments enter the market and advanced technologies become available. There can be no assurance that our competitors are not currently developing, or will not in the future develop, products that are equally or more effective or are more economically attractive than any of our current or future product candidates. Competing products may gain faster or greater market acceptance than our products, if any, and medical advances or rapid technological development by competitors may result in our product candidates becoming <span style="white-space:nowrap">non-competitive</span> or obsolete before we are able to recover our research and development and commercialization expenses. If we or our product candidates do not compete effectively, it may have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not have a sales or marketing infrastructure and have no experience in the sale or marketing of biotechnology products. To achieve commercial success for any approved product, we must develop or acquire a sales and marketing organization, outsource these functions to third parties or enter into strategic collaborations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may decide to establish our own sales and marketing capabilities and promote our product candidates if and when regulatory approval has been obtained in the United States or in other jurisdictions. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. Even if we establish sales and marketing capabilities, we may fail to launch our products effectively or to market our products effectively since we have no experience in the sales and marketing of biotechnology products. In addition, recruiting and training a sales force is expensive and time consuming and could delay any product launch. In the event that any such launch is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Factors that may inhibit our efforts to commercialize our products on our own include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability of sales personnel to obtain access to or educate adequate numbers of physicians on the benefits of our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of marketing and promotion above those anticipated by us. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales and marketing services, our product revenues or the profitability of these product revenues to us could be lower than if we were to market and sell any products that we develop ourselves. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy. In addition, we may not be successful in entering into arrangements with third parties to sell and market our products or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources and attention to sell and market our products effectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our products, if any, which in turn would have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. The revenues that we generate from our sales may be limited, and we may never become profitable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors and others in the medical community. If any product candidates for which we obtain regulatory approval does not gain an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. Market acceptance of our product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially more effective or safer treatments enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates are approved but do not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any product for which we receive marketing approval will depend on a number of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical indications for which our product candidates are approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">physicians, hospitals and patients considering our product candidates as a safe and effective treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential and perceived advantages of our product candidates over alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any side effects; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product labeling or product insert requirements of the FDA or comparable foreign regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of market introduction of our product candidates in relation to other potentially competitive products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of our product candidates in relation to alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount of upfront costs or training required for physicians to administer our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of coverage and adequate reimbursement from third-party payors and government authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of patients to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> in the absence of comprehensive coverage and reimbursement by third-party payors and government authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our sales and marketing efforts and distribution support; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the presence or perceived risk of potential product liability claims. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare reform may negatively impact our ability to profitably sell TX45 and any potential future product candidates, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of TX45 or any potential future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as the ACA, was enacted, which includes measures that have significantly changed the way health care is financed by both governmental and private insurers. There have been executive, judicial and congressional challenges and amendments to certain aspects of the ACA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, on August&#160;16, 2022, the Inflation Reduction Act (the &#8220;IRA&#8221;), was signed into law, which among other things, (1)&#160;directs the Department of Health and Human Services (the &#8220;HHS&#8221;), to negotiate the price of certain high expenditure, single-source biologics that have been on the market for 11 years covered under Medicare (the &#8220;Medicare Drug Price Negotiation Program&#8221;) and (2)&#160;imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA includes certain exemptions to the price negotiation program, including a limited exemption for products with orphan drug designation. This exemption applies only to products with one orphan drug designation that is (i)&#160;for a rare disease or condition and (ii)&#160;is approved for indication(s) for such rare disease or condition. By limiting price negotiation exemption to products with only one orphan drug designation, the IRA may decrease our interest in pursuing orphan drug designation for our product candidates in multiple indications. The IRA also, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025 and eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> cost through a newly established manufacturer discount program. These provisions began to take effect progressively in fiscal year 2023. On August&#160;15, 2024, HHS announced the agreed-upon reimbursement prices of the first ten drugs that were subject to price negotiations, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January&#160;17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. It is possible that the ACA and IRA may be subject to judicial or Congressional challenges in the future. It is unclear how any additional healthcare reform measures of the second Trump administration may impact the ACA or IRA, increase the pressure on drug pricing or limit the availability of coverage and adequate reimbursement for TX45 and any potential future product candidates, which would adversely affect our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has also been increasing executive, legislative and enforcement interest in the United States with respect to drug pricing practices. There have been U.S. congressional inquiries, presidential executive orders and proposed and enacted legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. For example, on December&#160;7, 2023, an initiative to control the price of prescription drugs through the use of <span style="white-space:nowrap">march-in</span> rights under the Bayh-Dole Act was announced. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of <span style="white-space:nowrap">March-In</span> Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise <span style="white-space:nowrap">march-in</span> rights. While <span style="white-space:nowrap">march-in</span> rights have not previously been exercised, it is uncertain if that will continue under the new framework. We expect that the healthcare reform measures that have been adopted and may be adopted in the future may result in more rigorous coverage criteria and additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS and related agencies.&#160;These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions may include, for example, directives to reduce agency workforce, rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation (&#8220;CMMI&#8221;) to consider new payment and healthcare models to limit drug spending and eliminating the Biden administration&#8217;s executive order that directed HHS to establishing an AI task force and developing a strategic plan.&#160;Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo (&#8220;Loper Bright&#8221;), the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such reforms could have an adverse effect on anticipated revenue from TX45 and any potential future product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries outside the United States, government-sponsored healthcare systems are the primary payors for drugs. With increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payors in many countries are applying a variety of measures to exert downward price pressure and we expect that legislators, policy makers and healthcare insurance funds in the EU Member States will continue to propose and implement cost cutting measures. These measures include mandatory price controls, price referencing, therapeutic-reference pricing, increases in mandates, incentives for generic substitution and biosimilar usage, government-mandated price cuts, limitations on coverage of target population and introduction of volume caps. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries implement health technology assessment (&#8220;HTA&#8221;), procedures that use formal economic metrics such as cost-effectiveness to determine prices, coverage and reimbursement of new therapies. These assessments are increasingly implemented in established and emerging markets. In the EU, Regulation (EU) 2021/2282 on Health Technology Assessment, which will become effective on January&#160;12, 2025, will allow EU member states to use common HTA tools, methodologies and procedures to conduct joint clinical assessments and joint scientific consultations whereby HTA authorities may provide advice to health technology developers. Each EU member state will, however, remain exclusively competent for assessing the relative effectiveness of health technologies and making pricing and reimbursement decisions. Given that the extent to which pricing and reimbursement decisions are influenced by the HTA process currently varies between EU member states, it is possible that our products may be subject to favorable pricing and reimbursement status only in certain EU countries. If we are unable to maintain favorable pricing and reimbursement status in EU member states that represent significant markets, including following periodic review, our anticipated revenue from and growth prospects for our products in the EU could be negatively affected. Moreover, in order to obtain reimbursement for our products in some EU member states, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Efforts to generate additional data for the HTA process will involve additional expenses which may substantially increase the cost of commercializing and marketing our products in certain EU member states. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of healthcare reform initiatives that may arise from future legislation or administrative action. However, it is possible that countries will continue taking aggressive actions to seek to reduce expenditures on drugs. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inadequate funding for the FDA and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies (including layoffs) may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, many staff members from the FDA and other agencies have recently been laid off. If a prolonged government shutdown or disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns and/or disruptions could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our relationships with healthcare providers, customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which, if violated, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, including physicians, and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we or our partner obtains marketing approval. Our arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our products for which we or our partner obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute prohibits persons from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for the furnishing or arranging for the furnishing, or the purchase, lease or order, or arranging for or recommending purchase, lease or order, of any good or service for which payment may be made under a federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (the &#8220;FCA&#8221;) or federal civil monetary penalties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FCA imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), imposes criminal liability for knowingly and willfully executing a scheme to defraud any healthcare benefit program, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense or knowingly and willfully making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), also imposes obligations on certain covered entity healthcare providers, health plans and healthcare clearinghouses, and their business associates that perform certain services involving the use or disclosure of individually identifiable health information as well as their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security, processing and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and <span style="white-space:nowrap">non-U.S.</span> laws which govern the privacy and security of health and other personal information in </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Sunshine Act, as amended, and its implementing regulations, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the HHS information related to &#8220;payments or other transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <span style="white-space:nowrap">non-governmental</span> third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and local laws requiring the registration of pharmaceutical sales representatives; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or pricing; federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and state and foreign laws that govern the privacy and security and other processing of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, additional regulatory oversight, litigation, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of EU member states, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business could be materially and adversely affected in the future by political unrest in China, as well as the effects of disease outbreaks, epidemics and pandemics. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disease outbreaks, epidemics and pandemics in regions where we may have clinical trial sites or other business operations could adversely affect our business, including by causing significant disruptions in our operations and/or in the operations of third-party manufacturers and CROs upon whom we rely. Disease outbreaks, epidemics and pandemics have negative impacts on our ability to initiate new clinical trial sites, to enroll new patients and to maintain existing patients who are participating in our clinical trials, which may include increased clinical trial costs, longer timelines and delay in our ability to obtain regulatory approvals of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TX45, TX2100 and any potential future product candidates, if at all. Disease outbreaks, epidemics and pandemics also could adversely impact clinical trial results for TX45 or other future potential product candidates, such as by diminishing or eliminating their efficacy or by producing a safety concern, either through direct biological effects or through confounding of the data collection and analysis. This adverse impact could terminate further development of TX45, result in a lack of product approval by the FDA or other regulatory authorities, delay the timing (and/or increase the cost) of a product approval by the FDA or other regulatory authorities, lead to a restrictive product label that significantly limits prescribing of an approved product, delay or preclude reimbursement by payors, or significantly limit or preclude the commercialization of TX45. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because our key manufacturer and supplier for TX45 is located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies, laws, rules and regulations of the United States or Chinese governments, as well as political unrest or unstable economic conditions in China. For example, trade tensions between the United States and China have been escalating in recent years. The U.S. government has indicated its intent to adopt a new approach to trade policy and in some cases to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements.&#160;For example, on February&#160;1, 2025, President Donald Trump signed executive orders imposing a 25% tariff on certain imports from Mexico and Canada, and a 10% tariff on certain imports from China, which were to take effect on February&#160;4, 2025.&#160;A <span style="white-space:nowrap">30-day</span> pause was granted to Canada and Mexico.&#160;However, these newly proposed and imposed tariffs have resulted in threatened and actual retaliatory tariffs against U.S. goods. Our components may in the future be subject to these tariffs, which could increase our manufacturing costs and could make our products, if successfully developed and approved, less competitive than those of our competitors whose inputs are not subject to these tariffs. We may otherwise experience supply disruptions or delays, and although we carefully manage our inventory and lead-times, our supplier may not continue to provide us with battery components in our required quantities, to our required specifications and quality levels or at attractive prices. In addition, certain Chinese biotechnology companies and CDMOs may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting the supply of material to us. For example, the House of Representatives of the prior Congress (the 118<sup style="font-size:75%; vertical-align:top">th</sup>Congress) passed the BIOSECURE Act, which proposed targeting U.S. government contracts, grants, and loans for entities that use biotechnology equipment or services from certain named Chinese biotechnology companies, and potentially additional Chinese biotechnology companies designated in the future.&#160;The language of the proposed BIOSECURE Act would, among other things, prohibit U.S. federal agencies from entering into or renewing any contract with any entity that uses biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern.&#8221;&#160;The version of the bill passed by the prior House of Representatives included a grandfathering provision allowing biotechnology equipment and services provided or produced by named biotechnology companies of concern under a contract or agreement entered into before the effective date until January&#160;1, 2032.&#160;The BIOSECURE Act did not become law in the 118<sup style="font-size:75%; vertical-align:top">th</sup> Congress.&#160;It is unclear whether the current Congress (the 119<sup style="font-size:75%; vertical-align:top">th</sup> Congress) will introduce the BIOSECURE Act or similar legislation in this congressional session and, if so, how the scope, prohibitions, or designated biotechnology companies of concern may differ from the version of the BIOSECURE Act passed by the House in the prior 118<sup style="font-size:75%; vertical-align:top">th</sup> Congress. If these bills become law, or similar laws are passed, they could severely restrict the ability of companies to work with certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government. Such disruption could have adverse effects on the development of our product candidates and our business operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General supply chain issues may be exacerbated during disease outbreaks, epidemics and pandemics and may also impact the ability of our clinical trial sites to obtain basic medical supplies used in our trials in a timely fashion, if at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our contract development and manufacturing organizations (&#8220;CDMOs&#8221;) are required to obtain an alternative source of certain raw materials and components, for example, additional testing, validation activities and regulatory approvals may be required which can also have a negative impact on timelines. Any associated delays in the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing and supply of drug substance and drug product for our clinical trials could adversely affect our ability to conduct ongoing and future clinical trials of TX45 or TX2100 on our anticipated development timelines. Likewise, the operations of our third-party manufacturers may be requisitioned, diverted or allocated by U.S. or foreign government orders. If any of our CDMOs or raw materials or components suppliers become subject to acts or orders of U.S. or foreign government entities to allocate or prioritize manufacturing capacity, raw materials or components to the manufacture or distribution of vaccines or medical supplies needed to test or treat patients in a disease outbreak, epidemic or pandemic, this could delay our clinical trials, perhaps substantially, which could materially and adversely affect our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meets our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement, the ability to gain market share and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than our expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain approval to market TX45 or other potential future product candidates, these products may become subject to unfavorable pricing regulations, reimbursement practices from third-party payors or healthcare reform initiatives in the United States and abroad, which could harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. In many regions, including the EU, Japan and Canada, the pricing of prescription drugs is controlled by the government and some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after regulatory approval for the product is granted. Regulatory agencies in those countries could determine that the pricing for our products should be based on prices of other commercially available drugs for the same disease, rather than allowing us to market our products at a premium as new drugs. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay or limit commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenue we generate from the sale of the product in that particular country. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtains marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success also depends on coverage and adequate reimbursement of our product candidates by third-party payors, including government payors, private health insurers, health maintenance organizations and other organizations, which may be difficult or time-consuming to obtain, may be limited in scope and may not be obtained in all jurisdictions in which we may seek to market our products. In the United States and markets in other countries, governments and private insurers closely examine medical products to determine whether they should be covered by reimbursement and, if so, the level of reimbursement that will apply. In the United States, the principal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decisions about reimbursement for new medicines are typically made by the CMS an agency within the HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular drugs. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drug products. We cannot be sure that coverage and reimbursement will be available for any product that we or our partners commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we or our partners obtain regulatory approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we and our partners may not be able to successfully commercialize any product candidate for which marketing approval is obtained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign health authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including costs of research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, ability to raise capital needed to commercialize products and overall financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, combination therapies, and methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. The patenting process is expensive and time-consuming, and we may not be able to file, prosecute and maintain all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue, obtain or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees. In addition, we cannot guarantee that patent applications or patents that we initially believe to be owned by the company will not be encumbered by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third party ownership or other third party rights that may not have been evident to us at the time of preparation or filing. For instance, such rights could arise from the intellectual contributions of company employees who were previously employed by third parties, such as universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors, or from the intellectual contributions of company consultants, advisors, or independent contractors with current or previous relationships with such third parties.&#160;Therefore, these patents and applications may not be prepared, filed, prosecuted or enforced in a manner consistent with the best interests of our business. Furthermore, licenses from such third parties may be required or desirable but may not be available on reasonable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or <span style="white-space:nowrap">in-license</span> may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents are successfully issued, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around its claims. If the breadth or strength of protection provided by the patent applications, we hold with respect to our product candidates is threatened, we could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim, and we may be subject to a third-party preissuance submission of prior art to the USPTO. There also may be prior art of which we are aware, but which we believe does not affect the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights or will design around the claims of patents that we have had issued that cover our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. For example, recent decisions raise questions regarding the award of patent term adjustment (PTA) for patents in families where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will/will not be viewed in future and whether patent expiration dates may be impacted. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have also </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased in recent years. In Europe, a new unitary patent system took effect June&#160;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single <span style="white-space:nowrap">UPC-based</span> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make or use compounds or cells that are similar to the biological compositions of our product candidates but that are not covered by the claims of our patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the active biological ingredients in our current product candidates will eventually become commercially available in biosimilar drug products, and no patent protection may be available with regard to formulation or method of use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any <span style="white-space:nowrap">in-licensed</span> patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may independently develop similar or alternative technologies or duplicate any of our technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that our pending patent applications will not result in issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that there are prior public disclosures that could invalidate us or our licensors&#8217; patents, as the case may be, or parts of ours or their patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that others may circumvent our owned or <span style="white-space:nowrap">in-licensed</span> patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to our own; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the laws of foreign countries may not protect ours or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the claims of our owned or <span style="white-space:nowrap">in-licensed</span> issued patents or patent applications, if and when issued, may not cover our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our owned or <span style="white-space:nowrap">in-licensed</span> issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inventors of our owned or <span style="white-space:nowrap">in-licensed</span> patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that our owned or <span style="white-space:nowrap">in-licensed</span> patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not develop additional proprietary technologies for which we can obtain patent protection. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents of others may have an adverse effect on our business. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent on patents, <span style="white-space:nowrap">know-how</span> and proprietary technology, both our own and licensed from others including Harvard. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense patent and other rights to third parties under collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inventorship or ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, intellectual property license agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which is described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our obligations under our patent license with a third party, we could lose license rights that are important to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a license agreement pursuant to which we <span style="white-space:nowrap">in-license</span> key patent and patent applications for our product candidates. These existing licenses impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed intellectual property. Termination of these agreements or reduction or elimination of our rights under </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may impede, delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may have limited control over the maintenance and prosecution of these <span style="white-space:nowrap">in-licensed</span> patents and patent applications, activities or any other intellectual property that may be related to our <span style="white-space:nowrap">in-licensed</span> intellectual property. For example, we cannot be certain that such activities by our licensor have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our proprietary information, our business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we rely upon <span style="white-space:nowrap">know-how,</span> as well as <span style="white-space:nowrap">non-disclosure</span> agreements and invention assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our proprietary information and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, proprietary information may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, courts outside the United States are sometimes less willing to protect proprietary information. If we choose to go to court to stop a third party from using any of our proprietary information, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and proprietary information, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to, or disclose, our technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus, we may not be able to meaningfully protect our proprietary information. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our proprietary information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, <span style="font-style:italic">inter partes </span>review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to our product candidates and programs. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for its products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and other development activities in the United States is protected under the Safe Harbor exemption as set forth in 35 U.S.C. &#167; 271. If and when TX45 or another one of our product candidates is approved by the FDA, certain third parties may seek to enforce their patents by filing a patent infringement lawsuit against us. While we do not believe that any claims of such patent that could otherwise materially adversely affect commercialization of our product candidates, if approved, are valid and enforceable, we may be incorrect in this belief, or we may not be able to prove it in a litigation. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Even if such a license is available, it may be <span style="white-space:nowrap">non-exclusive,</span> which could result in our competitors gaining access to the same intellectual property. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, we may need to indemnify our customers and distributors against claims relating to the infringement of intellectual property rights of third parties related to our product candidates, including TX45. Third parties may assert infringement claims against our customers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors, or may be required to obtain licenses for the product candidates or services they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products or services. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated proprietary information. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. In addition, we have used and continue to use consultants, advisors, and/or independent contractors with relationships with third parties, including institutions and/or other companies. We try to ensure that our employees, consultants, advisors, and/or independent contractors have the right to assign to us intellectual property generated during their engagement with us, and that they do not use the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for us. Although no claims against us are currently pending, there is no guarantee that in the future we may not be subject to claims that we or our employees, consultants, advisors, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including trade secrets or other proprietary information, of a former employer or other third parties, or improperly assign intellectual property rights to us. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <span style="white-space:nowrap">in-license</span> or use these proprietary rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may develop products containing <span style="white-space:nowrap">pre-existing</span> pharmaceutical compounds. We may be unable to acquire or <span style="white-space:nowrap">in-license</span> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to it. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be involved in lawsuits related to our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may&#160;refuse to stop the other party from using the technology at issue on the grounds that its patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and <span style="white-space:nowrap">in-licensed</span> issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering products or technology similar to ours. Any such patent application may have priority over our owned and <span style="white-space:nowrap">in-licensed</span> patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or <span style="white-space:nowrap">in-licensed</span> to us, we or, in the case of <span style="white-space:nowrap">in-licensed</span> technology, the licensor may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference proceeding involving a U.S. patent application on inventions owned by or <span style="white-space:nowrap">in-licensed</span> to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our proprietary or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <span style="white-space:nowrap">re-examination,</span> post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the patents included in our patent portfolio may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current or future owned or licensed patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects. We own or have exclusively <span style="white-space:nowrap">in-licensed</span> pending patent applications that relate to our proprietary technologies or our product candidates that if issued as patents are expected to expire from 2041 through 2044, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of these patent applications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in patent law in the U.S. and in <span style="white-space:nowrap">ex-U.S.</span> jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or in <span style="white-space:nowrap">ex-U.S.</span> jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case <span style="font-style:italic">Amgen Inc. v. Sanofi, </span>the Federal Circuit held that a well-characterized antigen is insufficient to satisfy the written description requirement of certain claims </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directed to a genus of antibodies that are solely defined by function; and in the case of <span style="font-style:italic">Assoc. for Molecular</span> <span style="font-style:italic">Pathology v. Myriad Genetics, Inc., </span>the Supreme Court held that certain claims to DNA molecules are not patentable. We cannot predict how these decisions or any future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as do federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to its business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Also, competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may incur substantial costs as a result of litigation or other proceedings relating to patents, and we may be unable to protect our rights to our products and technology. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our licensors choose to go to court to stop a third party from using the inventions claimed in our owned or <span style="white-space:nowrap">in-licensed</span> patents, that third party may ask the court to rule that the patents are invalid and/or should not be enforced against that third party. These lawsuits are expensive and would consume time and other resources even if we or they, as the case may be, were successful in stopping the infringement of these patents. In addition, there is a risk that the court will decide that these patents are not valid and that we or they, as the case may be, do not have the right to stop others from using the inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the third party on the ground that such third party&#8217;s activities do not infringe our owned or <span style="white-space:nowrap">in-licensed</span> patents. In </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, the Supreme Court has recently changed some legal principles that affect patent applications, granted patents and assessment of the eligibility or validity of these patents. As a consequence, issued patents may be found to contain invalid claims according to the newly revised eligibility and validity standards. Some of our owned or <span style="white-space:nowrap">in-licensed</span> patents may be subject to challenge and subsequent invalidation or significant narrowing of claim scope in proceedings before the USPTO, or during litigation, under the revised criteria which could also make it more difficult to obtain patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, or our licensors, may not be able to detect infringement against our owned or <span style="white-space:nowrap">in-licensed</span> patents, as the case may be, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our licensors detect infringement by a third party of our owned or <span style="white-space:nowrap">in-licensed</span> patents, we or our licensors, as the case may be, may choose not to pursue litigation against or settlement with the third party. If we, or our licensors, later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us or our licensors to enforce our owned or <span style="white-space:nowrap">in-licensed</span> patents, as the case may be, against such third party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If another party questions the patentability of any of our claims in our owned or <span style="white-space:nowrap">in-licensed</span> U.S. patents, the third-party can request that the USPTO review the patent claims such as in an <span style="font-style:italic">inter partes </span>review, <span style="font-style:italic">ex parte </span><span style="white-space:nowrap">re-exam</span> or post-grant review proceedings. These proceedings are expensive and may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings in foreign patent offices, where either our owned or <span style="white-space:nowrap">in-licensed</span> foreign patents are challenged. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. The costs of these opposition or similar proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result at the USPTO or other patent office may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may be involved in similar proceedings challenging the patent rights of others, and the outcome of such proceedings is highly uncertain. We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an <span style="font-style:italic"><span style="white-space:nowrap">ex-parte</span> </span><span style="white-space:nowrap">re-exam,</span> <span style="font-style:italic">inter partes </span>review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the foreign patent offices. The costs of these opposition proceedings could be substantial and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <span style="white-space:nowrap">non-provisional</span> filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed. Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trade names or trademarks that incorporate variations of our unregistered trade names or trademarks. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Reliance on Third Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture TX45, TX2100 and any other product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently lease or own any facility that may be used as our clinical-scale manufacturing and processing facility and currently rely on contract development and manufacturing organizations (&#8220;CDMO&#8221;), including WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;), to manufacture TX45 for use in our Phase 1a, Phase 1b and the recently initiated Phase 2 clinical trials. We currently have a sole source relationship with WuXi Biologics for our supply of TX45. If there should be any disruption in such supply arrangement or the supply arrangement with our CDMO for TX2100, including any adverse events affecting our sole supplier for TX45, Wuxi Biologics, it could have a negative effect on the clinical development of our product candidates and other operations while we work to identify and qualify an alternate supply source. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with CGMP requirements and any other regulatory requirements of the FDA or comparable foreign </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory authorities for the manufacture of a product candidate. We perform periodic audits of each CDMO facility that supports our supply of TX45 and TX 2100 and reviews and approves all TX45 and TX2100 CGMP-related documentation. We also have quality agreements with our CDMOs that document our mutual agreement on compliance with CGMPs and expectations on quality-required communications to us. Beyond this, we have no control over the ability of our CDMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities and the associated Quality Management System for the manufacture of a product candidate or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and materially and adversely affect our ability to develop, obtain regulatory approval for or market such product candidate, if approved. Similarly, our failure, or the failure of our CDMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of a product candidate or drug and harm our business and results of operations. In addition, we have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, our CDMOs may experience manufacturing difficulties due to resource constraints, governmental restrictions or as a result of labor disputes or unstable political environments. Supply chain issues, including those resulting from the a health pandemic and the ongoing military conflict between Russia and Ukraine, may affect our third-party vendors and cause delays. Furthermore, since we have engaged WuXi Biologics, a manufacturer located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Chinese governments or political unrest or unstable economic conditions in China. For example, the U.S. House of Representatives of the prior Congress (the 118th Congress) passed the BIOSECURE Act, which proposed targeting U.S. government contracts, loans, and grants to entities that use biotechnology equipment or services from certain Chinese biotechnology companies, including Wuxi Biologics, and would authorize the U.S. government to name other Chinese biotechnology companies of concern. The version of the BIOSECURE Act passed by the prior House of Representatives included a grandfathering provision allowing biotechnology equipment and services provided or produced by WuXi Biologics and other named biotechnology companies of concern under a contract or agreement entered into before the effective date until January&#160;1, 2032.&#160;The BIOSECURE Act did not become law in the 118<sup style="font-size:75%; vertical-align:top">th </sup>Congress.&#160;It is unclear whether the current Congress (the 119<sup style="font-size:75%; vertical-align:top">th</sup>&#160;Congress) will introduce the BIOSECURE Act or similar legislation in this congressional session and, if so, how the scope, prohibitions, or designated biotechnology companies of concern may differ from the version of the BIOSECURE Act passed by the House in the prior 118<sup style="font-size:75%; vertical-align:top">th</sup> Congress.&#160;In addition to the BIOSECURE Act, any additional U.S. executive action, legislative action, or potential sanctions with China could materially impact our work with WuXi Biologics.&#160;U.S. executive agencies have the ability to designate entities and individuals on various governmental prohibited and restricted parties lists.&#160;Depending on the designation, potential consequences can range from a comprehensive prohibition on all transactions or dealings with designated parties, or a limited prohibition on certain types of activities, such as exports and financing activities, with designated parties. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. For example, in the event that we need to transfer from WuXi Biologics, which is our sole manufacturing source for TX45, we anticipate that the complexity of the manufacturing process may materially impact the amount of time it would take to secure a replacement manufacturer. The delays associated with the verification of a new manufacturer, if we are able to identify an alternative source, could negatively affect our ability to supply product candidates, including TX45, in a timely manner or within budget. If any CDMO on which we will rely fails to manufacture quantities of a product candidate at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition, cash flows, and prospects could be materially and adversely affected. In addition, our CDMO and/or distribution partners are responsible for transporting temperature-controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications. We and our CDMO may also face product seizure or detention or refusal to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permit the import or export of products. Our business could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, contracted laboratories and third-party CROs, to conduct our preclinical studies and clinical trials in accordance with applicable regulatory requirements, to validate our assays and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with good laboratory practices (&#8220;GLPs&#8221;), as applicable, and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these GLPs and GCPs through periodic inspections of laboratories conducting GLP studies, trial sponsors, principal investigators and trial sites. If we, our investigators or any of our CROs or contracted laboratories fail to comply with applicable GLPs and GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our preclinical studies or clinical trials comply with applicable GLP or GCP regulations. In addition, our clinical trials must be conducted with product, including biologic product, produced in compliance with applicable CGMP regulations. Our failure to comply with these regulations may require us to repeat preclinical studies or clinical trials, which would delay the regulatory approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, these laboratories, investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent laboratories, investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if we can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, CROs or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Switching or adding additional laboratories or CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, clinical investigators may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the utility of the preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our clinical-stage product candidate or any future product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future collaborations will be important to our business. If we are unable to enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A part of our strategy is to strategically evaluate and, as deemed appropriate, enter into additional strategic collaborations in the future when strategically attractive, including potentially with major biotechnology or pharmaceutical companies. We have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we may enter into collaborations with other companies to provide us with important technologies and funding for our programs and technology. If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or future research programs and product candidates could be delayed, the commercial potential of our product could change and our costs of development and commercialization could increase. Furthermore, we may find that our programs require the use of intellectual property rights held by third parties, and the growth of our business may depend in part on our ability to acquire or <span style="white-space:nowrap">in-license</span> these intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future collaborations we enter into may pose a number of risks, including, but not limited to, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators have significant discretion in determining the efforts and resources that they will apply; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may not perform their obligations as expected; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product candidates discovered in collaboration with ours may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our collaborations do not result in the successful discovery, development and commercialization of product candidates or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report also apply to the activities of our therapeutic collaborators. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborative partners. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon an assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of preclinical studies or clinical trials, the likelihood of regulatory approval, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of any uncertainty with respect to our ownership of technology (which can exist if there is a challenge to such ownership regardless of the merits of the challenge) and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization, reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nonclinical research requires the use of <span style="white-space:nowrap">Non-Human</span> Primates (&#8220;NHP&#8221;), the supply of which could delay or prevent development of product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with various rules, regulations and CGMP requirements, our ability to advance our <span style="white-space:nowrap">pre-clinical</span> programs and successfully develop our product candidates requires access to animal research models sufficient to assess safety and in some cases to establish the rationale for therapeutic use. Failure to access or a significant delay in accessing animal research models that meet our needs or that fulfil regulatory requirements may materially adversely affect our ability to advance our <span style="white-space:nowrap">pre-clinical</span> programs and successfully develop our product candidates and this could result in significant harm to our business. During the <span style="white-space:nowrap">COVID-19</span> pandemic, researchers and CROs experienced significant limitations in their access to animal research models, specifically including a sharp reduction in the availability of NHPs originating from breeding farms in Southeast Asia and limited access to the generation of genetically-modified rodent models used in efficacy evaluations. If we are unable to obtain NHPs in sufficient quantities and in a timely manner to meet the needs of our <span style="white-space:nowrap">pre-clinical</span> research programs, if the price of NHPs that are available increases significantly, or if our suppliers are unable to ship the NHPs in their possession that are reserved for them, our ability to advance our <span style="white-space:nowrap">pre-clinical</span> programs and successfully develop our <span style="white-space:nowrap">pre-clinical</span> candidates may be materially adversely affected or significantly delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Business Operations, Employee Matters and Managing Growth </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on our management team, including Alise Reicin, M.D., our President and Chief Executive Officer, Daniel Lochner, our Chief Financial Officer, Peter McNamara, Ph.D., our Chief Scientific Officer and Marcella K. Ruddy, M.D., our Chief Medical Officer. Each of them may currently terminate their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development, and commercialization objectives. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the current and future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for our products or any prospects for commercialization of our products. Although we believe we currently maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage or that in the future we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, and those of our CROs, CDMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or <span style="white-space:nowrap">man-made</span> disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <span style="white-space:nowrap">man-made</span> or natural disaster or other business interruption. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to comply with health-related data protection laws and regulations could lead to government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any current and future collaborators are subject to federal, state/provincial, municipal and foreign data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, including Section&#160;5 of the Federal Trade Commission Act, that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to civil, criminal, and administrative penalties if we violate HIPAA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal, and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees, and other individuals about whom we or our current or future collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including <span style="white-space:nowrap">non-compliance</span> with regulatory standards and requirements and insider trading. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants, and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <span style="white-space:nowrap">non-compliance</span> with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our information technology systems, or the information technology systems of our CROs, our CDMOs, service providers, our current and potential future partners or other third parties with whom we work fail or suffer security breaches, we could experience adverse consequences, including but not limited to material disruptions to our business operations and product development programs, regulatory investigations or actions, litigation, fines and penalties, reputational harm, loss of revenue or profits, or other adverse consequences. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We collect, store, receive, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, share, and transmit (collectively, process) proprietary, confidential and sensitive information, including personal information (such as health-related data of clinical trial participants and employee information), in the course of our business. Similarly, third-parties with whom we work process certain of that information on our behalf. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities that threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats are constantly evolving and growing in frequency, sophistication, and intensity. For example, these threats may include (without limitation) malware, viruses, software vulnerabilities and bugs, software or hardware failure, hacking, denial of service attacks, social engineering (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing), ransomware, insider threats (such as theft of misuse by personnel), credential stuffing, telecommunications failures, loss or theft of devices, data or other information technology assets, attacks enhanced or facilitated by AI, earthquakes, fires, floods and similar threats. Threats such as ransomware attacks, for example, are becoming increasingly prevalent and severe, and attackers are increasingly leveraging multiple attack methods to extort payment from victims, such as data theft and disabling systems and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Security incidents may result from the actions of a wide variety of actors with a wide range of motives and expertise, including traditional hackers, our personnel or the personnel of the third parties with whom we work, organized criminal threat actors, hacktivists, sophisticated nation-states and nation-state-supported actors. During times of war and other major conflicts, we, the third parties upon which we rely, and our customers may be vulnerable to a heightened risk of these attacks, including retaliatory cyber- attacks, that could materially disrupt our systems and operations, supply chain, and ability to conduct our clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, and other threats to our business operations. For example, we rely on third parties to operate critical business systems and process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, personnel email, and other functions. We also rely on third parties, including CROs, clinical trial sites and clinical trial vendors, to collect, store, and transmit sensitive data as part of our research activities. Our ability to monitor these third parties is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related obligations to us, any award may be insufficient to cover damages, or we may be unable to recover such awards. Supply-chain attacks have also increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain functional areas of our workforce work remotely on a full- or part-time basis or otherwise utilize network connections, computers and devices outside of our premises or network, which imposes additional risks to our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. In the future we may be required to or choose to, expend significant resources or modify our business activities (including our clinical trial activities) in an effort to protect against security incidents, particularly where required by applicable data privacy and security laws or regulations or industry standards. Certain data privacy and security obligations require us to implement and maintain certain security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties with whom we work. For example, we have been the target of unsuccessful phishing attempts in the past and expect such attempts will continue in the future. If our information systems or data, or that of the third parties on which we rely, are compromised, it could interrupt our operations, disrupt our development programs and have a material adverse effect on our business, financial condition and results of operations, whether due to a loss of our trade secrets or other proprietary information or similar disruptions. For example, the loss or corruption of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation, cause us not to comply with applicable federal and/or state breach notification laws and foreign law equivalents and otherwise subject us to liability under applicable laws and regulations that protect the privacy and security of personal information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Likewise, we rely on third parties for the manufacture of TX45, to analyze clinical trial samples and to conduct clinical trials, and security incidents experienced by these third parties could have a material adverse effect on our business. Security incidents affecting us or the third parties we rely on or partners with could also result in substantial remediation costs and expose us to litigation (including class claims), regulatory enforcement action (for example, investigations, fines, penalties, audits and inspections), additional reporting requirements and/or oversight, fines, penalties, indemnification obligations, negative publicity, reputational harm, monetary fund diversions, diversion of management attention, interruptions in our operations (including availability of data), financial loss and other liabilities and harms. Additionally, such incidents may trigger data privacy and security obligations requiring us to notify relevant stockholders, including affected individuals, customers, regulators, and investors. Such disclosures may be costly, and related requirements or the failure to comply with them could lead to adverse consequences. Even a perceived security incident or failure in compliance by us or a third-party partner may result in negative publicity, harm to our reputation, or other adverse effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from claims related to our data privacy and security obligations. Additionally, we cannot be certain that our insurance coverage will be adequate for data security liabilities actually incurred, will continue to be available to us on economically and commercially reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveal competitively sensitive details about the company and could be used to undermine our competitive advantage or market position. Additionally, sensitive information of ours could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We, and the third parties with whom we work, are subject to rapidly changing and increasingly stringent U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations relating to privacy, data protection and information security. Our actual or perceived failure to comply with these obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and otherwise harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and the third parties with whom we work process proprietary, confidential and sensitive information, including personal information (including health-related data), which subjects us to numerous evolving and complex data privacy and security obligations, including various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts and other obligations that govern the processing of such information in connection with our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation, (&#8220;EU GDPR&#8221;) and the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;) and the Swiss Federal Data Protection Act (collectively, &#8220;European Data Protection Laws&#8221;) impose strict requirements for processing personal information, including relating to transfer of personal information to countries like the United States. European Data Protection Laws and other relevant laws govern patient confidentiality and storage of personal health data, including personal information from clinical trial participants and other individuals located in the EEA, the United Kingdom (the &#8220;UK&#8221;), or Switzerland Companies that violate the EU or UK GDPR can face private litigation, regulatory investigations and enforcement actions, prohibitions on data processing, other administrative measures, reputational damage and fines of up to the greater of 20&#160;million Euros /17.5&#160;million pounds sterling or 4% of their worldwide annual revenue, in either case, whichever is greater. Certain jurisdictions have enacted data localization restrictions or laws and regulations restricting cross-border transfers of personal information, except in limited circumstances where adequate safeguards are in place. In particular, regulators and courts in the EEA, the UK, and Switzerland have significantly restricted the transfer of personal information to the United States and other countries whose privacy laws they generally believe are inadequate. Other jurisdictions have in the past and may continue to adopt similarly stringent data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal information from the EEA, the UK, or Switzerland to the United States, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the <span style="white-space:nowrap">EU-U.S.</span> Data Privacy Framework (the &#8220;Framework&#8221;) and the UK extension thereto (which allows for transfers for to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If we are unable to implement a valid compliance solution for cross-border transfers of personal information, or if the requirements for a legally-compliant transfer are too onerous, we may face increased exposure to significant adverse consequences, including substantial fines, regulatory actions, as well as injunctions against the export and processing of personal information from the EEA, UK, Switzerland, or other countries that implement cross-border data transfer restrictions. Our inability to import personal information from the EEA, UK or Switzerland or other countries may also restrict or prohibit our clinical trial activities in those countries; limit our ability to collaborate with CROs, service providers, contractors and other companies subject to laws restricting cross-border data transfers; require us to increase our data processing capabilities in other countries at significant expense and may otherwise negatively impact our business operations. Depending on how these laws are interpreted, we may have to make changes to our business practices and products to comply with such obligations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, other countries have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Privacy and data security laws in the United States at the federal, state and local level are increasingly complex and changing rapidly. For example, at the federal level, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information. Additionally, at the state level, the privacy and data protection landscape is changing rapidly. Many states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to <span style="white-space:nowrap">opt-out</span> of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services if we become subject to these laws. For example, the California Consumer Rights Act (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) applies to personal information data of consumers, business representatives, and employees who are California residents and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain rights concerning their personal data. The CCPA provides fines for noncompliance and a limited private right of action in connection with certain data breaches. While the CCPA and other state privacy laws contains an exemption for certain personal information processed in connection with clinical trials, , these developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties with whom we work. Similar laws have been passed or are being considered in several other states, as well as at the federal and local levels. The evolving patchwork of differing state and federal privacy and data security laws increases the cost and complexity of operating our business and increases our exposure to liability, including from third party litigation and regulatory investigations, enforcement, fines, and penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are bound by contractual obligations and our efforts to comply with such obligations may not be successful. We publish privacy policies, marketing materials and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. Regulators are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations related to data privacy and security (and consumers&#8217; data privacy obligations) are quickly changing in an increasingly stringent fashion and creating uncertainty. These obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Monitoring, preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations have in the past and may in the future necessitate changes to our information technologies, systems and practices and to those of any third parties that process personal information on our behalf. In addition, these obligations may require us to change aspects of our business model. Although we endeavor to comply with applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could impact whether or not we are in compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we (or third parties with whom we work) fail, or are perceived to have failed, to address or comply with data privacy, protection and security obligations, we could face significant consequences, including (without limitation): government enforcement actions (e.g., investigations, fines, penalties, audits, inspections and similar); litigation (including class-related claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal information; orders to destroy or not use personal information; and/or imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to U.S. and certain foreign anti-corruption laws and regulations, export and import controls, sanctions and embargoes. We could face liability and other serious consequences for violations which can harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to anti-corruption laws and regulations, including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and other state and national anti-bribery laws in the countries in which we may conduct activities in the future. Anti-corruption laws are interpreted broadly and generally prohibit companies and their employees, agents, contractors and other third-party collaborators from offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly through third parties, to any person in the public or private sector to obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.&#160;We may engage third parties to sell our products or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals outside the United States.&#160;We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities.&#160;Any violation of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments and persons targeted by U.S. sanctions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors or collaborators, or those of our affiliates, will comply with all applicable anti-corruption, export and import control, and sanctions laws and regulations. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevent us from using all or a significant portion of our headquarters or other facilities, it may be difficult or, in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which could have a material adverse effect on our business. In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including raw materials and other natural resources, necessary to run our business. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legislation or other changes in U.S. tax law could adversely affect our business and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use our U.S. net operating loss carryforwards and certain other U.S. tax attributes may be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, we had U.S. federal net operating loss carryforwards of $399.3&#160;million. The amount of net operating loss carryforwards that we are permitted to deduct is limited to 80% of taxable income in each such taxable year to which the net operating loss carryforwards are applied. In addition, our U.S. federal net operating losses and tax credits may be subject to limitations under Sections 382 and 383 of the Code, if we have undergone or undergo an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in our&#160;equity ownership by certain stockholders over a rolling three-year period. We may have experienced such ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. Our net operating losses and tax credits may also be impaired or restricted under state law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to utilize our net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased tax liability to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, any necessary debt or equity financing that we undertake may be more difficult, more costly and more dilutive than it would be otherwise. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy and financial performance and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Geopolitical developments, such as the Russian invasion of Ukraine, the conflict in the Middle East or deterioration in the bilateral relationship between the United States and China, may impact government spending, international trade and market stability, and cause weaker macro-economic conditions. Certain political developments may also lead to regulatory uncertainty and to rules that may adversely affect our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred frequently in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. Compliance with new accounting standards may also result in additional expenses. As a result, we intend to invest all reasonably necessary resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we or any CDMOs and suppliers we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any CDMOs and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at third-party facilities. We could also incur significant costs associated with civil or criminal fines and penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with these laws, regulations and permitting requirements also may result in substantial fines, penalties or other sanctions or business disruption, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any third-party CDMOs and suppliers we engage will also be subject to these and other environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We incur significantly increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we incur significant legal, accounting and other expenses that Legacy Tectonic did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), as well as rules subsequently implemented by the SEC, and Nasdaq have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costlier. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Once we are no longer a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. We currently qualify as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule <span style="white-space:nowrap">12b-2</span> under the Exchange Act, which allows the us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this Quarterly Report and in our periodic reports and proxy statements. Once we are no longer a smaller reporting company or otherwise no longer qualify for these exemptions, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our common stock may be harmed. For example, if we or our independent auditor identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act, the regulations of Nasdaq, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. The Sarbanes-Oxley Act requires us to, among other things, establish corporate oversight and adequate internal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. Commencing with our fiscal year ending the year after the Merger is completed, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form <span style="white-space:nowrap">10-K</span> filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. Prior to the closing of the Merger, we were never required to test our internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner. If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholders previously filed lawsuits, which were subsequently dismissed, relating to the Merger; however, additional lawsuits could be filed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Merger, three actions were filed by purported stockholders of AVROBIO in connection with the Merger. One action has been filed in the United States District Court for the Southern District of New York captioned <span style="font-style:italic">Garofalo v. Avrobio, Inc. et al.</span>, <span style="white-space:nowrap"><span style="white-space:nowrap">24-cv-1493</span></span> (filed February&#160;27, 2024). Two actions have been filed in the Supreme Court of New York, captioned <span style="font-style:italic">Price v. Avrobio, Inc., et al.</span>, No.&#160;652555/2024 (filed May&#160;17, 2024) and <span style="font-style:italic">Keller v. Avrobio, Inc., et al.</span>, No.&#160;652597/2024 (filed May&#160;21, 2024). The foregoing actions are referred to as the &#8220;Merger Actions.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Actions generally allege that the Registration Statement (filed by AVROBIO on February 14, 2024, as amended on March 26, 2024, April 15, 2024 and April 29, 2024 (the &#8220;Registration Statement&#8221;)) misrepresents and/or omits certain purportedly material information in connection with the Merger, potential conflicts of interest of AVROBIO&#8217;s officers and directors, and the events that led to the signing of the Merger Agreement. The <span style="font-style:italic">Price</span> and <span style="font-style:italic">Keller</span> actions assert claims for breach of fiduciary duty against all defendants. The Merger Actions seek, among other things, an injunction enjoining the consummation of the Merger, rescission of the Merger if consummated, costs of the action, including plaintiff&#8217;s attorneys&#8217; fees and experts&#8217; fees and other relief the court may deem just and proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AVROBIO also received demand letters from eleven purported AVROBIO stockholders (the &#8220;Demands&#8221;). The Demands generally assert that the Registration Statement misrepresents and/or omits certain purportedly material information relating to the Merger. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AVROBIO believed that the disclosures set forth in the Registration Statement complied fully with all applicable law, that no supplemental disclosures were required under applicable law, and that the allegations in the Merger Actions and Demands were without merit. However, in order to moot the claims in the Merger Actions and Demands, avoid nuisance and possible expense and business delays, and provide additional information to its stockholders, and without admitting any liability or wrongdoing, AVROBIO decided voluntarily to supplement certain disclosures in the Registration Statement (the &#8220;Supplemental Disclosures&#8221;). On June&#160;4, 2024, AVROBIO made certain Supplemental Disclosures on Form <span style="white-space:nowrap">8-K</span> filed with the Securities and Exchange Commission. Following the issuance of the Supplemental Disclosures, each of the Merger Actions was voluntarily dismissed and each of the Demands were withdrawn. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional potential plaintiffs may file lawsuits challenging the Merger. The outcome of any current or future&#160;litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to us, including any costs associated with the indemnification of directors and officers. If a plaintiff were successful in obtaining an injunction obtaining a rescission of the Merger, then such injunction may rescind the Merger after its consummation. Regardless of the outcome, litigation can have a material and adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Ownership of Our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our common stock has been and is likely to continue to be volatile and fluctuate substantially. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock has been and is likely to continue to be highly volatile. Furthermore, the stock market in general and the market for biopharmaceutical and pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their shares at or above the price they paid for their shares. The market price of our common stock may be influenced by many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of clinical trials and preclinical studies of our product candidates, or those of our competitors or existing or future collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed financial and development projections we may provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed the financial and development projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if we do not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or departures of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant lawsuits, including patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of securities by us, the selling stockholders or other securityholders in the future; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the introduction of technological innovations or new therapies that compete with our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> fluctuations in our financial results; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the other factors described in this &#8220;Risk Factors&#8221; section. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming, and could divert our management&#8217;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sales of our common stock or the perception of such sales, by us or the selling stockholders pursuant to this prospectus, in the public market or otherwise, could cause the market price for our securities to decline, even though the selling stockholders would still realize a profit on sales at lower prices. Resales of the securities offered may cause the market price of such securities to drop significantly, even if our business is doing well. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of our common stock in the public market or otherwise, including sales pursuant to this prospectus, or the perception that such sales could occur, could harm the prevailing market price of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Resales of our common stock may cause the market price of our securities to drop significantly, even if our business is doing well. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the selling stockholders named in this prospectus acquired securities at prices that are significantly less than the current trading price of our common stock. Accordingly, certain of the selling stockholders could still realize a profit on sales at lower prices. Even if the trading price of our common stock falls to or significantly below the current trading price, selling stockholders may still have an incentive to sell and profit due to the nominal purchase prices paid by such selling stockholders, which are significantly lower than the purchase prices paid by the public stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the selling stockholders named in this prospectus hold a large portion of our outstanding common stock. The shares being offered for resale pursuant to this prospectus and our other similar prospectus by the selling stockholders represent approximately 35.7% of our outstanding common stock as of February&#160;28, 2025. Given the substantial number of shares of common stock being registered for potential resale by selling stockholders pursuant to this prospectus and our other similar prospectus, the sale of shares by the selling stockholders of a large number of shares, or the perception in the market that the selling stockholders of a large number of shares intend to sell shares, could increase the volatility of the market price of our common stock or result in a significant decline in the public trading price of our common stock. While certain of the selling stockholders may experience a positive rate of return on their investment in our common stock as a result, the public stockholders may not experience a similar rate of return on the securities they purchased due to differences in their purchase prices and the trading price. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain of our shares are subject to <span style="white-space:nowrap">lock-up</span> agreements in connection with the Private Placement. Following the expiration of these <span style="white-space:nowrap">lock-up</span> agreements, the relevant stockholders will not be restricted from selling shares our common stock held by them, other than by applicable securities laws. Stockholders not subject to these <span style="white-space:nowrap">lock-up</span> agreements will not be restricted from selling shares of our common stock held by them, other than by applicable securities laws. Common stock that is issued in connection with stock options and restricted stock units will also become eligible for sale in the public market, to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after any legal or contractual restrictions on resale lapse, the trading price of our common stock could decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The number of shares being registered for sale is significant in relation to the number of outstanding shares of our common stock. Future sales of shares by existing stockholders could cause our stock price to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&#160;28, 2025, we had approximately 18,662,672 shares of common stock outstanding. This prospectus is a part of a registration statement on Form&#160;S-1 that registers 3,689,465 shares of common stock for sale into the public market by the selling stockholders. These shares represent a significant number of our outstanding common stock, and if sold in the market all at once or at about the same time, such transactions could depress the market price of our common stock during the period the registration statement remains effective. Any such transaction could also adversely affect our ability to raise equity capital. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of shares outstanding as of December&#160;31, 2024, our executive officers, directors and principal stockholders, in the aggregate, beneficially own approximately 72% of our outstanding shares of common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect to not provide research coverage of our common stock and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have broad discretion in the use of our cash and cash equivalents and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have broad discretion over the use of our cash and cash equivalents. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to apply these resources effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds. You will not have the opportunity to influence our decisions on how to our cash resources. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we do not anticipate paying any cash dividends on our share capital in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely on an investment in our shares to provide dividend income. We have never declared or paid cash dividends on our share capital. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements or preferred equity may preclude us from paying dividends. As a result, capital appreciation, if any, of our common shares will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provisions in our charter and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our charter and bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of the Company or changes in our management. Our charter and bylaws, include provisions that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors (the &#8220;Board&#8221;) without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">create a classified board of directors whose members serve staggered three-year terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">specify that special meetings of our stockholders can be called only by the Board, the chairperson of the Board, our Chief Executive Officer or our President; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prohibit stockholder action by written consent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that our directors may be removed only for cause; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that vacancies on the Board may be filled only by a majority of directors then in office, even though less than a quorum; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">specify that no stockholder is permitted to cumulate votes at any election of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expressly authorize the Board to modify, alter or repeal our amended and restated <span style="white-space:nowrap">by-laws;</span> and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require supermajority votes of the holders of our common stock to amend specified provisions of our charter and bylaws. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the DGCL, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision of our charter, bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our bylaws contain exclusive forum provisions, which may limit a stockholder&#8217;s ability to bring a claim in a judicial forum it finds favorable and may discourage lawsuits with respect to such claims. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of breach of or based on a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (3)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; or (4)&#160;any action asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless AVROBIO consents in writing to an alternative forum, the United States District Court for the District of Massachusetts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision, as our principal executive offices are located in Watertown, Massachusetts. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize that the Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts. Additionally, these forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Section&#160;22 of the Securities Act creates a concurrent jurisdiction for state and federal courts over all suits brought concerning a duty or liability created by the securities laws, rules and regulations thereunder. While the Delaware Supreme Court and other state courts have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert the provision is unenforceable, and if the Federal Forum Provision is found to be unenforceable, we may incur additional costs with resolving such matters. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_5">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of common stock offered by the selling stockholders pursuant to this prospectus will be sold by the selling stockholders for their respective accounts. We will not receive any proceeds from any sales of shares of our common stock by the selling stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_6">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is currently listed on the Nasdaq Global Market under the symbol &#8220;TECX.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&#160;28, 2025, we had approximately 18,662,672 shares of common stock issued and outstanding, held by approximately 37 registered holders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividends </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends will be at the discretion of our Board and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our Board deems relevant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_7">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis of our financial condition and results of operations should be read together with our audited consolidated financial statements as of and for the fiscal year ended December&#160;31, 2024 and the related notes appearing elsewhere or incorporated by reference in this prospectus. This discussion and other parts of this prospectus contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results could differ materially from those described in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the &#8220;Risk Factors&#8221; section of this prospectus. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated or the context otherwise requires, references in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section to the Company, &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to the business and operations of Legacy Tectonic and its consolidated subsidiaries prior to the business combination with AVROBIO, Inc. completed on June&#160;20, 2024 (such business combination, the &#8220;Merger&#8221;), and the business and operations of Tectonic Therapeutic, Inc. (previously AVROBIO, Inc., referred to as &#8220;AVROBIO&#8221;) and its consolidated subsidiaries following the Merger. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. The discovery of biologics that can modulate GPCRs has historically been quite challenging. We have developed a proprietary technology platform called GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup>, with the aim of addressing these challenges to enable the discovery and development of GPCR-targeted biologic medicines that can modify the course of disease. We focus on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life or extend duration of life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead asset, TX45, is an <span style="white-space:nowrap">Fc-relaxin</span> fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, relaxin. In September 2024, we announced favorable results from a Phase 1a trial evaluating safety, tolerability and pharmacokinetic (&#8220;PK&#8221;) and pharmacodynamic (&#8220;PD&#8221;) properties for TX45. In this trial, TX45 was well-tolerated with no drug-related severe adverse events, no observed immunogenicity and demonstrated a favorable PK/PD relationship. Renal plasma flow was measured in each patient at several time points as a pharmacodynamic marker.&#160;This data was used to develop an exposure-response model which enabled the selection of doses for the APEX Phase 2 trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating TX45 in a Phase 1b hemodynamic clinical trial and in a Phase 2 clinical trial.&#160;Part A of the TX45 Phase 1b hemodynamic clinical trial is a single dose IV, open-label clinical trial evaluating the safety, tolerability and acute hemodynamic effects of TX45 in patients with Group 2 PH in Heart Failure with Preserved Ejection Fraction <span style="white-space:nowrap">(&#8220;PH-HFpEF&#8221;).&#160;We</span> have completed dosing of all 19 patients in the Part A of the Phase 1b trial. A preliminary analysis of hemodynamic data from 16 out of 19 patients demonstrated improvements which met and or exceeded our prespecified goals and demonstrated that TX45 both improved left heart function and pulmonary hemodynamics over the 8 hour period post dosing which was evaluated. Part B of the Phase 1b trial which is assessing acute hemodynamics effects of TX45 in patients with Group 2 <span style="white-space:nowrap">PH-HFrEF</span> is expected to enroll the first patient in the first half of 2025 with data expected to be announced in the second half of 2025.&#160;We dosed our first subject in the APEX Phase 2 clinical trial in October 2024.&#160;The APEX Phase 2 clinical trial is a global, <span style="white-space:nowrap">24-week,</span> placebo-controlled trial designed to evaluate the safety and efficacy TX45 administered subcutaneously (&#8220;SC&#8221;) in subjects with <span style="white-space:nowrap">PH-HFpEF.</span> Subjects will be randomized to 300 mg SC (2ml injection) once monthly of TX45, 300 mg SC once every other week of TX45, or placebo. We expect topline trial results from the APEX trial in 2026. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also evaluating TX002100 (&#8220;TX2100&#8221;) as our second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (&#8220;HHT&#8221;), the second most common genetic bleeding disorder with no approved therapy. TX2100 is a <span style="white-space:nowrap">VHH-Fc</span> fusion antagonist antibody that binds to an undisclosed GPCR target (&#8220;GPCR3&#8221;) which plays a key role in pathogenic angiogenesis. A rodent surrogate of TX2100 demonstrated reduced arteriovenous malformation development and bleeding in an animal model of HHT. A <span style="white-space:nowrap">4-week</span> <span style="white-space:nowrap">non-human</span> primate dose-range study with a functionally equivalent precursor to TX2100 showed no treatment-related toxicity observed at doses up to 100 mg/kg. A formulation supporting TX2100 SC dosing has been identified. Both IND enabling NHP GLP toxicology studies and technical development activities to generate GMP drug supply and drug product for TX2100 is expected to start in the second quarter of 2025.We expect to initiate a Phase 1 clinical trial for TX2100 in the fourth quarter of 2025 or the first quarter of 2026, subject to the results of IND enabling studies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Merger with AVROBIO </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;30, 2024, Legacy Tectonic entered into the Agreement and Plan of Merger and Reorganization (&#8220;Merger Agreement&#8221;) with AVROBIO and Alpine Merger Subsidiary, Inc. (&#8220;Merger Sub&#8221;). Pursuant to the Merger Agreement and the satisfaction of the conditions described in the Merger Agreement, on June&#160;20, 2024, Merger Sub merged with and into Legacy Tectonic, with Legacy Tectonic surviving as a wholly owned subsidiary of AVROBIO (the &#8220;Merger&#8221;). The Merger Agreement and the transactions contemplated therein were approved by the members of the AVROBIO Board of Directors and Legacy Tectonic Board of Directors. Subject to the terms and conditions of the Merger Agreement, at the effective time, (a)&#160;each outstanding share of Legacy Tectonic common stock (including shares of Legacy Tectonic common stock issued upon conversion of its preferred stock and the shares issued pursuant to that certain Subscription Agreement dated January&#160;30, 2024, entered into among Legacy Tectonic and the investors party thereto (the &#8220;Subscription Agreement&#8221;) and conversion of the SAFEs into the right to receive a number of shares of AVROBIO common stock equal to the exchange ratio; and (b)&#160;each then outstanding Legacy Tectonic stock option that was outstanding and unexercised immediately prior to the effective time was assumed by AVROBIO, subject to the exchange ratio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the Merger, AVROBIO securityholders as of immediately prior to the Merger owned approximately 24.8% of the outstanding shares of our capital stock on a diluted basis. Immediately after the Merger, Legacy Tectonic securityholders owned approximately 38.5% of the outstanding shares of our capital stock on a diluted basis. Investors participating in the Subscription Agreement and the SAFEs owned approximately 27.1% and 9.6% of the outstanding shares of our capital stock, respectively, on a diluted basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Tectonic stockholders received 10,956,614 shares of AVROBIO common stock in connection with the Merger, including 11,447 shares of AVROBIO common stock subject to vesting terms, based on the number of shares of Legacy Tectonic common stock outstanding immediately prior to the Merger, including Legacy Tectonic restricted stock, the number of shares of Legacy Tectonic common stock issued to investors participating in the Subscription Agreement and SAFEs, and Legacy Tectonic convertible preferred stock outstanding immediately prior to the Merger, which was converted into shares of Legacy Tectonic common stock on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis immediately prior to the closing of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Subscription Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of the Merger, on June&#160;20, 2024, certain investors completed the purchase of shares of Legacy Tectonic common stock pursuant to the Subscription Agreement for an aggregate purchase price of $96.6&#160;million. The shares of Legacy Tectonic common stock that were issued pursuant to the Subscription Agreement were converted into 4,163,606 shares of our common stock upon the closing of the Merger based on the exchange ratio, pursuant to the Merger Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of our Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the foreseeable future, if at all. If our development efforts for our product candidates are successful and result in regulatory approval, or if we enter collaboration or license agreements with third parties, we may generate revenue in the future from product sales or payments from collaboration or license agreements, or any combination thereof. We cannot predict if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs incurred for our research activities, including our discovery efforts and the development of our programs and platform. These expenses include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">employee-related expenses, including salaries and bonuses, related benefits and stock-based compensation expense, for employees engaged in research and development functions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses incurred in connection with research and the preclinical and clinical development of our programs and our product candidates, including fees paid to contract research organizations (&#8220;CROs&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to manufacturing material for our preclinical studies and clinical trials, including fees paid to contract development and manufacturing organizations (&#8220;CDMOs&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">laboratory supplies, consumables and other research materials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">facilities, depreciation and other expenses related to research and development activities, which include direct or allocated expenses for rent and maintenance of facilities, and utilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to compliance with regulatory requirements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payments made under third-party licensing agreements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on our evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense when the goods have been delivered or the services have been performed, or when it is no longer expected that the goods will be delivered or the services rendered. Upfront payments under license agreements are expensed upon receipt of the license, and annual maintenance fees under license agreements are expensed in the period in which they are incurred. Milestone payments under license or collaboration agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our direct research and development expenses relate to the development of TX45 and TX2100, as well as the nonclinical safety pharmacology and toxicology testing of our product candidates. Our external services expenses consist of the external costs and fees paid to consultants and other research laboratories in connection with our preclinical development and clinical development activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs that are deployed across multiple internal programs, including programs aimed at the discovery and development of potential therapies for fibrotic disease, and our platform technology and are not directly attributable to any single program are not allocated to any single program and, as such, are not separately </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
classified. These costs include multi-program employee-related costs, cross-program payments made under third-party licensing agreements, costs of laboratory supplies and facilities expenses, including rent, depreciation and other indirect costs, the costs of our discovery efforts and projects, and other expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#8217;s commercial potential. We will need to raise substantial additional capital in the future. Our clinical development costs are expected to increase significantly as we commence clinical trials. Our future expenses may vary significantly each period based on factors such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses incurred to conduct preclinical studies required to advance our product candidates into clinical development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">per patient trial costs, including based on the number of doses that patients received; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of patients who enroll in each trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of trials required for approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of sites included in the trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the countries in which the trials are conducted; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the length of time required to enroll eligible patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">drop-out</span> or discontinuation rates of patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential additional safety monitoring requested by regulatory agencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the duration of patient participation in the trials and <span style="white-space:nowrap">follow-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the phase of development of the product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to manufacture our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators or IRBs requiring that we or our investigators suspend or terminate clinical development for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the efficacy and safety profile of our product candidates. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of employee-related costs, including salaries and bonuses, related benefits and stock-based compensation expense, for our personnel in executive, legal, accounting, human resources and other administrative functions. General and administrative expenses also include legal fees relating to patents and corporate matters, professional fees paid for accounting, auditing, consulting and tax services, insurance, travel expenses, office and information technology costs and facilities and utilities, depreciation and other expenses related to general and administrative activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the future as we expect to incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance, and investor and public </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relations expenses associated with operating as a public company. We also expect to incur additional intellectual property-related expenses as we file patent applications to protect innovations arising from our research and development activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Income (Expense), Net </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loss on Issuance of SAFE Liabilities and Change in Fair Value of SAFE Liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October and December 2023, Legacy Tectonic issued SAFEs for proceeds of $34.1&#160;million. The SAFEs were recorded as liabilities in the Consolidated Balance Sheets at their fair value on the issuance dates. Until redemption on June&#160;20, 2024, the SAFEs were measured at a fair value on a recurring basis, with subsequent changes in fair value recorded in other income and expenses on the Consolidated Statement of Operations and Comprehensive Loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income primarily consists of interest earned on money market funds, which are included in cash and cash equivalents in the Consolidated Balance Sheets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Years Ended December&#160;31, 2024 and 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&#160;31, 2024 and 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year&#160;Ended</span><br/><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">$ Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">%&#160;Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">41,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">117</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">58,015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">44,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(58,015</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(44,648</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(13,367</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of the SAFE liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,610</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(4,865</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(388</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on issuance of SAFEs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">633</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(107</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(511</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(907</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(229</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(98</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(57,982</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(42,823</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(15,159</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:63%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year&#160;Ended</span><br/><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">$&#160;Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">%&#160;Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TX45</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(546</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TX2100</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,047</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platform development and unallocated expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related expenses, including stock-based compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,768</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External services</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab supplies and related expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,653</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other expenses, including depreciation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total platform development and unallocated expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">20,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">912</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">41,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total research and development expenses increased $4.4&#160;million for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. The increase in research and development expense was primarily the result of increased CRO and CDMO costs related to the discovery and development of TX2100. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:65%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended</span><br/><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">$&#160;Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">%&#160;Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related expenses, including stock-based compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,862</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,918</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consulting expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,009</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">220</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other expenses, including depreciation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">117</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased $9.0&#160;million for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. The increase is primarily attributable to an increase in employee-related expenses and professional and consulting expenses. Employee-related expenses increased $3.9&#160;million for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023 due to an increase in stock-based compensation for stock-based awards, the expense for the modification of certain stock options and severance costs related the reduction in force that occurred during the year ended December&#160;31, 2024. Professional and consulting expenses increased $4.8&#160;million for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. The increase in professional and consulting expenses was due to an increase in services fees to support Merger-related activities and an increase in audit, legal and administrative services to support our operations as a public company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other (Expense) Income, Net </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of SAFE Liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SAFE liabilities loss of $3.6&#160;million resulted from the remeasurement of the SAFE liabilities to fair value during the year ended December&#160;31, 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income increased by $3.7&#160;million for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023 primarily due to an increase in cash and cash equivalents as a result of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sources of Liquidity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our research programs and product candidates. We expect that our research and development and general and administrative costs will increase in connection with conducting additional preclinical studies and clinical trials for our current and future research programs and product candidates, contracting with CDMOs to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have any approved products and have never generated any revenue from product sales. We have funded our operations with proceeds from the sale of convertible preferred stock, the issuance of convertible promissory notes, the Merger, and sale of common stock. In February 2025, we sold shares of our common stock under a securities purchase agreement in exchange for gross proceeds of $185&#160;million. As of December&#160;31, 2024, we had $141.2&#160;million in cash and cash equivalents and an accumulated deficit of $148.6&#160;million. Based on our current business plans, management believes that our cash, cash equivalents and marketable securities on hand at December&#160;31, 2024 are sufficient to meet our operating requirements for at least the next 12 months from the issuance of the consolidated financial statements included in our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December 31, 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows a summary of our cash flows for the years ended December&#160;31, 2024 and 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:73%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended</span><br/><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="6"><span style="font-weight:bold">(in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(59,080</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(40,681</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(156</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(279</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">171,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">33,747</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">112,470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(7,197</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2024, cash used in operating activities was $59.1&#160;million. Cash used in operating activities was primarily used to fund our operations to develop our product candidates, resulting in a net loss of $58.0&#160;million and changes in our operating assets and liabilities of $10.3&#160;million, partially offset by <span style="white-space:nowrap">non-cash</span> charges of $9.2&#160;million related to the change in the fair value of the SAFE liabilities, stock-based compensation expense, depreciation and amortization expense and lease expense. The increase in operating assets and liabilities relates to accrued expenses for the Merger and prepayments to the CRO. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2023, cash used in operating activities was $40.7&#160;million. Cash used in operating activities was primarily used to fund our operations to development our product candidates, resulting in a net loss of $42.8&#160;million and changes in our operating assets and liabilities of $0.6&#160;million, partially offset by <span style="white-space:nowrap">non-cash</span> charges of $2.7&#160;million related to the change in the fair value of the SAFE liabilities, stock-based compensation expense, depreciation and amortization expense and lease expense. The increase in operating assets and liabilities relates to accrued expenses, timing of vendor payments, and timing of lease repayments. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2024 and 2023, net cash used in investing activities was $0.2&#160;million and $0.3&#160;million, respectively, related to purchases of property and equipment. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2024, net cash provided by financing activities was $171.7&#160;million, primarily due to net proceeds of $94.6&#160;million from the sale of shares pursuant to the Subscription Agreement, $76.0&#160;million in net proceeds and $1.6&#160;million in proceeds from the exercise of stock options. Net cash provided by financing activities during the year ended December&#160;31, 2023 was primarily due to the receipt of $34.1&#160;million of proceeds from the issuance of SAFEs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Funding Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and seek marketing approval for, our product candidates including our lead product candidate TX45 and TX2100. In addition, if we obtain marketing approval for TX45, TX2100 or any of our other product candidates, we expect to incur significant commercialization expenses related to program sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our existing cash and cash equivalents, together with the net proceeds from the Merger and the sale of securities pursuant to the Subscription Agreement, will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. Our future capital requirements will depend on many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of product discovery, preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, prioritization and number of our research and development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs, timing and outcome of regulatory review of our product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to access sufficient additional capital on a timely basis and on favorable terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of process development and manufacturing <span style="white-space:nowrap">scale-up</span> activities associated with our product candidates and other programs as we advance them through preclinical and clinical development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to establish and maintain collaborations on favorable terms, if at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the achievement of milestones or occurrence of other developments that trigger payments under the license agreements and any other collaboration agreements we enter into; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which we acquire or <span style="white-space:nowrap">in-license</span> other product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of securing manufacturing arrangements for commercial production; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of operating as a publicly traded company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the macroeconomic environment, including inflation and interest rates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of product candidates that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur additional costs associated with operating as a public company. In addition, we anticipate that we will need substantial additional funding in connection with our continuing operations. Our projections of operating capital requirements are based on our current operating plan, which includes several assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than our lease obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations&#160;&amp; Commitments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into license agreements under which we are obligated to make specified milestone and royalty payments. The payment obligations under these agreements are contingent upon future events, such as our achievement of specified development, regulatory, and sales milestones, or generating product sales. Generally, the timing or likelihood of achieving these milestones or generating future product sales are not determinable. For further details regarding our significant contracts, and the commitments and contractual obligations contained within each contract, please refer to Note 11, <span style="font-style:italic">License Agreements</span>, and Note 12, <span style="font-style:italic">Commitments and Contingencies</span>, and to our consolidated financial statements included in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have lease obligations including amounts due on leases of certain laboratory equipment and office and laboratory space under the terms of <span style="white-space:nowrap">non-cancelable</span> operating and finance leases. The leases expire at various </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
times through 2027. Minimum lease payments are $3.0&#160;million in 2025, $0.4&#160;million in 2026, and $0.1&#160;million in 2027. The commitment amounts are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Such amounts do not include obligations under agreements that we can cancel without a significant penalty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we enter into agreements in the normal course of business with vendors for preclinical research studies, clinical trials and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are generally cancelable upon written notice. Payments due upon cancellation consist only of payments for services provided and expenses incurred up to the date of cancellation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). The preparation of the consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities in our consolidated financial statements and the reported amounts of expenses during the reporting periods. We base our estimates on historical experience, known trends and events, and various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities recorded expenses that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Actual results may differ from these estimates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in the notes to our financial statements included elsewhere in this Annual Report, we believe that the following accounting policies are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Prepaid and Accrued Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our prepaid and accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a <span style="white-space:nowrap">pre-determined</span> schedule or when contractual milestones are met; however, some require advance payments. We make judgments and estimates of our prepaid and accrued research and development expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time, which includes corroboration of these estimates with the service providers. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust accrued expenses or prepaid expenses accordingly, which impact research and development expenses. To date, we have not experienced any material adjustments to our prior estimates of prepaid and accrued research and development expenses. Changes in these estimates that result in material changes to our accrued costs could materially affect our results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use the Black-Scholes-Merton (&#8220;BSM&#8221;) option pricing model. Prior to being publicly traded, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board with assistance from management and, in part, on input from an independent third-party valuation firm. The Board determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent to the Merger, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Select Market on the date of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the fair value of the Company&#8217;s stock, the estimated fair value of options granted to employees and <span style="white-space:nowrap">non-employees</span> requires a subjective estimate for the following input: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expected Volatility&#8212;The estimated volatility is determined by evaluating the average historical volatility of a peer group of companies for the period preceding the stock option grant for a term that is approximately equal to the stock options&#8217; expected term. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent accounting pronouncements are addressed in Note 2, <span style="font-style:italic">Summary of Significant Accounting Policies and Basis of Presentation</span>, in the Notes to the Consolidated Financial Statements included herein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Smaller Reporting Company Status </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of the common stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $250.0&#160;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of the common stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700.0&#160;million measured on the last business day of our second fiscal quarter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the information in this prospectus and that we provide to our investors in the future may be different than what you might receive from other public reporting companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Quantitative and Qualitative Disclosures About Market Risk </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Rate Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary exposure to market risk is related to interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. As of December&#160;31, 2024, we had cash and cash equivalents of $141.2&#160;million, which consisted of cash and money market funds. As of December&#160;31, 2024, we had an operating lease liability and a finance lease liability of $2.4&#160;million and $0.9&#160;million, respectively. Interest income and expenses are sensitive to changes in the general level of interest rates. However, due to the nature of these investments, an immediate 10% change in market interest rates would not have a material effect on the fair market value of our investment portfolio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inflation Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, we believe the effects of inflation, if any, on our results of operations and financial condition have been immaterial. We cannot assure you our business will not be affected in the future by inflation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_8">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In connection with the completion of the Merger, we changed our name from &#8220;AVROBIO, Inc.&#8221; to &#8220;Tectonic Therapeutic, Inc.,&#8221; and our business became primarily the business conducted by Legacy Tectonic. We are now a clinical stage biotechnology company focused on developing novel GPCR- targeted biologics to effectively and safely treat patients with serious medical conditions where there are currently limited or no medical options. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">As used in this Business Section, the words &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;Tectonic&#8221; refer, collectively to Tectonic Therapeutic, Inc. and its consolidated subsidiaries following completion of the Merger. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (&#8220;GPCRs&#8221;). The discovery of biologics that can modulate GPCRs has historically been quite challenging. We have developed a proprietary technology platform called GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup>, with the aim of addressing these challenges and to enable the discovery and development of GPCR-targeted biologic medicines that can modify the course of disease. We focus on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GPCRs are receptor molecules found on the surface of cells that act as sensors for various extracellular stimuli to enable communication between cells and their environment. These molecules regulate diverse aspects of human biology including blood pressure, glucose metabolism, transmission between neurons and immune surveillance. There are over 800 human genes encoding GPCRs, underscoring the extent to which human biology has relied on this molecular system for physiological control. The breadth of effects controlled by GPCRs is illustrated by the fact that greater than 30% of all approved drugs address targets in this class. The vast majority of these drugs, however, are small molecules, and their targets have been largely confined to a few GPCR subfamilies, many of which have a natural ligand that is also a small molecule. We believe there are many situations where biologics could present advantages over small molecules for this class of targets. For instance, when targeting a single member of a highly related family of GPCRs, the selectivity profile achievable with an antibody may be preferable to that of a small molecule in order to optimize the therapeutic efficacy and safety for the patient. Conversely, when multi-modal action is needed to achieve a desired physiological effect, proteins engineered for bispecific function allow for dual target engagement, unlike small molecules that are generally optimized for action on a single target. We are focused on developing biologics to address GPCRs with the goal of capturing such opportunities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It has been historically difficult to discover therapeutic proteins and antibodies that bind to and modulate the activity of GPCRs because of the low endogenous level of expression of many GPCRs, complex biochemistry and their inherent instability when removed from their natural environment in, the cell membrane. To unlock the potential for biologic therapeutics to broaden the clinical utility of GPCRs, we use our proprietary GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup><sup style="font-size:75%; vertical-align:top"> </sup>technology platform in an attempt to overcome the known challenges of GPCR-targeted drug discovery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial components of the platform, its first generation yeast library design and initial yeast selection protocols, were developed at the Harvard Medical School. However, over the last few years we have improved and modified all aspects of the platform including second and third generation library designs, optimized GPCR engineering strategies and yeast selection protocols better suited to GPCR antibody discovery. These modifications have resulted in selection campaigns that have a higher success rate with molecules that have higher affinity and potency and better biophysical properties compared to hits identified from initial antibody selection campaigns. The GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup> platform includes components aimed at optimizing the expression, purification, and stabilization of GPCRs and pairs these advances with our protein engineering and structural </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biology capabilities. While the current libraries, receptor engineering and selection strategies are producing GPCR-targeted antibodies, we continue to evolve and modify aspects of the platform, which we believe will lead to even better results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Development and Pipeline Programs </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes key information about our development programs and other pipeline programs: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g863285g09v09.jpg" alt="LOGO" style="width:6.26667in;height:3.36425in"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">TX000045 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead asset TX000045, referred to as TX45, is an <span style="white-space:nowrap">Fc-relaxin</span> fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, relaxin. Relaxin is an endogenous protein that is expressed at low levels in both men and women. In normal human physiology, relaxin is upregulated during pregnancy where it exerts vasodilatory effects, reduces systemic and pulmonary vascular resistance and increases cardiac output to accommodate the increased demand for oxygen and nutrients from the developing fetus. Relaxin also exerts anti-fibrotic effects on pelvic ligaments to facilitate delivery of the baby. Scientists have hypothesized that these unique dual aspects of relaxin biology may offer therapeutic potential in the treatment of cardiovascular disease. Unfortunately, the development of a viable therapeutic targeting <span style="white-space:nowrap">Fc-relaxin</span> has been challenging, primarily because of relaxin&#8217;s very short half-life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe TX45&#8217;s pharmacological profile, which is the direct result of applying our protein engineering capabilities, has the potential to overcome the limitations that have impeded previous attempts to develop relaxin as a therapeutic protein. We have identified Group 2 pulmonary hypertension (&#8220;PH&#8221;) in the setting of heart failure with preserved ejection Fraction (&#8220;HFpEF&#8221;) referred to as <span style="white-space:nowrap">PH-HFpEF,</span> as the initial disease in which to interrogate the therapeutic potential of relaxin. We hypothesize that treatment with relaxin could improve hemodynamics through effects on pulmonary and systemic vasodilation, cardiac diastolic dysfunction and potential remodeling in both the pulmonary vessels and the heart which could translate into a clinically meaningful improvement in exercise capacity in these patients. Clinical trials are ongoing to confirm this hypothesis. Despite this belief, our business carries substantial risks, including our limited experience in therapeutic discovery and development, and the risk that the platform may never result in the regulatory approval </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a product candidate. See &#8220;Risk Factors&#8212;Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates&#8212;We have limited experience in therapeutic discovery and development and our GEODe<sup style="font-size:75%; vertical-align:top">&#8482;</sup> platform may never result in the regulatory approval of a product candidate.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Group 2 PH is a subtype of PH which develops secondary to left heart disease (&#8220;LHD&#8221;). This is a common, chronic, life-threatening condition with complex causality for which there are presently no <span style="white-space:nowrap">FDA-approved</span> medications. <span style="white-space:nowrap">PH-HFpEF</span> is characterized by declining cardiac function, fibrotic tissue remodeling in the heart, and in some patients, fibrotic remodeling in the pulmonary vasculature as well. We have elected to prioritize development of TX45 in <span style="white-space:nowrap">PH-HFpEF</span> because of the high unmet medical need in this population and the specific physiological actions of relaxin that suggest that it could address the key pathophysiology of the disease which involves both impairment of left ventricular function and high pressures in the pulmonary arteries, and in some patients, high resistance in the pulmonary vasculature. There are no FDA approved therapies in Group 2 PH including <span style="white-space:nowrap">PH-HFpEF.</span> Furthermore, prior clinical data in patients with acute and chronic heart failure treated with a continuous infusion of a short half-life relaxin is supportive of the potential utility of relaxin administration in these patients. Clinical trials are ongoing to evaluate the hypothesis that relaxin could provide efficacy in patients with <span style="white-space:nowrap">PH-HFpEF.</span> Beyond <span style="white-space:nowrap">PH-HFpEF,</span> we believe there are additional areas where TX45 could provide benefit to patients, such as pulmonary hypertension in the setting of heart failure with reduced ejection fraction <span style="white-space:nowrap">(&#8220;PH-HFrEF&#8221;),</span> as well as with diseases that result in the chronic deterioration of lung and/or kidney function due to vasoconstriction and fibrotic remodeling. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2024, we announced favorable results from a Phase 1a trial evaluating safety, tolerability and pharmacokinetic (&#8220;PK&#8221;) and pharmacodynamic (&#8220;PD&#8221;) properties for TX45. In this trial, TX45 was well tolerated after intravenous (IV)&#160;doses ranging from 0.3mg/kg to 3 mg/kg and subcutaneous (&#8220;SC&#8221;) doses ranging from 150mg to 600mg. PK profile revealed dose proportional PK and a half-life of <span style="white-space:nowrap">14-20</span> days. PD response of TX45 on renal plasma flow (&#8220;RPF&#8221;) was assessed in each dose cohort at multiple timepoints post dose.&#160;From the multiple PK/PD measurements a robust exposure-response Emax model was developed to enable dose selection for our Phase 2 trial. Based on this exposure-response model the doses of 300 mg SC every 2 weeks and 300 mg SC every 4 weeks were chosen for the TX45 Phase 2 trial in <span style="white-space:nowrap">PH-HFpEF.</span> Both of these doses are expected to result in steady state trough exposures yielding near maximal (300mg Q4W) or maximal (300mg Q2W) pharmacodynamic effects throughout the dosing interval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 1b acute hemodynamic trial <span style="white-space:nowrap">(TX000045-002)</span> has completed enrollment in Part A which included 19 patients with <span style="white-space:nowrap">PH-HFpEF.</span> Part A included participants with both combined <span style="white-space:nowrap">pre-</span> and post-capillary PH (&#8220;CpcPH&#8221;) and isolated post-capillary PH (&#8220;IpcPH&#8221;). Top line data of Day1 hemodynamics and accumulated safety revealed that TX45 was well tolerated in this patient population after single IV doses ranging from 0.3mg/kg to 3mg/kg. There have been no serious or severe adverse events, no evidence of an immune related reaction, and no trial discontinuations. Data from an interim analysis of 16 of 19 patients reported in January 2025, showed that IV administration of TX45 resulted in significant improvements in various hemodynamic measures as assessed by right heart catheterization over the first 8 hours post dose. These improvements included the reduction in pulmonary capillary wedge pressure (&#8220;PCWP&#8221;) in the whole population and a reduction in pulmonary vascular resistance (&#8220;PVR&#8221;) in patients with CpcPH. Additionally, TX45 produced a reduction in mean pulmonary artery pressure (&#8220;mPAP&#8221;) and an increase in cardiac output and stroke volume. Part B of this trial is ongoing and plans to evaluate single IV safety and hemodynamic effects of TX45 in patients with <span style="white-space:nowrap">PH-HFrEF.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Phase 2 clinical trial, which we refer to as the APEX trial <span style="white-space:nowrap">(TX000045-003),</span> was initiated early in the fourth quarter of 2024. This trial is a Phase 2, randomized, double-blind, placebo-controlled <span style="white-space:nowrap">24-week</span> trial in <span style="white-space:nowrap">PH-HFpEF</span> patients, enriched for patients with CpcPH. In this trial, approximately 180 participants will be randomized in a 1:1:1 manner to either placebo, 300mg every 2 weeks or 300mg every 4 weeks. The primary endpoint for the Phase 2 trial is the change from baseline in PVR and a key secondary endpoint is change from baseline in PCWP. Other secondary endpoints include additional hemodynamic endpoints, change from baseline in 6 minute walk distance and change in symptoms as assessed by the Kansas City Cardiomyopathy Questionnaire (&#8220;KCCQ&#8221;).</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (&#8220;HHT&#8221;) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second program, TX2100, is aimed at the discovery and development of a GPCR targeting biotherapeutic as a potential treatment for HHT, the second-most common genetic bleeding disorder. In HHT, abnormal blood vessel formations result in telangiectasias and arterio-venous malformations or &#8220;AVMs.&#8221; These abnormal vessels are prone to spontaneous and severe bleeding that can be life-threatening. There are no currently approved therapies to treat HHT. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In HHT patients, mutations have been identified in BMP9, BMP10, Endoglin, ALK1 and SMAD4 proteins, all of which are members of a common signaling pathway. Preclinically, <span style="white-space:nowrap">knock-out</span> or inhibition of pathway members leads to increased expression of factors that drive angiogenesis and abnormal blood vessel formation that phenocopy the clinical situation. The GPCR target for our HHT program is a receptor for an angiogenic factor known to be upregulated in HHT animal models. By blocking the signaling of this receptor, we anticipate the potential for decreased bleeding resulting from the abnormal angiogenesis seen in HHT. We selected TX2100 as a development candidate. TX2100 is a <span style="white-space:nowrap">VHH-Fc</span> fusion antagonist to an undisclosed GPCR target (&#8220;GPCR3&#8221;). We intend to start IND enabling toxicology studies in the second quarter of 2025 and expect to initiate a Phase 1 clinical trial for TX2100 in the fourth quarter of 2025 or the first quarter of 2026, subject to the results of <span style="white-space:nowrap">IND-enabling</span> studies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">GPCR Modulator Bispecific for Fibrosis </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third program is aimed at the discovery and development of a potential therapy for fibrotic diseases and employs a bispecific format for the construction of a molecule with a differentiated mechanism of action. The strategy leverages two targets, one with previous human proof of concept and one novel target. Both targets are expressed on overlapping cell types with complementary and nonoverlapping modes of action that simultaneously could enhance the therapeutic potential over modulating either target on its own. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anticipated Milestones </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the next few years, we anticipate that several significant milestones could be achieved for our lead asset TX45. This includes presentation of the&#160;final data from Part A of our Phase 1b acute hemodynamic trial at a medical meeting later this year, data from Part B of the Phase 1b trial in patients <span style="white-space:nowrap">with&#160;PH-HFrEF</span> in the second half of 2025, and data from the randomized Phase 2 trial in patients with <span style="white-space:nowrap">PH-HFpEF</span> in 2026. A development candidate from our HHT program may also advance into clinical trials in the fourth quarter of 2025 or the first quarter of 2026 and could progress into efficacy trials in patients in late 2026 or early 2027. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our GEODe<sup style="font-size:75%; vertical-align:top">TM </sup>platform has been optimized over the last three years and is being used to discover biologic drugs targeting GPCRs. We are deploying our GEODe<sup style="font-size:75%; vertical-align:top">TM </sup>platform to generate additional pipeline assets by identifying and optimizing new GPCR targeted biologics that have the potential to address areas of substantial unmet need. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background on GPCRs </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GPCRs are a family of over 800 proteins found on the surface of cells throughout the body that mediate the body&#8217;s response to extracellular stimuli by initiating a series of enzymatic reactions on the inside of cells which result in changes to cellular physiology. The diversity, functional specificity and localization to particular cell or tissue types makes GPCRs an especially compelling class of drug targets. Over 30% of approved drugs spanning a wide range of therapeutic areas, including metabolic diseases, inflammation, respiratory diseases, neurology and cancer, exert their action by modulating GPCRs. The targets for these medicines, however, represent only approximately 12% of known GPCRs, leaving at least as many GPCRs that are considered druggable still unexploited. GPCRs have a complex topology which has made both the protein production and purification of GPCRs outside of their natural environment in the cellular lipid membrane, as well as the identification of viable drug candidates to target them, challenging. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background on Relaxin / RXFP1 Biology </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Relaxin is a naturally occurring peptide hormone that was first identified in 1926 in the setting of pregnancy. Relaxin is upregulated during pregnancy to allow for hemodynamic adaptation and increased cardiac output in response to the increased demands to the developing fetus and to allow for loosening of the pelvic ligaments prior to delivery. Relaxin is a member of the insulin superfamily of peptide hormones, and it consists of two peptide chains linked by disulfide bonds. Notably, activation of the RXFP1 receptor by relaxin does not result in internalization of the receptor, as is observed with many other GPCRs, which suggests there would be no receptor desensitization with chronic therapy using a relaxin-based agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Relaxin has long been of interest as a therapeutic agent for the treatment of cardiovascular disease because of its natural effects on hemodynamic function. The development of relaxin-based therapeutics, however, has been limited by the short half-life of the native peptide hormone, which necessitated continuous IV or subcutaneous administration to establish and maintain target therapeutic levels of the compound in circulation. Previous efforts to develop recombinant native human relaxin (&#8220;serelaxin&#8221;) to treat acute heart failure (&#8220;AHF&#8221;) have shown signs of clinical benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To address the pharmacological limitations of the native relaxin hormone and enable its development beyond AHF, we have engineered a single-chain <span style="white-space:nowrap">relaxin-Fc</span> fusion protein, TX45, that features differentiated pharmacokinetic and biophysical properties to enhance key pharmacodynamic properties. TX45 was developed in a subcutaneous formulation with the goal of chronic administration via intermittent subcutaneous injection. As noted above, to interrogate the therapeutic potential of relaxin, we have identified <span style="white-space:nowrap">PH-HFpEF</span> as the initial indication with an emphasis on the CpCPH subpopulation and have started to explore its potential in <span style="white-space:nowrap">PH-HFrEF</span> as well. We believe that in these settings, treatment with relaxin could improve hemodynamics and promote beneficial remodeling in both the pulmonary vessels and the heart, making it potentially ideally suited for this indication. Clinical trials are ongoing to confirm this hypothesis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background on Group 2 PH </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PH is a serious, life-threatening condition that affects hundreds of thousands of patients in the United States. In PH, the blood pressure in the pulmonary arteries is increased, exerting severe strain on the right side of the heart, which adapts poorly to the increased pressure. PH gradually causes worsening exercise capacity, shortness of breath and right-sided heart failure which can lead to death. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The World Health Organization has specified 5 different groups of PH. Group 1 PH is also known as pulmonary arterial hypertension (&#8220;PAH&#8221;) and is caused by spontaneous thickening and fibrosis of the pulmonary arteries and arterioles without underlying significant cardiac, lung parenchymal, or chronic thromboembolic disease. Group 2 PH is due to left-sided heart disease <span style="white-space:nowrap">(&#8220;PH-LHD&#8221;)</span> and is the largest group of PH. Although several Group 1 PH medications have been explored in Group 2 PH, no medications have yet been approved by the FDA for its treatment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Group 2 PH Pathophysiology and Epidemiology </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Group 2 PH is caused by left-sided heart disease, including heart failure with HFpEF, heart failure with reduced ejection fraction (&#8220;HFrEF&#8221;), and valvular heart disease (&#8220;VHD&#8221;). Group 2 PH itself consists of two disease subtypes, isolated IpcPH or CpcPH. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In patients with left-sided heart disease, whether HFpEF, HFrEF or VHD, the development of PH is associated with a much worse prognosis. In the various forms of heart failure, the heart fails to pump sufficient blood throughout the body to meet the metabolic demands of the individual. To compensate for inadequate cardiac output, the kidneys retain excess fluid to help increase the filling of the heart (&#8220;priming the pump&#8221;) during the relaxation phase of the cardiac cycle. This attempt to increase the filling of the heart leads to increased </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pressure during the relaxation phase. PH can develop in this setting when the pressure is transmitted backwards from the left atrium of the heart into the pulmonary veins and pulmonary arteries. This passive backflow of high pressure leads initially to post-capillary hypertension. These patients have a subtype of Group 2 PH called isolated post-capillary pulmonary hypertension (IpcPH). Over time this increased pressure can lead to the thickening and fibrosis of the pulmonary arteries and arterioles resulting in disease of the precapillary vasculature of the lung and this is demonstrated by increased PVR. When Group 2 PH results in both increased pulmonary artery pressures from the passive backflow of pressure from the left atrium along with intrinsic changes, such as thickening, fibrosis, and narrowing of the lumen of the pulmonary arteries, it is called Combined <span style="white-space:nowrap">pre-and</span> post-capillary Pulmonary Hypertension (CpcPH). To differentiate patients with IpcPH and CpcPH, a right heart catheterization is performed. Patients with elevated PVR, elevated pulmonary artery pressure (&#8220;PAP&#8221;) and an elevated Pulmonary Capillary Wedge Pressure (&#8220;PCWP&#8221;) have CpcPH, while those with just elevated PAP and PCWP and normal PVR have IpcPH. PH places a great strain on the right ventricle which is unable to compensate for this increased workload. Eventually, PH causes the right ventricle to dilate and fail, ultimately leading to death. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are an estimated 7.3&#160;million patients with heart failure in the United States, with HFpEF and HFrEF representing approximately 50% each of heart failure cases. We estimate the combined Group 2 PH population with HFpEF or HFmrEF (Left Ventricular Ejection Fraction between <span style="white-space:nowrap">40-50%)</span> who are NYHA Class&#160;II or III is approximately 1.4&#160;million and the prevalences of IpcPH of approximately 1&#160;million and CpcPH of approximately 0.4&#160;million using a PVR cutoff of &gt;3 Wood units. We estimate the combined Group 2 PH population, class II and III patients, with HFrEF (LVEF<span style="text-decoration:underline">&lt;</span>40%) at approximately 1.1&#160;million and the prevalences of IpcPH of approximately 0.8&#160;million and CpcPH of approximately 0.3&#160;million using a PVR cutoff of &gt;3 Wood units. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pathophysiology of <span style="white-space:nowrap">PH-HFpEF</span> and Therapeutic Potential of Relaxin </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients suffering from CpcPH typically face worse outcomes than those with IpcPH (23% survival at five years vs. <span style="white-space:nowrap">40%-50%,</span> respectively). Optimal treatment of heart failure may improve IpcPH to some extent. However, because of the specific pulmonary vascular pathology in CpcPH, treatment of heart failure alone is often insufficient to have a meaningful impact on this form of the disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several of the drugs used to treat pulmonary arterial hypertension (PAH, Group 1 PH) failed to demonstrate benefits in Group 2 <span style="white-space:nowrap">PH-HFpEF.</span> Most of these agents act as vasodilators in the lung, thereby increasing blood flow to the left side of the heart. However, pulmonary vasodilators have limited effect on left sided heart function especially diastolic function, or systemic circulation, and therefore, do not increase the ability of the left side of the heart to pump blood. This could worsen heart failure without improving exercise function. Relaxin&#8217;s hemodynamic effects are mediated both by inhibition of <span style="white-space:nowrap">endothelin-1</span> as well as activation of the nitric oxide signaling pathway. Relaxin also serves as a lusitropic agent via inhibition of SERCA2 in cardiomyocytes, which enables the heart to actively relax and fill adequately during diastole. In addition, relaxin exerts anti-fibrotic and anti-inflammatory effects via activation of metalloproteinases, inhibition of the <span style="white-space:nowrap">TGF-beta</span> pathway and inhibition of <span style="white-space:nowrap">IL-1beta</span> and <span style="white-space:nowrap">IL-6.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our support of TX45 is based upon our hypothesis that relaxin&#8217;s activities, through its pulmonary vasodilatory, remodeling and anti-fibrotic effects, may reverse the deleterious changes in the pulmonary vasculature present in CpcPH. Furthermore, relaxin&#8217;s pulmonary and systemic vasodilatory activity could unload the left ventricle, while relaxin&#8217;s anti-fibrotic and anti-inflammatory activities could promote reverse remodeling of the left ventricle in HFpEF. Lastly, relaxin&#8217;s ability to relax the heart muscle could improve diastolic filling in HFpEF where cardiac hypertrophy and fibrosis lead to diastolic dysfunction and heart failure. While we believe these benefits are most likely to be greatest in the CpCPH population, these benefits could also extend to IpcPH patients and thus to the entire <span style="white-space:nowrap">PH-HFpEF</span> population. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As depicted in the table below, we hypothesize that the inherent vasodilatory, anti-fibrotic, and anti-inflammatory activities of relaxin could be well suited to address both the pulmonary and cardiac pathologies of <span style="white-space:nowrap">PH-HFpEF.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:42%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Characteristics of Group 2 PH</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">IpcPH</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">CpcPH</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Anticipated Relaxin Effects</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Pulmonary artery narrowing, thickening, stiffening, fibrotic remodeling</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pulmonary vasodilation anti-inflammatory, anti-fibrotic</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Right ventricular dysfunction</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Right ventricular remodeling</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Thickening and stiffening of left ventricle</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Peripheral vasodilation, cardiac relaxation, left ventricular remodeling</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Compromised kidney function</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Improvement in kidney function</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Relaxin&#8217;s numerous physiologic activities, promoting vasodilation in both the systemic and pulmonary vasculature, increasing cardiac output and decreasing pulmonary capillary wedge pressure (PCWP, a measure of left ventricular diastolic function) have previously been demonstrated with serelaxin (recombinant native human <span style="white-space:nowrap">relaxin-2).</span> As reported by Ponikowski P. et al in <span style="font-style:italic">European Heart Journal </span>in 2014, patients with acute heart failure who had a right heart catheterization exhibited improved hemodynamics with relaxin treatment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background on TX45 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TX45 is a recombinant protein consisting of an engineered single chain human relaxin domain fused to the Fc domain of human immunoglobulin 1 (IgG1) using a peptide chain linker. The Fc portion of TX45 was modified to reduce Fc<span style="FONT-FAMILY:SYMBOL">g</span> receptor activation, and to increase binding to the neonatal Fc receptor (FcRn) with the goal of significantly increasing the half-life of the molecule in circulation, relative to the half-life of native human relaxin. TX45 was further engineered to reduce the isoelectric point (pI) of the molecule to enhance its pharmacokinetic properties and improve its biophysical profile. Reduction of the molecule&#8217;s pI was deemed necessary to avoid the <span style="white-space:nowrap">non-specific</span> clearance of high pI molecules from the circulation that takes place immediately following administration as a result of binding to negatively charged heparin proteoglycans on the blood vessel wall. This effect can dramatically reduce the amount of bioavailable drug to exert pharmacologic action. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">TX45 Pharmacology Studies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TX45 has been tested in several <span style="white-space:nowrap">non-clinical</span> <span style="font-style:italic">in vivo </span>PK and pharmacology studies. These include a rat renal blood flow model that is used as a PD endpoint that demonstrates the vasodilatory effects of relaxin. TX45 administration shows a dose-response and exposure-response relationship on increasing rat renal blood flow. TX45 also demonstrated a significant effect on a number of clinically relevant parameters in the rat monocrotaline-induced (MCT) model of PH. Significant reductions in pulmonary artery pressure, right ventricular hypertrophy, <span style="white-space:nowrap">NT-proBNP,</span> and pulmonary artery muscularization were demonstrated along with improvement in survival compared with control animals. The trough exposure corrected for human potency that is associated with maximal efficacy in this chronic rat model was approximately 2ug/ml. The trough exposure for maximal efficacy in this chronic model corresponds to a near maximal effect in our acute renal blood flow assay. This exposure is on the order of EC<sub style="font-size:75%; vertical-align:bottom">70</sub>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">TX45 <span style="white-space:nowrap">Non-clinical</span> Toxicology Studies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TX45 has been tested in rat and <span style="white-space:nowrap">non-human</span> primate (NHP) <span style="white-space:nowrap">1-month</span> GLP toxicology and <span style="white-space:nowrap">6-month</span> GLP toxicology studies at ITR in Canada. There is relatively low sequence homology between the active portion of TX45 and rat relaxin (approximately 50%) or NHP relaxin (approximately 73%). In the <span style="white-space:nowrap">1-month</span> GLP toxicology studies, there were no specific toxicities identified and no observable adverse effect level (NOAEL), which is the greatest dose of a drug at which no detectable adverse effects occur in an exposed population, was 100 mg/kg for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
both species. Administration of TX45 resulted in the development of anti-drug antibodies (ADAs) in some rats and monkeys, but the ADA response was most prevalent in rats receiving TX45 by subcutaneous injection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During weeks <span style="white-space:nowrap">6-9</span> of the <span style="white-space:nowrap">26-week</span> GLP chronic toxicology study in NHPs, 5/32 monkeys treated with TX45 developed monkey anti-human anti-drug antibodies. ADAs formed in these 5 animals while they were recovering from an upper respiratory infection (URI) during weeks <span style="white-space:nowrap">5-9</span> of the study. Three animals were terminated prematurely due to severe immune related reactions, two of which had measured ADAs at the time of termination. We believe the URI acted as an adjuvant to heighten the immunologic response to TX45. Only animals that had URI symptoms developed ADAs and no additional animals developed ADAs as of week 25 (out of 26) of the study. The development of ADAs was not unexpected since there is only 75% homology between human and monkey relaxin, and ADAs were previously reported in serelaxin chronic toxicology studies. There is no expected correlation between the development of ADAs against a substantially human protein administered to NHPs and the immunogenicity profile of the same protein in humans. The absence of high sequence homology between <span style="white-space:nowrap">non-clinical</span> species and human protein therapeutics is a common cause of immunogenicity in toxicology studies, particularly in longer-term studies, and does not predict immunogenicity in human clinical studies. The preclinical data for TX45 have not yet been published. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">TX45 Clinical Development Studies and Plans </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g863285g93v93.jpg" alt="LOGO" style="width:6.26667in;height:3.34578in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TX45 clinical development program was designed to provide data supporting key inflection points. <span style="white-space:nowrap">TX000045-001,</span> a first in human, single ascending dose trial, was completed in third quarter of 2024. This trial was designed to provide data on safety and tolerability, and immunogenicity as well as define the PK and PD profile of TX45 after single doses in healthy volunteers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Part A of the Phase 1b single dose acute hemodynamic trial in <span style="white-space:nowrap">PH-HFpEF</span> patients completed dosing of the 19 patients in this part of the trial. In January 2025, we reported interim data on the safety and day 1 hemodynamic effects of TX45 in 16 out of the total 19 participants in Part A. The final data is expected to be presented at an upcoming medical conference. Data from Part B of the Phase 1b trial in <span style="white-space:nowrap">PH-HFrEF</span> patients is anticipated to be reported in the second half of 2025. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first patient was enrolled in the Phase 2 <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> randomized, double-blind, placebo-controlled trial in <span style="white-space:nowrap">PH-HFpEF</span> in October 2024 and data from this trial is expected to be available in 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">pre-IND</span> consultation between us and the FDA occurred in early 2024. No significant issues were identified by the FDA with our planned clinical development strategy for TX45.&#160;The agency agreed that demonstration of an improvement in exercise capacity would be a suitable pivotal endpoint for regulatory approval. They confirmed that an appropriate endpoint for an assessment of exercise capacity would be <span style="white-space:nowrap">six-minute</span> walk distance (6MWD). Provided the Phase 1 and 2 trials result in sufficient safety and efficacy data to justify proceeding to Phase 3, the conduct of global Phase 3 pivotal trials including sites in the United States, and additional <span style="white-space:nowrap">non-clinical</span> development work including <span style="white-space:nowrap">scale-up</span> of GMP manufacturing to commercial scale would also be needed to generate the data package necessary to support regulatory approval for marketing authorization in the United States. through the submission of a Biologic License Application (&#8220;BLA&#8221;) to the FDA. We would also seek similar regulatory approvals through equivalent submissions to regulatory bodies in territories outside of the United States. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:26%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:23%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:23%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:22%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trial, Status</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trial Design</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Treatments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Subject Population and</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">TX000045-001</span> Phase 1a (Completed)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Randomized, double- blind, SAD</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TX000045 or placebo</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Single ascending IV and SC doses per clinical trial protocol: IV: 0.3mg/kg, 1mg/kg, 3mg/kg SC: 150mg, 300mg, 600mg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">47 Healthy male and female subjects</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each cohort had up to 8&#160;subjects, 6 on TX45 and 2 on placebo</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">TX000045-002</span> Phase 1b, Part A (Dosing Completed)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Open-label single dose</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">TX000045 0.3, 1, or 3&#160;mg/kg IV</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">19 patients with <span style="white-space:nowrap">PH-HFpEF</span> dosed</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">TX000045-002</span> Phase 1b, Part B (Ongoing)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Open-label single dose</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">TX000045 3 mg/kg IV</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Approximately 10&#160;patients with <span style="white-space:nowrap">PH-HFrEF</span> to be dosed</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">TX000045-003</span> Phase 2</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Ongoing)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Randomized, placebo-controlled, double-blind, repeated dose</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">TX000045 300 mg SC Q2W, 300 mg SC Q4W, or placebo</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">180 patients with <span style="white-space:nowrap">PH-HFpEF</span> to be randomized</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Completed Phase 1a Single Ascending Dose Trial <span style="white-space:nowrap">(TX000045-001)</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">TX000045-001</span> was a randomized, placebo-controlled, double-blind single ascending dose (SAD) trial in healthy volunteers which completed in the third quarter of 2024. In this trial, TX45 was well-tolerated after single IV doses ranging from 0.3mg/kg to 3 mg/kg and SC doses ranging from 150mg to 600mg. PK profile revealed dose proportional PK and a half-life of <span style="white-space:nowrap">14-20</span> days. The PD response of TX45 on RPF was assessed at multiple time points post dose for all dose cohorts. From these multiple PK/PD measurements we developed a robust exposure-response Emax model to enable dose selection for our Phase 2 study. We found the Emax effect of TX45 on RPF to be a 33% increase consistent with reported effect of relaxin from other relaxin compounds, such as Serelaxin (Voors, 2014) and Volenrelaxin (Tham, 2024). Based on our exposure-response model we selected TX45 doses for our Phase 2 trial as follows: 300mg SC every 4 weeks which is predicted to provide steady state trough exposure of approximately 2.6 ug/ml and near maximal effect on RPF at trough, and 300 mg SC every 2 weeks which is predicted to provide a trough exposure of approximately 8.7 ug/ml with&#160;maximal pharmacodynamic effects throughout the dosing interval. There was no evidence of immunogenicity or anti-drug antibodies in this trial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part A of the Acute Hemodynamic Phase 1b Trial (TX000045-002A) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">TX000045-002</span> is an open-label, single dose trial in patients with PH associated with heart failure designed to evaluate the safety, tolerability and acute hemodynamic effects of TX45 as assessed by right heart catheterization. Part A of this trial enrolled 19 patients&#160;with <span style="white-space:nowrap">PH-HFpEF,</span> including both CpcPH and IpcPH. The doses of TX45 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administered in this trial were 0.3 mg/kg IV, 1 mg/kg IV, and 3 mg/kg IV. The study evaluated safety and tolerability as well as the change from baseline in hemodynamic parameters including pulmonary capillary wedge pressure (&#8220;PCWP&#8221;) and PVR, mPAP, cardiac output (&#8220;CO&#8221;), and systemic vascular resistance (&#8220;SVR&#8221;) and additional hemodynamic measures. Notably, exposures over the first 8 hours after dosing were anticipated to be within the therapeutic range for all doses tested, therefore, it was prespecified that efficacy analyses would be done with pooling of patient data across doses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim data of 16 out of the total 19 patients, released in January 2025, revealed that TX45 administration was well-tolerated in <span style="white-space:nowrap">PH-HFpEF</span> patients. No serious adverse events or severe adverse events were reported in this cohort. The interim data analysis from the first 16 (of 19 in total) patients TX45 administration significantly reduced PCWP in the overall group, and significantly reduced PVR in patients with CpcPH. In addition, TX45 administration raised CO and stroke volume and reduced Total Pulmonary Resistance (TPR) and mPAP in the overall group. The chart below summarizes our findings: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g863285g96v96.jpg" alt="LOGO" style="width:6.28333in;height:3.44521in"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Ongoing Part B of the Phase 1b Acute Hemodynamic Trial (TX000045-002B) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Part B of the Phase 1b acute hemodynamic open-label trial in patients with <span style="white-space:nowrap">PH-HFrEF,</span> including both IpcPH and CpcPH, is currently being conducted. In this trial, approximately 10 patients with <span style="white-space:nowrap">PH-HFrEF</span> will receive a single IV dose of TX45 and hemodynamics will be monitored by right heart catheterization for 8 hours after dosing. We enrolled the first patient in the Part B Phase 1b trial in March 2025, and expect topline trial results in the second half of 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Ongoing Phase 2 Proof of Concept, Randomized, Placebo-Controlled, Double-Blind Trial in <span style="white-space:nowrap">PH-HFpEF</span> <span style="white-space:nowrap">(TX000045-003)</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ongoing Phase 2 randomized, placebo-controlled, double-blind <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> (POC) clinical trial in patients with <span style="white-space:nowrap">PH-HFpEF</span> is being conducted globally. In this trial, patients with <span style="white-space:nowrap">PH-HFpEF</span> are randomized to receive TX45 or placebo for 6 months. Two dose regimens of TX45 will be administered: 300 mg SC Q2W or 300 mg SC Q4W. Prior to dosing, right heart catheterization will be performed to determine baseline hemodynamics. After 6 months of treatment, patients will undergo a second right heart catheterization. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
primary endpoint is change from baseline in PVR in patients with CpcPH. The key secondary endpoint is change from baseline in PCWP in all subjects. Additional endpoints will include change from baseline in 6MWD, change from baseline in the Kansas City Cardiomyopathy Questionnaire score and change from baseline in additional hemodynamic parameters including cardiac output, mean pulmonary pressure, systemic vascular resistance and stroke volume and biomarkers such as <span style="white-space:nowrap">NT-proBNP.</span> Changes in relevant echocardiographic endpoints will also be explored. This trial enriches for patients with CpcPH based on baseline right heart catheterization with the goal of evaluating efficacy in both CpcPH as well as the whole population with <span style="white-space:nowrap">PH-HFpEF.</span> We currently expect that approximately 180 subjects will be enrolled in this trial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Group 2 PH with HFpEF Anticipated Pivotal Development Pathway </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the results of our Phase 2 trials and feedback received during the End of Phase 2 meeting with the FDA, we expect to initiate a randomized, placebo-controlled, double-blind Phase 3 clinical trial in Group 2 PH patients with HFpEF, as well as long term, open label extension trial for safety evaluation. Based on historical precedent across multiple PH subtypes and our <span style="white-space:nowrap">Pre-IND</span> consultation with the FDA regarding the specific requirements for approval in Group 2 PH with HFpEF, we believe that the achievement of a clinically significant change in a functional endpoint, such as <span style="white-space:nowrap">6-minute</span> walk distance could be sufficient for approval. The secondary endpoints may also include change from baseline to week 24 in: <span style="white-space:nowrap">KCCQ-12</span> score, and the percentage who improve in WHO functional class. An additional secondary endpoint may be the time to the first occurrence of a clinical worsening event or death and changes in relevant echocardiographic endpoints and biomarker endpoints such as NTproBNP. At this time, we do not anticipate that an assessment of TX45&#8217;s impact on long-term cardiovascular outcomes will be a requirement for approval. Commercialization in the United States and other countries will be contingent on approval by the regulatory authorities (the FDA in the United States) and an assessment by the regulators that the studies were conducted in accordance with accepted guidance and the data demonstrated that there was a positive benefit risk for patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background on HHT Opportunity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is the second most common genetic bleeding disorder. It has been estimated that there are approximately <span style="white-space:nowrap">70,000-75,000</span> HHT patients in the USA and it has also been estimated that up to <span style="white-space:nowrap">15-20%</span> of them have severe disease. Symptoms of this disorder typically arise in late teenage years or older, and the most common manifestation is recurrent epistaxis (nosebleeds), or gastrointestinal bleeding, that can be severe in some patients, requiring iron infusions or blood transfusions, Epistaxis is typically due to abnormal small blood vessels (telangiectasias) in the nasal mucosa. Patients with HHT can also develop large arterio-venous malformations (AVMs) in various organs, such as the brain, liver and lung. The presence of liver AVMs can lead to high output heart failure. AVMs can spontaneously bleed on occasion with potentially devastating results. While some AVMs can be treated by radiologic embolization, such as AVMs in the lung, others cannot, especially in the liver. Indeed, for patients with prominent liver AVMs, the only therapeutic option may be transplantation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are no approved medical therapies for HHT, anti-VEGF therapies including bevacizumab have been used on an <span style="font-style:italic">ad hoc </span>basis with results demonstrating that anti-angiogenic therapy has the potential to be an efficacious treatment. These therapies reduce angiogenesis and bleeding in mouse models of HHT. Importantly, these data have translated to the clinic: small investigator-sponsored trials in HHT patients demonstrated reduced epistaxis episodes and reduced transfusion dependence. The effects of anti-VEGF therapy suggest that targeting an alternative pathway, similar to the VEGF-VEGFR pathway in its ability to more specifically regulate angiogenesis, could be a productive strategy to address HHT. In addition to bevacizumab, pazopanib, a tyrosine kinase inhibitor, has been explored in small investigator-initiated studies with preliminary evidence of clinical benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HHT is a genetic disorder due to <span style="white-space:nowrap"><span style="white-space:nowrap">loss-of-function</span></span> mutations in proteins in the <span style="white-space:nowrap">BMP9/10-Endoglin-ALK1-</span> SMAD4 signaling pathway. BMP9 is a member of the <span style="white-space:nowrap">TGF-beta</span> family of growth factors that regulate blood </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vessel development. &#8220;GPCR3&#8221; (the specific GPCR target is not disclosed at this stage) and its ligand (&#8220;L3&#8221;) have been described to play a role in angiogenesis and AVM formation. Expression of L3 is also upregulated in HHT disease models and likely contributes to the development of abnormal blood vessels. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Development Candidate for the Treatment of HHT </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We identified TX2100 as a development candidate for the treatment of HHT. TX2100 is a <span style="white-space:nowrap">VHH-Fc</span> fusion antagonist antibody that binds to &#8220;GPCR3&#8221;. The Fc portion of TX2100 was modified to reduce Fc<span style="FONT-FAMILY:SYMBOL">g</span>receptor activation and to increase binding to FcRn, in order to extend the half-life of the molecule. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pharmacology Studies with Animal Models of HHT </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several murine models of HHT have been established. These include both genetic <span style="white-space:nowrap"><span style="white-space:nowrap">loss-of-function</span></span> models that disrupt the <span style="white-space:nowrap">BMP9/10-Endoglin-ALK1-SMAD4</span> signaling pathway at different points, and the BMP9/10 immunoblocked model. In these murine models of HHT, anti-VEGF or anti-VEGF receptor agents reduce AVM formation and bleeding. As referenced above, since bevacizumab, an anti-VEGF monoclonal antibody, has been shown to have a clinical impact in HHT patients at reducing epistaxis, the mouse models appear to be predictive of these human impacts. Despite these signs of clinical utility, neither bevacizumab nor small molecule VEGF receptor inhibitors have been approved for the treatment of HHT, and they are not widely used likely because of the lack of approval, concerns about toxicity and lack of adequate information about dose. We established a pharmacodynamic model of neonatal murine retinal angiogenesis. In this model, treatment with a potent mouse &#8220;GPCR3&#8221; <span style="white-space:nowrap">Nanobody-Fc</span> antagonist reduces <span style="white-space:nowrap">neo-angiogenesis</span> and the vascularized area in the neonatal mouse retina. We have also established the <span style="white-space:nowrap">BMP9/10-immunoblocked</span> mouse model of HHT. This model reliably leads to the development of hypervascularization, AVMs and bleeding in organs including the eye, GI tract and brain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this model, our &#8220;GPCR3&#8221; antagonist significantly reduces both arteriovenous malformations formation (AVM) and retinal hypervascularization induced by BMP9/BMP10 blockade to a similar degree as a VEGF antagonist. In addition, &#8220;GPCR3&#8221; antagonism significantly reduced bleeding as measured by reduced drop in hemoglobin compared to an isotype control antibody. This demonstrates that pharmacologic inhibition of &#8220;GPCR3&#8221; provides significant effects on endpoints relevant to HHT patients. Additional <span style="font-style:italic">in vivo </span>studies characterizing the effects of &#8220;GPCR3&#8221; antagonism on additional HHT relevant vascular pathology endpoints in mice are planned. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical Development Plans </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 1 program for TX2100 would consist of a randomized, placebo-controlled, double-blind ascending-dose trial performed in healthy volunteers. Likely primary endpoints would be the safety and tolerability of TX2100 in these subjects, and likely secondary endpoints would be the pharmacokinetic properties of TX2100. Assuming adequate PK and safety are established in Phase 1, we intend to conduct efficacy trial(s) including a Phase 2 randomized, placebo-controlled, double-blind <span style="white-space:nowrap">6-month</span> proof of concept (POC) trial in HHT patients with frequent epistaxis and anemia. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background on GEODe<sup style="font-size:75%; vertical-align:top">TM </sup>Platform </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our GEODe<sup style="font-size:75%; vertical-align:top">TM </sup>platform has the potential to advance the field of biologic drugs targeted to GPCRs. To date, only 12% of the more than 800 GPCRs in the human body have been successfully translated into targets for approved therapeutics with biologics representing only three of those approvals. GPCRs have proven to be elusive targets for biologics largely due to their dynamic structure and expression levels in the plasma membrane and the difficulty of translating them in a functional form outside of their native lipid microenvironment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of successful GPCR targeted therapeutics to date are small molecules, however, the success of this modality has been largely confined to just 6 GPCR subfamilies, many of which have a natural ligand that is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also a small molecule. Establishing and maintaining target engagement and selectivity, therefore, for small molecules has proven challenging for receptors of increased size and complexity, greater sequence homology in ligand binding sites, or where subfamilies have overlapping ligands. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GEODe<sup style="font-size:75%; vertical-align:top">TM </sup>was developed with the aim of addressing the challenges of GPCR targeted biologics via a combination of (1)&#160;GPCR protein engineering strategies that stabilize the pharmacologically relevant forms of the receptor and increase the cell surface receptor expression, enabling purification and formulation of the receptor at scale and in the correct conformation for na&#239;ve antibody selection campaigns; (2)&#160;using an optimized cell free yeast display platform with proprietary, highly diverse Fab and VHH antibody libraries designed to target GPCRs; and (3)&#160;structure-guided protein engineering strategies to identify optimal GPCR targeted biologics. The original platform technology was developed in Dr.&#160;Andrew Kruse&#8217;s lab at Harvard. This platform technology included yeast display selection protocols, first generation Fab and VHH library designs and protocols to detergent solubilize GPCRs. Our team has made significant changes and modifications to the original platform to optimize the quality of the molecules emerging from its na&#239;ve selections and affinity maturations including optimization of its receptor design strategy, the design of its naive and affinity maturation libraries and of the yeast display selection protocols. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of Our Expertise in GPCRs and mAb Discovery </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our optimized GPCR-targeted antibody discovery process comprises the following steps: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <span style="font-weight:bold">Optimization, stabilization, and formulation of GPCRs </span>using proprietary protein engineering and biochemistry techniques, to produce sufficient target material in the correct conformation, as a reagent for discovery campaigns. We use structure-based homology modeling and prediction to engineer changes to the receptor that can bias it into an active or inactive state. These changes can also increase receptor cell surface expression and stability. Also, because the lipid bilayer surrounding a receptor can strongly affect its activation, we have developed techniques to present our targets in a variety of different membrane mimetics that recapitulate the lipid bilayer environment that the receptor is embedded in. We have also taken a machine learning guided protein engineering approach to generate <span style="white-space:nowrap">G-protein</span> mimetics that can stabilize GPCRs in their active state conformation. This stabilized protein complex can be used to discover agonist antibodies during yeast display selection campaigns. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="font-weight:bold">Optimized and streamlined yeast display antibody selection protocols </span>that minimize false positive hits from <span style="white-space:nowrap">non-specific</span> binders and can productively pull initial hits from antibody discovery campaigns. We employ antibody libraries designed and optimized for targeting GPCRs, novel tagging strategies, and make extensive use of automated workflow. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <span style="font-weight:bold">High throughput GPCR binding assessment </span>to confirm binding of purified antibodies to the target of interest. This step enables rapid narrowing of the set of initial hits to focus on the best hits merging from the selection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <span style="font-weight:bold">GPCR signaling assays </span>to confirm that hits which were identified in the selection campaign and confirmed as target selective binders, are also functionally active to modulate signaling through the target of interest. We have implemented a wide range of signaling assays that can support characterization of hits against different GPCR targets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <span style="font-weight:bold">Antibody lead optimization </span>via affinity maturation to further improve either potency, selectivity, cross-species reactivity, developability and manufacturability characteristics or any combination of the above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Collaboration, License and Services Agreements</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Harvard Option and License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2020, Legacy Tectonic entered into an agreement with the President and Fellows of Harvard College (&#8220;Harvard&#8221;), for an option fee in the low five digits, whereby Harvard granted Legacy Tectonic an exclusive option to negotiate a worldwide, exclusive, royalty-bearing license under Harvard&#8217;s interest in the patent rights covering certain technology that was developed by Harvard. In October 2021, Legacy Tectonic exercised the option and on February&#160;10, 2022, entered into a license agreement (&#8220;License Agreement&#8221;) with Harvard to conduct research and development activities using certain materials, technology and patent rights owned by Harvard, with the intent to develop, obtain regulatory approval for, and commercialize products. The License Agreement will remain in effect until the expiration of the last valid claim within the patent rights covering a product developed under the License Agreement or the termination of the License Agreement. As consideration for the License Agreement, we paid Harvard a <span style="white-space:nowrap">one-time</span> license fee of $170,000 and issued 227,486 shares of common stock with a fair market value of $0.4&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are responsible for payment of (1)&#160;annual maintenance fees ranging from the low five digits to the low six digits during the term of the License Agreement (through the first commercial sale of a royalty-bearing product); (2) royalty payments as a percentage in the low single digits of the annual net sales that we generate from products that utilize the license technology (&#8220;Licensed Products&#8221;) and royalty payments as a percentage in the low single digits of the annual net sales that we generate <span style="white-space:nowrap">from&#160;know-how&#160;enabled</span> product licenses <span style="white-space:nowrap">(&#8220;Know-How</span> Enabled Products&#8221;) and (3)&#160;a percentage <span style="white-space:nowrap">between&#160;10-20%&#160;of</span> <span style="white-space:nowrap">all&#160;non-royalty&#160;income</span> received by us under sublicenses, strategic partnerships <span style="white-space:nowrap">and&#160;know-how&#160;enabled</span> product licenses that utilize the license technology. Subsequent to the first commercial sale of a royalty-bearing product, annual maintenance fees will increase to a low six digits for the remainder of the term of the License Agreement. The royalty term from sales of Licensed Products will terminate on <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;country-by-country&#160;and&#160;product-by-product&#160;basis</span></span></span></span> on the earlier of (i)&#160;the expiration of the patent rights covering the product, expected to be no earlier than May 2041, and (ii)&#160;the termination of the License Agreement. The royalty term from sales <span style="white-space:nowrap">of&#160;Know-How&#160;Enabled</span> Products will terminate on the earlier of (i)&#160;ten years after the first commercial sale of the <span style="white-space:nowrap">first&#160;Know-How&#160;Enabled</span> Product and (ii)&#160;twelve years after the first commercial sale of the first Licensed Product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">WuXi Master Development and Manufacturing Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;6, 2022, we entered into a development and manufacturing agreement (the &#8220;WuXi Biologics Manufacturing Agreement&#8221;) with WuXi Biologics. The WuXi Biologics Manufacturing Agreement governs the general terms under which WuXi Biologics, or one of its affiliates, will provide biologics development and manufacturing services as specified by us on <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;project-by-project&#160;basis.</span></span> Such services are performed under agreed-upon work orders. Under the terms of the WuXi Biologics Manufacturing Agreement, we have agreed to pay fees for WuXi Biologics&#8217; performance of services in addition to reimbursing WuXi Biologics for reasonable expenses authorized by us and as provided in each applicable work order. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of the WuXi Biologics Manufacturing Agreement will expire on the later of May&#160;6, 2025, or the completion of the services under all work orders executed by the parties prior to May&#160;6, 2025, provided that the term may be extended by us for additional periods. We will have the right to terminate the WuXi Biologics Manufacturing Agreement or any work order upon thirty days&#8217; prior written notice or immediately if, in our reasonable judgment, WuXi Biologics is or will be unable to perform the Services or WuXi Biologics fails to obtain or maintain any necessary licenses or approvals. Either party may terminate the WuXi Biologics Manufacturing Agreement or any work order if the other party files for bankruptcy, fails to cure a material breach during the cure period or a force majeure event that has lasted for the time period specified within the WuXi Biologics Manufacturing Agreement. WuXi Biologics has the right to terminate if the parties are unable to reach an agreement on an amendment to the services if such services become impossible due solely to changes in applicable law. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The WuXi Biologics Manufacturing Agreement includes customary terms relating to, among others, indemnification, intellectual property protection, confidentiality, remedies and warranties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Novotech Master Clinical Contract Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2023, we entered into a master clinical contract services agreement (the &#8220;Novotech CSA&#8221;) with Novotech (Australia) Pty Limited (&#8220;Novotech&#8221;). The Novotech CSA governs the general terms under which Novotech, or one of its affiliates, will provide clinical development related services (excluding manufacturing services) as specified by us on <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;project-by-project&#160;basis.</span></span> Such services are performed under agreed statements of work. Under the terms of the Novotech CSA, we have agreed to pay fees for Novotech&#8217;s performance of services in addition to reimbursing Novotech for reasonably incurred, pass through costs agreed to by us and as provided in each applicable statement of work. Additionally, under the terms of the Novotech CSA, all documentation, information, and biological, chemical or other materials controlled by us and furnished to Novotech by or on behalf of us shall remain our exclusive property, and we shall own all rights to, and Novotech shall assigns all right, title and interest to, all inventions, discoveries, improvements, ideas, processes, formulations, products, co computer programs, works of authorship, databases, trade <span style="white-space:nowrap">secrets,&#160;know-how,&#160;information,</span> data, documentation, reports, research, creations and all other products and/or materials arising from or made in the performance of Novotech&#8217;s service, except for Novotech&#8217;s background intellectual property rights as defined under the Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of the Novotech CSA will expire on the later of (i)&#160;five years from the effective date of the Novotech CSA, or March 2028, or (ii)&#160;the completion of the services under all statements of work executed prior to the fifth anniversary of the effective date of the Novotech CSA, or March 2028. We may terminate the Novotech CSA or any statement of work thereunder immediately if Novotech has committed an uncurable breach or has failed to cure a breach after thirty days&#8217; written notice. We may also terminate the Novotech CSA or any statement of work thereunder for any reason upon thirty days&#8217; prior written notice to Novotech. Novotech may terminate the Novotech CSA or any statement of work thereunder immediately if we have failed to cure a material breach after thirty days&#8217; written notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Novotech CSA includes customary terms relating to, among others, indemnification, intellectual property protection, <span style="white-space:nowrap">confidentiality,&#160;non-solicitation,&#160;remedies</span> and warranties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ARENSIA Master Agreement for Early Phase Clinical Services </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2023, we entered into a master agreement for early phase clinical services (the &#8220;Arensia CSA&#8221;) with ARENSIA Exploratory Medicine GmbH (&#8220;Arensia&#8221;). The Arensia CSA governs the general terms under which Arensia, or one of its affiliates, will provide early phase clinical research services in connection with clinical research programs as specified by us on <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;project-by-project&#160;basis.</span></span> Such services are performed under agreed work orders. Under the terms of the Arensia CSA, we have agreed to pay fees for Arensia&#8217;s performance of services in addition to reimbursing Arensia <span style="white-space:nowrap">for&#160;pre-approved,&#160;reasonable</span> expenses actually and necessarily incurred by Arensia as specified in each applicable work order. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of the Arensia CSA will expire on the later of: (i)&#160;five years from the effective date of the Arensia CSA, or October 2028, or (ii)&#160;the completion of the services under all work orders executed prior to the fifth anniversary of the effective date of the Arensia CSA, or October 2028. Work orders shall expire upon the completion of the services specified thereunder, provided that we may terminate a work order if the study governed by such work order is suspended for more than thirty days and either party may terminate a work order for reasonable scientific safety reasons. We may terminate the Arensia CSA in its entirety for any reason upon thirty days&#8217; prior written notice to Arensia. Either party may terminate the Arensia CSA or any statement of work thereunder immediately if the other party has failed to cure a material breach after thirty days&#8217; written notice or for the other party&#8217;s insolvency. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Arensia CSA includes customary terms relating to, among others, indemnification, intellectual property protection, confidentiality, remedies and warranties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">QPS Holdings Master Contract Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2023, we entered into a master contract services agreement (the &#8220;QPS Agreement&#8221;) with QPS Holdings, LLC (&#8220;QPS&#8221;). The QPS Agreement governs the general terms under which QPS, or one of its affiliates, will provide services (excluding GMP manufacturing and clinical development related services) as specified by Tectonic on <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;project-by-project&#160;basis.</span></span> Such services are performed under agreed statements of work. Under the terms of the QPS Agreement, Tectonic has agreed to pay for QPS&#8217;s performance of the services as specified in the applicable statement of work. Additionally, under the terms of the QPS Agreement, all documentation, information, and biological, chemical or other materials controlled by Tectonic and furnished to QPS by or on behalf of Tectonic shall remain the exclusive property of Tectonic, and Tectonic shall own all rights to, and QPS shall assigns all right, title and interest to, all inventions, discoveries, improvements, ideas, processes, formulations, products, co computer programs, works of authorship, databases, trade <span style="white-space:nowrap">secrets,&#160;know-how,&#160;information,</span> data, documentation, reports, research, creations and all other products and/or materials arising from or made in the performance of QPS&#8217;s services. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of the QPS Agreement will expire on the later of: (i)&#160;two years from the effective date of the QPS Agreement, or October 2025, or (ii)&#160;the completion of the services under all work orders executed prior to the second anniversary of the effective date of the QPS Agreement, or October 2025. Tectonic may terminate the QPS Agreement or any statement of work thereunder for any reason upon thirty days&#8217; prior written notice or immediately if QPS commits an uncurable breach of the QPS Agreement. QPS may terminate the QPS Agreement or any statement of work thereunder if Tectonic has failed to cure a material breach after thirty days&#8217; written notice or may terminate the QPS Agreement for any reason upon sixty days&#8217; prior written notice provided there are no active statements of work outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The QPS Agreement includes customary terms relating to, among others, indemnification, intellectual property protection, confidentiality, remedies and warranties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio includes three pending U.S. <span style="white-space:nowrap">non-provisional</span> applications, one pending international (Patent Cooperation Treaty) application, and nineteen pending foreign applications relating to <span style="white-space:nowrap">Fc-relaxin</span> fusion protein compositions (including TX45) and methods of use thereof. Specifically, we have exclusively <span style="white-space:nowrap">in-licensed</span> one patent family from the President and Fellows of Harvard College and wholly own two patents families, relating <span style="white-space:nowrap">Fc-relaxin</span> fusion protein compositions (including TX45) and methods of use thereof. The <span style="white-space:nowrap">in-licensed</span> patent family consists of one pending U.S. <span style="white-space:nowrap">non-provisional</span> patent application and nine pending foreign applications in Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico, and Singapore, with any patent issuing from these applications having an expected <span style="white-space:nowrap">20-year</span> expiry date of not earlier than May 2041. The first wholly owned patent family consists of one pending U.S. <span style="white-space:nowrap">non-provisional</span> patent application and nine pending foreign applications in Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico, and Singapore, with any patent issuing from these applications having an expected <span style="white-space:nowrap">20-year</span> expiry date of not earlier than November 2042, and the second family consists of one pending Patent Cooperation Treaty application, one pending U.S. <span style="white-space:nowrap">non-provisional</span> patent application, and one pending foreign application in Taiwan, with any patent issuing from </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these applications having an expected <span style="white-space:nowrap">20-year</span> expiry date of not earlier than May 2044. Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective <span style="white-space:nowrap">non-provisional</span> filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product by product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we rely upon trade secrets and <span style="white-space:nowrap">know-how</span> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <span style="white-space:nowrap">know-how</span> and inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or its product candidates or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future product candidates may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March&#160;16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. For more information, please see &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related to Intellectual Property</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sales and Marketing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our lead product candidate TX45. We currently rely, and expect to continue to rely for the foreseeable future, on third-party contract development and manufacturing organizations (&#8220;CDMOs&#8221;) to produce our product candidates for preclinical and clinical testing, as well as for future commercial manufacture of any products that we may commercialize. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We require our CDMOs to conduct manufacturing activities in compliance with Current Good Manufacturing Practices (&#8220;CGMPs&#8221;) requirements. We have assembled a team of experienced employees and consultants to provide the necessary technical, quality and regulatory oversight over its CDMOs. Currently, we contract with two third-party manufacturers, including WuXi Biologics, to provide biologics development and manufacturing services </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for our product candidates. In the future, we may engage additional third-party manufacturers to support any clinical trials for TX45 and TX2100 as well as commercialization of TX45, if approved, in the United States or other jurisdictions or the clinical development and potential commercialization of additional programs from our pipeline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on WuXi Biologics to perform all chemistry, manufacturing, and controls (&#8220;CMC&#8221;) activities related to our TX45 program. We require that WuXi Biologics produces bulk drug substances and finished drug products in accordance with CGMPs, and all other applicable laws and regulations. In addition, we rely on WuXi Biologics to operate facilities that meet regulatory requirements for production and testing of clinical and commercial products and to work closely with us to validate manufacturing processes prior to commercial launch. We oversee WuXi Biologics by performing technical and quality assurance review and/or approval of CGMP documentation, establishing quality agreements to define responsibilities and expectations for goods and services, and observing production and testing activities, among other activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense competition and a strong emphasis on intellectual property. We believe that our approach, strategy, scientific capabilities, <span style="white-space:nowrap">know-how</span> and experience provide us with competitive advantages. However, we expect substantial competition from multiple sources, including major pharmaceutical, specialty pharmaceutical, and existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research institutions worldwide. Many of our competitors, either alone or with their collaborations, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face competition from companies that are pursuing development of engineered proteins or small molecule agonists of relaxin including AstraZeneca, who is currently conducting Phase 2 trials. To our knowledge, Astra Zeneca is pursuing either the broader Heart Failure population or Group 2 PH in the setting of either HFpEF or HFrEF without enrichment for CpCPH patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the HHT space, Vaderis has been pursuing development of an oral AKT inhibitor and Diagonal Therapeutics has been pursuing agonist antibodies for the treatment of this condition. Investigator-initiated studies of nintendanib (Boehringer Ingelheim) and pazopanib (Novartis) are also ongoing to explore the potential utility of these kinase inhibitors to treat this condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our focus on biologic drugs differentiates us from many competitor GPCR companies whose primary focus is on small molecule drug discovery. Additionally, our GPCR membrane protein biochemistry experience, which is key for generating optimally stabilized and formulated receptors for antibody selection campaigns, combined with our experience using novel antigen formats differentiates us from in vitro display based antibody discovery. Specifically, our use of membrane mimetics that help maintain native receptor extra-cellular domain conformations combined with the membrane protein biochemistry expertise that we have built over the last three years is a key point of potential differentiation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several other companies are focused on discovery of GPCR-targeted therapeutics. Some may have an emphasis on small molecule approaches (Septerna, SOSEI-Heptares, Structure Therapeutics), on alternative biologic efforts (Abalone Bio, Orion Biotechnology), both (Abilitia Bio, Confo Therapeutic, Orion Biotechnology, Omeros), or on specific targets or target classes (GPCR Therapeutics). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of pharmaceutical products, including biological products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Licensure and regulation of biologics in the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, any product candidates we may develop would be regulated as biological products, or biologics, under the Public Health Service Act (&#8220;PHSA&#8221;) and the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The failure to comply with the applicable U.S. requirements at any time during the product development process, including preclinical testing, clinical testing, the approval process, or post-approval process, may subject an applicant to delays in the conduct of the study, regulatory review and approval and/or administrative or judicial sanctions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An applicant seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preclinical laboratory tests, animal studies and formulation studies performed in accordance with the FDA&#8217;s applicable Good Laboratory Practices (&#8220;GLP&#8221;) regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of the manufacture, under current good manufacturing practices (&#8220;CGMP&#8221;) conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an independent IRB representing each clinical site before each clinical trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance with current good clinical practices (&#8220;GCP&#8221;) regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation and submission to the FDA of a BLA for a biological product requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review of the product by an FDA advisory committee, where appropriate or if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with CGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payment of Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) fees, securing FDA approval of the BLA and licensure of the new biological product; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) and any post-approval studies or other post- marketing commitments required by the FDA. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preclinical studies and investigational new drug application </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any biological product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin or recommence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, submission of the IND may result in the FDA not allowing the trial to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial <span style="white-space:nowrap">30-day</span> period, or at any time during the IND review process, it may choose to impose a partial or complete clinical hold. Clinical holds are imposed by the FDA whenever there is concern for patient safety, may be a result of new data, findings, or developments in clinical, preclinical and/or chemistry, manufacturing and controls or where there is <span style="white-space:nowrap">non-compliance</span> with regulatory requirements. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed, and the FDA has notified the company that investigations may proceed. This could cause significant delays or difficulties in completing our planned clinical trials or future clinical trials in a timely manner. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Human clinical trials in support of a BLA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in order to use the trial as support for an IND or application for marketing approval. Specifically, the FDA requires that such trials be conducted in accordance with GCP, including review and approval by an independent ethics committee and informed consent from participants. The GCP requirements encompass both ethical and data integrity standards for clinical trials. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in <span style="white-space:nowrap">non-IND</span> foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that <span style="white-space:nowrap">non-IND</span> foreign trials are conducted in a manner comparable to that required for clinical trials in the United States. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board (&#8220;DSMB&#8221;). This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB has access. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 1 </span>clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 2 </span>clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 3 </span>clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are referred to as &#8220;pivotal.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about applicable clinical trials must be submitted within specific timeframes to the National Institutes of Health (&#8220;NIH&#8221;) for public dissemination on its <span style="font-style:italic">ClinicalTrials.gov </span>website. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric studies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act of 2003 (&#8220;PREA&#8221;), a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compliance with CGMP requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with CGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with CGMPs and other laws. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Review and approval of a BLA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product candidate development, preclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject to a substantial application user fee. The sponsor of a licensed BLA is also subject to an annual program fee. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has 60 days after submission of the application to conduct an initial review to determine whether it is sufficient to accept for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission has been accepted for filing, the FDA begins an <span style="white-space:nowrap">in-depth</span> review of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond to the applicant, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by FDA requests for additional information or clarification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent, and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of preclinical and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter or a complete response letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the application is not approved, the FDA will issue a CRL, which will contain the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a CRL may submit to the FDA information that represents a complete response to the issues identified by the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA approves a new product, it may limit the approved indication(s) for use of the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Expedited review programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is authorized to expedite the review of BLAs in several ways. Under the Fast Track program, the sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Breakthrough therapy designation. </span>To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Priority review. </span>A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Accelerated approval. </span>Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, for products being considered for accelerated approval, the FDA generally requires, as a condition for accelerated approval, <span style="white-space:nowrap">pre-approval</span> of promotional materials. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of these expedited programs change the standards for approval but they may help expedite the development or approval process of product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-approval regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post- approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including CGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Manufacturers and other parties involved in the drug supply chain for prescription drug and biological products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with CGMP regulations and other regulatory requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on post-approval clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product recall, seizure or detention, or refusal to permit the import or export of products; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Although healthcare providers may prescribe products for uses not described in the drug&#8217;s labeling, known as <span style="white-space:nowrap">off-label</span> uses, in their professional medical judgment, drug manufacturers are prohibited from soliciting, encouraging or promoting unapproved uses of a product. Drug manufacturers may only share truthful and <span style="white-space:nowrap">non-misleading</span> information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses, and a company that is found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses may be subject to significant liability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a company is found to have promoted <span style="white-space:nowrap">off-label</span> uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Biosimilars and exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2010 Patient Protection and Affordable Care Act, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;). The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing <span style="white-space:nowrap">FDA-licensed</span> &#8220;reference product&#8221;. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Additional guidance is expected to be finalized by the FDA in the near term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BPCIA, a manufacturer may submit an application for licensure of a biological product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. Since the passage of the BPCIA, many states have passed laws or amendments to laws, including laws governing pharmacy practices, which are state-regulated, to regulate the use of biosimilars. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Patent term restoration and extension </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, a patent claiming a new biological product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically <span style="white-space:nowrap">one-half</span> the time between the effective date of the IND and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other U.S. healthcare laws and compliance requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, including physicians, and third-party payors play a primary role in the recommendation and prescription of any product candidates that we may develop for which we obtain marketing approval. Our current and future arrangements with third-party payors, healthcare providers and customers may implicate broadly applicable fraud and abuse and other healthcare laws and regulations. Restrictions under applicable federal and state healthcare laws and regulations, including certain laws and regulations applicable only if we have marketed products, include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the civil False Claims Act (&#8220;FCA&#8221;), prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in very significant monetary penalties, for each false claim and treble the amount of the government&#8217;s damages. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute prohibits, among other things, persons or entities from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. The federal Anti-Kickback </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. A violation of the federal Anti-Kickback Statute can also form the basis for FCA liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and its implementing regulations, including the final omnibus rule published on January&#160;25, 2013, imposes, among other things, certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive, maintain, transmit, or obtain, protected health information in connection with providing a service for or on behalf of a covered entity, and their covered subcontractors. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Federal price transparency laws, including the provision commonly referred to as the Physician Payments Sunshine Act, and its implementing regulations, which requires applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the Centers of Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed health care practitioners (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous state and foreign laws and regulations, such as state anti-kickback, anti-bribery and false claims laws, which may apply to healthcare items or services that are reimbursed by <span style="white-space:nowrap">non-governmental</span> third-party payors, including private insurers. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, track and report gifts, compensation and other remuneration made to physicians and other healthcare providers, clinical trials and other activities, and/ or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in criminal and civil sanctions, including significant fines and civil monetary penalties, reputational risk, public reprimands, administrative penalties, exclusion from participation in governmental healthcare programs, disgorgement, or imprisonment. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Healthcare reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been and continue to be ongoing efforts to implement legislative and regulatory changes regarding the healthcare system. Such changes could prevent or delay marketing approval of any product candidates that we may develop, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Although we cannot predict what healthcare or other reform efforts will be successful, such efforts may result in more rigorous coverage criteria, in additional downward pressure on the price that we, or our future collaborators, may receive for any approved products or in other consequences that may adversely affect our ability to achieve or maintain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within the United States, the federal government and individual states have aggressively pursued healthcare reform, as evidenced by the passing of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Reconciliation Act of 2010 (the &#8220;ACA&#8221;), and the ongoing efforts to modify or repeal that legislation. The ACA substantially changed the way healthcare is financed by both governmental and private insurers and contains a number of provisions that affect coverage and reimbursement of drug products and/or that could potentially reduce the demand for pharmaceutical products such as increasing drug rebates under state Medicaid programs for brand name prescription drugs and extending those rebates to Medicaid managed care and assessing a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs, including Medicare and Medicaid. Other aspects of healthcare reform, such as expanded government enforcement authority and heightened standards that could increase compliance-related costs, could also affect our business. Modifications have been implemented and additional modifications or repeal may occur. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law. The IRA contains several provisions that may impact our business to varying degrees, including provisions that reduce the <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part&#160;D; allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain single-source high-cost biologics that have been on the market for at least 11 years without generic or biosimilar competition (the &#8220;Medicare Drug Price Negotiation Program&#8221;); require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January&#160;1, 2032 the implementation of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August&#160;15, 2024, HHS announced the agreed-upon price of the first ten drugs that were subject to price negotiations, although there is currently ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare Drug Price Negotiation Program. On January&#160;17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. Further, on December&#160;8, 2023, the National Institute of Standards and Technology </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
published for comment a Draft Interagency Guidance Framework for Considering the Exercise of <span style="white-space:nowrap">March-In</span> Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise <span style="white-space:nowrap">march-in</span> rights. While <span style="white-space:nowrap">march-in</span> rights have not previously been exercised, it is uncertain if that will continue under the new framework. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to pricing regulations, reforms of regulatory approval frameworks may adversely affect our pricing strategy. The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS and related agencies.&#160;These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions may, for example, include directives to reduce agency workforce, rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation (&#8220;CMMI&#8221;) to consider new payment and healthcare models to limit drug spending and eliminating the Biden administration&#8217;s executive order that directed HHS to establishing an AI task force and developing a strategic plan.&#160;Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo (&#8220;Loper Bright&#8221;), the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our potential product candidates. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of any product candidates we may develop to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Coverage and reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Coverage and reimbursement by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a covered benefit under its health plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">safe, effective and medically necessary; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appropriate for the specific patient; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost-effective; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">neither experimental nor investigational. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there is no uniform policy of coverage and reimbursement for products that exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a <span style="white-space:nowrap"><span style="white-space:nowrap">payor-by-</span></span> payor basis, with no assurance that coverage and adequate reimbursement will be obtained. The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for our product candidates, if approved, by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize, our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require patient <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs that patients find unacceptably high. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. Further, coverage policies and third-party payor reimbursement rates may change. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that our product candidates, even if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulation outside of the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be required to comply with comparable regulations in each jurisdiction outside of the United States in which we choose to manufacture, develop or seek marketing authorization for our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">European Union drug development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most countries outside of the United States require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In the European Union, for example, an application must be submitted to the national competent authority and an independent ethics committee in each country in which we intend to conduct clinical trials, much like the FDA and IRB, respectively. Under the new Clinical Trials Regulation (EU) No 536/2014, which replaced the previous Clinical Trials Directive 2001/20/EC on January&#160;31, 2022, a single application is now made through the Clinical Trials Information System for clinical trial authorization in up to 30 EU or European Economic Area (Norway, Iceland and Liechtenstein) (&#8220;EEA&#8221;) countries at the same time and with a single set of documentation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assessment of applications for clinical trials is divided into two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all European Union Member States in which an application for authorization of a clinical trial has been submitted (each, a &#8220;Member State Concerned&#8221;) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State Concerned. The role of the relevant ethics committees in the assessment procedure continues to be governed by the national law of the Member State Concerned, however overall related timelines are defined by the Clinical Trials Regulation. The new Clinical Trials Regulation also provides for simplified reporting procedures for clinical trial sponsors. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">European Union drug review and approval </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of countries outside the United States before we can commence marketing of the product in those countries. The approval process and requirements vary from country to country, so the number and type of nonclinical, clinical, and manufacturing studies needed may differ, and the time may be longer or shorter than that required for FDA approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval for our medicinal product candidates in the European Union, a marketing authorization application (&#8220;MAA&#8221;) needs to be submitted. There are a number of potential routes open to obtain a marketing authorization (&#8220;MA&#8221;) in the European Union. A centralized MA is issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA, and is valid throughout the European Union, and in the additional Member States of the EEA. The centralized procedure is compulsory for medicinal products manufactured using biotechnological processes, orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products containing a new active substance which is not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
yet authorized in the European Union and which is intended for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, auto-immune and other immune dysfunctions, viral diseases or diabetes. The centralized procedure is optional for any other products containing new active substances not authorized in the European Union or for products which constitute a significant therapeutic, scientific, or technical innovation or for which a centralized authorization is in the interests of patients at European Union level. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">National MAs are issued by the competent authorities of the EU Member States and only cover their respective territory. This procedure is available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU Member State, this national MA can be recognized in another Member State through the mutual recognition procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each Member State in which the MA is sought, one of which is selected by the applicant as the Reference Member State. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210&#160;days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. MAs in the European Union have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a <span style="white-space:nowrap">re-evaluation</span> of the risk-benefit balance. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Data protection regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area (&#8220;EEA&#8221;), the collection and processing of personal data, including personal health data is regulated by the General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;). Similarly, in the United Kingdom, the collection and processing of personal data, including personal health data is regulated by the UK General Data Protection Regulation and the UK Data Protection Act 2018 (&#8220;UK GDPR&#8221; and together with the EU GDPR, referred to as &#8220;GDPR&#8221;). The GDPR has extra-territorial application and applies not only to organizations with a presence in the EEA and the UK but also to <span style="white-space:nowrap">non-EEA/UK</span> based businesses that carry out processing that is related to (i)&#160;an offer of goods or services to individuals in the EEA/UK or (ii)&#160;the monitoring of their behavior so long as this takes place in the EEA/UK, even if the data is stored outside the EEA/UK. The GDPR imposes obligations on businesses (including companies that operate in our industry) with respect to the processing of personal data and the cross-border transfer of such data. We will be subject to the GDPR to the extent we process the personal data of individuals based in the EEA/UK. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, we had 51 full-time employees, 41 of whom were primarily engaged in research and development activities, and 22 of our employees had an M.D. or Ph.D. degree. None of our employees are represented by a labor union and we consider our employee relations to be good. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Market under the symbol &#8220;TECX&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in November 2015. Legacy Tectonic was incorporated under the laws of the State of Delaware in June 2019. Following the Merger with Tectonic Operating Company, Inc. (formerly Tectonic Therapeutic, Inc.) on June&#160;20, 2024, we changed our name from AVROBIO, Inc. to Tectonic Therapeutic, Inc. Our principal executive office is located at 490 Arsenal Way, Suite&#160;210, Watertown, Massachusetts 02472, and our telephone number is (339) <span style="white-space:nowrap">666-3320.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters consist of approximately 19,000 square feet of leased research laboratory and office space under a lease that expires in January 2026. We believe that our facilities are adequate to meet our current needs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Available Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website is www.tectonictx.com. We may use our website to comply with disclosure obligations under Regulation FD. Therefore, investors should monitor our website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts. The contents of our website are not intended to be incorporated by reference into this prospectus or in any other report or document we file with the SEC, and any references to our websites are intended to be inactive textual references only. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_9">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers and Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table lists the names and ages, as of December&#160;31, 2024, and positions of our executive officers and directors: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alise Reicin, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President, Chief Executive Officer and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Lochner, M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter McNamara, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Scientific Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcella K. Ruddy, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc Schwabish, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Business Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Directors:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phillip B. Donenberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terrance McGuire, M.S., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy A. Springer, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Praveen Tipirneni, M.D., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stefan Vitorovic, M.S., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Alise Reicin, M.D.</span>, has served as our President and Chief Executive Officer and member of our Board since August 2020. Prior to joining Tectonic, Dr.&#160;Reicin served as President, Global Clinical Development at Celgene Corporation, public pharmaceutical company, from November 2018 to December 2019 and was a member of the Executive Committee. Prior to Celgene, she served as Head of Global Clinical Development at EMD Serono Inc., a privately held pharmaceutical company, from May 2015 to October2018. Prior to EMD Serono, Dr.&#160;Reicin served as Vice President, Program and Pipeline Leadership, Oncology at Merck&#160;&amp; Co., Inc., a public pharmaceutical company. Prior to Merck, she was a faculty member at Columbia Medical School and a physician and researcher at Columbia Presbyterian Hospital. While at Merck, Dr.&#160;Reicin led the team that brought Keytruda from Phase 1 through its initial approvals and over the course of her career she has played a leadership role in the development and approval of over 10 novel medicines across a broad range of therapeutic areas. Dr.&#160;Reicin previously served on the board of directors of Homology Medicines, Inc., a public biopharmaceutical company and currently serves on the board of directors of Sana Biotechnology, Inc., a public cell and gene therapy company and Immatics, a company focused on the development of immunotherapies for cancer. She also serves on the board of directors of Sharsheret, a nonprofit devoted to improving the lives of patients and families with or at increased risk of ovarian and breast cancer. Dr.&#160;Reicin earned a B.A. in Biochemistry from Barnard College of Columbia University. She earned a M.D. in Medicine from Harvard University. We believe that Dr.&#160;Reicin is qualified to serve on our Board due to her clinical expertise and leadership roles in the biotechnology and biopharmaceuticals industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Daniel Lochner, M.B.A.</span>, has served as our Chief Financial Officer since June 2024. Mr.&#160;Lochner most recently served as Chief Financial Officer and Chief Business Officer for the Eye Care Division of Viatris Inc., a global healthcare company, from 2023 to 2024. Prior to Viatris, Mr.&#160;Lochner was the Chief Financial Officer and Chief Business Officer of Oyster Point Pharma, Inc., a biotechnology company that was acquired by Viatris in 2023, from 2019 to 2023 where he led a successful initial public offering, other equity and debt financings, the transition to a commercial-stage company and the acquisition to Viatris. Previously, Mr.&#160;Lochner was a Managing Director within the Investment Management Division of Goldman, Sachs&#160;&amp; Co where he served as a lead equity portfolio manager and healthcare investor for various fund strategies. Mr.&#160;Lochner joined the Investment Management Division of Goldman, Sachs&#160;&amp; Co in 2005 as an equity investor, a position he maintained during his tenure at the firm. Mr.&#160;Lochner received a B.A. in Economics from the University of Richmond and an M.B.A. from Columbia University. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Peter McNamara, Ph.D.</span>, has served as our Chief Scientific Officer since June 2022. Prior to that, Dr.&#160;McNamara served as our Senior Vice President, Head of Research from June 2021 to June 2022. Prior to joining Tectonic, he held various positions at the Genomics Institute of the Novartis Research Foundation (NIBR, San Diego), a privately held pharmaceutical company, from 2005 to April 2021, most recently as Executive Director of Biotherapeutics and Biotechnology from June 2018 to April 2021 where he served on the executive committee and strategy council responsible for managing a portfolio of approximately 50 preclinical and early-stage clinical drug discovery programs across different modalities in a broad range of therapeutic areas. Over the course of his career, Dr.&#160;McNamara has played a critical role in the obtainment of over 10 INDs, two of which are now approved. Prior to Novartis, Dr.&#160;McNamara served as Director of Pharmacology at Phenomix Corporation, a privately-held biotechnology company. Prior to Phenomix, he was a faculty member of the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania. Dr.&#160;McNamara earned both a Ph.D. and B.S. in Biochemistry from the National University of Ireland, at Galway. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Marcella K. Ruddy, M.D., </span>has served as our Chief Medical Officer since July 2021. She has over 20 years of experience in drug development across all stages of clinical drug development. She currently serves as a member of the board of directors of Upstream Bio since January 2023 and Sionna Therapeutics since January 2025. She previously served on the Board of Directors of Polarean Imaging from August 2022 through August 2024. Prior to joining Tectonic, Dr.&#160;Ruddy was the Head of Clinical Development for the Immunology/Inflammation Therapeutic Area at Regeneron Pharmaceuticals. In that role she led the clinical development of Dupixent<sup style="font-size:75%; vertical-align:top">&#174;</sup> through over nine Phase 3 trial initiations and multiple regulatory approvals globally. Dr.&#160;Ruddy spent 10 years in early development at Merck and took many compounds from preclinical development through proof of concept in the clinic. Prior to entry into drug development, Dr.&#160;Ruddy was a member of the Pulmonary Unit at Massachusetts General Hospital/Harvard Medical School where she founded and directed the Adult Cystic Fibrosis Program. Dr.&#160;Ruddy earned an A.B. from Princeton University and a M.D. and M.S. from Washington University, St. Louis. She completed her internal medicine and pulmonary fellowship training at Harvard Medical School affiliated hospitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Marc Schwabish, Ph.D.</span>, has served as our Chief Business Officer since March 2021. Prior to joining Tectonic, Dr.&#160;Schwabish served as SVP Business Development and US Operations at Fusion Pharmaceuticals Inc. from February 2018 to December 2020 where his transactions, amongst others, included the company&#8217;s Series B financing, IPO, and an expansive partnership with AstraZeneca plc. Prior to working at Fusion Pharmaceuticals, Dr.&#160;Schwabish was Head of U.S. Pharma Business Development at Bayer, Inc. He also held roles in Business Development and Alliance Management at Eisai Inc., Strategy Consulting at Leerink Swann, and Healthcare Investment Banking at RBS. Dr.&#160;Schwabish earned a B.S. in Biological Sciences from Cornell University. He earned a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard University. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Phillip B. Donenberg</span>, has served as a member of our Board since June 2024. Mr.&#160;Donenberg had served on the board of directors and as Audit Committee Chairman of AVROBIO, Inc., a publicly traded gene therapy company, since June 2018, prior to AVROBIO&#8217;s reverse merger with Tectonic in June 2024. Mr.&#160;Donenberg has served on the board of directors and as chairman of the audit committee of Taysha Gene Therapies, Inc., a publicly traded gene therapy company, since August 2020. Mr.&#160;Donenberg served as Senior Vice-President and Chief Financial Officer of Jaguar Gene Therapy, LLC, a privately held early-stage gene therapy company, from February 2020 to March 2023. Previously, Mr.&#160;Donenberg served as Chief Financial Officer and Senior Vice-President of Assertio Therapeutics, Inc., a pharmaceutical company, from July 2018 to November 2018. He served as Senior Vice-President and Chief Financial Officer of AveXis, Inc., a publicly traded gene therapy company, from 2017 to June 2018 and as Vice-President, Corporate Controller from 2016 to 2017. Mr.&#160;Donenberg earned a B.S. in accountancy from the University of Illinois, Champaign-Urbana College of Business and is a Certified Public Accountant. We believe that Mr.&#160;Donenberg is qualified to serve as a director of our Board based on his financial expertise and his experience as an audit chair, director and executive of companies in the biotechnology and pharmaceutical industries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Terrance McGuire M.S., M.B.A</span>, has served as a member of our Board since September 2019. Mr.&#160;McGuire was a <span style="white-space:nowrap">co-founder</span> and is currently a general partner of Polaris Partners. He currently serves on the board of directors of Seer, Inc. and Invivyd, Inc., as well as several private companies, including Adimab, LLC. Mr.&#160;McGuire previously served on the boards of directors of Alector, Inc., Acceleron Pharma, Inc., Akamai Technologies, Inc., Cubist, Inc., Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr.&#160;McGuire is the former chairman of the National Venture Capital Association and a current member of the board of advisors of the Thayer School of Engineering at Dartmouth College. He is a member of the boards of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr.&#160;McGuire is also on the Scientific Advisory Board of the Brigham and Women&#8217;s Hospital. Mr.&#160;McGuire holds a B.S. in physics and economics from Hobart College, an M.S. in engineering from the Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School. We believe that Mr.&#160;McGuire is qualified to serve on our Board because of his extensive experiences as a venture capitalist focused on the biotechnology industry, as well as his many years of experience as a director of biotechnology companies guiding them in the execution of their corporate strategy and objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Timothy A. Springer, Ph.D.</span>, has served as a member of our Board since June 2019. Dr.&#160;Springer <span style="white-space:nowrap">co-founded</span> our Company in June 2019 and previously served as a scientific advisor. Dr.&#160;Springer served as Chair of our Company from June 2019 until August 2020. Since 1989, Dr.&#160;Springer has served as the Latham Family Professor at Harvard Medical School. He has also served as Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children&#8217;s Hospital since 2012, and as a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Medicine at Boston Children&#8217;s Hospital since 2011. He was also the founder of Morphic Therapeutic and served as a scientific advisor and as a member of its board of directors from June 2015 to August 2024, when it was acquired by Eli Lilly. He has also served Selecta Biosciences Inc. (now Cartesian Therapeutic) as a scientific advisor since December 2008 and as a member of its board of directors since June 2016. Dr.&#160;Springer is also a Founder and Board Member of Seismic Therapeutic, a private company. Dr.&#160;Springer is a member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, the Basic Research Prize from the American Heart Association, the Canada International Gairdner Award, the Lasker Basic Medical Research Award and the Robert Koch Prize. Dr.&#160;Springer received a B.A. in Biochemistry from the University of California, Berkeley, and a Ph.D. in Biochemistry and Molecular Biology from Harvard University. We believe that Dr.&#160;Springer is qualified to serve on our Board because of his extensive knowledge of therapeutically important cell surface molecules and his investment, business and board experience with biopharmaceutical companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Praveen Tipirneni, M.D., M.B.A.</span>, has served as a member of our Board since February 2020. Dr.&#160;Tipirneni currently serves as a member of the board of directors of The Ras, Inc. d/b/a BridgeBio Oncology Therapeutics. He previously served as Chief Executive Officer and as a member of the board of directors of Morphic Holding, Inc. until its acquisition by Eli Lilly in August 2024. Dr.&#160;Tipirneni received a B.A. in Mechanical Engineering from Massachusetts Institute of Technology, an M.D. from McGill University and an M.B.A. from the Wharton School of Business of the University of Pennsylvania. We believe Dr.&#160;Tipirneni is qualified to serve on our Board because of his experience with biotechnology companies, including working with and serving in various executive positions in life sciences companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Stefan Vitorovic, M.S., M.B.A.</span>, has served as a member of our Board since August 2021. Mr.&#160;Vitorovic was the <span style="white-space:nowrap">co-founder</span> and Managing Director of Vida Ventures, a role he served in from January 2017 to December 2024. Prior to founding Vida Ventures, Mr.&#160;Vitorovic was an investment professional at Third Rock Ventures, an early-stage life sciences venture capital firm, from July 2014 to January 2017. At Third Rock, he was part of the founding team of Decibel Therapeutics, Inc. (acquired by Regeneron Pharmaceuticals, Inc.), a hearing-focused drug discovery and development platform company. Before Third Rock, he was an investor at TPG Capital from August 2012 to June 2014, where he focused on majority, control stakes in healthcare companies. Mr.&#160;Vitorovic worked on a variety of equity and debt financings, including Aptalis Pharmaceutical Technologies (now Adare Pharma Solutions) and Biomet, Inc. (now Zimmer Biomet Holdings, Inc.).Prior to TPG, Mr.&#160;Vitorovic was an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment banker at Credit Suisse&#8217;s healthcare banking group from 2004 to 2008. Mr.&#160;Vitorovic currently serves on the board of directors of Vigil Neuroscience, Inc. He was previously Director or Observer of Oyster Point Pharma, Inc., Dyne Therapeutics, Sutro Biopharma, Inc., Kyverna Therapeutics, Inc., Praxis Precision Medicines, Inc., Volastra Therapeutics, Inc., and Souffle Therapeutics, Inc. He received a B.S. with Honors in Biological Sciences and an M.S. in Biology from Stanford University, where he received the Firestone Award for his research. Mr.&#160;Vitorovic received his M.B.A. from Harvard Business School. We believe Mr.&#160;Vitorovic is qualified to serve on our Board because of his deep expertise in life sciences research and investing, as well as his extensive experience in new company formation and operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Election of Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers are appointed by, and serve at the discretion of, our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Involvement in Certain Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no material legal proceedings to which any of our executive officers is a party adverse to the Company or the Company&#8217;s subsidiaries or in which any such person has a material interest adverse to the Company or the Company&#8217;s subsidiaries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Governance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Composition of Our Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board currently consists of six directors divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three-year term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our certificate of incorporation (the &#8220;Certificate of Incorporation&#8221;), our Board is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with one class of directors being elected in each year and each class serving a three-year term. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors. The Board is divided among the following classes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;I, which consists of Alise Reicin, M.D. and Praveen Tipirneni, M.D., whose terms will expire at the annual meeting of stockholders to be held in 2025; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;II, which consists of Timothy A. Springer, Ph.D. and Stefan Vitorovic, whose terms will expire at the annual meeting of stockholders to be held in 2026; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;III, which consists of Terrance McGuire and Phillip B. Donenberg, whose terms will expire at the annual meeting of stockholders to be held in 2027. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election and until their successors are duly elected and qualified, or their earlier resignation, removal, retirement or death. This classification of the Board may have the effect of delaying or preventing changes in our control or management. Our directors may be removed for cause by the affirmative vote of the holders of at least 66 2/3% of our voting stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Independence of Our Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than Dr.&#160;Reicin, our president and chief executive officer, all members of the Board are independent, and all members of committees of the Board are independent. To determine independence, the Board reviewed all relevant identified transactions or relationships between each director, or any of such director&#8217;s family members, and us, our senior management and our independent auditors. Our Board has affirmatively determined that the following five current directors are independent directors within the meaning of the applicable Nasdaq listing standards: Phillip B. Donenberg, Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic. In making this determination, our Board found that none of these directors or nominees for director had a material or other disqualifying relationship with Tectonic. Dr.&#160;Reicin was determined as not being independent by virtue of her executive leadership role with us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, a majority of our directors are independent, as required under applicable Nasdaq rules. In making this determination, our Board considered the applicable Nasdaq rules and the current and prior relationships that each <span style="white-space:nowrap">non-employee</span> director has with our company and all other facts and circumstances our Board deemed relevant in determining their independence, including their beneficial ownership of our share capital. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Committees of Our Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The standing committees of our Board are the following: audit committee, compensation committee and nominating and corporate governance committee, and each operates pursuant to a charter. Our Board may establish other committees from time to time to assist us and our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee oversees our corporate accounting and financial reporting process. Among other matters, the audit committee&#8217;s oversight responsibilities include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our accounting and financial reporting processes, systems of internal control over financial reporting and audits of financial statements, as well as the quality and integrity of our financial statements and reports; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the qualifications, independence and performance of our independent registered public accountant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our compliance with legal and regulatory requirements, including compliance with ethical standards adopted by us; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the review and assessment of our risk management, risk assessment and major risk exposures with respect to financial, accounting, operational, tax, privacy and cybersecurity and information technology risks. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee consists of Phillip Donenberg, Terrance McGuire and Stefan Vitorovic. Phillip Donenberg serves as the chair of the audit committee and is a financial expert under the rules of the SEC. To qualify as independent to serve on our audit committee, listing standards of Nasdaq and the applicable SEC rules require that a director not accept any consulting, advisory or other compensatory fee from us, other than for service as a director, or be an affiliated person of us. We believe that the composition of the audit committee complies with the applicable requirements of the rules and regulations of Nasdaq and the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee oversees policies relating to compensation and benefits of our officers and directors. Among other matters, the compensation committee&#8217;s responsibilities include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and reviewing our overall compensation philosophy in light of our specific business objectives; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">setting compensation, or recommending to the full Board the compensation, for our Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">setting compensation for our other executive officers and directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">administering incentive and equity-based compensation plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing our compensation-related disclosures required by the SEC; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing our policies and strategies relating to human capital management. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee consists of Praveen Tipirneni and Stefan Vitorovic. Praveen Tipirneni serves as the chair of the compensation committee. Each member of the compensation committee is a <span style="white-space:nowrap">&#8220;non-employee&#8221;</span> director within the meaning of Rule <span style="white-space:nowrap">16b-3</span> of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. We believe that the composition of the compensation committee complies with the applicable requirements of the rules and regulations of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee&#8217;s responsibilities include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying individuals qualified to become members of the Board (consistent with criteria approved by the Board), reviewing the qualifications of, and considering stockholders&#8217; recommendations for, director candidates and recommending to the Board qualified director nominees for appointment, election or reelection to the Board at each annual stockholders&#8217; meeting and as necessary to fill vacancies and newly created directorships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and recommending to the Board for adoption the corporate governance guidelines applicable to us, periodically reviewing such guidelines, recommending changes to the same from time to time as appropriate and overseeing and monitoring compliance with such guidelines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing evaluations of the Board, its committees, and Board members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying individuals qualified to become members of our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying directors qualified to serve on the various committees of the Board and recommending to the Board qualified nominees for membership on each such committee; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing succession planning for the Board and key leadership roles on the Board and its committees. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee consists of Timothy Springer and Terrance McGuire. Timothy Springer serves as the chair of the nominating and corporate governance committee. We believe that the composition of the nominating and corporate governance committee meets the requirements for independence under, and the functioning of such nominating and corporate governance committee complies with, any applicable requirements of the rules and regulations of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct and Ethics for Employees, Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a Code of Business Conduct and Ethics (the &#8220;Code of Conduct&#8221;) that is applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website at <span style="font-style:italic">https://investors.tectonictx.com/governance-documents</span>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. The Board, and audit committee of the Board, will be responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. We plan to disclose any amendments to the Code of Conduct, or any waivers of its requirements, on our website. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_10">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Overview </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers (&#8220;NEOs&#8221;) for the year ended December 31, 2024 who appear in the Summary Compensation Table below are: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Alise Reicin, M.D., our President, Chief Executive Officer and Director; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Daniel Lochner, M.B.A., our Chief Financial Officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Marcella K. Ruddy, M.D., our Chief Medical Officer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt could vary significantly from our historical practices and currently planned programs summarized in this discussion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2024 Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the total compensation awarded to, earned by and paid to our NEOs for services during the fiscal year ended December 31, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:38%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Salary<sup style="font-size:75%; vertical-align:top">(1)</sup></span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Stock</span><br/><span style="font-weight:bold">Awards</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option</span><br/><span style="font-weight:bold">Awards</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(3</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Equity</span></span><br/><span style="font-weight:bold">Incentive Plan</span><br/><span style="font-weight:bold">Compensation</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(4)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">All Other</span><br/><span style="font-weight:bold">Compensation</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alise Reicin, M.D.<span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(5)</sup></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">606,151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">600,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,291,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">392,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,267</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,900,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">President and Chief Executive&#160;Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Lochner, M.B.A</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">277,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,855,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">126,311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,744</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(7)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,284,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcella K. Ruddy, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">476,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,140,034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">223,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">742</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(8)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,840,892</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Medical Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Salary amounts represent actual amounts paid during 2024. With respect to Drs. Reicin and Ruddy, the amounts reflect increases to base salary effective April&#160;1, 2024 and further increases to base salary effective June&#160;20, 2024. Mr.&#160;Lochner&#8217;s base salary was effective June&#160;3, 2024 pursuant to his employment agreement. See &#8220;&#8212;<span style="font-style:italic">Narrative to the Summary Compensation Table&#8212;Base Salary</span>&#8221; below. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amount reported represent the aggregate grant date fair value of RSUs granted during the year ended December&#160;31, 2024, calculated in accordance with FASB ASC 718 for share-based compensation transactions. The assumptions used in calculating the grant date fair value of the RSUs reported in this column are set forth in &#8220;Note 2. <span style="font-style:italic">Summary of Significant Accounting Policies and Basis of Presentation&#8212;Stock-Based Compensation</span>&#8221; and &#8220;Note 8. <span style="font-style:italic">Equity Incentive Plans</span>&#8221; to our consolidated financial statements for the year ended December&#160;31, 2024 included elsewhere in this registration statement of which this prospectus forms a part. This amount does not reflect the actual economic value that may be realized upon vesting and settlement of the RSUs or any sale of the underlying shares of common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported represent the aggregate grant date fair value of the stock option awards granted during the year ended December&#160;31, 2024, calculated in accordance with FASB ASC 718 for share-based compensation transactions. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in &#8220;Note 2. <span style="font-style:italic">Summary of Significant Accounting Policies and Basis of Presentation&#8212;Stock-Based Compensation</span>&#8221; and &#8220;Note 8. <span style="font-style:italic">Equity Incentive Plans</span>&#8221; to our consolidated financial statements for each of the years ended December&#160;31, 2024 and 2023 included elsewhere in this registration statement of which this prospectus forms a part. These amounts do not correspond to the actual economic value that may be received by our NEOs upon the exercise of the stock options or any sale of the underlying shares of common stock. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts disclosed for fiscal year 2024 reflect performance-based cash bonuses earned in 2024 and paid in early 2025. See &#8220;&#8212;<span style="font-style:italic"><span style="white-space:nowrap">Non-Equity</span> Incentive Plan Compensation</span>&#8221; below for a description of the material terms of the program pursuant to which this compensation was awarded. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Reicin also served as a member of our Board but did not receive any additional compensation for her service as a director. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i)&#160;commuting expenses in the amount of $9,505, and (ii)&#160;life insurance premiums in the amount of $762 paid by us on behalf of Dr.&#160;Reicin. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i)&#160;commuting expenses in the amount of $16,189, (ii) $8,133 in matching employer contributions to a 401(k) plan, and (iii)&#160;life insurance premiums in the amount of $422 paid by us on behalf of Mr.&#160;Lochner. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(8)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents life insurance premiums in the amount of $742 paid by us on behalf of Dr.&#160;Ruddy. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative to the 2024 Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Base Salary </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each NEO&#8217;s base salary was a fixed component of annual compensation for performing specific duties and functions, and was established by our Board taking into account each individual&#8217;s role, responsibilities, skills, and expertise. Base salaries are reviewed annually, typically in connection with our annual performance review process, approved by our Board, and adjusted from time to time to realign salaries with market levels and internal benchmarking, after taking into account individual responsibilities, performance and experience. Please see the &#8220;Salary&#8221; column in the Summary Compensation Table above for the actual base salary amount received by each NEO during the year ended December 31, 2024. The annual base salaries for Drs. Reicin and Ruddy were $579,251 and $455,260, respectively, for the period from January&#160;1, 2024 through April&#160;1, 2024 and $602,160 and $473,200, respectively, for the period from April&#160;1, 2024 to June&#160;20, 2024. In connection with the completion of the Merger, the annual base salaries for Dr.&#160;Reicin and Dr.&#160;Ruddy were increased to $620,000 and $486,850, respectively. We entered into an employment agreement with Mr.&#160;Lochner, effective June&#160;3, 2024, pursuant to which Mr.&#160;Lochner&#8217;s annual base salary for the year ended December&#160;31, 2024 was $475,000. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Equity</span> Incentive Plan Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our annual incentive program is intended to reward our NEOs for performance during a fiscal year. From time to time, our compensation committee or our Board, as applicable, in their discretion may have approve annual incentives for our NEOs based on individual performance, company performance, or as otherwise determined appropriate. Each of our NEOs were eligible to receive a target bonus at the discretion of our Board with respect to the year ended December 31, 2024 (as a percentage of base salary) based upon their performance. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:80%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span><br/><span style="font-weight:bold">Bonus</span><br/><span style="font-weight:bold">Target</span><br/><span style="font-weight:bold">(%)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span><br/><span style="font-weight:bold">Bonus</span><br/><span style="font-weight:bold">Target</span><br/><span style="font-weight:bold">(%)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alise Reicin, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Lochner, M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcella K. Ruddy, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2025, based on the NEO&#8217;s performance, our Board determined that Dr.&#160;Reicin, Mr.&#160;Lochner and Dr.&#160;Ruddy were eligible to receive 115% of their target annual bonus for the year ended December 31, 2024, and as a result, approved annual performance bonuses for Dr.&#160;Reicin, Mr.&#160;Lochner and Dr.&#160;Ruddy in the amounts of $392,150, $126,311 and $223,951, respectively, as reflected in the <span style="white-space:nowrap">&#8220;Non-Equity</span> Incentive Plan Compensation&#8221; column of the Summary Compensation Table above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Equity-Based Incentive Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Merger, our Compensation Committee approved option grants to certain of our employees, including Dr.&#160;Reicin, Mr.&#160;Lochner and Dr.&#160;Ruddy. As a result, on June&#160;20, 2024, Dr.&#160;Reicin received an option grant to purchase 289,600 shares of our common stock, Mr.&#160;Lochner received an option grant to purchase 118,000 shares of our common stock and Dr.&#160;Ruddy received an option grant to purchase 81,700 shares of our common stock, each with an exercise price per share equal to $16.80, which was the closing price per share of our common stock as reported on the Nasdaq Global Market on the day of closing of the Merger (as adjusted for the reverse stock split). The shares subject to these option grants will vest 1/4 on the first anniversary of the grant date, and thereafter the remaining 3/4 of the shares will vest in equal monthly installments over the following three years, in each case subject to the recipient&#8217;s continuous service through the applicable vesting dates, such that the options are vested in full on the four-year anniversary of the grant date. Mr.&#160;Lochner also received an option grant to purchase 15,000 shares of our common stock with an exercise price per share equal to $16.80. The shares subject to this option grant will vest 1/2 on June&#160;1, 2026 if we raise $100&#160;million by June&#160;1, 2026 and have a minimum of a two year cash runway as of June&#160;1, 2026 (i.e. until June&#160;1, 2028), and 1/2 on June&#160;1, 2028 if we have a minimum of a two year cash runway as of June&#160;1, 2028 (i.e.&#160;until June&#160;1, 2030), in each case, as determined by our Board (or the Compensation Committee) in its sole discretion, in each case subject to the recipient&#8217;s continuous service through the applicable vesting dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, Dr.&#160;Reicin received an option grant to purchase 6,000 shares of our common stock with an exercise price per share equal to $51.28. The shares subject to this option grant will vest 1/4 on June&#160;20, 2025, and thereafter the remaining 3/4 of the shares will vest in equal monthly installments over the next 36 months, in each case subject to her continuous service through the applicable vesting dates, such that the options are vested in full on June&#160;20, 2028. In addition, in December 2024, Dr.&#160;Reicin received a grant of 11,717 restricted stock units of which 1/4 of the units will vest on each of the first four anniversaries of June&#160;20, 2024, in each case subject to her continuous service through the applicable vesting dates, such that the units are vested in full on June&#160;20, 2028. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at Fiscal 2024 <span style="white-space:nowrap">Year-End</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding outstanding equity awards held by our NEOs as of December&#160;31, 2024. All awards were granted pursuant to the Tectonic 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) and the Tectonic 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;). See &#8220;<span style="font-style:italic">&#8212;Equity Incentive Plans&#8212;Tectonic 2019 Equity Incentive Plan</span>&#8221; and &#8220;<span style="font-style:italic">&#8212;Equity Incentive Plans&#8212;Tectonic 2024 Equity Incentive Plan</span>&#8221; for additional information. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option Awards<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Stock Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name&#160;and&#160;Principal&#160;Position</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Vesting<br/>Commencement<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Exercise<br/>Price<br/>($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of<br/>Shares or<br/>Units of<br/>Stock<br/>That</span><br/><span style="font-weight:bold">Have Not<br/>Vested (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Market<br/>Value of<br/>Shares or<br/>Units of<br/>Stock<br/>That<br/>Have Not<br/>Vested<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alise Reicin, M.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/28/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3/31/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,235</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">06/27/31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" rowspan="2"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer and President</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">20,040</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11/30/33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">289,600</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">06/19/34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/4/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">51.28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/03/34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/4/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,717</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">600,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Lochner, M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5/31/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">118,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">06/19/34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5/31/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">06/19/34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcella K. Ruddy, M.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9/17/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7/19/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,085</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">09/16/31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Medical Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,028</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11/30/33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">87,100</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">06/19/34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All option awards have been granted pursuant to the terms of the Legacy Tectonic 2019 Plan or Tectonic 2024 Plan, the terms of which are described below in the subsection titled &#8220;<span style="font-style:italic">&#8212;Equity Incentive Plans&#8212;Tectonic 2019 Equity Incentive Plan and 2024 Equity Incentive Plan.</span>&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All of the option awards listed in the table granted prior to the Merger have an exercise price per share that is no less than the fair market value of Legacy Tectonic common stock on the date of grant of such award, as determined in good faith by the Legacy Tectonic Board. All option awards listed in the table granted subsequent to the Merger have an exercise price based on the closing price per share of common stock as reported on the Nasdaq Select Market on the date of grant. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares subject to this option grant vested or will vest 1/4 on the first anniversary of the vesting commencement date, and thereafter the remaining 3/4 of the shares will vest in equal monthly installments over the following three years, in each case subject to the officer&#8217;s continuous service through the applicable vesting dates, such that the options are vested in full on the four-year anniversary of the vesting commencement date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares subject to this option vest in equal monthly installments beginning on January&#160;1, 2024 over the following four years, in each case subject to the officer&#8217;s continuous service through the applicable vesting dates, such that the options are vested in full on the four-year anniversary of the vesting commencement date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares will vest in equal annual installments beginning on June&#160;20, 2025 over the following three years, in each case subject to the officer&#8217;s continuous service through the applicable vesting dates, such that the shares are vested in full on the four-year anniversary of the vesting commencement date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares subject to this option grant will vest 1/2 on June&#160;1, 2026 if we raise $100&#160;million by June&#160;1, 2026 and have a minimum of a two year cash runway as of June&#160;1, 2026 (i.e. until June&#160;1, 2028), and 1/2 on June&#160;1, 2028 if we have a minimum of a two year cash runway as of June&#160;1, 2028 (i.e. until June&#160;1, 2030), in each case, as determined by our Board (or the Compensation Committee) in its sole discretion, and in each case subject to the officer&#8217;s continued service through the applicable vesting dates. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employment Arrangements with Our Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below are descriptions of the material terms of our employment agreement and offer letters with the NEOs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Alise Reicin, M.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, Legacy Tectonic entered into an executive employment agreement with Dr.&#160;Reicin (the &#8220;Reicin Employment Agreement&#8221;) in connection with her appointment as Legacy Tectonic&#8217;s President and Chief Executive Officer and as a member of the Legacy Tectonic Board. In connection with the Merger, we entered into an amended and restated executive employment agreement with Dr.&#160;Reicin. The material terms of the amendment are as follows: (i)&#160;Dr.&#160;Reicin shall remain President and Chief Executive Officer and shall continue to serve as an executive director to the Board; (ii)&#160;an annual base salary of $620,000; (iii) eligibility for an annual, performance-based cash bonus with a target bonus percentage of 55% of Dr.&#160;Reicin&#8217;s base salary subject to her continuous employment through February 15<sup style="font-size:75%; vertical-align:top">th</sup> of the following calendar year; (iv)&#160;following the closing of the Merger, issuance of an option award to purchase our common stock, such that when combined with Dr.&#160;Reicin&#8217;s prior securities holdings or rights to acquire securities in the combined company, Dr.&#160;Reicin will hold or have the right to acquire shares representing at least 4.34% of our post-Merger common stock; and (v)&#160;eligibility to participate in our executive severance plan and other employee benefit, welfare and other plans, as may be maintained by us from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the employment related agreement for Dr.&#160;Reicin does not purport to be complete and is subject to and qualified in its entirety by reference to the copy of the amended and restated employment agreement for Dr.&#160;Reicin included as an exhibit to the registration statement of which this prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Daniel Lochner, M.B.A </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 28, 2024, we entered into an employment agreement with Daniel Lochner. The material terms of the employment agreement are as follows: (i)&#160;Mr.&#160;Lochner shall be employed as Chief Financial Officer of the Company, effective June 3, 2024; (ii) an annual base salary of $475,000; (iii) eligibility for an annual, performance- based cash bonus with a target bonus percentage of 40% of Mr.&#160;Lochner&#8217;s base salary subject to his continuous service through the payment of the bonus set to occur no later than April 15<sup style="font-size:75%; vertical-align:top">th</sup> the following calendar year; (iv)&#160;an issuance of an option award to purchase shares of common stock of the Company, representing 0.80% of the combined Company&#8217;s post- merger outstanding shares of common stock; (v)&#160;a performance-based equity award to purchase a number of shares of common stock equal to 0.10% of the combined Company&#8217;s post-merger outstanding shares of common stock; and (vi)&#160;eligibility to participate in the Company&#8217;s executive severance plan and other employee benefit, welfare and other plans, as may be maintained by the Company from time to time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Marcella K. Ruddy, M.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Tectonic entered into an offer letter with Dr.&#160;Ruddy (the &#8220;Ruddy Offer Letter&#8221;) in June 2021, in connection with her appointment as Legacy Tectonic&#8217;s Chief Medical Officer. The Ruddy Offer Letter provides for a base salary and target bonus opportunity, which shall be reviewed and may be adjusted on an annual basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To qualify for the annual target bonus set at a percentage of her adjusted base salary in respect of any calendar year, Dr.&#160;Ruddy must remain employed with Legacy Tectonic through the time the bonus payment was paid by Legacy Tectonic in the following year. Under the Ruddy Offer Letter, Legacy Tectonic granted Dr.&#160;Ruddy an option to purchase 142,233 shares of Tectonic common stock pursuant to the terms of Legacy Tectonic&#8217;s 2019 Equity Incentive Plan (the &#8220;Tectonic 2019 Plan&#8221;), at an exercise price of $1.27 per share. The option award is subject to automatic acceleration in the event of (i)&#160;a Change in Control (as defined in the Tectonic 2019 Plan) and (ii)&#160;provided that within the twelve months after such Change in Control either (x)&#160;Dr.&#160;Ruddy&#8217;s continuous service is terminated without Cause (as defined in the Ruddy Offer Letter) or (y)&#160;Dr.&#160;Ruddy resigns for Good Reason (as defined in the Ruddy Offer Letter). Dr.&#160;Ruddy is also eligible for additional equity awards under Legacy Tectonic equity compensation plans, as may be granted from time to time. As an NEO, Dr.&#160;Ruddy is also eligible to participate in the Company&#8217;s executive severance plan and other employee benefit, welfare and other plans, as may be maintained by the Company from time to time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Payments and Benefits upon a Termination or Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the completion of the Merger, our Board adopted the Severance Plan pursuant to which certain employees are eligible to participate, including the NEOs (each a &#8220;Participant&#8221; and collectively, the &#8220;Participants&#8221;). Pursuant to the Severance Plan, the Participants are eligible to receive the severance and change in control benefits described below, contingent upon the respective Participant&#8217;s execution of a participation agreement and a general release of claims as further described in the Severance Plan. The benefits provided pursuant to the Severance Plan supersede and replace any severance and/or change in control benefits to which the Participants were previously entitled, including pursuant to their employment agreements and offer letters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Participant&#8217;s employment with the Company is terminated by us without Cause or due to the Participant&#8217;s resignation for Good Reason (each as defined in the Severance Plan) during the period commencing three months prior to, and ending 12 months following, the effective date of a Change in Control (as defined in the Severance Plan) (the &#8220;Change in Control Period&#8221;), the Participant will be entitled to (i)&#160;a cash payment in an amount equal to 12 months (or 18 months for Dr.&#160;Reicin) of the Participant&#8217;s base salary; (ii)&#160;a cash payment of an amount equal to 100% (or 150% for Dr.&#160;Reicin) of the Participant&#8217;s annual target bonus for the year in which the change in control termination occurs; (iii)&#160;a cash payment of an amount equal to the Participant&#8217;s annual target bonus for the year in which the change in control termination occurs, <span style="white-space:nowrap">pro-rated</span> for the portion of the year elapsed in such year; (iv) 12 months (or 18 months for Dr.&#160;Reicin) of COBRA premiums; and (v)&#160;accelerated vesting of 100% of the Participant&#8217;s then-outstanding time-vesting equity awards. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Participant&#8217;s employment with the Company is terminated by us without Cause or due to the Participant&#8217;s resignation for Good Reason at a time that is not during the Change in Control Period, the Participant will be entitled to (i) 9 months (or 12 months for Dr.&#160;Reicin) of the Participant&#8217;s base salary; (ii)&#160;a cash payment of an amount equal to the Participant&#8217;s annual target bonus for the year in which the termination occurs, <span style="white-space:nowrap">pro-rated</span> for the portion of the year elapsed in such year; and (iii) 9 months (or 12 months for Dr.&#160;Reicin) of COBRA premiums. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the Severance Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Health and Welfare and Retirement Benefits; Perquisites </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These payments and benefits discussed above are in addition to eligibility to participate in benefits available generally to salaried employees, including medical, vision, dental, and life insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our NEOs, except in limited circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Retirement Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains a <span style="white-space:nowrap">tax-qualified</span> 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a <span style="white-space:nowrap">tax-advantaged</span> basis. Pursuant to the terms of such 401(k) plan, depending on facts and circumstances of the employee population in any given year, the Company may make a 3% mandatory contribution under and pursuant to the terms of the plan and applicable law. The Company does not maintain any defined benefit pension plan or nonqualified deferred compensation plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity Incentive Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2024 Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board adopted the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) in connection with and effective as of the closing of the Merger, which provides for the grant of nonstatutory stock options, (&#8220;NSOs&#8221;) stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of our affiliates. Initially, the maximum number of shares of common stock that may be issued under the 2024 Plan will not exceed 12.5% of the Company&#8217;s fully diluted shares outstanding determined as of immediately after the Effective Time (the &#8220;2024 Plan&#8217;s initial share reserve&#8221;). In addition, the number of shares of common stock reserved for issuance under the 2024 Plan will automatically increase on January 1 of each year, starting on January&#160;1, 2025, through and including January&#160;1, 2034, in an amount equal to (1) 5% of the total number of shares of common stock outstanding on the last day of the preceding calendar year, or (2)&#160;a lesser number of shares of common stock determined by the Board prior to the date of the increase. The maximum number of shares of common stock that may be issued on the exercise of ISOs under the 2024 Plan is three multiplied by the 2024 Plan&#8217;s initial share reserve. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2024 Employee Stock Purchase Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board adopted the 2024 Employee Stock Purchase Plan (the &#8220;2024 ESPP&#8221;) in connection with the Merger pursuant to which the Company may provide eligible employees with an opportunity to purchase shares of the common stock through accumulated contributions. The 2024 ESPP is designed to allow eligible U.S. employees to purchase common stock in a manner that may qualify for favorable tax treatment under Section&#160;423 of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 ESPP authorizes the issuance of a number of shares of common stock equal to 1% of the total number of shares of common stock issued and outstanding determined as of immediately after the effective time of the Merger (the &#8220;2024 ESPP&#8217;s initial share reserve&#8221;), pursuant to purchase rights granted to the Company&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees or to employees of any of the Company&#8217;s designated affiliates. The number of shares of common stock reserved for issuance will automatically increase on January&#160;1 of each year, from January 1, 2025 through and including January 1, 2034, by the lesser of (1) 1% of the total number of shares of common stock outstanding on the last day of the preceding calendar year, and (2)&#160;a number of shares of common stock equal to three times the 2024 ESPP&#8217;s initial share reserve; <span style="font-style:italic">provided</span>, that prior to the date of any such increase, the Board may determine that such increase will be less than the amount set forth in clauses (1)&#160;and (2). To date the Company has not made any offerings under the 2024 ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tectonic 2019 Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Tectonic Board adopted the Tectonic 2019 Plan and Legacy Tectonic stockholders approved the Tectonic 2019 Plan in June 2019. No additional awards have been made under the Tectonic 2019 Plan after the 2024 Plan became effective, and all awards under the Tectonic 2019 Plan were assumed by the Company after application of the exchange ratio. The terms and conditions of such assumed awards are the same as they were under the Tectonic 2019 Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2024 <span style="white-space:nowrap">Non-Employee</span> Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Table </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation for each person who served as a <span style="white-space:nowrap">non-employee</span> director of our Board during the year ended December&#160;31, 2024. Dr.&#160;Reicin, our Chief Executive Officer and President, did not receive any additional compensation for her service on our Board. The compensation received by Dr.&#160;Reicin as a NEO, is set forth in &#8220;<span style="font-style:italic">2024</span> <span style="font-style:italic">Executive Compensation&#8212;2024 Summary Compensation Table.</span>&#8221; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:56%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Fees&#160;Earned&#160;or</span><br/><span style="font-weight:bold">Paid in Cash</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option&#160;Awards</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phillip B. Donenberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">27,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">197,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">225,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terrance McGuire, M.S., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">197,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">238,318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy A. Springer, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">197,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">221,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Praveen Tipirneni, M.D., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">197,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">222,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stefan Vitorovic, M.S., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">26,250</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">197,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">223,818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported represent the aggregate grant date fair value of the stock option awards granted during the year ended December&#160;31, 2024, calculated in accordance with FASB ASC 718 for share-based compensation transactions. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in &#8220;Note 2. <span style="font-style:italic">Summary of Significant Accounting Policies and Basis of Presentation&#8212;Stock-Based Compensation</span>&#8221; and &#8220;Note 8. <span style="font-style:italic">Equity Incentive Plans</span>&#8221; to our consolidated financial statements for the year ended December&#160;31, 2024 included elsewhere in this registration statement of which this prospectus forms a part. These amounts do not correspond to the actual economic value that may be received by our <span style="white-space:nowrap">non-employee</span> directors upon the exercise of the stock options or any sale of the underlying shares of common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The following table provides information regarding the number of shares of common stock underlying options held by our <span style="white-space:nowrap">non-employee</span> directors that were outstanding as of December&#160;31, 2024: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option&#160;Awards</span><br/><span style="font-weight:bold">Outstanding&#160;at</span><br/><span style="font-weight:bold"><span style="white-space:nowrap">Year-End</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phillip B. Donenberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terrance McGuire, M.S., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy A. Springer, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Praveen Tipirneni, M.D., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stefan Vitorovic, M.S., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">$13,125 of fees earned by Mr.&#160;Vitorovic were paid to Vida Ventures and $13,125 of fees earned were paid to Mr.&#160;Vitorovic. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Director Compensation After the Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Merger, Legacy Tectonic did not have a formal compensation policy with respect to service on its board of directors. Legacy Tectonic reimbursed its <span style="white-space:nowrap">non-employee</span> directors for their reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in attending board and committee meetings, and occasionally granted stock options and restricted stock awards as compensation for service. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Merger, our Board approved certain option grants to our directors, other than Dr.&#160;Reicin. As a result, on June&#160;20, 2024, each of Phillip B. Donenberg, Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic received an option grant to purchase 11,760&#160;shares of our common stock, in each case, with an exercise price per share equal to $16.80, which was the closing price per share of our common stock as reported on the Nasdaq Global Market on the closing date of the Merger (as adjusted for the reverse stock split). The shares subject to these option grants will vest 1/3 on the first anniversary of the grant date, and thereafter the remaining 2/3 of the shares will vest in equal monthly installments over the following two years, in each case subject to the recipient&#8217;s continuous service through the applicable vesting dates, such that the options are vested in full on the three-year anniversary of the grant date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our <span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy, which was established in connection with the Merger, each of our <span style="white-space:nowrap">non-employee</span> directors is eligible to receive compensation for service on our Board and committees of our Board as set forth below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy provides our <span style="white-space:nowrap">non-employee</span> directors with the following cash compensation for their services: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$40,000 per year for each <span style="white-space:nowrap">non-employee</span> director; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$70,000 per year for the <span style="white-space:nowrap">non-executive</span> chairperson (if applicable) in lieu of the annual amount above; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$15,000 per year for chair of the audit committee or $7,500 per year for each other member of the audit committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$10,000 per year for chair of the compensation committee or $5,000 per year for each other member of the compensation committee; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$8,000 per year for chair of the nominating and corporate governance committee or $4,000 per year for each other member of the nominating and corporate governance committee. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cash compensation above is payable to our eligible <span style="white-space:nowrap">non-employee</span> directors in equal quarterly installments in arrears, prorated for any partial quarter of service. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equity Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the cash compensation structure described above, the <span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy provides for the following equity incentive compensation program for <span style="white-space:nowrap">non-employee</span> directors. All such equity compensation will be granted under the 2024 Plan or any successor equity plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Initial Grant</span>. Each <span style="white-space:nowrap">non-employee</span> director who joins our Board will automatically, upon the date of his or her initial election or appointment to be a <span style="white-space:nowrap">non-employee</span> director (or, if such date is not a business day, on the first business day thereafter), be granted a <span style="white-space:nowrap">one-time,</span> initial equity award of options (the &#8220;initial grant&#8221;) to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase 14,800 shares of common stock with a cash value not to exceed $800,000. <span style="white-space:nowrap">One-third</span> of the initial grant will vest on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments thereafter until the third anniversary of the date of grant, subject to continuous service through each applicable vesting date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Annual Grant</span>. On the first business day following each annual meeting of our stockholders, each person who is then a <span style="white-space:nowrap">non-employee</span> director of ours will automatically be granted an option to purchase 7,400 shares of common stock with a cash value not to exceed $400,000 (the &#8220;annual grant&#8221;). Each annual grant will vest on the earlier of the <span style="white-space:nowrap">one-year</span> anniversary of the annual award&#8217;s grant date or the date of our next annual stockholder meeting following the annual award&#8217;s grant date, subject to continuous service through the vesting date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <span style="white-space:nowrap">non-employee</span> director&#8217;s then-outstanding equity awards granted under the policy (and any other then-outstanding equity awards held by the <span style="white-space:nowrap">non-employee</span> director that were outstanding and unvested immediately prior to the date of the execution of the underwriting agreement related to our initial public offering) will become fully vested upon a change in control (as defined in our 2024 Plan), subject to the <span style="white-space:nowrap">non-employee</span> director remaining in continuous service until immediately prior to the closing of the change in control. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_11">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the compensation agreements and other arrangements with the Company and the Company&#8217;s directors and executive officers in the section titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>&#8221; elsewhere in this prospectus, the following is a description of each transaction involving the Company or Legacy Tectonic since January&#160;1, 2023 in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Legacy Tectonic&#8217;s or the Company&#8217;s total assets at <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years, as applicable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any of our directors, executive officers, or holders of more than 5% of our capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legacy Tectonic&#8217;s Transactions and Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Legacy Tectonic Subscription Agreement and SAFEs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;30, 2024, concurrently with the execution and delivery of the Merger Agreement, Legacy Tectonic entered into a subscription agreement with certain investors named therein, pursuant to which such investors agreed to purchase shares of Legacy Tectonic common stock, at a purchase price of $12.39908 per share (the &#8220;Subscription Agreement&#8221;), and certain investors consummated certain additional purchases of Legacy Tectonic common stock pursuant to the terms of the SAFEs entered into by such investors and Legacy Tectonic, for an aggregate purchase price among the private financings contemplated by the Subscription Agreement and such SAFEs of approximately $130.7&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the purchase of Legacy Tectonic common stock pursuant to the Subscription Agreement and the entry into the SAFEs by Legacy Tectonic&#8217;s related persons: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:81%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Stockholder</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total</span><br/><span style="font-weight:bold">Purchase</span><br/><span style="font-weight:bold">Price ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Timothy A. Springer, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">41,999,997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Polaris Partners IX, L.P.<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,999,989</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Vida Ventures<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,499,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Polaris Founders Capital Fund II, L.P.<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,499,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Kruse, Ph.D.<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">125,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents entry into the SAFEs and purchase of Legacy Tectonic common stock pursuant to the Subscription Agreement. Dr.&#160;Timothy&#160;A. Springer served as a director on the Legacy Tectonic Board and serves as a director of the Board. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents entry into the SAFEs and purchase of Legacy Tectonic common stock pursuant to the Subscription Agreement. PP IX owned more than five percent of Legacy Tectonic&#8217;s outstanding capital stock and owns more than five percent of the Company&#8217;s outstanding capital stock. Terrance McGuire served as a director of the Legacy Tectonic Board, serves as a director on the Board and holds an interest in Polaris Partners GP IX, L.L.C., the general partner of PP IX. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents entry into the SAFEs and purchase of Legacy Tectonic common stock pursuant to the Subscription Agreement. Stefan Vitorovic served as a director on the Legacy Tectonic Board, serves as a director of the Board and was a member of the investment committee of VV Manager II, LLC, which is affiliated with Vida Ventures. Entities affiliated with Vida Ventures collectively owned more than five percent of Legacy Tectonic&#8217;s outstanding capital stock and own more than five percent of the Company&#8217;s outstanding capital stock. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents purchase of Legacy Tectonic common stock pursuant to the Subscription Agreement. Terrance McGuire served as a director on the Legacy Tectonic Board, serves as a director of the Board and is a managing member of Polaris Founders Capital Management Co. II, L.L.C., the general partner of Polaris Founders Capital Fund II, L.P. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents entry into the SAFEs. Dr.&#160;Andrew Kruse served as a director on the Legacy Tectonic Board. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Support Agreements Under the Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain Legacy Tectonic stockholders entered into support agreements with Legacy Tectonic pursuant to which, among other things, each such stockholder, solely in his, her or its capacity as a Legacy Tectonic stockholder, agreed to vote all of such stockholder&#8217;s shares of Legacy Tectonic capital stock in favor of (i)&#160;the adoption of the Merger Agreement, (ii)&#160;the approval of the merger and related transactions contemplated by the Merger Agreement, (iii)&#160;the approval of an amendment to Legacy Tectonic&#8217;s certificate of incorporation to increase its authorized stock, (iv)&#160;to the extent such person was entitled to vote or exercise a right to consent with respect to such matter, effecting the preferred stock conversion immediately prior to conversion of the SAFEs, which SAFEs conversion occurred immediately prior to the consummation of the private placement financings, (v)&#160;waiving any preemptive right, right of participation, right of maintenance, anti-dilution right or any similar right as may otherwise have been provided to such stockholder under Legacy Tectonic&#8217;s certificate of incorporation or bylaws in connection with the Merger and related transactions contemplated by the Merger Agreement and (vi)&#160;against any Acquisition Proposal from a third party. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">February 2025 Private Placement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Entities affiliated with Deep Track Capital, LP, entities affiliated with FMR LLC, TAS Partners, LLC, entities affiliated with EcoR1, Dr.&#160;Springer and Mr.&#160;Lochner purchased shares of our common stock in the Private Placement. The following table summarizes the purchase of shares of our common stock by such parties: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:81%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Stockholder</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total</span><br/><span style="font-weight:bold">Purchase</span><br/><span style="font-weight:bold">Price ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Deep Track Capital, LP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with FMR LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,527,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TAS Partners, LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">33,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy A. Springer, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,999,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Lochner, M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Private Placement, we also entered into a registration rights agreement with investors thereto, including the purchasers listed above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Indemnification Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of its directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in the Company&#8217;s right, on account of any services undertaken by such person on the Company&#8217;s behalf or that person&#8217;s status as a member of the Board to the maximum extent allowed under Delaware law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the indemnification agreements does not purport to be complete and is qualified in its entirety by the full text of the form of indemnification agreement, which is attached as an exhibit to the registration statement of which this prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Person Transaction Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board adopted a written related person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of &#8220;related person transactions.&#8221; For purposes of the policy only, a &#8220;related person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we or any of our subsidiaries are participants involving an amount that exceeds $120,000, in which any &#8220;related person&#8221; has a material interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions involving compensation for services provided to us as an employee, consultant or director will not be considered related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of our voting securities (including the common stock), including any of their immediate family members and affiliates, including entities owned or controlled by such persons. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, the related person in question or, in the case of transactions with a holder of more than 5% of any class of our voting securities, an officer with knowledge of a proposed transaction, must present information regarding the proposed related person transaction to the audit committee (or, where review by the audit committee would be inappropriate, to another independent body of the board) for review. The audit committee will approve only those transactions that it determines are fair to us and in our best interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the transactions described above were entered into prior to the adoption of such policy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_12">PRINCIPAL SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding beneficial ownership of the Company&#8217;s common stock as of February&#160;28, 2025, by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person known to be the beneficial owner of more than 5% of the Company&#8217;s outstanding common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of the Company&#8217;s executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of the Company&#8217;s executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power with respect to the securities as well as any shares of common stock that the individual or entity has the right to acquire within 60 days of February&#160;28, 2025 the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, the Company believes, based on the information provided to them, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table lists applicable percentage ownership based on 18,662,672 shares of common stock outstanding as of February&#160;28, 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares&#160;beneficially&#160;owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and address of beneficial owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">5% or Greater Stockholders:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Persons and entities affiliated with Timothy A. Springer, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,382,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with FMR LLC<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,516,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Deep Track Capital, LP<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,401,938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Partners IX, L.P.<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,157,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Vida Ventures<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,028,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Named Executive Officers and Directors:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy A. Springer, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,382,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terrance McGuire, M.S., M.B.A.<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,157,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stefan Vitorovic, M.S., M.B.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alise Reicin, M.D.<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">334,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcella K. Ruddy, M.D.<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">110,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Praveen Tipirneni, M.D., M.B.A.<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Lochner, M.B.A.<sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phillip B. Donenberg<sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">62,693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">All executive officers and directors as a group (10&#160;persons)<sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,241,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">38.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than one percent. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;4,226,058 shares of common stock held by Dr. Springer, (ii)&#160;186,134 shares held by Dr.&#160;Chafen Lu and (iii)&#160;970,223 shares of common stock held by TAS Partners, LLC (&#8220;TAS&#8221;). Dr.&#160;Lu is the spouse of Dr.&#160;Springer. Dr.&#160;Springer is the sole managing member of TAS. Dr.&#160;Springer exercises sole voting and dispositive power over the shares held by him directly and the shares held by TAS. Dr.&#160;Springer disclaims beneficial ownership of the shares held by TAS. Dr.&#160;Lu exercises sole voting and dispositive power over the shares held by her directly. The principal business address of each of Dr.&#160;Springer, Dr.&#160;Lu and TAS is 36 Woodman Road, Newton, MA 02467. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These shares of common stock are owned by funds and accounts managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 1,401,938 shares of common stock held by Deep Track Biotechnology Master Fund, Ltd. (&#8220;Deep Track Master&#8221;). David Kroin is the managing member of Deep Track Capital GP, LLC, the General Partner of Deep Track Capital, LP. Deep Track Capital, LP is the Investment Manager of Deep Track Biotechnology Master Fund. Ltd. The address of the above persons and entities is 200 Greenwich Avenue, 3<sup style="font-size:75%; vertical-align:top">rd</sup> Floor, Greenwich, CT 06830. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All the shares are held of record by Polaris Partners IX, L.P. (&#8220;PP IX&#8221;). Polaris Partners GP IX, L.L.C. (&#8220;PP GP IX&#8221;) is the general partner of PP IX and may be deemed to have sole voting and dispositive power with respect to the shares held by PP IX. David Barrett, Brian Chee, Amir Nashat and Amy Schulman (collectively, the &#8220;PP GP IX Managing Members&#8221;) are the managing members of PP GP IX, and Terrance McGuire, a member of the Board, holds an interest in PP GP IX. Each of the PP GP IX Managing Members and Terrance McGuire, in their respective capacities with respect to PP GP IX, may be deemed to have shared voting and dispositive power with respect to the shares held by PP IX. The principal business address for all entities and individuals affiliated with Polaris Partners is c/o Polaris Partners, One Marina Park Drive, 8th Floor, Boston, MA 02210. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;1,000,900 shares of common stock held by Vida Ventures II, LLC (&#8220;Vida II Main Fund&#8221;) and (ii)&#160;27,774 shares of common stock held by Vida Ventures <span style="white-space:nowrap">II-A,</span> LLC (&#8220;Vida II Parallel Fund,&#8221; and together with the Vida II Main Fund, &#8220;Vida II&#8221;). VV Manager II, LLC (&#8220;VV Manager II&#8221;) is the manager of Vida II. Arie Belldegrun, Fred Cohen, and Leonard Potter are the members of the management committee of VV Manager II (the &#8220;Management Committee&#8221;) and Arie Belldegrun, Fred Cohen, Helen Kim, Rajul Jain, and Joshua Kazam are the members of the investment committee of VV Manager II (the &#8220;Investment Committee&#8221;). Each of the Management Committee, the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaim beneficial ownership over the securities held of record by Vida II. The address of all entities affiliated with Vida is 40 Broad Street, Suite&#160;201, Boston, MA 02109. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;20,262 shares of common stock held by Polaris Founders Capital Fund I, L.P. (&#8220;PF I&#8221;), (ii)&#160;consists of 64,652 shares of common stock held by Polaris Founders Capital Fund II, L.P. (&#8220;PF II&#8221;) and (iii)&#160;1,073,063 shares of common stock held by PP IX. Polaris Founders Capital Management Co. I, L.L.C. (&#8220;PFC I GP&#8221;) is the general partner of PF I and may be deemed to have sole voting and dispositive power with respect to the shares held by PF I. Polaris Founders Capital Management Co. II, L.L.C. (&#8220;PFC II GP&#8221;) is the general partner of PF II and may be deemed to have sole voting and dispositive power with respect to the shares held by PFC II. Terrance McGuire, a member of the Board, and Jonathan Flint (together, the &#8220;PFC GP Managing Members&#8221;) are the managing members of PFC I GP and PFC II GP. Each of the PFC GP Managing Members, in their respective capacities with respect to PFC I GP and PFC II GP, may be deemed to have shared voting and dispositive power with respect to the shares held by PF I and PF II. PP GP IX is the general partner of PP IX and may be deemed to have sole voting and dispositive power with respect to the shares held by PP IX. The PP GP IX Managing Members are the managing members of PP GP IX, and Terrance McGuire, a member of the Board, holds an interest in PP GP IX. Each of the PP GP IX Managing Members and Terrance McGuire, in their respective capacities with respect to PP GP IX, may be deemed to have shared voting and dispositive power with respect to the shares held by PP&#160;IX. The principal business address for all entities and individuals affiliated with Polaris Partners is c/o&#160;Polaris Partners, One Marina Park Drive, 8th Floor, Boston, MA 02210. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;166,580 shares of common stock held by Dr.&#160;Reicin, 11,372 of which are subject to repurchase as of February&#160;28, 2025, (ii)&#160;124,530 shares of common stock held by the 2020 Reicin-Boiarsky Family Trust (the &#8220;2020 Reicin Trust&#8221;) and (iii)&#160;43,738 shares of common stock issuable upon exercise of options granted to Dr.&#160;Reicin that are exercisable within 60 days of February&#160;28, 2025. Robert Boiarsky is a <span style="white-space:nowrap">co-trustee</span> of the 2020 Reicin Trust and the spouse of Dr.&#160;Reicin. Dr.&#160;Reicin may be deemed to have shared voting and dispositive power over the securities held by the 2020 Reicin Trust. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(8)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;32,065 shares of common stock held by Dr.&#160;Ruddy and (ii)&#160;46,784 shares of common stock issuable upon exercise of options granted to Dr.&#160;Ruddy that are exercisable within 60 days of February&#160;28, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(9)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;3,037 shares of common stock held by Dr.&#160;Tipirneni and (ii)&#160;12,166 shares of common stock issuable upon exercise of options granted to Dr.&#160;Tipirneni that are exercisable within 60 days of February&#160;28, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(10)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;4,617 shares of common stock held by Mr.&#160;Lochner and (ii)&#160;1,369 shares of common stock issuable upon exercise of options granted to Mr.&#160;Lochner that are exercisable within 60 days of February&#160;28, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(11)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 166 shares of common stock held by Mr.&#160;Donenberg and (ii)&#160;9,372 shares of common stock issuable upon exercise of options granted to Mr.&#160;Donenberg that are exercisable within 60 days of February&#160;28, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(12)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;6,766,837 shares of common stock and (ii)&#160;113,429 shares of common stock issuable upon exercise of options that are exercisable within 60 days of February&#160;28, 2025. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_13">SELLING STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock being offering by the selling stockholders consist of the Shares issued to the selling stockholders in the Private Placement. For additional information regarding the issuance of the Shares in connection with the Private Placement, see the section &#8220;Prospectus Summary&#8212;Private Placement&#8221; above. We are registering the resale of the Shares issued to the selling stockholders in order to permit such selling stockholders to offer the Shares for resale from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below lists the selling stockholders and other information regarding their ownership of the Shares offered hereby. The second column lists the number of shares of common stock beneficially owned by the selling stockholders as of February&#160;28, 2025. The selling stockholders may have sold or transferred some or all of the common stock indicated below and may in the future sell or transfer some or all of the common stock indicated below in transactions exempt from the registration requirements of the Securities Act rather than under this prospectus. The third column lists the shares of common stock being offered by this prospectus by the selling stockholders. The fourth column assumes the sale of all of the shares of common stock offered by the selling stockholders pursuant to this prospectus. The selling stockholders may sell all, some or none of their shares of common stock in this offering. See &#8220;<span style="font-style:italic">Plan of Distribution</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the selling stockholders have sole voting and investment power with respect to all shares of common stock that they own, subject to applicable community property laws. Beneficial ownership for the purposes of the table below is determined in accordance with the rules and regulations of the SEC. These rules generally provide that a person is the beneficial owner of securities if such person has or shares the power to vote or direct the voting thereof, or to dispose or direct the disposition thereof or has the right to acquire such powers within 60 days. Percentage of beneficial ownership is based on 18,662,672 shares of common stock outstanding as of February&#160;28, 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Beneficial&#160;Ownership<br/>Before Offering</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Maximum&#160;Number&#160;of<br/>Shares Offered<br/>Pursuant&#160;to&#160;Prospectus</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Beneficial&#160;Ownership&#160;After<br/>Offering</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of Shares</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of Shares</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage<br/>(%)</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd.<sup style="font-size:75%; vertical-align:top"> (1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1,401,938</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">800,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">601,938</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">3.23%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">245,985</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">30,544</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">215,441</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1.15%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Biotechnology Portfolio<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">442,889</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">160,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">282,889</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1.52%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">175,705</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">42,727</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">132,978</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">*</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">651,163</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">169,171</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">481,922</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">2.58%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Growth Company Commingled Pool, By: Fidelity Management Trust Company, as Trustee<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1,007,880</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">234,884</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">772,996</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">4.14%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust : Fidelity Growth Company K6 Fund<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">241,174</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">53,218</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">187,956</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1.01%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TAS Partners, LLC<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">970,223</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">660,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">310,223</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1.66%</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Beneficial&#160;Ownership<br/>Before Offering</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Maximum&#160;Number&#160;of<br/>Shares Offered<br/>Pursuant&#160;to&#160;Prospectus</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Beneficial&#160;Ownership&#160;After<br/>Offering</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of Shares</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of Shares</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage<br/>(%)</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy A. Springer, Ph.D.<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">5,382,415</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">129,294</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">525,3121</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">28.15%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with EcoR1 Capital LLC<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1,024,143</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">500,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">524,143</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">2.81%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point 72 Associates, LLC<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">200,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">200,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#8212;&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Farallon Capital Management, L.L.C.<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">853,050</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">140,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">713,050</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">3.82%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Baker Bros. Advisors LP<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">100,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">100,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#8212;&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woodline Master Fund LP<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">330,878</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">100,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">230,878</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1.24%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners, LP<sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">285,715</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">100,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">185,715</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1.00%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ally Bridge Medalpha Master Fund L.P.<sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">117,222</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">80,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">37,222</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">*</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel CEMF Investments Ltd.<sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">65,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">65,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#8212;&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">StemPoint Capital LP<sup style="font-size:75%; vertical-align:top">(13)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">96,764</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">60,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">36,764</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">*</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soleus Capital Master Fund<sup style="font-size:75%; vertical-align:top">(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">76,841</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">60,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">16,841</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">*</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Lochner, M.B.A.<sup style="font-size:75%; vertical-align:top">(15)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">5,986</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">4,617</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">1,369</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">*</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than one percent. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 1,401,938 shares of common stock held by Deep Track Biotechnology Master Fund, Ltd. (&#8220;Deep Track&#8221;). David Kroin is the managing member of Deep Track Capital GP, LLC, the General Partner&#160;of Deep Track Capital, LP. Deep Track Capital, LP is the Investment Manager of Deep Track Biotechnology Master Fund. Ltd. The address of the above persons and entities is 200 Greenwich Avenue, 3<sup style="font-size:75%; vertical-align:top">rd</sup>&#160;Floor, Greenwich, CT 06830. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 970,223 shares of common stock held by TAS. Dr.&#160;Springer is the sole managing member of TAS and exercises sole voting and dispositive power over the shares held by TAS. Dr.&#160;Springer disclaims beneficial ownership of the shares held by TAS. The principal business address of each of Dr.&#160;Springer and TAS is 36 Woodman Road, Newton, MA 02467. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;4,226,058 shares of common stock held by Dr.&#160;Springer, (ii)&#160;186,134 shares held by Dr.&#160;Chafen Lu and (iii)&#160;970,223 shares of common stock held by TAS. Dr.&#160;Lu is the spouse of Dr.&#160;Springer. Dr.&#160;Springer is the sole managing member of TAS. Dr.&#160;Springer exercises sole voting and dispositive power&#160;over the shares held by him directly and the shares held by TAS. Dr.&#160;Springer disclaims beneficial ownership of the shares held by TAS. Dr.&#160;Lu exercises sole voting and dispositive power over the shares&#160;held by her directly. The principal business address of each of Dr.&#160;Springer, Dr.&#160;Lu and TAS is 36&#160;Woodman Road, Newton, MA 02467. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 470,000 shares of common stock purchased in the Private Placement by EcoR1 Capital Fund Qualified, L.P. (&#8220;Qualified Fund&#8221;); and (ii) 30,000 shares of common stock purchased in the Private Placement by EcoR1 Capital Fund, L.P. (&#8220;Capital Fund&#8221;, and together with Qualified Fund, the &#8220;EcoR1 Capital Funds&#8221;). EcoR1 Capital LLC (&#8220;EcoR1&#8221;) is the general partner of the EcoR1 Capital Funds. Oleg Nodelman is the control person of EcoR1 and may be deemed to share dispositive voting power over the shares held by the EcoR1 Capital Funds. Mr.&#160;Nodelman and EcoR1 both disclaim beneficial ownership of all shares except to the extent of their pecuniary interest. The address for EcoR1 Capital LLC, the EcoR1 Capital Funds and Oleg Nodelman is 357 Tehama Street #3, San Francisco, CA 94103. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Point72 Asset Management, L.P. maintains investment and voting power with respect to the securities held by certain investment funds it manages, including Point72 Associates, LLC. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr.&#160;Steven&#160;A. Cohen controls each of Point72&#160;Asset Management, L.P. and Point72 Capital Advisors, Inc. By reason of the provisions of Rule <span style="white-space:nowrap">13d-3</span> of the Exchange Act, each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&#160;Cohen may be deemed to beneficially own the securities directly held by Point72 Associates, LLC reflected herein. Each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&#160;Cohen disclaims beneficial ownership of any such securities. The address of the above person and entities is 72 Cummings Point Road, Stamford, CT 06902. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The securities that are the subject of this resale registration statement are held directly by the Farallon Funds (as defined below), as follows: (i)&#160;Farallon Capital Partners, L.P. (&#8220;FCP&#8221;) holds 25,592 shares of common stock; (ii)&#160;Farallon Capital Institutional Partners, L.P. (&#8220;FCIP&#8221;) holds 38,780 shares; (iii)&#160;Farallon Capital Institutional Partners II, L.P. (&#8220;FCIP II&#8221;) holds 1,036 shares; (iv)&#160;Farallon Capital Institutional Partners III, L.P. (&#8220;FCIP III&#8221;) holds 3,360 shares; (v)&#160;Four Crossings Institutional Partners V, L.P. (&#8220;FCIP V&#8221;) holds 4,046 shares; (vi)&#160;Farallon Capital Offshore Investors II, L.P. (&#8220;FCOI II&#8221;) holds 57,862 shares; (vii)&#160;Farallon Capital (AM) Investors, L.P. (&#8220;FCAMI&#8221;) holds 3,360 shares; and (viii)&#160;Farallon Capital F5 Master I, L.P. (&#8220;F5MI&#8221; and, together with FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II and FCAMI, the &#8220;Farallon Funds&#8221;) holds 5,964 shares. Farallon Partners, L.L.C. (the &#8220;Farallon General Partner&#8221;), as the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner (as defined below), may be deemed a beneficial owner of the shares held by the Farallon Funds other than F5MI. Farallon Institutional (GP) V, L.L.C. (the &#8220;FCIP V General Partner&#8221;), as the general partner of FCIP V, may be deemed a beneficial owner of the shares held by FCIP V. Farallon F5 (GP), L.L.C. (the &#8220;F5MI General Partner&#8221;), as the general partner of F5MI, may be deemed a beneficial owner of the shares held by F5MI. Each of Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Cheng Luo, Rajiv A. Patel, Dr.&#160;Thomas&#160;G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes, John&#160;R. Warren and Mark C. Wehrly (collectively, the &#8220;Farallon Managing Members&#8221;), as a senior managing member or managing member, as the case may be, of the Farallon General Partner, and a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, in each case with the power to exercise investment discretion, may be deemed a beneficial owner of all such shares held by the Farallon Funds. Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner, and the Farallon Managing Members hereby disclaims any beneficial ownership of any such shares. The address of each of the entities and individuals referenced in this note is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, CA 94111. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(8)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 91,596 shares of common stock held by Baker Brothers Life Sciences, L.P. (&#8220;Life Sciences&#8221;) and 8,404 shares of common stock held by 667, L.P (&#8220;667&#8221;). Life Sciences and 667 are direct holders under the advisement of Baker Bros. Advisors LP. Baker Bros. Advisors (GP) LLC is the sole general partner of Baker Bros. Advisors LP. Julian C. Baker and Felix. J. Baker are managing members of Baker Bros. Advisors (GP) LLC. The address of the above person and entities is 860 Washington Street,3<sup style="font-size:75%; vertical-align:top">rd</sup> Floor, New&#160;York, NY 10014. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(9)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 330,878 shares of common stock held by Woodline Master Fund LP. Woodline Partners LP (&#8220;Woodline Partners&#8221;) serves as the investment manager of Woodline Master Fund LP and may be deemed to be the beneficial owner of the shares. Woodline Partners disclaims any beneficial ownership of these shares. The address of the foregoing entities is 4 Embarcadero Center, Suite 3450, San Francisco, CA&#160;94111. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(10)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 100,000 shares of common stock held by Adage Capital Partners, LP (&#8220;Adage&#8221;). Bob Atchinson and Phillip Gross are the managing members of Adage Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C., which is the general partner of Adage, and each such person or entity, as the case may be, has shared voting and/or investment power over the securities held by Adage and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(11)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 80,000 shares of common stock held by Ally Bridge Medalpha Master Fund L.P. (&#8220;MedAlpha&#8221;). Mr.&#160;Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages investments of MedAlpha. As such, each of the foregoing entities and Mr.&#160;Fan Yu may be deemed to share beneficial ownership of the shares held by MedAlpha. Each of them disclaims any such beneficial ownership. The address of the above person and entities is 430 Park Avenue, 12<sup style="font-size:75%; vertical-align:top">th</sup> Floor, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(12)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 65,000 shares of common stock held by Citadel CEMF Investments Ltd. (&#8220;Citadel CEMF&#8221;). Citadel Advisors LLC (&#8220;Citadel Advisors&#8221;) is the portfolio manager of Citadel CEMF. Citadel Advisors Holdings LP (&#8220;CAH&#8221;) is the sole member of Citadel Advisors and Citadel GP LLC (&#8220;CGP&#8221;) is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&#160;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote, or to direct the vote of, and/or shared power to dispose of, or to direct the disposition over, the 65,000 shares held by Citadel CEMF. This disclosure is not and shall not be construed as an admission that Mr.&#160;Griffin or any of the Citadel-related entities listed above is the beneficial owner of any securities of the Company other than the securities actually owned by such person (if any). The address of Citadel CEMF is c/o Citadel Enterprise Americas LLC, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(13)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 60,000 shares of common stock held by StemPoint Capital LP (&#8220;StemPoint&#8221;). Michelle Ross is the sole managing member of StemPoint and exercises sole voting and dispositive power over the securities beneficially owned by StemPoint. Ms.&#160;Ross disclaims beneficial ownership of the shares held by StemPoint. The address of the above person and entity is 520 Madison Avenue, 19<sup style="font-size:75%; vertical-align:top">th</sup> Floor, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(14)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 60,000 shares of common stock held by Soleus Capital Master Fund (&#8220;Soleus Master Fund&#8221;). Soleus Capital, LLC is the sole general partner of Soleus Master Fund, Soleus Capital Group, LLC (&#8220;SCG&#8221;) is the sole managing member of Soleus Capital, LLC, Soleus Capital Management, L.P. (&#8220;SCM&#8221;) is the investment manager of Soleus Master Fund, Soleus GP, LLC is the general partner of SCM, and Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr.&#160;Levy disclaims beneficial ownership of the shares held by Soleus Master Fund except to the extent of their pecuniary interest therein. The address of the above persons is 104 Field Point Road, 2nd Floor, Greenwich, CT 06830. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(15)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 5,986 shares of common stock held by Mr.&#160;Lochner. Mr.&#160;Lochner exercises sole voting and dispositive power over the shares held by him. The principal address of Mr.&#160;Lochner is 55 Iris Avenue, Boulder, CO 80304. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_14">DESCRIPTION OF CAPITAL STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following description of our capital stock and provisions of our charter and bylaws are summaries and are qualified by reference to such charter and bylaws and applicable provisions of Delaware corporate law. Copies of these documents are filed as exhibits to the registration statement of which this prospectus forms a part. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized Capital Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to receive dividends ratably, if any, as may be declared by our Board out of legally available funds, subject to any preferential dividend rights of any our preferred stock then outstanding </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share of our common stock held of record for the election of directors of the Company and on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Distributions on Liquidation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of the Company&#8217;s dissolution, liquidation or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. All outstanding shares are fully paid and <span style="white-space:nowrap">non-assessable.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights, and no sinking fund provisions are applicable to our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our charter provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable the Board to discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, the Board were to determine that a takeover proposal is not in the best interests of the Company stockholders, the Board could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our charter grants the Board broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of the Company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Effects of Delaware Law and Provisions of the Company&#8217;s Charter and Bylaws </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of the DGCL and of the Company&#8217;s charter and bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of the Company. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire control of the Company to first negotiate with the Board. These provisions might also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests. However, the Company holds that the advantages gained by protecting its ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could improve their terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Delaware Anti-Takeover Statute </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&#160;203 of the DGCL. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the date that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">before the stockholder became interested, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at or after the time the stockholder became interested, the business combination was approved by the board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <span style="white-space:nowrap">two-thirds</span> of the outstanding voting stock which is not owned by the interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 defines a business combination to include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any merger or consolidation involving the corporation or any direct or indirect majority-owned subsidiary of the corporation and the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any sale, transfer, lease, pledge or other disposition (in one or more transactions) involving the interested stockholder of 10% or more of either the aggregate market value of all (i)&#160;the assets of the corporation or (ii)&#160;the outstanding capital stock of the corporation, involving the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject to exceptions, any transaction that results in the issuance or transfer by the corporation or by any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or any subsidiary to the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject to exceptions, any transaction involving the corporation or any direct or indirect majority- owned subsidiary of the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation or of any subsidiary beneficially owned by the interested stockholder; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation or any direct or indirect majority-owned subsidiary. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&#160;203 defines an &#8220;interested stockholder&#8221; as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of the corporation and who beneficially owned 15% or more of the outstanding voting stock of the corporation at any time within the three year period immediately prior to the date of determining whether such entity or person is an interested stockholder, and any affiliate or associate of that entity or person. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Board Composition and Filling Vacancies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our charter provides for the division of the Board into three classes serving staggered three-year terms, with one class being elected each year. Our charter also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of <span style="white-space:nowrap">two-thirds</span> or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on the Board, however occurring, including a vacancy resulting from an increase in the size of the Board, may only be filled by the affirmative vote of a majority of directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of the Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No Written Consent of Stockholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our charter provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of the Company&#8217;s bylaws or removal of directors by stockholders without holding a meeting of stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Meetings of Stockholder </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our charter and bylaws provide that only a majority of the members of the Board then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Advance Notice Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of Company stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_15">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS TO <span style="white-space:nowrap">NON-U.S.</span> HOLDERS OF OUR COMMON STOCK<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary describes the material U.S. federal income tax consequences of the ownership and disposition of our common stock acquired in this offering by <span style="white-space:nowrap">Non-U.S.</span> Holders (as defined below). This discussion is not a complete analysis of all potential U.S. federal income tax consequences relevant to a <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s particular circumstances, and does not deal with <span style="white-space:nowrap">non-U.S.,</span> state and local tax consequences that may be relevant to <span style="white-space:nowrap">Non-U.S.</span> Holders, nor does it address any U.S. federal tax consequences (such as gift and estate taxes) other than income taxes. Special rules different from those described below may apply to certain <span style="white-space:nowrap">Non-U.S.</span> Holders that are subject to special treatment under the U.S. Internal Revenue Code of 1986, as amended, or the Code, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks, insurance companies and other financial institutions, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">brokers, dealers and certain electing traders in securities who mark their securities positions to market for U.S. tax purposes, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain former U.S. citizens or long-term residents, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;controlled foreign corporations,&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;passive foreign investment companies,&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">corporations that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state thereof or the District of Columbia that are nonetheless treated as U.S. income taxpayers for U.S. federal tax purposes, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that hold our common stock as part of a &#8220;straddle,&#8221; &#8220;conversion transaction,&#8221; &#8220;synthetic security,&#8221; integrated investment or other risk reduction strategy, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to the alternative minimum tax, the federal Medicare contribution tax on net investment income or the special tax accounting rules under Section&#160;451(b) of the Code, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-qualified</span> retirement plans, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who acquire our common stock through the exercise of an option or otherwise as compensation, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that own or have owned, actually or constructively, more than 5% of our common stock, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partnerships and other pass-through entities or arrangements, and investors in such pass-through entities or arrangements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this discussion assumes that the <span style="white-space:nowrap">Non-U.S.</span> Holder holds our common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). Furthermore, the discussion below is based upon the provisions of the Code, Treasury regulations promulgated thereunder, rulings and judicial decisions, in each case as of the date hereof, and such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discussed below. We have not requested a ruling from the U.S. Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons considering the purchase of our common stock pursuant to this offering should consult their tax advisors concerning the U.S. federal income, estate and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing jurisdiction, including any state, local or <span style="white-space:nowrap">non-U.S.</span> tax consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this discussion, a <span style="white-space:nowrap">&#8220;Non-U.S.</span> Holder&#8221; is, for U.S. federal income tax purposes, a beneficial owner of common stock that is neither a U.S. Person, nor a partnership (or other entity or arrangement treated as a partnership for U.S. federal income tax purposes regardless of its place of organization or formation). A &#8220;U.S. Person&#8221; means any person that is, for U.S. federal income tax purposes, any of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized in or under the laws of the United States, any state thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust if it (1)&#160;is subject to the primary supervision of a court within the United States and one or more &#8220;United States persons&#8221; (within the meaning of Code Section&#160;7701(a)(30)) have the authority to control all substantial decisions of the trust or (2)&#160;has a valid election in effect under applicable Treasury regulations to be treated as a United States person. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of a beneficial owner of our common stock that is classified as a partnership for U.S. federal income tax purposes, the tax treatment of a person treated as a partner in such partnership for U.S. federal income tax purposes generally will depend on the status of the partner, the activities of the partner and the partnership and certain determinations made at the partner level. A person treated as a partner in a partnership or who holds our common stock through another pass-through entity should consult his, her or its tax advisor regarding the tax consequences of the ownership and disposition of our common stock through a partnership or other pass-through entity, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Distributions</span>. Distributions, if any, made on our common stock to a <span style="white-space:nowrap">Non-U.S.</span> Holder to the extent made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) generally will constitute dividends for U.S. federal income tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty, subject to the discussions below regarding effectively connected income, backup withholding and foreign accounts. To obtain a reduced rate of withholding under a treaty, a <span style="white-space:nowrap">Non-U.S.</span> Holder generally will be required to provide us or the applicable withholding agent with a properly executed IRS Form <span style="white-space:nowrap">W-8BEN</span> (in the case of individuals) or IRS <span style="white-space:nowrap"><span style="white-space:nowrap">Form&#160;W-8BEN-E</span></span> (in the case of entities), or other appropriate form, certifying the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s entitlement to benefits under that treaty and, in certain circumstances, providing such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s U.S. taxpayer identification number and/or foreign tax identifying number. This certification must be provided prior to the payment of dividends and must be updated periodically. In the case of a <span style="white-space:nowrap">Non-U.S.</span> Holder that is an entity, Treasury regulations and the relevant income tax treaty provide rules to determine whether, for purposes of determining the applicability of an income tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a <span style="white-space:nowrap">Non-U.S.</span> Holder holds our common stock through a financial institution or other agent acting on its behalf, it will be required to provide appropriate documentation to such agent, which will then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If the <span style="white-space:nowrap">Non-U.S.</span> Holder is eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and does not timely file the required certification, it may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. <span style="white-space:nowrap">Non-U.S.</span> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and other applicable withholding agents are not required to withhold tax on dividends paid to a <span style="white-space:nowrap">Non-U.S.</span> Holder that are effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that it maintains in the United States) if a properly executed IRS Form <span style="white-space:nowrap">W-8ECI,</span> stating that the dividends are so connected, is furnished to the applicable withholding agent prior to the payment of such dividends. In general, such effectively connected dividends will be subject to U.S. federal income tax, on a net income basis at the regular rates applicable to U.S. Persons. A corporate <span style="white-space:nowrap">Non-U.S.</span> Holder receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax,&#8221; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s effectively connected earnings and profits, subject to certain adjustments. <span style="white-space:nowrap">Non-U.S.</span> Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted basis in our common stock, but not below zero, and then will be treated as capital gain to the extent of any excess, and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain on Disposition of Our Common Stock</span>. Subject to the discussions below regarding backup withholding and foreign accounts, a <span style="white-space:nowrap">Non-U.S.</span> Holder generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the gain is effectively connected with a trade or business of the <span style="white-space:nowrap">Non-U.S.</span> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such <span style="white-space:nowrap">Non-U.S.</span> Holder maintains in the United States), </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the <span style="white-space:nowrap">Non-U.S.</span> Holder is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met, or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(c)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">we are or have been a &#8220;United States real property holding corporation,&#8221; or USRPHC, within the meaning of Code Section&#160;897(c)(2) at any time within the shorter of the five-year period preceding such disposition and such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s holding period. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, we would be a USRPHC if the aggregate fair market value of our &#8220;United States real property interests&#8221; (within the meaning of Code Section&#160;897(c)(1)), or USRPIs, equaled or exceeded fifty percent (50%) of the combined fair market value of our USRPIs, our <span style="white-space:nowrap">non-U.S.</span> real property interests and our other business assets. We believe that we have not been and are not, and do not anticipate becoming, a USRPHC. Even if we are or were to become a USRPHC, gain realized by a <span style="white-space:nowrap">Non-U.S.</span> Holder on a disposition of our common stock will not be subject to U.S. federal income tax under the provisions applicable to USRPIs so long as our common stock is &#8220;regularly traded,&#8221; as defined by applicable Treasury regulations, on an established securities market. There can be no assurance that we are not or will not become a USRPHC or that our common stock will qualify as regularly traded on an established securities market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-U.S.</span> Holders described in (a)&#160;above will be required to pay tax on the gain derived from the sale or other taxable disposition at regular U.S. federal income tax rates applicable to U.S. Persons, and corporate <span style="white-space:nowrap">Non-U.S.</span> Holders described in (a)&#160;above may, in addition, be subject to a branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty, as adjusted for certain items. A <span style="white-space:nowrap">Non-U.S.</span> Holder described in (b)&#160;above will be subject to U.S. federal income tax at a flat 30% rate, or such lower rate as may be specified by an applicable income tax treaty, on gain realized upon the sale or other taxable disposition, which gain may be offset by certain U.S.-source capital losses of the <span style="white-space:nowrap">Non-U.S.</span> Holder (even though the <span style="white-space:nowrap">Non-U.S.</span> Holder is not considered a resident of the United States), provided that the <span style="white-space:nowrap">Non-U.S.</span> Holder has timely filed U.S. federal income tax returns with respect to such losses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Information Reporting Requirements and Backup Withholding. </span>Generally, we or an applicable withholding agent will be required to report information to the IRS with respect to any distributions we pay on our common stock (even if the payments are exempt from withholding), including the amount of any such distributions, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the <span style="white-space:nowrap">Non-U.S.</span> Holder to whom any such distributions are paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#8217;s country of residence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions to a <span style="white-space:nowrap">Non-U.S.</span> Holder that are classified as dividends paid by us may also be subject to U.S. backup withholding currently at a rate of 24%. U.S. backup withholding generally will not apply to a <span style="white-space:nowrap">Non-U.S.</span> Holder who provides a properly executed IRS Form <span style="white-space:nowrap">W-8BEN,</span> IRS Form <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E,</span></span> or IRS Form <span style="white-space:nowrap">W-8ECI,</span> or otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the applicable payor has actual knowledge, or reason to know, that the <span style="white-space:nowrap">Non-U.S.</span> Holder is a U.S. Person who is not an exempt recipient. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a sale or other taxable disposition of our common stock effected by or through a U.S. office of any broker, U.S. or foreign, except that information reporting and such requirements may be avoided if the <span style="white-space:nowrap">Non-U.S.</span> Holder provides a properly executed IRS Form <span style="white-space:nowrap">W-8BEN,</span> IRS Form <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E</span></span> or IRS Form <span style="white-space:nowrap">W-8ECI,</span> or otherwise meets documentary evidence requirements for establishing <span style="white-space:nowrap">non-U.S.</span> Person status or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a <span style="white-space:nowrap">Non-U.S.</span> Holder where the transaction is effected outside the United States through a <span style="white-space:nowrap">non-U.S.</span> office of a <span style="white-space:nowrap">non-U.S.</span> broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the payor has actual knowledge, or reason to know, that the <span style="white-space:nowrap">Non-U.S.</span> Holder is, in fact, a U.S. Person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. payors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against the U.S. federal income tax liability of a <span style="white-space:nowrap">Non-U.S.</span> Holder subject to backup withholding, provided that the required information is timely furnished to the IRS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Foreign Accounts</span>. Sections 1471 through 1474 of the Code and the related Treasury regulations, together with other U.S. Treasury and IRS guidance issued thereunder and intergovernmental agreements, legislation, rules and other official guidance adopted pursuant to such intergovernmental agreements (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain payments to a &#8220;foreign financial institution&#8221; (as defined in the Code) which does not provide the withholding agent with sufficient documentation evidencing either (x)&#160;an exemption from FATCA or (y)&#160;its compliance (or deemed compliance) with FATCA (which may alternatively be in the form of compliance with an intergovernmental agreement with the United States) to withhold on certain payments and to collect and provide to the U.S. tax authorities certain information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). FATCA also generally imposes a federal withholding tax of 30% on certain payments to a <span style="white-space:nowrap">non-financial</span> foreign entity (as defined in the Code) which does not provide the withholding agent with sufficient documentation evidencing either (x)&#160;an exemption from FATCA or (y)&#160;either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the entity. An intergovernmental agreement between the United States and an applicable foreign country may modify those requirements. The withholding tax described above will not apply if the foreign financial institution or <span style="white-space:nowrap">non-financial</span> foreign entity otherwise qualifies for an exemption from FATCA. Prospective investors are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding provisions described above generally apply to payments of dividends. Under proposed Treasury regulations, the preamble to which states that taxpayers may rely on them until final Treasury regulations are issued, this withholding tax does not apply to payments of gross proceeds from a sale or other disposition of common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY CHANGES IN APPLICABLE LAW SUBSEQUENT TO THE DATE HEREOF. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_16">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders, which as used herein includes donees, pledgees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> selling shares of common stock or interests therein received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests therein on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">distributions to members, partners, stockholders or other equityholders of the selling stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exchange distribution in accordance with the rules of the applicable exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">short sales and settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a combination of any such methods of sale; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted pursuant to applicable law. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling stockholders for purposes of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a selling stockholder that is an entity may elect to make an <span style="white-space:nowrap">in-kind</span> distribution of securities to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is an affiliate of ours (or to the extent otherwise required by law), we may file a prospectus supplement in order to permit the distributees to use the prospectus to resell the securities acquired in the distribution. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#8220;underwriters&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering). Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &#8220;underwriters&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares of common stock offered by this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the selling stockholders to use reasonable best efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i)&#160;the date on which the selling stockholders shall have resold or otherwise disposed of all the shares covered by this prospectus pursuant to Rule 144 or pursuant to the registration statement of which this prospectus constitutes a part, and (ii)&#160;the date on which the securities covered by the registration statement of which this prospectus constitutes a part no longer constitute &#8220;Registrable Securities&#8221; as such term is defined in the Registration Rights Agreement, such that they may be resold by the selling stockholders without registration and without regard to any volume or <span style="white-space:nowrap"><span style="white-space:nowrap">manner-of-sale</span></span> limitations and without current public information pursuant to Rule 144 under the Securities Act or any other rule of similar effect. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_17">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the common stock being offered by this prospectus has been passed upon for us by Cooley LLP, New York, New York. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_18">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Tectonic Therapeutic, Inc. as of December&#160;31, 2024 and 2023, and for the years then ended, included in this Prospectus, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc863285_20">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act and in accordance therewith, file annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains our filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at www.sec.gov. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also make available free of charge on or through our website at www.tectonictx.com, our Annual Reports on Form <span style="white-space:nowrap">10-K,</span> Quarterly Reports on Form <span style="white-space:nowrap">10-Q,</span> Current Reports on Form <span style="white-space:nowrap">8-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or otherwise furnishes it to the SEC. The website addresses are inactive textual references and except as specifically incorporated by reference into this prospectus, information on those websites is not part of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Other documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC&#8217;s website, as provided above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like to request documents, please send a request in writing or by telephone to the following address: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Tectonic Therapeutic, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">490 Arsenal Way </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Suite 210 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Watertown, MA 02472 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Attn: Daniel Lochner </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(339) <span style="white-space:nowrap">666-3320</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Email: investor@tectonictx.com </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden136075766" contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="hidden136075759" contextRef="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="hidden136075767" contextRef="PAsOn11_19_2020">P5Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tecx-20241231.xsd"/></ix:references></ix:header></div><div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">TECTONIC THERAPEUTIC, INC. </div></div></div><div id="toc863285_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 95%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Audited Financial Statements as of and for the Years ended December</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;31, 2024 and 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin863285_1">Independent Auditor&#8217;s Report .</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin863285_2">Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin863285_3">Consolidated Statements of Operations and Other Comprehensive Income (Loss)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin863285_4">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit .</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin863285_5">Consolidated Statements of Cash Flows .</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin863285_6">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-1 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin863285_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To the shareholders and the Board of Directors of Tectonic Therapeutic, Inc. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Opinion on the Financial Statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have audited the accompanying consolidated balance sheets of Tectonic Therapeutic, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit, and cash flows, for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America . </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Critical Audit Matters </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1)&#160;relate to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accrued and prepaid contract research and development, and manufacturing expenses &#8212; Refer to Notes 2 and 6 to the financial statements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Critical Audit Matter Description </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As disclosed in Note 2 to the financial statements, the Company records accrued and prepaid research and development and manufacturing expenses for third-party contract research organizations (&#8220;CROs&#8221;) and contract </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">development and manufacturing organizations (&#8220;CDMOs&#8221;). Estimates of expenses incurred are determined by reviewing information provided to the Company by its service providers and through discussions with both internal personnel and external service providers as to the status of specific tasks within arrangements. Expenses incurred in excess of amounts invoices are recorded as accrued expenses. Payments made in excess of costs incurred are recorded as prepaid expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We identified auditing the estimates of the progress to completion of specific tasks performed by CROs and CDMOs as a critical audit matter due to the (i)&#160;level of judgment required by management and the volume of such estimates made by management and (ii)&#160;the degree of auditor judgment, subjectivity, and increased extent of effort in performing procedures to evaluate the reasonableness of management&#8217;s estimates of progress to completion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">How the Critical Audit Matter Was Addressed in the Audit </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Our audit procedures related to accrued and prepaid research and development expenses and manufacturing costs included the following, among others: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We tested the design and implementation of controls over the estimation of accrued and prepaid research and development expenses and manufacturing costs. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For a sample of contracts with service providers performing research and development and manufacturing activities, we performed the following: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Evaluated the appropriateness of the method used by management to develop its estimates of progress to completion of specific tasks. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tested the completeness and accuracy of the underlying data used in the estimates of progress to completion through inspection of the terms of contracts and statements of work between the Company and its service providers and testing of actual billed expenses under the contracts. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Performed corroborating inquiries with Company personnel responsible for overseeing the activities performed by the Company&#8217;s CRO and CDMO, which may include the service providers&#8217; estimate of completed tasks or progress of completion of certain tasks within the arrangement. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Merger &#8212; Refer to Notes 1 and 3 to the financial statements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Critical Audit Matter Description </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As disclosed in Notes 1 and 3 to the financial statements, on June&#160;20, 2024, the Company completed a merger with AVROBIO, Inc. (&#8220;AVROBIO&#8221;). The merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP with the Company as the accounting acquirer of AVROBIO. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We identified the evaluation of the accounting for the merger with AVROBIO, Inc. as a critical audit matter due to the (i)&#160;level of judgment required by management related to the determination of the accounting acquirer and the assessment of the transaction as a reverse recapitalization and (ii)&#160;the moderate degree of auditor judgment and extensive audit effort in evaluating the Company&#8217;s determination of the accounting acquirer and assessment of the transaction as a reverse recapitalization. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">How the Critical Audit Matter Was Addressed in the Audit </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Our audit procedures related to the reverse merger included the following, among others: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We tested the design and implementation of controls related to the transaction, including controls over management&#8217;s determination of the (i)&#160;accounting acquirer and (ii)&#160;accounting model as a reverse recapitalization. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We evaluated the Company&#8217;s determination of the (i)&#160;accounting acquirer and (ii)&#160;accounting model as a reverse recapitalization. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We tested the retrospective application of the reverse recapitalization to all outstanding common shares, convertible preferred shares, stock options, and restricted stock. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We inspected minutes of Board of Directors&#8217; meetings, executed merger transaction agreements, and other information to assess the nature and structure of the reverse merger in evaluating management&#8217;s conclusions. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">/s/ Deloitte&#160;&amp; Touche LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Boston, Massachusetts </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">March&#160;20, 2025 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have served as the Company&#8217;s auditor since 2022. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-4 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">TECTONIC THERAPEUTIC, INC. </div></div></div><div id="fin863285_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 81%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21216">141,239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21217">28,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21218">5,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21219">2,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21220">146,857</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21221">30,884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21222">2,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21223">3,122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Finance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> assets, net</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21224">919</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21225">1,437</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21226">2,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21227">2,669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21228">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21229">669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21230">587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21231">587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21232">156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21233">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21234">152,905</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21235">39,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21236">976</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21237">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21238">7,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21239">8,141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:SAFELiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21240">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:SAFELiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21241">30,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21242">2,295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21243">1,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21244">489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21245">475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21246">11,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21247">40,888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease liability, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21248">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21249">1,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Finance lease liability, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21250">387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21251">876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21252">12,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21253">43,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and contingencies (Note 12)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" xsi:nil="true" id="ixv-21254"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-21255"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Convertible preferred stock (Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-2,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-3</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-4),</div> $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21256"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21257">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21258"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21259"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21260">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued or outstanding as of December&#160;31, 2024; <div style="display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21261">3,647,675</ix:nonFraction></div></div> shares authorized as of December&#160;31, 2023; <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21262"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21263">3,647,675</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023; aggregate liquidation preference of $<div style="display:inline;"></div><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21264">87,459</ix:nonFraction> as of December&#160;31,&#160;2023</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21265">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21266">80,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stockholders&#8217; Equity (Deficit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21267">10,000,000</ix:nonFraction> shares and <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21268">no</ix:nonFraction> shares authorized as of December&#160;31, 2024 and 31, 2023, respectively; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21269"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21270"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21271"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21272">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2024 and 2023, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21273">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21274">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21275"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21276">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21277"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21278">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2024 and 2023, respectively; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21279"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21280">14,856,309</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21281"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21282">1,407,753</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2024 and 2023, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21283">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21284">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21285">289,351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21286">5,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21287">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21288">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21289">148,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21290">90,604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stockholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21291">140,776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21292">84,636</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities, convertible preferred stock and stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21293">152,905</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21294">39,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-5 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">TECTONIC THERAPEUTIC, INC. </div></div></div><div id="fin863285_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21295">41,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21296">36,966</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21297">16,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21298">7,682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21299">58,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21300">44,648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21301">58,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21302">44,648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other income, net:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in fair value of SAFE liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:ChangeInFairValueOfSafeLiabilities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21303">3,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ChangeInFairValueOfSafeLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21304">1,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on issuance of SAFEs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LossOnIssuanceOfSAFEs" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21305">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:LossOnIssuanceOfSAFEs" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21306">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21307">4,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21308">581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21309">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21310">152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other (expense) income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21311">511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21312">396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other income, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21313">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21314">1,825</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21315">57,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21316">42,823</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other comprehensive loss:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21317">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21318">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21319">57,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21320">42,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21321"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21322">6.83</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"></div><div style="display:inline;"></div>(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21323"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21324">33.76</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average common shares outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21325"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21326">8,490,171</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21327"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21328">1,268,512</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-6 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">TECTONIC THERAPEUTIC, INC. </div></div></div><div id="fin863285_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 36%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/> Preferred<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Comprehensive</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Income (Loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balances&#160;as&#160;of&#160;January&#160;1, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21329">6,825,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21330">80,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21331">2,525,771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21332">2,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21333">47,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21334">45,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Retroactive application of reverse recapitalization</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21335">3,177,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21336">1,175,989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Adjusted balance, beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:AdjustedBalanceBeginningOfPeriodShare" contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21337">3,647,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:AdjustedBalanceBeginningOfPeriodValue" contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21338">80,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:AdjustedBalanceBeginningOfPeriodShare" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21339">1,349,782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:AdjustedBalanceBeginningOfPeriodValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21340">2,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:AdjustedBalanceBeginningOfPeriodValue" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21341">47,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:AdjustedBalanceBeginningOfPeriodValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21342">45,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21343">57,971</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21344">121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21345">121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21346">1,121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21347">1,121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Contribution from related party investors related to SAFEs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ContributionFromRelatedPartyInvestorsRelatedToSAFEs" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21348">2,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ContributionFromRelatedPartyInvestorsRelatedToSAFEs" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21349">2,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21350">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21351">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21352">42,823</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21353">42,823</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of January&#160;1, 2024</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21354">3,647,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21355">80,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21356">1,407,753</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21357">5,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21358">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21359">90,604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21360">84,636</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Conversion of convertible preferred stock into common stock in connection with the Merger</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21361">3,647,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21362">80,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21363">3,647,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21364">80,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21365">80,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21366">388,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21367">1,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21368">1,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Vesting of restricted common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21369">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21370">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21371">3,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21372">3,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock to related party investors upon redemption of the SAFEs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21373">1,470,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21374">34,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21375">34,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock under subscription agreement, net of offering costs of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="P01_01_2024To12_31_2024_AtTheMarketFacilityMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21376">2,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockUnderSubscriptionAgreement" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21377">4,163,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21378">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21379">94,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21380">94,601</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock upon the Merger, net of transaction costs of $<ix:nonFraction name="tecx:TransactionCosts" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21381">9,300</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockUponTheMerger" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21382">3,777,709</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockUponTheMergerValue" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21383">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockUponTheMergerValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21384">68,890</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:IssuanceOfCommonStockUponTheMergerValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21385">68,891</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" contextRef="P01_01_2024To12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21386">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21387">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21388">57,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21389">57,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of December&#160;31, 2024</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21390">14,856,309</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21391">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21392">289,351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21393">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21394">148,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21395">140,776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-7 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">TECTONIC THERAPEUTIC, INC. </div></div></div><div id="fin863285_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from operating activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21396">57,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21397">42,823</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation and amortization expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21398">1,645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21399">1,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21400">3,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21401">1,121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on disposal of fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21402">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21403">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on issuance of SAFEs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LossOnIssuanceOfSAFEs" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21404">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LossOnIssuanceOfSAFEs" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21405">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> lease expense</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:NonCashLeaseExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21406">434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:NonCashLeaseExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21407">1,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in fair value of SAFE liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ChangeInFairValueOfSafeLiabilities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21408">3,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:ChangeInFairValueOfSafeLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21409">1,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21410">3,194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21411">1,019</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21412">544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21413">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21414">1,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21415">165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21416">5,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21417">1,611</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21418">565</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21419">950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> liabilities</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21420">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21421">59,080</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21422">40,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from investing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21423">156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21424">279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21425">156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21426">279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from financing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from the issuance of SAFEs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ProceedsFromSimpleAgreementForFutureEquity" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21427">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ProceedsFromSimpleAgreementForFutureEquity" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21428">34,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from the Subscription Agreement, net of offering costs of $<ix:nonFraction name="tecx:OfferingCost" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21429">2,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ProceedsFromSubscriptionAgreement" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21430">94,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ProceedsFromSubscriptionAgreement" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21431">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash acquired in connection with the Merger, net of transaction costs of $<ix:nonFraction name="tecx:TransactionCosts" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21432">9,300</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:CashAcquiredInConnectionWithTheMerger" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21433">75,965</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:CashAcquiredInConnectionWithTheMerger" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21434">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from exercise of common stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21435">1,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21436">121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Repayment of finance lease obligations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21437">475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21438">499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21439">171,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21440">33,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Effect of exchange rate changes on cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21441">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21442">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net increase (decrease) in cash and cash equivalents and restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21443">112,470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21444">7,197</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents and restricted cash as of beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21445">29,356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21446">36,553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents and restricted cash as of end of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21447">141,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21448">29,356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Components of cash, cash equivalents and restricted cash:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21449">141,239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21450">28,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21451">587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21452">587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total cash, cash equivalents and restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21453">141,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21454">29,356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Conversion of SAFEs to Common Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ConversionOfSimpleAgreementsForFutureEquityToCommonStock" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21455">34,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ConversionOfSimpleAgreementsForFutureEquityToCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21456">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Conversion of Convertible Preferred Stock to Common Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ConversionOfConvertiblePreferredStockToCommonStock" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21457">80,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ConversionOfConvertiblePreferredStockToCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21458">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of equipment through finance leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:PurchaseEquipmentOfFinanceLeases" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21459">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:PurchaseEquipmentOfFinanceLeases" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21460">234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Merger transaction costs included in accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21461">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21462">669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Supplemental disclosure of cash flow information:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash paid for interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21463">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21464">152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-8 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">TECTONIC THERAPEUTIC, INC. </div></div></div><div id="fin863285_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share and per share data) </div></div></div><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075572" id="ixv-13146"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. NATURE OF BUSINESS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Description of the Business </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Tectonic Therapeutic, Inc. (formerly AVROBIO, Inc.) (the &#8220;Company&#8221; or &#8220;Tectonic&#8221;) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">G-protein</div> coupled receptors (&#8220;GPCRs&#8221;). The Company focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Merger and <div style="white-space: nowrap;display:inline;">Pre-Merger</div> Financing Transaction not </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;20, 2024, the Company completed its previously announced merger transaction in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of January&#160;30, 2024 (the &#8220;Merger Agreement&#8221;) with AVROBIO, Inc. (&#8220;AVROBIO&#8221;), pursuant to which Alpine Merger Subsidiary, Inc., a wholly owned subsidiary of AVROBIO, merged with and into the entity formerly known as Tectonic Therapeutic, Inc., now known as Tectonic Operating Company, Inc. (&#8220;Legacy Tectonic&#8221;), with Legacy Tectonic continuing as a wholly owned subsidiary of the surviving corporation of AVROBIO (the &#8220;Merger&#8221;). The Merger was accounted for as a reverse recapitalization in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), with AVROBIO treated as the acquired company for financial reporting purposes, and Legacy Tectonic treated as the accounting acquirer. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the closing of the Merger, each outstanding share of Legacy Tectonic&#8217;s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO&#8217;s common stock based on an exchange ratio of <ix:nonFraction name="tecx:ConversionOfStockSharesPercentage" contextRef="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21465">0.53</ix:nonFraction> (the &#8220;Exchange Ratio&#8221;), as defined in the Merger Agreement, after giving effect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis" id="ixv-21466">1-for-12</ix:nonNumeric></div></div> reverse stock split of AVROBIO common stock that was effected on June&#160;20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Each outstanding and unexercised option to purchase shares of Legacy Tectonic&#8217;s common stock immediately prior to closing was assumed by AVROBIO and was converted into an option to purchase shares of AVROBIO common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio. Legacy Tectonic&#8217;s restricted common stock, outstanding and unvested immediately prior to the closing, was assumed by AVROBIO in the Merger. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Legacy Tectonic stockholders received <ix:nonFraction name="tecx:StockIssuedDuringThePeriodSharesReverseRecapitalization" contextRef="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21467">10,956,614</ix:nonFraction> shares of AVROBIO common stock in connection with the Merger, including <ix:nonFraction name="tecx:StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" contextRef="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21468">11,447</ix:nonFraction> shares of AVROBIO restricted common stock subject to vesting terms, based on the number of shares of Legacy Tectonic common stock outstanding immediately prior to the Merger, including restricted stock, the number of shares of common stock issued to investors participating in the Subscription Agreements (as defined below) and Simple Agreements for Future Equity (&#8220;SAFEs&#8221;), and Legacy Tectonic convertible preferred stock outstanding immediately prior to the Merger, which was converted into shares of Legacy Tectonic common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">one-for-one</div></div> basis immediately prior to the closing of the Merger. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Concurrently with the closing of the Merger, certain investors of Legacy Tectonic completed the purchase of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_30_2024To01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21469">7,790,889</ix:nonFraction> shares of Legacy Tectonic common stock pursuant to the Subscription Agreement dated January&#160;30, 2024 (the &#8220;Subscription Agreement&#8221;) at a purchase price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21470">12.40</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_30_2024To01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21471">96.6</ix:nonFraction>&#160;million. Shares of Legacy Tectonic common stock issued pursuant to the Subscription Agreements were converted into <ix:nonFraction name="tecx:StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" contextRef="P01_01_2024To12_31_2024_AvorbioCommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21472">4,163,606</ix:nonFraction> shares of AVROBIO common stock at the closing of the Merger based on the Exchange Ratio, pursuant to the Merger Agreement. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-9</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075572" continuedAt="TextSelectionAppend_136075572_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075572_1" continuedAt="TextSelectionAppend_136075572_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075572_2"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance reporting capabilities. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s proprietary GEODe<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">&#8482;</div> platform is currently in development. There can be no assurance that current and future research and development activities will be successfully completed, that adequate protection for owned intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Since inception, the Company has incurred recurring losses and negative cash flows from operations and expects such losses to continue in the future as it conducts research and development activities and continues to develop its product candidates. The Company generated net losses of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-21474">58.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-21475">42.8</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively and had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-21476">148.6</ix:nonFraction>&#160;million as of December&#160;31, 2024. The Company has financed its operations primarily through the sale and issuance of common stock, convertible preferred stock, convertible promissory notes, SAFEs and the Merger. In February 2025, the Company sold shares of its common stock under a securities purchase agreement in exchange for gross proceeds of $<ix:nonFraction name="tecx:ProceedsReceivedPursuantToAgreement" contextRef="P02_01_2025To02_28_2025" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-21477">185</ix:nonFraction>&#160;million, as described in Note 16, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events</div></div>. The Company has devoted substantially all of its financial resources and efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As the Company continues to develop its proprietary platform and potential product candidates, it will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. It may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital to fund its operations. The Company had cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21478">141.2</ix:nonFraction>&#160;million as of December&#160;31, 2024. Management believes that the Company&#8217;s current cash and cash equivalents will be sufficient to fund its planned operations for at least 12 months&#160;from the issuance date of these consolidated financial statements. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075574" id="ixv-13204"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION </div></div></div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13208"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying consolidated financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP, as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13215"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-10</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075574" continuedAt="TextSelectionAppend_136075574_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075574_1" continuedAt="TextSelectionAppend_136075574_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075574_2" continuedAt="TextSelectionAppend_136075574_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075574_3" continuedAt="TextSelectionAppend_136075574_4"><ix:nonNumeric name="tecx:ReverseStockSplitAndExchangeRatioPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13240"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reverse Stock Split and Exchange Ratio </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon the closing of the Merger, each outstanding share of Legacy Tectonic&#8217;s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO&#8217;s common stock based on the Exchange Ratio of <ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="P06_20_2024To06_20_2024" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21480">0.53</ix:nonFraction>, after giving effect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">1-for-12</div></div> reverse stock split of AVROBIO common stock that was effected on June&#160;20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13248"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include those related to the valuation of stock-based awards, income taxes, the fair value determination of the SAFEs and certain research and development accruals. Management&#8217;s estimates are based on historical experience and various other assumptions that it believes are reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13255"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The operations of each of the Company&#8217;s entities are measured using the currency of the primary economic environment in which the subsidiary operates (&#8220;functional currency&#8221;). Assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">period-end</div> exchange rates. Expenses are translated at the average exchange rate in effect during each fiscal month during the year. The effects of foreign currency translation adjustments are included as a component of Accumulated other comprehensive income (loss) in the Consolidated Balance Sheets. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13262"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer, who reviews financial information on a consolidated basis for the purpose of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. See Note 16, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information</div></div> for additional information regarding the Company&#8217;s segment information. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13270"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash, Cash Equivalents, and Restricted Cash </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of cash on deposit with banks denominated in U.S. dollars and investment in money market funds. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn11_19_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21481">0.6</ix:nonFraction>&#160;million as collateral in connection with a letter of credit issued with the corporate headquarters and lab space lease agreement entered into on November&#160;19, 2020. The Company may not access these funds until after the expiration of the lease term on <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="P01_01_2024To12_31_2024" format="ixt:date-monthname-day-year-en" id="ixv-21482">January 31, 2026</ix:nonNumeric>. The Company has classified the certificate of deposits collateralizing the letter of credits issued as a security deposit as restricted cash in the noncurrent asset section of the Consolidated Balance Sheets. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075582" id="ixv-13279"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk <div style="white-space: nowrap;display:inline;">and&#160;Off-Balance&#160;Sheet</div> Risk </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in accredited financial institutions in </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-11</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_136075582" continuedAt="TextSelectionAppend_136075582_1"><ix:continuation id="TextSelectionAppend_136075574_4" continuedAt="TextSelectionAppend_136075574_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075574_5" continuedAt="TextSelectionAppend_136075574_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075574_6" continuedAt="TextSelectionAppend_136075574_7"><ix:continuation id="TextSelectionAppend_136075582_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">excess of governmental insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have a high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13304"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of each asset, generally <div style="-sec-ix-hidden:hidden136075766;display:inline;">three</div> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-21484">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the assets&#8217; expected useful life or the <div style="-sec-ix-hidden:hidden136075759;display:inline;">remaining lease term</div>. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Construction-in-progress</div></div> reflects amounts incurred for property and equipment for use in the research and development process and have not yet been placed in service and are not depreciated or amortized. Expenditures for major renewals and improvements that extend the useful life of the asset are capitalized as part of the asset. Expenditures for repairs and maintenance are expensed as incurred. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13316"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying amount of the asset is not recoverable, an impairment will be recognized and measured as the amount by which the carrying amount of the asset exceeds its fair value. <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21485"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21486">No</ix:nonFraction></ix:nonFraction> impairment was identified during the years ended December&#160;31, 2024 and 2023. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13323"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;1</div></div></div></div>&#8212;Unadjusted quoted prices in active markets for identical, unrestricted assets or liabilities that are accessible at the measurement date; </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;2</div></div></div></div>&#8212;Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar asset or liabilities in markets that are not active or valuations with significant inputs other than quoted prices that are observable, either directly or indirectly; and, </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;3</div></div></div></div>&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments are categorized in their entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire fair value measurement. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075586" id="ixv-13359"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of costs incurred for research activities, including discovery efforts and the development of the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-12</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_136075586" continuedAt="TextSelectionAppend_136075586_1"><ix:continuation id="TextSelectionAppend_136075574_7" continuedAt="TextSelectionAppend_136075574_8"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075574_8" continuedAt="TextSelectionAppend_136075574_9"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075586_1" continuedAt="TextSelectionAppend_136075586_2"><ix:continuation id="TextSelectionAppend_136075574_9" continuedAt="TextSelectionAppend_136075574_10"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></ix:continuation></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075574_10" continuedAt="TextSelectionAppend_136075574_11"><ix:continuation id="TextSelectionAppend_136075586_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Company&#8217;s programs and platform and include (1)&#160;expenses incurred in connection with research and the preclinical and clinical development of the Company&#8217;s programs and product candidates, including agreements with third parties and contract research organizations (&#8220;CROs&#8221;), (2) costs related to manufacturing material for preclinical studies and clinical trials, including fees paid to contract development and manufacturing organizations (&#8220;CDMOs&#8221;), (3) employee-related expenses, including salaries and bonuses, related benefits and stock-based compensation expense, for employees engaged in research and development functions (4)&#160;facilities, depreciation and other expenses related to research and development activities, which include direct or allocated expenses for rent, maintenance of facilities and utilities, (5)&#160;licensing and license maintenance fees incurred under license agreements where no alternative future use exists, and (6)&#160;costs related to compliance with regulatory requirements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the Consolidated Balance Sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. The Company accrues expenses based upon estimates of percentage of work completed and the contract milestones remaining. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13391"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for leases in accordance with ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;). The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of the contract. The Company&#8217;s operating and finance lease assets are included <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">in&#160;right-of-use</div></div> assets, net, and the current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> portions of the finance and operating lease liabilities are included in&#160;lease liabilities,&#160;and&#160;lease liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current,&#160;respectively,</div> on the balance sheets. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Right-of-use</div></div> assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Right-of-use</div></div> assets are based on the corresponding lease liability adjusted for (i)&#160;payments made at or before the commencement date, (ii)&#160;initial direct costs incurred, and (iii)&#160;tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. For finance leases, right of use assets are amortized on a straight-line basis over the shorter of the lease term or the estimated useful life of the leased assets. The Company accounts for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components as a single lease component for operating leases. The discount rate used to calculate the present value of the Company&#8217;s lease liabilities is based on either an explicit rate stipulated in the contract for finance leases or the incremental borrowing rate based on the information available at the lease commencement date. The Company&#8217;s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determines the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated. The Company has elected the practical expedient to not recognize leases with a lease term of twelve months or less on the balance sheet (&#8220;short-term leases&#8221;) and will recognize lease payments for such short-term leases as an expense on a straight-line basis. </div></ix:nonNumeric><ix:nonNumeric name="tecx:SimpleAgreementsForFutureEquityPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075588" id="ixv-13408"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Simple Agreements for Future Equity </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE instruments do not represent legal form debt (i.e., no creditor rights), but allow for redemption based upon certain triggering events that are outside of the control of the Company. The Company accounts for the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-13</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_136075588" continuedAt="TextSelectionAppend_136075588_1"><ix:continuation id="TextSelectionAppend_136075574_11" continuedAt="TextSelectionAppend_136075574_12"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075574_12" continuedAt="TextSelectionAppend_136075574_13"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075574_13" continuedAt="TextSelectionAppend_136075574_14"><ix:continuation id="TextSelectionAppend_136075588_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE instruments as a liability at fair value on a recurring basis. Triggering events include an equity financing, public listing transaction, change of control or dissolution. Changes in the liability&#8217;s fair value are recognized in the Company&#8217;s statements of operations and comprehensive loss. The SAFE liabilities were adjusted to fair value upon the closing of the Merger and all SAFE instruments were converted to common stock of AVROBIO pursuant to the Merger Agreement. The SAFEs were redeemed for common stock shares upon closing of the Merger. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13432"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recorded all shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company&#8217;s control, such as a merger, acquisition, or sale of all or substantially all of the Company&#8217;s assets (each, a &#8220;deemed liquidation event&#8221;), the convertible preferred stock became redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of convertible preferred stock was not probable of occurring. All outstanding shares of convertible preferred stock were converted to common stock shares upon the closing of the Merger. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075590" id="ixv-13439"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prior to being publicly traded, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent to the Merger, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Select Market on the date of grant. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company utilizes the Black-Scholes-Merton (&#8220;BSM&#8221;) option pricing model to determine the estimated fair value of options granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees,</div> including directors. In addition to the fair value of the Company&#8217;s common stock, the BSM mode requires the input of several assumptions. These assumptions include: </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Term&#8212;The expected life represents the period of time that the stock options are expected to be outstanding. Because the Company does not have substantial historical exercise behavior, it determines the expected term in accordance with the simplified method, which is an average of the contractual term of the stock option and its vesting period. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Volatility&#8212;The estimated volatility is determined by evaluating the average historical volatility of a peer group of companies for the period preceding the stock option grant for a term that is approximately equal to the stock options&#8217; expected term. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-Free Interest Rate&#8212;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury&#160;issues with a term that is equal to the stock options&#8217; expected term at the grant date. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Dividend&#8212;The expected dividend yield is assumed to be zero as the Company has not declared or paid dividends to date and does not anticipate declaring dividends for the foreseeable future. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units (RSUs) are measured and recognized over the vesting period and are based on the quoted market price of the Company&#8217;s stock on the grant date. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-14</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_136075590" continuedAt="TextSelectionAppend_136075590_1"><ix:continuation id="TextSelectionAppend_136075574_14" continuedAt="TextSelectionAppend_136075574_15"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075574_15" continuedAt="TextSelectionAppend_136075574_16"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075590_1" continuedAt="TextSelectionAppend_136075590_2"><ix:continuation id="TextSelectionAppend_136075574_16" continuedAt="TextSelectionAppend_136075574_17"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></ix:continuation></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075574_17" continuedAt="TextSelectionAppend_136075574_18"><ix:continuation id="TextSelectionAppend_136075590_2"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">All stock-based compensation expense is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss, on the basis of the respective employee and nonemployee&#8217;s role within the Company. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13517"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic&#160;740,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Taxes</div></div>&#160;(&#8220;ASC 740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determined deferred tax assets and liabilities on the basis of the differences between the consolidated financial statements and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">income,&#160;tax-planning&#160;strategies,</div> and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company records uncertain tax positions in accordance with ASC 740 on the basis of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;two-step&#160;process</div> in which (1)&#160;the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">the&#160;more-likely-than-not&#160;recognition</div> threshold, the Company recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13530"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Basic and diluted net loss per common share is presented in conformity with ASC 260,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Earning Per Share,</div></div>&#160;for all periods presented. In accordance with this guidance, basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period. Basic net loss and diluted net loss per share are calculated without consideration of potentially dilutive securities. </div></ix:nonNumeric><ix:nonNumeric name="tecx:RelatedPartyTransactionsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13538"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Related Party Transactions </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies ASC 850,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Related Party Disclosure</div></div>s, for the identification of related parties and disclosure of related party transactions. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13546"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. The comprehensive loss for the Company equals its net loss plus changes in foreign currency translation for all periods presented. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13553"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the FASB under its ASCs or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. </div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-15</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_136075574_18" continuedAt="TextSelectionAppend_136075574_19"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075574_19" continuedAt="TextSelectionAppend_136075574_20"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075574_20"><ix:nonNumeric name="tecx:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13573"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (Topic 740) (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09&#8221;),</div> which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> are effective for fiscal years beginning after December&#160;15, 2024, and early adoption is permitted. The Company is currently evaluating the impact of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on its consolidated financial statements. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2024-03</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</div></div> (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">220-40)</div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03&#8221;),</div> which requires disaggregated disclosure of certain income statement captions within the footnotes to the financial statements. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> are effective for fiscal years beginning after December&#160;15, 2026, and early adoption is permitted. The Company is currently evaluating the impact of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on its consolidated financial statements. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13594"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. MERGER </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As described in Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Nature of the Business</div></div>, the Company completed its Merger with AVROBIO on June&#160;20, 2024. The Merger was accounted for as a reverse recapitalization in accordance with GAAP with Legacy Tectonic as the accounting acquirer of AVROBIO. At the effective time of the Merger, substantially all the assets of AVROBIO consisted of cash and cash equivalents, as well as other nominal assets. Under such reverse recapitalization accounting, the assets and liabilities of AVROBIO were recorded at their fair value at the effective time of the Merger, which approximated book value due to the short-term nature. No goodwill or intangible assets were recognized. Consequently, the consolidated financial statements of the Company reflect the historical operations of Legacy Tectonic for accounting purposes together with the issuance of shares to the former shareholders of AVROBIO, the legal acquirer, and a recapitalization of the equity of Legacy Tectonic, the accounting acquirer. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock of Legacy Tectonic. </div><ix:nonNumeric name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13601"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As part of the recapitalization, Legacy Tectonic recognized the assets and liabilities listed below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21491">85,230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21492">319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21493">1,988</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21494">5,405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21495">78,156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company incurred transaction costs of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21496">9.3</ix:nonFraction>&#160;million which was recorded as a reduction to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Consolidated Balance Sheet. </div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-16 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075603" id="ixv-13688"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. FAIR VALUE MEASUREMENTS </div></div></div><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13692"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following tables present information about financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 62%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21497">139,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21498">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21499">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21500">139,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21501">139,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21502">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21503">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21504">139,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 63%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21505">27,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21506">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21507">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21508">27,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21509">27,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21510">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21511">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21512">27,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21513">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21514">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21515">30,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21516">30,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21517">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21518">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21519">30,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21520">30,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds are included in cash and cash equivalents on the Company&#8217;s Consolidated Balance Sheets and are classified within Level&#160;1 of the fair value hierarchy because they are valued using quoted market prices. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">There were <ix:nonFraction name="tecx:FairValueInputAmountTransferInBetweenLevels" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21521"><ix:nonFraction name="tecx:FairValueInputAmountTransferInBetweenLevels" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21522">no</ix:nonFraction></ix:nonFraction>&#160;transfers between the Level&#160;1, Level&#160;2 or Level&#160;3 categories during the years ended December&#160;31, 2024 and 2023. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">SAFE Liabilities </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">From October through December 2023, Legacy Tectonic entered into multiple SAFE agreements with certain existing investors and received proceeds of $<ix:nonFraction name="tecx:ProceedsFromSimpleAgreementForFutureEquity" contextRef="P10_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21523">34.1</ix:nonFraction>&#160;million. Prior to redemption, the SAFE liabilities were valued using a probability weighted scenario analysis and discount rates derived by application of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">build-up</div> method to reflect the cost of equity. The valuation model required a variety of inputs, including the probability of occurrence of events that would trigger conversion or redemption of the SAFEs, the expected timing of such events, and a discount rate. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon the closing of the Merger, the principal balance of the SAFE instruments was automatically redeemed for <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21524">2,752,216</ix:nonFraction>&#160;shares of Legacy Tectonic common stock at the conversion price of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21525">12.40</ix:nonFraction>&#160;per share immediately prior to the Merger closing. As such the valuation inputs utilized to adjust the SAFE liability to fair value upon the closing of the Merger was $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024_AvrobioMemberTECXTypeOfCommonStockAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21526">12.40</ix:nonFraction>. At closing, shares of Legacy Tectonic common stock issued pursuant to the redemption of Legacy Tectonic SAFEs were converted into <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024_AvrobioMemberTECXTypeOfCommonStockAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21527">1,470,839</ix:nonFraction>&#160;shares of AVROBIO common stock based on the Exchange Ratio, pursuant to the Merger Agreement. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-17</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075603" continuedAt="TextSelectionAppend_136075603_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075603_1" continuedAt="TextSelectionAppend_136075603_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075603_2"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14246"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table presents activity for the SAFE liabilities that were measured at fair value using significant unobservable Level&#160;3 inputs during the years ended December&#160;31, 2024 and 2023 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 77%;"/>
<td style="width: 19%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">SAFE&#160;Liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of January&#160;1, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21529">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Initial fair value recognition</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" contextRef="P01_01_2023To12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21530">31,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on issuance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21531">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2023To12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21532">1,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21533">30,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2024To12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21534">3,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="P01_01_2024To12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21535">34,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21536">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14360"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. PROPERTY AND EQUIPMENT, NET </div></div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14364"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net is comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21537">4,590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21538">4,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Office equipment, furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21539">281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21540">405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21541">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21542">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21543">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21544">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21545">4,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21546">4,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21547">2,745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21548">1,856</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21549">2,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21550">3,122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation expense was $<ix:nonFraction name="tecx:DepreciationAndAmortizationExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21551">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="tecx:DepreciationAndAmortizationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21552">1.0</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and is primarily attributable to research and development activities. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14538"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14542"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities is comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued compensation and related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:AccruedCompensationAndRelatedExpenses" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21553">3,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:AccruedCompensationAndRelatedExpenses" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21554">2,856</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:AccruedResearchAndDevelopmentExpenses" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21555">2,787</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:AccruedResearchAndDevelopmentExpenses" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21556">3,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued professional fees and other expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21557">1,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21558">2,071</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21559">7,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21560">8,141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075621" id="ixv-14662"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. STOCKHOLDERS&#8217; EQUITY </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, the Company&#8217;s amended and restated certificate of incorporation authorized the Company to issue up to&#160;<ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21561">11,947,558</ix:nonFraction>&#160;shares of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21562">0.0001</ix:nonFraction>&#160;par value common stock, of which,&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21563"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21564">2,634,246</ix:nonFraction></ix:nonFraction>&#160;shares were issued and outstanding. Voting, dividend and liquidation rights of the holders of common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock. <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis" id="ixv-21565">Holders of common stock were entitled to one vote for each share of common stock</ix:nonNumeric>; however, the holders of the common stock were </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-18</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075621" continuedAt="TextSelectionAppend_136075621_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075621_1" continuedAt="TextSelectionAppend_136075621_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075621_2" continuedAt="TextSelectionAppend_136075621_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075621_3" continuedAt="TextSelectionAppend_136075621_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">not entitled to vote on any amendment to the amended and restated certificate of incorporation that related solely to the terms of one or more outstanding series of preferred stock. The Company had included in issued and outstanding common stock shares of restricted common stock granted by the Company. As of December&#160;31, 2023, there were&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_RestrictedCommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21567"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_RestrictedCommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21568">2,634,246</ix:nonFraction></ix:nonFraction>&#160;common shares issued and outstanding, of which&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_UnrestrictedCommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21569">2,598,752</ix:nonFraction>&#160;relate to shares of unrestricted common stock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company amended and restated its certificate of incorporation, effective June&#160;20, 2024, in connection with the Merger. The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21570">150,000,000</ix:nonFraction> shares of common stock at a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-21571">0.0001</ix:nonFraction>. <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2024To12_31_2024" id="ixv-21572">Holders of voting common stock are entitled to one vote per share.</ix:nonNumeric> In addition, holders of voting common stock are entitled to receive dividends, if and when declared by the Company&#8217;s Board of Directors. As of December&#160;31, 2024, <ix:nonFraction name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-21573">no</ix:nonFraction> dividends had been declared. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14694"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company reserved common stock for future issuance as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-21574">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21575">3,647,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21576">1,626,841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21577">1,002,535</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-21578">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21579">18,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21580">25,612</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-21581">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFEs (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-21582">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_SimpleAgreementsForFutureEquityMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21583">1,519,331</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity awards available for future issuance under the 2019 Equity Incentive Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-21584">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21585">25,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity awards available for future issuance under the 2024 Equity Incentive Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21586">976,082</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-21587">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares reserved for purchase under the 2024 Employee Stock Purchase Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21588">147,343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-21589">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21590">2,775,878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21591">6,213,717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to the conversion upon the closing of the Merger, Legacy Tectonic issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;A-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-2,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-3</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-4</div> convertible preferred stock (the &#8220;Convertible Preferred Stock&#8221;). Upon the closing of the Merger, all outstanding shares of the Convertible Preferred Stock were converted into&#160;<ix:nonFraction name="tecx:CommonStockSharesIssuableOnConversionIntoPermanentEquity" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21592">3,647,675</ix:nonFraction>&#160;shares of common stock.&#160;<ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-21593">No</ix:nonFraction>&#160;shares of Convertible Preferred Stock are authorized for issuance as of December&#160;31, 2024. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Subsequent to the Merger, the Company authorized the issuance of <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2024_UnrestrictedCommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21594">10,000,000</ix:nonFraction> shares of undesignated preferred stock, however <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2024_UndesignatedPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21595"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2024_UndesignatedPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21596">no</ix:nonFraction></ix:nonFraction> such shares were issued or outstanding as of December&#160;31, 2024. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Changes in Capital Structure </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon the closing of the Merger, all outstanding shares of convertible preferred stock were converted into an aggregate of&#160;<ix:nonFraction name="tecx:CommonStockSharesIssuableOnConversionIntoPermanentEquity" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21597">3,647,675</ix:nonFraction>&#160;shares of the Company&#8217;s common stock and $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21598">80.6</ix:nonFraction>&#160;million of mezzanine equity was reclassified to common stock and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. As of December&#160;31, 2024, there were&#160;<ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21599"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-21600">no</ix:nonFraction></ix:nonFraction>&#160;shares of convertible preferred stock issued or outstanding. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon the closing of the Merger, the principal balance of the SAFE instruments was automatically redeemed for <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_20_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21601">2,752,216</ix:nonFraction> shares of Legacy Tectonic common stock at the conversion price of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn06_20_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21602">12.40</ix:nonFraction> per share immediately </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-19</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_136075621_4" continuedAt="TextSelectionAppend_136075621_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075621_5" continuedAt="TextSelectionAppend_136075621_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075621_6"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">prior to the Merger closing. At closing, shares of Legacy Tectonic common stock issued pursuant to the redemption of Legacy Tectonic SAFEs were converted into <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024_AvrobioMemberTECXAgreementAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21604">1,470,839</ix:nonFraction> shares of common stock based on the Exchange Ratio, pursuant to the Merger Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Concurrently with the closing of the Merger, on June&#160;20, 2024, certain investors completed the purchase of shares of Legacy Tectonic common stock pursuant to the Subscription Agreement at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn06_20_2024_SubscriptionAgreementMemberTECXAgreementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21605">12.40</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P06_20_2024To06_20_2024_SubscriptionAgreementMemberTECXAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21606">96.6</ix:nonFraction>&#160;million. The shares of Legacy Tectonic common stock that were issued pursuant to the Subscription Agreement were converted into <ix:nonFraction name="tecx:StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" contextRef="P01_01_2024To12_31_2024_AvorbioCommonStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberTECXAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21607">4,163,606</ix:nonFraction> shares of common stock upon the closing of the Merger based on the exchange ratio, pursuant to the Merger Agreement. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075633" id="ixv-14912"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. EQUITY INCENTIVE PLANS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2019 Equity Incentive Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Legacy Tectonic 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) provides employees, consultants and advisors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> members of the Board of Directors with the opportunity to receive grants of stock options, stock awards and equity awards. Following the effectiveness of the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) as described below, no further grants will be made under the 2019 Plan; however, any outstanding equity awards granted under the 2019 Plan will continue to be governed by the terms of the 2019 Plan. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2024 Equity Incentive Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On June&#160;20, 2024, the Company adopted the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) which became effective upon completion of the Merger. The 2024 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, consultants, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> directors of the Company. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The 2024 Plan initially provided for the issuance of up to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21608">1,938,799</ix:nonFraction>&#160;shares of common stock (the &#8220;Initial Share Reserve&#8221;). Subject to any other adjustments as defined in the 2024 Plan, <ix:nonNumeric name="tecx:CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" contextRef="P01_01_2024To12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" id="ixv-21609">such aggregate number of shares of common stock will automatically increase on January 1st of each year for a period of ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to 5% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase; provided</ix:nonNumeric>, however that the Board of Directors may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of common stock. The maximum number of shares of common stock that may be issued under the 2024 Plan pursuant to the exercise of incentive stock options shall not exceed three times the Initial Share Reserve. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2024 Employee Stock Purchase Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;20, 2024, the Company adopted the 2024 Employee Stock Purchase Plan (the &#8220;2024 ESPP&#8221;), which became effective upon completion of the Merger. The maximum number of shares of common stock that may be issued under the 2024 ESPP will not exceed <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21610">147,343</ix:nonFraction>&#160;shares (the &#8220;Initial ESPP Share Reserve&#8221;), plus <ix:nonNumeric name="tecx:CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" contextRef="P01_01_2024To12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" id="ixv-21611">the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to the lesser of (x) 1% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase and (y)&#160;a number of shares equal to three times the Initial ESPP Share Reserve</ix:nonNumeric>. Notwithstanding the foregoing, the Board of Directors may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. No offering periods under the 2024 ESPP had been initiated as of December&#160;31, 2024. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-20</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075633" continuedAt="TextSelectionAppend_136075633_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075633_1" continuedAt="TextSelectionAppend_136075633_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075633_2" continuedAt="TextSelectionAppend_136075633_3"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075633_3" continuedAt="TextSelectionAppend_136075633_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The equity activity below reflects the reverse stock split and retroactive application of the exchange ratio as discussed in Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Nature of Business</div></div>. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14961"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the stock option activity under the 2019 Plan and 2024 Plan during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 52%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21613">1,002,485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21614">3.11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-21615">8.2</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2022_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21616">2,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21617">982,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21618">18.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21619">335,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21620">2.54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21621">5,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options forfeited and expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21622">115,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21623">8.98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21624">1,534,361</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21625">12.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-21626">8.5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21627">51,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and exercisable as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21628">364,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21629">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-21630">6.6</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21631">15,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21632">1,534,361</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21633">12.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-21634">8.5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21635">51,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the stock option activity for the options that were assumed from AVROBIO upon the Merger closing during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 53%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options assumed from AVROBIO upon Merger closing</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21636">365,428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21637">89.92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21638">52,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21639">14.61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21640">1,344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options forfeited and expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21641">220,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21642">136.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21643">92,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21644">22.69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-21645">1.1</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21646">2,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and exercisable as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21647">92,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21648">22.69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-21649">1.1</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21650">2,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21651">92,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21652">22.69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-21653">1.1</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21654">2,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the years ended December&#160;31, 2024 and 2023, the Company granted options with a weighted-average grant-date fair value of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21655">14.90</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21656">4.04</ix:nonFraction>&#160;per share, respectively. The fair value of options that vested during the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21657">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21658">1.1</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2024, the total unrecognized stock-based compensation expense for stock options was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21659">13.3</ix:nonFraction>&#160;million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-21660">3.3</ix:nonNumeric> years. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-21</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_136075633_4" continuedAt="TextSelectionAppend_136075633_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075633_5" continuedAt="TextSelectionAppend_136075633_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075633_6" continuedAt="TextSelectionAppend_136075633_7"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-15569"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The table below discloses assumptions for the fair value of options granted: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 61%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value per share of underlying common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21662">16.09</ix:nonFraction>&#160;-&#160;$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21663">51.28</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21664">2.50</ix:nonFraction>&#160;-&#160;$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21665">4.21</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-21666">6.00</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-21667">6.25</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-21668">5.81</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-21669">6.04</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21670">100.0</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21671">104.0</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21672">93.4</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21673">111.2</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21674">4.10</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21675">4.26</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21676">3.64</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21677">4.90</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21678">0</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21679">0</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units (RSUs) are granted to certain employees. The value of an RSU award is based on the Company&#8217;s stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest. <ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075638" id="ixv-21680">Activity with respect to the Company&#8217;s restricted stock units during the year ended December&#160;31, 2024 was as follows (in thousands, except share, contractual term, and per share data):</ix:nonNumeric> </div></div><ix:continuation id="TextSelection_136075638" continuedAt="TextSelectionAppend_136075638_1"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 55%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;Date<br/> Fair Value<br/> per Unit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-21681">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-21682">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-21683">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21684">26,337</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21685">44.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21686">725</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21687">34.51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21688">25,612</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21689">44.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-21690">1.9</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21691">1,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21692">25,612</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21693">44.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-21694">1.9</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21695">1,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2024, the total unrecognized stock-based compensation expense for RSUs was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21696">1.1</ix:nonFraction>&#160;million, which is expected to be recognized over a weighted average period of&#160;<ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-21697">3.2</ix:nonNumeric> years. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Common Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Legacy Tectonic granted restricted common stock to founders, employees and consultants. The purchase price of the restricted common stock is the estimated fair value on the grant date and the restricted stock is subject to various vesting schedules. Unvested restricted common stock is subject to repurchase rights held by the Company at the original issuance price in the event the restricted common stockholders&#8217; service to the Company is terminated either voluntarily or involuntarily. </div></div><ix:continuation id="TextSelectionAppend_136075638_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes restricted common stock activity during the year ended December&#160;31, 2024: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 75%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock awards as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21698">18,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Early exercise of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21699">6,859</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21700">25,827</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock awards as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-21701">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-22</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_136075633_7" continuedAt="TextSelectionAppend_136075633_8"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075633_8" continuedAt="TextSelectionAppend_136075633_9"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075633_9" continuedAt="TextSelectionAppend_136075633_10"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075633_10"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted-average grant date fair value and the weighted average value of the vested restricted common stock for the years ended December&#160;31, 2024 and 2023 were immaterial. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-16032"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table is a summary of stock-based compensation expense by function recognized (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21703">2,309</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21704">705</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21705">1,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21706">416</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21707">3,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21708">1,121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Modification of Certain Stock Options </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2024, the Company entered into a separation agreement with the Company&#8217;s Chief Operating Officer (the &#8220;Former Executive&#8221;). As part of the termination of employment, the Former Executive will serve as an advisor to the Company through March&#160;31, 2025 (&#8220;Consulting Period&#8221;) on an as needed basis. Pursuant to the separation agreement, certain modifications to the Former Executive&#8217;s vested and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-vested</div> stock option awards were executed including continued vesting of options during the Consulting Period and the extension of the post-termination exercise period of certain stock option awards. The services performed during the Consulting Period do not qualify as substantive services under ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div>; therefore, the continued vesting of these awards represents a modification to the original award. During the year ended December&#160;31, 2024, the Company recorded stock compensation expense of $<ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21709">0.4</ix:nonFraction>&#160;million for the modification of the stock options of the Former Executive. This amount is included in general and administrative expenses on the consolidated statement of operations and comprehensive loss. </div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075672" id="ixv-16148"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. NET LOSS PER SHARE </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-16152"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 66%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21710"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21711">57,982</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21712"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21713">42,823</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average common shares outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:WeightedAverageCommonShareOutstandingDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21714"><ix:nonFraction name="tecx:WeightedAverageCommonShareOutstandingBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21715">8,490,171</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:WeightedAverageCommonShareOutstandingDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21716"><ix:nonFraction name="tecx:WeightedAverageCommonShareOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21717">1,268,512</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21718"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21719">6.83</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21720"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21721">33.76</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-23</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075672" continuedAt="TextSelectionAppend_136075672_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075672_1" continuedAt="TextSelectionAppend_136075672_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075672_2"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-16315"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-21723">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21724">3,647,674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21725">1,626,841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21726">1,002,535</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock units and common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21727">25,612</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21728">18,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFEs (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_SimpleAgreementForFutureEquityMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-21729">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_SimpleAgreementForFutureEquityMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21730">1,519,331</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21731">1,652,453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21732">6,188,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075687" id="ixv-16447"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. LEASES </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2020, Legacy Tectonic executed a facilities lease agreement to occupy <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" contextRef="PAsOn11_30_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis" unitRef="Unit_sqft" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21733">18,768</ix:nonFraction> square feet of office and laboratory space, that was subsequently amended on <ix:nonNumeric name="tecx:OperatingLeaseDateOfExpiry" contextRef="P11_19_2020To11_19_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis" format="ixt:date-monthname-day-year-en" id="ixv-21734">April 21, 2022</ix:nonNumeric>. The lease requires the Company to pay fixed base rent, which is included in the measurement of the lease, as well as its proportionate share of the facilities operating expenses which are treated as variable lease costs based on the Company&#8217;s election to combine lease and associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components and are excluded from the measurement of the lease. The lease expires on <ix:nonNumeric name="tecx:OperatingLeaseDateOfExpiryRevised" contextRef="P11_19_2020To11_19_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis" format="ixt:date-monthname-day-year-en" id="ixv-21735">January 31, 2026</ix:nonNumeric>, and contains a <div style="-sec-ix-hidden:hidden136075767;display:inline;">five</div>-year renewal option exercisable by the Company which is not included in the measurement of the lease. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Legacy Tectonic has also entered into various financing leases for laboratory equipment used in research and development activities. </div></div><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-16456"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of lease expense and other information are as follows (dollars in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Finance lease amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21736">448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21737">488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21738">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21739">151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:FinanceLeaseCostAndExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21740">555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:FinanceLeaseCostAndExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21741">639</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21742">1,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21743">1,404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Short-term lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21744">545</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21745">749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Variable lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21746">911</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21747">786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21748">3,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21749">3,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 73%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average remaining lease terms (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2024" format="ixt-sec:duryear" id="ixv-21750">1.06</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-21751">2.09</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2024" format="ixt-sec:duryear" id="ixv-21752">2.26</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-21753">3.23</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21754">8.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21755">8.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21756">9.76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21757">9.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-24</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075687" continuedAt="TextSelectionAppend_136075687_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075687_1" continuedAt="TextSelectionAppend_136075687_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075687_2" continuedAt="TextSelectionAppend_136075687_3"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075687_3"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-16754"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Future commitments due under these lease agreements as of&#160;December 31, 2024&#160;are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21759">2,396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21760">552</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21761">2,948</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21762">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21763">363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21764">495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21765">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21766">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21767">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total undiscounted cash flows</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21768">2,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21769">959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21770">3,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21771">101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21772">83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:LeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21773">184</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21774">2,427</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21775">876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:TotalLeaseLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21776">3,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21777">2,295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21778">489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21779">2,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21780">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21781">387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:LeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21782">519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="tecx:LicenseAgreementDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-17033"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. LICENSE AGREEMENTS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Harvard Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2020, Legacy Tectonic entered into an agreement with the President and Fellows of Harvard College (&#8220;Harvard&#8221;), for an option fee in the low five digits, whereby Harvard granted Legacy Tectonic an exclusive option to negotiate a worldwide, exclusive, royalty-bearing license under Harvard&#8217;s interest in the patent rights covering certain technology that was developed by Harvard. In October 2021, Legacy Tectonic exercised the option and on February&#160;10, 2022, entered into a license agreement (&#8220;License Agreement&#8221;) with Harvard to conduct research and development activities using certain materials, technology and patent rights owned by Harvard, with the intent to develop, obtain regulatory approval for, and commercialize products. The License Agreement will remain in effect until the expiration of the last valid claim within the patent rights covering a product developed under the License Agreement or the termination of the License Agreement. As consideration for the License Agreement, the Company paid Harvard a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> license fee of $<ix:nonFraction name="tecx:UpfrontLicenseFees" contextRef="P02_10_2022To02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21783">170,000</ix:nonFraction>&#160;and issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21784">227,486</ix:nonFraction>&#160;shares of common stock with a fair market value of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_10_2022To02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21785">0.4</ix:nonFraction>&#160;million. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is responsible for payment of <ix:nonNumeric name="tecx:LicenseAgreementsPaymentsDescription" contextRef="P01_01_2024To12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis" id="ixv-17044">(1)&#160;annual maintenance fees ranging from the low five digits to the low six digits during the term of the License Agreement (through the first commercial sale of a royalty-bearing product); (2) royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from products that utilize the license technology (&#8220;Licensed Products&#8221;) and royalty payments as a percentage in the low single digits of the annual net sales that the Company generates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">from&#160;know-how&#160;enabled</div> product <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">licenses&#160;(&#8220;Know-How&#160;Enabled</div> Products&#8221;) and (3)&#160;a percentage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">between&#160;10-20%&#160;of</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">all&#160;non-royalty&#160;income</div> received by the Company under sublicenses, strategic partnerships <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">and&#160;know-how&#160;enabled</div> product licenses that utilize the license technology</ix:nonNumeric>. Subsequent to the first commercial sale of a royalty-bearing product, annual maintenance fees will increase to a low six digits for the remainder of the term of the License Agreement. The royalty term from sales of Licensed Products will terminate on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">a&#160;country-by-country&#160;and&#160;product-by-product&#160;basis</div></div></div></div> on the earlier of (i)&#160;the expiration of the patent rights covering the product, expected to be no earlier than May 2041, and (ii)&#160;the termination of the License Agreement. The royalty term from sales <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">of&#160;Know-How&#160;Enabled</div> Products will terminate on the earlier of (i)&#160;ten years after the first commercial sale of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first&#160;Know-How&#160;Enabled</div> Product and (ii)&#160;twelve years after the first commercial sale of the first Licensed Product.&#160;The Company incurred expense of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21786">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023_HarvardAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21787">0.2</ix:nonFraction>&#160;million related to the License Agreement during the years ended December&#160;31, 2024 and 2023, respectively. <ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21788"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2023_HarvardAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21789">No</ix:nonFraction></ix:nonFraction>&#160;amounts were due to Harvard related to the License Agreement as of December&#160;31, 2024 and 2023, respectively. </div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-25 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-17064"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. COMMITMENTS AND CONTINGENCIES </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Commitments </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company enters into contractual agreements with various suppliers in the normal course of its business. All contracts are terminable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would only be obligated for the products or services that the Company had received through the time of termination. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is also party to commitments, which are described elsewhere in these consolidated financial statements: Lease commitments, as described in Note 10,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Leases, </div></div>and&#160;royalty and maintenance based commitments, as described in Note 11,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;License Agreements.</div></div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with the Merger, the Company and its designated rights agent entered into a contingent value rights agreement (the &#8220;CVR Agreement&#8221;). Pursuant to the CVR Agreement, each holder of AVROBIO common stock immediately prior to the closing received a contractual contingent value right (&#8220;CVR&#8221;) subject to and in accordance with the terms and conditions of the CVR Agreement, representing the contractual right to receive a pro rata portion of any net proceeds, if any, resulting from a disposition of certain AVROBIO intellectual property (including a license of AVROBIO&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-closing</div> assets as defined in the CVR Agreement) after the closing and prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="tecx:PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" contextRef="P01_01_2024To12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durmonth" id="ixv-21790">18</ix:nonNumeric>-month</div> anniversary of the closing, received within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="tecx:ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" contextRef="P01_01_2024To12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:duryear" id="ixv-21791">10</ix:nonNumeric>-year</div> period following the closing; provided that <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="PAsOn12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21792">no</ix:nonFraction> contingent payment will be payable to any holder of the CVRs until such time as the then-outstanding and undistributed proceeds exceeds $<ix:nonFraction name="us-gaap:BusinessCombinationAcquiredReceivablesGrossContractualAmount" contextRef="PAsOn12_31_2024_CvrAgreementMemberTECXAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21793">0.4</ix:nonFraction>&#160;million in the aggregate. The Company believes that any receipt of payments resulting from the disposition of AVROBIO&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-closing</div> assets described in the CVR Agreement are highly susceptible to factors outside the Company&#8217;s influence that are not expected to be resolved within the timeline outlined in the CVR Agreement, if at all. In particular, these amounts are primarily influenced by the actions and judgments of third parties and the buyers of such assets and are based on the buyers of such assets progressing the specific platform and intellectual property and early stage of research and development programs. If the Company were to record a receivable for such contingent payments, it would also record a corresponding liability. As of December&#160;31, 2024, <ix:nonFraction name="us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" contextRef="PAsOn12_31_2024_CvrAgreementMemberTECXAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21794">no</ix:nonFraction> receivables or liabilities were recorded on the Consolidated Balance Sheet relating to such contingent payments. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. There are no matters pending that the Company currently believes are reasonably possible or probable of having a material impact to the Company&#8217;s financial position, results of operations, or statements of cash flows. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the normal course of operations, the Company may become involved in various legal proceedings. As of December&#160;31, 2024 and 2023, the Company has not recorded accruals for probable losses related to any existing or pending litigation as the Company&#8217;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#8217;s consolidated financial statements. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075697" id="ixv-17090"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">13. INCOME TAXES </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company did<div style="display:inline;">&#160;<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21795"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21796"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024_FederalMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21797"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023_FederalMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21798">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div>t record a federal or state income tax provision or benefit for the years ended December&#160;31, 2024&#160;and&#160;2023, as it has been incurring net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-26</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075697" continuedAt="TextSelectionAppend_136075697_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075697_1" continuedAt="TextSelectionAppend_136075697_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075697_2" continuedAt="TextSelectionAppend_136075697_3"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075697_3" continuedAt="TextSelectionAppend_136075697_4"><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-17115"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense consists of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21800">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21801">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21802">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21803">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21804">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21805">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21806">13,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21807">11,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21808">3,181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21809">3,361</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21810">741</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21811">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21812">16,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21813">14,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21814">16,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21815">14,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21816">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21817">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company had an effective tax rate of&#160;<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21818"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21819">0</ix:nonFraction></ix:nonFraction>% for the years ended December&#160;31, 2024&#160;and&#160;2023. <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075756" id="ixv-21820">The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows: </ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075756"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 81%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal statutory income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21821">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21822">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21823">5.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21824">7.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign rate differential</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21825">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21826">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Permanent differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:EffectiveIncomeTaxRateReconciliationPermanentDifference" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21827">0.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:EffectiveIncomeTaxRateReconciliationPermanentDifference" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21828">1.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:Effectiveincometaxratereconciliationchangeinstock1" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21829">1.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:Effectiveincometaxratereconciliationchangeinstock1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-21830">0.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock liability fair value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:PreferredStockLiabilityFairValueAdjustment" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-21831">1.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:PreferredStockLiabilityFairValueAdjustment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="-2" scale="-2" format="ixt:fixed-zero" id="ixv-21832">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-21833">2.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-21834">4.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-21835">29.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-21836">34.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="-2" scale="-2" format="ixt:fixed-zero" id="ixv-21837">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="-2" scale="-2" format="ixt:fixed-zero" id="ixv-21838">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-27</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_136075697_4" continuedAt="TextSelectionAppend_136075697_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075697_5" continuedAt="TextSelectionAppend_136075697_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075697_6" continuedAt="TextSelectionAppend_136075697_7"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-17550"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024&#160;and&#160;2023, were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21840">109,392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21841">11,392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21842">13,946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21843">4,336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:DeferredTaxAssetsLeaseLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21844">660</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:DeferredTaxAssetsLeaseLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21845">817</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Capitalized research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21846">40,742</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21847">14,595</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accruals&#160;&amp; other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21848">863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21849">1,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:DeferredTaxAssetsAmortization" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21850">3,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:DeferredTaxAssetsAmortization" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21851">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21852">2,112</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21853">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21854">171,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21855">32,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21856">170,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21857">30,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21858">1,093</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21859">1,939</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:DeferredTaxLiabilitiesDepreciation" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21860">485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:DeferredTaxLiabilitiesDepreciation" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21861">1,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Right of use asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21862">608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="tecx:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21863">729</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21864">1,093</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21865">1,939</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets (liability)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21866">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21867">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferred Tax Assets and Valuation Allowance </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December&#160;31, 2024 and 2023, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December&#160;31, 2024 and 2023. The Company&#8217;s valuation allowance increased during the year by $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21868">140.0</ix:nonFraction>&#160;million for the year ended December&#160;31, 2024 due primarily to the generation of net operating losses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">NOL Carryforwards </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on AVROBIO&#8217;s value immediately prior to the ownership change multiplied by the long-term tax exempt rate which is published monthly. Subsequent ownership changes may further affect the limitation in future years. The Company has not yet conducted a Section&#160;382 study to assess whether the Reverse Merger resulted in an ownership change under Section&#160;382 that could limit the ability to use the net operating loss carryforwards of AVROBIO and Tectonic.&#160;Nor has the Company completed a Section&#160;382 study to assess whether an ownership change or changes has/have occurred related to Tectonic Therapeutic&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-merger</div> activity. However, the Reverse Merger is expected to result in an ownership change for AVROBIO. Therefore, the Company does not </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-28</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_136075697_7" continuedAt="TextSelectionAppend_136075697_8"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075697_8" continuedAt="TextSelectionAppend_136075697_9"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075697_9" continuedAt="TextSelectionAppend_136075697_10"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075697_10"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">expect to be able to utilize a material portion, if any, of the historic net operating losses and tax credit carryforwards from AVROBIO. The impact of this would not materially impact the financial statements, given the full valuation allowance. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2024, the Company has net operating loss carryforwards for federal and state tax reporting purposes of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21870">399.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21871">71.9</ix:nonFraction>&#160;million, respectively. Net operating loss carryforwards generated after December&#160;31, 2017 for federal tax reporting purposes of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21872">399.3</ix:nonFraction>&#160;million have an indefinite life. Net operating loss carryforwards for state purposes of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="PAsOn12_31_2024_ExpirationThrough2040MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21873">71.9</ix:nonFraction>&#160;million, which begin to expire in 2040. As of December&#160;31, 2024, the Company also has federal and state research and development tax credits of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ExpirationThrough2040MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21874">10.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2024_ExpirationThrough2035MemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21875">4.4</ix:nonFraction>&#160;million, which being to expire in 2040 and 2035, respectively. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Tax Cuts and Jobs Act (TCJA) resulted in significant changes to the treatment of research and development expenditures under Section&#160;174. For tax years beginning after December&#160;31, 2021, taxpayers are required to capitalize and amortize all research and development expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;D activities must be amortized over <ix:nonNumeric name="tecx:AmortizationPeriodRDActivities" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:durwordsen" id="ixv-21876">five years</ix:nonNumeric> and costs for foreign research and development activities must be amortized over <ix:nonNumeric name="tecx:AmortizationPeriodForeignRDCosts" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-21877">15</ix:nonNumeric> years&#8212;both using a midyear convention. During the year ended December&#160;31, 2024, the Company capitalized $<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21878">40.3</ix:nonFraction>&#160;million of research and development expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Uncertain Tax Position </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluates its uncertain tax positions under ASC&#160;740&#160;which requires that realization of an uncertain income tax position be recognized. The benefit to be recorded is the amount most likely to be realized assuming a review by tax authorities having all relevant information and applying current conventions. The Company concluded that there are no uncertain tax positions in any of the periods presented. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The earliest tax years that remain subject to examination by jurisdiction is 2020 for both federal and state. However, to the extent the Company utilizes net operating losses from years prior to 2020, the statute remains open to the extent of the net operating losses or other credits are utilized. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075704" id="ixv-17946"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">14. RELATED PARTY TRANSACTIONS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scientific Advisory Board Member </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">One of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-founders</div> and former director is a member of the Company&#8217;s Scientific Advisory Board (&#8220;SAB&#8221;) and meets the criteria of a related party. For each of the years ended December&#160;31, 2024 and 2023, the Company incurred expense of $<ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2023To12_31_2023_AdvisoryServicesAgreementMemberusgaapRelatedPartyTransactionAxis_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21879"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2024To12_31_2024_AdvisoryServicesAgreementMemberusgaapRelatedPartyTransactionAxis_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21880">0.1</ix:nonFraction></ix:nonFraction>&#160;million for advisory services provided. There were <ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2024_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21881"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2023_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21882">no</ix:nonFraction></ix:nonFraction>&#160;amounts due to this related party as of December&#160;31, 2024 or 2023. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">License Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Harvard meets the criteria of a related party resulting from the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-founders&#8217;</div> employment as professors in the Harvard Department of Molecular Pharmacology. Core intellectual property utilized by the Company is licensed from Harvard under the License Agreement described in Note 11, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">License Agreements</div></div>. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company incurred expense of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21883">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21884">0.2</ix:nonFraction>&#160;million related to the License Agreement during the years ended December&#160;31, 2024 and 2023, respectively. <ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21885"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21886">No</ix:nonFraction></ix:nonFraction> amounts were due to Harvard related to the License Agreement as of December&#160;31, 2024 and 2023. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Adimab Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">One member of the Company&#8217;s Board of Directors also services on the board of Adimab, LLC (&#8220;Adimab&#8221;), an antibody discovery company. In May 2023, Legacy Tectonic entered into a discovery agreement with Adimab </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-29</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075704" continuedAt="TextSelectionAppend_136075704_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075704_1" continuedAt="TextSelectionAppend_136075704_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075704_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">whereby Legacy Tectonic and Adimab collaborated on human antibody discovery in accordance with an agreed upon research program. The Company incurred expense of $<ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2023To12_31_2023_AdimabAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21888"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2024To12_31_2024_AdimabAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21889">0.2</ix:nonFraction></ix:nonFraction>&#160;million during each of the years ended December&#160;31, 2024 and 2023. The Company terminated the agreement with Adimab in July 2024. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">SAFE Agreements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From October through December 2023, Legacy Tectonic entered into multiple SAFE agreements with certain existing investors and received proceeds of $<ix:nonFraction name="tecx:ProceedsFromSimpleAgreementForFutureEquity" contextRef="P10_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21890">34.1</ix:nonFraction>&#160;million. All investors were considered related parties of the Company. The SAFE agreements had no maturity date, bore no interest, and were redeemable by Legacy Tectonic upon the occurrence of a triggering event, including the Merger which qualified as a public listing transaction under the SAFE agreements. The SAFEs were redeemed for shares of Legacy Tectonic common stock in connection with the closing of the Merger. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DefinedContributionPlanTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-17993"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">15. EMPLOYEE BENEFIT PLAN </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has a 401(k) retirement plan (the &#8220;Plan&#8221;) that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company&#8217;s funding policy is to contribute <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="P01_01_2024To12_31_2024_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21891">3</ix:nonFraction>% (&#8220;Nonelective Contribution&#8221;) of employees&#8217; eligible pay to the Plan. As defined by the Plan, highly compensated employees are not eligible to receive the Nonelective Contribution. The Company contributed $<ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P01_01_2023To12_31_2023_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21892"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P01_01_2024To12_31_2024_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21893">0.2</ix:nonFraction></ix:nonFraction>&#160;million to the Plan in each of the years ended December&#160;31, 2024 and 2023. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_136075713" id="ixv-17999"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">16. SEGMENT INFORMATION </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We operate in&#160;<ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_Segment" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-21894">one</ix:nonFraction>&#160;operating segment, and therefore&#160;<ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_Segment" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-21895">one</ix:nonFraction>&#160;reportable segment, focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer as chief operating decision maker (&#8220;CODM&#8221;) in evaluating financial performance and deciding how to allocate resources on a consolidated basis. The significant expense categories outlined below align with the segment-level information that is regularly provided to the CODM. When evaluating the Company&#8217;s financial performance, the CODM reviews one measure of profitability, net loss, and makes decisions using this information. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No segment asset information is provided below as the CODM is focused on how expenses impact ending cash by period and overall cash runway. Any review of segment assets, which would focus on cash and cash equivalents, would be at the same level as the consolidated balance sheet. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-30</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_136075713" continuedAt="TextSelectionAppend_136075713_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_136075713_1" continuedAt="TextSelectionAppend_136075713_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075713_2" continuedAt="TextSelectionAppend_136075713_3"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_136075713_3"><ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-18027"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table presents the segment net loss and significant segment expenses for the years ended December&#160;31, 2024, and 2023 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee-related expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development employee-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21897">11,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21898">10,351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative employee-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21899">5,553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21900">3,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">External research and development expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Research and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> expenses</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ExternalResearchAndDevelopmentLiability" contextRef="PAsOn12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndPre-ClinicalExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21901">8,477</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ExternalResearchAndDevelopmentLiability" contextRef="PAsOn12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndPre-ClinicalExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21902">8,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Clinical and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ExternalResearchAndDevelopmentLiability" contextRef="PAsOn12_31_2024_ClinicalAndDevelopmentExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21903">15,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ExternalResearchAndDevelopmentLiability" contextRef="PAsOn12_31_2023_ClinicalAndDevelopmentExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21904">7,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Chemistry, manufacturing, and control expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ExternalResearchAndDevelopmentLiability" contextRef="PAsOn12_31_2024_ChemistryManufacturingAndControlExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21905">3,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:ExternalResearchAndDevelopmentLiability" contextRef="PAsOn12_31_2023_ChemistryManufacturingAndControlExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21906">8,947</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Non employee-related general and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:Non-ControllableExpenses" contextRef="P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21907">8,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="tecx:Non-ControllableExpenses" contextRef="P01_01_2023To12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21908">3,988</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other segment items<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">1</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21909">5,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2023To12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21910">774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21911">57,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21912">42,823</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; text-align: left; vertical-align: top;"><div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">1</div>&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other segment expenses include stock-based compensation, depreciation and amortization, changes in the fair value of the SAFE liabilities, loss on the issuance of SAFEs, interest income, and interest expense. </div></div></td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-18233"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">17. SUBSEQUENT EVENTS </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In February 2025, the Company entered into a securities purchase agreement pursuant to which the Company issued an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_01_2025To02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21913">3,689,465</ix:nonFraction> shares of common stock, at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_FundInvestorsMembersrtTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21914">50.00</ix:nonFraction> per share to fund investors and $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_IndividualInvestorsMembersrtTitleOfIndividualAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21915">54.14</ix:nonFraction> per share to individual investors that are either an officer or director of the Company, in exchange for aggregate consideration of approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="P02_01_2025To02_28_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21916">185.0</ix:nonFraction>&#160;million.</div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-31 </div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:160pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g863285g01v82.jpg" alt="LOGO" style="width:1.50248in;height:0.396429in"/>
 </p> <p style="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 3,689,465 Shares of Common Stock </p> <p style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;&#8195;&#8195;&#8195;, 2025 </p> <p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;13. Other Expenses of Issuance and Distribution. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,037.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">262,037.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;14. Indemnification of Directors and Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the Delaware General Corporation Law, or the DGCL authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys&#8217; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&#160;145 permits corporations to pay expenses (including attorneys&#8217; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&#160;145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section&#160;145. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(7) of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty, provided that such provision shall not eliminate or limit the liability (i)&#160;for any breach of the duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which an improper personal benefit was derived. The Bylaws provide that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. The Bylaws provide that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain general liability insurance that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, from the effective time of the Merger through the sixth anniversary of the date of the effective time, we agreed to indemnify and hold harmless each person who was, as of January&#160;30, 2024, the signing date of the Merger Agreement, or had been at any time prior, or who becomes prior to the effective time of the Merger, a director or officer of our company or Legacy Tectonic, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, pertaining to claims arising out of the fact that such person was a director or officer of our company or Legacy Tectonic, at or prior to the effective time of the merger, to the fullest extent permitted under the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, we agreed not to amend, modify or repeal provisions in the Fourth Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws that were in effect as of January&#160;30, 2024, the date of the Merger Agreement, with respect to indemnification, advancement of expenses and exculpation of our present and former directors and officers for a period of six years from the effective time of the Merger in a manner that would adversely affect the rights of such individuals who at the effective time of the Merger were our officers or directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, we purchased an insurance policy in effect for six years from the effective time of the Merger, providing no less favorable coverage as the current directors&#8217; and officers&#8217; liability insurance policies maintained by us with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against our current and former officers and directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;15. Recent Sales of Unregistered Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sold the securities described below within the past three years which were not registered under the Securities Act. All of the sales listed below were made pursuant to an exemption from registration afforded by Section&#160;4(a)(2) of the Securities Act (and Regulation D thereunder) or Rule 701 promulgated under Section&#160;3(b) of the Securities Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Shares of Legacy Tectonic stock have not been adjusted to reflect the exchange for our common stock in the Merger and reflect actual shares issued by Legacy Tectonic. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, Legacy Tectonic (i)&#160;issued and sold to certain investors 2,883,654 shares of its Series <span style="white-space:nowrap">A-1</span> Preferred Stock and Series <span style="white-space:nowrap">A-2</span> Preferred Stock at a purchase price of $13.1876 per share for an aggregate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase price of $38,028,475.61, (ii) issued 696,516 shares of its Series <span style="white-space:nowrap">A-3</span> Preferred Stock upon the conversion of certain outstanding convertible notes at a conversion price of $10.55008 per share and (iii)&#160;issued 361,659 shares of its Series <span style="white-space:nowrap">A-4</span> Preferred Stock upon the conversion of certain outstanding convertible notes at a conversion price of $11.20946 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, the Legacy Tectonic Board determined that Legacy Tectonic had achieved the milestone events pursuant to the terms of its Series A Preferred Stock Purchase Agreement and issued and sold to certain investors (i)&#160;an aggregate additional 2,466,372 shares of Legacy Tectonic&#8217;s Series A-1 Preferred Stock, and (ii)&#160;an additional 437,282 shares of Legacy Tectonic&#8217;s Series A-2 Preferred Stock in a subsequent closing, at a purchase price of $13.1876 per share for an aggregate purchase price of $38,028,475.61. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, Legacy Tectonic entered into a Subscription Agreement on January 30, 2024 with certain investors to consummate the <span style="white-space:nowrap">Pre-Closing</span> Financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an aggregate of 7,790,889 shares of Legacy Tectonic common stock, at a price of $12.39908 per share, for aggregate gross proceeds of approximately $96.6&#160;million. In addition, in connection with the closing of the Merger, Legacy Tectonic&#8217;s outstanding SAFEs converted into 2,752,216 shares of Legacy Tectonic common stock at a conversion price of $12.39908 per share. The aggregate purchase price between the <span style="white-space:nowrap">Pre-Closing</span> Financing and the SAFEs was approximately $130.7&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;3, 2025, we entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which we agreed to issue and sell 3,689,465 shares of our common stock, $0.0001 par value per share, at a price of $50.00 per share to certain institutional accredited investors and $54.14 per share to individual accredited investors that are either an officer or director of the Company. Our total gross proceeds from the sale of the shares in the Private Placement were approximately $185.0&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;16. Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:50%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:10%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="9" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation by Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filed</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Herewith</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524018812/d221662dex21.htm">Agreement and Plan of Merger and Reorganization, dated as of January&#160;30, 2024, by and among AVROBIO, Inc., Alpine Merger Subsidiary, Inc. and Tectonic Therapeutic, Inc.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">1/30/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524200609/d878693dex31.htm">Fourth Amended and Restated Certificate of Incorporation of the Company, as amended through June&#160;20, 2024.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">10-Q</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">8/14/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518202460/d153924dex32.htm">Amended and Restated Bylaws, as currently in effect. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/25/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000095017025042648/tecx-ex4_1.htm">Description of Capital Stock. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/20/2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d863285dex51.htm">Opinion of Cooley LLP </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">X</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524164480/d852858dex101.htm">Contingent Value Rights Agreement dated June&#160;20, 2024, by and between Tectonic Therapeutic, Inc. and Computershare Trust Company, LLC </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/20/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524164480/d852858dex102.htm">Form of Indemnification Agreement between Tectonic Therapeutic, Inc. and each of its directors and executive officers.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/20/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:49%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:11%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="9" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation by Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filed</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Herewith</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524164480/d852858dex103.htm">Subscription Agreement, dated as of January&#160;29, 2024, by and among Tectonic Therapeutic, Inc. and the purchasers thereunder</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/20/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.4#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524034461/d770053dex1042.htm">Tectonic Therapeutic, Inc. 2019 Equity Incentive Plan, and form of award agreements thereunder. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.42</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/20/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.5#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524164480/d852858dex106.htm">Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/20/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.6#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524164480/d852858dex107.htm">Forms of Option Grant Notice, Option Agreement and Notice of Exercise under Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/20/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.7#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524164480/d852858dex108.htm">Tectonic Therapeutic, Inc. 2024 Employee Stock Purchase Plan. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/20/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.8&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524076669/d770053dex1035.htm">License Agreement, dated February&#160;10, 2022, by and between Tectonic Therapeutic, Inc. and President and Fellows of Harvard College. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.35</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/26/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.9&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524076669/d770053dex1036.htm">Master Agreement for Early Phase Clinical Services, dated October&#160;23, 2023, by and between Tectonic Therapeutic, Inc. and ARENSIA Exploratory Medicine GmbH. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.36</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/26/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.10&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524076669/d770053dex1037.htm">Master Contract Services Agreement, dated October&#160;17, 2023, by and between Tectonic Therapeutic, Inc. and QPS Holdings, LLC. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.37</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/26/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.11&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524076669/d770053dex1038.htm">Master Contract Services Agreement, dated February&#160;16, 2022, by and between Tectonic Therapeutic, Inc. and ITR LABORATORIES CANADA INC. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.38</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/26/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.12&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524076669/d770053dex1039.htm">Development and Manufacturing Services Agreement, dated May&#160;6, 2022, by and between Tectonic Therapeutic, Inc. and WuXi Biologics (Hong Kong) Limited. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.39</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/26/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.13&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524076669/d770053dex1040.htm">Master Clinical Contract Services Agreement, dated March&#160;6, 2023, by and between Tectonic Therapeutic, Inc. and Novotech (Australia) Pty Limited CAN. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.40</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/26/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.14#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524164480/d852858dex104.htm">Amended and Restated Employment Agreement, dated as of June&#160;20, 2024, by and between Tectonic Therapeutic, Inc. and Alise Reicin, M.D. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">6/20/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.15#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524095517/d770053dex1043.htm">Offer Letter dated June&#160;16, 2021, by and between Tectonic Therapeutic, Inc. and Marcella Ruddy. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">4/15/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:46%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:11%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="9" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation by Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filed</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Herewith</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.16#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000095017025042648/tecx-ex10_17.htm">Offer Letter dated May&#160;28, 2025, by and between Tectonic Therapeutic, Inc. and Daniel Lochner. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/20/2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.17#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524095517/d770053dex1047.htm">Form of Severance Plan and Form of Participation Agreement of Tectonic Therapeutic, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">333-277048</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">4/15/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.18#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000095017024125304/tecx-ex10_1.htm"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy of Tectonic Therapeutic, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/20/2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.19</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312525018840/d843684dex101.htm">Form of Securities Purchase Agreement </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">2/3/2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.20</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312525018840/d843684dex102.htm">Form of Registration Rights Agreement </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">2/3/2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.21</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312524175599/d859790dex101.htm">Separation Agreement, dated as of July&#160;5, 2024, by and among Tectonic Therapeutic, Inc. and Christian Cortis </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">7/5/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">19.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000095017025042648/tecx-ex19_1.htm">Insider Trading Policy of Tectonic Therapeutic, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">19.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/20/2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d863285dex211.htm">List of Subsidiaries </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">X</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d863285dex231.htm">Consent of Deloitte&#160;&amp; Touche LLP, independent registered public accounting firm</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">X</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d863285dex51.htm">Consent of Cooley LLP (included in Exhibit&#160;5.1 hereto). </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">X</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">24.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#sig">Power of Attorney (included on signature page). </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">X</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">97.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000095017025042648/tecx-ex97_1.htm">Incentive Compensation Recoupment Policy of Tectonic Therapeutic, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="white-space:nowrap">001-38537</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">97.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">3/20/2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Schema Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Calculation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Definition Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Label Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Presentation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d863285dexfilingfees.htm">Filing Fee Table </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">X</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#8224;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i)&#160;are not material and (ii)&#160;is the type of information that the registrant treats as private or confidential. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">#</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates a management contract or any compensatory plan, contract or arrangement. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Annexes, schedules and exhibits have been omitted pursuant to Item 601(b)(2) or 601(a)(5), as applicable, of Regulation <span style="white-space:nowrap">S-K.</span> The registrant agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;17. Undertakings. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned registrant hereby undertakes: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(iii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that: Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post- effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii) or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top;text-align:left">
relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(iii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(iv)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(c)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned registrant hereby undertakes that: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form <span style="white-space:nowrap">S-1</span> and has duly caused this </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on March&#160;26, 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:99%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">TECTONIC THERAPEUTIC, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Alise Reicin</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name: Alise Reicin</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title: Chief Executive Officer, President and Director</td></tr>
</table></div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Alise Reicin and Daniel Lochner, as such person&#8217;s true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent with full power of substitution and resubstitution, for such person in such person&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the date indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Signature</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Title</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Date</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alise Reicin</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Alise Reicin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, President and Director</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Principal Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;26, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Lochner</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Daniel Lochner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Principal Financial Officer and Principal Accounting Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;26, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terrance McGuire</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Terrance McGuire</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;26, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stefan Vitorovic</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Stefan Vitorovic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;26, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Timothy A. Springer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Timothy A. Springer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;26, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Praveen Tipirneni</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Praveen Tipirneni</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;26, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Phillip B. Donenberg</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Phillip B. Donenberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;26, 2025</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d863285dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g863285dsp193.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brandon Fenn </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 212 479 6626
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">bfenn@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;26, 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tectonic Therapeutic, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">490 Arsenal Way, Suite 210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Watertown, MA 02472 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tectonic Therapeutic, Inc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Tectonic
Therapeutic, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the filing by the Company of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B><I>Registration
Statement</I></B>&#148;) with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;), including the prospectus included in the Registration Statement (the &#147;<B><I>Prospectus</I></B>&#148;), covering the registration
for resale of up to 3,689,465 shares (the &#147;<B><I>Shares</I></B>&#148;)<B><I> </I></B>of the Company&#146;s common stock, par value $0.0001 per share, issued pursuant to that certain Securities Purchase Agreement by and among the Company and the
investors named therein (the &#147;<B><I>Agreement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon (a)&nbsp;the
Registration Statement and the Prospectus, (b)&nbsp;the Company&#146;s certificate of incorporation and bylaws, each as currently in effect, (c)&nbsp;the Agreement and (d)&nbsp;such other records, documents, opinions, certificates, memoranda and
instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures; the authenticity of all documents submitted to us as originals; the conformity to
originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where
authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion herein is expressed solely with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any
other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COOLEY LLP 55 HUDSON YARDS, NEW YORK, NY 10001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T: (212) <FONT STYLE="white-space:nowrap">479-6000</FONT> F: (212) <FONT STYLE="white-space:nowrap">479-6275</FONT> COOLEY.COM </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g863285dsp193.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tectonic Therapeutic, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;26, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares are validly
issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be
implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect
any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the reference to
our firm under the caption &#147;Legal Matters&#148; in the Prospectus and to the filing of this opinion as an exhibit to the Registration Statement. In giving such consents, we do not thereby admit that we are in the category of persons whose
consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COOLEY LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brandon Fenn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brandon Fenn</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COOLEY LLP 55 HUDSON YARDS, NEW YORK, NY 10001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T: (212) <FONT STYLE="white-space:nowrap">479-6000</FONT> F: (212) <FONT STYLE="white-space:nowrap">479-6275</FONT> COOLEY.COM </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d863285dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>List of Subsidiaries </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jurisdiction of incorporation or organization</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AVROBIO Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ontario, Canada</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AVROBIO Australia Pty Ltd</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AVROBIO Securities Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Massachusetts</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tectonic Therapeutic Pty Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tectonic Therapeutic Securities Corp.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Massachusetts</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tectonic Operating Company, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d863285dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of our report dated March&nbsp;20, 2025, relating to
the financial statements of Tectonic Therapeutic, Inc. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;26, 2025 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d863285dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tectonic
Therapeutic, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Type</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Class</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Calculation</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>or
Carry</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Forward</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rule</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price Per</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Share<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate Offering</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registration</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="17" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" COLSPAN="17" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Newly Registered Securities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees to</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">stock,&nbsp;$0.0001</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">par value
per</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(c)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">3,689,465<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$21.31</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$78,622,499.15</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0.0001531</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$12,037.11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$78,622,499.15</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$12,037.11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Fees Previously Paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>Net Fees Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$12,037.11</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the number of shares of common stock, par value $0.0001 per share (&#147;Common Stock&#148;) of
Tectonic Therapeutic, Inc. that will be offered for resale by the selling stockholders named in this registration statement (the &#147;Registration Statement&#148;). Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), the Registration Statement shall also cover any additional shares of Common Stock that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt
of consideration that increases the number of outstanding shares of Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under
the Securities Act, based on the average of the high and low sales price of the Common Stock as reported on the Nasdaq Global Market on March&nbsp;25, 2025, a date within five business days prior to the filing of the Registration Statement.
</P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tecx-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-March-2025 [08:15:31] {PM}-->
<schema targetNamespace="http://www.aw.com/20241231" elementFormDefault="qualified" xmlns:tecx="http://www.aw.com/20241231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.aw.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" id="CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited">
<link:definition>1005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" id="CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical">
<link:definition>1006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
<link:definition>1008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/NatureOfBusiness" id="NatureOfBusiness">
<link:definition>1009 - Disclosure - Nature of Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/Merger" id="Merger">
<link:definition>1011 - Disclosure - Merger</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1012 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1013 - Disclosure - Property and Equipment, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
<link:definition>1014 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1015 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EquityIncentivePlans" id="EquityIncentivePlans">
<link:definition>1016 - Disclosure - Equity Incentive Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1017 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/Leases" id="Leases">
<link:definition>1018 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/LicenseAgreements" id="LicenseAgreements">
<link:definition>1019 - Disclosure - License agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1020 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1021 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1022 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
<link:definition>1023 - Disclosure - Employee Benefit Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SegmentInformation" id="SegmentInformation">
<link:definition>1024 - Disclosure - Segment Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1025 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1026 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/MergerTables" id="MergerTables">
<link:definition>1027 - Disclosure - Merger (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1028 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1029 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
<link:definition>1030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1031 - Disclosure - Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/LeasesTables" id="LeasesTables">
<link:definition>1032 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EquityIncentivePlansTables" id="EquityIncentivePlansTables">
<link:definition>1033 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1034 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1035 - Disclosure - INCOME TAXES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SegmentInformationTables" id="SegmentInformationTables">
<link:definition>1036 - Disclosure - Segment Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail" id="NatureOfBusinessAdditionalInformationDetail">
<link:definition>1037 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail">
<link:definition>1038 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - (Additional Information) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/MergerAdditionalInformationDetail" id="MergerAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Merger - (Additional Information) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail" id="MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail">
<link:definition>1040 - Disclosure - Merger - Summary Of The Company Obtain The Assets And Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
<link:definition>1041 - Disclosure - Fair Value Measurements - (Additional Information) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" id="FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<link:definition>1042 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail" id="FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail">
<link:definition>1043 - Disclosure - Fair Value Measurements - Summary of Activity for the Safe Liabilities that were Measured at Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<link:definition>1044 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition>1045 - Disclosure - Property and Equipment, Net (Additional Information) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
<link:definition>1046 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1047 - Disclosure - Commitments and Contingencies - (Additional Information) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1048 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail" id="LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail">
<link:definition>1049 - Disclosure - Leases - Schedule of Components of Lease Expense and Other Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail" id="LeasesScheduleOfInformationAboutTheCompanysLeasesDetail">
<link:definition>1050 - Disclosure - Leases - Schedule of Information About the Company's Leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail" id="LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail">
<link:definition>1051 - Disclosure - Leases - Schedule of Future Commitments Due Under These Lease Agreements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1052 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" id="StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail">
<link:definition>1053 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail" id="EquityIncentivePlansAdditionalInformationDetail">
<link:definition>1054 - Disclosure - Equity Incentive Plans - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail" id="EquityIncentivePlansSummaryOfTheStockOptionActivityDetail">
<link:definition>1055 - Disclosure - Equity Incentive Plans - Summary of the Stock Option Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail" id="EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail">
<link:definition>1056 - Disclosure - Equity Incentive Plans - Summary of Fair Values of the Options Granted (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail" id="EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail">
<link:definition>1057 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Units (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail" id="EquityIncentivePlansSummaryOfRestrictedStockActivityDetail">
<link:definition>1058 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail" id="EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail">
<link:definition>1059 - Disclosure - Equity Incentive Plans - Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail" id="LicenseAgreementsAdditionalInformationDetail">
<link:definition>1060 - Disclosure - License agreements (Additional Information) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1061 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail" id="IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail">
<link:definition>1062 - Disclosure - Income Taxes - Schedule Of Components of Income Tax Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" id="IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail">
<link:definition>1063 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
<link:definition>1064 - Disclosure - INCOME TAXES - Schedule of Deferred tax assets and liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" id="NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail">
<link:definition>1065 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" id="NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail">
<link:definition>1066 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1067 - Disclosure - Related Party Transactions  - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail" id="EmployeeBenefitPlanAdditionalInformationDetail">
<link:definition>1068 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SegmentInformationAdditionalInformationDetail" id="SegmentInformationAdditionalInformationDetail">
<link:definition>1069 - Disclosure - Segment Information (Additional Information) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail" id="SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail">
<link:definition>1070 - Disclosure - Segment Information - Schedule of segment net loss and significant segment expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
<link:definition>1071 - Disclosure - Subsequent Events (Additional Information) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1" id="LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1">
<link:definition>1072 - Statement - Leases - Schedule of Future Commitments Due Under These Lease Agreements (Detail) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="tecx-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="tecx-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="tecx-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="tecx-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
<import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
<import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
<import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
<import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="SAFELiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_SAFELiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInFairValueOfSafeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ChangeInFairValueOfSafeLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossOnIssuanceOfSAFEs" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_LossOnIssuanceOfSAFEs" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustedBalanceBeginningOfPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_AdjustedBalanceBeginningOfPeriodValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustedBalanceBeginningOfPeriodShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_AdjustedBalanceBeginningOfPeriodShare" substitutionGroup="xbrli:item" />
<element name="ContributionFromRelatedPartyInvestorsRelatedToSAFEs" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockUnderSubscriptionAgreementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceOfCommonStockUnderSubscriptionAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockUponTheMergerValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_IssuanceOfCommonStockUponTheMergerValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceOfCommonStockUponTheMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_IssuanceOfCommonStockUponTheMerger" substitutionGroup="xbrli:item" />
<element name="ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AtTheMarketFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AtTheMarketFacilityMember" substitutionGroup="xbrli:item" />
<element name="TransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_TransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_NonCashLeaseExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromSimpleAgreementForFutureEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ProceedsFromSimpleAgreementForFutureEquity" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromSubscriptionAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ProceedsFromSubscriptionAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashAcquiredInConnectionWithTheMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_CashAcquiredInConnectionWithTheMerger" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ConversionOfSimpleAgreementsForFutureEquityToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfConvertiblePreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ConversionOfConvertiblePreferredStockToCommonStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PurchaseEquipmentOfFinanceLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_PurchaseEquipmentOfFinanceLeases" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_OfferingCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MergerAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_MergerAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_LicenseAgreementsAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_LicenseAgreementDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="ReverseStockSplitAndExchangeRatioPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="SimpleAgreementsForFutureEquityPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_RelatedPartyTransactionsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="NatureOfOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_NatureOfOperationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="SubscriptionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_SubscriptionAgreementMember" substitutionGroup="xbrli:item" />
<element name="AvroAvrobioCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AvroAvrobioCommonStockMember" substitutionGroup="xbrli:item" />
<element name="AvorbioCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AvorbioCommonStockMember" substitutionGroup="xbrli:item" />
<element name="NatureOfOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_NatureOfOperationsLineItems" substitutionGroup="xbrli:item" />
<element name="ConversionOfStockSharesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ConversionOfStockSharesPercentage" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringThePeriodSharesReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" substitutionGroup="xbrli:item" />
<element name="StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" substitutionGroup="xbrli:item" />
<element name="ProceedsReceivedPursuantToAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ProceedsReceivedPursuantToAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MergerTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_MergerTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="MergerLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_MergerLineItems" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SimpleAgreementsForFutureEquityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_SimpleAgreementsForFutureEquityMember" substitutionGroup="xbrli:item" />
<element name="TypeOfCommonStockAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_TypeOfCommonStockAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TypeOfCommonStockDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_TypeOfCommonStockDomain" substitutionGroup="xbrli:item" />
<element name="AvrobioMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AvrobioMember" substitutionGroup="xbrli:item" />
<element name="FairValueInputAmountTransferInBetweenLevels" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_FairValueInputAmountTransferInBetweenLevels" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SAFELiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_SAFELiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DepreciationAndAmortizationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_DepreciationAndAmortizationExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedCompensationAndRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_AccruedCompensationAndRelatedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_AccruedResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CvrAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_CvrAgreementMember" substitutionGroup="xbrli:item" />
<element name="InstallmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_InstallmentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InstallmentDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_InstallmentDomain" substitutionGroup="xbrli:item" />
<element name="AvrobioIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AvrobioIncMember" substitutionGroup="xbrli:item" />
<element name="PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" substitutionGroup="xbrli:item" />
<element name="ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseForOfficeAndLaboratorySpacesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseDateOfExpiry" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_OperatingLeaseDateOfExpiry" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseDateOfExpiryRevised" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_OperatingLeaseDateOfExpiryRevised" substitutionGroup="xbrli:item" />
<element name="FinanceLeaseCostAndExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_FinanceLeaseCostAndExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="WeightedAverageRemainingLeaseTermsInYearsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" substitutionGroup="xbrli:item" />
<element name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_WeightedAverageDiscountRateAbstract" substitutionGroup="xbrli:item" />
<element name="LeaseLiabilityPaymentsDueNextTwelveMonths" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseLiabilityPaymentsDueYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_LeaseLiabilityPaymentsDueYearTwo" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseLiabilityPaymentsDueYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_LeaseLiabilityPaymentsDueYearThree" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseLiabilityPaymentsDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_LeaseLiabilityPaymentsDue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseLiabilityUndiscountedExcessAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_LeaseLiabilityUndiscountedExcessAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TotalLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_TotalLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_LeaseLiabilityCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_LeaseLiabilityNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UndesignatedPreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_UndesignatedPreferredStockMember" substitutionGroup="xbrli:item" />
<element name="RestrictedCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_RestrictedCommonStockMember" substitutionGroup="xbrli:item" />
<element name="UnrestrictedCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_UnrestrictedCommonStockMember" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesIssuableOnConversionIntoPermanentEquity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_TwoThousandAndNineteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyFourEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" substitutionGroup="xbrli:item" />
<element name="TwoThousandNineteenAndTwoThousandTwentyFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" substitutionGroup="xbrli:item" />
<element name="HarvardAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_HarvardAgreementMember" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_LicenseAgreementLineItems" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementsPaymentsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_LicenseAgreementsPaymentsDescription" substitutionGroup="xbrli:item" />
<element name="UpfrontLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_UpfrontLicenseFees" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_IncomeTaxesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FederalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_FederalMember" substitutionGroup="xbrli:item" />
<element name="ExpirationThrough2040Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_ExpirationThrough2040Member" substitutionGroup="xbrli:item" />
<element name="ExpirationThrough2035Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_ExpirationThrough2035Member" substitutionGroup="xbrli:item" />
<element name="IncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_IncomeTaxesLineItems" substitutionGroup="xbrli:item" />
<element name="AmortizationPeriodForeignRDCosts" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_AmortizationPeriodForeignRDCosts" substitutionGroup="xbrli:item" />
<element name="AmortizationPeriodRDActivities" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_AmortizationPeriodRDActivities" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationPermanentDifference" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" substitutionGroup="xbrli:item" />
<element name="Effectiveincometaxratereconciliationchangeinstock1" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_Effectiveincometaxratereconciliationchangeinstock1" substitutionGroup="xbrli:item" />
<element name="PreferredStockLiabilityFairValueAdjustment" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_PreferredStockLiabilityFairValueAdjustment" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_DeferredTaxAssetsLeaseLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_DeferredTaxAssetsAmortization" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxLiabilitiesDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_DeferredTaxLiabilitiesDepreciation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_DeferredTaxLiabilitiesRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WeightedAverageCommonShareOutstandingBasic" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_WeightedAverageCommonShareOutstandingBasic" substitutionGroup="xbrli:item" />
<element name="WeightedAverageCommonShareOutstandingDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_WeightedAverageCommonShareOutstandingDiluted" substitutionGroup="xbrli:item" />
<element name="SimpleAgreementForFutureEquityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_SimpleAgreementForFutureEquityMember" substitutionGroup="xbrli:item" />
<element name="MemberOfTheScientificAdvisoryBoardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_MemberOfTheScientificAdvisoryBoardMember" substitutionGroup="xbrli:item" />
<element name="AdvisoryServicesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AdvisoryServicesAgreementMember" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_LicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="AdimabAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_AdimabAgreementMember" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionByRelatedPartyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_RelatedPartyTransactionByRelatedPartyAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RelatedPartyTransactionByRelatedPartyDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_RelatedPartyTransactionByRelatedPartyDomain" substitutionGroup="xbrli:item" />
<element name="ResearchAndPre-ClinicalExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_ResearchAndPre-ClinicalExpensesMember" substitutionGroup="xbrli:item" />
<element name="ClinicalAndDevelopmentExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_ClinicalAndDevelopmentExpensesMember" substitutionGroup="xbrli:item" />
<element name="ChemistryManufacturingAndControlExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_ChemistryManufacturingAndControlExpensesMember" substitutionGroup="xbrli:item" />
<element name="ExternalResearchAndDevelopmentLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="tecx_ExternalResearchAndDevelopmentLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Non-ControllableExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="tecx_Non-ControllableExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FundInvestorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_FundInvestorsMember" substitutionGroup="xbrli:item" />
<element name="IndividualInvestorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_IndividualInvestorsMember" substitutionGroup="xbrli:item" />
<element name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="tecx_SecuritiesPurchaseAgreementMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>tecx-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-March-2025 [08:15:31] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.aw.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.aw.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail" roleURI="http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" roleURI="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail" roleURI="http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail" roleURI="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail" roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1" roleURI="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AccruedCompensationAndRelatedExpenses" xlink:label="loc_TECX_AccruedCompensationAndRelatedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_TECX_AccruedCompensationAndRelatedExpenses" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_TECX_AccruedResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_TECX_AccruedResearchAndDevelopmentExpenses" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SAFELiabilitiesCurrent" xlink:label="loc_TECX_SAFELiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_TECX_SAFELiabilitiesCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredCosts" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="26" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCash" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LossOnIssuanceOfSAFEs" xlink:label="loc_TECX_LossOnIssuanceOfSAFEs" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TECX_LossOnIssuanceOfSAFEs" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NonCashLeaseExpense" xlink:label="loc_TECX_NonCashLeaseExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TECX_NonCashLeaseExpense" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ChangeInFairValueOfSafeLiabilities" xlink:label="loc_TECX_ChangeInFairValueOfSafeLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TECX_ChangeInFairValueOfSafeLiabilities" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_TECX_ProceedsFromSimpleAgreementForFutureEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TECX_ProceedsFromSimpleAgreementForFutureEquity" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSubscriptionAgreement" xlink:label="loc_TECX_ProceedsFromSubscriptionAgreement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TECX_ProceedsFromSubscriptionAgreement" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CashAcquiredInConnectionWithTheMerger" xlink:label="loc_TECX_CashAcquiredInConnectionWithTheMerger" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TECX_CashAcquiredInConnectionWithTheMerger" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments" use="optional" order="25" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ChangeInFairValueOfSafeLiabilities" xlink:label="loc_TECX_ChangeInFairValueOfSafeLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_TECX_ChangeInFairValueOfSafeLiabilities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LossOnIssuanceOfSAFEs" xlink:label="loc_TECX_LossOnIssuanceOfSAFEs" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_TECX_LossOnIssuanceOfSAFEs" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpenseNonoperating" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" use="optional" order="7" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsLeaseLiability" xlink:label="loc_TECX_DeferredTaxAssetsLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_TECX_DeferredTaxAssetsLeaseLiability" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xlink:label="loc_TECX_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_TECX_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsAmortization" xlink:label="loc_TECX_DeferredTaxAssetsAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_TECX_DeferredTaxAssetsAmortization" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilities" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_TECX_DeferredTaxLiabilitiesDepreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_TECX_DeferredTaxLiabilitiesDepreciation" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_TECX_DeferredTaxLiabilitiesRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_TECX_DeferredTaxLiabilitiesRightOfUseAssets" use="optional" order="13" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:label="loc_TECX_EffectiveIncomeTaxRateReconciliationPermanentDifference" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_TECX_EffectiveIncomeTaxRateReconciliationPermanentDifference" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_Effectiveincometaxratereconciliationchangeinstock1" xlink:label="loc_TECX_Effectiveincometaxratereconciliationchangeinstock1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_TECX_Effectiveincometaxratereconciliationchangeinstock1" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PreferredStockLiabilityFairValueAdjustment" xlink:label="loc_TECX_PreferredStockLiabilityFairValueAdjustment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_TECX_PreferredStockLiabilityFairValueAdjustment" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FinanceLeaseCostAndExpense" xlink:label="loc_TECX_FinanceLeaseCostAndExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_TECX_FinanceLeaseCostAndExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_FinanceLeaseCostAndExpense" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_FinanceLeaseCostAndExpense" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_ShortTermLeaseCost" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_VariableLeaseCost" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiability" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDue" xlink:label="loc_TECX_LeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_TECX_LeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_LeaseLiabilityPaymentsDue" xlink:to="loc_TECX_LeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_TECX_LeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_LeaseLiabilityPaymentsDue" xlink:to="loc_TECX_LeaseLiabilityPaymentsDueYearTwo" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueYearThree" xlink:label="loc_TECX_LeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_LeaseLiabilityPaymentsDue" xlink:to="loc_TECX_LeaseLiabilityPaymentsDueYearThree" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDue" xlink:label="loc_TECX_LeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_TECX_LeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_LeaseLiabilityPaymentsDue" xlink:to="loc_TECX_LeaseLiabilityUndiscountedExcessAmount" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TotalLeaseLiabilities" xlink:label="loc_TECX_TotalLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_LeaseLiabilityPaymentsDue" xlink:to="loc_TECX_TotalLeaseLiabilities" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityCurrent" xlink:label="loc_TECX_LeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_TotalLeaseLiabilities" xlink:to="loc_TECX_LeaseLiabilityCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityNoncurrent" xlink:label="loc_TECX_LeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TECX_TotalLeaseLiabilities" xlink:to="loc_TECX_LeaseLiabilityNoncurrent" use="optional" order="21" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" xlink:label="loc_TECX_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_TECX_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" use="optional" order="4" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>tecx-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-March-2025 [08:15:31] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CoverPage" roleURI="http://www.aw.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" roleURI="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" roleURI="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#NatureOfBusinessAdditionalInformationDetail" roleURI="http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#MergerAdditionalInformationDetail" roleURI="http://www.aw.com/role/MergerAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#FairValueMeasurementsAdditionalInformationDetail" roleURI="http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail" roleURI="http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.aw.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" roleURI="http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansAdditionalInformationDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfTheStockOptionActivityDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfRestrictedStockActivityDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail" roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" roleURI="http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EmployeeBenefitPlanAdditionalInformationDetail" roleURI="http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail" roleURI="http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_106" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_DocumentInformationTable_147" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_107" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_107_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_107_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_104" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_104" xlink:to="loc_dei_AddressTypeDomain_109" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_109_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_104" xlink:to="loc_dei_AddressTypeDomain_109_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_109" xlink:to="loc_dei_BusinessContactMember_1115" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_DocumentType_103" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_AmendmentFlag_105" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityRegistrantName_114" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityCentralIndexKey_115" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityFilerCategory_117" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityEmergingGrowthCompany_118" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntitySmallBusiness_119" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityTaxIdentificationNumber_127" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressAddressLine1_128" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressAddressLine2_129" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressCityOrTown_130" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressStateOrProvince_131" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressPostalZipCode_132" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_CityAreaCode_133" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_LocalPhoneNumber_134" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityIncorporationStateCountryCode_135" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityPrimarySicNumber_1113" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_ContactPersonnelName_1114" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_190" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_StatementTable_188" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementClassOfStockAxis_187" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187" xlink:to="loc_us-gaap_ClassOfStockDomain_192" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_192_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187" xlink:to="loc_us-gaap_ClassOfStockDomain_192_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_192" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_186" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_185" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_189" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_191" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_193" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_194" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_195" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_PreferredStockSharesIssued_196" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_197" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_198" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_199" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CommonStockSharesIssued_200" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_201" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_238" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StatementTable_230" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_230" xlink:to="loc_us-gaap_StatementClassOfStockAxis_231" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_231" xlink:to="loc_us-gaap_ClassOfStockDomain_237" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_237_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_231" xlink:to="loc_us-gaap_ClassOfStockDomain_237_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_237" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_229" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_230" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_234" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_234" xlink:to="loc_us-gaap_EquityComponentDomain_227" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_227_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_234" xlink:to="loc_us-gaap_EquityComponentDomain_227_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_PreferredStockMember_228" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_CommonStockMember_233" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_236" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_240" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_RetainedEarningsMember_242" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockholdersEquity_226" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_SharesOutstanding_232" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_235" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdjustedBalanceBeginningOfPeriodValue" xlink:label="loc_tecx_AdjustedBalanceBeginningOfPeriodValue_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_AdjustedBalanceBeginningOfPeriodValue_239" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdjustedBalanceBeginningOfPeriodShare" xlink:label="loc_tecx_AdjustedBalanceBeginningOfPeriodShare_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_AdjustedBalanceBeginningOfPeriodShare_241" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_243" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_244" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" xlink:label="loc_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs_245" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_246" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_247" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_248" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_249" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" xlink:label="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue_250" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" xlink:label="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption_251" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" xlink:label="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue_252" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" xlink:label="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement_253" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUponTheMergerValue" xlink:label="loc_tecx_IssuanceOfCommonStockUponTheMergerValue_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockUponTheMergerValue_254" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUponTheMerger" xlink:label="loc_tecx_IssuanceOfCommonStockUponTheMerger_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockUponTheMerger_255" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" xlink:label="loc_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss_257" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_NetIncomeLoss_258" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_272" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_272" xlink:to="loc_us-gaap_StatementTable_267" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_267" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_269" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_269" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_268" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_269" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_268_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AtTheMarketFacilityMember" xlink:label="loc_tecx_AtTheMarketFacilityMember_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_268" xlink:to="loc_tecx_AtTheMarketFacilityMember_264" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_267" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_271" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_271" xlink:to="loc_us-gaap_EquityComponentDomain_265" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_265_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_271" xlink:to="loc_us-gaap_EquityComponentDomain_265_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_265" xlink:to="loc_us-gaap_CommonStockMember_266" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_272" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_263" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TransactionCosts" xlink:label="loc_tecx_TransactionCosts_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_272" xlink:to="loc_tecx_TransactionCosts_270" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NatureOfOperationsLineItems" xlink:label="loc_tecx_NatureOfOperationsLineItems_475" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NatureOfOperationsTable" xlink:label="loc_tecx_NatureOfOperationsTable_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_NatureOfOperationsTable_469" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementAxis" xlink:label="loc_tecx_AgreementAxis_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tecx_NatureOfOperationsTable_469" xlink:to="loc_tecx_AgreementAxis_465" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tecx_AgreementAxis_465" xlink:to="loc_tecx_AgreementDomain_462" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_462_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tecx_AgreementAxis_465" xlink:to="loc_tecx_AgreementDomain_462_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SubscriptionAgreementMember" xlink:label="loc_tecx_SubscriptionAgreementMember_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_AgreementDomain_462" xlink:to="loc_tecx_SubscriptionAgreementMember_468" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tecx_NatureOfOperationsTable_469" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_470" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_470" xlink:to="loc_us-gaap_EquityComponentDomain_463" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_463_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_470" xlink:to="loc_us-gaap_EquityComponentDomain_463_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvroAvrobioCommonStockMember" xlink:label="loc_tecx_AvroAvrobioCommonStockMember_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_463" xlink:to="loc_tecx_AvroAvrobioCommonStockMember_464" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tecx_NatureOfOperationsTable_469" xlink:to="loc_us-gaap_StatementClassOfStockAxis_472" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_472" xlink:to="loc_us-gaap_ClassOfStockDomain_474" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_474_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_472" xlink:to="loc_us-gaap_ClassOfStockDomain_474_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvorbioCommonStockMember" xlink:label="loc_tecx_AvorbioCommonStockMember_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_474" xlink:to="loc_tecx_AvorbioCommonStockMember_466" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_467" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_NetIncomeLoss_471" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_473" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ConversionOfStockSharesPercentage" xlink:label="loc_tecx_ConversionOfStockSharesPercentage_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_ConversionOfStockSharesPercentage_476" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" xlink:label="loc_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization_477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization_477" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" xlink:label="loc_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization_478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization_478" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_480" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_481" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xlink:label="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization_482" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsReceivedPursuantToAgreement" xlink:label="loc_tecx_ProceedsReceivedPursuantToAgreement_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_ProceedsReceivedPursuantToAgreement_483" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_484" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xlink:to="loc_srt_RangeAxis_491" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_491" xlink:to="loc_srt_RangeMember_489" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_489_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_491" xlink:to="loc_srt_RangeMember_489_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_489" xlink:to="loc_srt_MaximumMember_488" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_489" xlink:to="loc_srt_MinimumMember_495" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_496" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_496" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_490" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_490_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_496" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_490_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_490" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_492" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_494" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_Cash_497" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_499" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_500" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_AssetImpairmentCharges_501" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_LeaseExpirationDate1_502" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/MergerAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerLineItems" xlink:label="loc_tecx_MergerLineItems_510" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerTable" xlink:label="loc_tecx_MergerTable_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_tecx_MergerLineItems_510" xlink:to="loc_tecx_MergerTable_506" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tecx_MergerTable_506" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_505" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_505" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_507" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_507_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_505" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_507_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_MergerLineItems_510" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_517" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_us-gaap_FinancialInstrumentAxis_527" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_527" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_535" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_535_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_527" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_535_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityMember_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_535" xlink:to="loc_tecx_SimpleAgreementsForFutureEquityMember_529" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_srt_StatementScenarioAxis_536" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_536" xlink:to="loc_srt_ScenarioUnspecifiedDomain_530" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_530_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_536" xlink:to="loc_srt_ScenarioUnspecifiedDomain_530_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_538" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_538" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_531" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_531_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_538" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_531_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TypeOfCommonStockAxis" xlink:label="loc_tecx_TypeOfCommonStockAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_tecx_TypeOfCommonStockAxis_540" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TypeOfCommonStockDomain" xlink:label="loc_tecx_TypeOfCommonStockDomain_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tecx_TypeOfCommonStockAxis_540" xlink:to="loc_tecx_TypeOfCommonStockDomain_532" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TypeOfCommonStockDomain" xlink:label="loc_tecx_TypeOfCommonStockDomain_532_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tecx_TypeOfCommonStockAxis_540" xlink:to="loc_tecx_TypeOfCommonStockDomain_532_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvrobioMember" xlink:label="loc_tecx_AvrobioMember_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_TypeOfCommonStockDomain_532" xlink:to="loc_tecx_AvrobioMember_534" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_533" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_us-gaap_CommonStockSharesIssued_537" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_539" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FairValueInputAmountTransferInBetweenLevels" xlink:label="loc_tecx_FairValueInputAmountTransferInBetweenLevels_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_tecx_FairValueInputAmountTransferInBetweenLevels_541" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_567" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_567" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_546" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_546" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_546" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_555" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_561" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_564" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_560" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_560" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_557" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_557_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_560" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_557_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_557" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_559" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_563" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_563" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_558" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_558_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_563" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_558_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_558" xlink:to="loc_us-gaap_MoneyMarketFundsMember_553" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_565" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_565" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_550" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_550_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_565" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_550_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_550" xlink:to="loc_us-gaap_CashEquivalentsMember_548" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_566" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_566" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_549" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_549_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_566" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_549_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SAFELiabilitiesMember" xlink:label="loc_tecx_SAFELiabilitiesMember_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_549" xlink:to="loc_tecx_SAFELiabilitiesMember_554" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_567" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_556" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_556" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_551" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_567" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_562" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_562" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_545" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_572" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_572" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_570" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_570" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_571" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_571_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_570" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_571_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SAFELiabilitiesMember" xlink:label="loc_tecx_SAFELiabilitiesMember_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_571" xlink:to="loc_tecx_SAFELiabilitiesMember_573" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_574" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" xlink:label="loc_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition_576" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_577" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_578" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_579" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_587" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_587" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_585" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" xlink:to="loc_us-gaap_OfficeEquipmentMember_586" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_590" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" xlink:to="loc_us-gaap_ConstructionInProgressMember_592" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_593" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_583" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_588" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_591" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_650" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_us-gaap_OtherCommitmentsTable_626" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_TypeOfArrangementAxis_622" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_622" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_616" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_616_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_622" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_616_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_srt_CounterpartyNameAxis_631" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_631" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_611" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_611_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_631" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_611_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementAxis" xlink:label="loc_tecx_AgreementAxis_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_tecx_AgreementAxis_635" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tecx_AgreementAxis_635" xlink:to="loc_tecx_AgreementDomain_606" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_606_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tecx_AgreementAxis_635" xlink:to="loc_tecx_AgreementDomain_606_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CvrAgreementMember" xlink:label="loc_tecx_CvrAgreementMember_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_AgreementDomain_606" xlink:to="loc_tecx_CvrAgreementMember_620" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_638" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_638" xlink:to="loc_us-gaap_EquityComponentDomain_612" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_612_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_638" xlink:to="loc_us-gaap_EquityComponentDomain_612_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_InstallmentAxis" xlink:label="loc_tecx_InstallmentAxis_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_tecx_InstallmentAxis_640" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_InstallmentDomain" xlink:label="loc_tecx_InstallmentDomain_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tecx_InstallmentAxis_640" xlink:to="loc_tecx_InstallmentDomain_621" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_InstallmentDomain" xlink:label="loc_tecx_InstallmentDomain_621_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tecx_InstallmentAxis_640" xlink:to="loc_tecx_InstallmentDomain_621_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_642" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_642" xlink:to="loc_us-gaap_RelatedPartyDomain_625" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_625_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_642" xlink:to="loc_us-gaap_RelatedPartyDomain_625_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvrobioIncMember" xlink:label="loc_tecx_AvrobioIncMember_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_625" xlink:to="loc_tecx_AvrobioIncMember_618" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_srt_ProductOrServiceAxis_644" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_644" xlink:to="loc_srt_ProductsAndServicesDomain_607" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_607_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_644" xlink:to="loc_srt_ProductsAndServicesDomain_607_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_srt_RangeAxis_646" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_646" xlink:to="loc_srt_RangeMember_617" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_617_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_646" xlink:to="loc_srt_RangeMember_617_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_648" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_648" xlink:to="loc_us-gaap_LossContingencyNatureDomain_624" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_624_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_648" xlink:to="loc_us-gaap_LossContingencyNatureDomain_624_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" xlink:label="loc_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement_639" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" xlink:label="loc_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid_641" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_643" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount_645" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_647" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_675" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_675" xlink:to="loc_srt_RangeAxis_670" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_670" xlink:to="loc_srt_RangeMember_672" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_672_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_670" xlink:to="loc_srt_RangeMember_672_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_675" xlink:to="loc_us-gaap_LeaseContractualTermAxis_677" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_677" xlink:to="loc_us-gaap_LeaseContractualTermDomain_674" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_674_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_677" xlink:to="loc_us-gaap_LeaseContractualTermDomain_674_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" xlink:label="loc_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_674" xlink:to="loc_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember_676" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_682" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseDateOfExpiry" xlink:label="loc_tecx_OperatingLeaseDateOfExpiry_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_tecx_OperatingLeaseDateOfExpiry_683" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_684" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseDateOfExpiryRevised" xlink:label="loc_tecx_OperatingLeaseDateOfExpiryRevised_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_tecx_OperatingLeaseDateOfExpiryRevised_685" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_749" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_736" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_736" xlink:to="loc_us-gaap_StatementClassOfStockAxis_734" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_734" xlink:to="loc_us-gaap_ClassOfStockDomain_748" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_748_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_734" xlink:to="loc_us-gaap_ClassOfStockDomain_748_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvorbioCommonStockMember" xlink:label="loc_tecx_AvorbioCommonStockMember_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_tecx_AvorbioCommonStockMember_735" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_us-gaap_PreferredStockMember_742" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_us-gaap_CommonStockMember_746" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UndesignatedPreferredStockMember" xlink:label="loc_tecx_UndesignatedPreferredStockMember_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_tecx_UndesignatedPreferredStockMember_750" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RestrictedCommonStockMember" xlink:label="loc_tecx_RestrictedCommonStockMember_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_tecx_RestrictedCommonStockMember_752" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UnrestrictedCommonStockMember" xlink:label="loc_tecx_UnrestrictedCommonStockMember_754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_tecx_UnrestrictedCommonStockMember_754" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementAxis" xlink:label="loc_tecx_AgreementAxis_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_736" xlink:to="loc_tecx_AgreementAxis_741" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tecx_AgreementAxis_741" xlink:to="loc_tecx_AgreementDomain_733" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_733_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tecx_AgreementAxis_741" xlink:to="loc_tecx_AgreementDomain_733_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SubscriptionAgreementMember" xlink:label="loc_tecx_SubscriptionAgreementMember_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_AgreementDomain_733" xlink:to="loc_tecx_SubscriptionAgreementMember_737" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvrobioMember" xlink:label="loc_tecx_AvrobioMember_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_AgreementDomain_733" xlink:to="loc_tecx_AvrobioMember_743" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_736" xlink:to="loc_us-gaap_FinancialInstrumentAxis_745" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_745" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_740" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_740_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_745" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_740_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityMember_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_740" xlink:to="loc_tecx_SimpleAgreementsForFutureEquityMember_738" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" xlink:label="loc_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity_739" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_744" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_747" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_751" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_753" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_755" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_756" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_757" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockSharesIssued_758" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_759" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockVotingRights_760" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_761" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_762" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_763" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xlink:label="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization_764" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_773" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_773" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_769" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_769" xlink:to="loc_us-gaap_StatementClassOfStockAxis_767" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_767" xlink:to="loc_us-gaap_ClassOfStockDomain_775" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_767" xlink:to="loc_us-gaap_ClassOfStockDomain_775_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_768" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityMember_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_tecx_SimpleAgreementsForFutureEquityMember_772" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember_774" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember_778" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember_780" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_769" xlink:to="loc_us-gaap_AwardTypeAxis_771" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_771" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_771" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" xlink:to="loc_us-gaap_EmployeeStockOptionMember_777" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" xlink:to="loc_us-gaap_RestrictedStockMember_779" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_781" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_773" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_770" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" xlink:to="loc_us-gaap_PlanNameAxis_785" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_785" xlink:to="loc_us-gaap_PlanNameDomain_786" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_786_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_785" xlink:to="loc_us-gaap_PlanNameDomain_786_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_786" xlink:to="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember_784" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_786" xlink:to="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember_791" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_786" xlink:to="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember_794" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" xlink:to="loc_us-gaap_AwardTypeAxis_792" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_799" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" xlink:to="loc_srt_RangeAxis_795" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_795" xlink:to="loc_srt_RangeMember_788" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_788_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_795" xlink:to="loc_srt_RangeMember_788_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_797" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_800" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_801" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_802" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_806" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" xlink:label="loc_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription_807" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_809" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_816" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_816" xlink:to="loc_us-gaap_PlanNameAxis_815" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_815" xlink:to="loc_us-gaap_PlanNameDomain_814" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_814_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_815" xlink:to="loc_us-gaap_PlanNameDomain_814_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" xlink:label="loc_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_814" xlink:to="loc_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember_817" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_813" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_818" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_820" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_821" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_822" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_824" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_825" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_826" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_827" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_828" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_829" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_830" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_832" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_833" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_834" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_835" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_836" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_837" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_838" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_840" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_841" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_847" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_847" xlink:to="loc_srt_RangeAxis_844" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_844" xlink:to="loc_srt_RangeMember_846" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_846_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_844" xlink:to="loc_srt_RangeMember_846_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_846" xlink:to="loc_srt_MaximumMember_845" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_846" xlink:to="loc_srt_MinimumMember_850" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_848" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_851" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_852" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_853" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_854" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_855" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_860" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_860" xlink:to="loc_us-gaap_AwardTypeAxis_859" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_866" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_858" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_861" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_863" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_868" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_869" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_870" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="loc_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_872" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_873" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_874" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_875" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_879" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_884" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_884" xlink:to="loc_us-gaap_AwardTypeAxis_883" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_888" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_888_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_888_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_888" xlink:to="loc_us-gaap_RestrictedStockMember_892" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_882" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_887" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_889" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_901" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_901" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_898" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_898" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_896" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_896" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_897" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_897_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_896" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_897_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_897" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_900" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_897" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_902" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_901" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_899" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementLineItems" xlink:label="loc_tecx_LicenseAgreementLineItems_915" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_906" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_906" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_911" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_911_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_906" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_911_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" xlink:to="loc_us-gaap_TypeOfArrangementAxis_912" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_912" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_907" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_912" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_907_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_HarvardAgreementMember" xlink:label="loc_tecx_HarvardAgreementMember_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_907" xlink:to="loc_tecx_HarvardAgreementMember_905" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_CommonStockSharesIssued_914" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementsPaymentsDescription" xlink:label="loc_tecx_LicenseAgreementsPaymentsDescription_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_tecx_LicenseAgreementsPaymentsDescription_917" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_918" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_919" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_920" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UpfrontLicenseFees" xlink:label="loc_tecx_UpfrontLicenseFees_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_tecx_UpfrontLicenseFees_921" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesLineItems" xlink:label="loc_tecx_IncomeTaxesLineItems_945" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesTable" xlink:label="loc_tecx_IncomeTaxesTable_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_tecx_IncomeTaxesTable_930" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_929" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_929" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_932" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_932_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_929" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_932_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_932" xlink:to="loc_us-gaap_DomesticCountryMember_933" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FederalMember" xlink:label="loc_tecx_FederalMember_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_932" xlink:to="loc_tecx_FederalMember_938" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_932" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_941" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_937" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_937" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_934" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_934_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_937" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_934_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_us-gaap_TaxPeriodAxis_940" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_940" xlink:to="loc_us-gaap_TaxPeriodDomain_928" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_928_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_940" xlink:to="loc_us-gaap_TaxPeriodDomain_928_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExpirationThrough2040Member" xlink:label="loc_tecx_ExpirationThrough2040Member_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_928" xlink:to="loc_tecx_ExpirationThrough2040Member_927" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExpirationThrough2035Member" xlink:label="loc_tecx_ExpirationThrough2035Member_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_928" xlink:to="loc_tecx_ExpirationThrough2035Member_936" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_943" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_943" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_931" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_931_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_943" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_931_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_935" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_939" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_942" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_946" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_949" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_950" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_951" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_952" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AmortizationPeriodForeignRDCosts" xlink:label="loc_tecx_AmortizationPeriodForeignRDCosts_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_tecx_AmortizationPeriodForeignRDCosts_953" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AmortizationPeriodRDActivities" xlink:label="loc_tecx_AmortizationPeriodRDActivities_954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_tecx_AmortizationPeriodRDActivities_954" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_955" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesLineItems" xlink:label="loc_tecx_IncomeTaxesLineItems_1117" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_1116" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_958" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_960" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_961" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_962" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_963" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_964" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_965" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_966" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_967" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesLineItems" xlink:label="loc_tecx_IncomeTaxesLineItems_976" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_StatementTable_973" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_973" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_974" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_974" xlink:to="loc_us-gaap_EquityComponentDomain_971" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_971_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_974" xlink:to="loc_us-gaap_EquityComponentDomain_971_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_970" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_975" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_977" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:label="loc_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference_978" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_Effectiveincometaxratereconciliationchangeinstock1" xlink:label="loc_tecx_Effectiveincometaxratereconciliationchangeinstock1_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_tecx_Effectiveincometaxratereconciliationchangeinstock1_979" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PreferredStockLiabilityFairValueAdjustment" xlink:label="loc_tecx_PreferredStockLiabilityFairValueAdjustment_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_tecx_PreferredStockLiabilityFairValueAdjustment_980" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_981" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_982" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_983" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1016" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1016" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1012" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1012" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1014" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1014" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1014" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1010" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1015" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" xlink:to="loc_us-gaap_RestrictedStockMember_1017" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementForFutureEquityMember_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" xlink:to="loc_tecx_SimpleAgreementForFutureEquityMember_1018" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1016" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1013" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1053" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1025" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1025" xlink:to="loc_us-gaap_RelatedPartyDomain_1035" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1035_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1025" xlink:to="loc_us-gaap_RelatedPartyDomain_1035_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MemberOfTheScientificAdvisoryBoardMember" xlink:label="loc_tecx_MemberOfTheScientificAdvisoryBoardMember_1031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1035" xlink:to="loc_tecx_MemberOfTheScientificAdvisoryBoardMember_1031" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1037" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1037" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1034" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1034_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1037" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1034_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdvisoryServicesAgreementMember" xlink:label="loc_tecx_AdvisoryServicesAgreementMember_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1034" xlink:to="loc_tecx_AdvisoryServicesAgreementMember_1029" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementMember" xlink:label="loc_tecx_LicenseAgreementMember_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1034" xlink:to="loc_tecx_LicenseAgreementMember_1038" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdimabAgreementMember" xlink:label="loc_tecx_AdimabAgreementMember_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1034" xlink:to="loc_tecx_AdimabAgreementMember_1042" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_1041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_1041" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_1022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_1041" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_1022" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_1022_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_1041" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_1022_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_srt_RangeAxis_1046" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1046" xlink:to="loc_srt_RangeMember_1030" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1030_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1046" xlink:to="loc_srt_RangeMember_1030_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionByRelatedPartyAxis" xlink:label="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis_1049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis_1049" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionByRelatedPartyDomain" xlink:label="loc_tecx_RelatedPartyTransactionByRelatedPartyDomain_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis_1049" xlink:to="loc_tecx_RelatedPartyTransactionByRelatedPartyDomain_1032" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionByRelatedPartyDomain" xlink:label="loc_tecx_RelatedPartyTransactionByRelatedPartyDomain_1032_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis_1049" xlink:to="loc_tecx_RelatedPartyTransactionByRelatedPartyDomain_1032_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1050" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1050" xlink:to="loc_us-gaap_ClassOfStockDomain_1044" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1044_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1050" xlink:to="loc_us-gaap_ClassOfStockDomain_1044_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1051" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1051" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1028" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1028_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1051" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1028_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_srt_ProductOrServiceAxis_1052" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1052" xlink:to="loc_srt_ProductsAndServicesDomain_1021" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1021_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1052" xlink:to="loc_srt_ProductsAndServicesDomain_1021_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_us-gaap_ProfessionalFees_1023" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_1036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_1036" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1040" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_1048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_1048" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1065" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_1057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1065" xlink:to="loc_us-gaap_DefinedContributionPlanTable_1057" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1057" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_1061" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1061" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1060" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1060_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1061" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1060_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis_1063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1057" xlink:to="loc_us-gaap_RetirementPlanNameAxis_1063" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_1058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_1063" xlink:to="loc_us-gaap_RetirementPlanNameDomain_1058" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_1058_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_1063" xlink:to="loc_us-gaap_RetirementPlanNameDomain_1058_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameOtherMember" xlink:label="loc_us-gaap_RetirementPlanNameOtherMember_1056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_1058" xlink:to="loc_us-gaap_RetirementPlanNameOtherMember_1056" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1065" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1059" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1065" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1064" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1086" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1077" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1077" xlink:to="loc_us-gaap_SegmentDomain_1076" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1076_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1077" xlink:to="loc_us-gaap_SegmentDomain_1076_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_1080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" xlink:to="loc_srt_ConsolidationItemsAxis_1080" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_1074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1080" xlink:to="loc_srt_ConsolidationItemsDomain_1074" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_1074_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1080" xlink:to="loc_srt_ConsolidationItemsDomain_1074_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1074" xlink:to="loc_us-gaap_OperatingSegmentsMember_1072" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1083" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1083" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1075" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1075_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1083" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1075_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1078" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1081" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ResearchAndPre-ClinicalExpensesMember" xlink:label="loc_tecx_ResearchAndPre-ClinicalExpensesMember_1084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_tecx_ResearchAndPre-ClinicalExpensesMember_1084" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ClinicalAndDevelopmentExpensesMember" xlink:label="loc_tecx_ClinicalAndDevelopmentExpensesMember_1087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_tecx_ClinicalAndDevelopmentExpensesMember_1087" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ChemistryManufacturingAndControlExpensesMember" xlink:label="loc_tecx_ChemistryManufacturingAndControlExpensesMember_1089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_tecx_ChemistryManufacturingAndControlExpensesMember_1089" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_1079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_1079" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExternalResearchAndDevelopmentLiability" xlink:label="loc_tecx_ExternalResearchAndDevelopmentLiability_1082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_tecx_ExternalResearchAndDevelopmentLiability_1082" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_Non-ControllableExpenses" xlink:label="loc_tecx_Non-ControllableExpenses_1090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_tecx_Non-ControllableExpenses_1090" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_1091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_us-gaap_OtherIncome_1091" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_us-gaap_NetIncomeLoss_1092" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1112" xlink:to="loc_us-gaap_SubsequentEventTable_1104" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1103" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1099" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1099_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1099_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1099" xlink:to="loc_us-gaap_SubsequentEventMember_1102" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_srt_TitleOfIndividualAxis_1107" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1107" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1107" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FundInvestorsMember" xlink:label="loc_tecx_FundInvestorsMember_1105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096" xlink:to="loc_tecx_FundInvestorsMember_1105" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IndividualInvestorsMember" xlink:label="loc_tecx_IndividualInvestorsMember_1108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096" xlink:to="loc_tecx_IndividualInvestorsMember_1108" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1110" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1110" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1101" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1101_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1110" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1101_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SecuritiesPurchaseAgreementMember" xlink:label="loc_tecx_SecuritiesPurchaseAgreementMember_1095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1101" xlink:to="loc_tecx_SecuritiesPurchaseAgreementMember_1095" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1111" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1111" xlink:to="loc_us-gaap_EquityComponentDomain_1098" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1098_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1111" xlink:to="loc_us-gaap_EquityComponentDomain_1098_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1098" xlink:to="loc_us-gaap_CommonStockMember_1100" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1112" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1097" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1112" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1106" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_1109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1112" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_1109" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="loc_us-gaap_UsefulLifeDescriptionOfTermDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeTermOfLeaseMember" xlink:label="loc_us-gaap_UsefulLifeTermOfLeaseMember" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="loc_us-gaap_UsefulLifeTermOfLeaseMember" order="1.0" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>tecx-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-March-2025 [08:15:31] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Finance right-of-use assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred Costs, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SAFELiabilitiesCurrent" xlink:label="loc_tecx_SAFELiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_SAFELiabilitiesCurrent" xml:lang="en-US">SAFE Liabilities Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_SAFELiabilitiesCurrent" xml:lang="en-US">SAFE liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_SAFELiabilitiesCurrent" xlink:to="lab_tecx_SAFELiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_SAFELiabilitiesCurrent" xml:lang="en-US">Safe liabilities current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liability, non-current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liability Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Finance lease liability, non-current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Finance Lease Liability Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 12)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Convertible preferred stock (Series A-1, A-2, A-3 and A-4), $0.0001 par value; no shares authorized, issued or outstanding as of December 31, 2024; 3,647,675 shares authorized as of December 31, 2023; 3,647,675 shares issued and outstanding as of December 31, 2023; aggregate liquidation preference of $87,459 as of December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity (Deficit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, 10,000,000 shares and no shares authorized as of December 31, 2024 and 31, 2023, respectively; no shares issued and outstanding as of December 31, 2024 and 2023, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 14,856,309 and 1,407,753 shares issued and outstanding as of December 31, 2024 and 2023, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings (accumulated deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Convertible Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Convertible Preferred stock, authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Convertible Preferred stock, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Convertible Preferred stock, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research And Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income, net:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ChangeInFairValueOfSafeLiabilities" xlink:label="loc_tecx_ChangeInFairValueOfSafeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ChangeInFairValueOfSafeLiabilities" xml:lang="en-US">Change In Fair Value Of SAFE Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ChangeInFairValueOfSafeLiabilities" xml:lang="en-US">Change in fair value of SAFE liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tecx_ChangeInFairValueOfSafeLiabilities" xml:lang="en-US">Change in fair value of SAFE liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ChangeInFairValueOfSafeLiabilities" xlink:to="lab_tecx_ChangeInFairValueOfSafeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ChangeInFairValueOfSafeLiabilities" xml:lang="en-US">Change in fair value of SAFE liabilities.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LossOnIssuanceOfSAFEs" xlink:label="loc_tecx_LossOnIssuanceOfSAFEs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LossOnIssuanceOfSAFEs" xml:lang="en-US">Loss On Issuance Of SAFEs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tecx_LossOnIssuanceOfSAFEs" xml:lang="en-US">Loss on issuance of SAFEs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_LossOnIssuanceOfSAFEs" xml:lang="en-US">Loss on issuance of SAFEs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LossOnIssuanceOfSAFEs" xlink:to="lab_tecx_LossOnIssuanceOfSAFEs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LossOnIssuanceOfSAFEs" xml:lang="en-US">Loss On Issuance Of SAFEs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xml:lang="en-US">Interest Expense, Nonoperating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xml:lang="en-US">Other comprehensive loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share, basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share, diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average common shares outstanding, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average common shares outstanding, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ending balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Retroactive application of reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdjustedBalanceBeginningOfPeriodValue" xlink:label="loc_tecx_AdjustedBalanceBeginningOfPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AdjustedBalanceBeginningOfPeriodValue" xml:lang="en-US">Adjusted Balance Beginning Of Period Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_AdjustedBalanceBeginningOfPeriodValue" xml:lang="en-US">Adjusted balance, beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AdjustedBalanceBeginningOfPeriodValue" xlink:to="lab_tecx_AdjustedBalanceBeginningOfPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AdjustedBalanceBeginningOfPeriodValue" xml:lang="en-US">Adjusted balance beginning of period value.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdjustedBalanceBeginningOfPeriodShare" xlink:label="loc_tecx_AdjustedBalanceBeginningOfPeriodShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AdjustedBalanceBeginningOfPeriodShare" xml:lang="en-US">Adjusted Balance Beginning Of Period Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_AdjustedBalanceBeginningOfPeriodShare" xml:lang="en-US">Adjusted balance, beginning of period (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AdjustedBalanceBeginningOfPeriodShare" xlink:to="lab_tecx_AdjustedBalanceBeginningOfPeriodShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AdjustedBalanceBeginningOfPeriodShare" xml:lang="en-US">Adjusted balance beginning of period share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options Exercised, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" xlink:label="loc_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" xml:lang="en-US">Contribution from related party investors related to SAFEs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" xml:lang="en-US">Contribution from related party investors related to SAFEs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" xlink:to="lab_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" xml:lang="en-US">Contribution from related party investors related to SAFEs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Vesting of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Conversion of convertible preferred stock into common stock in connection with the Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Reclassification of euity upon conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Conversion of convertible preferred stock into common stock in connection with the Merger (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" xlink:label="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" xml:lang="en-US">Issuance Of Common Stock To Related Party Investors Upon Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" xml:lang="en-US">Issuance of common stock to related party investors upon redemption of the SAFEs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" xlink:to="lab_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" xml:lang="en-US">Issuance of common stock to related party investors upon redemption value.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" xlink:label="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" xml:lang="en-US">Issuance Of Common Stock To Related Party Investors Upon Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" xml:lang="en-US">Issuance of common stock to related party investors upon redemption of the SAFEs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" xlink:to="lab_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" xml:lang="en-US">Issuance of common stock to related party investors upon redemption.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" xlink:label="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" xml:lang="en-US">Issuance Of Common Stock Under Subscription Agreement Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" xml:lang="en-US">Issuance of common stock under subscription agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" xlink:to="lab_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" xml:lang="en-US">Issuance of common stock under subscription agreement value.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" xlink:label="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" xml:lang="en-US">Issuance Of Common Stock Under Subscription Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" xml:lang="en-US">Issuance of common stock under subscription agreement (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" xlink:to="lab_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" xml:lang="en-US">Issuance of common stock under subscription agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUponTheMergerValue" xlink:label="loc_tecx_IssuanceOfCommonStockUponTheMergerValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IssuanceOfCommonStockUponTheMergerValue" xml:lang="en-US">Issuance Of Common Stock Upon The Merger Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_IssuanceOfCommonStockUponTheMergerValue" xml:lang="en-US">Issuance of common stock upon the merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IssuanceOfCommonStockUponTheMergerValue" xlink:to="lab_tecx_IssuanceOfCommonStockUponTheMergerValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IssuanceOfCommonStockUponTheMergerValue" xml:lang="en-US">Issuance of common stock upon the merger value.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUponTheMerger" xlink:label="loc_tecx_IssuanceOfCommonStockUponTheMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IssuanceOfCommonStockUponTheMerger" xml:lang="en-US">Issuance Of Common Stock Upon The Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_IssuanceOfCommonStockUponTheMerger" xml:lang="en-US">Issuance of common stock upon the merger (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IssuanceOfCommonStockUponTheMerger" xlink:to="lab_tecx_IssuanceOfCommonStockUponTheMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IssuanceOfCommonStockUponTheMerger" xml:lang="en-US">Issuance Of Common Stock Upon The Merger.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" xlink:label="loc_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" xml:lang="en-US">Foreign Currency Transaction And Translation Adjustment Net Of Tax Other Comprehensive Income Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" xlink:to="lab_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" xml:lang="en-US">Foreign currency transaction and translation adjustment net of tax other comprehensive income loss.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AtTheMarketFacilityMember" xlink:label="loc_tecx_AtTheMarketFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AtTheMarketFacilityMember" xml:lang="en-US">At the Market Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AtTheMarketFacilityMember" xml:lang="en-US">At the Market Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AtTheMarketFacilityMember" xlink:to="lab_tecx_AtTheMarketFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AtTheMarketFacilityMember" xml:lang="en-US">At the market facility member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TransactionCosts" xlink:label="loc_tecx_TransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_TransactionCosts" xml:lang="en-US">Transaction Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_TransactionCosts" xlink:to="lab_tecx_TransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_TransactionCosts" xml:lang="en-US">Transaction Costs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NonCashLeaseExpense" xlink:label="loc_tecx_NonCashLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_NonCashLeaseExpense" xml:lang="en-US">Non Cash Lease Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_NonCashLeaseExpense" xml:lang="en-US">Non-cash&#160;lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_NonCashLeaseExpense" xlink:to="lab_tecx_NonCashLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_NonCashLeaseExpense" xml:lang="en-US">Non cash lease expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Change in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other&#160;non-current&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued expenses and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Other non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property, equipment and improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ProceedsFromSimpleAgreementForFutureEquity" xml:lang="en-US">Proceeds From Simple Agreement For Future Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ProceedsFromSimpleAgreementForFutureEquity" xml:lang="en-US">Proceeds from the issuance of SAFEs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity" xlink:to="lab_tecx_ProceedsFromSimpleAgreementForFutureEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ProceedsFromSimpleAgreementForFutureEquity" xml:lang="en-US">Proceeds from simple agreement for future equity.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSubscriptionAgreement" xlink:label="loc_tecx_ProceedsFromSubscriptionAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ProceedsFromSubscriptionAgreement" xml:lang="en-US">Proceeds From Subscription Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ProceedsFromSubscriptionAgreement" xml:lang="en-US">Proceeds from the Subscription Agreement, net of offering costs of $2,000</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ProceedsFromSubscriptionAgreement" xlink:to="lab_tecx_ProceedsFromSubscriptionAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ProceedsFromSubscriptionAgreement" xml:lang="en-US">Proceeds from subscription agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CashAcquiredInConnectionWithTheMerger" xlink:label="loc_tecx_CashAcquiredInConnectionWithTheMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_CashAcquiredInConnectionWithTheMerger" xml:lang="en-US">Cash acquired in connection with the Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_CashAcquiredInConnectionWithTheMerger" xml:lang="en-US">Cash acquired in connection with the Merger, net of transaction costs of $9,300</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_CashAcquiredInConnectionWithTheMerger" xlink:to="lab_tecx_CashAcquiredInConnectionWithTheMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_CashAcquiredInConnectionWithTheMerger" xml:lang="en-US">Cash acquired in connection with the Merger.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of common stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Finance Lease, Principal Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Repayment of finance lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents and restricted cash as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents and restricted cash as of end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xml:lang="en-US">Components of cash, cash equivalents and restricted cash:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of&#160;non-cash&#160;financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" xlink:label="loc_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" xml:lang="en-US">Conversion Of Simple Agreements For Future Equity To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" xml:lang="en-US">Conversion of SAFEs to Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" xlink:to="lab_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" xml:lang="en-US">Conversion of simple agreements for future equity&#160; to common stock.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ConversionOfConvertiblePreferredStockToCommonStock" xlink:label="loc_tecx_ConversionOfConvertiblePreferredStockToCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ConversionOfConvertiblePreferredStockToCommonStock" xml:lang="en-US">Conversion Of Convertible Preferred Stock To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tecx_ConversionOfConvertiblePreferredStockToCommonStock" xml:lang="en-US">Conversion of Convertible Preferred Stock to Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ConversionOfConvertiblePreferredStockToCommonStock" xlink:to="lab_tecx_ConversionOfConvertiblePreferredStockToCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ConversionOfConvertiblePreferredStockToCommonStock" xml:lang="en-US">Conversion of convertible preferred stock&#160; to common stock.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PurchaseEquipmentOfFinanceLeases" xlink:label="loc_tecx_PurchaseEquipmentOfFinanceLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_PurchaseEquipmentOfFinanceLeases" xml:lang="en-US">Purchase Equipment of Finance Leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_PurchaseEquipmentOfFinanceLeases" xml:lang="en-US">Purchase of equipment through finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_PurchaseEquipmentOfFinanceLeases" xlink:to="lab_tecx_PurchaseEquipmentOfFinanceLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_PurchaseEquipmentOfFinanceLeases" xml:lang="en-US">Purchase Equipment of Finance Leases</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US">Merger transaction costs included in accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OfferingCost" xlink:label="loc_tecx_OfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_OfferingCost" xml:lang="en-US">Offering Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_OfferingCost" xml:lang="en-US">Offering Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_OfferingCost" xlink:to="lab_tecx_OfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_OfferingCost" xml:lang="en-US">Offering cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerAbstract" xlink:label="loc_tecx_MergerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_MergerAbstract" xml:lang="en-US">Merger [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_MergerAbstract" xlink:to="lab_tecx_MergerAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Equity Incentive Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xml:lang="en-US">Lessor, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementsAbstract" xlink:label="loc_tecx_LicenseAgreementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LicenseAgreementsAbstract" xml:lang="en-US">License Agreements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LicenseAgreementsAbstract" xlink:to="lab_tecx_LicenseAgreementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LicenseAgreementsAbstract" xml:lang="en-US">License agreements.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementDisclosureTextBlock" xlink:label="loc_tecx_LicenseAgreementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">License Agreement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LicenseAgreementDisclosureTextBlock" xlink:to="lab_tecx_LicenseAgreementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">License agreement disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanAbstract" xlink:label="loc_us-gaap_DefinedContributionPlanAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanAbstract" xml:lang="en-US">Defined Contribution Plan [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanAbstract" xlink:to="lab_us-gaap_DefinedContributionPlanAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xml:lang="en-US">Defined Contribution Plan [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xml:lang="en-US">Employee Benefit Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xlink:label="loc_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xml:lang="en-US">Reverse Stock Split and Exchange Ratio [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xml:lang="en-US">Reverse Stock Split and Exchange Ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xlink:to="lab_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xml:lang="en-US">Reverse Stock Split and Exchange Ratio [Policy Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" xml:lang="en-US">Simple Agreements for Future Equity [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" xml:lang="en-US">Simple Agreements for Future Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:to="lab_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" xml:lang="en-US">Simple Agreements for Future Equity [Policy Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionsPolicyTextBlock" xlink:label="loc_tecx_RelatedPartyTransactionsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_RelatedPartyTransactionsPolicyTextBlock" xml:lang="en-US">Related Party Transactions [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_RelatedPartyTransactionsPolicyTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_RelatedPartyTransactionsPolicyTextBlock" xlink:to="lab_tecx_RelatedPartyTransactionsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_RelatedPartyTransactionsPolicyTextBlock" xml:lang="en-US">Related Party Transactions [Policy Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="lab_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">New accounting pronouncements not yet adopted.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xml:lang="en-US">Summary of the Recognized Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of Activity for the Safe Liabilities that were Measured at Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of Property and Equipment Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of Accrued Expenses and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xml:lang="en-US">Summary of Common Stock Reserved for Future Issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Schedule of Components of Lease Expense and Other Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Future Commitments Due Under These Lease Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of The Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of Fair Values of the Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Summary of Restricted Stock Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Summary of Basic and Diluted Earnings Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Summary of Diluted Net Loss Per Share Attributable to Common Stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">ScheduleOfComponentsOfIncomeTaxExpenseBenefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">ScheduleOfEffectiveIncomeTaxRateReconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">ScheduleOfDeferredTaxAssetsAndLiabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of segment net loss and significant segment expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NatureOfOperationsTable" xlink:label="loc_tecx_NatureOfOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_NatureOfOperationsTable" xml:lang="en-US">Nature Of Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_NatureOfOperationsTable" xlink:to="lab_tecx_NatureOfOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_NatureOfOperationsTable" xml:lang="en-US">Nature of operations.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementAxis" xlink:label="loc_tecx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AgreementAxis" xlink:to="lab_tecx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AgreementDomain" xlink:to="lab_tecx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AgreementDomain" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SubscriptionAgreementMember" xlink:label="loc_tecx_SubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_SubscriptionAgreementMember" xml:lang="en-US">Subscription Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_SubscriptionAgreementMember" xml:lang="en-US">Subscription Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_SubscriptionAgreementMember" xlink:to="lab_tecx_SubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_SubscriptionAgreementMember" xml:lang="en-US">Subscription agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvroAvrobioCommonStockMember" xlink:label="loc_tecx_AvroAvrobioCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AvroAvrobioCommonStockMember" xml:lang="en-US">AVRO Avrobio Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_AvroAvrobioCommonStockMember" xml:lang="en-US">AVRO Avrobio Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AvroAvrobioCommonStockMember" xlink:to="lab_tecx_AvroAvrobioCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AvroAvrobioCommonStockMember" xml:lang="en-US">AVRO Avrobio common stock.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvorbioCommonStockMember" xlink:label="loc_tecx_AvorbioCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AvorbioCommonStockMember" xml:lang="en-US">Avorbio Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AvorbioCommonStockMember" xml:lang="en-US">Avorbio Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AvorbioCommonStockMember" xlink:to="lab_tecx_AvorbioCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AvorbioCommonStockMember" xml:lang="en-US">Avorbio common stock.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NatureOfOperationsLineItems" xlink:label="loc_tecx_NatureOfOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_NatureOfOperationsLineItems" xml:lang="en-US">Nature Of Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_NatureOfOperationsLineItems" xlink:to="lab_tecx_NatureOfOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_NatureOfOperationsLineItems" xml:lang="en-US">Nature of operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Reverse stock split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ConversionOfStockSharesPercentage" xlink:label="loc_tecx_ConversionOfStockSharesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ConversionOfStockSharesPercentage" xml:lang="en-US">Conversion of Stock Shares Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_ConversionOfStockSharesPercentage" xml:lang="en-US">Conversion of stock shares percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ConversionOfStockSharesPercentage" xlink:to="lab_tecx_ConversionOfStockSharesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ConversionOfStockSharesPercentage" xml:lang="en-US">Conversion of stock shares percentage.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" xlink:label="loc_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" xml:lang="en-US">Stock Issued During The Period Shares Reverse Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" xml:lang="en-US">Stock issued during the period shares reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" xlink:to="lab_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" xml:lang="en-US">Stock issued during the period shares reverse recapitalization.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" xlink:label="loc_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" xml:lang="en-US">Stock Shares Issued During The Period Subject To Reverse Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" xml:lang="en-US">Stock shares issued during the period subject to reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" xlink:to="lab_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" xml:lang="en-US">Stock shares issued during the period subject to reverse recapitalization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during the period shares new issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock issue price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Shares issued price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from the issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xlink:label="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xml:lang="en-US">Stock issued during the period shares new issues converted pursuant to reverse recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xml:lang="en-US">Stock issued during the period shares new issues converted pursuant to reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xlink:to="lab_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xml:lang="en-US">Stock issued during the period shares new issues converted pursuant to reverse recapitalization.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsReceivedPursuantToAgreement" xlink:label="loc_tecx_ProceedsReceivedPursuantToAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ProceedsReceivedPursuantToAgreement" xml:lang="en-US">Proceeds Received Pursuant To Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_ProceedsReceivedPursuantToAgreement" xml:lang="en-US">Proceeds received pursuant to agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ProceedsReceivedPursuantToAgreement" xlink:to="lab_tecx_ProceedsReceivedPursuantToAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ProceedsReceivedPursuantToAgreement" xml:lang="en-US">Proceeds received pursuant to agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stock split, conversion ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash maintain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerTable" xlink:label="loc_tecx_MergerTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_MergerTable" xml:lang="en-US">Merger [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_MergerTable" xlink:to="lab_tecx_MergerTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerLineItems" xlink:label="loc_tecx_MergerLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_MergerLineItems" xml:lang="en-US">Merger [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_MergerLineItems" xlink:to="lab_tecx_MergerLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xml:lang="en-US">Reduction to additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" xlink:label="loc_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accured Expenses And Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Accrued expenses and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" xlink:to="lab_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed accured expenses and other current liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xml:lang="en-US">Net assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_SimpleAgreementsForFutureEquityMember" xml:lang="en-US">Simple Agreements for Future Equity [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_SimpleAgreementsForFutureEquityMember" xml:lang="en-US">SAFE [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_SimpleAgreementsForFutureEquityMember" xml:lang="en-US">SAFEs (as converted to common stock) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_SimpleAgreementsForFutureEquityMember" xlink:to="lab_tecx_SimpleAgreementsForFutureEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_SimpleAgreementsForFutureEquityMember" xml:lang="en-US">Simple agreements for future equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xml:lang="en-US">Operating Activities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xml:lang="en-US">Operating Activities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TypeOfCommonStockAxis" xlink:label="loc_tecx_TypeOfCommonStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_TypeOfCommonStockAxis" xml:lang="en-US">Type of Common Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_TypeOfCommonStockAxis" xlink:to="lab_tecx_TypeOfCommonStockAxis" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TypeOfCommonStockDomain" xlink:label="loc_tecx_TypeOfCommonStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_TypeOfCommonStockDomain" xml:lang="en-US">Type of Common Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_TypeOfCommonStockDomain" xlink:to="lab_tecx_TypeOfCommonStockDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvrobioMember" xlink:label="loc_tecx_AvrobioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AvrobioMember" xml:lang="en-US">AVROBIO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AvrobioMember" xml:lang="en-US">AVROBIO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AvrobioMember" xlink:to="lab_tecx_AvrobioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AvrobioMember" xml:lang="en-US">AVROBIO.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FairValueInputAmountTransferInBetweenLevels" xlink:label="loc_tecx_FairValueInputAmountTransferInBetweenLevels" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_FairValueInputAmountTransferInBetweenLevels" xml:lang="en-US">Fair Value Input Amount Transfer In Between Levels</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_FairValueInputAmountTransferInBetweenLevels" xml:lang="en-US">Fair value input amount transfer in between levels</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_FairValueInputAmountTransferInBetweenLevels" xlink:to="lab_tecx_FairValueInputAmountTransferInBetweenLevels" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_FairValueInputAmountTransferInBetweenLevels" xml:lang="en-US">Fair value input amount transfer in between levels.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SAFELiabilitiesMember" xlink:label="loc_tecx_SAFELiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_SAFELiabilitiesMember" xml:lang="en-US">SAFE Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_SAFELiabilitiesMember" xml:lang="en-US">SAFE Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_SAFELiabilitiesMember" xlink:to="lab_tecx_SAFELiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_SAFELiabilitiesMember" xml:lang="en-US">Safe Liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Opening Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" xlink:label="loc_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Initial Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" xml:lang="en-US">Initial fair value recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" xlink:to="lab_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis initial recognition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Loss on issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair value adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xml:lang="en-US">Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Laboratory equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Office equipment, furniture and fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in progress [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property plant and equipment gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DepreciationAndAmortizationExpense" xlink:label="loc_tecx_DepreciationAndAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_DepreciationAndAmortizationExpense" xml:lang="en-US">Depreciation And Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_DepreciationAndAmortizationExpense" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_DepreciationAndAmortizationExpense" xlink:to="lab_tecx_DepreciationAndAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_DepreciationAndAmortizationExpense" xml:lang="en-US">Depreciation and amortization expense.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AccruedCompensationAndRelatedExpenses" xlink:label="loc_tecx_AccruedCompensationAndRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AccruedCompensationAndRelatedExpenses" xml:lang="en-US">Accrued compensation and related expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AccruedCompensationAndRelatedExpenses" xml:lang="en-US">Accrued compensation and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AccruedCompensationAndRelatedExpenses" xlink:to="lab_tecx_AccruedCompensationAndRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AccruedCompensationAndRelatedExpenses" xml:lang="en-US">Accrued compensation and related expenses</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_tecx_AccruedResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Accrued research and development expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Accrued research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_tecx_AccruedResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Accrued research and development expenses</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional fees and other expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable" xml:lang="en-US">Other Commitments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CvrAgreementMember" xlink:label="loc_tecx_CvrAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_CvrAgreementMember" xml:lang="en-US">CVR Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_CvrAgreementMember" xml:lang="en-US">CVR Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_CvrAgreementMember" xlink:to="lab_tecx_CvrAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_CvrAgreementMember" xml:lang="en-US">CVR Agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_InstallmentAxis" xlink:label="loc_tecx_InstallmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_InstallmentAxis" xml:lang="en-US">Installment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_InstallmentAxis" xlink:to="lab_tecx_InstallmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_InstallmentAxis" xml:lang="en-US">Installment.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_InstallmentDomain" xlink:label="loc_tecx_InstallmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_InstallmentDomain" xml:lang="en-US">Installment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_InstallmentDomain" xlink:to="lab_tecx_InstallmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_InstallmentDomain" xml:lang="en-US">Installment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvrobioIncMember" xlink:label="loc_tecx_AvrobioIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AvrobioIncMember" xml:lang="en-US">AVROBIO, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AvrobioIncMember" xml:lang="en-US">AVROBIO, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AvrobioIncMember" xlink:to="lab_tecx_AvrobioIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AvrobioIncMember" xml:lang="en-US">AVROBIO, Inc.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xml:lang="en-US">Other Commitments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" xlink:label="loc_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" xml:lang="en-US">Period After Closing With Which Assets May Be Disposed To Pay The Amount As Per Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" xml:lang="en-US">Period after closing with which assets may be disposed to pay the amount as per agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" xlink:to="lab_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" xml:lang="en-US">Period after closing with which assets may be disposed to pay the amount as per agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" xlink:label="loc_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" xml:lang="en-US">Threshold Period Of Receipt Of Consideration On Disposal Of Assets Based On Which Amount As Per Agreement Shall Be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" xml:lang="en-US">Threshold period of receipt of consideration on disposal of assets based on which amount as per agreement shall be paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" xlink:to="lab_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" xml:lang="en-US">Threshold period of receipt of consideration on disposal of assets based on which amount as per agreement shall be paid.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xml:lang="en-US">Business combination, contingent consideration, liability, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount" xml:lang="en-US">Business Combination, Acquired Receivables, Gross Contractual Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount" xml:lang="en-US">Business combination, acquired receivables, gross contractual amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount" xlink:to="lab_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Amount Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xml:lang="en-US">Liability recorded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" xlink:label="loc_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" xml:lang="en-US">Operating Lease for Office and Laboratory Spaces [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" xml:lang="en-US">Operating Lease for Office and Laboratory Spaces [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" xlink:to="lab_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" xml:lang="en-US">Operating lease for office and laboratory spaces.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of Real Estate Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of real estate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseDateOfExpiry" xlink:label="loc_tecx_OperatingLeaseDateOfExpiry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_OperatingLeaseDateOfExpiry" xml:lang="en-US">Operating Lease Date Of Expiry</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_OperatingLeaseDateOfExpiry" xml:lang="en-US">Operating lease date of expiry</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_OperatingLeaseDateOfExpiry" xlink:to="lab_tecx_OperatingLeaseDateOfExpiry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_OperatingLeaseDateOfExpiry" xml:lang="en-US">Operating lease date of expiry.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Operating lease renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseDateOfExpiryRevised" xlink:label="loc_tecx_OperatingLeaseDateOfExpiryRevised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_OperatingLeaseDateOfExpiryRevised" xml:lang="en-US">Operating Lease Date of Expiry Revised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_OperatingLeaseDateOfExpiryRevised" xml:lang="en-US">Operating lease date of expiry revised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_OperatingLeaseDateOfExpiryRevised" xlink:to="lab_tecx_OperatingLeaseDateOfExpiryRevised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_OperatingLeaseDateOfExpiryRevised" xml:lang="en-US">Operating lease date of expiry revised.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease, Cost [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xml:lang="en-US">Finance lease amortization of right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xml:lang="en-US">Finance Lease, Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xml:lang="en-US">Interest of finance lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FinanceLeaseCostAndExpense" xlink:label="loc_tecx_FinanceLeaseCostAndExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_FinanceLeaseCostAndExpense" xml:lang="en-US">Finance Lease Cost and Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_tecx_FinanceLeaseCostAndExpense" xml:lang="en-US">Finance lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_FinanceLeaseCostAndExpense" xlink:to="lab_tecx_FinanceLeaseCostAndExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_FinanceLeaseCostAndExpense" xml:lang="en-US">Finance Lease Cost and Expense</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Operating Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-Term Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpenses" xml:lang="en-US">Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CostsAndExpenses" xml:lang="en-US">Total lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="loc_tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xml:lang="en-US">Cash Paid for Amounts included in the Measurement of Lease Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" xlink:label="loc_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" xml:lang="en-US">Weighted Average Remaining Lease Terms in Years [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" xml:lang="en-US">Weighted-average remaining lease terms (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" xlink:to="lab_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" xml:lang="en-US">Weighted average remaining lease terms in years.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_WeightedAverageDiscountRateAbstract" xlink:label="loc_tecx_WeightedAverageDiscountRateAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_WeightedAverageDiscountRateAbstract" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_WeightedAverageDiscountRateAbstract" xml:lang="en-US">Weighted-average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_WeightedAverageDiscountRateAbstract" xlink:to="lab_tecx_WeightedAverageDiscountRateAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_WeightedAverageDiscountRateAbstract" xml:lang="en-US">Weighted average discount rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total undiscounted cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Finance Lease, Liability, to be Paid, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Total undiscounted cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lease Liability Payments Due Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lease Liability Payments Due Next Twelve Months</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_tecx_LeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lease Liability Payments Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_tecx_LeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lease Liability Payments Due Year Two</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueYearThree" xlink:label="loc_tecx_LeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lease Liability Payments Due Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LeaseLiabilityPaymentsDueYearThree" xlink:to="lab_tecx_LeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lease Liability Payments Due Year Three</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDue" xlink:label="loc_tecx_LeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LeaseLiabilityPaymentsDue" xml:lang="en-US">Lease Liability Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_tecx_LeaseLiabilityPaymentsDue" xml:lang="en-US">Total undiscounted cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LeaseLiabilityPaymentsDue" xlink:to="lab_tecx_LeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LeaseLiabilityPaymentsDue" xml:lang="en-US">Lease Liability Payments Due</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_tecx_LeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lease Liability Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tecx_LeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_tecx_LeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lease Liability Undiscounted Excess Amount</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TotalLeaseLiabilities" xlink:label="loc_tecx_TotalLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_TotalLeaseLiabilities" xml:lang="en-US">Total Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_tecx_TotalLeaseLiabilities" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_TotalLeaseLiabilities" xlink:to="lab_tecx_TotalLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_TotalLeaseLiabilities" xml:lang="en-US">Total Lease Liabilities</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityCurrent" xlink:label="loc_tecx_LeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LeaseLiabilityCurrent" xml:lang="en-US">Lease Liability Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_LeaseLiabilityCurrent" xml:lang="en-US">Lease Liability Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LeaseLiabilityCurrent" xlink:to="lab_tecx_LeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LeaseLiabilityCurrent" xml:lang="en-US">Lease Liability Current</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityNoncurrent" xlink:label="loc_tecx_LeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LeaseLiabilityNoncurrent" xml:lang="en-US">Lease Liability Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tecx_LeaseLiabilityNoncurrent" xml:lang="en-US">Lease Liability Noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LeaseLiabilityNoncurrent" xlink:to="lab_tecx_LeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LeaseLiabilityNoncurrent" xml:lang="en-US">Lease Liability Noncurrent</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UndesignatedPreferredStockMember" xlink:label="loc_tecx_UndesignatedPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_UndesignatedPreferredStockMember" xml:lang="en-US">Undesignated Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_UndesignatedPreferredStockMember" xml:lang="en-US">Undesignated Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_UndesignatedPreferredStockMember" xlink:to="lab_tecx_UndesignatedPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_UndesignatedPreferredStockMember" xml:lang="en-US">Undesignated preferred stock.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RestrictedCommonStockMember" xlink:label="loc_tecx_RestrictedCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_RestrictedCommonStockMember" xml:lang="en-US">Restricted Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_RestrictedCommonStockMember" xlink:to="lab_tecx_RestrictedCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_RestrictedCommonStockMember" xml:lang="en-US">Restricted Common Stock [Member]</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UnrestrictedCommonStockMember" xlink:label="loc_tecx_UnrestrictedCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_UnrestrictedCommonStockMember" xml:lang="en-US">Unrestricted Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_UnrestrictedCommonStockMember" xlink:to="lab_tecx_UnrestrictedCommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" xlink:label="loc_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" xml:lang="en-US">Common Stock Shares Issuable On Conversion Into Permanent Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" xml:lang="en-US">Common stock issuable upon conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" xlink:to="lab_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" xml:lang="en-US">Common stock shares issuable on conversion into permanent equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xml:lang="en-US">Convertible Preferred Stock, Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xml:lang="en-US">Convertible preferred stock authorized for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common stock, voting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xml:lang="en-US">Common stock, dividends, per share, declared</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Nineteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xml:lang="en-US">2019 Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:to="lab_tecx_TwoThousandAndNineteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Nineteen Equity Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Twenty Four Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xml:lang="en-US">2024 Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xlink:to="lab_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xml:lang="en-US">2024 Equity Incentive Plan.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand And Twenty Four Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xml:lang="en-US">2024 Employee Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xlink:to="lab_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xml:lang="en-US">2024 employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">us-gaap_AwardTypeAxis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options to Purchase Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Unvested Restricted Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Total shares of authorized common stock reserved for future issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock, capital shares reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share based compensation by share based award equity instruments other than options unvested and outstanding unrecognized compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Options Granted, Weighted-average grant-date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" xlink:label="loc_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Term Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" xml:lang="en-US">Common stock capital shares reserved for future issuance term description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" xlink:to="lab_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" xml:lang="en-US">Common stock capital shares reserved for future issuance term description.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Stock Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" xlink:label="loc_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" xml:lang="en-US">Two Thousand Nineteen And Two Thousand Twenty Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" xml:lang="en-US">2019 and 2024 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" xlink:to="lab_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" xml:lang="en-US">Two Thousand Nineteen And Two Thousand Twenty Four Member</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xml:lang="en-US">Options assumed from AVROBIO upon Merger closing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding as of January 1, 2024</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Closing Balance, Number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options Granted, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Options Forfeited and expired, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Options vested and exercisable, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Options vested and expected to vest as of December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Opening Balance, Weighted- Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Closing Balance, Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options Granted, Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options Exercised, Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options Forfeited and expired, Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options assumed from AVROBIO upon Merger closing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Options vested and exercisable, Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options vested and expected to vest, Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options vested and exercisable, Weighted-Average Remaining Contractual Term (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years) Unvested and expected to vest as of December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Opening Balance, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Ending Balance, Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Options Exercised, Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Options vested and exercisable, Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Fair value per share of underlying common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Expected volatility ,Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Expected volatility ,Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Unvested restricted stock awards as of January 1, 2024</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Unvested restricted stock awards as of December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Restricted stock units granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Restricted stock units forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding as of January 1, 2024</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding as of December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Restricted stock units granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Restricted stock units forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="loc_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Equity Instruments Other Than Options Unvested And Expected To Vest Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested and expected to vest as of December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="lab_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Equity Instruments Other Than Options Unvested And Expected To Vest Weighted Average Grant Date Fair Value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding as of January 1, 2024</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding as of December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Early exercise of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_HarvardAgreementMember" xlink:label="loc_tecx_HarvardAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_HarvardAgreementMember" xml:lang="en-US">Harvard Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_HarvardAgreementMember" xml:lang="en-US">Harvard Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_HarvardAgreementMember" xlink:to="lab_tecx_HarvardAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_HarvardAgreementMember" xml:lang="en-US">Harvard Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementLineItems" xlink:label="loc_tecx_LicenseAgreementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LicenseAgreementLineItems" xml:lang="en-US">License Agreement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LicenseAgreementLineItems" xlink:to="lab_tecx_LicenseAgreementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LicenseAgreementLineItems" xml:lang="en-US">License agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementsPaymentsDescription" xlink:label="loc_tecx_LicenseAgreementsPaymentsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LicenseAgreementsPaymentsDescription" xml:lang="en-US">License Agreements Payments Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_LicenseAgreementsPaymentsDescription" xml:lang="en-US">License Agreements Payments Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LicenseAgreementsPaymentsDescription" xlink:to="lab_tecx_LicenseAgreementsPaymentsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LicenseAgreementsPaymentsDescription" xml:lang="en-US">License Agreements Payments Description</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xml:lang="en-US">Other Sundry Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xml:lang="en-US">Amount Due to Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xml:lang="en-US">Amount Due to Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UpfrontLicenseFees" xlink:label="loc_tecx_UpfrontLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_UpfrontLicenseFees" xml:lang="en-US">Upfront License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_UpfrontLicenseFees" xml:lang="en-US">One-time license fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_UpfrontLicenseFees" xlink:to="lab_tecx_UpfrontLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_UpfrontLicenseFees" xml:lang="en-US">Represents the amount of the upfront license fees.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesTable" xlink:label="loc_tecx_IncomeTaxesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IncomeTaxesTable" xml:lang="en-US">Income Taxes [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IncomeTaxesTable" xlink:to="lab_tecx_IncomeTaxesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IncomeTaxesTable" xml:lang="en-US">Income taxes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Country [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FederalMember" xlink:label="loc_tecx_FederalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_FederalMember" xml:lang="en-US">Federal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_FederalMember" xlink:to="lab_tecx_FederalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_FederalMember" xml:lang="en-US">Federal [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExpirationThrough2040Member" xlink:label="loc_tecx_ExpirationThrough2040Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ExpirationThrough2040Member" xml:lang="en-US">Expiration Through2040 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ExpirationThrough2040Member" xml:lang="en-US">Expiration Through 2040 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ExpirationThrough2040Member" xlink:to="lab_tecx_ExpirationThrough2040Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ExpirationThrough2040Member" xml:lang="en-US">Expiration Through2040 [Member]</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExpirationThrough2035Member" xlink:label="loc_tecx_ExpirationThrough2035Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ExpirationThrough2035Member" xml:lang="en-US">Expiration Through2035 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ExpirationThrough2035Member" xml:lang="en-US">Expiration Through 2035 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ExpirationThrough2035Member" xlink:to="lab_tecx_ExpirationThrough2035Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ExpirationThrough2035Member" xml:lang="en-US">Expiration Through2035 [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesLineItems" xlink:label="loc_tecx_IncomeTaxesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IncomeTaxesLineItems" xml:lang="en-US">Income Taxes [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IncomeTaxesLineItems" xlink:to="lab_tecx_IncomeTaxesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IncomeTaxesLineItems" xml:lang="en-US">Income taxes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective income tax rate continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current federal tax expense benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current state and local tax expense benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation allowance deferred tax asset change in amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xml:lang="en-US">Deferred tax assets operating loss carryforwards not subject to expiration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Deferred tax assets operating loss carryforwards domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">Deferred tax assets operating loss carryforwards state and local</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred tax assets tax credit carryforwards research</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AmortizationPeriodForeignRDCosts" xlink:label="loc_tecx_AmortizationPeriodForeignRDCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AmortizationPeriodForeignRDCosts" xml:lang="en-US">AmortizationPeriodForeignR&amp;DCosts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AmortizationPeriodForeignRDCosts" xml:lang="en-US">Amortization period foreign R&amp;D costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AmortizationPeriodForeignRDCosts" xlink:to="lab_tecx_AmortizationPeriodForeignRDCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AmortizationPeriodForeignRDCosts" xml:lang="en-US">AmortizationPeriodForeignR&amp;DCosts</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AmortizationPeriodRDActivities" xlink:label="loc_tecx_AmortizationPeriodRDActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AmortizationPeriodRDActivities" xml:lang="en-US">AmortizationPeriodR&amp;DActivities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AmortizationPeriodRDActivities" xml:lang="en-US">Amortization period R&amp;D activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AmortizationPeriodRDActivities" xlink:to="lab_tecx_AmortizationPeriodRDActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AmortizationPeriodRDActivities" xml:lang="en-US">AmortizationPeriodR&amp;DActivities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xml:lang="en-US">Deferred tax liabilities deferred expense capitalized research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit), Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State And Local Income Tax Expense Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Foreign Income Tax Expense Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xml:lang="en-US">Deferred Tax, Business Combination or Joint Venture Formation, Valuation Allowance, Available to Reduce Income Tax Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xml:lang="en-US">Less change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:to="lab_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit), Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Federal statutory income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:label="loc_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Difference</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" xml:lang="en-US">Permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:to="lab_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" xml:lang="en-US">Effective income tax rate reconciliation permanent difference.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_Effectiveincometaxratereconciliationchangeinstock1" xlink:label="loc_tecx_Effectiveincometaxratereconciliationchangeinstock1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_Effectiveincometaxratereconciliationchangeinstock1" xml:lang="en-US">Effectiveincometaxratereconciliationchangeinstock1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_Effectiveincometaxratereconciliationchangeinstock1" xml:lang="en-US">Equity-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_Effectiveincometaxratereconciliationchangeinstock1" xlink:to="lab_tecx_Effectiveincometaxratereconciliationchangeinstock1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_Effectiveincometaxratereconciliationchangeinstock1" xml:lang="en-US">Effectiveincometaxratereconciliationchangeinstock1</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PreferredStockLiabilityFairValueAdjustment" xlink:label="loc_tecx_PreferredStockLiabilityFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_PreferredStockLiabilityFairValueAdjustment" xml:lang="en-US">Preferred stock liability fair value adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_PreferredStockLiabilityFairValueAdjustment" xml:lang="en-US">Preferred stock liability fair value adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_PreferredStockLiabilityFairValueAdjustment" xlink:to="lab_tecx_PreferredStockLiabilityFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_PreferredStockLiabilityFairValueAdjustment" xml:lang="en-US">Preferred stock liability fair value adjustment</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Research credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsLeaseLiability" xlink:label="loc_tecx_DeferredTaxAssetsLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_DeferredTaxAssetsLeaseLiability" xml:lang="en-US">Deferred Tax Assets Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_DeferredTaxAssetsLeaseLiability" xml:lang="en-US">Lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_DeferredTaxAssetsLeaseLiability" xlink:to="lab_tecx_DeferredTaxAssetsLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_DeferredTaxAssetsLeaseLiability" xml:lang="en-US">Deferred Tax Assets Lease Liability</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xlink:label="loc_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up And Organizational Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xml:lang="en-US">Capitalized research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xlink:to="lab_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xml:lang="en-US">Deferred tax assets capitalized start up and organizational costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xml:lang="en-US">Accruals and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsAmortization" xlink:label="loc_tecx_DeferredTaxAssetsAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_DeferredTaxAssetsAmortization" xml:lang="en-US">Deferred Tax Assets Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_DeferredTaxAssetsAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_DeferredTaxAssetsAmortization" xlink:to="lab_tecx_DeferredTaxAssetsAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_DeferredTaxAssetsAmortization" xml:lang="en-US">Deferred Tax Assets Amortization</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_tecx_DeferredTaxLiabilitiesDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Deferred Tax Liabilities Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tecx_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_DeferredTaxLiabilitiesDepreciation" xlink:to="lab_tecx_DeferredTaxLiabilitiesDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Deferred Tax Liabilities Depreciation</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_tecx_DeferredTaxLiabilitiesRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tecx_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Right of use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_tecx_DeferredTaxLiabilitiesRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net loss, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_WeightedAverageCommonShareOutstandingBasic" xlink:label="loc_tecx_WeightedAverageCommonShareOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_WeightedAverageCommonShareOutstandingBasic" xml:lang="en-US">Weighted Average Common Share Outstanding Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_WeightedAverageCommonShareOutstandingBasic" xml:lang="en-US">Weighted-average common shares outstanding, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_WeightedAverageCommonShareOutstandingBasic" xlink:to="lab_tecx_WeightedAverageCommonShareOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_WeightedAverageCommonShareOutstandingBasic" xml:lang="en-US">Weighted average common share outstanding basic.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_WeightedAverageCommonShareOutstandingDiluted" xlink:label="loc_tecx_WeightedAverageCommonShareOutstandingDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_WeightedAverageCommonShareOutstandingDiluted" xml:lang="en-US">Weighted Average Common Share Outstanding Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_WeightedAverageCommonShareOutstandingDiluted" xml:lang="en-US">Weighted-average common shares outstanding, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_WeightedAverageCommonShareOutstandingDiluted" xlink:to="lab_tecx_WeightedAverageCommonShareOutstandingDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_WeightedAverageCommonShareOutstandingDiluted" xml:lang="en-US">Weighted average common share outstanding diluted.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementForFutureEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_SimpleAgreementForFutureEquityMember" xml:lang="en-US">Simple Agreement For Future Equity [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_SimpleAgreementForFutureEquityMember" xml:lang="en-US">Simple Agreement For Future Equity [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_SimpleAgreementForFutureEquityMember" xlink:to="lab_tecx_SimpleAgreementForFutureEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_SimpleAgreementForFutureEquityMember" xml:lang="en-US">Simple agreement for future equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MemberOfTheScientificAdvisoryBoardMember" xlink:label="loc_tecx_MemberOfTheScientificAdvisoryBoardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_MemberOfTheScientificAdvisoryBoardMember" xml:lang="en-US">Member of the Scientific Advisory Board [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_MemberOfTheScientificAdvisoryBoardMember" xml:lang="en-US">Member of the Scientific Advisory Board [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_MemberOfTheScientificAdvisoryBoardMember" xlink:to="lab_tecx_MemberOfTheScientificAdvisoryBoardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_MemberOfTheScientificAdvisoryBoardMember" xml:lang="en-US">Member of the scientific advisory board.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdvisoryServicesAgreementMember" xlink:label="loc_tecx_AdvisoryServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AdvisoryServicesAgreementMember" xml:lang="en-US">Advisory Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AdvisoryServicesAgreementMember" xml:lang="en-US">Advisory Services Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AdvisoryServicesAgreementMember" xlink:to="lab_tecx_AdvisoryServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AdvisoryServicesAgreementMember" xml:lang="en-US">Advisory services agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementMember" xlink:label="loc_tecx_LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_LicenseAgreementMember" xlink:to="lab_tecx_LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_LicenseAgreementMember" xml:lang="en-US">License agreement.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdimabAgreementMember" xlink:label="loc_tecx_AdimabAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_AdimabAgreementMember" xml:lang="en-US">Adimab Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_AdimabAgreementMember" xml:lang="en-US">Adimab Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_AdimabAgreementMember" xlink:to="lab_tecx_AdimabAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_AdimabAgreementMember" xml:lang="en-US">Adimab Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xml:lang="en-US">Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="lab_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionByRelatedPartyAxis" xlink:label="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_RelatedPartyTransactionByRelatedPartyAxis" xml:lang="en-US">Related Party Transaction By Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis" xlink:to="lab_tecx_RelatedPartyTransactionByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_RelatedPartyTransactionByRelatedPartyAxis" xml:lang="en-US">Related party transaction by related party.</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionByRelatedPartyDomain" xlink:label="loc_tecx_RelatedPartyTransactionByRelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_RelatedPartyTransactionByRelatedPartyDomain" xml:lang="en-US">Related Party Transaction By Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_RelatedPartyTransactionByRelatedPartyDomain" xlink:to="lab_tecx_RelatedPartyTransactionByRelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_RelatedPartyTransactionByRelatedPartyDomain" xml:lang="en-US">Related party transaction by related party</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xml:lang="en-US">Defined Contribution Plan [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xml:lang="en-US">Retirement Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xml:lang="en-US">Retirement Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameOtherMember" xlink:label="loc_us-gaap_RetirementPlanNameOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameOtherMember" xml:lang="en-US">Retirement Plan Name, Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameOtherMember" xlink:to="lab_us-gaap_RetirementPlanNameOtherMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined contribution plan employee mathing contribution percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xml:lang="en-US">Contribution by company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsAxis" xml:lang="en-US">Consolidation Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsDomain" xml:lang="en-US">Consolidation Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingSegmentsMember" xml:lang="en-US">Operating Segments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ResearchAndPre-ClinicalExpensesMember" xlink:label="loc_tecx_ResearchAndPre-ClinicalExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ResearchAndPre-ClinicalExpensesMember" xml:lang="en-US">Research and Pre-clinical Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ResearchAndPre-ClinicalExpensesMember" xlink:to="lab_tecx_ResearchAndPre-ClinicalExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ResearchAndPre-ClinicalExpensesMember" xml:lang="en-US">Research and Pre-clinical Expenses</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ClinicalAndDevelopmentExpensesMember" xlink:label="loc_tecx_ClinicalAndDevelopmentExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ClinicalAndDevelopmentExpensesMember" xml:lang="en-US">Clinical and Development Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ClinicalAndDevelopmentExpensesMember" xlink:to="lab_tecx_ClinicalAndDevelopmentExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ClinicalAndDevelopmentExpensesMember" xml:lang="en-US">Clinical and Development Expenses</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ChemistryManufacturingAndControlExpensesMember" xlink:label="loc_tecx_ChemistryManufacturingAndControlExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ChemistryManufacturingAndControlExpensesMember" xml:lang="en-US">Chemistry, Manufacturing, and Control Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ChemistryManufacturingAndControlExpensesMember" xlink:to="lab_tecx_ChemistryManufacturingAndControlExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ChemistryManufacturingAndControlExpensesMember" xml:lang="en-US">Chemistry, manufacturing, and control expenses</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Employee-related Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Total employee-related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExternalResearchAndDevelopmentLiability" xlink:label="loc_tecx_ExternalResearchAndDevelopmentLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_ExternalResearchAndDevelopmentLiability" xml:lang="en-US">External Research and Development Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_ExternalResearchAndDevelopmentLiability" xml:lang="en-US">Total external research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_ExternalResearchAndDevelopmentLiability" xlink:to="lab_tecx_ExternalResearchAndDevelopmentLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_ExternalResearchAndDevelopmentLiability" xml:lang="en-US">External Research and Development Liability</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_Non-ControllableExpenses" xlink:label="loc_tecx_Non-ControllableExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_Non-ControllableExpenses" xml:lang="en-US">Non-controllable Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_Non-ControllableExpenses" xml:lang="en-US">Non-controllable expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_Non-ControllableExpenses" xlink:to="lab_tecx_Non-ControllableExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_Non-ControllableExpenses" xml:lang="en-US">Non-controllable Expenses</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Other Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title and Position [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title and Position [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FundInvestorsMember" xlink:label="loc_tecx_FundInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_FundInvestorsMember" xml:lang="en-US">Fund Investors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_FundInvestorsMember" xml:lang="en-US">Fund Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_FundInvestorsMember" xlink:to="lab_tecx_FundInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_FundInvestorsMember" xml:lang="en-US">Fund Investors [Member]</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IndividualInvestorsMember" xlink:label="loc_tecx_IndividualInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_IndividualInvestorsMember" xml:lang="en-US">Individual Investors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_IndividualInvestorsMember" xml:lang="en-US">Individual Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_IndividualInvestorsMember" xlink:to="lab_tecx_IndividualInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_IndividualInvestorsMember" xml:lang="en-US">Individual Investors [Member]</label>
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SecuritiesPurchaseAgreementMember" xlink:label="loc_tecx_SecuritiesPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tecx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tecx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tecx_SecuritiesPurchaseAgreementMember" xlink:to="lab_tecx_SecuritiesPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tecx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Shares issued under securities purchase agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xml:lang="en-US">Aggregate consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeTermOfLeaseMember" xlink:label="loc_us-gaap_UsefulLifeTermOfLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UsefulLifeTermOfLeaseMember" xml:lang="en-US">Useful Life, Lease Term [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UsefulLifeTermOfLeaseMember" xlink:to="lab_us-gaap_UsefulLifeTermOfLeaseMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>tecx-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-March-2025 [08:15:31] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CoverPage" roleURI="http://www.aw.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.aw.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" roleURI="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" roleURI="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.aw.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.aw.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#NatureOfBusiness" roleURI="http://www.aw.com/role/NatureOfBusiness" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.aw.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#Merger" roleURI="http://www.aw.com/role/Merger" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#FairValueMeasurements" roleURI="http://www.aw.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#PropertyAndEquipmentNet" roleURI="http://www.aw.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#StockholdersEquity" roleURI="http://www.aw.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlans" roleURI="http://www.aw.com/role/EquityIncentivePlans" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#NetLossPerShare" roleURI="http://www.aw.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#Leases" roleURI="http://www.aw.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LicenseAgreements" roleURI="http://www.aw.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CommitmentsAndContingencies" roleURI="http://www.aw.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxes" roleURI="http://www.aw.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#RelatedPartyTransactions" roleURI="http://www.aw.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EmployeeBenefitPlan" roleURI="http://www.aw.com/role/EmployeeBenefitPlan" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SegmentInformation" roleURI="http://www.aw.com/role/SegmentInformation" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SubsequentEvents" roleURI="http://www.aw.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#MergerTables" roleURI="http://www.aw.com/role/MergerTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#FairValueMeasurementsTables" roleURI="http://www.aw.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.aw.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#StockholdersEquityTables" roleURI="http://www.aw.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesTables" roleURI="http://www.aw.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansTables" roleURI="http://www.aw.com/role/EquityIncentivePlansTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#NetLossPerShareTables" roleURI="http://www.aw.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesTables" roleURI="http://www.aw.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SegmentInformationTables" roleURI="http://www.aw.com/role/SegmentInformationTables" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#NatureOfBusinessAdditionalInformationDetail" roleURI="http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#MergerAdditionalInformationDetail" roleURI="http://www.aw.com/role/MergerAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail" roleURI="http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#FairValueMeasurementsAdditionalInformationDetail" roleURI="http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail" roleURI="http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.aw.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" roleURI="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.aw.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail" roleURI="http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesScheduleOfInformationAboutTheCompanysLeasesDetail" roleURI="http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail" roleURI="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" roleURI="http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansAdditionalInformationDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfTheStockOptionActivityDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfRestrictedStockActivityDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail" roleURI="http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail" roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" roleURI="http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" roleURI="http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#EmployeeBenefitPlanAdditionalInformationDetail" roleURI="http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SegmentInformationAdditionalInformationDetail" roleURI="http://www.aw.com/role/SegmentInformationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail" roleURI="http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="tecx-20241231.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_107" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_104" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_104" xlink:to="loc_dei_AddressTypeDomain_109" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_109" xlink:to="loc_dei_BusinessContactMember_1115" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_dei_DocumentInformationLineItems_106" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_DocumentType_103" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_AmendmentFlag_105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityRegistrantName_114" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityCentralIndexKey_115" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityFilerCategory_117" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityEmergingGrowthCompany_118" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntitySmallBusiness_119" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityTaxIdentificationNumber_127" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressAddressLine1_128" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressAddressLine2_129" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressCityOrTown_130" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressStateOrProvince_131" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityAddressPostalZipCode_132" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_CityAreaCode_133" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_LocalPhoneNumber_134" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityIncorporationStateCountryCode_135" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_EntityPrimarySicNumber_1113" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_106" xlink:to="loc_dei_ContactPersonnelName_1114" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_149" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_149" xlink:to="loc_us-gaap_AssetsAbstract_154" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_AssetsCurrentAbstract_155" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_155" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_150" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_155" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_156" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_155" xlink:to="loc_us-gaap_AssetsCurrent_162" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_161" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_166" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_170" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_DeferredCosts_174" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_178" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_180" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_Assets_182" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_149" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_152" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_AccountsPayableCurrent_151" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_157" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SAFELiabilitiesCurrent" xlink:label="loc_tecx_SAFELiabilitiesCurrent_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_tecx_SAFELiabilitiesCurrent_163" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_167" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_171" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_LiabilitiesCurrent_175" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_158" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_164" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_Liabilities_168" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_CommitmentsAndContingencies_172" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_176" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_StockholdersEquityAbstract_179" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_179" xlink:to="loc_us-gaap_PreferredStockValue_153" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_179" xlink:to="loc_us-gaap_CommonStockValue_159" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_179" xlink:to="loc_us-gaap_AdditionalPaidInCapital_165" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_179" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_169" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_179" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_173" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_179" xlink:to="loc_us-gaap_StockholdersEquity_177" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_181" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_184" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_184" xlink:to="loc_us-gaap_StatementTable_188" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementClassOfStockAxis_187" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187" xlink:to="loc_us-gaap_ClassOfStockDomain_192" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_192" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_186" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementLineItems_190" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_185" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_189" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_191" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_193" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_194" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_195" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_PreferredStockSharesIssued_196" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_197" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_198" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_199" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CommonStockSharesIssued_200" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_201" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_OperatingExpensesAbstract_206" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_206" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_205" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_206" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_209" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_206" xlink:to="loc_us-gaap_OperatingExpenses_212" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_206" xlink:to="loc_us-gaap_OperatingIncomeLoss_215" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_210" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ChangeInFairValueOfSafeLiabilities" xlink:label="loc_tecx_ChangeInFairValueOfSafeLiabilities_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_210" xlink:to="loc_tecx_ChangeInFairValueOfSafeLiabilities_207" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LossOnIssuanceOfSAFEs" xlink:label="loc_tecx_LossOnIssuanceOfSAFEs_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_210" xlink:to="loc_tecx_LossOnIssuanceOfSAFEs_211" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_210" xlink:to="loc_us-gaap_InvestmentIncomeInterest_214" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_210" xlink:to="loc_us-gaap_InterestExpenseNonoperating_217" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_210" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_219" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_210" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_221" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_NetIncomeLoss_213" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_216" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_216" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_204" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_216" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_208" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_EarningsPerShareBasic_218" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_EarningsPerShareDiluted_220" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_222" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_225" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_225" xlink:to="loc_us-gaap_StatementTable_230" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_230" xlink:to="loc_us-gaap_StatementClassOfStockAxis_231" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_231" xlink:to="loc_us-gaap_ClassOfStockDomain_237" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_237" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_229" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_230" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_234" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_234" xlink:to="loc_us-gaap_EquityComponentDomain_227" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_PreferredStockMember_228" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_CommonStockMember_233" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_236" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_240" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_227" xlink:to="loc_us-gaap_RetainedEarningsMember_242" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_230" xlink:to="loc_us-gaap_StatementLineItems_238" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockholdersEquity_226" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_SharesOutstanding_232" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_235" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdjustedBalanceBeginningOfPeriodValue" xlink:label="loc_tecx_AdjustedBalanceBeginningOfPeriodValue_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_AdjustedBalanceBeginningOfPeriodValue_239" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdjustedBalanceBeginningOfPeriodShare" xlink:label="loc_tecx_AdjustedBalanceBeginningOfPeriodShare_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_AdjustedBalanceBeginningOfPeriodShare_241" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_243" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_244" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs" xlink:label="loc_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs_245" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_246" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_247" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_248" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_249" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue" xlink:label="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue_250" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption" xlink:label="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption_251" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue" xlink:label="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue_252" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUnderSubscriptionAgreement" xlink:label="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement_253" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUponTheMergerValue" xlink:label="loc_tecx_IssuanceOfCommonStockUponTheMergerValue_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockUponTheMergerValue_254" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IssuanceOfCommonStockUponTheMerger" xlink:label="loc_tecx_IssuanceOfCommonStockUponTheMerger_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_IssuanceOfCommonStockUponTheMerger_255" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss" xlink:label="loc_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss_257" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_NetIncomeLoss_258" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockholdersEquity_259" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_SharesOutstanding_260" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_262" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_262" xlink:to="loc_us-gaap_StatementTable_267" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_267" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_269" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_269" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_268" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AtTheMarketFacilityMember" xlink:label="loc_tecx_AtTheMarketFacilityMember_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_268" xlink:to="loc_tecx_AtTheMarketFacilityMember_264" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_267" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_271" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_271" xlink:to="loc_us-gaap_EquityComponentDomain_265" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_265" xlink:to="loc_us-gaap_CommonStockMember_266" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_267" xlink:to="loc_us-gaap_StatementLineItems_272" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_272" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_263" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TransactionCosts" xlink:label="loc_tecx_TransactionCosts_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_272" xlink:to="loc_tecx_TransactionCosts_270" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_274" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" xlink:to="loc_us-gaap_ProfitLoss_278" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_287" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_287" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_275" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_287" xlink:to="loc_us-gaap_ShareBasedCompensation_284" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_287" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_292" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LossOnIssuanceOfSAFEs" xlink:label="loc_tecx_LossOnIssuanceOfSAFEs_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_287" xlink:to="loc_tecx_LossOnIssuanceOfSAFEs_299" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NonCashLeaseExpense" xlink:label="loc_tecx_NonCashLeaseExpense_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_287" xlink:to="loc_tecx_NonCashLeaseExpense_305" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ChangeInFairValueOfSafeLiabilities" xlink:label="loc_tecx_ChangeInFairValueOfSafeLiabilities_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_287" xlink:to="loc_tecx_ChangeInFairValueOfSafeLiabilities_309" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_295" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_295" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_277" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_295" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_286" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_295" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_294" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_295" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_300" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_295" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_306" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_295" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_310" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_301" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_288" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_288" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_280" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_288" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_289" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_296" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_296" xlink:to="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_283" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSubscriptionAgreement" xlink:label="loc_tecx_ProceedsFromSubscriptionAgreement_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_296" xlink:to="loc_tecx_ProceedsFromSubscriptionAgreement_291" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CashAcquiredInConnectionWithTheMerger" xlink:label="loc_tecx_CashAcquiredInConnectionWithTheMerger_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_296" xlink:to="loc_tecx_CashAcquiredInConnectionWithTheMerger_298" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_296" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_308" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_296" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_312" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_296" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_314" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_302" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_307" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_311" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_313" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_315" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_315" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_276" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_315" xlink:to="loc_us-gaap_RestrictedCash_285" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_315" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_293" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_316" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock" xlink:label="loc_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_316" xlink:to="loc_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock_282" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ConversionOfConvertiblePreferredStockToCommonStock" xlink:label="loc_tecx_ConversionOfConvertiblePreferredStockToCommonStock_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_316" xlink:to="loc_tecx_ConversionOfConvertiblePreferredStockToCommonStock_290" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PurchaseEquipmentOfFinanceLeases" xlink:label="loc_tecx_PurchaseEquipmentOfFinanceLeases_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_316" xlink:to="loc_tecx_PurchaseEquipmentOfFinanceLeases_297" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_316" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_303" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_274" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_317" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_317" xlink:to="loc_us-gaap_InterestPaidNet_281" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_319" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OfferingCost" xlink:label="loc_tecx_OfferingCost_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_319" xlink:to="loc_tecx_OfferingCost_320" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TransactionCosts" xlink:label="loc_tecx_TransactionCosts_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_319" xlink:to="loc_tecx_TransactionCosts_321" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/NatureOfBusiness">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_343" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_343" xlink:to="loc_us-gaap_NatureOfOperations_344" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_346" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_346" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/Merger">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerAbstract" xlink:label="loc_tecx_MergerAbstract_349" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_MergerAbstract_349" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_350" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_352" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_352" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_355" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_355" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_358" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_358" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_361" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_361" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlans">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_364" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_364" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_367" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_367" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_368" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_370" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_370" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_371" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LicenseAgreements">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementsAbstract" xlink:label="loc_tecx_LicenseAgreementsAbstract_373" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementDisclosureTextBlock" xlink:label="loc_tecx_LicenseAgreementDisclosureTextBlock_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_LicenseAgreementsAbstract_373" xlink:to="loc_tecx_LicenseAgreementDisclosureTextBlock_374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_376" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_376" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_377" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_379" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_379" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_382" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_382" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EmployeeBenefitPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanAbstract" xlink:label="loc_us-gaap_DefinedContributionPlanAbstract_385" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanAbstract_385" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SegmentInformation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_388" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_388" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_389" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_391" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_391" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_392" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_394" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_395" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_396" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xlink:label="loc_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock_397" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_UseOfEstimates_398" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_399" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_400" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_401" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_403" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_404" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_405" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_406" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_407" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_408" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock_409" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_410" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_411" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_412" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_413" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionsPolicyTextBlock" xlink:label="loc_tecx_RelatedPartyTransactionsPolicyTextBlock_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_tecx_RelatedPartyTransactionsPolicyTextBlock_414" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_415" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_416" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_394" xlink:to="loc_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_417" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/MergerTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_419" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_419" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_420" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_422" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_422" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_423" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_422" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_424" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_426" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_426" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_427" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_430" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_430" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_431" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_433" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_433" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_434" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_436" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_436" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_437" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_436" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_438" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_440" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_440" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_440" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_442" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_440" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_443" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_440" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_444" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_446" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_446" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_447" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_446" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_448" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_450" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_450" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_451" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_450" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_452" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_450" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_453" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SegmentInformationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_458" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_458" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_459" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_461" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NatureOfOperationsTable" xlink:label="loc_tecx_NatureOfOperationsTable_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_461" xlink:to="loc_tecx_NatureOfOperationsTable_469" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementAxis" xlink:label="loc_tecx_AgreementAxis_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsTable_469" xlink:to="loc_tecx_AgreementAxis_465" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_AgreementAxis_465" xlink:to="loc_tecx_AgreementDomain_462" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SubscriptionAgreementMember" xlink:label="loc_tecx_SubscriptionAgreementMember_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_AgreementDomain_462" xlink:to="loc_tecx_SubscriptionAgreementMember_468" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsTable_469" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_470" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_470" xlink:to="loc_us-gaap_EquityComponentDomain_463" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvroAvrobioCommonStockMember" xlink:label="loc_tecx_AvroAvrobioCommonStockMember_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_463" xlink:to="loc_tecx_AvroAvrobioCommonStockMember_464" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsTable_469" xlink:to="loc_us-gaap_StatementClassOfStockAxis_472" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_472" xlink:to="loc_us-gaap_ClassOfStockDomain_474" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvorbioCommonStockMember" xlink:label="loc_tecx_AvorbioCommonStockMember_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_474" xlink:to="loc_tecx_AvorbioCommonStockMember_466" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_NatureOfOperationsLineItems" xlink:label="loc_tecx_NatureOfOperationsLineItems_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsTable_469" xlink:to="loc_tecx_NatureOfOperationsLineItems_475" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_467" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_NetIncomeLoss_471" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_473" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ConversionOfStockSharesPercentage" xlink:label="loc_tecx_ConversionOfStockSharesPercentage_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_ConversionOfStockSharesPercentage_476" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization" xlink:label="loc_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization_477" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization" xlink:label="loc_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization_478" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_480" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_481" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xlink:label="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization_482" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsReceivedPursuantToAgreement" xlink:label="loc_tecx_ProceedsReceivedPursuantToAgreement_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_tecx_ProceedsReceivedPursuantToAgreement_483" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_NatureOfOperationsLineItems_475" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_484" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_486" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_486" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xlink:to="loc_srt_RangeAxis_491" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_491" xlink:to="loc_srt_RangeMember_489" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_489" xlink:to="loc_srt_MaximumMember_488" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_489" xlink:to="loc_srt_MinimumMember_495" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_496" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_496" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_490" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_490" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_492" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_494" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_Cash_497" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_499" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_500" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_AssetImpairmentCharges_501" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_498" xlink:to="loc_us-gaap_LeaseExpirationDate1_502" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/MergerAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerAbstract" xlink:label="loc_tecx_MergerAbstract_504" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerTable" xlink:label="loc_tecx_MergerTable_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_MergerAbstract_504" xlink:to="loc_tecx_MergerTable_506" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_MergerTable_506" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_505" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_505" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_507" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MergerLineItems" xlink:label="loc_tecx_MergerLineItems_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_MergerTable_506" xlink:to="loc_tecx_MergerLineItems_510" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_MergerLineItems_510" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_517" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_519" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_519" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_520" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_519" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_521" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_519" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_522" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities" xlink:label="loc_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_519" xlink:to="loc_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities_523" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_519" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_524" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_526" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_526" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_us-gaap_FinancialInstrumentAxis_527" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_527" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_535" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityMember_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_535" xlink:to="loc_tecx_SimpleAgreementsForFutureEquityMember_529" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_srt_StatementScenarioAxis_536" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_536" xlink:to="loc_srt_ScenarioUnspecifiedDomain_530" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_538" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_538" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_531" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TypeOfCommonStockAxis" xlink:label="loc_tecx_TypeOfCommonStockAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_tecx_TypeOfCommonStockAxis_540" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TypeOfCommonStockDomain" xlink:label="loc_tecx_TypeOfCommonStockDomain_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_TypeOfCommonStockAxis_540" xlink:to="loc_tecx_TypeOfCommonStockDomain_532" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvrobioMember" xlink:label="loc_tecx_AvrobioMember_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_TypeOfCommonStockDomain_532" xlink:to="loc_tecx_AvrobioMember_534" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_528" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_533" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_us-gaap_CommonStockSharesIssued_537" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_539" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FairValueInputAmountTransferInBetweenLevels" xlink:label="loc_tecx_FairValueInputAmountTransferInBetweenLevels_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_542" xlink:to="loc_tecx_FairValueInputAmountTransferInBetweenLevels_541" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_544" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_544" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_546" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_546" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_555" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_561" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_564" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_560" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_560" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_557" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_557" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_559" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_563" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_563" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_558" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_558" xlink:to="loc_us-gaap_MoneyMarketFundsMember_553" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_565" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_565" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_550" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_550" xlink:to="loc_us-gaap_CashEquivalentsMember_548" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_566" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_566" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_549" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SAFELiabilitiesMember" xlink:label="loc_tecx_SAFELiabilitiesMember_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_549" xlink:to="loc_tecx_SAFELiabilitiesMember_554" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_552" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_567" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_567" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_556" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_556" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_551" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_567" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_562" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_562" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_545" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_569" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_569" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_572" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_572" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_570" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_571" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SAFELiabilitiesMember" xlink:label="loc_tecx_SAFELiabilitiesMember_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_571" xlink:to="loc_tecx_SAFELiabilitiesMember_573" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_572" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_574" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition" xlink:label="loc_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition_576" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_577" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_578" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_579" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_580" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_582" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_582" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_587" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_587" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_585" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" xlink:to="loc_us-gaap_OfficeEquipmentMember_586" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_590" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" xlink:to="loc_us-gaap_ConstructionInProgressMember_592" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_584" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_593" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_587" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_583" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_588" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_589" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_591" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/PropertyAndEquipmentNetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_595" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DepreciationAndAmortizationExpense" xlink:label="loc_tecx_DepreciationAndAmortizationExpense_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_595" xlink:to="loc_tecx_DepreciationAndAmortizationExpense_597" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_599" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AccruedCompensationAndRelatedExpenses" xlink:label="loc_tecx_AccruedCompensationAndRelatedExpenses_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_599" xlink:to="loc_tecx_AccruedCompensationAndRelatedExpenses_600" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_tecx_AccruedResearchAndDevelopmentExpenses_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_599" xlink:to="loc_tecx_AccruedResearchAndDevelopmentExpenses_601" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_599" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_602" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_599" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_603" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_605" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_605" xlink:to="loc_us-gaap_OtherCommitmentsTable_626" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_TypeOfArrangementAxis_622" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_622" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_616" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_srt_CounterpartyNameAxis_631" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_631" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_611" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementAxis" xlink:label="loc_tecx_AgreementAxis_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_tecx_AgreementAxis_635" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_AgreementAxis_635" xlink:to="loc_tecx_AgreementDomain_606" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CvrAgreementMember" xlink:label="loc_tecx_CvrAgreementMember_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_AgreementDomain_606" xlink:to="loc_tecx_CvrAgreementMember_620" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_638" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_638" xlink:to="loc_us-gaap_EquityComponentDomain_612" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_InstallmentAxis" xlink:label="loc_tecx_InstallmentAxis_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_tecx_InstallmentAxis_640" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_InstallmentDomain" xlink:label="loc_tecx_InstallmentDomain_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_InstallmentAxis_640" xlink:to="loc_tecx_InstallmentDomain_621" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_642" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_642" xlink:to="loc_us-gaap_RelatedPartyDomain_625" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvrobioIncMember" xlink:label="loc_tecx_AvrobioIncMember_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_625" xlink:to="loc_tecx_AvrobioIncMember_618" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_srt_ProductOrServiceAxis_644" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_644" xlink:to="loc_srt_ProductsAndServicesDomain_607" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_srt_RangeAxis_646" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_646" xlink:to="loc_srt_RangeMember_617" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_648" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_648" xlink:to="loc_us-gaap_LossContingencyNatureDomain_624" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_626" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_650" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement" xlink:label="loc_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement_639" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid" xlink:label="loc_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid_641" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_643" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount_645" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_647" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_669" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_675" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_675" xlink:to="loc_srt_RangeAxis_670" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_670" xlink:to="loc_srt_RangeMember_672" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_675" xlink:to="loc_us-gaap_LeaseContractualTermAxis_677" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_677" xlink:to="loc_us-gaap_LeaseContractualTermDomain_674" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember" xlink:label="loc_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_674" xlink:to="loc_tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember_676" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_675" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_682" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseDateOfExpiry" xlink:label="loc_tecx_OperatingLeaseDateOfExpiry_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_tecx_OperatingLeaseDateOfExpiry_683" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_684" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_OperatingLeaseDateOfExpiryRevised" xlink:label="loc_tecx_OperatingLeaseDateOfExpiryRevised_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_681" xlink:to="loc_tecx_OperatingLeaseDateOfExpiryRevised_685" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_687" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_687" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_688" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_687" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_689" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FinanceLeaseCostAndExpense" xlink:label="loc_tecx_FinanceLeaseCostAndExpense_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_687" xlink:to="loc_tecx_FinanceLeaseCostAndExpense_690" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_687" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_691" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_687" xlink:to="loc_us-gaap_ShortTermLeaseCost_692" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_687" xlink:to="loc_us-gaap_VariableLeaseCost_693" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_687" xlink:to="loc_us-gaap_CostsAndExpenses_694" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="loc_tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_696" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract" xlink:label="loc_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_696" xlink:to="loc_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract_699" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract_699" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_698" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract_699" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_701" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_WeightedAverageDiscountRateAbstract" xlink:label="loc_tecx_WeightedAverageDiscountRateAbstract_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_696" xlink:to="loc_tecx_WeightedAverageDiscountRateAbstract_702" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_WeightedAverageDiscountRateAbstract_702" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_697" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_WeightedAverageDiscountRateAbstract_702" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_700" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_704" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_706" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_707" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_708" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_709" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_710" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_OperatingLeaseLiability_711" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_712" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_713" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_715" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_716" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_717" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_718" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_719" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_FinanceLeaseLiability_720" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_721" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_722" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths_723" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_tecx_LeaseLiabilityPaymentsDueYearTwo_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_tecx_LeaseLiabilityPaymentsDueYearTwo_724" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDueYearThree" xlink:label="loc_tecx_LeaseLiabilityPaymentsDueYearThree_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_tecx_LeaseLiabilityPaymentsDueYearThree_725" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityPaymentsDue" xlink:label="loc_tecx_LeaseLiabilityPaymentsDue_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_tecx_LeaseLiabilityPaymentsDue_726" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_tecx_LeaseLiabilityUndiscountedExcessAmount_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_tecx_LeaseLiabilityUndiscountedExcessAmount_727" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TotalLeaseLiabilities" xlink:label="loc_tecx_TotalLeaseLiabilities_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_tecx_TotalLeaseLiabilities_728" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityCurrent" xlink:label="loc_tecx_LeaseLiabilityCurrent_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_tecx_LeaseLiabilityCurrent_729" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LeaseLiabilityNoncurrent" xlink:label="loc_tecx_LeaseLiabilityNoncurrent_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_704" xlink:to="loc_tecx_LeaseLiabilityNoncurrent_730" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_732" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_732" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_736" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_736" xlink:to="loc_us-gaap_StatementClassOfStockAxis_734" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_734" xlink:to="loc_us-gaap_ClassOfStockDomain_748" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvorbioCommonStockMember" xlink:label="loc_tecx_AvorbioCommonStockMember_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_tecx_AvorbioCommonStockMember_735" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_us-gaap_PreferredStockMember_742" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_us-gaap_CommonStockMember_746" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UndesignatedPreferredStockMember" xlink:label="loc_tecx_UndesignatedPreferredStockMember_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_tecx_UndesignatedPreferredStockMember_750" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RestrictedCommonStockMember" xlink:label="loc_tecx_RestrictedCommonStockMember_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_tecx_RestrictedCommonStockMember_752" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UnrestrictedCommonStockMember" xlink:label="loc_tecx_UnrestrictedCommonStockMember_754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_748" xlink:to="loc_tecx_UnrestrictedCommonStockMember_754" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementAxis" xlink:label="loc_tecx_AgreementAxis_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_736" xlink:to="loc_tecx_AgreementAxis_741" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AgreementDomain" xlink:label="loc_tecx_AgreementDomain_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_AgreementAxis_741" xlink:to="loc_tecx_AgreementDomain_733" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SubscriptionAgreementMember" xlink:label="loc_tecx_SubscriptionAgreementMember_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_AgreementDomain_733" xlink:to="loc_tecx_SubscriptionAgreementMember_737" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AvrobioMember" xlink:label="loc_tecx_AvrobioMember_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_AgreementDomain_733" xlink:to="loc_tecx_AvrobioMember_743" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_736" xlink:to="loc_us-gaap_FinancialInstrumentAxis_745" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_745" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_740" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityMember_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_740" xlink:to="loc_tecx_SimpleAgreementsForFutureEquityMember_738" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_736" xlink:to="loc_us-gaap_ClassOfStockLineItems_749" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity" xlink:label="loc_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity_739" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_744" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_747" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_751" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_753" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_755" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_756" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_757" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockSharesIssued_758" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_759" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockVotingRights_760" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_761" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_762" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_763" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization" xlink:label="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_749" xlink:to="loc_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization_764" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_766" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_766" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_769" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_769" xlink:to="loc_us-gaap_StatementClassOfStockAxis_767" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_767" xlink:to="loc_us-gaap_ClassOfStockDomain_775" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_768" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementsForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementsForFutureEquityMember_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_tecx_SimpleAgreementsForFutureEquityMember_772" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember_774" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember_778" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_775" xlink:to="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember_780" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_769" xlink:to="loc_us-gaap_AwardTypeAxis_771" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_771" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" xlink:to="loc_us-gaap_EmployeeStockOptionMember_777" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" xlink:to="loc_us-gaap_RestrictedStockMember_779" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_781" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_769" xlink:to="loc_us-gaap_ClassOfStockLineItems_773" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_773" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_770" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_783" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_783" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" xlink:to="loc_us-gaap_PlanNameAxis_785" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_785" xlink:to="loc_us-gaap_PlanNameDomain_786" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_786" xlink:to="loc_tecx_TwoThousandAndNineteenEquityIncentivePlanMember_784" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_786" xlink:to="loc_tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember_791" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_786" xlink:to="loc_tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember_794" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" xlink:to="loc_us-gaap_AwardTypeAxis_792" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_799" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" xlink:to="loc_srt_RangeAxis_795" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_795" xlink:to="loc_srt_RangeMember_788" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_789" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_797" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_800" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_801" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_802" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_806" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription" xlink:label="loc_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription_807" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_798" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_809" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_811" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_811" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_816" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_816" xlink:to="loc_us-gaap_PlanNameAxis_815" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_815" xlink:to="loc_us-gaap_PlanNameDomain_814" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember" xlink:label="loc_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_814" xlink:to="loc_tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember_817" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_813" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_818" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_820" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_821" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_822" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_823" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_824" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_825" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_826" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_827" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_828" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_829" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_830" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_831" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_832" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_833" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_834" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_835" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_836" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_837" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_838" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_839" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_840" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_841" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_843" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_843" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_847" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_847" xlink:to="loc_srt_RangeAxis_844" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_844" xlink:to="loc_srt_RangeMember_846" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_846" xlink:to="loc_srt_MaximumMember_845" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_846" xlink:to="loc_srt_MinimumMember_850" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_847" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_848" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_851" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_852" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_853" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_854" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_855" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_857" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_857" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_860" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_860" xlink:to="loc_us-gaap_AwardTypeAxis_859" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_866" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_858" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_861" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_863" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_865" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_868" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_869" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_870" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_871" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="loc_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_872" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_873" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_874" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_875" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_878" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_879" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_881" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_881" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_884" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_884" xlink:to="loc_us-gaap_AwardTypeAxis_883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_888" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_888" xlink:to="loc_us-gaap_RestrictedStockMember_892" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_882" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_887" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_889" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_893" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_895" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_895" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_898" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_898" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_896" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_896" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_897" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_897" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_900" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_897" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_902" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_901" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_901" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_899" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementsAbstract" xlink:label="loc_tecx_LicenseAgreementsAbstract_904" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_LicenseAgreementsAbstract_904" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_906" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_906" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_911" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" xlink:to="loc_us-gaap_TypeOfArrangementAxis_912" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_912" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_907" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_HarvardAgreementMember" xlink:label="loc_tecx_HarvardAgreementMember_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_907" xlink:to="loc_tecx_HarvardAgreementMember_905" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementLineItems" xlink:label="loc_tecx_LicenseAgreementLineItems_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_910" xlink:to="loc_tecx_LicenseAgreementLineItems_915" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_CommonStockSharesIssued_914" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementsPaymentsDescription" xlink:label="loc_tecx_LicenseAgreementsPaymentsDescription_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_tecx_LicenseAgreementsPaymentsDescription_917" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_918" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_919" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_920" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_UpfrontLicenseFees" xlink:label="loc_tecx_UpfrontLicenseFees_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_LicenseAgreementLineItems_915" xlink:to="loc_tecx_UpfrontLicenseFees_921" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_924" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesTable" xlink:label="loc_tecx_IncomeTaxesTable_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_924" xlink:to="loc_tecx_IncomeTaxesTable_930" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_929" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_929" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_932" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_932" xlink:to="loc_us-gaap_DomesticCountryMember_933" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FederalMember" xlink:label="loc_tecx_FederalMember_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_932" xlink:to="loc_tecx_FederalMember_938" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_932" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_941" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_937" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_937" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_934" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_us-gaap_TaxPeriodAxis_940" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_940" xlink:to="loc_us-gaap_TaxPeriodDomain_928" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExpirationThrough2040Member" xlink:label="loc_tecx_ExpirationThrough2040Member_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_928" xlink:to="loc_tecx_ExpirationThrough2040Member_927" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExpirationThrough2035Member" xlink:label="loc_tecx_ExpirationThrough2035Member_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_928" xlink:to="loc_tecx_ExpirationThrough2035Member_936" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_943" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_943" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_931" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesLineItems" xlink:label="loc_tecx_IncomeTaxesLineItems_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesTable_930" xlink:to="loc_tecx_IncomeTaxesLineItems_945" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_935" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_939" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_942" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_946" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_949" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_950" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_951" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_952" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AmortizationPeriodForeignRDCosts" xlink:label="loc_tecx_AmortizationPeriodForeignRDCosts_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_tecx_AmortizationPeriodForeignRDCosts_953" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AmortizationPeriodRDActivities" xlink:label="loc_tecx_AmortizationPeriodRDActivities_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_tecx_AmortizationPeriodRDActivities_954" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_945" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_955" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_957" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_957" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_1116" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesLineItems" xlink:label="loc_tecx_IncomeTaxesLineItems_1117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_1116" xlink:to="loc_tecx_IncomeTaxesLineItems_1117" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_958" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_960" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_961" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_962" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_963" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_964" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_965" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_966" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_1117" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_967" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_969" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_969" xlink:to="loc_us-gaap_StatementTable_973" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_973" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_974" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_974" xlink:to="loc_us-gaap_EquityComponentDomain_971" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IncomeTaxesLineItems" xlink:label="loc_tecx_IncomeTaxesLineItems_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_973" xlink:to="loc_tecx_IncomeTaxesLineItems_976" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_970" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_975" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_977" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:label="loc_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference_978" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_Effectiveincometaxratereconciliationchangeinstock1" xlink:label="loc_tecx_Effectiveincometaxratereconciliationchangeinstock1_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_tecx_Effectiveincometaxratereconciliationchangeinstock1_979" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_PreferredStockLiabilityFairValueAdjustment" xlink:label="loc_tecx_PreferredStockLiabilityFairValueAdjustment_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_tecx_PreferredStockLiabilityFairValueAdjustment_980" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_981" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_982" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_IncomeTaxesLineItems_976" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_983" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_985" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_986" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_987" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsLeaseLiability" xlink:label="loc_tecx_DeferredTaxAssetsLeaseLiability_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_tecx_DeferredTaxAssetsLeaseLiability_988" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xlink:label="loc_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts_989" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_990" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxAssetsAmortization" xlink:label="loc_tecx_DeferredTaxAssetsAmortization_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_tecx_DeferredTaxAssetsAmortization_991" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_992" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_993" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_994" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_995" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_tecx_DeferredTaxLiabilitiesDepreciation_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_tecx_DeferredTaxLiabilitiesDepreciation_996" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_tecx_DeferredTaxLiabilitiesRightOfUseAssets_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_tecx_DeferredTaxLiabilitiesRightOfUseAssets_997" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxLiabilities_998" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_985" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_999" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1001" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1001" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1002" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1001" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1003" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_WeightedAverageCommonShareOutstandingBasic" xlink:label="loc_tecx_WeightedAverageCommonShareOutstandingBasic_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1001" xlink:to="loc_tecx_WeightedAverageCommonShareOutstandingBasic_1004" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_WeightedAverageCommonShareOutstandingDiluted" xlink:label="loc_tecx_WeightedAverageCommonShareOutstandingDiluted_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1001" xlink:to="loc_tecx_WeightedAverageCommonShareOutstandingDiluted_1005" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1001" xlink:to="loc_us-gaap_EarningsPerShareBasic_1006" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1001" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1007" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1009" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1009" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1012" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1012" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1014" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1014" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1010" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1015" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" xlink:to="loc_us-gaap_RestrictedStockMember_1017" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SimpleAgreementForFutureEquityMember" xlink:label="loc_tecx_SimpleAgreementForFutureEquityMember_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1011" xlink:to="loc_tecx_SimpleAgreementForFutureEquityMember_1018" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1012" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1016" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1016" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1013" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1020" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1020" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1025" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1025" xlink:to="loc_us-gaap_RelatedPartyDomain_1035" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_MemberOfTheScientificAdvisoryBoardMember" xlink:label="loc_tecx_MemberOfTheScientificAdvisoryBoardMember_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1035" xlink:to="loc_tecx_MemberOfTheScientificAdvisoryBoardMember_1031" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1037" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1037" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1034" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdvisoryServicesAgreementMember" xlink:label="loc_tecx_AdvisoryServicesAgreementMember_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1034" xlink:to="loc_tecx_AdvisoryServicesAgreementMember_1029" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_LicenseAgreementMember" xlink:label="loc_tecx_LicenseAgreementMember_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1034" xlink:to="loc_tecx_LicenseAgreementMember_1038" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_AdimabAgreementMember" xlink:label="loc_tecx_AdimabAgreementMember_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1034" xlink:to="loc_tecx_AdimabAgreementMember_1042" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_1041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_1041" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_1041" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_1022" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_srt_RangeAxis_1046" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1046" xlink:to="loc_srt_RangeMember_1030" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionByRelatedPartyAxis" xlink:label="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis_1049" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_RelatedPartyTransactionByRelatedPartyDomain" xlink:label="loc_tecx_RelatedPartyTransactionByRelatedPartyDomain_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tecx_RelatedPartyTransactionByRelatedPartyAxis_1049" xlink:to="loc_tecx_RelatedPartyTransactionByRelatedPartyDomain_1032" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1050" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1050" xlink:to="loc_us-gaap_ClassOfStockDomain_1044" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1051" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1051" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1028" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_srt_ProductOrServiceAxis_1052" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1052" xlink:to="loc_srt_ProductsAndServicesDomain_1021" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1033" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1053" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_us-gaap_ProfessionalFees_1023" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_1036" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1040" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1053" xlink:to="loc_tecx_ProceedsFromSimpleAgreementForFutureEquity_1048" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanAbstract" xlink:label="loc_us-gaap_DefinedContributionPlanAbstract_1055" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_1057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanAbstract_1055" xlink:to="loc_us-gaap_DefinedContributionPlanTable_1057" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1057" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_1061" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1061" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1060" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1057" xlink:to="loc_us-gaap_RetirementPlanNameAxis_1063" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_1058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_1063" xlink:to="loc_us-gaap_RetirementPlanNameDomain_1058" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameOtherMember" xlink:label="loc_us-gaap_RetirementPlanNameOtherMember_1056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_1058" xlink:to="loc_us-gaap_RetirementPlanNameOtherMember_1056" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1057" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1065" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1065" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1059" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1065" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1064" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SegmentInformationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1067" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1067" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1068" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1067" xlink:to="loc_us-gaap_NumberOfReportableSegments_1069" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1071" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1071" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1077" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1077" xlink:to="loc_us-gaap_SegmentDomain_1076" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_1080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" xlink:to="loc_srt_ConsolidationItemsAxis_1080" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_1074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1080" xlink:to="loc_srt_ConsolidationItemsDomain_1074" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1074" xlink:to="loc_us-gaap_OperatingSegmentsMember_1072" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1083" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1083" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1075" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1078" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1081" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ResearchAndPre-ClinicalExpensesMember" xlink:label="loc_tecx_ResearchAndPre-ClinicalExpensesMember_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_tecx_ResearchAndPre-ClinicalExpensesMember_1084" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ClinicalAndDevelopmentExpensesMember" xlink:label="loc_tecx_ClinicalAndDevelopmentExpensesMember_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_tecx_ClinicalAndDevelopmentExpensesMember_1087" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ChemistryManufacturingAndControlExpensesMember" xlink:label="loc_tecx_ChemistryManufacturingAndControlExpensesMember_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1075" xlink:to="loc_tecx_ChemistryManufacturingAndControlExpensesMember_1089" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1073" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1086" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_1079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_1079" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_ExternalResearchAndDevelopmentLiability" xlink:label="loc_tecx_ExternalResearchAndDevelopmentLiability_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_tecx_ExternalResearchAndDevelopmentLiability_1082" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_Non-ControllableExpenses" xlink:label="loc_tecx_Non-ControllableExpenses_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_tecx_Non-ControllableExpenses_1090" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_us-gaap_OtherIncome_1091" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1086" xlink:to="loc_us-gaap_NetIncomeLoss_1092" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1094" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1094" xlink:to="loc_us-gaap_SubsequentEventTable_1104" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1103" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1099" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1099" xlink:to="loc_us-gaap_SubsequentEventMember_1102" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_srt_TitleOfIndividualAxis_1107" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1107" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_FundInvestorsMember" xlink:label="loc_tecx_FundInvestorsMember_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096" xlink:to="loc_tecx_FundInvestorsMember_1105" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_IndividualInvestorsMember" xlink:label="loc_tecx_IndividualInvestorsMember_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1096" xlink:to="loc_tecx_IndividualInvestorsMember_1108" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1110" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1110" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1101" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="tecx-20241231.xsd#tecx_SecuritiesPurchaseAgreementMember" xlink:label="loc_tecx_SecuritiesPurchaseAgreementMember_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1101" xlink:to="loc_tecx_SecuritiesPurchaseAgreementMember_1095" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1111" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1111" xlink:to="loc_us-gaap_EquityComponentDomain_1098" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1098" xlink:to="loc_us-gaap_CommonStockMember_1100" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1104" xlink:to="loc_us-gaap_SubsequentEventLineItems_1112" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1112" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1097" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1112" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1106" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1112" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_1109" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g863285dsp193.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g863285dsp193.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( #D H ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H :[I$C22,L<<:L[N[!$1$!9F9F("JJ@DDX  HV\DAQC
M*4E&*<I2:225VV]$DEJVWHDCS'4?C;\'=)NI+'4?BE\/[2\@.)K67Q;H8G@;
M (2:);TM"^"#M<*<$'&"*XI9C@*;Y98VC%K=>TA=>NNA]AA/#SCS&T(8G"<&
MYU7P\]85(99C'":VO"7L4I*ZM>+:NFKW1V>@^*/#/BFU^W>&/$6A^(K(8!N]
M"U:PU:V!/0&>PN)4!]B:Z*5>C67-1JPJQ76$HR7WQ;/ S+)\WR6M]6SC*\7E
M6(_Y]8S#5L-4_P# *T(2_ W:U/-"@ H * "@ H * "@#\TO^&ROB?_PT'_PJ
M?^PO ?\ PCO_  N3_A7GVW^R_$/]M?V+_P )M_PC?VK[1_PE'V;^U/L/[SS/
ML?E>;\WD;/W=?(_V_C/[4^H^RH^R^M>PORSY^3VOL[W]I;FMK?EM?I;0_KK_
M (@'P=_Q"[_7;^TLY_M7_5;^W/9?6,%]4^M_V3]?]G[/^S_;?5_;>[R>W]I[
M/3VO-[Y^EM?7'\BA0 4 % !0 4 % ''^/?''A_X;^$M:\9^)[K[)I&AVAN)M
MNTW%U,S"*TL+.-F437MU<O%!$F0"\HW%5!9>?%8FE@Z%3$5GRPI*_FWLHI=Y
M.R7^1[O#7#F:<5YWE_#^3T?;8_,*BA!.ZA3@DY5*U623Y*5&FI5*DK.T8NR;
MLG^,7C'XJ_'/]K#QE_PBWAJUU0:3<LYT_P $:%=/;Z+8:?&P!O\ Q+?LT,-V
M5!3S+S4'2%9)!';QQ&58W^ KXW,<ZQ'L:2ER/X:,':$8KK-Z)VTO*=DG\*5T
MC^_LAX*\./!'(%G.;UL.\=14?;9MC*:GBZU=K2CE]!*I.E>SY*&%C*JX1<Z\
MYJ$IQ]AT;_@G3XUN=/6;7OB'X;TC4F1F-AIVE:CK5LC;CY<<FH33Z>=VS:7*
M6SA6)"EP S=]/A7$N/[W%4Z<_P"6,937_@3Y?P3^9\'F'TJ^'Z.*=/+.%<?C
ML'%I*M7Q-#"5&K+F:H0ABE9.ZBG6BY*SDH-N*X/Q;^R=\??@9-_PG/@C5O[<
MCT8FX.K^![N_M-?L+:+][)+>:--''+<6?[I?-AMI+]&0_O4,8?'-7R3,\M?U
MG#SYU2UYZ+DIQ2ZN+2=NZ7,K;Z7/I<C\;?#+Q%I_ZN<1X'^S98_W%ALWIT:F
M"JU)>Y&-+%QE*-.JN9^SJ588649+]W-3Y;_LCX?N9[S0=$N[E_,N;K2--N;B
M0JJ;YY[.&65]J*JKND9CA0 ,\ "OO:+<J5*3=W*$6WYM)L_@C,J5/#YCCZ%*
M/)2H8FO"$;M\L(591BKMMNR25VV^[9KUH<04 % !0 4 % !0!^#O_-Z7_=T/
M_O5Z_-O^:@_[J'_NR?Z4_P#./W_>/?\ WVS]XJ_23_-8* "@ H * "@ H _+
MC_@HMXSN1<?#[X?6]R$M?L]_XOU2T5UWS3-,^CZ)-(@;<L<:PZ\%RH5FE;!)
MB.WXWBK$-2PN%3M%)U9+SOR0?RM/[_(_LGZ*G#]+V?%'%%6BW6C.CEF&J-.T
M8J*Q6+C%VLY2<L&Y6?-%15TE/7Z4_8T^&>E> O@SH&N1VT'_  D/CZT@\3:U
MJ*J#/-9W)FD\/V E/S"UM=+FC<19VB>\NG S(:];A_!PPN I5++VN)2J2EUY
M=>2-^RCK;^9R/R/Q\XOQO$O'V9Y=*M-97PQ5GE^$H-^Y"K3Y8XVMRK3VE;$0
ME%SW=&E1BW:"/K.O</Q(* .-\>^-_#_PT\':WXS\1S&UT7P_9>?*D"H9[B5F
M2WL=.L8F9%>[NKN2"VA0LB[YEW,B!F7GQ.(I8+#U,15?+3HJ]ENWM&,5IK)V
M2V6NK2U/>X:X=S3BW/LNX?RFG[7,,SJ\D7-M0IQ2<ZM>K)*3C2HTXSJU9)2E
MR1?+&4FHO\B]7^-_[3?[2WB>_P!'^&2>(=(TF!5DC\/>#;]=%@TZS+NL,WB#
MQ8\UDS33[2I^U7EO;R-$5A@4A]WPT\QSC-JTJ>$YX0CM3I2Y%%=.>I>._P#>
MDHM[11_<F!\._"#PBR?"X[C"6!QV.J-QEC<THO%2KU4ESPP66QCB$H4KW_=8
M>K6@I)U:S3C:'7?!?[9GP,M'\82ZWXR32K",W%_?Z;XL7Q;I=E&K*'EU?1;B
M[NXS;J%1FGN+%X$7[T@P0%4P^?9;'V[G5C".KE&I[2*_QPYI*R[RCR^9IEO$
M'@#XC5HY#3RW*_KN)DH4:-?+?[,Q%65G:.&Q=.G0DIMMJ-.EB8U92^&#NK_=
MO[+'[3D7QOL+[P]XDM[32_B!H-JEY<Q6>8K#7]*\Q('U73K>21GMIH)Y(8[J
MW+,JFY@DB8I*T=M])DN<?VA&5&LE#%4E=VTC..W-%=&G926VJ:T;4?YN\9O!
M^?AUB<-F>4U:N,X8S*HZ5.57WJV"Q"BYK#5YQC&,XU(1G/#U4HRDJ=2%2*E!
M3J]K^T=\?]*^ _A.WO1;1:MXMUU[BU\+Z))(8X'DMD0W>J:DR,)%TNT\Z ,L
M>'FDGBA0H'>:#IS;,X990345.O4NJ<'MIO*77EC=:+5MI*VK7SWA1X8XWQ)S
MNIAO;2P.298H5,PQ<8WG&,VU3P]!-.+Q%?DGRN?N4X0G5DIN,:=3\V-%A_;#
M_:0>X\2Z1K/BQ]":>>.*Z@\0+X*\)1/#(V;73+*"\LXK\PR*(3+##=R*T0%Q
M-O5FKY&FL]S6]6G.JZ=[74_94E;I%7BG;:Z4G_,[G]:YA/P&\)8TLGQV7Y:L
MRC"$I4YX+^ULR:E%6J8BK.E7E0]I%^T4)U*$'&5Z-)0<4+-X[_:R_9>UK3F\
M87GB*XT6XNFCAL/%&ICQ=X5UJ*W0JUK9:H+RZ;393!MF6.UN;.X7:AEB*J\9
M;Q.=Y-4A[>53D;TC4E[2G)+HI7ERNVMHRC):7705/AOP1\8<OQ4<@P^!H9C0
MIJ4JN7X?^S,QPDIM-5*N&]E0CB(J=Z<IUJ.(HN[5.HI.$U^K7P9^+?A_XT>!
MK#QEH2FTD9WL-;T>259KG0]:MTC>ZT^:143SDV2PS0S;$\V&XB<JC,R)]IE^
M.I8_#1KTEROX9PO=PFMXWZK5-.RNFM$[I?Q9Q]P/FGA_Q'B<@S)^VC%*MA,3
M&+A3Q>$FY*G7A%N7*[QE3JT^:7LZL)PYI)*<OQS_ .;TO^[H?_>KU\)_S4'_
M '4/_=D_O3_G'[_O'O\ [[9^OWQU^,6D?!'P#?>+]0@%_J$DT>E^'=&\SRFU
M76[F.62"&209,-E###-<W$H!*Q6[*F99(U?[G,L?#+L+*O)<TV^6G#^:;3M?
MLDDW)]E9:M'\)^&_ >.\0N)L-D6%J?5,+"#Q&.Q7+S+#82G*,9S4=I59RE"E
M1@VDZDXN35.,Y1_-'PUI_P"U[^U(;OQ/8^+;_0/#'VJ>&UN'US4?!OA+S$G7
M?9:5I^B12W.JI:NOEFZD@O"C0-')<M.K*?D:,,\SCFJQK2IT4VD^>5*EH]HQ
MA=RY=KVE:UG*Y_7.;XGP*\&50R;$Y'1S3./9PE4IK!T,US+E<'RU<36Q<H4<
M,ZR?,J,*E!2C.,X8=4G%D>L:O^UE^R=JNEZEXCU^_P#$/A:\NEA_T[6;SQ;X
M/U.1$+2:89=2"WN@WK0H71HTL))/))C,T<4J!3GG>1SA*K5E4HR=E>3JTI6^
MS[WO0=MK<K=M+I,K 8#P1\;<%C,)E.64<HSK#4W)>QPM++,SP\6THXA1P[>'
MQE)2?+-2EB80YDIJE.=.3^V_'/C+Q!\:/V</^%E?!K7]=\,^([*UDU]+'2KM
MX[YI]$,\'B3PM>+''_I4BQ+=26Y6)3-);V;QXCN?F^AQ.(JYAE/UO 59T*L%
MS\L)-.\+JI3=M[*[CIJU&VC/YXX<R#*_#_Q87"7'^683-\IKU8X*57$4TZ*A
MB^2> S&DW+]W%R=.-=.;5*G.O"=ZE+3R+]B']H+Q'XYO_$WP^\?Z_>Z[KJQ?
M\))X<U35)O-NYK*(6]GJ^DF78N1 QM+J%,LQ6>]/W8ACBX=S.KB)U<+BJLJE
M1+VE.4G=V5E*-_+227^+L?=?2(\+\IX:PV3\3\,992RS+7+ZACL/AX\M.%:7
M/5PV)Y;NWM4JM&J[**<*"^*>OW9XZ\8:7X \'>)/&>LMMT[PWI-WJ<Z!T22X
M>",_9K&!I"%^TW5TT%M$I/S23HO>OI,37AA,/5Q%32%&+DUM>VT5YR=HKS:/
MYNX;R+&<39]E/#^7J^+S7$TL/!V;C34Y>_5FHIOV=&FIU:C2TIPD^A^;G[(W
MCGXV?&;XKZGK/B3QWXCE\&>&8KK7-9TF&Z>'1;C4=5EGBT70(K<$F&R61KJZ
M6+<P$6C^4QQ(,_)9'B,PQ^.E4JXFHZ%"\YQYGR<TKJ$+7T5[M+:T+=3^L_''
MAOP\X X*P>791PW@8<09M*GA,+B9TU/%PH8:,)8O&RGM*K)*G1E/EBW4Q3J1
M2<';-_X*+>%YX?%/P]\:)!(UK?\ A^^\+SW(#F**?1]1FU6T@D.XK'))'KEZ
MZ#:I<6\O+"/"3Q51<:^%KV]V5-TV^SA)R2\K\[MZ/MIV?13SFG/)N*>'I58Q
MK87&T<PA3=E*4,30CAJLXJUY1A+"48RU:BYPTBYWE]G?LE>-M,\9_ GP0+&5
M/MGA738?!^L6@93+9WNA1I;0>:H8D"XTW[#=J3C*W6."I ]_(\1"OEN'Y7[U
M"/LI+LX:+[X\K^?D?@'C?P]C.'O$CB+ZS!JAG&(GFF%J6?+5HXR4JDN5M*_L
M:_MJ$ETE3>Z:;^DZ]<_)0H _/'_@HGJU];?#[P)HT$DD=CJGBR[N[U49D69]
M*TJ1;2*4+Q)&&U"638V1OA1L90%?E>*IRCAL+33M&523?K"-E_Z4_N\C^I?H
MK8'#U>*>(\=4A&6(P664Z=%M)N"Q&)C[24;_  RM1C#F6O+.4;VDT_8OV+_#
M.BZ!\ /"-]I:VTMYXG?5M;UN_@5 ]UJ U>^TY()71W)-C:6-O9;2WRO:RML1
MI'4=_#]&G2RRA*"7-6<IS:ZM3E%+_MU14;=T]FV?!^/^;YAF7B=GN&QCJ4Z&
M3K#83"49MVI4%AJ-9SBFHV6)J59XA-+6-2"YIQC&3^J)8HIXI()HXYH9HWBE
MAE19(I8I%*21R1N"KQLA*E2"""01@U[32:::NGHT]K=K'XQ"<Z4X5*<G3J4V
MI1E%N,HRB[QE%JSBXM)IJS35T?B9\+[.'X??MJVV@>%9BVE6'Q+\2^&;>&UD
MD,::-=MJNGRZ?-M=_.6QMY=C[R1YFGAR%9?D_/,'%83B"-*A\$,1.FDOY&Y1
M:>]^5/7S5S_0OC&O4XG^CW5S/.J?+C<1D.7X^<ZD5S/%4OJU:->%U'D>)G'F
MCRV_=U^1.2E[VI^W)>3ZU^T-::)?WHLM.T_P]X6TJVN)F_T:PMM0FN+Z[OF1
MY(T 6:_E9V+IE;=0S@(-M\1R<\T]G*7+&$*<4^B3]YOIUD[^FYQ_1RH4\N\+
M<1F&%PWUC%XC'9CB)TX+]Y6J4(4Z-*BG&,Y:QHQ4$HRM*I)Q@W)W_8[0M$TS
MPSHNE>']%M(K#2=%L+73-.LX45([>TLH4@AC"J ,[$!+8RS$L>2:^^I4H4*<
M*5*/+3I148I=$E9'\%YCF&,S;'XS,\?7EB,;CZU2O7JS;<IU:LG.<FVV]WHM
MDK):(\T^/WAC1/%GP;^(VEZ\MLMI!X3UO5[>\NE4II>HZ)I]QJ>G:HK,RF,V
MUU;1NQ5TW1^9&3LD8'CS2C3K9?BX5$N6-.<TW]F4(N49>5FOFKK9L^M\,LXS
M#(N/>%,9ECJ.O/,L)AITJ;:>(H8JO##U\.TD^;VM.I**3C+EGRS2YHQ:^ _^
M"<NJWJ>(_B7H0:1M.GT30]59"[F&&]LKZZLXV2/[J22P7\@9A@L+9 <A!M^8
MX4G)5L72^Q*$9?.,FE]ZD_N/Z;^E;@L.\KX0S'EC'%TL5C,,G9*<J52C2JM-
M_$XTYT4XIW474DU9R=_GG_F]+_NZ'_WJ]>9_S4'_ '4/_=D_5/\ G'[_ +Q[
M_P"^V?1/_!1O4[I]?^&&C9G6QM]'\0ZFH^9;:6ZN[W3[5C][;)/%#8IU&46Y
MX.)37J<5SE[7!TM5&,)R7:[:7WI17I?S/RKZ*&#HQRWC''6@\14Q.!P[>GM(
M4Z5*O472\83E5?6TY4]5>".?\%^.?VW?#OA'PUHGA/P'?+X9TS1--M=",?@C
M3I1+IB6L1M+AIF4-<231%9GF;YI'E9V^9C6.'Q/$-&A1IT,/)480BH6H1^&V
MCO;6ZU;ZMW/2X@X<^CMFF>9OF&=<34GFV+Q>(J8Q/-J\>7$.I+VD%!:0C3E>
M$8+W81BH1TBBMX[UC]MKXD>%M3\'>+/ASJ=]H>JBV^U01^"=/MYU>TNH;RWE
MM[B,;[>9)[>,AT(.,C.&.9Q-3B'%T98>OA9RIRM=>Q2>C35FE=--=#7AK ?1
MYX2SG!Y]DG%E'#9C@7/V<I9K7G"U2G.E.,X-<LX2A.2<976SW2/I[]AGP5X^
M\!>#?&^@^.?#6J^&DG\2V>K:5;:M:O;/<FZTJ.ROYH@S%9$ TZQ0X ((&<@C
M'L\-X?%8:AB:6(HRHISC**FFKWC:5K[_  Q/Q_Z1O$/#/$V?\.YEPYF^'S9T
MLOJ8;$5,-44U3]EB95:,9:)Q?[^JUT?2UG?XG^-GAG5OV7_VCK#Q;X4M_(T>
M35$\:>%8E_<VDFG7<TL.O^&#(L3+# OFZAI[(@9TL[VV?AI :^?S"C/)LUC6
MH+EIJ2JTELN5NTZ>BT2]Z%M^1I]3^A?#S-\#XQ>$^)R+.JO/CZ>'>4YC)^]4
MC7I1C/ YAR\R<IODHXE2DU&>*HUH_#%H]I_;=^/.E^*/!WP_\%^#[XSZ;XPT
MK3?B#K3A620:5.I_X1O3+@,I$<S7:7MQ<0$K)#)IMKN&),'T.(<RA7H87#X>
M5X5XQKS_ ,+_ (<7V=^9R6Z<8GY]]';PUQF39]Q/Q!GN&]EB\@Q-?),)&Z:^
MM0=L?7@T]8QI.E2HU$G3JPQ%;E=X'U[^R=\*Q\*_@]H5M>6WD>)/%*IXJ\1[
MT=+B&ZU.")M/TV59"6A:QTI;.!XAA5N!=. #*V?=R/!?4L!24H\M6O\ O)][
MM>['RY8V3727-W/PSQLXT?&?'F95L/6]IE.3-Y;@.5IPE2P\Y*M7BXI*2Q.(
M=6K";O)T71@VU"-O0/C/\*-$^,O@+5/!>L%;>68I?:)JHB26;1=<M$D%CJ$(
M89V8EE@F12K26]U<1AE,FX=688&GC\+/#S]UOWH2M\$U\+]-6FNL6U='R_ '
M&N8\ <2X+B#+TZD*=Z.+PW,XPQ6#J./M:$[=?=C4I2::A7ITJCC+DL_QQT36
M_C3^QS\1)[>ZL/LAN@([_2[S[1<^%/&6EP2 I=V-U'Y8G:+S"8;N'9<6KS-'
M,BAYK>3X*G4S#(<6TX\K>DHN[IU8K9IJU[7TDK2BVT[7E%_WKF&7>'WCSPK2
MJT,3[;V'O4<12Y*>995B)QUI5J<N=P4^6U6A/FHXB,%.E-N-*M'[6TG_ (**
M?#N6PB?7? ?C2PU3RQYUKI,NAZM8+*"@817UYJ.G2M'M,A!:T4Y51CYBR_0T
M^*L+RKVN&JQFMU%PE'[VX/\ \E/Y\QOT5>*J>)G'+>),IQ.#4GR5,3'&8:MR
MZV<J-+#XN"E?E32KM:MWT2?DGQ._;\\3^);27P_\*?"\WA>2_P 6B:_J4T>J
M>(B+@&(1Z3I=I$;;3[YI&14F:6_;G]VB2;73@QG$U:K%TL%1]AS:<\GS3UT]
MV*5HOSO)]K/5?;\'_1DR?)ZT,SXUSF&<0PEZKP6'C+#X%>S:ES8G$U9*M6HJ
M*;G34,,M/?G.'-&7V#^T'\'-1^,OP.T[1;!6_P"$RT"TT?Q%H4=V_DR7FJ6F
MEFVOM)NI;@CRI+RTN;J,&5D47*6[2LJ(Q'O9I@)X_+:=.'^\45"<$]&Y*-I0
M;>SDF][>\E=I7/PCPMX]PO 'B+B<PQ+2R',JF)P.,=)<RI8:IB%4HXFG&%^9
M4*E.G-J"DW0=6-.+E**?P3^SC^U/J'P"BU+X<?$+P]K%YX;L]4NWCM[6*.#Q
M'X5U5IO+U2R:PU"6W2XM'N$>1[=Y;>2&8S,"_G%%^9RG.998IX7$TI2HQD]%
MI4I2VDN65DU=:Q;33N^MC^F/%?P8POB9/"<6<*YIA:&;5\/24IU)2G@<QPZA
M?#556H1JRIU8P:A&K&%6%6E[.+4/9J4OHWXA_P#!03P-::%=P?#71->U;Q+<
M6TD=C>Z]8VVFZ)ID\@9$NKF);V:YU"2$XD%LD4228"M.F2*];%<48>-*2PE*
M<JS5DYI1A%]VE)N36]K)/N?E'"OT7^(ZV94*G%N88/ 911J1E6I8.M/$8O$0
MC9NG3E[*%&BI_ ZTISG#5JC*R/*/V(O@UXD\2^.9/CGXMANUTO39-5N-"O-0
M5Q/XE\2ZLES;7^JQ^80T]G:Q7=ZS7!4H]U/&(V9K:;R^'AW 5:V)_M&LFJ=/
MF<'+>I4E=.6NZC=MRZRM9MIV^U^D/Q]E.4<.0\-\BJ4GC,5'#0QE*@UR9?@,
M*Z=2AAGRW4*M:5*DHTD^:&'A+VD5&M3YO1/V\?@=K/B*/3?B[X7LYM0DT'2/
M[(\86%LIDN(M'M)[B\L-=A@4;IHK5KN\BNRNYDA-O+M$4$SQ]?$N75*G)CJ,
M7+V4>6K%;J*;<9VZJ-VI=E9[*37RWT:_$; 93/%\"YQB(X2&98GZSEE:H^6#
MQ52$*5;!SF](RK*E2GAKVC*JJM.[J5:499/P7_;UT+3?#&F>'?BSI6MMJVD6
MD5C%XGT*WMK^#5;:TB$=O-JMC-=P36NI&)$222#[0DT@,I6 .57/+^):=.C"
MCC:<W.FE%5()/F25ES)M-2LK-J]WK9'=Q_\ 1HS+%9QB\TX'QF$C@<;4E6EE
M^,J3H3PLZDG*<,-5C3J4ZE!2;E"-3V4Z4+4[U7%2?"?M&_MH6_Q(\-W?P\^&
M.E:O8:1KA6SU[7-6BA@U/4[(R(3I.E:?:7$YM[6Z=566663S98BT'DH)'+<V
M:\0+%T7A<)"5.G/2<Y64I+^6,8MV3ZMN[6EDKW^D\*/H_P!7A+-J'%/&&-PN
M(QN6WJX/!X:4IX?#U5%_[3B:]6%-3J45>5.%./LZ=1*K[63A%+ZB_8J^".K?
M"OP1J?B/Q59R:?XI\=O87#Z7<)LNM'T+3TN#I=K=QDDP7\\E[<W,T1"M&KVT
M4JK+"ZI[/#V73P6'G6K1Y:V(Y7RO>$(WY4UTE*[;71<J=FFE^-_2"\1,%QGQ
M%@\JR6O'$Y+PU&M3CB(.]/%8RNX+$5:3LN>C25*G1I3UC-QJU*;=.I&4OSP_
MYO2_[NA_]ZO7R_\ S4'_ '4/_=D_JC_G'[_O'O\ [[9^@'[<7P:U?XB^!M(\
M6^&+&;4M?\ RW\UQIMJCRWFH>'=32W.HFT@C4M=75G/96MPL(&XPF[V;I-B2
M?3<1X"IBL/3KT8N53"\UXK=TY6YK);N+2=NW-ULC^8/HZ<?8'A/B/'9'G&)C
MA,KXFC1A"O4:C2H8[#N?U?VLVTJ=.O"K4I2F_=57V'/RPYIQ\-_9V_;<T#PC
MX/T7P#\4=/U98_#=G;Z3H?B?1[>*^1M'M%$-A9:OIWFQ30M96B16\<]J+@RQ
M11AXE=&DG\[*N(:>'H4\+C(2M12C"I!)^ZM$I1NFN562<;W5KJZN_P!'\5/H
M\9IGF?9AQ-P;B<,Y9K5GB<7E^*J2HR6*J/GK5<-7<9TY+$5'*K.G6=%4ZDI<
ME24)1A3ZCXN_M_Z-!I_]F_!O3;R[U9YH&E\2>)-/2WTNUMXY%DEBLM):<W%[
M/,BF)GN!:K$KLR"1L%-L=Q/!0Y,!!N=U>I4BE%)=(QNVV]KOEMT3W7C<#?1B
MS"IBOK?'N+I8; QC-1P& KN>)J3<7&,JN)4/9480;YU&DZTJCBHR=.-^;[E^
M$OB?Q;XR^'_AWQ+XW\+#P9XAU2T^T76A^?)*T41=EM;MX9HUETXW< 2X%E.9
M)K=9ECE<R*P'T>!K5\1A:57$T?859*[A?IT=GK'F6O*[N-[-W/YRXVR?(\@X
MGS7*.'<Y_M[*L%5Y*>,Y(P4I63J4E*$G"LJ$[TGB*:C2KN#J4HJFXW\._;0^
M&$'C_P"#>K:S;QP+KOP[2X\6:?<2,L;'2K6#=XDL?-*DA)-*B:Y6,8\R?3+5
M<C.:\[B#!K$X"=1)>UPEZD7_ '4OWD;_ .%<UNKBD?HWT?\ C"IPQQ]@<!4G
M/^S>*73RVO3BFTL14G; 5N6Z5X8F2I2F_@HUZTK/8_,C]E;X7R_%?XP>'K&_
M@>Z\-^%MGB7Q$9MS0'3])EC-AI9+QNC+>:J]G UN2A:W:[9/]4:^/R;!?7<=
M2A)7HT?WE3MRP:M'_MZ5DU_+=K8_K_QIXQI\$\!YI7PM14,VSF^ P*C93]MB
M(R5?$64HR3H8:-6HJJ4N6O[",OC1^]]?IA_F>% '/>)O"7ACQEIDFC>+- TC
MQ%I<AW-8ZQ86]_ D@&%FB6XC;R+A>JRQE'4@%6!&:RK4*.(A[.O2C5AVE%->
MJOL_-6:/4RC.\XX?QD,?DF9XG*<9#15L+6J4)\O6$G"4>:#VE"7-"2TE%H^;
M[[]B;]G:]N7N4\(:A8;W:1K>Q\3^(4MMSMN(2*?4)3"F<X2-D50<*   /)EP
M]E4G=490\HU)V_%O\#]8PWTA?%3#48T7GU'$<J45.ME^!=2R5E>4*$.9]Y34
MI-ZR;;;?J/@+X!_"#X9RI=>#O NCZ?J,18QZQ=K<:SK,18Y;R-5UF>ZN;53@
M92"6)>!QQ79A<LP&":>'PT8SCM)WG)>DIMN/R:/C>)?$OCKBZ$J.?<1XK%82
M5KX6FX87".VW/AL+"C1J-=)5(2EYGL%=Y\*>1?$/X#_";XJ2K=^-O!FFZGJ:
M(D:ZS;/=Z3K)CB!$44VJ:3<6UQ=P("P2&X>6-=QVJ":X,5EF!QKOB,/&4U]M
M7A/RO*+3:71.Z1]SPKXD\;\%P=#AW/Z^#PDFY/"S5/$X3F?Q2CAL3"K2ISE9
M<U2E&$Y65Y-(\\\/?L<?L]^';Z+48_ XU>>!@\,?B'5M5UBQ4C'$NEW-V;.[
M7C[MS!,O/2N6ED&5T9*7U?G<=E.4I+YQ;Y7Z231]3FGCUXHYIAIX2?$;P-*:
MM*6"PV&PM:W]W$4J2Q%)^=*K3?F?3<$$%I!#;6L,5M;6\:0P6\$:0P00Q*$C
MBABC 6*-$4*JJ    !@5["2BE&*45'1)*R26R26UC\@J5*E:I.K5J2JU:DG*
M<YR<IRDW>4I2DVY2;=VVVV]62D#&,<=,'ICTQ3(V\K'SEXP_9.^ OC749M6U
M/P+;:?J5Q(TMS=>';W4/#Z7$CL7DEGL=,N8K)YW<LSS?9O,=F)9R3FO)KY'E
MF(DYRPRA-[NFY0O_ -NQ:C?N^6[ZL_5LA\;/$OAW"T\#@N)*F)P=%*-.GCJ-
M#&NG&*Y8QA6Q%.=>,(Q24*:J^SBDE&*2-KP!^S;\%_AI>Q:KX7\$6":S;OYE
MOK.K37FN:E:RA/+\VQGU:><:=*4+ O:) Q#L,X8BM,+E&7X.2G1PZ]I':<FY
MR7FN9M1?G%(\_B;Q9\0.+<//!9SQ%6E@*BY9X7#0I8/#U(WYN6M##0I>WBFD
MU&NZB3C%VNDSW.O2/SD\&_X9D^"'_":?\+#_ .$)_P"*P_X2C_A,_P"U_P#A
M)/%W_(R_VM_;G]I?V?\ V_\ 8O\ D*?OOL_V;[/_  >5Y?R5YO\ 8^7?6/K7
MU?\ ?^T]KS>TJ_Q.;GYN7GY?BUM;EZ6MH?I7_$7_ !%_U?\ ]5?]8?\ A!_L
M_P#LKZK]0RS_ '#ZM]3]A[?ZE]8_W?\ =^U]K[;[?M.?WCWFO2/S4^?O'/[+
MGP.^(.H2ZQKO@>TM]7G<R7.I:#=W^@3W4C,&DFO(-*N(;6\N'(^:>>WDE.3\
M^3FO+Q&39=BI.I4PZC-[R@W!ONVHM1;?5M-^9^G\.>,GB-PMA88#+.(JL\!2
M2C3P^,I4<;"E%*T8TI8FG4JTH1^S3I5(4U9>YH/\"?LP?!#X=:C%K'AWP1:2
M:S;21RVNJ:W=WVO75G+%O\N:Q35;F:"PN%WMB:WABDR%);*+@PV39=@Y*I2P
MZ=2.JE-N;36S2DVHM=TD_,GB3QA\1.*L+/ 9IQ%5C@*B<:F'PE.C@J=6,K<T
M*SPU.G4K0?*O<JSG#>T5S._OU>H?F1\#?MZ_%8>%_ .G_#?2[I4UGQY+Y^K+
M&V)K;PKIDR/*&VD&+[?J:00*3D216E\A%?,<38WV&&A@X.T\1K+NJ<7^'-))
M+NHR1_3'T:."O[8XFQ/%>,HN67\,QY<,VO=J9C7BXPM=-2^K4'.K)*SA4J8:
M9UW[$?PK_P"$ ^$T/B;4;;R?$/Q%DAUV?S(U6>VT")9(O#EH7 W%)+:2?40"
M>/[6"E0T9K?AW!?5<$JTU:KB[3\U!:4U\U>?_;R['A_2'XT_UFXWJ91A:O/E
M?"L98.GRR;A/&R:ECJMMDXU(PPMTM?JW,FU)'V77T!^!A0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 ?E+XZ^ 'QJ^.'[11\1>-?!U[H?P[G\06^GK>
MW&L:%)]B\"Z&\C0P1P:?JSW<-WJ5O#,^$C8Q76LL2=B%A\3B,LS#,,U]KB,/
M*EA7-1NY0]VC#96C)M.23V6DI=C^U.&O$[P^\.O"G^R>'<^I9AQ52P4Z[HPP
MN,C[7.,6HJ4Y3KX94)4\'.4(^]**JX?"I)<TDG^JEO;P6D$%K:Q1V]M;0Q6]
MO!"BQQ000HL<444:@!(TC5550  % '2OM8I02C%<L8I));)+1)+R/XNJ5*E:
MI4JU9RJ5:LI3G.3;E*<FY2E)O5RDVVV]6V34R H * "@ H * "@ H * "@ H
5 * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g863285g01v82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g863285g01v82.jpg
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MV>2B>E;&GO6M;(:(M-TJ@1%GMY-O%Y'H'3U+%:I5$W>F-R.UB?&-EPT,KG6
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M9#_WT*NKKIEL=-(YE!2U=;E\?(1M/5GM]"@U/%>]*^)I'R2&GML!SYV0-.X
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M7(!C&M<RF+]@#1\.3UCO6]7/(_L8T\L4?N3:(4&CC K&NU7OB;PV&>=W_?N
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MB*)8*N-.EECK\)>Z#6CPB@>'!W$L<=5P[R#V*QU%-*DK(M']Z,A&1B#1UEP
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MPWL=W=94AI--T!B'A=ED$N6WDIP0>\;%MX7SCNC*S+E+9EQ*F=.^)63B##E
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M%X8E)7+<L;#&![%AS5?04;7U(_\ D3>7)V'AV9*2HBBVWNRZ26R"(BX="(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
/(@"(B (B( B(@"(B __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g863285g02v02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g863285g02v02.jpg
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M<G."DI2SP30U.)6B)"5#8\+A\/%$4V2C_\0 &@$! 0$! 0$!
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M)W[%F3@UY4:BII^9FRO$TL<$3Y9Y&1Q,&LY[SD&CG)*]/<UC'/>X-:T9DDY
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M/DZN"*>/Y,K X=Q6C#AVRP2<I#9[=&_Y3*9@/J741=MG*0 R&0V!$1<.A$1
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MIV:U5;B91D-IC/PQZ >Q9=#6)&WO"T=),_.MMX$+P=[F?$=W#+L4\< YI:X
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M.+I3P R=_P"EW)JEDGJK;NVJVYHQPVC%@PZ+\UW45*W?)MM=.GW)3;;ZZ]X
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;1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g863285g09v09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g863285g09v09.jpg
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M^(Z,K,UYY1<7A9M.ZN@B(LE"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MUJK&W"V4=:QA8VIA9,&GB YH./VK ];<K5HT]=V66WTT]YO;WB(4M,0 UY.
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MK?"XIF!H><^B1Q'#CP6/:4Y<[)>YZX5='/;:>DIG5+YII X$!S6[( WDDN&
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MW*\HB\3=WP.P1$4 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M ) _$@!<A\D3Q'RF:;+MW_C6-_$[EV\M#\H7(W71ZE9J70CX6U39VU1HI';
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M<8.T,-&[=P6I.+T=0NK_ !(D\=S="(B_/.YS7]*32DT-UI-34T9=33L;3U)
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MVAGKF5KJBHY\/9&6;/H@8P2>I9VBXSTBI46&3X&E",7=!<S?2Q_C)8OZH_\
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M31X.0V@UA:+37S::@M]?8*N8OIY+@]U.Z1S?1+VM:'$ XP0>K<OK2<B%VO\
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M2W8,T39-GJR,X7H4- :T-:  !@ ="E?FG<UM](>CDJ^2NZ&%I<8'Q3$#[(>
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M:NCK)%IS2]LM$.,4D#8W$?SG\7._%Q)_%>BM64J,<^1B,+3>1>$1%X#L$1$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@/'>FUCK/7MMCFMKS!(*<NX"39.SG\<+FGD<NEJL.K[TSE*
M8^&\3!K8I[FPNV3D[8)=G!/H^EPP./7U$O-6T%'7L#*ZDIZE@X-FC#Q^T+M3
MJJ$7%KF9E&[N8K)J+D_CB,CKGIK9 SNEA/[%J346FK?RD\H]NFT=;N9LE.&^
M'W%D!AAE(=D[.0-IV-V0.GJ&5O>#3%A@>'P62UQO&_:921@_L"NS6AK0UH
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M6&? TIIJZ,S1<8^>'7?;\GR\7Y5TYR?VK4,%%2U^H]2SW*6> .=3"GBCB87
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M!02&>JFHZATLH&.=F=&1D#H&X >H+D;2[Z6+4MI?<8V243:N(SLD&6NCVQM
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M0PH^/T4/XVWG^HC_ !&KIY<N<C5#JK0FI*BLKM(7FHI*F P2"&'TV>D"' '
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M8_T3</EG]RCQ!>,?Z)N'RS^Y;N\HKOVC4?VD\HKOVC4?VE/;*'^I_4OL;/\
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M?9FIUHYS\G+WV-<OE7]R>3=\[&N7RK^Y=&>45W[1J/[2>45W[1J/[2>UE/\
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MS,Q&7L+MY#-^,>K/J5EJ].4]FTG:;Q<X:JJ=<G/+&12"-D3!C&T=DY<[B.'
M\4AI,)I->+M\Q/19P;3\%?Y&((LFNUGMTM'8Y-.NJIY[A))$Z"8M+HY 6 ,W
M 9^MG/2"."N.K--VO1YI**YNJ+A=I8A-,V"4110@Y  ):XN.X]7L6M?&Z7B[
M\/@9U$K-^"MQ^/(PA%D]UM-G;I2*[VJKJ7S250@DII@W,'H..\CZV<#!P.!W
M*Y7/2%+IG35%<M1NJ)*ZN/\  4,+Q'L-QDN>X@]8W =/%-HAP7BW:P6CS=WX
M)7N8,BSFGT=3WW2-5>]./G$U$2*JAG<'N  SM,< ,C&_!'0>K?<]):)L>H=&
M5UVIWW)UPHFNYRD;,S#G!N1@[&<'H_$+$M+IQ3;\'9^YFXZ)4DTEXJZ]Z-9H
MK[IJCMM9-7NN;*P4M/ ^?;@E:TM W-:<M.<N+6YW<5E>@M'6/4UBNU?.ZY4[
M[?EQ8R9C@\;)<.+-QW86ZND1I)N7)?R8I:/*JTH\W_!K=%E=HHM.W&&I;)%=
MJ.;F)GTTCIV21R21L+]@_P &W'1PZQUJ[\E6CK3K$UT-;)703TS6OVX9&;+P
M21P+21C'65)Z1&G%RDFDBT]&E4DHP:;9KU%L/2.B[7K!MS@M4]90U]'@M;4O
M;*R0$D#>UK2-X]?'I7DY.--6;4-YGL]ZGK:6O&US1AD9LO+>+<%IW[B>._!_
M&/2H)2O_ (\RK19R<4O\N1@Z+*KIIV*@UX^Q/IJLQ-F$0!G:'N:>$FUL8 V<
M'ANW[U9;\RVQW2>.RNJ'T+'%K))W NDP?K;@, ]2Z1J*=K>*N<I4G"]_!V+>
MB(NAS"EO'\"H4MX_@4!"(B (B( BV1H'1EEU)IFYW*KDN,,MO!+VQRL+9,,V
MMV6;N'K5NY.=/V+5%WJJ&ODKZ,AO.0O;,PC&0W9<2SCEPP1QX8Z_.]*@L7/\
MO,]*T6;P\OS<C"$64:QTM)I'4?@ER9-/0N)?%+&X,,K/42" X=(Q^\%91IC1
M.G[[J^YV5C[K$RDBYQLQFC)?O:""WF]WUNOH26E0C#6>%KB.BU)3U?)WL:O1
M9W:M,V*\ZFK+!2U-=0US))(J>6H<R6.5S"=Q :TMR!GI6*7^T5=BNU3;K@P,
MJ8'8=@Y!'$$'J(P5N%:,Y8?'G\C$Z,H1Q>'+YEO1;#Y*]&VG6$=?'6R5]//2
M!KBZ&1FR\.+N@MR,8ZRK58*'35SKVTU3#>*-DKC%'/X1'(SG,'9:[^#&,K+T
MB.*4;/\ +S-+1I.,975I<C$46R^3S0MGUA8JE[:RLI;K$2P-<]AC>[&00-G.
M.L96,VFP10ZM\2:CAJX9.<YHF![6EIZ#O:=H'=U<<HM)@W*/C'F'HTTHR\)<
MF8TB^M08G3O\&9(R(GT&O<'. ]9 &?<LLUYHJ;2U!9:B0O=X93@S9_\ ES<2
MWV8(]Q7252,9*+YLYQI2E&4ER7,PY%D_)W9:#46I:>TW$U3!4!VQ+ ]K=DM:
M7;P6G.<>I933Z#LM;KBY:8IZBXP5%-'MQU,CF2-><-)!8&M(^MU]"Y5-)A3D
MXR\%?Y'6GHLZD5*/B[?,U>BV'H;0]#=]5W73]WEJHZJB#SSU-(W8=LO#<8+2
M>G.<_@L1U/2T=!?:VBM[:@0TTSX=J>0.<\M<1G<T8X<-_M6H5XSFX+GS,SH2
MA!3?+D6I%FW);IBV:MNL]NN#ZR&5D)F;+!(T# +1@M+3]KCG\%%!8[#/KZ:Q
M5#KC#1MF?3-GYZ,N#FDC:/H8V3CAT=94>D14I1\4KECH\I1C+P;LOB84BSGE
M)T(_2-;!-3OEJK//CFYB1M ]+20,9Z0<?N5GOEMH&NM$5DAKGU%="R79FE:_
MTG.+0QH#1TCCZ^"L*\*D5*/)DGH\Z<G&7-&/(LXU5IBVZ.CHZ6[.J*Z[SQ\]
M)%!*(HX&DD 9+7%QR#U<%;KC:;.=)"\6NJJ73FK93R4LVSF'+'NSM#ZP.R,'
M X'<D:\9)27)^(EH\HMQ?-<T8PJF_5?[/^:I53?JO]G_ #78X%*(B (B( B(
M@"(B (MDZ1T99;UH6Y7ZH?<8YJ 2;<3)F;,A8P.W$LW9SZ\>M>:/1%'=="SZ
MELD]2SP4N\(I*DM<<-P7;+P!T$'>%YMKIIM/P=OF>K9*C2:\5?Y&OT6RKMHV
MQ4?)U3:FC=<W25 :&P.FCPUQ)&\[&\;E3I#1MDO>B+G?:A]RCEMXDVXHYF;,
MA8P.W$LW9SZ\>M3:Z>%RXV3M\R['4Q*'"]K_ "-;HOH6B6?9IV/PYV&,)VG;
MSN&0!D_@LLY1-&RZ1FMC7.=(RJIFN<X\!*/KM'J&1CVKNZD8R4'S9PC3E*+F
MN2YF'HLHT;ID7JAO-PJ.>=26N#G7Q08YR5QSAH)!P/1))P>'!114=AN%FNT[
M/#*6OI(1+'"^5KV2C;:TD'9!! /#?U]"RZT4VLK7^9I49-)YWM\C&$6RY]'6
M"'DYAU3FZ.,A#?!O"(Q@[99];F_5G@L:JZ"QR:<J:NC;<J:Y0/B_@*F1CVOC
M?GT@0QIZO>.*S#2(SY)\';YFIZ-*'-KE?Y&,HJXFA\K&N>V-I."]V<-]9P"?
M<%G-^T316OD]H]0PW"2KEJIF,:!'L,:TAV=QWDY;QW>Q;G5C3:4O'@8ITI5$
MW'PXLP-$1=#D$1$ 1$0!2.#O8H4C@[V("$1$ 1$0!$1 $1$ 1;)TUHRR770%
M?J*=UR9+1!X?"R9FR\M:#N)9N!SZ\>M>9^B*.NT([4]FGJ1' 3X125!:7 -.
M#LO  X;]X7FVNG=IYV^9ZMDJ6NLK_(U^BV3J#1ECMO)]1:CA=<GR588&0.F9
MACG G>=C>!CU9]2:9T;8[MH&X:AF=<F2T/.-?"R9F'N:T.W$LW [0Z\>M-KI
MX<7&U[?,NQU,6#A>U_D:V1?5D9GJ1'3,>3(_9C9G:<<G</65E/*-H^32%?10
M[;I(JBG:_;/_ )@&'@>K.\>HA=G4BI*#?%G!4Y2BYI<%_)B*+*=(Z9;=K3>K
MM4B=]);(@XPP8#Y7'. "0<  $DX.Y4TM'8:ZP7:KB\,IKA1QL>RG?*U[)&F5
MC20[9!! =P]8/00LNM&[2\++ZFE1DTGG=_0QA%LNX:.L%'R>TFI__BCS4%K?
M!_"(Q@EQ!]+F_4>A8S<*"R.TW+64(N-/<8IHFNIZJ1CVF-[7.#VD-:3P'O'6
MLPTB,^2?.WS-3T:4.;7*_P C&D7JM=)X=714YEC@:XDOED^K&T#+G'V $K9,
M.A--7O2MPKM+7>KJ*ZWQE\K9V!K78!/U< C.#@Y*M6O"E;%_?B2EH\ZU\']^
M!JQ$1=C@$1$ 1$0!91H+_/:K^C'[UBZRC07^>U7]&/WK\;_R'_XVM\/Y1^W_
M ..?_)T?C_#,V1$7\=/[,$1$ 1$0!$1 $1$ 1$0!%>Z*PR5.FZNYC:VHGC8;
M]IH^L?V_L*L\'-B9G/AYBSZ080#CU9725*4,+EPOQ.<*L9XE'C;@RA%ENH=)
MQTEM;76N66>)N^5K\$M'7N'1TJR1T]&^U-FV:@5!F$1],;'#.<;.?PS^*Z5-
M%J4I89\.%SG3TJG5CCAQXV+:BRVU6*TW*]U-!!)6;$#2>=+V^D00-PV>&]6^
M6CM3&W%O_C!/2.P&F1N)&[8:3G9W'>M/1)J.)M6X]N9E:7"4L*3OP[\BQ(LH
MU58J&S4=+)"ZIDDJ,D;;VX;@#CAN_BO)1V1C+(^[7)[VTY.S%%'@.D.<<3P'
M<I+1*D9NF^:5W[D6.ETY051<F[+WLL2*\VNDMMQDDC+IZ:5K'/:TN#Q)@$XS
M@8.[UJXTMBMTNEY+NXU8='D&(2-P2#CCLI#19U%>+7)OZ<Q/2H4W:2?-+Z\C
M%464:2L5#>XJKGG5,3X,'T'M((.?]7U*BU6"FO5MJI[>^:*HI^,<I#P[=D;P
M!C@>A6.AU)J+CQQ7M\N9):93A*49<,-K_/D8TB]EGHG7&YT](S.97@$CH'2?
M<OI?K<ZUW:HI#DM8[+">EIW@KCJI8-9;A>QWUL<>KOQM?Y%O17NDHK:^.V1R
MNJGU56X!P8]K6L!>6@[P<G=P5RNEBM-NOE/;YY*S9F:TB4/;Z))(&1L\-W%=
M8Z+.4<2:MP[\CC+2X1EAL[\>W,Q)%E<=BMSM,RW8FKS&2TQ"1N\[6SQV5:C3
MVZ6V5,L0JX:J-K7L9(]KFO:7!I((:.M26C2A:[7%7^18:5"=[)\';YEI1939
M[%05NG*JY2&J:^G#MIC7MPXAH.[T=W'UKS6ZQ0WFAGEM4DC:F#>ZGF(.T.C#
MACJZEK9*CM;C=71G;*:Q7X6=F8^BEN&O'. D [P#@K*Z[3=)Y.FXV^6=TK&L
M?)%(0=D%H<> ' .!7.E0G53<? Z5:\*3BI>/ Q-%=--VV.Z7%D,[W1P;@YS>
M.2< #\?V K[:DM]%:;N:2,5$C(P"\ND:"[(SN]'=^U%0EJ];X7L'7CK-4N=K
MEE195J:Q6^RT])(PU<QJ,G!D:W  '^KZU3J6Q4%JME+40NJI'U(]$/>W#=V=
M_H[UUGH=2&*]ORVO\^1RAIM.>&U_S7M\N9BZ*N$QB1IF:]T?2&.V3[\%91J:
MQ6ZR^!X%94&HS@"1K<8Q_JG/%<J="4X2FN2Y_,ZU*\:<XP?.7+Y&*(KK745*
MYM#XM,^W.XQOCF(RQX(&-P'6OO=:"AM5S-#5,JG[(;MS-<!G(SEK<</QZ$="
M2NWR5N/Q"TB+LES=^'PX%C17ZKH+72"L=)+42ADC8X!&YHVP6Y+B2"O=>;%;
M+7;J"KD-9(RIQEK9&@MRW/V=_P"Q=-DG9NZX<_K8Y[7"Z5GQY?2YB:*_4]@\
M87^2BMLCC3-:U_/2;\,(!R<=._@OD^&T,N9I#X480_FS4\XWCG&UL[/#\>"Q
ML\TKO@KV^9O:8-V7%VO\O[X<RS(LAJM/MMM_IZ&XND?3U#@V.6' )R<9W@\.
MD*O56FO%,<531R.GHG@>F<$M/KQT'K6GHE51E)K]/,RM,I2E&*?ZN7O,;17.
MJAH(J6BF9'5$S!SGM,K=P!(P/1]65>-26.W65E&X>&3^$9('.-;C&/\ 5/6H
MM&DXRDFK*U_GR*])BI1BT[N]OES,417UMII:VIMT-M?.Q]0]\<K9\$QEN">
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M&X5$%7=+,,N?"_;R&#>,\=[,'VA:E?>P;"^U-MM$R)TW/\ZTR<YM8(&_;P0
M2 "/VY5VT;KNNTE25,%MH:"05!'.NG$CB[&<;@\ <3P"]&D4:DWK(_J35O@>
M?1ZU.FG3G^EIW^/]L>CD[U5<-&\[<&4PJ;54R"">,NP=L#((/0<$^H[UF.J[
M;I76.D+EJ+3D0H[A1 23QANQGK#FC=DC.".)"UY2:I%/;*ZW.M-!)0UDXG?"
M=O\ @R!@;!VLMQOWY/''!?)^HWPV:>U6RECHZ*I>U]1A[GOFV>#7./\ -'4
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M*?;E_?>6^Q_Z:H/ZQ'_>"R#E,_T[#_5V_P!YRQNWU7@=7'4-ACD=&X.:U^<
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M*_R1E_\ D-%_XLZU1$7[!\^$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M(@"HF_0O]BK5$WZ%_L1 MR(B['$(B( B(@"(B (B( B(@"(B (B( B(@"(B
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MJ)I(HXYA+(UIYP@-)'1QW\5F?*)J.]Z2TC)>XZ>W57@P9X1$2]N2YX:"P_\
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M^01$4*$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!:1^DG^DT][*C_IK=RTC])/\
M2:>]E1_TU[_PS]S'Y_9GY_XI^UE\ONC2BRGDZTD[6%]?0^$BFBBB,TDFSM'
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B +2/TD_P!)I[V5'_36[EI'Z2?Z33WLJ/\
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MC(72&CNI^EKQ['.>D*G^I/P[\,S9**V5%_M%-,8JBY4D<@?S9#I0,/\ LD\
M?5Q7HK[G14!C%;50P&7.P'N +L<<#IPN."61VQQS/6BMCM06AL4,IN=(8Y@X
MQN$H(<&G#B/4",$\ O=2U,-73LGI9630O&6R1N#FN'J(XHXR7%H*47P3/JB(
MLF@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"L.O\ ^(NH
M_P#=U1_AN5^5AU__ !%U'_NZH_PW+4/U(CY'""(B^A/"$1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >^VV
MR6OAJ9F2P114X!D?*_9&\X&.O@KA/I:KIZ2EJIZBCCIZG'-2.D(#LC(Z-V[K
M5D;-(V%\+7$1O<'.;UD9Q^\K/=9_Q T[[&?X97YFEUZU*M3A%JTW;ER5O/L?
MH:-2I5*4Y-<8J_/W^18Z/1ESJYJF*G?2OEIW;$K>=WM/1T<"K91VE]7X48ZF
MF:VF&U(Y[BT8SC(R.LXQQ7LTK>JR@U!!41;<[I2(I(QQD;N&/:,#W+(.4>WM
MBIXJ^UB,VZL?SLKH]^U)C<2>K&<>LGK7&6DZ12TE:/5:_,E9V\?%/X^!UCH]
M&I0=:FG^6]U[O!K^3!H:>2>I;!3CG9'NV&!@^L<[L*Y5>GZVFOL=I=S;JMY:
M!LNRW>,\<*\:6M-="ZW5E-1S2&HF:3,UI+8H@_!W]9P<]0]JN^IWT=OUW+57
MF"H-%+3[##&/K$M#3OR.@G@K5_$9:]TJ7&T9>]MJWA]12T&.I52IP_,O<K.Y
MC=YTA<[/0/JZWP=L32&^C)DDD] PL=69:FM5JFLGC;3]5*^!D@9-#(XG8)X'
M?O"PU>K\/KRKTG*;N[VY8;>YJ[^YYM-HQI5,,%96SO?WWL@B(O<>,NMRBDV*
M:EAC>\11AS@UI/I.WE?"CI1SCO#*>JV,;N;9OS^*N=3*V.Y3N?6OI@]K"W98
M7;0PGA47;4OPBN2;L=+*YY_!K=_Y-Q_L!>J-C'0M;S+Z>W1'G'F7<Z0] 5/A
M4?1>I/QA*\];3S5$1GCK/#(H][F\"W_A4^)4?.KJ7;3ZJ3=-+NC;]AJMU/*Z
M"=DK#Z3' K[W($S\YG+'@%I7D2BDXXL_[8Z:2[3U:Y1_M_F>Z]1MCN$A9]23
M$@_'>O"KC>]T\#3Q; P'VX5N76/(\[YG=')G<W7C0%@KI';4LE(P/=UN:-EQ
M]X*R58'R$QNCY*-/A_$QR._ RO(_8L\7X%16FTLSVQY((B+!0B(@"(B (B(
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M#K&1T$K:K--V6.Z&Y,M=&VO)VN?$0VMKK]OKXJJ#3MHIY(7PVZF887;<8:P
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M6I?Y;]%_[OKOW,6Q4!9]6:CMVE;,^Z7B4Q4C9(XB0,G+W!HW>K.3Z@5>&D.
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MANRT MW9P04!F6G+JZ\VF*MDM];;G/<YO@];'L2MV7$9(R=QQD>HJY$@ DD
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MS7:I-/4T-))5L,4>VR9K6Y&"2,9W=!Z5DG*RZQQ:XAFNXN$SV4T)-/"UC6/
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M.>6"IGBB<Z&G ,K\;FY.!GVG_FMHZ5@BI?I!304T4<,,=75-9'&T-:T".3
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ME7?[#=3:PU]HAAABC$Y+7B(Y9M;LYSQQQ]2QS45R%XO==<A#S#JN9T[HP_:
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M=T0%H\8W/L2;YB/O3QC<^Q)OF(^]7=$!:/&-S[$F^8C[T\8W/L2;YB/O5W1
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M,?QB@^5E_*BL2)A>?V%_<?H:B(OGCW!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MBXB5C=H^W&?Q14HM0GF[,8GQ1D&F^4M][T==-3-LDD%MH8Y'>E4@OD<P D
M;AOXDKQZAY5*S3VG:&\WC2M334M8\,B8ZK9SF]I<"6XW;AT[_4O!]'>AI[GR
M12T5:SG*:>IFCD9G&TT[.0O']*W^)=I_W@/\-ZTH0UNKMXDN\.(R4\I%<RV6
M2YS:8J!:[K)"R.I95,>(N<(#=L8R./LZ,K8Y(:"20 -Y)6%<G%#3W'DKTW35
MD?.0FC@?LYQO:0YI_ M!5SUU,\V=ELIWEM5=IFT+"WBUKLF1P_V8P\^T!<)*
M+EA2L;3=KL^7)_K*BUI;*NMM[=AM/524Q:79)#3Z+_8YI!]XWX5XOE94T%LG
MJJ*C%9+$TO,/.B,N !)P2",[N"Y[Y&ZB70G*_=])5CR*:K<8HR[I<W+HG?\
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MDBADD#W[!&03@#&>I4ZQO4^GK#572&@\.BI8W2S,$PC<&-&21D'..K<KV
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MY/'/X*-)W^VVK36H[=6BL,]UA9"UT4;2V/9=M9.7 G.Y51DJ:7C?^273G?\
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M[LK:>JM=V"PBMI],7*GK=07RJ8V-E.]LK8I7-9$'G&X !H.#DD^KAL_F8O\
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MU:^TJ+X[>]/'5K[2HOCM[UPJB;$LQK#NKQU:^TJ+X[>]?>CO=J$IS<Z$;O\
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MS^G*C4-905%Q:)?!J&@A:XFHEQDN=L[]AHSG''&,A8M?Q7QUSHKI1"AG9_\
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MRV54KZ^F9SDT$M-+"YC<@;P]HZ2-RT'4_P#VIA_7V?X(71)L5.-5-OK,-J?
MW4<@#?KM+VN:2?5@C_B]2Z5:<()<^*N9C)L]=WN--:+75W"ODYNEI8G2R.XX
M:!D^TKZ6^K@N%#3UE)()*>HC;+&\?SFN&0?<M<\N<=?>=.SZ>LQS4/IY*^I
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M (BZC_W=4?X;E?E8=?\ \1=1_P"[JC_#<M0_4B/D<((B+Z$\(1$0!$1 $1$
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M$1 $1$ 1$0!$1 %ZJ'B_\%Y5ZJ'B_P#!9ER-1YGJ1$7,Z!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!:1^DG^DT][*C_IK=RTC])/])I[V5'_
M $U[_P ,_<Q^?V9^?^*?M9?+[HTHB(OK#Y-$*%*A9-(^]NJ317"EJ@W:,$K9
M0.O9(/\ R6:\L<0J]1LO]$3-;+I#')#,.&T&AKF'J<-G>/6L"*OND=4U^F:]
MLU*6S4Y/\+2R[XI1ZQU]1XA>>I!XE4CS5_F>BE-873ER=OD99I&6#3O)O?*F
M[B1C;W)%301-QSDD;2=M[0>C#W8/#("N&A:G3%=KRGJ*">]>$\S,V**6GB;$
MR,0O&R"'D[FYQUGCQ)6':RNMGU!72W.G?<J:JE&7TTV)HVNZF/V@0WU8W='4
ML9I*F>CG$U)/+!, 0)(GEK@",'>.L$A<-G=2,FVTY?\ 1Z->J<HI)-1\[GUN
MHH&UT@M+ZI]'NV'5+&MD.[?D-)''/2O;IS3]9>7330TE7-24V#,::)TCCG@U
MH .\^X<2K,KA07RZVZ$PV^Z5U+"3M%D%0]C<]> >*],E+#:+XGG@XXKRY%UO
M]NU!<*R&6KM%93[6S2TE,8'-(:T'98QI&78 WGK.3O*N')M755INMUAK>=BM
M8HIVU\,H(;]0AH(/\XOV6CIWX6-5%]NU344\]3=*Z:>G.U#))4/<Z,];23NX
M#@J+I>KG=3FY5]55;\_PTI=OX9WKBZ<I0P.UCM&I&,\:O<^-JH9;G<Z2AIQF
M:IE;"SVN./\ FKQRA5T59JFK92'_ ,%1AM%3CHYN(; /XX)_%62BJZBAJ8ZF
MCFD@J(SEDD;L.:?45YR<Y)XK;C>>(RI6AA-CZ F;=N3_ %3I>$CQC/L5E+'T
MS%A:7-'6<,&!Z_4L,TS9JJ\ZAI+=!$_G'R@2;L<VT'TG.Z@!G*MD;WQ2-?&Y
MS'M.6N:<$'K!6P(>4"*Z:7?8]3Q5;G8&S<*-^)G8X"5I($@]I_;O7"49TVW!
M7OV]_O/1"4:B2F[6[^1XN5R]T]_Y0*NHH'B6FCV*>.1N\/V1O(]6<X]2GEN_
ME,O/_P!R_P )BQ-\K:*L;):JNH]'>V79YIX/X../>J;A<JZXR"2XUE35O'!T
M\KI"/Q)5A2P.-N25OMY$E5Q*5^;=_OYGD8QTCVLC:7/<<-:!DD]06;-T[J*S
MT%114-DNCZVM8(ZF9E)(0R,G/--..G VCZL#=G.&4\\U-.R>FEDAFC.TR2-Q
M:YIZP1O!5V.K-1$$&_W8@_\ [Y)^9:J*3_384W%<S*+])++R162GIGG%LKYZ
M>M9&[(#W.+F...C&<%?'7M7X5H71#JUQ?=1!/MN=]<P"3$>UTXP#C\5A=!<*
MRWND=0U4U.9&[+^;>6[0ZCUCVKYU=5/63.FJYI)YG8R^1Q<3CAO*YJC9IY-O
MZ_\ 9T=6Z?O27T/AT*%/0H7<Y(@J"I*@J&D0H*E05#2(*A25"A40H4J%#05*
MJ5*% X*.A2."CH4-(IZ%"GH4(5 J%)4*&D05!4E05"H@J%)4(5$(B*&B%2JE
M2H4@HA1"D%0I*A0T@5254524*@H4J$*BE$10T$1% ?H:B(OG#WA$1 $1$ 7P
MKB&T-07' $;B3^!7W7BO%JI+Q1.I+@Q\E.[ZS&ROCVMQ&#LD9&_@=RJY\0<Y
M_1./_P"<M\'3X(W^^%T!K0@:.OQ)P!03_P"&Y6RT<G6E;/6-JK5:A1U W<Y#
M/*TD9S@X=O&X;BKY?++0WVB-)=(734SOK1B5[ [U'9(R/45WK58U*F-&(1<8
MV- ?17H:2XTFKZ6OIH:FGD;2M='*P.!!Y[H*VM0W"DT52:9TG%+'4W*>44\4
M+7;VP@N<Z0]( :/Q/XKUV[DXTK;'O?;;6:1SQAQIZF:,N'4</&5Z+7H33=KO
M++M0VMC+DS.*ATCWOW@@[W./02%:M6%23EQL_(D8N*L:&Y?B//39M_"*E_Q7
M+I>XUU-;:*:LKYXZ>EA:7R2R.PUH'65B]?R::2N%8^KK[.VIJ7G+I99Y7./X
MER^U?R?::N,38[A;Y*J-OU6SU<SP/8"])U(3C&/'A_<RJ+3;*+3K**?D_FU7
M71B&D#)IXV#<3$U[A&#G^<X!OXN5AIM$ZAK=&U-JN%YMS&W)DDM7&ZVN>]LL
MI+W>GSPR6N. <?S1NW++;AH^Q7"R4MGJZ!LELI@&Q4PD>U@ X9P=^/7E7&GM
M=-3VTT$(F%,6EN#.\N /4\G:'OW+&-1_3F6U^9SS]&^]S:?UA=](7-VPZ9[]
MAI.YM1$2' >UH/\ 8"W/,YOG6I&Y&UXEF..G]/$OBSDQT@RM%8RS-;6!_.\^
M)Y=O;SG:VMK.<[\JX2Z*L,MX%UDHY3<APJ/"I=L#.< [6X>K@MU:L)R<EXHS
M&+2L:UY?^34W>G?J:P1$76F;M5,48WSL'\X8_GM'O'K 5PY"#-J3DONS;G,Z
M6:OJJB.:5W%VU&UI)]:VXK?9;+062*IBM=.VGBJ)W5+V-^KMNQM$#HX<!N6=
M>W3P/PY%P?FN<]?1];-I'E-O.G+VWP:KGA,; [<'O8[(V>L%I<0?4LV^D557
M"P:;IKQ9;M<J*KDK&0/;%4N$9:6//U<X!] </6MB:CTI9-1F)UXM\51+"<Q3
M EDL?3Z+VD.&_J*M]9R?V"X<R+M%67-D)VHV5U=-,QIZ]ESB"?:%MUHRJ*H_
MF10:CA1X>1D5-3H.V7.X7"MKJVMCYR5]3.YX'I.P&@[ANZN*TS]'\CSSWK>-
M\-5CXK5TC+:*%]J%M; (:$-#&Q4[C"&M'0-@@@>Q8Y0\F>D;?5-J:"SMIJEO
MU989Y6.'XAV5(UHI3OXAQ?#W&J/I;$;>F!G?BI_Z:V?:M-45;;M%7H1P0U=M
M@CE=/L@.=&ZG+2TGJRYIW]2N-\T!IF_5IJ[S;!65!_G2S2''J VL >H*).3_
M $W)0MHI*"5]&UNR('5<QC Z@W;QA'5C@C#CP_GYC"[MF/:FFCY3=$:MMUDV
M)88)1!2SM=NGFC#9#@\,9PT'\>"Q'Z+-TCI[?>].U9YBX0U7A @D]%Y!:&.W
M'?D%@S[0MS:>L5LT[;_ ;+2,I*3;+^;821M'B=Y)Z%:]0Z#TY?ZYM=<+<WP]
MN]M5!(^"7^TP@G\5%5CA=/P9<+NI>)=;[>:*R47A-?*6@N#(XVC:DE>>#&-&
M]SCU!7!IVF@X(R,X*L-FT?9K16"LIZ:2:N V14U<\E1*T=372$EOX85\J(63
MP20R;6P]I:[9<6G!ZB,$>T+B\/@:5SF*H<#]*4$$8\8-'_\ B 74!.!D\%AO
MFQTAX;X9XF9X7M\YS_/R[>UG.UM;6<YZ5DM5:Z2JM+K;4,D?1O9S;FF9^TYO
M479VC[]ZZUJD:F&W@K&81<;F$:<@O5]K[KJ6U76AI:6OE\'IFST)G)@A+F-<
M'"5N YVV[&/YRTS:#-R4\N(IZR:,T%2X,ED8SFXS#+O!#23@-=CI/U2NE=/:
M?MNGJ4TUGIW4U.>$7.O>UO'@'$@<3P5FNG)OI.ZUCZJYVAM74NXR33RO=[,E
MW#U+<*\8MI\F1P;M;F>C5.IH+'>M/T5=S+:.[2R4SGR<&NV<L'5@G=^(6MN6
M3DET\-.W2_6B,6NLI(G3NCBW0RXWD;/\TGHQC?T+9URT98+G0T-%<;>VJI:(
M.$$<TCGAFT,'>3D^KJZ%\'Z%LDL,<%6RNJZ.,@LI:JOGFA&.&6.>00.HY"Q3
MJ*FTXMK^2N-^#,,T ZM=]'><W+;VQ;:L1%_'FME^Q^&.'JPL7^B/^AU2/]:F
M_P"JMX7JPVZ]4 H;C3F2C QS+9'QM(QC!#2,CU'<K39>3_3-CJ346>V>!3$8
M+H9Y6[0ZCZ6\>U:UT7":?^3)A=T\BUUD=RU%KNHEL]PI:6"PQ^#!\]*:AKJB
M4!TF 'MP6L#!G)^NX+2W+%;+MH;E%M6J754%3/4O$_.04Y@89(\!S2W:=Q;C
M)SOR5T38M)V:PU4U1::1]/+,XNE(GD<)''BYP+B"?6=Z^.H=$:>U%4B>]V_P
MV0?5YV:39;N ]%NU@<!P"M.NH2]UK"4&U[R[V:XT]WM5'<:)X?35439HSZG#
M/O6$\OM%+6\E5Z; "YT0CF('2ULC2[W#)_!9?I^PV[3U#X'9Z<TU+G:$0D<Y
MK3ZMHG'X+WU,$533RP5$;9(96ECV.&0YI&"#^"X1DH34EX&VKJS,=Y,)&R\G
M>FG,.1XO@'XA@!_<M":!:Q_TE[DUX:YIKJ_<1D'](MZ:4L,MBMTFFYF2SV=N
MV:2I9(6N9&3GFGD$.#ADX<.(ZB-_RI^3'2%/5MJZ>S,BJFNVQ,R>5KP>O:#L
MY7>%2,'/WF'%NWN,"^E3#%'HJU&.-C";@/JM _\ ER+.^18YY+M.X_5O_<5<
M;_HC3VH9F27NW^&N8 &"6>0AN[&X;6!P_%?:U:2LUHML]OME+)34<PPZ*.HE
M &_/H^EZ/KQC*RZD724/&Y5%XKG/?) UDG+]>&R-:YIEK<!PR#Z964_2MBBB
MT]8N;C8PFJ?]5H&?06QZ3DQTA1U;:JCLS8*EIRV6*>5KP>L$.RO9J#0VG=0U
M0J+W;O#91N;SLTA#=P&X;6!P' +H](CK5/CP,X'A:/ER4'/)MIK'ZA%_="TI
M]+(CQYI\9WBFD./^(+H'3VG[;IZD-+9Z<TU,3GFN=>]H]@<3CCT*SWCD[TM>
M:QU7=K4*RH=QDFGE<0,YP,NW#>=PW+G2JQA5QOD:E%N-C(;,<VBA(X<PS^Z%
MJ/Z34#Z^T::MM.-JIJKD&1@<2=DM_>X+;-FM-'9J,4MNC?'3M^JQTKY W=C
MVB<#=P&Y6 V.6^:NI+W=H##2VMKVV^F>07.D=N=,_&X;@ T<1Q.#N&:4E">/
M(LE=6,L:-EH'4,*41<301$0!$1 $1$ 1$0!6'7_\1=1_[NJ/\-RORL.O_P"(
MNH_]W5'^&Y:A^I$?(X01$7T)X0B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@,AI-+35592TD==1>%5$0F;%E^6M+=K>=G ./6OE4:=?!X<UUPHC)1$":,%
M^T!M!N1Z.\9/0O?R<2/EUE2.D<7.V'C)Z@P@?L5OU;(]FI[N&.(#YG-=CI&<
MX_8OR8U:[TMZ.Y\HJ7)9V?8_3=.BM&UV'G)KF\N'<^]WTI56RU1W&6JI9::3
M&PZ(N=M9&1_-W?BK?6VHTM-32FKIY'U#0]D+ _;P3@9!;N_YK,N3JN966V>S
M79K7T,KMB$O.,N.\L'NSZOQ"Q+4E/66W4%0RK>14,?M-D;N!'\TMZAC&.K&.
MA9T72:TJ\M&JR_-'C_\ Z7A]/'^VND4*4:,:]-<)</@_'T+EY$7$VR6KBFI)
M7Q#,D$<FT]OJ.-V?5E6^P:<K[Y(12"-K ,N?(\# Z\<3[E<=+W#Q!;*^NE<>
M>JX^9IHOMG.]Y]0X>LY"N/)*TMO=>UP(<*8@@]'I-7.OI6E4*->;:>&UG;ZJ
MU_#,Z4='T>M5I02:Q<U?Z>'B8;;Z&>X5T5)2,VYY';+1_P _8O;76.>GH9:N
M*6.HIX9C!*Z//H/'7D<#T%9!R4-8[4]07XVFT[RSV[31^[*NND8X9=/:C958
MYDU)VL\/5^W"NE_B4Z%622X1P_/$VGZ>\FBZ!"M33;XRQ?+"O[<Q*+2]:]T,
M.U&VMG@-1'3'.VYGNP"<'=ZE8B""0001N(*VW<=W*I:\?JA_=(M<:K:QFI;H
MV+&P*A_#VG*W^':?4TF:C/QBI?"[:M]C&G:%"A%RAX2<>R=RU(-YW(JHB!(P
MG@"%^P?EERNT4G.QTT,;W,IXPT[+2?2.\E?&BIF;3O#8:H#'H\VS]^5<YY6Q
M7&L#Z]],2X$ ,+L[AO3PIG;4GP2N2;M8Z65SS>#6[_R[A_8"]C SFF.?"^GM
M]/Z>)/K2NZ-RH%4WMIWP5YJR":0-J?"_#(&.!=CBW\%/B5)7/E5U#@9)I/\
M.9^ ^PU>.AG--5Q2C^:X$^SI5=Q:X5+G$Y:_>T^I>56BDXXLS>D-J>#DH_V_
MS/7=H1!<9V-^KM9'L.__ )J_\E5R=:N473U4UVR/#&1./^J\[#OV.*LU^_TB
MX=+6-!]N%]-),=)JFS,C^NZMA QU[86FKPXY''E([X1$7SY[0B(@"(B (B(
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MVF=U1 TXYSFGM:3U N !_!71)1<7:2LQ&2DKQ=T$5,L@BC<]P<6M&2&M+C^
M&\_@K+0ZLLE=;:ZOI:YKZ2BSX0\QN;S>!G>" 55"4E=(CG&+LV7Q%X[-<Z2\
MVV"OMLPFI9@2QX!&<'!W'?Q!7L4::=F5-25T$14MEC<Z1K7M)C.'@'ZIQG?U
M;B"H4J16O3]_MNH::6HL]4*B**0Q/<&EN'#VCUC>KHK*+B[25F2,E)7B[H(B
M*%"(B (B( B(@"(B (B( B(@"L.O_P"(NH_]W5'^&Y7Y6'7_ /$74?\ NZH_
MPW+4/U(CY'""(B^A/"$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!>-+WB
M.QW%M:ZE=42L!#!SNP!D8.?1.5\+U7P7*[2UHIY(A,_;D9SH=OZ<'9W?M5N1
M<-FIJJZUOS-6O=\OL=M?/5ZJ_P"6]^2YEWKKI3S24!I:6:ECI  UK9P23G.T
M#L[G$\3OX!7346J:2_.IGU=I+9("/2;48+V]+3Z/_P"18HBYO0:+E&5N,;V=
MWX\_$VM,JI2C?A*U^"\.7@9QY;T +'#35'ML :QQ<"6XX?S.A6K2VI&6*HJ*
MDT;ZFHF:6N<9MD8)SPV3^]8XBYQ_#-&C"5-1X2Y\7X?,Z/\ $-(<U/%Q7+@O
M(N=MNKK7>(Z^W,='L'(9(_:R#Q!( 7JJ[_M6NJH*&!T$-5.9YBY^T3PPT;AN
M&%8D7>6BTI24Y+BK=N7QM[SC'2:D8N*?!W[\_J90S5TOA=-7RT^W<J>G-.R4
MO]$\<.+<<=YZ=ZQF1[I9'R2.+GO)<XGB2>E4HK1T:E0;=-6_O+X<25=(J55:
M;N$1%W.)<KD/":6GK&[SLB*7U.'3^(7FHJR6C+S$&':X[3<JJWU8IW/9*W;I
MY!B1G_,>M5UEO=&SGJ<\]3'@]O1ZCU+*X<&:]Z/KXZJ>ED'PU[:>>-T0KX8V
MLV3L5,31N+3TX6/KTT56^D>\L#7->TM<UW A1P5N 4LSW5\#(2^!SAS>.<@>
M>D=2\MII^?JVE^Z*/TY#T !>JD#KA;O!BQQDB=F.0_5:.D$KY5E1%3TQHZ)V
MTTG,LOVSU#U+,8X;I'2<\:3?@>.MF\(JY9C_ #W$CV="S?D,LSKSRFV9@:3%
M2R&KD/4(]X_^K9'XK EU3]&O1C['IV6^5\196W,#FFN&]D WC^T=_L#5G2*B
MITV9IK%(W(B(OPSUA$1 $1$ 1$0!$1 $1$ 5$WZ%_L5:HF_0O]B(%N1$78XA
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!>JAXO_!>5>JAXO\
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M;Q4913=FTEPY>/$QAK1G)*Z3D^//PX?WZGSMFL+]>-8W*RT!M\<3*1M5!--
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M5#Q?^"S+D:CS/4B(N9T"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MRR*>+:@:.;;Q:.CIW+S-O.DZZCH(KG1WX5$672"EJ(6QNE<<O?AS"<G<-YX
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M*&>: $<?X1C"TXZ2"<+2'*/07VR::UKJ"HA?:(]47"EIA2![2^* !VT]Y:2
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MB( B(@"(B (B( B(@"(B (B( O50\7_@O*O50\7_ (+,N1J/,]2(BYG0(B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B +2/TD_TFGO94?]-;N6D?
MI)_I-/>RH_Z:]_X9^YC\_LS\_P#%/VLOE]T:41$7UA\FB%"E0LFD&N<Q[7,<
M6N!R"#@@KZS5E3.S8FJ9I&<=E[R1^U?$J%EI&DSZP5513M(@GEB!WD,>6Y]R
M@UE283$:B;FCQ9MG'N7Q4*61I-GI\85O.LE\,J.<C;L,?SKLM'4#G<%1'75<
M41BCJIV1N&"QLA (]F5=+/IZ6Z6:ZW&&JIVLMT8EEA=M;9!.!C=C]JL?2L)Q
M=TO Z6DDF_$^U+55%(\OI)Y8'D8+HWEI(ZMR^+G%SBYQ)<3DD\2BNEAL-9>C
M4NIN;BIJ5G.5%3,[9BA;UN/KZ ,D] 2345=EBG)V1X8JZKAC#(:J>-@X-;(0
M!^&5\JBHFJ"'5$TDK@, O<7$>]9!2:6?<VSML5QI+C4PL,CJ:-KV2/:.)8'M
M&U[ <^I6FRVJHO%R@H*0Q-GF>(V\[(&#). ,G]PWK"G#B\CIAEP69Y:>IGIG
M.=3321.<TM<8W%I(ZCCH4R5M5)%S4E3.Z+&-ATA(]R]5PM4E#?I[5/-")8:@
MTSY2XB,$.V2[)'#UKVWC2]7;]1-M$<]+62R-:^.:GE!B<TC.UM'<  #DGA@J
M8HE49%HDK*J6+FY:F9\?V7/)'N4FXUIF$QK*DRANP'F5VT&]6<\/4LFKM#5$
M=AJ;K;;K:[K!28-4RCE<Y\(/200,CUKY6O1;ZVW4]747^P6XSMVV05M48Y=G
M) ):&G .,CU+&MIVN=%3J7L8TZMJG0\RZIG,6,;!D.SCJPLEY+[M06'5M/<[
MK.Z*G@9(,,C+W.+F.;N ]N5;=5Z>FTY704T];15AF@;4-DI'N>S8=G9WEHX@
M9]A"LBK4:L&ER83E3FF^:/57U$TKQ%)6R5<47HQN<YQ 'J#N"HEK:J5FQ+4S
MO8-X#I"0O.G0M61+L]+KC6NE?*ZLJ3*YG-N>97;1;]DG/#U*@U]60P&JJ"&$
M%H,AW8ZMZ^'0H4LC2;/5XRKLEWAM3M'<3SKN]?,UM5S3HO"9^;=G+.<.#GCN
M7P*@J61I-GW-;5&E%*:F<TP.1%SAV,_[/!4TU94TFWX+4S0[8P_FWENT.HXX
MKXJ"I9%3)ED?(09'N>0 T%QS@#@%]8*VJ@9L05,\;..RR0@>X+X%0C14S[^&
MU7,LA\)GYF-VVQG.'9:[K Z"@KZQL\LS:NH$TH+9)!(=IX/$$YWKSJ%+(U<^
M]-6U5*R1E-4SPLD&'MCD+0[VXXKS*I4H4]-MKJJV5L-903O@J87!\<C#@M(6
M8ZMUG0:S@@FOUOFI;O"P1^&43PYD@_UHG8W^L._Y+!1P4="Q*G&3Q/FCI&;2
MMX!^R'.V"2W.XD8)'L261\TCI)7ND>[BYQR3^*IZ%"I$?6"IGIG%U--+$XC!
M,;BTGW*N:OK)XS'/5U$D9XM?(2#^!*\Y4*61I,]--<*REBDBI:NHABD^NR.1
MS6N]H!WKR%25!2Q2NIGFJ9C+4RR32NP"^1Q<XX&!O/J"^2DJ$*0B(H:(5*J5
M*A2"B%$*05"DJ%#2!5)515)0J"A2H0J*41%#01$4!^AJ(B^</>$1$ 1$0!8+
M6Z/K[9K.JU/I.HIF3U[&QW"@J]IL-26_5>'M!+'CKP0<G<LZ1 8)==-WK4FI
M=.7*["WVZ"RU#JEL5/,^I=.XMQC)8P-'X%?.W:6O5-RLW'54GBXT-71MHN9;
M._G&M:YIV_J8)]'AGIXK/T0%EUGINAU;INMLMT#O!JEN-IGUF.!RUP]8(!5E
MT_3ZUM%OAMM6VRW1L#1%'7OJ9()'M&X%\8C<"[''#MZS1$!KOE)TA?\ 5%@M
MM!3U=ODJ*>OCKI9IRZ)N6;6(V,:UV[>-Y<3[5]M9Z,N%SN]IU+IZ>EMNJ*(A
MDA>YSH*F$_6BD(:"1U''_(C/D0'@K'7,V>0TD5(VZ&,[#9)7&%K_ %N#<D#C
MP&?4O)I"V5%HTO0T%8(7U<,6)G,D+FRR'>]Y):#Z3B7'=T]*O2(#4]@T%J*T
MZ0UAIR.2U&WW4U/@#!/)_P"#;,"TL/\ ![P 0=V-^>O=<J_1][J*'0<+#;0_
M3TL4L^9WXEV(^;PW^#Z1OW^SUK8R(#7<>C[]3W'6K**OHX*&_P"U+#4M+_"*
M>4P[&-D#& 0#M9SNX;\BWT.C-51-T/)*^Q1R:=<Z,Q1&79E8Z(QF3:V?K=.S
M@#.?26U$0&G*6EOM_N5VOUCH-*W6V5E4YL<M7+-"^2.([+0]K0YKL.:2"[?T
M[MP&1>*+A>KQ8=:VYE-37>"GDHZJDEE+H:B$N.YLK6DX#AMM=L[P1D*]NT%I
M9UQEKC8:'PB5VW(>;]%[NLL^J3ZR%DS0&M#6@  8 '0@,&K-(UM9+J>ZRFD\
M<W:@\701\X[FJ>(-<-[MG+B7.+CZ(X #K-LK-$WR;2NA+6QUMYW3U72U,SS.
M_9E$#"P!O\'NVLYW\/6MF(@,(MNF[Q3:]U'?'NH64]SI8J>(,F>9(C&UP#B"
MP Y)Z]WK5NN>@:J^7*VW&X,M]#=8*6:"JK:-SBZKVX3'AP+6^CEVUO)(P .M
M;(1 8QR<6F[6+2E!:;TZA<^AA931NI'/<'M8,!Q+@,$C&[&[K.=V15E/'5TD
M]-.-J*9CHWCK:00?WKZH@-4>2UUK>2]NC:6L@I[M:I8V$3Y$55 R3,>UC?L/
M8 #C.\.;T%7BDT]J>+7GE'*;,X2VH4,E.Q\C1&YLA>W9=LG:!SO) QU;M^>E
MC#()"UNV 6AV-X!QD9_ >Y5(#4HY.[ZWDDM6D6S6PU='4LE=.9I-AS6S&48&
MQG)X?M]2R5FGKU2\HU5J"C=;G4=?10T]1'*]^W$Z-Q/H8;AP.<9.,<<'&#FJ
M(#"=":4K+0S4<5]BMU3!=;K-<FLC<9 WG"/0<', .-GC^Q5\H.DI[OI1]NTW
MX%03>$Q5#HW1[$-0&.!,<FR,[)P,[CPPLS1 :XETOJB35==>GOLI\.L_B^2$
M/D:(G!SB-D[)VAZ6\D#V+R3:#OCM Z1L+)+9X39:VGJ9)#-)L2-A)(#?X/()
MST\/6MI(@-37:GO.H]8WBLL%+IRXP40;;)!6R2PR1N VI8\Q@[;27#ZPQNP!
MQ)]VHK5>];Z!?:(Z2UVZM@K(V2;-0YU.!"YCQS9:S)&[9P0-D@C?A93<=#Z:
MN5T?<:VRT<M:_'.2[&#)C[6-SOQRK]3014T$<%-%'##&T-9'&T-:T#H ' (#
M$*G3-PIM<-U3:32FHJ:,4=?132N:R0-.6O9(&D[0X;VX(ZE;KM0'2UDU=J"M
MJZ:.\WIS&!Y9SD,;MD0P1@.QM $C). <DD !;$7FN5!272AFHKE30U5),-F2
M&9@<UP]8* U1#8+];+8VWW:PZ:\554/BQ[Z"LFY^.*;#'<TV1N.G:+01G"O^
MC[%K6UV^ELETN=IDM5(&Q,K8&R"KEA;]5I!]%IP -H$G'KWK)+%I"P6&82VF
MU4U-,!AL@;M.:.H$Y('J"OJ PRU:?N]#K[4E^(H'TURIX(H8^>>'M,0< 7>A
MC?M=&<>M8I!R=7^'DSL>F!+:G5%ON#:QTQGD#7M;,9  .;R"<X_!;>1 :]N.
MF-36[6E9J+2=3:__ (K%$RXT5>9-C;C;LMDC<P9SC=@@9_==M3MKXM&5=M=.
MVMOEQADIHMANPTR2 @D-R=F-@.3DG &\DG?EBC VMK SC&4!X=/6R.RV&VVN
M!Q=%14T=.UQXD,:&Y_8O>B( B(@"(B (B( B(@"(B (B( B(@".^J?8B.^J?
M8@+6B(NQQ"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"]%%^E/
ML7G7HHOTI]BCY%CS/8B(N1U"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M'O3:;]H>] 2BC:;]H>]-IOVA[T!**-IOVA[TVF_:'O0$HHVF_:'O3:;]H>]
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MZQ[T!**-IO6/>FTWK'O0$HHVF]8]Z;3>L>] 2BC:;UCWIM-ZQ[T!*]5#Q?\
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M^ WN3R5L/8UO^ WN5Y1 6;R5L/8UO^ WN3R5L/8UO^ WN5Y1 6;R5L/8UO\
M@-[D\E;#V-;_ (#>Y7E$!9O)6P]C6_X#>Y/)6P]C6_X#>Y7E$!9O)6P]C6_X
M#>Y/)6P]C6_X#>Y7E$!9O)6P]C6_X#>Y/)6P]C6_X#>Y7E$!9O)6P]C6_P"
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M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %8=?_ ,1=1_[NJ/\
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MYV6G=O R<#HR5\K;8[3:Y'/MEKH:-[A@NIZ=D9(]9 "N")=BP1$4 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5
MAU__ !%U'_NZH_PW*_*PZ_\ XBZC_P!W5'^&Y:A^I$?(X01$7T)X0B(@"(B
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M(%N1$78XA$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!>JAXO\
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M0+<B(NQQ"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"]5#Q?\
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M"H@J%)4(5$(B*&B%2JE2H4@HA1"D%0I*A0T@5254524*@H4J$*BE$10T$1%
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MOW<%;%$[FK6"I52I0H'!1T*1P4="AI%/0H62QZ<ADT%/J)E:\R0UC*-U,8L
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M+"YXC=/"8F B)QW;60/<>I:-*R/2-UM%%276CO=-5.CKHV,;549;ST.R[:(
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MIB?!-CCD,> 3^&5K+Z+=M9Y-7:]3YDKJRL,;I7G+BUK0>)ZW.<3U[EY_I34
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M''(CE8[?L]0(SGU@+Q\FX'^4I=-PW5==C_ZUK9E%R4O!7)K+VL=$WW4-ML5
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M=8J,55VJF4\3GB-F02Y[SP:UHR7$]0!*LM?K^P6R,ONT]5;F[)>WPRCEAYS
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MS>%25,Y;)$(HX&ES(0,8*Q*7!M^!TI0Q245XGEKANVYB75,AVW;_ *HZE]J
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MX55)+#323Q34L@&2&$@GB"-P6J/HZ7N^:LJKO57V^5]2VA,(CA+P&.+]O)<
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MM=4,54;IWS-^R]^'D?@78_!;XT5<::T\E-BKZ^5L-+3VF"21[C@ ")J^VIM
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B *PZ_P#XBZC_ -W5'^&Y7Y6'7_\
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M/%_X+RKU4/%_X+,N1J/,]2(BYG0(B( B(@"(B (B( B(@"(B (B( B(@"(B
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MT-1$7SA[PB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M+]*?8O.O11?I3[%'R+'F>Q$1<CJ$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M\RCS6ZR[%?\ 'B_,FTT>M?5&MFK=#^C,)4=*S;S6ZR[$?\>+\RCS6ZR[$?\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M34/#(86&1[CT- R3^Q6/Q_*Q]M=44[88ZZ.65K7$[4+6,VPY_P"&,@<"0,E
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %8HZ&\B[OJ9*N
M@,#GX $#S(V/.=AI+L#.-YQO_ 8OJ(#X4;:EK9?#)(GN,CC'S;"W#,^B#DG)
MQQ*^Z(@+1=K2^HNE!<Z21C*RD#V!L@);(QV,M.-XX @[_85X:VQ5U94W*M=4
M0PUE31^!0AH+FP-))<[.XN))'0. 62H@/):*,6^U4=&T- IXFQ#9X>B,?\E;
M*&T5=KN%QDMTE.ZFKIC4.9,"#%(0 XC'U@< XW>U7Y$!CCM.R55RND]SFCJ(
MJRC%&T!N"QF7$^K>79]6!QXKUTEDCEM5#37N.GKYZ5@8)7,XD #:P>!.!E7A
M$!C-;IVIJ::[-\*BYRLJXZEN6'&RPLPQV_@0S&[K*BNTW55S[J:BMCV;@R&)
MX:P^C&PY<T;^!!=_:RLG1 8OJ:.6:LA92N@IWT<1E9SP<ULP<'-+&N:0X8 &
M<9XMW*:2Q.?74]P93TT$<E%%":2:/:\&+278;C=_.Q[0"LG1 8_56":J9J%L
ME6&>,V")CF,WQM$8:,[]^_:/_$5\ZFP5$UJIX&&BAEBGAF+(XR(Y.;(.''.3
MG ]F!Q62(@+39K944=PN=555#)G5<C7#986[(#  WCP!!Q[5XZ?3SS3OIJR9
MCZ>2L?63;#<&=Q?M-:[J ]$8WYV1P&Y9$B QJYZ;EKI[J]]2S9JWT[F-+#N;
M$6NV'>HD._M>I5W?3\ER;62OFC%54,CA&02QD+7ASF#I.UOR?9U+(D0&/NL,
MSI+NWPD;%S+.=D P]K0P,+6]&\ X/1M'<5:JZE)N)?3T]/)31F*B=;I YKWL
M8_<\8."!M9 <",#B,E9JB QFJTY432UDPJH^=DKXJV,%AP1&&@,=OX>CT<"<
M[U[KS;:JZ6^6DG=3.BGB>R1A:<-<<;#@>/HX)Z,D]&%>$0%GO=IEN&G76UE3
M_"[,8,L@SM[+FDAV.AVS@^U?&.T5WAMVJY*R+GJNF;#%LL/\#LAV,;^&7$^O
MU*_(@,:?IV=]LH*!TT+8J00&*1C2'Q.C.\MZ\M]'W\<X7MM%LJ;?-6M$T;J>
MHJ7U.ULG;&U_-ZMQZ>K=CI5X1 8];-.FGH;51U,K9*>W/YQ@:,&5XSLO=U8S
MG&_?OSN42:;,MNO-,ZJ+37NF,;FM_0B3C[3U^[VY$B L,EDFET]56\.I::2H
MB$+G4\9  QAQWG))&<=27*P\_<[=4P>#F&E@?3^#SL+F!KMG> .D;.,'B.I7
MY$!B]RT]73R7DTU;%&+A3,@#S&=J/9:1@;\!IVB?5D^U7*[VJ2MTY+;(I61F
M2,1;6R=G9R,C'46Y"NR(#&[AIR6JCO)\(CY^OBCIVNV" R)HWMX])+_>.I>Q
MEIG\<3UDE0W8?2,IF!C,.9@N)(ZLDC^R/QO"(#&[38*BWZ>?;XY:2.H%,:=E
M1'$02<8#W9.?7CKZ5ZA88F/LD<;FBDM;261$?6>&;+7?@"X^TJ](@,3M>FJ^
M@KA4BN@<]T4L;G<T<M<^4R%[=_$D@'/4.I>BBT_44]+I^ U,;A;272>@?3=L
M%NT-_'TG'?TG/J62(@,6DM?-V.OLU1.V6MN'/R,+(R!E[R=HGU%S?<,+(Z:!
MT%*(]O:DP2YY'UG'B<>WH7V1 8A1:7KZ7Q3(VN@,]#3R1 F(D;;MG+AOXG#L
M_P"TO2=-2B(LAGCBC?<FUYAP7,:  =D</YX#^@9RLF1 8W)IN5T3L5$?/37(
M5TSW,)#@T^@WC_-PS^SZUXJN.6>]OJA#!/%)41T\M#('-DPQY EW'#AOV\.&
M, $%9BB MFH;2+O20L$O,ST\[*F"39V@V1AR,CI'$$>M>:IME97W*W5=:ZG8
MRA+Y&0QDN$DA:6AQ) V0,G=@\>*OB(#&;39;I;K6^EBJJ,SR323R5)C<3M/<
M22&YX@' WKV-M4])?:VY4+HG&MBCCE9*2-ES,AK@0#G<[>-W#BKTB Q2NTI)
M+3;,=1&^>>LCK*V65I_A]@@MC 'U6C  XX Z<Y5SGL[Z^X4M5=)FR,I7<Y!3
MQMPQLF,![B22XC?C@!G@KPB L6EK(^RTD=/(ZGD,0<T3,C(DD!=G+B3Z]XZ]
MZ\[S/6ZOJS3.B;X%1B%CW[]E\CMIQ Z<!C.D<5DJ("P6K3OBVX-DIY\4S*04
M[ 1E^UM.<]Q/#+B03ZPO);]-UU-!9(W5D!%M#P V,X>XM+0\[_K;W>\K*D0&
M(VR@<'6*VB3GFVQ[Y:F0,+1SC6%K>/')>7>O!7LMVG#!06^AJ9FR4U%,9QLC
M?,_:+FEW5@G.-^2 ?4<B1 8YY-E]C?;Y9VN-35^$U;]G]*#+MN;ZL@!OL2MT
MY)4>'N$\0DJZN&9Y<PD<U'L[,?'_ %2?^(K(T0 #  )R>M$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0%<'Z9G^T/WHD'Z9G^T/WHHRHH1$5($1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0%<'Z9G
)^T/WHB*,J/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g863285g93v93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g863285g93v93.jpg
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M-38W8G6BLR6"8X/"\"8X0T3#\2=D982CA?_$ !H! 0$  P$!
M   ! @,$!0;_Q  V$0$  0,!!04( @(# 0$! 0   0(#$002(3%1D1,4%4%2
M!2)A<8&AT>$RL<'P(S1"4S/Q)?_:  P# 0 "$0,1 #\ ^J0
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MKC33+E3Q\Q.QRQ5$&<\W(B(O!>M%145%]QM9S54S3.)9Q.=\  (H
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MF,3AG&\ !
M
M                                                         !@:
M[3<-9K&V:@EE7G:"GE@CBV\%5^,NSZ$14^\REU_V76?V+_X5+HM;K_LNL_L7
M_P *F69G&4P_/P^_=._[ MG]UB_@0^ C[]T[_L"V?W6+^!#T=?PI:+'FL:/3
M4-+K2X:ACF7G:VECII(=O#+%7#\_9A,>@R-[M5)>[35VVY1)+25,:QR,7Q+U
MIXE3I1>I4+T'F[4YRWX?"NO]*5>CM3U5IK,N:Q=\$N,)+$N=KD_<OB5%0ZMH
M+E6NM3H>+2]OBDJ-5.>VCH)53*)$J+_2.7QL1,>I>.%-\^$?8[7<=$I6UDC8
M;E2R(VB<C<NF<Y<+$B)Q7/3Z,9\9\OZ=O%=IC4-+<J)715E'+G:Y%3..#F.3
MQ*F45#UZ)C4VLS&^'-/_ !U;GVMH'2M+I#3L-NIW<[,J\[4U#OG3RK\YZ_X>
MA$-B,/I'4%'JC3U'=[<[,-0S*M5>,;NAS5]*+P,E754%#1SU=7*V*G@8Z221
MW0UJ)E57[D/)JVIJG:XNF,8W-<Y0]5MTM96OIXNZKM6/2GH*1.*S3+P3AXDZ
M5]76<&Y;]+NTWHVQ.KINZKU75DM3<*I>*R2JU."+]%O0B>\Z;H'9JK4<VN;Y
M+%%'AT%FI)7HBP0="RJG4YW'[E7JP:M\*RH@GLM@2&:.14J)<['(N/!3Q'98
M]RY%$?5JKWTS*P^"3^?:F_LZ?]\AU3EMO7>/DTO,S7;9JB/N2/QJLB[5Q]C5
M<OW')_@GSQ0UVI.>E9'NC@1-SD3/%YUWE2T+\?;324$ESDH(H)N>7;$DF]V%
M1,IE.C*^LE_$:C-7#<49V-SEND^7RS6BS6ZV2V"MB@I(&0(Z&9DBJC41,X7;
MTXSTG6M$\H6G=9(K+-6_Z4U-SJ69NR5$\>.M/2BJ<0O7P=;S3Q/?:+Q1UJHF
M4CFC6%SO0GSD]:H<GK*.]Z,U#&VJBJ+;=:1Z2,5>"HJ=#D5."IZ4RBF[L+-[
M/9SO8[=='\GWF#!:$OJ:FTA:KQM1KZJ!'2-3H1Z>"Y$]&Y%,Z>;,3$XET1.6
M"U[_ +C:C_Z=4?\ B<?!Z=*'WAKW_<;4?_3JC_Q./@].E#T]!_&ISWN,/T-.
M.?"BL\=9H6GN2-3GZ"I;X77L?X*IZ]GJ.QG.?A"JU.2:\[NMT")]O/,.'3SB
MY3CFW5QFF7SOR&:AET_RBVS#U2FKGI1SMSP<CUPU?N=M7UGU_?KQ06&U5%RN
MU2RFHX$R][OV(B=:KU(A\,:.CDFU;9(X<\X^N@:W'CYQ,'7_ (55^FEOMLL4
M;U2EIX.ZI&HO!TCE<B9^Q&\/UE.[468N7:8YM%NO9IET2P\IUXU9W9/H_2,E
M;;Z9VQ9ZJM93J]V,[6MPO'&.OK3.#+\GG*;:]8U<]N6":VWF#/.450J*JX7#
MMKNO'6F$7T&A\A^OM):;Y/J.ANMWBI:Y999)8UB>JHJO7'%&JGS4:<@NVHH:
M'E=JM066HWTS;FM3'(Q%1'L5^7<%PN%153[S7&GBN:J=G&.$[V6WB(G+Z>Y2
M=?OT,R&HJK'5UENDPWNJ*5B-;(N? 5%XIP3.>CB:IIWERBU%=H;;9M,5]36R
MHJMC2HC;E$3*KE<(G!#I.M+!!JC2UQM%1C;51*UCE_J/3BUWW.1%/B[2]SJM
M&ZVHZV1CF5%NJML\?7A%5LC/O3<ACI[5%VB=WO0M=4TS\'V-K'4M;IRRMN;;
M%45T$<3I:I(IXVK3HB(JYROA=?S<]!2Y/=6S:QMCKCWEJK=1.QS$L\C7<]Q5
M%PB<41,=*].>!A^5RZ.K=*T%FM$J.JM2S1TD#V\<0N\*23[$9T_K&T7"2GTG
MHRIDI8T2FM5"YT;/1&Q<)^Q#GQ&Q&[?+9G>UC7_*I:-)W".U0P372]2*UK:.
MG5$VJ[YJ.=U*N4PB(J^@Q][Y3KMI3N.?66DY*&WU3MB5%+6-J%C=C.US<)QQ
ME>GJ7&3YST#>*=.4NV7G4=5MB2L6JJ*B1%=X7%V5QE?G8.P<N^O=*ZET%)0V
M>[15=:VICE9&D;T7"915RK43H4ZITT454T;.<\9WM47)F)G+N=HN5)=[;3W"
MVSLJ*.H8CXY&=#D_^^KJ/C7EN_XJ:B_MV_P-.N_!0N\L]EO=IE>KHZ66.>)%
M7YJ/14<B>C+$7[U.1<MW_%347]NW^!IEI;?9WJJ?@ERK:HB7U9R5?\-],_W"
M'^%#&<H?*C8]%2)25'.UMT<B*VCI\;FHO0KU7@W/WKZ"='71MDY%K9=)&[FT
M=G;/M^EMCSC[\'RWHB6;4/*C9I[I(L\U7<HY9G._K+O15^XU6K$7*JJJN$,Z
MJ]F(B'T=>.4;4>G[3'=]0:)DI[4Y6[WPU[9)84<O#<S:F/%T]/!<&YZ-U;:-
M86I*^R5/.QHNV2-R;9(G>)S>K]R]11Y2J5E9R?:DAD3*+;YW)^LUBN1?6B'R
MMR%ZCGT_RB6QK)%2EN$C:.=F>#D>N&K]J.5%]?C)1:IO6YJB,3!-4TU1$OHG
ME%Y2I-#534N&GJV:@D<C(:R.9FR1VW*ICI1>GIZ<+@PUAY=;+=*2OFEMU93N
MID8D4**DDE1(]51K&-3I7@6OPJ_]Q+;_ -1;_P".0T;X*M!35&K;I53PM?/3
M4J+"YR9V*YV%5/3CAGTJ946K<V>TF-Z355M[+:ZOE]J+7=&TU]T=74$;O"Q)
M*K9=OC1KF)GU_>==T[J*@U)8&7:Q2=UP/:NUB+M=O3^H[/S5^WQ^(Y;\*FVQ
M3Z,MUQV)W12UB1H_''8]KLIZVM--^"K>IH-37.S.>JTU33=T-;G@DC'(F4^U
M'+ZD)-JBNSVE$8F"*IBK9ENU^Y=8;!=)[==],7&FK853?&Z9BXRF47*<%3'6
MADJ[EIM,&G+=74MNJZNY5T;IF6Z%4<^-C7N;N>Y,[47;XE7T'&?A*_\ %"I_
MNT/[CMGP=+91TO)C;:V"G8RKK%E=/+CPG[97M:BKXD1J</>97+5JBU3<QQ*:
MJIJFG+6=-?"&M]==(J:]6A]NIY'(WNED_.HQ5ZW)M3AZ4S]AMG*#RLVS2T\E
M'0TD]XN,3$DECIUQ'"U>**]^%QX\87TX/FGE>IXZ7E+U'% Q&,[K<[:B83+N
M*_M53ZLY(K91T/)U8^Y:>.-:JDCGG<B<97N:BN<Y>M>/^ O6K5N*:XCCY%%5
M4S,--T'R[VS4-Y@MEUMS[7-4.2.&5)N=C<Y>AKEPBMST=?W'9#X$O\;:/4ER
MCIOZ-L-7(V/;PVHCUQCU'W+>[KWJTI77:1$<M+1OJ51>M6L5V/V&&JL4T33-
M'FMNN9SEJ>O^52T:3N$=JA@FNEZD5K6T=.J)M5WS4<[J5>&$1%7T&/O?*==M
M*=QSZRTG)0V^J=L2HI:QM0K'8SM<W"<<97IZEQD^<] 7BG;REVN\ZCJML25B
MU5142(KO"XNRN,K\[!U_EWU[I74N@WT-GNT576MJ8Y61I&]%PF45<JU$Z%-D
MZ:**J:-G.>,L8N3,3.79I+ZVJTTV\:>IUO+)&-DAB@D:Q945<+A781%3CP7C
MPQTG)9_A$VZGGDAFT]<(Y8W*Q['2M16JBX5%*?P4+O+/9;W:97JZ.EE9/$B]
M2/14<B>C+,_>IP37/^^NH/\ J%1_Y'"SIJ)KJHJC@57)Q$P^F=;<M5NL+WP6
MJVU%VJ(6M6H<QVR&!53YKGX7+DZTQ]^>!/)ORU6S5UVCM5;1/ME?-E(<R))'
M*OT=V$5%\2*G'QYX&[V&RVZET1!;*:DBCHI*-&OC1O!^YGA*OC5<KE5/BC2<
MKX-4V>6)RMD960N:J=2H]"6;5N[35$1OCS6JJJF8?:VOK[7:>T[-66FTU-UK
ME7FXH(&*["JBKN?CCM3''[DZ\GQ@^^U]VU?!>+D^6MKI*J.5R)TO5')AK4ZN
MA$1#[MJ?S:7]1?W'P1IC_>2T_P![B_C0ST.-FK<E[C#[-T5JZNU'5U,-;IB[
M69L3$>V2M9M;(N<83ATFW 'GU3$SNC#= ?!&K?\ >J]?WV;_ ,CC[W/@C5O^
M]5Z_OLW_ )''=[/XU--[A#['Y'O^&.F_[FW_ !/F[X1D\<W*I<6QJBK%##&_
M'TMB+^Y4.JZ";RD3<GUFBL#M,T]"M*U(9IUF=,C>.%5,*W/W*ABK7R UUQO$
MEQUG?VU#YI%EF;2M572JJY7+W(F/N;ZA:FFU<JKJDJB:J8B(>O@R17"@T=J.
MYT]#)6))/&V"G:]K%E<Q%W85V$_KIQ]!?UOPA*&AK)Z6KTY<(:B!ZQR1NE8B
MM<BX5%^]#LEGME'9K93V^V4[*>C@;LCC9T(G^*]>>L^*>5;_ (DZE_O\O\2B
MS%&IN535!5FW3&'T5KGELM&FXJ6*DI'W"XS0LG? V1&-@1S4<B/=A?"PO0B>
MHSG)3RD4>OZ2KYND?15U(K>=@<_>BM=G#FNPF>A>K@8;3_)CI^\\E-KH*JF:
MVIJZ:.K?7,:G/),YJ.W;E3*IQQA>HJ:<T;;^2+26H;M3U,M=5I3K*Z25J-1=
MB*K&(U.C*KQXFFJ+.S--/\F<;6<SP9+E"Y4[)HVI2A>V6X79V,4=-C+<]&]?
MZN?%Q7T&-O?*/J+3=NANFI-%R4UK>YK7R05[)9(<]&YNU/W]/ ^=N39TE\Y5
MK'-<I'3S3W!L\KW\5>Y';US]Z'U?RKTK*SDVU)%(B*B4,DB?:Q-R?M:AG<M4
M6JJ:)C.>+&FJ:HF60TAJFTZMM+;A9*E)H<[7L5,/C=]%S>I?_M#SK'5=ITA:
M5N%[J.:B5=L;&IN?*[Z+4ZU_8G6?*W(#J.>Q<HE! V14I+DY*29F>"J[YB_:
MCL?<J^,V#X5$]4_7-!!,KNY8Z%KH4ZLJ]VY?MX(GW(6=)$7MC.X[3W<NHZ=Y
M3;]JRFJJS2VC75-!3N5G.U->R%SW(F=J)M7CA4Z\<>DQ='\(2Q(CX[M9KM25
MC'*Q\,;62HBIP5,JYJY^XSWP<F,;R4VU68W.EG5^/'SCD_<B'S7RD3/H.5'4
M$]#(Z&6&Y2R1O8N%:Y'JN4^\RMVK=RNJC'!*JJHB)R^L--ZY@U1I:KO.G;97
M5*P2K"E+-LADD<FU5PJN5N,.SQ7J.>U7PAK?25,U/4Z=N$4\+UCD8Z5J*UR+
MA47TY0[+9*B6KLU!4U#=LTU/'(]N,8<K454]9\1<I7_$/4__ %.I_P#*XPTU
MJB[55$PMRJ:8B8?2&O>6VTZ9DAI:*C?<KBZ-LDL3948R'<F=KG87+N/0B&P<
ME7*+1Z_M]5)#2OHZRD<U)H'/WHB.SM<UV$RBX7JX8,-;N2W3]YY,;9;:BG;%
M534\=2ZNC:G/<\YJ.<Y7+Q5%553"]7V(7^AN3&ET;IV]45MKIIJ^Y1+&ZJD;
MMV^"Y&X1.A$5RKTJ85=CL3$?R91MYSY*4W*G!<-1S6+1EJFO]?"BNED;,V"!
MB(J(J[W9SA51."8X\,F*U'RM7?2%;3QZNT?)24\^>;GIJULR.QTX\%$SZ%5#
M1>1_DTUEI[E"I:ZMI>X:&FWI/-SS'-F8J*FU$155<KA>CAC/2AFOA0WRTUNG
M;?;Z.X4E17PUJ/?#%(CWL;L>BYQT<53I-L6K?:113&8YL=JK9F9W.QZ1U-:]
M66=ERLM1SU.Y=KD5,/C=UM<G4IS[5_+,FD[LZWWK3%P@FQOC7GXU;(S*HCD5
M,IC@:9\$J:1*_4<&Y>:6*%^WJSEZ9_:6GPL?]Y+%_='_ ,9*;%$7YMSO@FN=
MC:AT2EY:[+-I9MV6AJ^ZI:A]/3V^/$DTJM1JJ[AT-\)./[S6*#X1=.MR2&ZZ
M=FI:;=M>^.HWOCX];5:F?LR7OP5;91II.XW/N=BU[JU]/SRIER1HR-R-1>I,
MN5>'3]QS'X2-/'!RHU;HF(U9J>&1^$Z7;<9_8AG;M6IN3;PDU513%67?]9<J
M5ET_1TCZ-LMXK*R%*BGIJ/BJQJF4>Y?ZK?N5?0:5IOX0UNK;G'37NT26Z"1R
M-[H9/SJ,]+DVHN/2F?L-A^#A;:2GY-J*NA@8VLJWR<]-C+G[9'-:F?$B(G#H
M/G7EA@CIN4W4<<#$8SNI781,)ER(J_M526;-JJJJW,</,JJJB(J?;;7(]J.:
MJ.:J914Z%0DUODTE?/R>Z;DE<KGK;X,JO7X"&R'!5&)F&Z-[ Z\OGQ;T==KN
MF%?2P.=&B]"O7@Q%_P#<J'PSF>Y7',KW2U-3+X3W+E7.<O%5^U5/KWX0S'OY
M)KSS><(Z!78\7/,/DO3"HFI+2KOFI5Q9^S>AZ>AB(MS4T7N,0^\K7116ZVTE
M%3M1L--$R%B)U-:B(G[BY /+=#XSY>K8RV<J-Y;$U&QU"LJ41/&]J*[_ +MQ
MV?X-FIJBY:$K;?(UU356AVV%FY$5\;D56-RO1Q1R<>A,>(Y?\)M6KRF.V]*4
M46?MR[_(VGX)+']UZF>F>;2.G1?MS)C_ !/5NQM::)GX.:G=<PV*[\OE+9[E
M46^Y::N%/64[]DD;IF9:OW=/VF\\GFM*C6=(E=%8JFAMCVNYJJEF8Y)'([:K
M4:B[O'QQC@<B^%/I9(:NWZFIH\-G_P!%JE1/ZR(JL<OVHBI_[4,C\%74G.T%
MST[._P .!W==.BK_ %'81Z)]B[5_]RFBNU1-GM*(WLXJG;V9;E=N4ZNMFJ*:
MP3Z0N+KE5>%3L941.25N5\)%1<(G!<Y7AUF]W.[TMHLTESO,C**GAC1\RR.S
ML]'#I7/#ATKT&C:,:FI>4K46IG)NH[<B6>@7J56KNE<G_N7"+XE4YU\*V_3+
M7VBP1O5L#8EK)6HOSG*JM;G[-KO6:Z;47*XHB,<V4U3$3+>[%RH735DU8[1F
ME):ZAI5VNJ*NL;3[G=2(F%X_?XLX,IH#E/MNJ[E46BHIIK5?(%<U]'.Y%RK5
MPY&N3I5,<4PBG/\ D'UWI33&@VT=WNT5)7/J9)9(UC>J\<(BY1JIT-0Y1K#4
M4$/*Q6Z@T_4)+"VN;50RL16H_H5>"X7BN44W1IXKJJHV<8X2P[3$1.7U5RA:
MNGT?;DN'>2JN- Q,SS02,;S/%$3*+Q5%STHAI^C^7&TZCOT-M6VU%"Q[))'5
M$TK=D;6,<]57[FJ;3RMR-EY+-0R,7+'T2N1?0N#Y2Y)K1!?>4.RVZL174LTJ
MK*S.-[6M<Y6KZ%VX7[3&Q9HKM5551OA:ZIBJ(AVJ\_"*MU-=70VNRS5E"QVU
M:A\_-*]/&UNU>'BRJ?<;KJ7E+BM&EK?J.DLU9<++5QM>ZHCD8WF5<N$:YJKG
M.>&>C/#)C]>\B]BU3705=+(MHF8U(Y$I86[)&IT>#PPJ=&?<;BS25M9HE=+-
M8Y;;W*M+X2Y=A4^=^MGC]IKJFQBF:8^;*(KWY<VLO+U37NZ4]NM>FJ^>LJ';
M8XTGC3<N,]*\$X(ITB_WVXVG3\5RCL%15RI'SE331U$:.@1&Y7BJX=CH\')\
M8-[OT7K-,ILK[36?<KF._<N/4I]7\H^ITDY-XI[*[G*N_MBHZ!$Z5=.F/N5&
MJ[[%0VW[%--5.Q&Z6-%<S$Y5]#:]JM7VBKN5!INMCI8XW+ ^2>-.Z9&_U&Y7
MA^LO#TFD7CEWMM#<Y*2ZZ4K8ZZD>K',E?&KHW)XE_P 4.O:8L\&G]/6^TTN.
M:I(6Q(N,;E1.+OM5<K]Y\?<N'_%347]LW_QM,=/1;NUS&-Q7-5-,2^PM,W=E
M^T_;[K#$Z&.LA;,V-RY5J.3.%-.U[RJVG2USCM%-3S7:]R.:Q*2G5$VN=\U'
M.ZE7*<$15*FD[IWDY$+?=,(Y:.SI,UJ]:MCRB?>N#YBY.+Q2P\I=KO&HZO;"
MVI=4U%1(BN\+#E15PBK\[!+.GBN:IGA"U5XB(YOHJ]\I]UTI)12:TTI)04%4
M[8VHI:QM1L=TX<W"<<<>GJ7&3H=-=(;A9&W.SJVOAEA66!(W(G.\.#45>"*J
M\./1UG#.7O7>EM3:%2BLUVBJZQE7'*V-L;VKA$<BKE6HG67_ ,%*[RU.GKS:
MI7JYE%.R6-%_JI(BY1/1EBK]ZDKL_P#%VF,3!%?O;.52N^$'0T%;/25FG+A#
M4P/6.2-TK,M<BX5%.A6/5=PO&D._E+INKW2(U]/2.J(T?/&N/#1<X3I7@O%<
M>DX)\)W37>S5\%Y@9BGND?AJB<$F9A%];=J_;DZ=\'+4\=RY/74=5*B36=RQ
MO5R]$2Y<QR^A$W)_[3.Y:H[*+E$)35.U-,L*_P"$7;(Y'1OT_7M>U=JM65J*
MB^(Z75ZDNU+I;OL_2]6L[55TE$E3$LC(T15WYSA>CYJ<>)\=:Y5]1J.LNB4C
MJ6DNDLE;2M5,;HG2/1%];5/I.LU?-7<AMMJ*)V^[7:*.U0IGBZ=RK&Y?V/7U
M&5[3TTQ3-,<4HKF<YEM?)QK236UOEKX[-54%"B[8III&JDRHJHJ-1./#'3T&
MX&-TU:(+#8+?:J7_ %-)"V)%Q\Y43B[[57*_>9(X:YB:IV>#=&<;P &*@
M
M
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MENY'*BHJ</08Z.NFC:IJG"W8F<3#ZU5S4<C55$<O0F>DDYYR?:<U++70W[E
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M
M
M
M                              .%_"HNM _3-OMC*N!]P;6ME=3M>BO:
MQ(WIE4ZOG)T^,TGX,5[H+5JRY07&JAINZZ5&Q/E>C6N<UR+MRO7A5]1]+5FG
M;+6U+ZBML]NJ*A^-TLM,Q[G83'%53*\"C\4M.?4%H_!Q_P IUTWZ8M=E,-4T
M3M;3,L<U[&N8Y'-<F45%RBH2>8HV0Q,BA8V.-C4:UC4PC43H1$ZD/1R-H
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M :JZIKJFJ?-E$8C  #%0
M
M
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M.]J8661$1SU\:X1$]2%N6IMSB9C/^_0M78NQFF)QS_W>J@ U-H
M
M
M
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M^NQ7OV>$MD !Y[T0
M
M
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M5<IBF>$<(;;5BFW555'&>,@ -+<
M
M
M
M
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M T-@
M
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M(
M
M                                      XO\))<6>A_O#/X9#Y_WG??
MA,+BR4']Y9_!(?/.\][V?/\ PN#41[ZYWC>6V\;SNRY\+G>-Y;;QO&3"YWC>
M6V\;QDPN=XWEMO&\9,+G>-Y;;QO&3"YWC>6V\;QDPN=XWEMO&\9,+G>-Y;;Q
MO&3"YWC>6V\;QDPN=XWEMO&\9,+G>-Y;;QO&3"YWC>6V\;QDPN=XWEMO&\9,
M+G>-Y;;QO&3"YWC>6V\;QDPN=XWEMO&\9,+G>-Y;;QO&3"YWFR<FS\Z^T_\
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M7_G?_&IY_M&?^+ZNG31[[JH /#=P
M
M
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M.75%1SKY/$JX:B)]B)UF,WF?Y0='W'1-[[WW)62->WG(9X_FRMSC/H5.M/\
M)36-YU451-,33.8:YB8G>N-XWEOO&\RRF%QO&\M]XWC)A<;QO+?>-XR87&\;
MRWWC>,F%QO&\M]XWC)A<;QO+?>-XR87&\;RWWC>,F%QO/J/X.*YT2Q?^=_\
M&I\J;SZI^#:N=#,7_G?_ !J<'M"?^+Z_EOT\>\ZT #Q78
M
M
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MP2ES3:G_ %Z?]TA\X[CZ+^".N:;5'Z]-^Z0YM9/_  S_ +YMEJ/>AP6]N_\
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M_!I7.A(_UY/XU/D[<?6'P9^.@X_UY/XU.+7S_P 7U;K$>\Z\ #QW4
M
M
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M-3Y%R?7'P8>.@(OUY/XU./6S_P ?U;;/\G80 >4Z0
M
M
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M\
M
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M_"Q_RCY*='?45O\ PL?\IO(&W5S,0T;Y*='?45O_  L?\H^2G1WU%;_PL?\
M*;R!MU<S$-&^2G1WU%;_ ,+'_*/DIT=]16_\+'_*;R!MU<S$-&^2G1WU%;_P
ML?\ */DIT=]16_\ "Q_RF\@;=7,Q#1ODIT=]16_\+'_*/DIT=]16_P#"Q_RF
M\@;=7,Q#1ODIT=]16_\ "Q_RCY*='?45O_"Q_P IO(&W5S,0T;Y*='?45O\
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MMU<S$-&^2G1WU%;_ ,+'_*/DIT=]16_\+'_*;R!MU<S$-&^2G1WU%;_PL?\
M*/DIT=]16_\ "Q_RF\@;=7,Q#1ODIT=]16_\+'_*/DIT=]16_P#"Q_RF\@;=
M7,Q#1ODIT=]16_\ "Q_RCY*='?45O_"Q_P IO(&W5S,0T;Y*='?45O\ PL?\
MIL6G=/6_3U.M/:8&4].O1%&QK6IQRN$1$,N"35,\97  "
M                    ,2R.:JK:MO=4T;8W(B(U>'%"MW!+Y]4^M!;_ ,_N
M'Z[?W%^5&/[@E\^J?61W#+Y]4^LR!"@RL.X9?/JGUCN&7SZI]9? "Q[AE\^J
M?6.X9?/JGUE\ +'N&7SZI]8[AE\^J?67P L>X9?/JGUCN&7SZI]9? "Q[AE\
M^J?6.XI?/JGUE\0!8]Q2^?5/K'<4OGU3ZR^ %CW%+Y]4^L=Q3>?5/K+XA0++
MN*;SZH]8[BF\^J/67H LNXIO/JCUD=QS>?5'K+X 6/<<WGU1ZQW'-Y]4>LO
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M0     #R     @       !2"5(      !!) $      4!2"  4  0  !
M    (4@E2       020      "%)(4$  "@    #R     @     4@E2
M'D]'D                "        0H"@      CJ()ZB       020
M  !U =0$          B@    "%()4@L(            "*
M                          +T'D]+T'DL(  *\A0% @@D@ >3T>0@I!*D
M %()4@".H@GJ( $$D ""2 !!) $&3T[^=5/ZK3&&3T[^=5/ZK0,Z
M                             Q]O_/[A^NW]Q?EA;_S^X?KM_<7Y81!"
MDD*$A  "@       !!)    "%)(4      \@    (        4@E2
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MU.GJT]R;=7D  WM   !!)       '4!U 0         "*     (4@E2"P@
M          (H                                        O0>3TO0>
M2P@  KR% 4"""2 !Y/1Y""D$J0 4@E2 (ZB">H@ 020 ()( $$D 09/3OYU4
M_JM,89/3OYU4_JM SH                                    #'V_\
M/[A^NW]Q?EA;_P _N'Z[?W%^6$00I)"A(0  H        020    A22%
M  /(    "        %()4@      $$D 0     !0%(( !0 !   $
MA2"5(      !!)    6EW_V56_V#_P"%3D)UZ[_[*K?[!_\ "IR$^<]N?SH^
M4OIO8/\ "OYP  \)[P
M                /<$KX)F2Q.VO8N44Z;9J]EQH63L^=T/;XE.7F8TQ=%MU
M<B/7^@E\%_H\2GJ>R]9V%S8J_C/]O+]JZ/O%O;I_E3_7)T8!%14147**#ZQ\
M@   020      !U =0$          B@    "%()4@L(            "*
M                                     +T'D]+T'DL(  *\A0% @@D@
M >3T>0@I!*D %()4@".H@GJ( $$D ""2 !!) $&3T[^=5/ZK3&&3T[^=5/ZK
M0,Z                                     Q]O_ #^X?KM_<7Y86_\
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M@   \@    (        4@E2       020!      % 4@@ %  $   0
M "%()4@      $$D   !:7?_ &56_P!@_P#A4Y"=>N_^RJW^P?\ PJ<A/G/;
MG\Z/E+Z;V#_"OYP  \)[P                     VS2VG*&^4DC^?J8I(E
M1KT\%47*=*&$JHJ""YOA3NIU/&Y6.=ENY51<91,&X\EOYK</UV?N4UROME(Z
MOJ7.O%(U5E<JM5DF4XKP^:>K<L4]VMUT1&9SG_9>5:OU=YNVZZIQ&,?7Y,GJ
M+2]!9K<E4^HJ9=ST8UJ(U,JJ*O'AZ#33IG*3_N[3_P!X;_"XUO3=CBFLU;=:
MN-9FQ-<D,**J(]R)TKCCC/\ B76:2)U'968Q&,IHM7,:;M;TYG.&K@VF>SQ5
M>EG7-E.E)4PR;9&-RC7-RG'"]'3^PK72BMMJK;;3TL5-71S(G.N<]SGKQQG@
MN$3CP.2='7$;4S&-T]75&MHF=F(G.^.C4H>;YUO/;N;SX6WIQZ#9-6Z=@LM-
M32P3RR\ZY45'HB8X>@\ZXLE/9ZV#N/<D,S578JYVJB]2^+B9WE,_V;;OUU_<
M=%.EBW;O4W(]ZG'W:*M5-RY9JMS[M6?LTJBMT]73551$U$AIF;WN7H^Q/29K
M2.GZ6^PU'.33Q20JW.W"HJ+G'[C8[;+ G)[)*E)$D>QVZ-%5$>J.QE5Z<K@M
M^3)[));L^.-(F*L:HQJJJ-^?PX\3=8T=NF]:IJWQ5&9Z3+1?UMRJS=JIW33.
M(ZQ#0)F;)7L1<HURH>3>M-T-GO$]?2.H7HZ/CS[I%W.RJIG"<$^SB8.Q4U#'
MJ-]ON<+9HEE="CU<K5:Y%5$7@O6<4Z.KW9BJ,53CS_#NIUE,[<33.:8SY?;>
MP(-OOMGIZ+5%'2PT<24DJ(OA.?Q3^LJKGJPJ\#6*^2&6KE=2PI#!GP&(JKA.
MK.5Z35>T]5F9BJ=\3AMLZBF]$33&Z8RMP :&\                  &\Z-N
MO=-/W),[^EB3P57^LTV4Y/15,E)4QSPKA[%S]IT^VUD==1QU$2\')Q3Q+XCZ
MOV5K.VM]G5_*G^GR?M;1]A<[2G^-7VE<@ ]5Y 020      !U =0$
M   B@    "%()4@L(            "*
M           +T'D]+T'DL(  *\A0% @@D@ >3T>0@I!*D %()4@".H@GJ( $
M$D ""2 !!) $&3T[^=5/ZK3&&3T[^=5/ZK0,Z
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M02I       ()( @     "@*00 "@ "   (       !"D$J0      ""2
MM+O_ +*K?[!_\*G(3KUW_P!E5O\ 8/\ X5.0GSGMS^='RE]-[!_A7\X  >$]
MX                     ='Y,:>6*AK))8WL9(]JL5R8W)A>*>LTJYT%7WZ
MJ84IIEE=*Y6M1BY5-R\4]!8)-*B(B2/1$ZD<HYV3=NYQ^[HSE3MN:FFY9HM8
M_C\?TXK6EKMWJ[VU_+X<OJZ=RA4\T^GHFPQ/D<R9KG(Q,X3:Y,_M0L=#5#*W
M3=7;&2\U5-1Z-PN%PY.#D^Q30.?E\J_M*>(WNC>CHW.:Y.A6KA4-]7M&)O\
M;13Y8F,N>GV;,:?L)J\\Q.&P5%MNT*[+O52T\#GHS,DRN1^5QP3/'QYZ#9[W
M:I+7'0,LL;(*;?FHJ-R-=C*?.<O''2<ZFFEG?NFD?([QO<JK^TF2HFDC;')+
M(YC?FM<Y51/L0U4:JW1%413._A.=_P#3=7I+E<TS-4;N,8W?VWOE,IIII;>Z
M&-SV^$SP4SX2JF$*O*7$];70N1CE:QZHY43@G#K.?R5$TBLYR:1^S@W<Y5V_
M80Z61R8=(]4\2JIG=UU-?:^[_/'GPQ]&NUH*K?99J_AGRXY^KH5BB?6<GDU/
M3)SDRH]NQ%XYW9QZB>3>DEI'71LJ(O&-NYO%NY$=E$7K5,X4Y[%/+$CDBE>Q
M'<'(URIG[2&RR-3#7O1/$BX+1KZ::K=<T[Z(QQ^G)*_9]55%RB*MU<YX?'/-
MOG)Y!+%=[JLD3V(G@KN:J87=G!J%];)!?:Y51S'I4/<F4POSE5%+))I4SB1Z
M9Z?"4S.FHK552U+;W.YCE8G-.5RHF>.<KZC5VL7Z*=/3NQ,[YEM[*;%RO45;
M\Q$8B.39=1W6"JTI25^$[LE:L+53^JJIB3]B+ZSGQ?W26-&04=-+SL-.BY>B
M*B/>Y?"5,]7!$^XL##67YO5YGRB.OFV:*Q%BW,1YS/3R  <CK
M        ,_I&Z]Q5G,2N_H)EQQ_JN\9@ ;M/?JL7(N4^33J+%-^W-NKS=>!A
M-)7%U?;E;+E9851BN\:=1FS[:U=IO41<IX2^&O6JK-<VZN,!!)!L:P     '
M4!U 0         "*     (4@E2"P@            (H
M                       O0>3TO0>2P@  KR% 4"""2 !Y/1Y""D$J0 4@
ME2 (ZB">H@ 020 ()( $$D 09/3OYU4_JM,89/3OYU4_JM SH
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M?%J\0+L T'E.U9=]+5NG$H(:&2DN=RAH9'2HY9&[UXJB(J)T(O3D#?B%)(4
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M($      4!2"  4  0  !        (4@E2       020   %I=_]E5O]@_\
MA4Y"=>N_^RJW^P?_  J<A/G/;G\Z/E+Z;V#_  K^<  /">\
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MH"          10    !"D$J06$            !%
M                    %Z#R>EZ#R6$  %>0H"@0020 /)Z/(04@E2 "D$J0
M!'403U$ ""2 !!)  @D@"#)Z=_.JG]5IC#)Z=_.JG]5H&=
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M:UO_ )3Q_#XWVEK.\W?=_C'#\@ /0><$$D       =0'4!          (H
M   A2"5(+"             B@
M    "]!Y/2]!Y+"  "O(4!0(()( 'D]'D(*02I !2"5( CJ()ZB !!)  @D@
M 020!!D]._G53^JTQAD]._G53^JT#.@
M       ,?;_S^X?KM_<7Y86_\_N'Z[?W%^6$00I)"A(0  H  !J.M])7#4=;
M;YK?JBZ62.GW-FBHUPD[78Z>/!?$JYQXC;@!:VJ@IK5;::@H8TCI::-L4;>G
M#43"<>M?2>VTD#:U]6D3>Z7L2-9%XKM1<[4\29XX0K@ 020    A22%
M /(    #1K3H2HI]4SW:ZZDN=UI4J'5-)05#OZ*G>N<*G'CM151J81$Z<9-X
M5,HJ  4:*E@HJ9E/21-BA9\UK4^]5^U5XYZRL    !2"5(      !!) $
M   4!2"  4  0  !        (4@E2       020   %I=_\ 95;_ &#_ .%3
MD)UZ[_[*K?[!_P#"IR$^<]N?SH^4OIO8/\*_G  #PGO
M                                          &VZ)M6YRW"=O!.$2+X
M^MW^!@++;WW*O9 W*,Z7N^BWK.FPQ,AB9%$U&L8B-:B=2'L^R-'VE?;5<(X?
M/]/%]L:SLZ.QHXSQ^7[>P ?3OE@  ""2       .H#J @         $4
M 0I!*D%A             10
M  !>@\GI>@\EA  !7D* H$$$D #R>CR$%()4@ I!*D 1U$$]1  @D@ 020 (
M)( @R>G?SJI_5:8PR>G?SJI_5:!G0
M     &/M_P"?W#]=O[B_+"W_ )_</UV_N+\L(@A22%"0@ !0        @D@
M  !"DD*      >0    $        *02I       ()( @     "@*00 "@ "
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MEMMZ<XG^D2X=(OB\2?<98GJ(/H+5JFU1%%/"'SUV[5>KFY7QD !L:P  ""2
M      .H#J @         $4     0I!*D%A             10
M                             !>@\GI>@\EA  !7D* H$$$D #R>CR$%
M()4@ I!*D 1U$$]1  @D@ 020 ()( @R>G?SJI_5:8PR>G?SJI_5:!G0
M                                &/M_Y_</UV_N+\L+?^?W#]=O[B_+
M"((4DA0D(  4        ()(    0I)"@     'D    !        "D$J0
M   ""2 (      H"D$  H  @  "        0I!*D       @D@      $*20
MH(  %     'D    !      I!*D    /)Z/(                $
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MAD]._G53^JTN.\5/Y:H[2>XN:"WQ43WNB?(Y7HB+O5%_P O
M                         &,YVMGJZF."2)C(G(GA-STH>]ER\O3]A0,@
M#';+EY>G["C;<O+T_84#(@QVVY>7I^PHVW+R]/V% R(,=MN7EZ?L*-MR\O3]
MA0,B#';;EY>G["C;<O+T_84#(@QVVY>7I^PHVW+R]/V% R(,=MN7EZ?L*1MN
M7EZ?L*!D@8W%R\M3]A1BY>6I^PH&2!C<7+RU/V%&+EY:G["@9(&-Q<O+4_84
M8N7EJ?L*!D@8W%R\M3]A2,7+RU/V% R8,9_ZEY:G["C_ -2\M3]A0,F#&?\
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M7=E?Y2'LCNRO\I#V0,Z#!=V5_E(>R.[*_P I#V0,Z#!=V5_E(>R.[:_RD/9
MSH,%W;7^4A[([MK_ "D/9 SH,%W;7^4A[([MK_*0]D#.@P7=M?Y2'LCNVO\
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M0-D!K??6M^E%V2_LU;/52S,G5J[$14VI@#*@
M            ,?;_ ,_N'Z[?W%^6%O\ S^X?KM_<7Y81!"DD*$A  "@
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M      H"D$  H  @  "        0I!*D       @D@      $*20H(  %
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MG4WHV?*=^]P7L1IK,[6=\;MSE@/4L;XI'1RL<Q[5PK7)A4^X\GSO!]'Q
M    #.Z0N/<=PYF1<0SX;]CNI?\  P01<+E.DVV+M5FY%RGR:K]FF_;FW5PE
MUP&,T[<.^-M9(Y<RL\"3[4Z_O,F?;V[E-VB*Z>$OAKENJU7-%7&$*02I!LAJ
M   541%55PB'S!<JVF7X3S*A*B'N=*V)JR[TVYYEK<9Z.GA]I]/2,;)&YDC6
MO8Y%:YKDRBHO4J&-^+UE^J+=^&9[@.'\N=1"G*_HIRRQ[8W0.>NY/!3G\Y7Q
M<#SROSQ?+WHQ>=9B-:3>NY/!_P!(<O'Q<#NC[#:)'9?:J!RX1,K3L7@B81.C
MQ();':9GJ^6UT,CUPBN=3L5>"83J\05P?4];36KX3M)6W*>.EI&L8JS2KM8B
M+3JU%RO5G@6O+$K*3E0TUJ>LCJ5L-7'"JR)OC<C4<NY.&'(NU4=C@O'[3Z%K
M+/;*Z:&:MMU'42P?ZI\L#7NC_554X?<5J^BI;A3.IZ^F@JJ=WSHIHT>U?M1>
M ,M(TK3Z&?J1*_37-UERYE72UD53).D4>,8D<YRHF>A$7CPZ,(ISGX-L\2ZV
MU>U)69D5',3<GA)SCN*>/I3UG>:.U6^BHGT=%04E/2/14=!%"UK'9Z<M1,+D
M\4]EM=-,V:GME%%*Q<M>R!C7)]BHA!Q3X6$C.]>GH][><YZ5VW/'&UO'!4^$
MG/$_DWTZUDK'.?4QO:B.1=S4A?Q3T<4]9VJLM5OK94EK:"DJ)$3:CY86O7'B
MRJ'B6RVN9L;9;;1/;&W:Q'0-5&IXDX<$ X%R]312<EVAT9(QRN9&Y$1R+E$A
M1%4\_",FCDT9HA(Y&.58E<FUR+E.;9Q^P[\^QVJ1D;)+70N9&FUC5IV*C4SG
M"<.'%57[Q)8[3(C$DM="](V[6(ZG8NU,JN$X<$RJ^L"XMKVR6ZE?&Y',=$U4
M5%RBI@TWEPGAAY+[\V65C'20M:Q'.1%<N]O!/&;M3P14T+8:>)D43$PUC&HU
MJ?8B%&MMM#7.:M=14U2K.#5FB:_'V90#D?P6*B%="U\"2LY]MP>Y8]WA(BQQ
MX7'BX+ZC&<K5NGMW+5I"_P!2BI:Y):>%9E^;&]LBY15ZN#D7U^([726BVT<R
M34EOHX)43"/B@:UR?>B%S5TL%93OIZR"*>!Z8='*Q'-<GI1>"@<*Y2K?/J#E
M^TS2VQ%D?10P3U+V<>9:V5SUW+U<,8_63QF/AKJ6W_"CKIZZ>.G@XM621VUJ
M*M,U$RO0G'@=^MEJM]JC>RV4%+1L>N7-IX6QHY?3A.)Q6GT[>UY=*O4=5IVL
MDL=1NB<KDC<JM6%(\JS=Q3*='B4*L*!K=3?"6GN5I>V>W6]$?-4QKEB;8=GS
MNCBY<?<H^#Q/$[E'UDK96*DF]S,.3PDYY>*>-.*'>*"T6VWTDE-06^DIJ:3.
M^*&%K&.STY1$PIYI[+:Z:3G*>VT44F%3<R!K5PJ85,HGB".#\D=5 WEYUE*Z
M>)(G)5JUZO3"IS[5RB_8F2/@Q5$,<.M.<EC9X,+_  G(G@ISN5^SBAW9M@L[
M5RVTV]%QCA3,]Q,=CM,>_F[70LWMVNVT[$RGB7AT ?/GP>Z.2Z:'UY;:9[4J
MJJG2*-,X7+HY$3[LJ6_(K+I1MFO-DUO+W)4Q5"N6*JJY(&/8J(CF*U'(U516
MKE%3/'T</I"CM5OHI5EHJ"DIY%3:KXH6L54\643T%&HL-HJ:]M=4VJ@FK6X5
M*B2G8Z1,='A*F0/GCEBME)::S1-XM-%/2Z;@\"-CFN\#$RR95'*JIN1RN1%X
MX3H3H*_PE+W;+G<]+][JZGJFP\X^1T+T>UJ.5BIE4X9PBKCI]9]&5M)3UU,^
MGK:>*HIWIAT4K$>UWVHO!2S@L-HIXX606J@C9#GFFLIV(C,XSMX<,X3/V(!?
M4M1#54\<]++'-!(FYDD;D<UR>-%3I.8ZYUC9-4\G&LX;)6=T24,"QS)L5N,K
MA%3*<47"\4\1U%J(UJ(U$1$Z$0Y_4\E=J6*\TUOKJZWT%W>CZRGITCP_"YPU
MSF*YJ95>&<>+ &G_  >*UUIY([]<5@?,E-4SSI&WIDVPL7">K!IT6J(=3<FV
MJJBZ7&.EK$<K:.S4/]!$UO@N616,XR?ULJ[*)MRO4?1^G+%;].V:GM=I@2&C
MA14:W.555XJJKUJJDTE@L]&E0E):J"!*A%;,D=.QO.(O2CL)Q3[0/F&X5M*_
MX.%LI65$+JF.ZKOB1Z*]N5E5,ITIP-DY79X9.071#62L<Y5IL(CD5>%.]%]2
M\%.\1Z=LL5.R".SVYL+%56QI3,1K57IPF.O![=8[2Z-D;K70*QF=K5IV8;GI
MPF. %GH%[7Z'T\YCD<WO?3IE%S_^FTSI2I::"DA;#20Q00MZ&1L1K4^Y"J!I
M_*;KJ@T/8UJ:A4EKILMI:9%XR.\:_P#*G6OW=9RC37*Y8K?#/!9K9<JO4=SD
M3G*RK;&WGYW+AJNPY51B*J8:G!$X>D[Y6VR@KGM?6T-+4O:F$=-$UZHGB3*%
M&*Q6B*1LD5JH&2,5'-<VG8BHJ="HN -(M7*SI6[7:NLES>Z@EA>Z%RW%C613
M;55%XJJHG1T.P4N2S35);=7:KN]C8D5@K71,HT8F&2*B9D<S_DW*J(O1TXX&
M^U%CM-35]UU-KH9JKRTE.QS^TJ9,@G!. &H<KULFN_)M?Z2F:KIEI^<:U.EV
MQR/PGV[3QR25,<O)CIV7<U&-HVL5RKA$VY:O[4-R7H4UNRZ=99UJJ"F9!+8J
MA[Y4II$SS#G+ES6IC"L5<KA<;55>E%PE@<!Y*ZJD?R^W:5\T*P33UG-N<Y-K
M\O54PO7E#Z?1$1,(B(GB0QGQ?LWU1;OPS/<90#YZL6MX=2ZJU+%>*MMCH8F/
MYFBI?Z"6LD15:B2/;X;W?\J+QST<%SAN1BLIHN3+E @EJ(63NI'O2-ST1RIS
M3DSCQ95$^U4/HV*RVN*XON$5MHF5[_G5+8&I(OVNQDIQ:?L\,<[(;3;XV3NW
MRM;3L1)'>-W#BOV@<O\ @N2QKH.OB1[5D;<7N5F>*(L<>%Q]RFO<M$T=%RWZ
M.K*MZ0TL:4SWROX-:C:ARN55]"'=Z.UV^BD62BH:6GD5-JNBA:Q53Q91"+E:
MK?<TC2Y4%)6)&N6)40MDVKXTRBX FUW"GNE"RKHGK)329YM^,(]$54W)XT7&
M47K3"FH:QJ8KWJ>U:8I[FE)*S-QJ'1*QSVI&J<TW#D5%57JCL*B\&&\M:C6H
MUJ(C43"(G0A8OM%M?4]TOM]&ZHW;^=6%JOW>/.,Y X9\(C2DT%CH[U4WNIKZ
MFGE2'%0R&-48[/S>;8U5PY$Z<]*G3^2?5#-5Z+H*MTK7UL3$AJFYXI(WAE?U
MDP[[S9JVVT-<]KZVBIJAS4PU98FO5$]&4**6Z"@@F?9Z"BBJG-PF&)$UWZRM
M3. CF=OI)+A\(RZ5<:+S%MM[&2.ZMSV)A/4Y5^XZV8?3=CCLT-4]TG/U];*M
M15U*MPLLB^).IJ)P1.I$ZURJY@".H@GJ( $$D ""2 !!) $&3T[^=5/ZK3&&
M3T[^=5/ZK0,Z                                     Q]O_/[A^NW]
MQ?EA;_S^X?KM_<7Y81Q3X6<,;^36ED<QJR,N,>URIQ3+),X+7X*E#2UG)?<X
MJNFAGCFN4K)&R,1R/;S47!<]*%[\+#_AC#_U&+^"0U;X.5IU!<^3:O99=1QV
MBG=<)&.Q0I-(CN;CRY'*Y$3ACJX8Z0L<'.^2VOJ].\N4-!8Y9.XY;F^BDB:Y
M5;)!O5O%.O">%GT&:O"LB^%6URJUC$NL+E5>")X#553N/)MR0V+1%<ZY1RSW
M&[N142JJ<>!GIV-3H5>M5ROIXJ<(U/14]Q^%"^DK8FS4TUSA9)&[H>W8S*+Z
M"*^AZ/E6T367MMIIM04KZQS^;;P<D;G=&$DQM7U\3:KS=:"RV^6NNU7#1T<7
MSI9GHUJ>C[?0?+WPM+?24&I["^AIH:9SZ-R.YEB,SM?X/1XLG4N6;23M8Z L
MTM1?::U1T:,J9IJQ<1.RS&57Z29X?:I4PVF;E.TI334\==<)Z%*C_4RUE%/3
MQR>E'O8C<>G.#;)ZVE@H7ULU1#'1L9SKIW/1&(S&=V[HQCK/FOERU)2WODEM
M%/;TN%RIZ2KAC=>98.:AJ)&Q/:[;N5'.55RN414X+Q,I1VR\ZE^"G14EIYVI
MJVY58FKETL4=0[P$\>$1,)_RX!AU-.4_224W=4ESDBHERC*J6DF9!(J=*-D5
MB-<O#J7B;+67FW45G[ZUM9#3VY(TE6>9VQJ-7HZ?'E.'2?,FB>6"VR:5;HCE
M MCV6]M.E!W7"WPHV(FUN]B\45N$\)..41<9/?PI[NYC=+6&AJ%DM3*)M4US
M792;.6,<N."X:U<?K*##OELY0M-7&LHZ6&X/BEK4S2+4TTL#:E/_ (;I&HC^
MKH5>DVHX!RKV75.NM+6*DL>D*JC=0R-EBEDK:?&S9A$;A^4_JK]QV[3BURZ?
MMBWAG-W+N6+NIN47$NU-Z93@OA9Z BI=Z!;E2=S]V5=(U7(KGTLB,>Y./@[L
M91/2F%X=)\@VZ@9;/A)T]%#+/+%!>D8UT\BR/5-W#+EXK]JGV6?'\O\ ^:1/
M^N-_>@6'TIRM-:[DRU2CD14[W3KQ3K1BJAPCX,VJ[)I33^I*F_U\=)&^>%&(
MJ*Y[\-?G#6HJKCK7' [QRK_\,]5?]-J/X%..? _I8'T6IYWPQNFWPQ;U;E=B
MH]5;]B@C@[=I+6%AU=323:>N4-8V)421K45KV9Z,M<B*GVX,^?(NDGNTG\):
M6AM68J26XR4JPLX-YJ3*HW'B15:O_M0^N@DP  #R     @       !2"5(
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MG!W\    /(    "        %()4@      $$D 0     !0%(( !0 !   $
M      A2"5(      !!)       (4DA00  *     /(    "     !2"5(
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MU7IL1')TY5,8QU@;N     A2"5(      !!)       (4DA00  *     /(
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M7*B9^]<?>75BN%5W[;0WVB9#<VP.YNHA7,<\:*F<=:+G'#TKT ;0
MO0>3TO0>2P@  KR% 4"""2 !Y/1Y""D$J0 4@E2 (ZB">H@ 020 ()( $$D
M09/3OYU4_JM,89/3OYU4_JM SH
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MDLE!04E+)+QD=#"UBO\ M5$XA%Z     A2"5(      !!)       (4DA00
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M7I8LCU1$SG#>/@IGCPP7<%!!#4<^U'OFV<VCY'N>J-SG"97AU?:70
M  +T'D]+T'DL(  *\A0% @@D@ >3T>0@I!*D %()4@".H@GJ( $$D ""2 !!
M) $&3T[^=5/ZK3&&3T[^=5/ZK0,Z
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MF]O@M1,HGA+P:@,.B  "        %()4@      $$D 0     !0%(( !0 !
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MZ=_.JG]5IC#)Z=_.JG]5H&=
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MD@A:QTB^E43B$9(  0        I!*D       @D@"      * I!  *  (
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MMJ(IJ:9TC)FN<K<IE$\2^DW        'F61D43Y)7M9&Q%<YSEPC43I55 ]
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MKVY]#D5/N,BB(BJJ(B*JY7TG/^1JL[KMVI]JYABU!6LB\6U7([A][E W\
M  4@E2    'D]'D                "        0H"@      CJ()ZB
M   020      !U =0$&@:T_VT[^S:;^:!K3_ &T[^S:>3[9_Z_UC_+U_8O\
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M) $&3T[^=5/ZK3&&3T[^=5/ZK0,Z
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MTE;D[T]6:6TS2V:LK(*QE*BMBECB6-517*[PD55\?4;,
M "]!Y/2]!Y+"  "O(4!0(,?WK@;=EN,*OAJ'M1DW-KALZ(B[=Z=:IG@O3U9Q
MP,@0 /)Z/(04@E2 "D$J0!'403U$ "TN5&E?2.IGS311OX/6%VUSF];<]*(O
MC3"^E"[( I4E/#24T5/2Q,A@B:C&1L3#6M3H1$*A)  @D@"#)Z=_.JG]5IC#
M)Z=_.JG]5H&=                                     8^W_G]P_7;^
MXORPM_Y_</UV_N+\L(@A22%"0@ !0        @D@   !"DD*      >0
M$        *02I       ()( @     "@*00 "@ "   (       !"D$J0
M   ""2       0I)"@@  4     >0    $     "D$J0    \GH\@
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MYMGT&^H>!SZ_M^SQZ/\ Y_?].3@ZQS;/H-]0YMGT&^HG@<^O[?L\>C_Y_?\
M3DX.L<VSZ#?4.;9]!OJ'@<^O[?L\>C_Y_?\ 3G.G[?WPN4<;D_HF^')]B=7W
MG2$1$3"<$0AK6M^:U$^Q"3U-%HXTE$TYS,^;R]=K9U=<58Q$>0 #M<(
M                        +T'D]+T'DL(  *\A0% @@D@ >3T>0@I!*D %
M()4@".H@GJ( $$D ""2 !!) $&3T[^=5/ZK3&&3T[^=5/ZK0,Z
M                           L9;9%),^7G)V.>N5V/PAY[U1^<57M#( #
M']ZH_.*KV@[U1^<57M#( #']ZH_+U7M!WJC\O5>T,@ ,?WJC\O5>T'>J/R]5
M[0R  Q_>J/R]5[0=ZH_+U7M#( #']ZH_+U7M!WJC\O5>T,@ ,?WJC\O5>T'>
MJ/R]3[0R  Q_>J+R]3[0=ZHO+U/M#( #']ZHO+U/M!WJB\O4^T,@ ,?WJB\O
M4^T'>J+R]3[0R  Q_>J+R]3[0=ZHO+U/M#( #']Z8O+U/M!WIB\O4^T,@ ,?
MWIB\O4^T'>F+R]3[0R  Q_>F+R]3[0=Z8O+U/M#( #']Z8O+U/M!WIB\O4^T
M,@ ,?WIB\O4^T'>F+R]3[0R  Q_>F+R]3[0=Z8O+U/M#( #']Z8O+U/M!WIB
M\O4^T,@ ,?WIB\O4^T'>F+R]3[0R  Q_>F+R]3[0CO3%Y:I]H9$ 8[O3%Y:I
M]H.],7EJGVAD0!CN],7EJGV@[TQ>6J?:&1 &.[TQ>6J?:#O3%Y:I]H9$ 8[O
M3%Y:I]H.],7EJGVAD0!CN],7EJGV@[TQ>6J?:&1 &.[TQ>6J?:#O3%Y:I]H9
M$ 8[O1#Y:I]H.]$/EJGVAD0!CN]$/EJGV@[T0^6J?:&1 &.[T0^6J?:#O1#Y
M:I]H9$ 8[O1#Y:I]H.]$/EJGVAD0!CN]$/EJGV@[T0^6J?:&1 &.[T0^6J?:
M#O1#Y:I]H9$ 8[O1#Y:I]H.]$/EJCVAD0!CN]$/EJCV@[T0^6J/:&1 &.[T0
M^6J/:#O1#Y:H]H9$ 8[O1#Y:H]H.]$/EJCVAD0!CN]$/EJCV@[T0^6J/:&1
M&.[T0^6J/:#O1#Y:H]H9$ 8[O1#Y:H]H.]$/EJCVAD0!CN]$/EJCV@[T0^6J
M/:&1 &.[T0^6J/:#O1#Y:H]H9$ 8[O/#Y6H]H.\\'E:CVAD0!CN\\'E:CV@[
MSP>5J/:&1 &.[SP>5J/:#O/!Y6H]H9$ 8[O/!Y6H]H.\\'E:CVAD0!C>\\'E
M:CV@[SP>5J.V9( 8WO/!Y6H[8[SP>5J.V9( 8WO/!Y6H[8[SP>5J.V9( 8WO
M/!Y6H[8[SP>5J.V9( 8WO/!Y6H[8[SP>5J.V9( 8WO/!Y6H[8[SP>5J.V9(
M8WO/!Y6H[8[SP>5J.V9( 8WO/!Y6H[8[SP>5J.V9( 8WO/!Y6H[8[SP>5J.V
M9( 8WO/!Y6H[8[SP>5J.V9( 8WO/!Y6H[8[SP>5J.V9( 8WO/!Y6H[8[SP>5
MJ.V9( 8WO/!Y6H[8[SP>5J.V9( 8WO/!Y6H[8[S0>5J.V9( 8WO-!Y6H[8[S
M0>5J.V9( 8WO-!Y6H[8[S0>5J.V9( 8WO-!Y6H[8[S0>5J.V9( 8WO-!Y6H[
M8[S0>5J.V9( 8WO-!Y6H[8[S0>5J.V9( 8WO-!Y6H[8[S0>5J.V9( 8WO-3^
M4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO
M-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9(
M8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V
M9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E
M)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S
M4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[
M8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^
M4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO
M-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9( 8WO-3^4G[8[S4_E)^V9(
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M_G]P_7;^XORPB"%)(4)"  %        ""2    $*20H     !Y     0
M    I!*D       @D@"      * I!  *  (   @       $*02I       ()
M(      !"DD*"  !0    !Y     0     *02I    #R>CR
M   !        (4!0      1U$$]1       ()(       Z@.H"
M10    !"D$J06$            !%
M        %Z#R>EZ#R6$  %>0H"@0020 /)Z/(04@E2 "D$J0!'403U$ ""2
M!!)  @D@"#)Z=_.JG]5IC#)Z=_.JG]5H&=
M           8^W_G]P_7;^XORPM_Y_</UV_N+\L(@A22%"0@ !0        @
MD@   !"DD*      >0    $        *02I       ()( @     "@*00 "@
M "   (       !"D$J0      ""2       0I)"@@  4     >0    $
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M'/ /&M1RC[_D\#T_.>L?AT/XRVOSAWLW>X?&6U^<.]F[W'/ /&M1RC[_ )/
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M7S6,!!)  @D@"#)Z=_.JG]5IC#)Z=_.JG]5H&=
M               8^W_G]P_7;^XORPM_Y_</UV_N+\L(@A22%"0@ !0
M   @D@   !"DD*      >0    $        *02I       ()( @     "@*0
M0 "@ "   (       !"D$J0      ""2       0I)"@@  4     >0    $
M     "D$J0    \GH\@                0       "%-?UO_L3_P":W_$V
M!37];_[$_P#FM_Q.37?]>OY.O0?]FCYPY^ #XI]P
M
M                                  #9])W+_P#8IG>F)5_:ALQS-CG,
M>US%5'-7**G4IOMEN#;A1H]<)*W@]/3XSZ7V1K-NGL*^,</E^GS'MC1;%7;T
M<)X_/]K\@D@]MX8020!!D]._G53^JTQAD]._G53^JT#.@
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M#$DBE8N4<U4RBEPISWX/U#5T')-8HJ]'-D>Q\S&NZ6L?(YS?6BHOWG0E"
M  #R     @       !2"5(      !!) $      4!2"  4  0  !
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M%<?7YOA]7IJM-=FW/T^0020=+F09/3OYU4_JM,89/3OYU4_JM SH
M                            #'V_\_N'Z[?W%^6%O_/[A^NW]Q?EA'%_
MA8?\,8?^HQ?P2&L?!OT99M3<G-<Z]15<[>^,D:Q,K9HHW-2.->+&/1J]*\53
M)O\ RTZ*U'KVVQ6FW5%JI+;',VH629TBRO<C53&$;A$\)?'GAT%+D6T/J7D_
MH9K575%HK+9-4.J'/B?(DK'*Q&\$5N%3P6^+K^P$<&\:8TK8]+TSX-/VRFH6
M/^>L;?"?XMSEXK]ZGS'=_P#\US/^JP?P-/K9<X7'2<"J^2+5E1RG)K/NVQ-J
M$JV524V^56^#A$;G9GH3I"PU?X8*?_B/3R]?<DG\9T7EB9HUW)]8I-<25:)&
MQCJ2.C<B32OV)N:U%X8QC*KT<.)9\L_)7J+E"OM)505EIHZ6D@YJ-KW2.>Y5
M7+E7#<=/!/L])/*QR57S6VF]/(RJM\-YM<3H9&;W\Q*U=J9:[;E%\%%QCKQG
MAQ#2N62NNURY&+'4K;*6T:>[H@90TKI'35*QI$]&.>[@UJ;4Z,*O%./CV/2&
MEOCE\&>U69E7%2U4LDCJ9\JX:Z1L\BHU?M3*</MXX*M\Y*M;:@Y-Z2QWF_VY
M]1;^;[DIHHU;$Y&(K4YR3;N5R-7"81$\><Y3(63DWU=1\FMJT^Z[6RGKJ"X1
MU=/+"Q[DA:U[WJKE7Y[E5W1AJ83I4#E5KUEKKDG>RQ:JMKJNQ*BQ=RU;=S'Q
MKP<D4J<,87HXHF>A"K\)VZQW6JTA/;T<VTS6IM13,5,(W>[BF.I41&(=FU_I
M?5VN;#'I^Y06&CI72LDGKXIY)78:N<QQ*Q-KE]+EX*J9*G*/R26_56C;59Z*
M;N.JM$2144[TW)M1J-5K_&B[47*="IGQHHRQ&J^3O4'*/IBU17/4]L91HC*N
M%:>UN:O%G#BLRY3#CJFGJ"6U6"VV^>H[IEI*:.!\^W;SBM:C5=C*XSC/2<IT
M-H[E.M=LAL-QU';*:RPIS;9Z9JRU38_H1N<U$3AP15RJ=70AV"AI8J&C@I:=
M')#!&V-B.<KEPB83*KQ5?2H14DD9%&Z25[61L17.<Y<(B)TJJG**BQ?*EJ2D
MNMW:K-'6URK04K^"W"3KF<G5'U-3I5./0O',<L.E]3ZOL[+3IZYT5OH9<]UK
M,KT?*G4Q%:BX;X_']F<\5_)LU-C_ &Y:?7+_ "A8?3-KN]#7UM?14$B2.M[F
M13*S&QKE;G8BIUHF,IU90R*FC<C6B)M!:0[U5<\$]5)4/GEDASM55PB8RB+T
M-0WE0@     \@    (        4@E2       020!      % 4@@ %  $
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MU7W54N1(V-=(UV,KQ7"=>,FF W=[M]GL1;C...?NT1I+G:;<W)Q,\,?8.F:
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M       ()(      !"DD*"  !0    !Y     0     *02I    #R>CR
M            !        (4U_6_^Q/\ YK?\38%-?UO_ +$_^:W_ !.37?\
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M7JLJ=+=JY0L*IKJVX4;J>.1&PNW/E<U6ICQ)GI%U3N2NIZ]OS<\U+^JO0O\
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M)]R'*=':5J+9RK7VBAD:NG*:5MXA@3_].IF:YFW[$3G%QU> =<"   !0%((
M!0 !   $        A2"5(      !!)       (4DA00  *     /(    "
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MJ:ZN,A!)!FP09/3OYU4_JM,89/3OYU4_JM SH
M             #'V_P#/[A^NW]Q?EA;_ ,_N'Z[?W%^6$00I)"A(0  H
M    020    A22% %*IAY^GDA5\D:/:K5=&[:Y,^)>I?250!0HJ6"BI(J:DC
M;%!$U&,8WH1$*X 'D    !        "D$J0      #7=<4.H*^S)%I*ZP6NX
MMF:_G9H4D:YB9RW"HN,\%SCJ])L1 &#TC99K-02]\*SNZZ54G/UE5L1B2281
M$1&]34:B-1/$AFP    !0%(( !0 !   $        A2"5(      !!)
M  (4DA00  *     /(    "     !2"5(    >3T>0                (
M      !"FOZW_P!B?_-;_B; IK^M_P#8G_S6_P")R:[_ *]?R=>@_P"S1\X<
M_ !\4^X
M
M#W#$^:5D<;5<]RX1"Q$S.()F(C,KZQ6Y;A6(UR+S+.+U]'B^\WMK4:U&M1$:
MB81$ZBUM5"R@HVPMPKNE[O&I=GV'L_21IK>_^4\?P^,]HZR=5=W?QCA^0@D@
M[WGA!) $&3T[^=5/ZK3&&3T[^=5/ZK0,Z
M          Q]O_/[A^NW]Q?EA;_S^X?KM_<7Y81!"DD*$A  "@       !!)
M    "%)(4      \@    (        4@E2       020!      % 4@@ %
M$   0       "%()4@      $$D       A22%!   H     \@    (
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M*UR^A%VT'Q6N7T(NVAT #P;3_'K^CQO4<HZ?MS_XK7+Z$7;0?%:Y?0B[:'0
M3P;3_'K^E\:U'PZ?MS_XK7+Z$7;0?%:Y?0B[:'0 /!M/\>OZ/&M1\.G[<_\
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MO^U;]ZB;=6(B>0020>B\T()( $$D 09/3OYU4_JM,89/3OYU4_JM SH
M                               #'V_\_N'Z[?W%^6%O_/[A^NW]Q?EA
M$$*20H2$  *        $$D    (4DA0     #R     @       !2"5(
M  !!) $      4!2"  4  0  !        (4@E2       020      "%)(4
M$  "@    #R     @     4@E2    'D]'D                "
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M
M
M
M
M
M
M
M
M
M
M
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M7<F4X\<IGK VD'F'G.99SR-27:F]&+E,]>/0>@
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M!?$H%T
M         #B/PCKD_G+/;&NQ'A]2]/&OS6__ %>LXJ==^$;3O;?K34JB[)*9
MT:+Z6O55_B0Y$?7>S8B--3C_ '>^/]I3,ZFO/^[@ ':X0
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MBL%12UL5NJ*][)*FL<C\JU7+AF6-5V.")CHZ?&:N]1;NUTS&_,1QW;X^7_\
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M1C>AO@Y:C4]'3TJ9D
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M,;/EG./BWU:R[5.UYXQGX)555555557BJJ0 =3D
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MTE!%S5#2P4T?T8F(Q/4A<
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M3LJ/3'1AOBKI_P"HK7^%9[A\5=/_ %%:_P *SW&9 [6OU2=E1Z8Z,-\5=/\
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M  K/</BKI_ZBM?X5GN,R!VM?JD[*CTQT8;XJZ?\ J*U_A6>X?%73_P!16O\
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M3-BB>CXK+;6.3H5M*Q%_<95C6L:C6-1K4X(B)A$)!C-557&65---/"  &+(
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M[<9,V8F"U3,U%+<Y*EKV.I8Z=L?-X5-KG*JYSUJY.&.I#+
M
M
M
M
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MFB@A16Q1,1C45<X1$PA4
M
M
M
M
M
M
M
M
M                                                      /GW\IN
MU?H[7?B&>X?E-VK]':[\0SW'RZ#T>[V^3A[>OF^HORF[5^CM=^(9[A^4W:OT
M=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF
M^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W
M:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([
M>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A
M^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[
M?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(
M9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H
M'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM
M=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<
M?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5
M^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ
M#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HOR
MF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=
MKOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^
MHORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:
MOT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>
MOF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^
M4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?
M([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9
M[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'
M=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=
M^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?
M+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^
MCM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#
M/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF
M[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=K
MOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^H
MORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:O
MT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>O
MF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4
MW:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?(
M[>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[
MA^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=
M[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^
M(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+
MH'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^C
MM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/
M<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[
M5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KO
MQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HO
MRF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT
M=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF
M^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W
M:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([
M>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A
M^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[
M?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(
M9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H
M'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM
M=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<
M?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5
M^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ
M#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HOR
MF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=
MKOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^
MHORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:
MOT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>
MOF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^
M4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?
M([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9
M[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'
M=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=
M^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?
M+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^
MCM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#
M/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF
M[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=K
MOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^H
MORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:O
MT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>O
MF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4
MW:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?(
M[>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[
MA^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=
M[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^
M(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+
MH'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^C
MM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/
M<?+H'=[?([>OF^HORF[5^CM=^(9[A^4W:OT=KOQ#/<?+H'=[?([>OF^I&?"9
MM;GM;\7:WBN/]>SW ^7H/]<S]9/W@DZ>CDL7J^;P #H:0
M
M
M
M
M                                                     ![@_P!<
0S]9/W@0?ZYGZR?O!)6'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g863285g96v96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g863285g96v96.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$(! H'70,!(@ "$0$#$0'_Q  =  $
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M #\ ]4HB("(B B(@(B("(B B(@(O-^WZRU>C8;97V&_WV*"ID=%)#)<)7AI
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M+PZ[IEFNING&&ZD6J-O='2T&F:N\Q7.ZT=W>Z.&E935LC&ROR!N]&#CZ.\>
MSP6%LWV975UKBK=:7^^OJY@'"BCN$K&Q#L>0<EWF!&/.N4:5=F^9:W3G&&Y$
M0< L:YUU-;+?45U?,R"EIV&221QX-:%QZMLE%XGVIZ[K-:ZEDJRZ2&@AS'24
M^<;C,\S_ ,1YGU#J7L;3''35ISY)#_ %Z-7P\Z58F9ZL5ONF8A)(M4_*,U!5
MVC1M/1VN:>*ON%2&-= XMD#&#><01QYAH]:\V]^]8?:>H/V\WXK6CX6=6N[.
M$MJ;9P]T(O(>RK\JK_KVT4=7=+X*,2]-/TE1*&EC/"(.3UXW?6O7BYZVCPIQ
MG*TMNC(B(N+82 ,D@#SHM$_*EU.:2U6[3]+*6S53^Z9]TX(C:<-'K=D_]"V3
MLJU,-6:&MMR>\.J@SH:GS2MX.]O!WH<%UG1F-.-3NS%HFVU;41%R:$1$!%'W
M^TPWNV2451-50,?@])2SNAD:1R(<TY]7)>)JO4NH::Y34XU!=W-BF=&":R3C
MAQ'C+T:'A^-G$]&+WVO=*+XSZ(]"^KSMB @D@$$CFH/7+[C'HZ\OL8>;FVED
M-/N#+M[!^CY^SSX7D_8Q57WYS[5WODJGRR5 [M!+CO19_I"_U9Y]>.M>C2T.
M)6;9Z,6OMF(>S$1%YVQ$1 1$0$1$!$1 1%@WJUP7B@=253ZAD3B#O4\[X7@C
ML<P@I'J,Y%XPVCW&]:=UO>+30ZAO1I::;=CWZV0N#2 0"<\<9PO56S*>6IV?
M:=GJ97S324,3GR2.+G.):,DD\RO1J^'X=8MG.6*WW3A941%YVQ$1 1$0$1$!
M$6-<Z&*XT$U)4.F;%*-UQAE=&\>AS2"/44&2B\G;;X;IHK5L5':=17LT=13-
MJ&,DKI'%A+G-(SGB/!SZU+;!K56:XEO#[WJ/4 CHA$&,@KY&;Q?O9).3XO[U
MZY\+$4XF[DY<3GMP]-HM:7'9-%-$X46K=54LN.!-P=(T'S@X)]JU_H&@U/IG
M;?0V._WBOK:=T,TD;GU#W1SLZ-V';I//(Y=1'K7.NE6T3-;=&IM,=8>BT1%P
M;$1$!$1 1$0$1$!$1 1$0$47J&QTU]HVT]7+61-:[>:^EJ7P.!P1S81GGR.0
MO&6I;[?[7J*ZV^'4-Y?%25<L#7.K),D,>6@GCSX+T:&AQLXEB]]KW"BPK$YS
M[);WO<7/=3QDN)R2=T<5FKSSR;$1$!$5)VHZ>BN.G;I<F5USHZZCHI'Q/I*R
M2)N6-<X98#NGCS.,XZUJL1,XE)Y0NR+QELRU+?:G:#IV"IO5SFADKHFOCDJI
M'-<"X9!!/$+V:NNOH3HS$3+-+[HR(B+@V(B("*-U%9XKY:I:&>HJZ8/XB6EF
M=%(P]1#FG]QX+Q.W4^HHKD(7:@NS@R7</_C)..'8\9>C0\/QHG$]&+WVO=2*
M/OUJBO5KFH:B:J@9)C^DI9G12-(Y$.:<_P#9>)JW4FHJ2YSTWY0W=PAF='GN
MR3CAQ'C)H>'XV<3T+WVO=*+A"<PL)Y[H7->=L1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0:,^5A_AFR?KCOX"M??)C_.9_^92_>U;!^5A_AFR?
MKCOX"M4;"77MNN<Z89;GW#N63A7EXCW>&?H<<\E]31C/AIC[O/;^(]'[<YXZ
M?97J RD8?$R-N>MQD: O(&F:*HN6HK91T37.J9JF-C,=1+AQ]7->C-9Z"VBZ
MY9%37^\6*DM['A_<]&)=W>[3EN2>/6<*T[,MD]HT1)W;TCKA=RTM[ID:&B,'
MF&-ZL]N25STM6FAIS&<S*VK-[*;\K+^XK!^LR?PA5+Y/&J;9I*V:IK[O*X-)
MIF10QC>DF?\ TN&L;UE6WY67]Q6#]9D_A"@_DHVRCJ;G?:^HIXY*ND9"V"1P
MR8]_?WL=A.Z./XK5,?NO/_>:3_$Y):7Y13:>YNAJ]+U$-.TX=O5.)0.W=+0,
M^;/K6ZM-7RAU)9*6ZVJ7I:2H;EI(P0>1:1U$'@5YY^5A31,U)9*AK )9:5['
MN XD-?PS[Q5R^2K*]^A+E&YQ+8[@[='9F-A7+5TJ3HQJ5C#=;3NVRNFT':+9
MM$B&&NZ:JN,XS#1TX!>X9P"<\ ,\//U J'O6MM9VFURW2JT(T4,3.DE:VYL=
M*QG62T-ZASQG"UUMMV::KOVT&>Z6:B-;1U3(@QS96-Z$M8&EIWB,<03GEQ6W
MJVYTFF]"0T>K+Q1MKQ0"&5TTH!F?N8. >+LGS+.RE:UF.<SU7,S,YY(_9SM8
ML>MJCN*%LM#<]TN%-.0=\#GN.'TL=G ^97:\7.CLULJ;C<YVT]'3LWY)'<@/
M^YZL=:\0;.)I(-H&FGQ/+'=\:=N1V&1H(]8)"])?*<CJG[-0:4.,3*V)U1N_
M5X>!GS;Y8M:WAJUU:UCI+--29K,R[[%M+O>JNZ*G2&CY*RV0O,?=%56LIS(>
MP @\>76>:[[)M5;<-9T&EZK3]?;KK*YXJ&U+F[L0;&YX+2/IYQV <<\5I_8K
MM;AT=0.LU[I9)+8Z4R1SPC+XB>8+?\S>OM''GU;SHZ33^M=06+5UCN4,\ML$
MC'&)N2]KV$!CP<%I!)(R.L]J:NE73F8M7EY3S6MIM'*4SK75UIT=:37WJ<L8
M3NQQ,&])*[L:/_J!UJDT&TK4=TL$NH+7HITMEC#GA[Z]K99&-^DYK-WJP?9P
MRM)?*$OTUXVCUU,YY-+;@*6%F> ( +SZ2XGU +=.BMI.A[9HFS6RHOD$<L-#
M%%+&8I#A^X-X?1[<I.ALTXMMS,D7S:8SA;=GFO;1KFWR3VMSXZB' GI9<!\>
M>1X<P>HC]RMB\9[#;N^T;4K5T+R(*N0TD@')S7\!_P#%NGU+V8N7B=&-*^(Z
M-:=MT<Q$1>=MX?VM#&TK4N/+I/O7K#8]^;'3?ZHU>3]K7YR]2_KTGWKUAL>_
M-CIO]4:OI>+_ (-?]\GGTOS2KGREOS7U'ZU#]Y6C]@6H*33>L*RMK63RE] ^
M&&"GC+Y9Y#)'AC&CF3@^Q;P^4M^:^H_6H?O*U%\EV"*;:/.^6-KW0V^5\9(^
MB[?8W(\^'$>M-#'[M;*W_B0OEUV\5MENK:>]:+K:&-WA 3S%DA;XP:6 'V^M
M;8T;JJUZOLS+E99S)"3NO8\8?$[K:X=1_=V*A?*9M,-;LZ?7N8.GM]1&]C\<
M0U[MQP]!W@?4%JCY,EZFH-H!MH>>YKE ]KF=6^P%[7>G </6N?"IJ:,ZE8Q,
M+NFMMLO6"(B\+LT'\J75<E-1T.F:20M-2.Z:K!YL!PQOH+@3_P!(6W]"6YEI
MT99*%C0WH:.)K@/&W07'UDDKRKM]JG5FUF[M>26PF&%H[ (VD_O)7L6)@CB8
MP<F@ +V:]=FE2(\^;E2<VF5+VU?FMU%^KC^,+R)H7_&VGO\ F-/_ +K5Z[VU
M?FMU%^KC^,+Q[I,U U39C0B(U?=L/0B;.X7[XW=[''&<9PO1X+^%9C5_-#WM
M+(R&)\DC@UC&ESG'D .97Y\5+Q)42O:,-<\D#L!*]7ZGL>U/4EMFMTU?IJVT
MD[2R7N0S;[VGF"7-/ ^;"P= ;![;8ZZ*OU!5BZ5,3@Z.!K-V%KAUG/%W[AYB
MN7A[TT*S-IS,]FKUF\\EOT-4PZ2V2V>HU%,*6*EHF/E=)G+-[B&XYYX@8[>"
MC+-M%O6J:>:KT=I*2KMT;S&*FLK64^^X<P&X)_>N_;QI>ZZKT0VCL31+50U+
M)S#OAO2M#7 @$\,^$#Q[%!; --WO1=CN\FJWLM]'-(Q\4$TS<1D ASR0<-SX
M(Y_Y5RB*32=2?S9Z-<XG;Y%+MQI:&_2V?6-BJK)51/#)'"03M83R)P <8XY&
M5MZ">.HIXYZ>1LL,C0]CV'(<TC((/85X]^4!=+=>-HD]5:*N"KI^YXV&6%P<
MTN (/$<^I>A]@DTDVR>PNE>7.:V5@)[!*\ >H !:U]&M=.NI$8RE+S-IK*NZ
MFVW,TS=7VZ]Z7N%-5L =NF>-P+3R((R".'4LRKVV6.ET91WR6EG[IK'/;3T
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M^].#FDM([DFYC_H6:TM?\L969B.K8:*GZ8VDZ5U/=6VZR7,U%8YCGB,T\K.
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ML_K9=;R>^8/ZF/\ 1"YKA!_4Q_HA<U\YW$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M4,$LSW=0RTL ]KOW%;%VET&N-I3:.TT>G'V>U12=+++6U#,O?@@$AI)P 3P
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MG+'7&@<\LB>[=$K'XR 3P!RT8SPYK5FS31>U#3EUG=9J-EM94-$<[ZQ\;HB
M>!P"22,G! ZU[M'9P9VS$6<;9W<^B#^431TU!M&DIZ&GAIJ=E)"&Q0L#&MX'
MD!P6_?D_?FEL?_Y;_>>M3;5=D.J9;G!<J&:?4-141CNR5Q:QXER?HMR,,Q@
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MJN]"R4-":@-!B;6M?]%H;DGADG'8LW9EH?:-H.].JZ2WTE123-W*BE=6-:)
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M8X-H%>RWV,$&:CIMQLM4/%<6<FGKX^KK&XZ>"*FIXH*>-L4,30QC&# :T#
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M3&)P[0(B* B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B(! (((R#S!6OZ?3M?HBYU59I2
MG[LL=7)TM3:&N#7POZY(">'+FPXY<#R"V BU6TU28R(B+*B(B B(@(B("(B
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MO%NC.1$7!L1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M<.('!W#Z/,9XK5^P^DO6D-;BNNVFK^VDFIWTSGLM\IW"XM()&[R\']Z:,?\
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MHRU[L\3C(P2>K&%]/Q,;M&(CK&'FT^5IEMZ_W>CL-FJ[I<Y>BHZ9F_([&3V
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M7[*;MJ+4WY0:LHWT5NZ<U1@F:6OJ'EV]C=/$-SS)Y\ASR->'_P##-K7Y)?\
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M>[O-!(]65)+!L-MBLUEH+;3DF&C@9 PGF0UH&3[%G+Y<XSR>F!$10$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M,W\ZU?MVT%I#3UDI38(32WN6=L<5)',^5TS3G/@.)/9Q'7PZUM2'9-I>!H9
MRY10C_RF7&<-]F\IK3^A]-Z?J.Z+5::>*J\H?F27WW$D>U=*Z^R<[IG_ '[I
M-,QC#'V56>JL&SZR6VX MJH8<R-/-A<XNW3Z-['J5K1%YK6W3,RW$8C B(HH
MB(@(B("(B#BUC&9W&M;GG@87)$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1!YIVKWNZTNT"[PTMSKH86/9NQQU#VM']&WD 54ORCO?VS<O
MBG_BIW;!^<:]?IQ_[;535^R\-2LZ-.7E']GXOQ.I:-:_/SG^Z5_*.]_;-R^*
M?^*?E'>_MFY?%/\ Q44B[\.G:'#B7[RE?RCO?VS<OBG_ (I^4=[^V;E\4_\
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MOBG_ (I^4=[^V;E\4_\ %12)PZ=H.)?O*5_*.]_;-R^*?^*?E'>_MFY?%/\
MQ44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS
M<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS<OBG_ (I^4=[^V;E\4_\
M%12)PZ=H.)?O*5_*.]_;-R^*?^*?E'>_MFY?%/\ Q44B<.G:#B7[RE?RCO?V
MS<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q4
M4B<.G:#B7[RE?RCO?VS<OBG_ (I^4=[^V;E\4_\ %12)PZ=H.)?O*5_*.]_;
M-R^*?^*?E'>_MFY?%/\ Q44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q
M44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS<
MOBG_ (I^4=[^V;E\4_\ %12)PZ=H.)?O*5_*.]_;-R^*?^*?E'>_MFY?%/\
MQ44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS
M<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS<OBG_ (I^4=[^V;E\4_\
M%12)PZ=H.)?O*5_*.]_;-R^*?^*?E'>_MFY?%/\ Q44B<.G:#B7[RE?RCO?V
MS<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q4
M4B<.G:#B7[RE?RCO?VS<OBG_ (I^4=[^V;E\4_\ %12)PZ=H.)?O*5_*.]_;
M-R^*?^*?E'>_MFY?%/\ Q44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q
M44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS<
MOBG_ (I^4=[^V;E\4_\ %12)PZ=H.)?O*5_*.]_;-R^*?^*?E'>_MFY?%/\
MQ44B<.G:#B7[RE?RCO?VS<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS
M<OBG_BGY1WO[9N7Q3_Q44B<.G:#B7[RE?RCO?VS<OBG_ (I^4=[^V;E\4_\
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M0<2_>4K^4=[^V;E\4_\ %/RCO?VS<OBG_BHI$X=.T'$OWE*_E'>_MFY?%/\
MQ3\H[W]LW+XI_P"*BD3AT[0<2_>4K^4=[^V;E\4_\4_*.]_;-R^*?^*BD3AT
M[0<2_>4K^4=[^V;E\4_\4_*.]_;-R^*?^*BD3AT[0<2_>4K^4=[^V;E\4_\
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M0<2_>4K^4=[^V;E\4_\ %/RCO?VS<OBG_BHI$X=.T'$OWE*_E'>_MFY?%/\
MQ3\H[W]LW+XI_P"*BD3AT[0<2_>4K^4=[^V;E\4_\4_*.]_;-R^*?^*BD3AT
M[0<2_>4K^4=[^V;E\4_\4_*.]_;-R^*?^*BD3AT[0<2_>4K^4=[^V;E\4_\
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M%K:UR21,F8VB83&\D!PZ1_ X(./05.:GT?I&VZ&@OSK7+&2R&8QQ5#R7EV/
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M:7K-5W<4='_1QL;OS3EN6Q-[3VD\@%LR\:0TY?-F3M162W&V5$<#IPT2N?\
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M/^;1?[:I"N]!^9^Z?\VB_P!M</$=*_>/[O1X?K;[3_92$1%W><1$0$1$!$1
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MZEAVZ]W*W7<72CK)65^\7F8G)<3SWL\\]>5;+GM6U%7TS8WMH(Y6CP:AE/\
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MI'B]?.C$SENRFJK?K79;35MY?X-'NS5+N9#X3E_O-S[Z\\W:OEN=TJZZH/\
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M2T ?O:52M!4LT6V:*%T;NDAK*C?&/H@!_$^95*QZAN%CO!N5JE;33DG+6-\
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M4U?M?"_P:?:/[/Q'BOXU_O/]Q$1=G 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%=Z#\S]T_YM%_MJD*
M[T'YG[I_S:+_ &UP\1TK]X_N]'A^MOM/]E(1$7=YQ$1 1$0$1$!$1 1$0$1$
M!$1 1$0%+:1_Q59?UV'_ '&J)4MI'_%5E_78?]QJQJ?DG[-Z?YX^[T!LVNT6
MH+7?[%7XD=2U,T+FG_-"]SL>SPAZ@M%3:8J8M:.T\XXF;4]#OGD&<]_T;OA>
MA6#1E_\ R?VIU$TC]VEJ*N6FGSRW7/.#ZC@^HJ^[::>CLPFOL3@VZ5U,;?&T
M#D#].3T[F6_]07R=/=X;7FE>EXY?=]B^WQ/AXO;K2>?V2FQRXQW,7^6F&[1Q
MU+(*9OBQ,8&L'L&?22M%ZJIY:K7-WIZ=ADFEN$K&,'-SC(0 MN_)Q_N*[_K+
M?X51["8F[<"9\;G?68#/C;S]W]^$T)X7B-:8\H_M":\<7P^C$^<_WE]OVC+/
MI66U4>H:JMFKZT!TG<A8UE.W.,^$"7\<]G)85_V=W"V:SHK##*R85QS3U!&Z
M"WCDN'41@Y'XJ^[=:N&VW6U5-19:*O$D+F-EJ'2@M+79P-Q[1_FSQ52FU1J3
M7^H;)%14]-25]-(\T\\ <T-R 7%Q)/  9QY^O*Z:&KK7I75SRF)S,]/1SU]'
M0I>VECG$QB(SGU_J5VC[%:=84NF[I)=C43F-K:R,QMC<7\ 0P@G=SP^EU%1&
MO]&/T;>::&IG-305'AQRL;NO+0?"&#PR,CS<0KO>Z2EL^T"PPWRHJ;[J"HF@
M+IY'=%# WI,-W6-XDY!.,X\W%<OE)?U^G_T9_O8IH^(O.KIUSF+1.?7UCS76
M\/IQHZEL8FLQCT])\F#=-EUJ@TC%?(;S/#!)'%-O5+!AC'XSD-XDX/ #F<!<
M8MFEFO.CY;OI>ZU=1-$UQW:A@:'N;Q+< 9:>SB>85NUG^8:F_4:/[XUPV'_F
MTN'ZQ-_MM7G_ 'G6C1G5W<XMCRZ/3^[:,ZT:6R,37/GU>>ULOY/W^.I/U.3^
M)BUHME_)^_QU)^IR?Q,7U/&_^O?[/E>!_P#8I]U.UI_C"^_KTW\;EO7:_''4
M[*A+0@.IF=!(S=Y;G #U<0M%:T_QA??UZ;^-RF-,Z[O]OM[;+3-@N%)+_1,I
M:J'I1X7#= R"0>SDN.MH6U(TM2G\O-WT->FG.KIW_FY?W;>V14[:S90VFJ1F
M&45$9!\4N<#]Y54V4Z)%\T-622UE30FJJP6R08#G,C! 'HWG.]@5KU=>XM%;
M.8J*1M-#=:FG,4=/3,#&M>X>&X-'(-)/'K..U:$A@O=NH8KA#'<:6C>?Z.H8
M'L83YG#@O'X?3OK1J7K;;NMR_3+U^(U*:,Z=+5W;:\_UPV%KC9M?+';IJZWW
M:HN-'$TNE82YLC&]9QDAP'7]RUUIIE/)J*ULKBT4CJJ(2[W+<WQG/FQE;;V.
MZ[K[C4U=IU!.:NF93/F$\O%S&M^D''K&#S*TK*6F1YC&&9./0O=X6=7\>EJ]
M8\X]7B\5&C^#6T>D^4^C=FWAESNM\LMDM]--)"YAE;NM.ZYY);Q/(;H'J#E6
MJ.&WLN\MUE+:BRZ9IHX(W?Y:JH&2&CM!D+G>@>=5*+4&H;A3PVB.YU\T,I$+
M*?IG$.SP#>?$>97J@M-+<=4V71$+P^WV\NGN#V'A/4 9?ZA@,'9Q7&-.?#Z<
M:=IY1$].WG/W\H^[MQ8\1JSJ5CG,QU[^4?;SG[*,;3J'4<M5=H[;75G3/=))
M-'"YS22>..'[@H)P+7%K@00<$'J6X-L6HZTZBH],Z>DDIHJ7HV]'3$L+I78W
M6C'4 6X':?,M=ZZDCEU?=G0N:YO3N!<WDYPX.</203ZUZO#:UM2(FT8B8S'V
M>3Q.C33F8K.9B<3]T$O3MSHVZ4V15=/1C<?#0%KG-YF1XPYWIRXE>8EZAN%2
MW5VR:IFHCTDE10D[C>)$C1DM].\,+R?M/.=//Y<\_P#?ZO9^R\8U<?FQR_W^
MCR\IBV7^IH+#=[0T;])<&LWFD_0<QX<'#U#'L[%#K(IZ.IJ8JB6G@DDCIV;\
MKFM)#&YQD]G$KZ=HK,?B?+I:U9_"VS\G#^][U_H,_B*K6V_\XUP_TXO]MJLO
MR</[WO7^@S^(JM;;_P XUP_TXO\ ;:OF:?\ _0O]OA]34_\ YU/_ +?*U:._
M,-J'_4E^YBTRMS:._,-J'_4E^YBTRO1X/\^K_P#9Y_&?DTO_ *_Y$1%[7@$1
M$!$1 1$0$1$!$1 1$0$1$!$1!/Z _P ;V#]>A_C"Z-9?XOOOZ]/_ +CEWZ _
MQO8/UZ'^,+HUE_B^^_KT_P#N.7#_ )_T_P O1_P?K_A#HB+N\XB(@(B("(B
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M)YXGTEN/;53W2_ZWH+130R"FA@#FO<"(V[Q)?(YW(  #)\Q4-234=-<+EJH
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MQ.X#C &3SP3Z%042G@]*DQ:L<X]9+^,UKQ-;3RGTALK5FTZ'4>G76BHL?0Q
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M?)]%U^\>_P /+R+U#\U6COL@_%3?SI\U6COL@_%3?SI]9T.T^WR?1=?O'O\
M#R\B]0_-5H[[(/Q4W\Z?-5H[[(/Q4W\Z?6=#M/M\GT77[Q[_  \O(O4/S5:.
M^R#\5-_.GS5:.^R#\5-_.GUG0[3[?)]%U^\>_P /+R+U#\U6COL@_%3?SI\U
M6COL@_%3?SI]9T.T^WR?1=?O'O\ #R\B]0_-5H[[(/Q4W\Z?-5H[[(/Q4W\Z
M?6=#M/M\GT77[Q[_  \O(O4/S5:.^R#\5-_.GS5:.^R#\5-_.GUG0[3[?)]%
MU^\>_P /+R+U#\U6COL@_%3?SI\U6COL@_%3?SI]9T.T^WR?1=?O'O\ #R\B
M]0_-5H[[(/Q4W\Z?-5H[[(/Q4W\Z?6=#M/M\GT77[Q[_  \O(O4/S5:.^R#\
M5-_.GS5:.^R#\5-_.GUG0[3[?)]%U^\>_P /+R+U#\U6COL@_%3?SI\U6COL
M@_%3?SI]9T.T^WR?1=?O'O\ #R\B]0_-5H[[(/Q4W\Z?-5H[[(/Q4W\Z?6=#
MM/M\GT77[Q[_  \O(O4/S5:.^R#\5-_.GS5:.^R#\5-_.GUG0[3[?)]%U^\>
M_P /+R+U#\U6COL@_%3?SI\U6COL@_%3?SI]9T.T^WR?1=?O'O\ #R\B]0_-
M5H[[(/Q4W\Z?-5H[[(/Q4W\Z?6=#M/M\GT77[Q[_  \O(O4/S5:.^R#\5-_.
MGS5:.^R#\5-_.GUG0[3[?)]%U^\>_P /+R+U#\U6COL@_%3?SI\U6COL@_%3
M?SI]9T.T^WR?1=?O'O\ #R\B]0_-5H[[(/Q4W\Z?-5H[[(/Q4W\Z?6=#M/M\
MGT77[Q[_  \O(O4/S5:.^R#\5-_.GS5:.^R#\5-_.GUG0[3[?)]%U^\>_P /
M+R+U#\U6COL@_%3?SI\U6COL@_%3?SI]9T.T^WR?1=?O'O\ #S[H#_&]@_7H
M?XPNC67^+[[^O3_[CEZ1M^S;2MOKJ>LI+68ZBGD;+&_NB4[K@<@X+L%<:W9I
MI.MK)ZJIM9?//(Z61W=$HRYQ))P'8YE<_JVCQ-^)QC'E\NOTG6X6S,9SGS^'
MEA%ZA^:K1WV0?BIOYT^:K1WV0?BIOYUT^LZ':?;Y<OHNOWCW^'EY%ZA^:K1W
MV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1
MWV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ
M':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW
M^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1W
MV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1
MWV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ
M':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW
M^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1W
MV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1
MWV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ
M':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW
M^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1W
MV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1
MWV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ
M':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW
M^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1W
MV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1
MWV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ
M':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW
M^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1W
MV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1
MWV0?BIOYT^LZ':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ
M':?;Y/HNOWCW^'EY%ZA^:K1WV0?BIOYT^:K1WV0?BIOYT^LZ':?;Y/HNOWCW
M^'EY>I-C7YN+/Z)/]UZX?-5H[[(/Q4W\ZM5EM5'9;;#06V+H:2'.XS>+L9))
MXDD\R5X?'^/T_$Z<4I$]?/\ 7U>_]G_L_4\-J3>\QTQR_P#QFHB+Y#[ B(@(
MB("(B B(@(B("(B B(@(B(*I>?[RG](^X+#69>?[RG](^X+"7LKTAQGJ^HOB
M+2/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(
M@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#
MZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J
M+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HO
MB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(
M@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#
MZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J
M+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HO
MB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZB^(
M@^HOB(/J+XB#ZB^(@^HOB(/J+XB#ZK59/[LA]?WE516NR?W9#Z_O*XZW1NG5
MFHB+SN@B(@(B("(B B(@(B("(B B(@(B(*I>?[RG](^X+".<'&,]65FWG^\I
M_2/N"PE[*](<9ZM2:EVL7'3^J#8JK3U/)5ES&L='7'<=OXW>)C':KMJ2\WBR
MZ9FNAMM%/)31OFJ86U;@&M''P'&/PCC/,#UK16V63HMLL,FX]^X:5VZP9<[&
M. ':MI:ZU8*K1E\@[PZ@AZ2CE9TDU%NL;EIXN.> 6(M//,M8Z/NS7:)7:XJJ
MD4]F@I:6EW.FD?5ESO"SC=:&<3X)YD+8ZT5\ES^HU'^E!_\ 2*V5FM*Z[[2Q
MI.QS,I(*9KG5=9T8D>7!N2U@=P&"0"2#U]G&UM^',DQSQ#9*+5EIUM=:BMU9
MI^IJ(6W:T,DGIJL0C$T;.I[,XSQ;R[?-QBMGNL-::WM-T;13VRFJ*9S<5#X2
M<9!PT-SC)(YGEV'/"[X3;+="+3&S/7>J]:6^NM\#J"*XT^Z\U\L?@AAS@=&.
M;LCGP&.KMD=CFO+OJ&\7:RZ@Z&6JHVE[9XF!N</W7 @<.9&#PZTB\2368;61
M:PM.M:_6&O:^RV*H;06NWQN=)5"-LDDS@X-\'>RT#)[#P'GX=^@]=U5;J^Z:
M4OXB=<:.2005,3=P3M:>MO4[''APY]G%O@VRV._>W';@!=C@"<#*UO2;2:L[
M1V:1KK/#%.7[CIXJHO:/Z/?! +!GAA18UO?=5[1:C3VE:JFM]#1;YFJY(!,Y
M^X=UQ ) QO$ <NW/4JC1]V?^DC"+GT)JQ* \PY#'8IL!P!XC(P<<<9QD\UF;
M],+%>[T6BT]M;UIJ?1E^I!334SK16#>8]U/O.80?";SXX!!'I\RN=TKKI)=-
M.4MGN<+F5L;I9WNIP[,36@F0<>&2YC<<O"\RWNCHSA;D6G=5:ZU)9=J%-I^E
M?255+421=&Q\6X[#SP:79_?CU+JO.M]5:4VBVVU7VHH*VAKNC<6P0;@C:]Y9
MX)YY!!YDY'[IOA=LMSHM>[1M9UMCU)8+)01.C[Y2 250BZ0L:7;N&-Y%W6<Y
MP.HJ(O>MKQI':/;;%<:EETMM>V(B1\+8Y8M]Y9S;@'!&>7))O$$5EME%J/;)
MKB_:-O%O;;)Z9]+5L<[HY(,EA:0#AV>.<K#VCZQUGHZKM=PJ)K:ZAK'._P#
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M3R-GNEPEZ>KG P'.ZFM'4UHX ?BIQ9K&%F<M0;,J)]IVO:WHI@0Z;_Q4>?\
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MHV[C#] R;O(<' ^EI*VSM3;3.T/<()J6&IEJ&BEI(GL#OZ>0]'&6]A!=G(Y
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M5:Q%EV<V^^W5F_5S4T1;%]$RRN;GU#F3V!8B_.8MRP\]-><VKJ1C"Z$AH))
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M4]59 8XZ>KWNB=&0!C+03RR/^XP@A[G/6N^4%I1]73QTCI;;.WHV2[[BS$A
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M4;@./:3[5/\ R=_S2V?].?\ WGKMV6Z+N>E])U]AO$M%-%4222-FIGN)&^T
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MFDJ-GVFY9G%\CK?!EQYGP L[5O\ A6]?J4W\#EC:$ME=9=*VVU7+N8S44#(
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MY+=,VV4N>\?_ (9,.!:W_A;Q!=VD@=HJ7RAJADM%8HZ-S32Q2SQ/#!X+7M#
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MJ^NQDF60Y<1GEPXYZF@85_T[!66J]R6J>Z55SB[D;4%]407L?OEO @#P78.
M<XW3Q4+>M'7.+:)#JJR&CG>6;DM/5/<S!W-S>:X-/5CJ^]6VQVR2C=555;*V
M>X5;@Z9[!AK0!AK&CQ1Q]))/6LUB<\W+2I:+3GOR^RF[?/\  +OUJ+_YE==-
M?X=M7ZI%_ %2MOG^ 7?K4?\ \RNNFO\ #MJ_5(OX K'YY;K_ !K?:$DB(NCT
M"(B B(@(B("E*+^S,]?WJ+4I1?V9GK^]9MT6KN1$7-H1$0$1$!$1 1$0$1$!
M$1 1$0$1$$76?VE_J^Y=*[JS^TO]7W+I76.C B(J"(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B#HK8YY:61E),R"=PPV1\>^&_P#3
MD9]JJ>S?1,NB*&>A@NO=E'+,ZH+9*<->'D '#@[EX(X85S10$1%01$0$1$!$
M1!\=DM.Z0'8X$C."J/8-#5=GUC=-1-O39JBY;HJ8G4@#"!C ;AV0<#&>/K5Y
M10$1%01$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!=[?[&_P#3"Z%WM_L;_P!,*20Z$1%01$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 49J"Q6S4-$VDO5''5TS9!*UCR<!P! /#TGVJ31!AVVVTUN8]M()0U^,]),
M^3EV;Q./4LQ$0$1$!$1 1$0$1$!$1 1$0$1$!$1!"WK2]HO8E;=:9]3'+C?B
M?/)T;L<O #MWJ'4I6F@CIJ>*"!@9#$P,8T<FM P![%VH@(B("(B B(@(B("(
MB"GZNT)37^\4UYI;E7VB\T\?0LJZ-X!='DG=<TC!&25V6K2$T;V/OM_NEZW"
M'"*H+(X<CD2Q@&]_U$CS*V(I@R(B*@B(@(B("(B B(@(B("(B#LI_P"OC_2"
M^3?UTGZ1^]?:?^OC_2"^3?UTGZ1^]3S'!$14$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$$$[2-A-5-4]ZJ83S.+Y) W!<2<DDCSJ<' 8"^HI$1'1F*Q'2!$1
M5H1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!"7#2MCN,KY*ZV4]0][
MMYQD&<GM4Q#$R"&.*%H9'&T-:T<@!P 7-%,1#,5B.<0(B*M"(B B(@(B("E*
M+^S,]?WJ+4I1?V9GK^]9MT6KN1$7-H1$0$1$!$1 1$0$1$!$1 1$0$1$$%<;
MD^"LEC$,+@W'%S3GEZ5C=]Y/J*?W3^*ZKS_>4_I'W!82]5:1B'*9G*2[[R?4
M4_NG\4[[R?44_NG\5&HKLJF927?>3ZBG]T_BG?>3ZBG]T_BHU$V5,RDN^\GU
M%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C4394S*2[[R?4
M4_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ-1-E3,I+OO)]1
M3^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_BHU$V5,RDN^\GU%
M/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C4394S*2[[R?44
M_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ-1-E3,I+OO)]13
M^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_BHU$V5,RDN^\GU%/
M[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C4394S*2[[R?44_
MNG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ-1-E3,I+OO)]13^
MZ?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_BHU$V5,RDN^\GU%/[
MI_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C4394S*2[[R?44_N
MG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ-1-E3,I+OO)]13^Z
M?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_BHU$V5,RDN^\GU%/[I
M_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C4394S*2[[R?44_NG
M\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ-1-E3,I+OO)]13^Z?
MQ3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_BHU$V5,RDN^\GU%/[I_
M%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C4394S*2[[R?44_NG\
M4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ-1-E3,I+OO)]13^Z?Q
M3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_BHU$V5,RDN^\GU%/[I_%
M.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C4394S*2[[R?44_NG\4
M[[R?44_NG\5&HFRIF4EWWD^HI_=/XK*9<7FW23=##D2!N-TXY>E0:SX_[FE_
MUA]RDTA8F7/OO)]13^Z?Q3OO)]13^Z?Q4:BNRJ9E)=]Y/J*?W3^*=]Y/J*?W
M3^*C4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=
M/XJ-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T
M_BHU$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3
M^*C4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/
MXJ-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_
MBHU$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^
M*C4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/X
MJ-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_B
MHU$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*
MC4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ
M-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_BH
MU$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C
M4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ-
M1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?>3ZBG]T_BHU
M$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=]Y/J*?W3^*C4
M394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIWWD^HI_=/XJ-1
M-E3,IBDNDDE5$PPP .>!D-.1Q]*^5-TD942L$$!#7D9+3GGZ5@6[^W4_^HW[
MU\K?[9/_ *COO*FR,KF<,OOO)]13^Z?Q3OO)]13^Z?Q4:BNRJ9E)=]Y/J*?W
M3^*=]Y/J*?W3^*C4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=
M/XIWWD^HI_=/XJ-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T
M_BG?>3ZBG]T_BHU$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3
M^*=]Y/J*?W3^*C4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/
MXIWWD^HI_=/XJ-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_
MBG?>3ZBG]T_BHU$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^
M*=]Y/J*?W3^*C4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/X
MIWWD^HI_=/XJ-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_B
MG?>3ZBG]T_BHU$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*
M=]Y/J*?W3^*C4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XI
MWWD^HI_=/XJ-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG
M?>3ZBG]T_BHU$V5,RDN^\GU%/[I_%.^\GU%/[I_%1J)LJ9E)=]Y/J*?W3^*=
M]Y/J*?W3^*C4394S*2[[R?44_NG\4[[R?44_NG\5&HFRIF4EWWD^HI_=/XIW
MWD^HI_=/XJ-1-E3,I+OO)]13^Z?Q3OO)]13^Z?Q4:B;*F927?>3ZBG]T_BG?
M>3ZBG]T_BHU$V5,RDN^\GU%/[I_%3MMF,]%'(YK6DYX-'#F54%:[)_=D/K^\
MKGJUB(Y-4GFS41%P=!$1 1$0$1$!$1 1$0$1$!$1 1$052\_WE/Z1]P6"[.Z
M=T NQP!.!E9UY_O*?TC[@L)>RO2'&>K7%9M+?:]>4VFKW:HJ?IG,:*J*J,C!
MOCP3@L;UX![%L=:9VG:;.H:S6+Z=I-?;X**J@(YG FWFCTMSZP%=-GVKX+UL
M_AO5;*UKZ6)S:UQ_RNC'A'UC#O6LUF<S$K,<LPC=H.TQFE;]26FFMIN%3,UI
M=_3]&(RXX:TG=/$\_1A7ZB=4/IF.K8HHJ@_29%(9&CT.+6D^Q>?MHE',R'2-
MSKV%MPNUS?6S-/-@<8Q''_TL#1Z<K=.M-10Z:LPJY.C=-+*RG@;(_<:9'G W
MG=31Q)/8"E;<YR3'3">1:GU7KRKTRRCN,.H+/?*9TPCJJ*G:QKV-.?"C(>3P
MQUYYA7'6-]N%#:K=+I^A?6S5]1'"V01E[86/X](X#B0!YP.T]NMT)A9T5&N-
M_N.G]<6"T5E4ROHKNV1N\Z(,DA>P @C=P"TY P1GSKKVD:HO.G+MIZ&W14DM
M-<:QE.]KP>D/A-X!V<#.<9P<)N@POJ+6U^U#J;3&I;$;M46ZJM=UJ12N@@A<
MQU.XD $.)R[GS//!X!;)5B<DP*M6/5]%=]67NQ4Y'36T,R[/]9G@_'Z)P#YR
MLW5MV=9K#4U4+.DJSB*FB^LF>=UC?>(]65J74EI^;;5.E-01/+J:4=QW.7ZQ
M[LETA\YRYW_0%FUL+$9;R774F9L#S2LCDF \%LCRQI/G(!(]A78"' $$$'B"
M$6V6N--[0+SJ&ZW>WT&G:45%K?T<XDN):"[><WP3T9SQ:>Q2MEUU#4:D_)Z]
MV^>T7ES=^**5[9(YAQXL>.?(]0Y'KX+7NS&^6VRZ_P!>NNE4VG;+6'<+@3O8
MEDSR'G"DJFFJ-=[5K/=[92U,5DM#6EU;-$Z(3.#B[# X D9('M\V>46G'5N8
MA8-2:_N-AU=;['562GQ<'M;351K2(W9=N\?Z/((.,CCS"O[#)T(+VL$V[Q:'
M$MSV9QR\^%0=N&G77S1DM32@]WVP]UPEOTL#Z8'JX^EH69IG6]/7;-&ZDJ7
MOIZ=W=#1SZ5@P6_]1QC](+43B9B4QRY,S3>HKG=K]=:":U4\%-;I1#+4LJR\
M/>6[V&#<&< C.2,9ZU#7G7EUMNMJ33(L---5U;.D@D%<6L+?"XG,>1] ]JL6
M@[7-:]-4[:WC<*DNJZMW69I#O.]F<>I:XU[614&WK3%34=+T4=%X711.E=QZ
M8<&M!)Y]04F9B"(B96V\Z[JM,S4YU78WT=!.\1BMI:@5$;7=CANM<.1ZNI7B
M&1DT3)8GM?&]H<US3D$'D0M.Z[O1VFVW\G]&4TM4UM0Q]563-Z*. #.!AV'9
MSYNH\UM>R4 M=FH+>UYD%+!' 'G_ #;K0,_N5K.9]"8Y,U0-BN5XJ[[>::Y6
MD4=!3/:VDJ=_/=#3G)Q[#Z\*=?O;CMP NQP!.!E4;1NI[M=-<:DL]U92,BMH
MC$8IP[CO9.22>/#'4%9GFD+TBUU<=4:BBVF-TW2QVYT,M&:B%[FN&[Q(R\YX
MXW3P;C.1Q',<[#J&^T.T5^E]13TE:RHI>ZZ:H@AZ(C!.6EN3V'V#M3=!AL)1
M&J=16[3%IDN-WFZ.!IW6M RZ1W4UHZRI=:5VDR&[[:M)V6I\*A@#)S&>3G%S
MG'/J8T>U+3B"L97FVWK5=WIFUE)8:"BI7C>CCN%8YLSV]1+6,(;Z"<KY8M85
MM;K%VGKG9)+=4QTCZESW3"1C\.:T;A &0<GCYL85R6)+;J>6YTUP>S_Q5/&^
M)CAXKRTD'UM"8GN9AEHM9TVJ-57#:!>M-TS+5":2G;(V8A[FLWMT[Q&<N.'8
MQX(Z^KCSL6J;_:=>1Z7U>:6H[LC,M%6T\>X'8R=TC_I(\QQSRIN@VMDHJK)>
MJN[:GKK)998Z>.W,8ZMJWLZ0A[^+8V-SC.!DDYQRPN&F[AJ)NJKI:+U2&>WP
MQMEI;FV+HQ(#CP' <"[B>6.7+B%<F$36Z]NU-KF/2S;#2R5TK.ECD[O(C+=T
MNR3T>1]$]2R:[7TEAN-+2ZNL\EKAJG;D59%.)X"[L<<-+?6%3M3U]+;/E#6R
MJKYFPT[*+PGD$@99(!R\Y7?M4K#M"I[=I[2D$]815-GGK#"YL,+0US>+G  _
M2SP[.U8W3SYM8A<-I&LJO1=OBN'>N&MH9)!#O"J+'AQ!/%NX1C@>.58K-5UU
M;:(ZJJI*>GJ)8Q(R%DY>WBW(#G;HP>W /K6M_E"0"EV9T5.'%PBJX8PX\SAC
MQE6>TZQ@CM5$PV;4+BV%@RVURD'P1R..*UG\4Q*8Y,"VZ\NE=KJLTNVQTK*N
MD:9)9C7$LW,-.1_1Y/TF\,=:V$M*:$K&U^W_ %%4LAJ(&R4/".HB,<C<=".+
M3Q');K2DY+1AU551#24TM14R,B@B:7OD><!K0,DDJ/M]QJ[C;7UE+1M8V0!U
M*RHD,9D;XSL-)9GF!@G'/'(5#:M6.J+KI33@)Z"Z5P=4@?YXHRTEA\Q)_<MB
M<N2N<RF.36^E]H%YU)6W:EM^G*836R013B6XEN79<,-_HSGZ)[%+V'74%;J)
M^G[O03VB]!N^R"5P>R5N,Y8\<#P!ZAR/85KS9+?K99-6:[-TJVTXEK? WFD[
MV))<\AYPI,4M3K?:W;+[;Z6I@L=JB#>ZYXG1=.X%QPP. )&78] /:%B+3AJ8
MA/ZIU_<-/:KM]EJ;) 67"1K*>K-:6QG+MWPOZ/((R,CCS"O\9D,+3(U@FW>+
M6N):#V9QR\^%0]MFG#?]%3RTS2:^W'NJ M^E@#P@/2./I 63I'6U/<-FK=15
M;P7TM.[NH#GTK!Q'I=P(_2"U$XF8E,<LPS=/:BN=UU%=;=+:J:&GMLC8I:IE
M67A[G-W@&#<&2 1G)&,]:AK[KRZ6K6E%IL6*FGJJUN_!**XM86^%]+,>0?!/
M:K!H&VS6[3<!KA_ZQK'.K*L]?2R'>(]60W_I6NMHE7%0[<M*5-1TG11TN7='
M$Z1W.4<&M!)]04F9B,D1$RMMZUU6:9D@?JJQ/I*"9XC%925(J&,<?&&ZUPY=
MBN\$L<\$<T+VR12-#V/:<AP(R"%I_7=\.TJV/T[HREEJR)V.JZN9O0QP $XS
MO8=G([.H\UM33]N%HL5NMP>9!24\<&^?\VZT#/[E:SF?0F.3[?;D+1::FO?3
MU%2V!N^Z*G9O2.&>.!U]JC],:NLFIHMZSU\4T@&70N\&5GI8>/KY*>5)UWI/
M2M9"^YWET5JJ8SO"XPRB"1KNW>_S'T@E6<^21A=D6GMF^J-1U6I1;:.:;4.F
MVDM-UGIC"Z, '_,3X?' X\2MPI6VZ,DQA6]3ZBJZ"I9;[%:9+O=G1]*86R-B
M9$S) <][N R0<#F<'L4#I7:%4U>I_P G-469]GNSVE\(Z3?9*,$\#Z <8R#@
M]:OD-+##45$\<8$TY:9'=;L# ]0'5Z>U:_OU!W_VNV,TS<QV*!T]7*.0<_\
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M+YJ=I.-X@M ?C/$ CUJP37!TMJBK[3$VNB>ULK6L?NF2,C.69X$XY XSRR%
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M-Y.:PMCWSZ7M#O1E<]TXAK'5MK5VH*NP]PFFM?=XJZAE*QK)PQXD=G' MQC
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MU,2C$4GWI=Y3#[2G>EWE,/M*;ZF)1B*3[TN\IA]I3O2[RF'VE-]3$HQ9\?\
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M&4-"QW$=*\XWCYFCB?4.M2MKL=)0VHT4K15])X51+4 /=4/ZWOSS)[.0& .
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MG3/A# (V-P2]I;RX'>!]!4#LRTC:8M)]TU5II>EN[GUDL<L37;D<CMYD>".
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MC+=HRBL]@L$#FR,U#6U4;I*J*1S)QGPY0' YW0P.'9G!YE776>EJ'5EK;17
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M_>64=LT[/<H#"V0S,#R 22-W@TCJ'M5CT7>*N^6&*NN-O?;ZA[G-,#P00 <
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M8(IV.@9T98-W  '$?1''*NZ1"S+6.K=GMW.L7:JT1=X;9=9F".JBJ&%T,X
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MVLC:&L: UK1R '4N2(MNJE[2=*W34D-"^RW9]!44KG.#=]S6OSC!);Q!&.'
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M'2&:N@$U)64C7,8XG>&XYCB2#EIP<]G#CPUE,-@HM=MU]4WW759IC2<-*YU
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MU5D1$5!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MO-!WG #S K)VD:+O-WT5!2T%2VMNT=8VMGWR&-J'8(P 3@ 9  /4WGGBGEG
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MIZ>[4[Q401C=:2 [)P.7%K3Z05U;-JROH]>;07T5M=<(3<<2-BE8R1IZ27!
M>0TCGGB#RYJZ6>P5MPUH_5%]A;320P=RT-&'A[HFG.\][APWCDC ) !YE2L9
MB,$SB5>T6 -N.ML#']!%_"Q<8_\ VBY?^5_@N^NLFI;!M+N.H+#:X;O0W.%D
M<L1J6PNB< T9R[J\'/ 'FN='IK4PVI1ZEJ(;?T#Z,0S-$Q 9GFUG EQ  XD
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MZ086.+B3R ( ZSC"V"K7/FDX$1%MD1$0$1$!$1 1$0$1$!9\?]S2_P"L/N6
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M &0 #QSGL&%F8_\ +$X\F+5F->+8Y85[9E6OU%KZ[W*X?TKV0N$+7\1$TO
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MD:[  SDM:1Z%((ICGE<^0B(J@B(@(B("(B B(@(B("(B B(@(B("(B L^/\
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M^HW[U\K?[9/_ *COO*S_ #+Y.A$1:01$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M=?H/2]PO7?:ML='-<"X.,KV9WB.LMY$^<A2--IVSTU;55E/;::.LJ2735#6
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M]S0B8W9[B(BZ/0(B("(B B(@*4HO[,SU_>HM2E%_9F>O[UFW1:NY$1<VA$1
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MT"#@BY[L?E-/^T";L?E-/^T"#@BY[L?E-/\ M F['Y33_M @X(N>['Y33_M
MF['Y33_M @X+"N%JM]RW.^-!25>YG<Z>%LF[GGC(..2D-V/RFG_:!-V/RFG_
M &@08%OM=!;0\6ZAI:0/QO=!"V/>QRS@<>:S%SW8_*:?]H$W8_*:?]H$'!%S
MW8_*:?\ :!-V/RFG_:!!P1<]V/RFG_:!-V/RFG_:!!P1<]V/RFG_ &@3=C\I
MI_V@0<$7/=C\II_V@3=C\II_V@01%3IZRU4[YZFSVZ:9YRZ22F8YSCVDD9*D
M*>"*F@9#311PPL&&LC:&M:.P <EW[L?E-/\ M F['Y33_M @X(N>['Y33_M
MF['Y33_M @X(N>['Y33_ +0)NQ^4T_[0(."+GNQ^4T_[0)NQ^4T_[0(."+GN
MQ^4T_P"T";L?E-/^T"#@BY[L?E-/^T";L?E-/^T"#@BY[L?E-/\ M F['Y33
M_M @X(N>['Y33_M F['Y33_M @X(N>['Y33_ +0)NQ^4T_[0(."+GNQ^4T_[
M0)NQ^4T_[0(."+GNQ^4T_P"T";L?E-/^T"#@N]O]C?\ IA=>['Y33_M NYK6
M=RN'3PXWAX6_P0AC(N>['Y33_M F['Y33_M @X(N>['Y33_M F['Y33_ +0(
M."+GNQ^4T_[0)NQ^4T_[0(."+GNQ^4T_[0)NQ^4T_P"T"#@BY[L?E-/^T";L
M?E-/^T"#@BY[L?E-/^T";L?E-/\ M @X(N>['Y33_M F['Y33_M @X(N>['Y
M33_M F['Y33_ +0(."+GNQ^4T_[0)NQ^4T_[0(."+GNQ^4T_[0)NQ^4T_P"T
M"#@BY[L?E-/^T";L?E-/^T"#@BY[L?E-/^T";L?E-/\ M @X(N>['Y33_M F
M['Y33_M @X(N>['Y33_M F['Y33_ +0(."+GNQ^4T_[0)NQ^4T_[0(."+GNQ
M^4T_[0)NQ^4T_P"T"#@BY[L?E-/^T";L?E-/^T"#@BY[L?E-/^T";L?E-/\
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M[0(."+GNQ^4T_P"T";L?E-/^T"#@BY[L?E-/^T";L?E-/^T"#@BY[L?E-/\
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M("(B B(@(B("(B#(MW]NI_\ 4;]Z^5O]LG_U'?>5]MW]NI_]1OWKY6_VR?\
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M7/1]/#4[*K1'411RQFV,\%[01_5J-UH]TFP^H>\DN=:X22>LX:I?0_YK[/\
M\K9_MI_-^AY(#Y/'YN(?UF7[PMCU,\-+ ^>IECAAC&\^21P:UH[23R6N/D\?
MFXA_69?O"V60",$9"M/RP6ZJI+M#TK'23U/?B!\,,G1%T8<_>=C.&@#+N'6,
MA2.E]46?5%+)/8ZUE2V,@/;@M<PGEEI (6OM@M+ VJU=.(8Q,+D^,/W1D-R3
MN@]BX4]$RR?*%;%;&"*GN5O=-41L&&Y\+CC])@/I)68M/*3$=&PZK5%K@J*J
M!LD]3)2?V@4M/),(?,XL! /FYK*I+Y:ZNSMNT%?3&VN;O"I+PU@&<<2>7'AQ
M53T@RW6ZKO='HZ.:O=)6.EK*FHFQ!%*>; X#+B.P ^=RBOD\YDT5<62X<UMS
MF:!C@!NL./:2K%IS@PLM5M&TK36UU?)=XG4HG-.'L8YV\\ $[H R0 X<1PX\
MU#77:32LUO9[12-J#12,=/45 IWNZ1IC<6"-H:2X9P2X#J]*A?D^VJ@J]&7@
M5=)!.V:X/B>V5@<',#6$-P>K))61?&,B^4%IB.-K6,;;'M:UHP  )L !9W3,
M1*XC.%HUI<]'2VNE?JR6D-/EM1#%4M<),]1$?T_5CTJV5$\5-3R3U$K(H8VE
MSWO<&M:!S))Y!:L^4FQIT'3.+1O"OCP<<?H2+/VO5O\ X_1]HG.*"X7-@J0>
M3VM<W##YB7#V+6[$RF,K')K>Q1&G-14S4\%0X,AJ9Z:6.&0GEB1S0WCVYP5T
MZ^K-(QT<+-8S4+HXWB:**8[S\C."&CPCU]6%*:ITY;]3V=UMNT;GTQ<UXW';
MKFN'(@^T>M:[^4530T^SJBCB8 V*LB8S/$@"-XYI:9B)(Q,MCW[4-IL%.)KS
M<*>D81EHD=X3OT6\SZ@H.Y;2M*6Z>**KNS&OD:UW@Q/>&APR-X@'=.#R/%1>
MWMK3LQN)+02'PX)'+^D:IVU6.WU^SZBM<U+%W'/0QAS T  E@\+]+/'//*9G
M.(,1C*>%PHS;N[Q50]P]'TO3[XW-S&=[>Y8PH8ZSLK6TLDM1/#353@R"IFII
M&0R$\L/+0WCU'.#U+6FS"*BN6Q:[4.IZM]/:(:J2,SM?NEC 6/X'!_S$\,'.
M<+)VJ5$D^R'%#1/I[/$VG9!)5/\ Z:1@<T-=N < 1CB3GS!3?.,FWGALW46I
M;/IV 2WJX04K2,M:XY<[T-'$^Q1=SVA:8ME>RDK+HQDKG!I(8YS&$]3G 8:?
M,3PZU4]MY,FR*!\GA/WJ9V3VD<UG[4Z.FAV,5D44$;(HH(',:UH :=]G$>?B
M?:DVGF1$+!M"U;%I+3DMQZ&2IE<-V%K&$MWCP!<X<&MR1SY\@N_1VH(+OI^E
MJ)99>GCI8I*F26!\+=XLRX@N: 1D'B,A4;7;W2?)X@>\ESG4-"23U^%$K=26
MMUZV6TML9+T+ZNTQPMD\4F( 9\RL3,R8C#,_+"SB*&9TU0RFG>UD-0ZEE$4A
M<<-W7[N#GJ/7U*P+2]IUC-8Z>GTGM)MKZ2-C60P5\8S$\,(W'$^; \(>L!;H
M:0X M((/$$*UG*3&!$1:01$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!9\?]S2_ZP^Y8"SX_[FE_UA]RS988"(BT@B(@(B("(B B(@(B("(B
M B+A/((8))2US@QI=NL&2<#D!VH.:I&V)U=3:$NE;07*JHGP1M($!#2[+P#E
MV,\CU$>M<J/:'3557!3MT_J:,RR-C#Y+<6L;DXRXYX#M*^[9_P V5^_TF?[C
M5B9B8G#41B4WHMSGZ.L+GDN<:" DDY)/1M7/5%#5W.S34%!4FD?4D1OJ&G#H
MHR?"+?\ BQD#SG/4NO1'^#+!_P OI_\ ;:II:CHGFU9>]G=NL]EK;C4ZEU.8
MZ6%TKO\ Q^,[HSCZ/6HM]=<[)HW1%@-;4LN&H*AO=-4Z0F6.-SFEP:X\0[#V
MCS8*MVU)QN++)IJ,^%>*UHF Y]SQ^')]P'K7W:AI&JU%1VRJLLL4-WM4XJ*7
MI.#'<B6GLXM:?5YUSF.N&HGNP-I%N;I739U!IEIHZVWR1N>&..[41EP:YL@S
MX7,')X\.:O=EN$=VL]#<(!B*JA9,T'J#@#C]ZU;M7O=\DV=U5/=;-!;Y:MT=
M.!W4)G2O+@<1M:/^$GB?45LC2%N?:=+6BWS?UM-2QQ/_ $@T _O6H_-R2>BE
MWYIK=MMLH*B6<T1M!E,#9G,87B209(!&2MC4T$=- R&%I;&P8 ))_>5KNX_G
M^M?_ "1W^X]6+4FL(+#7MI);1>ZQSHQ)TE%1F5@R2,9!Y\.7G"1.,S)*QS->
M^)S8Y#&\C > "1Y\'@M:[-9ZQVT76]+6W"JK6TSX61NG<"6M\,X   '/J 5[
MT]=V7NW"LBI*VD:7%O15D)BDX=>[V*A;.?SI[0?]6#[G)/6"/-L]4R\Z5EU9
M65;KY6U]-;HW]%2TE--T0<!SD?CZ1)S@<@ .TJYK'N%;!;Z.6JJY!'#&,N.,
MGS #F23P '$DK4QGJD-7: ;<M+[2;AI&2OJ*^TNI.ZZ8SNWGQ#(&,^LCLX \
M%>=7W2HIJ4T-J<!=*B-[F.(R((VCPI2/-P '6X@<LJ+LU"ZUOONL+]&YE;40
ME_0CPG4U-&W+8_.X@9=U9X=2K-MVB:5%NN-77W<.N]PC/2-%/,1$,'<A:=SD
MW//K)<>M8B<1AKJG=ADTD^S2V2SR/DE>^<N>\Y)/2OYE3^M-44&D[)-<+C(T
M$ B&'/A3/ZF@?>>I4?8!J*URZ1M]BCJLW6$32O@Z-W!O2$YWL;O)PZ^M2>WQ
MC3LSN3BUI<U\."1Q'](WDD3^#,$Q^)<K%=Z2[VZ*II:JFF/1M=*(90\1N(R0
M<'AZUQI=06:JJQ2TMVH)JD\!%'4,<X^@ Y6N=I-8:33.D;5#_04MVJ:>&K='
MX)=%AN\TD=N?W*U[2K%27#0=R@$,<;J*G=/2N8-TPOC:7-W<<N6.'4KF4PMR
M*J[++M4WO05GKZYQ?4OB+'O/-Y:XMWCYSNY75>-=T]KN4]$^QZAJ'0NW3+34
M!DC=PSX+L\5=T8RF/)DZDL]7J&O%!+5U=%9HX@^5U*_HWU$A)&YO<PUH&3V[
MP[%K^6UU>SK:#IV"SW&LJ;->9C3RTE1)O[CL@%P]&\#GGP(/-;;MU<RMMD%=
MT<U/'+&)-RH;T;V#_B!Y%5F@MYU'JNGU%4M(MU!&Z.V,<.,CG?3G([",!O:!
MGK"DQGHL2N*I]TT3!J%TTVHZJLEE>X]#%!4NCCIVY\'= X%V.)<<Y/FP%<%#
M:ILDM^MLE''=:ZW->TM<ZE+ 7 ]1):3CT$+4QE(5G8O-<GZ?N$%QJ9:RFI:^
M6GHZF4Y=+$TXSGK&<X/JZEPVNWBL9IJ\45GE,<L%+TM9.W_RF'@U@_XG<?0T
M$]85<TKJ:XZ)HM466_3=VBQB'N28@\62<&!V,G=XM/60,CC@+&U1K32CMG5X
MME%>#672LC+Y9#32M,\Q(R<EN .& ,\  .I<]T;<-8YY;*TK1P7'0VGV5C72
M#N&!WTW-.>C''(/G5>V1OE%QUE3/GGEAIKL^*%LLKI-Q@S@ N).%)[*]16N\
MZ7M]';:KIJB@HX(ZEG1N;N.W,8R0 >+3RRHO9+_?FO/^=2_>5>R=UHUO8S?M
M/5=-!--!6B-QII8971ELF.'$$<"0 <JF[$JFGOVA)J2OZ:2M@F=!5F29_2..
M<M.<Y' XX>*5M!:.?<XMF^UN^=TY9:;M2NK& <ND <X#TEP>T#_B"6Y3DCG&
M&7LFD-LVB:DT]=*RHK*JF=OT<LU0Y_@ G(P3C.ZYI/H*N&LK;%>-6:?H&2U,
M<F7U548)WQY@8,!KMTC@Y[V^?@5KG5EJJ=&2:1UD]I[MZ8]]2!Q<Z4E[A['2
M-]35L_1<C+S=+SJ)C@^"HD%'1O'$&"+(+AYG2%Y]04K_ /\ ,K/=0]H5$VDV
MI:2H*2HK(**M+1/#'52-:_#^S>X9'#@MQMI86TG<H9_0;NYNY/+T\UJ;:;PV
MPZ$)Y;^,_P#6MOK5>LI/2%$T'9X*?4>J)#-52]S5XB@;+4/>V)AB8\@ G'-Y
M]@5[56T=_?FKSU&YM_\ L>%6E6O1)$1%I!$1 1$0$1$!$1 1$0$1$&1;O[=3
M_P"HW[U\K?[9/_J.^\K[;O[=3_ZC?O7RM_MD_P#J.^\K/\R^3H1$6D$1$!$1
M 1%4];ZR;I::DC=;Y:ONAKG98_=W<$>8]JS:T5C,LWO%(W6Z+!>'5@M\HMC6
MFK?AD;G_ $6$G&^>T <<=>%I[:#HBJL=";[%>*FKJ&2-Z9\G@O!)P'-(/;CA
MYULS16IFZHM\]4VCDI!%+T>Z]V\3P!SR':HK6---JRJ98*%Q910R-DN%2.3<
M<6Q-[7=9[.'H7'5BNI7,?H\^M6NK3='/LS='WYTV@J2[WB3=+(7.ED/-P:XC
M/I.!ZRJ[IFON.T"Y55143345@IG;C::!Y8Z=W/#W#CRP2!VCTKOVJ-@H=GTM
M!;=UL-/)# ]C3]!O, __  GUJJ6^PTDFR%]UB:Z.XPO=*V9CW C$FZ1C..06
M+6M$Q7KB,SZN=[VBT4ZXC,^K<]!0TMO@Z&BIXX(LY+6-QD]I[3YUQN<53/2.
MBHYQ3R/(!EQDL;UEHY;V.6?3YE4]D5ZJKSI8FOD=+-33&'I'')>W (R>L\<>
MI79>BDQ:N8>NEHO2)CI+2NU;2U+8HJ*XVZJK#6S3]&X23%[WG!.\#SSD?O"V
MKIN2J;IF@ENQ<VK;3M=.7\P<<<^?M5$VIZ+EJJ>HOE'753YJ9IE=!*\N:UHX
MGH_%QSPK#LNN53>=&027%QED:Y\)>_B9&CD3V\#CU+CIQMU)C&,O-I1LUK1C
M&53TEW1M!U%77&[R3=Z*0[L-*V0L;D\LX/,#B3VD=2DIVUIL-/#17FY/GN-1
M)!0Q=(W B#W8D+MW?(# '?2[.U2=GT1)9H:VDI;Q)'9ZEYDDA$0$@&,$=)G@
M,#&<9]'-1%??HK105&IA TM<.X+/3D8:(AS?CL<1GT #K68KMC\77S9BLTK^
M/KYRV%:+?#:[;3T5,#T4+-T$\W'K)\Y.2?2LM4'3TVH8[;;KQ=KFZ1];/$TT
M)B:&".1P P0,AP!WO0,%7Y>BELQTP]>G:+1RC#6FW$GO9: "0'56#@XR-U7^
MVVNAMC'MM]+%3M?C>Z-N-['+/:J!MQ_NVS?K?_97K45T%FLM5<#"Z<0-#NC:
M<%W$#_NN=<1>TSZ.5<1J7M/EA(K7NI-$W#50FJ[C<Y*:3)[FHPW,<3>K>X\7
M'F2.6>O"[M*[167^]P6YMJGIS*''I'R9 PTGECS*R:FNDENHA'11F>YU.8Z6
M$<W/\8]C1S)5F::E<^2S.GK4SUAK_8A<Z]U1<[35R/D@IVAS XYZ-V]@M'F/
M9YESTM<FZSV@W-UP:VHMU)"\4U/(-Y@\(-WMWD21GCY_,K5HO3<&EK6:>2=K
M[E7.)EE\=^"=UOF R?:5K[82QT>I+HQX(>VFP0>HAX7&(FNRDO/$6IP].R=V
M87V:+4=WTW42OD@IY9.Y2\Y+0QY!;GLQ@CT%;/6D="Q/?MCN+F [L<]4YWHW
MG#[R%NY=?#S,UYNWA;3-)SY2U'MHFNU!3T7_ *VE-/5.>UT$3>C:,8QR.3SZ
MR5LG2O\ ABT?J</\ 6N]OW]CLW^I+]S5L32O^&+1^IP_P!2G\6T)I_Q[Q]E#
MVAW>X7/5=#I2TSOIFR[IJ)(SAQ!XD9[ WCYU+"U4UGN4\%NNE=;J"EHA/5;D
M@>,Y."=\. )#7$XQU+.O.D75.IZ>_P!LK^XJ^-NX_?A$K'C!'+(P<''L6!<*
M.%]>ZTOG?-"W%QO-5)C+VCZ$9QP .[]'J:WS\9-9B9F4FMHM-K=^7^_W2&@K
M=*REGNU<Z=]7<#OM[H?O/CA_R,)ZN!R<8XGS*U+6>F;S?=;7:LGHJY]JLU*=
MV,11M<][NK)<#U<3U<AYU>].U<M?9*.IJ-TRR1@N+1@./+(\QY^M=-*T3&(=
M=&\3&*]/[N^ZW&EM5!-6U\S8:>(9<X_<.T^94W06MH[_ '"Y]UU,-.'S-91T
MSW@/+<'D.LGK5KU&UKM/W,.:'#N:0\1G_*5KG8)&QUONKG,:7-F9@D<1P*S>
MUN)6L,ZEK1JUK'1LVXW&CML39*^JAIV..ZTR. WCV#M/H7&W7.AN37F@JH9^
MC.'ACLEI[".8]:U735DMVVWM95DNBHWR1PL/)NZP\1Z^*:IK);/MEH9J,EIJ
M>A9,UO)X<=T@^H ^H*<;S\LX9_>/YL<LX;@1%K*3:Q&RJ=#WDJ3NOW-[I1VX
MSR76^I6GYG:^K73_ #2N5\L1ODCH:^JF9;@T!L%.\L+W=9>>L<L#EUGS:NTE
M;ZJR[5I;99IIIJ"%Y$YSEO1EN?"ZL@G'I"W)<*45M'+3F::$2#'20OW'M]!Z
MEI*[6FX: UE;YZ"LEGIZR4;I<>,@W@',>.L\1Q\^5PUHQ,6P\_B:[9K?'2>K
M:FJK77WPLM\%7)06\LWIYXOIR'.!&WCP'63Z!VK4\M!<- :]M]/1UDD\%0Z,
MCJZ5CG;I:YO+//\ <5O:>:.G@DFG>V.*-I<][C@- YDJCVNSOOVI_P J;LPP
MTD#0V@@D&#N#)$K^SB20/..Q:U=/,Q,=6M?2W3$U_-_A>U'ZBN M5BKZXD P
M0N>W/6[' >W"SHI&2Q,DC<',> YKAR(/(J-U+98-06B6W54LT4,I:7&$@..#
MD#B#PR%VMG')Z+9VSMZM36[9^RZ.Q1:QI:F4\7-B\(^S?RMM:9M(LECI+>)3
M,86X=(?\[B<D^TK4^J-F-18Z22Z6*OEE[E'2ECANR- X[S7#F1SZEM'1=QFN
MVEK;6U7]?+$-\XQD@D$^O&?6O/HUBMIB8Q+R^'K%+36:XE0*2HJ=>Z[JZ:>:
M5EAMQ.88WEHDP<#>QS).3Z!A2M0):"U7)]#=+ET/=AH[?2LD:0]^ T-#G-+L
M!^_R=R:I*@T7-:[M<JBSW9])2U[MZ:(0!SVG)/@.)X?2..!454W"CMD=1>6Q
M9M-D::.WQ9_KISP>_/7Q\'/Z13;-8S;JFV:QF_7GS_WRPN>F;2VRV>"DWS+,
M/#FE<<F60\7.)/G_ '86=64L%;3OIZN%DT+\;S'C(.#E:[L%?J2LL,FI:^Y=
M&PO#H*%L+>C>S>Q@\,\>0XYY'BME+M28M&(AZ-*T6KB(Y-6Z<IH:';-=*6D8
M(J9E+EL;?HMRV,G ])*VDM9VK\^-W_5!_!&MF+.CTG[RSX?I;[R(B+L[B(B
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M(@(B("(B B(@(B("SX_[FE_UA]RP%GQ_W-+_ *P^Y9LL,!$1:01$0$1$!$1
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MZ/2MW&X&>!+2[!]J&%R10VIK_!8J".8P3UE1.\14U+3-WI)WD$X:.S ))/
M*C4VU:>AU!26S6&F*VP,K'[E/4R2B6,DG !(  YCD3C/'AQ3)AM)$7":6.&%
M\LSVQQ,:7/>XX#0.9)Z@J.:(B B(@(BINM-:RZ?N,%!;;#<;Y6.BZ:6.B;DP
M,)PTNX'Z1#L?HE07)%5]$ZDN6HFU4EPT[6V2*'=:P5AP^4GG@8' <./G5H5!
M% ZJU5;=,PP&O?))4U+^CIJ2!N_-4/[&-Z_2<#SK)LM5=:L=+<K=!01N;EL7
M='2R@_\ %AH:/47>E02J*GZUUG+IZMIJ*W6.X7NMEC,TD-$W)ACS@.=P/,Y
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M8Y]1/,\MCBQS:, EQX@=6%STCK6&]7BX66LI^X[O1/<U\0?OLD#3@N8[ \W
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M-V&(<Y97'=8P>EQ ]:TG<[7+LNU]I6_SS.D@NC#2W>8G@Z=YWGO)[,D. _\
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MV.VT @EIJ <=1Z5Y_P"X3S/)!;,JO66T#1]15SZG-M(JY&"6"E8Z1Y#6X''
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M+C;J&YP=#<J.FK(<YZ.HB;(W/H(*CW4-BTW;JNHIZ2VVJ#</221Q,@:>'60
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1$0$1$!$1 1$0$1$!$1!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tectonic Therapeutic, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001681087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-0710585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">490 Arsenal Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">666-3320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">490 Arsenal Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">666-3320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Daniel Lochner<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 141,239<span></span>
</td>
<td class="nump">$ 28,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,618<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">146,857<span></span>
</td>
<td class="nump">30,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,151<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance right-of-use assets, net</a></td>
<td class="nump">919<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">2,235<span></span>
</td>
<td class="nump">2,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">152,905<span></span>
</td>
<td class="nump">39,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,850<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_SAFELiabilitiesCurrent', window );">SAFE liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,610<span></span>
</td>
<td class="nump">40,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, non-current</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,129<span></span>
</td>
<td class="nump">43,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock (Series A-1, A-2, A-3 and A-4), $0.0001 par value; no shares authorized, issued or outstanding as of December 31, 2024; 3,647,675 shares authorized as of December 31, 2023; 3,647,675 shares issued and outstanding as of December 31, 2023; aggregate liquidation preference of $87,459 as of December 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity (Deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, 10,000,000 shares and no shares authorized as of December 31, 2024 and 31, 2023, respectively; no shares issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 14,856,309 and 1,407,753 shares issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">289,351<span></span>
</td>
<td class="nump">5,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(148,586)<span></span>
</td>
<td class="num">(90,604)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">140,776<span></span>
</td>
<td class="num">(84,636)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 152,905<span></span>
</td>
<td class="nump">$ 39,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_SAFELiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Safe liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_SAFELiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">14,856,309<span></span>
</td>
<td class="nump">1,407,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">14,856,309<span></span>
</td>
<td class="nump">1,407,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,647,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,647,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,647,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary Equity, Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 41,364<span></span>
</td>
<td class="nump">$ 36,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,651<span></span>
</td>
<td class="nump">7,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">58,015<span></span>
</td>
<td class="nump">44,648<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(58,015)<span></span>
</td>
<td class="num">(44,648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ChangeInFairValueOfSafeLiabilities', window );">Change in fair value of SAFE liabilities</a></td>
<td class="num">(3,610)<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LossOnIssuanceOfSAFEs', window );">Loss on issuance of SAFEs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(511)<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(57,982)<span></span>
</td>
<td class="num">(42,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Comprehensive loss</a></td>
<td class="num">$ (57,973)<span></span>
</td>
<td class="num">$ (42,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (6.83)<span></span>
</td>
<td class="num">$ (33.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (6.83)<span></span>
</td>
<td class="num">$ (33.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">8,490,171<span></span>
</td>
<td class="nump">1,268,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">8,490,171<span></span>
</td>
<td class="nump">1,268,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ChangeInFairValueOfSafeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of SAFE liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ChangeInFairValueOfSafeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LossOnIssuanceOfSAFEs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Issuance Of SAFEs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LossOnIssuanceOfSAFEs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Convertible Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (45,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47,781)<span></span>
</td>
<td class="nump">$ 80,627<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,525,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,825,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Retroactive application of reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,175,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,177,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AdjustedBalanceBeginningOfPeriodValue', window );">Adjusted balance, beginning of period</a></td>
<td class="num">(45,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,781)<span></span>
</td>
<td class="nump">$ 80,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AdjustedBalanceBeginningOfPeriodShare', window );">Adjusted balance, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,349,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,647,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs', window );">Contribution from related party investors related to SAFEs</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss', window );">Foreign currency translation adjustment</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(42,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="num">(84,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,979<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(90,604)<span></span>
</td>
<td class="nump">$ 80,627<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,647,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">52,833<span></span>
</td>
<td class="nump">388,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of convertible preferred stock into common stock in connection with the Merger</a></td>
<td class="nump">80,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (80,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of convertible preferred stock into common stock in connection with the Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,647,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,647,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue', window );">Issuance of common stock to related party investors upon redemption of the SAFEs</a></td>
<td class="nump">34,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption', window );">Issuance of common stock to related party investors upon redemption of the SAFEs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue', window );">Issuance of common stock under subscription agreement</a></td>
<td class="nump">94,601<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">94,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement', window );">Issuance of common stock under subscription agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,163,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IssuanceOfCommonStockUponTheMergerValue', window );">Issuance of common stock upon the merger</a></td>
<td class="nump">68,891<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">68,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IssuanceOfCommonStockUponTheMerger', window );">Issuance of common stock upon the merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,777,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss', window );">Foreign currency translation adjustment</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(57,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 140,776<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 289,351<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (148,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,856,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AdjustedBalanceBeginningOfPeriodShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted balance beginning of period share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AdjustedBalanceBeginningOfPeriodShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AdjustedBalanceBeginningOfPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted balance beginning of period value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AdjustedBalanceBeginningOfPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution from related party investors related to SAFEs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency transaction and translation adjustment net of tax other comprehensive income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to related party investors upon redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to related party investors upon redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IssuanceOfCommonStockUnderSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock under subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IssuanceOfCommonStockUnderSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock under subscription agreement value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IssuanceOfCommonStockUponTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Upon The Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IssuanceOfCommonStockUponTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IssuanceOfCommonStockUponTheMergerValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon the merger value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IssuanceOfCommonStockUponTheMergerValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="nump">$ 9,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="nump">9,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tecx_AtTheMarketFacilityMember', window );">At the Market Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Net of offering costs</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tecx_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tecx_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (57,982)<span></span>
</td>
<td class="num">$ (42,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,491<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LossOnIssuanceOfSAFEs', window );">Loss on issuance of SAFEs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_NonCashLeaseExpense', window );">Non-cash&#160;lease expense</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ChangeInFairValueOfSafeLiabilities', window );">Change in fair value of SAFE liabilities</a></td>
<td class="nump">3,610<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,194)<span></span>
</td>
<td class="num">(1,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other&#160;non-current&#160;assets</a></td>
<td class="nump">544<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,421)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(5,642)<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(565)<span></span>
</td>
<td class="num">(950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(59,080)<span></span>
</td>
<td class="num">(40,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, equipment and improvements</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ProceedsFromSimpleAgreementForFutureEquity', window );">Proceeds from the issuance of SAFEs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ProceedsFromSubscriptionAgreement', window );">Proceeds from the Subscription Agreement, net of offering costs of $2,000</a></td>
<td class="nump">94,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_CashAcquiredInConnectionWithTheMerger', window );">Cash acquired in connection with the Merger, net of transaction costs of $9,300</a></td>
<td class="nump">75,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">1,624<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Repayment of finance lease obligations</a></td>
<td class="num">(475)<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">171,714<span></span>
</td>
<td class="nump">33,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">112,470<span></span>
</td>
<td class="num">(7,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of beginning of period</a></td>
<td class="nump">29,356<span></span>
</td>
<td class="nump">36,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of end of period</a></td>
<td class="nump">141,826<span></span>
</td>
<td class="nump">29,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract', window );"><strong>Components of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">141,239<span></span>
</td>
<td class="nump">28,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">141,826<span></span>
</td>
<td class="nump">29,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of&#160;non-cash&#160;financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock', window );">Conversion of SAFEs to Common Stock</a></td>
<td class="nump">34,125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ConversionOfConvertiblePreferredStockToCommonStock', window );">Conversion of Convertible Preferred Stock to Common Stock</a></td>
<td class="nump">80,627<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_PurchaseEquipmentOfFinanceLeases', window );">Purchase of equipment through finance leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Merger transaction costs included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_CashAcquiredInConnectionWithTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in connection with the Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_CashAcquiredInConnectionWithTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ChangeInFairValueOfSafeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of SAFE liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ChangeInFairValueOfSafeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock&#160; to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of simple agreements for future equity&#160; to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LossOnIssuanceOfSAFEs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Issuance Of SAFEs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LossOnIssuanceOfSAFEs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ProceedsFromSimpleAgreementForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from simple agreement for future equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ProceedsFromSimpleAgreementForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ProceedsFromSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ProceedsFromSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_PurchaseEquipmentOfFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Equipment of Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_PurchaseEquipmentOfFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_OfferingCost', window );">Offering Cost</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="nump">$ 9,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_OfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_OfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. NATURE OF BUSINESS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Description of the Business </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Tectonic Therapeutic, Inc. (formerly AVROBIO, Inc.) (the &#8220;Company&#8221; or &#8220;Tectonic&#8221;) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">G-protein</div> coupled receptors (&#8220;GPCRs&#8221;). The Company focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Merger and <div style="white-space: nowrap;display:inline;">Pre-Merger</div> Financing Transaction not </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;20, 2024, the Company completed its previously announced merger transaction in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of January&#160;30, 2024 (the &#8220;Merger Agreement&#8221;) with AVROBIO, Inc. (&#8220;AVROBIO&#8221;), pursuant to which Alpine Merger Subsidiary, Inc., a wholly owned subsidiary of AVROBIO, merged with and into the entity formerly known as Tectonic Therapeutic, Inc., now known as Tectonic Operating Company, Inc. (&#8220;Legacy Tectonic&#8221;), with Legacy Tectonic continuing as a wholly owned subsidiary of the surviving corporation of AVROBIO (the &#8220;Merger&#8221;). The Merger was accounted for as a reverse recapitalization in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), with AVROBIO treated as the acquired company for financial reporting purposes, and Legacy Tectonic treated as the accounting acquirer. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the closing of the Merger, each outstanding share of Legacy Tectonic&#8217;s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO&#8217;s common stock based on an exchange ratio of 0.53 (the &#8220;Exchange Ratio&#8221;), as defined in the Merger Agreement, after giving effect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">1-for-12</div></div> reverse stock split of AVROBIO common stock that was effected on June&#160;20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Each outstanding and unexercised option to purchase shares of Legacy Tectonic&#8217;s common stock immediately prior to closing was assumed by AVROBIO and was converted into an option to purchase shares of AVROBIO common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio. Legacy Tectonic&#8217;s restricted common stock, outstanding and unvested immediately prior to the closing, was assumed by AVROBIO in the Merger. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Legacy Tectonic stockholders received 10,956,614 shares of AVROBIO common stock in connection with the Merger, including 11,447 shares of AVROBIO restricted common stock subject to vesting terms, based on the number of shares of Legacy Tectonic common stock outstanding immediately prior to the Merger, including restricted stock, the number of shares of common stock issued to investors participating in the Subscription Agreements (as defined below) and Simple Agreements for Future Equity (&#8220;SAFEs&#8221;), and Legacy Tectonic convertible preferred stock outstanding immediately prior to the Merger, which was converted into shares of Legacy Tectonic common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">one-for-one</div></div> basis immediately prior to the closing of the Merger. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Concurrently with the closing of the Merger, certain investors of Legacy Tectonic completed the purchase of 7,790,889 shares of Legacy Tectonic common stock pursuant to the Subscription Agreement dated January&#160;30, 2024 (the &#8220;Subscription Agreement&#8221;) at a purchase price of $12.40 per share for an aggregate purchase price of $96.6&#160;million. Shares of Legacy Tectonic common stock issued pursuant to the Subscription Agreements were converted into 4,163,606 shares of AVROBIO common stock at the closing of the Merger based on the Exchange Ratio, pursuant to the Merger Agreement. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance reporting capabilities. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s proprietary GEODe<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">&#8482;</div> platform is currently in development. There can be no assurance that current and future research and development activities will be successfully completed, that adequate protection for owned intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Since inception, the Company has incurred recurring losses and negative cash flows from operations and expects such losses to continue in the future as it conducts research and development activities and continues to develop its product candidates. The Company generated net losses of $58.0&#160;million and $42.8&#160;million for the years ended December&#160;31, 2024 and 2023, respectively and had an accumulated deficit of $148.6&#160;million as of December&#160;31, 2024. The Company has financed its operations primarily through the sale and issuance of common stock, convertible preferred stock, convertible promissory notes, SAFEs and the Merger. In February 2025, the Company sold shares of its common stock under a securities purchase agreement in exchange for gross proceeds of $185&#160;million, as described in Note 16, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events</div></div>. The Company has devoted substantially all of its financial resources and efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As the Company continues to develop its proprietary platform and potential product candidates, it will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. It may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital to fund its operations. The Company had cash and cash equivalents of $141.2&#160;million as of December&#160;31, 2024. Management believes that the Company&#8217;s current cash and cash equivalents will be sufficient to fund its planned operations for at least 12 months&#160;from the issuance date of these consolidated financial statements. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying consolidated financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP, as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reverse Stock Split and Exchange Ratio </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon the closing of the Merger, each outstanding share of Legacy Tectonic&#8217;s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO&#8217;s common stock based on the Exchange Ratio of 0.53, after giving effect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">1-for-12</div></div> reverse stock split of AVROBIO common stock that was effected on June&#160;20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include those related to the valuation of stock-based awards, income taxes, the fair value determination of the SAFEs and certain research and development accruals. Management&#8217;s estimates are based on historical experience and various other assumptions that it believes are reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The operations of each of the Company&#8217;s entities are measured using the currency of the primary economic environment in which the subsidiary operates (&#8220;functional currency&#8221;). Assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">period-end</div> exchange rates. Expenses are translated at the average exchange rate in effect during each fiscal month during the year. The effects of foreign currency translation adjustments are included as a component of Accumulated other comprehensive income (loss) in the Consolidated Balance Sheets. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer, who reviews financial information on a consolidated basis for the purpose of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. See Note 16, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information</div></div> for additional information regarding the Company&#8217;s segment information. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash, Cash Equivalents, and Restricted Cash </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of cash on deposit with banks denominated in U.S. dollars and investment in money market funds. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $0.6&#160;million as collateral in connection with a letter of credit issued with the corporate headquarters and lab space lease agreement entered into on November&#160;19, 2020. The Company may not access these funds until after the expiration of the lease term on January 31, 2026. The Company has classified the certificate of deposits collateralizing the letter of credits issued as a security deposit as restricted cash in the noncurrent asset section of the Consolidated Balance Sheets. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk <div style="white-space: nowrap;display:inline;">and&#160;Off-Balance&#160;Sheet</div> Risk </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in accredited financial institutions in </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">excess of governmental insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have a high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of each asset, generally <div style="-sec-ix-hidden:hidden136075766;display:inline;">three</div> to five years. Leasehold improvements are amortized over the shorter of the assets&#8217; expected useful life or the <div style="-sec-ix-hidden:hidden136075759;display:inline;">remaining lease term</div>. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Construction-in-progress</div></div> reflects amounts incurred for property and equipment for use in the research and development process and have not yet been placed in service and are not depreciated or amortized. Expenditures for major renewals and improvements that extend the useful life of the asset are capitalized as part of the asset. Expenditures for repairs and maintenance are expensed as incurred. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying amount of the asset is not recoverable, an impairment will be recognized and measured as the amount by which the carrying amount of the asset exceeds its fair value. No impairment was identified during the years ended December&#160;31, 2024 and 2023. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;1</div></div></div></div>&#8212;Unadjusted quoted prices in active markets for identical, unrestricted assets or liabilities that are accessible at the measurement date; </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;2</div></div></div></div>&#8212;Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar asset or liabilities in markets that are not active or valuations with significant inputs other than quoted prices that are observable, either directly or indirectly; and, </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;3</div></div></div></div>&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments are categorized in their entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire fair value measurement. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of costs incurred for research activities, including discovery efforts and the development of the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Company&#8217;s programs and platform and include (1)&#160;expenses incurred in connection with research and the preclinical and clinical development of the Company&#8217;s programs and product candidates, including agreements with third parties and contract research organizations (&#8220;CROs&#8221;), (2) costs related to manufacturing material for preclinical studies and clinical trials, including fees paid to contract development and manufacturing organizations (&#8220;CDMOs&#8221;), (3) employee-related expenses, including salaries and bonuses, related benefits and stock-based compensation expense, for employees engaged in research and development functions (4)&#160;facilities, depreciation and other expenses related to research and development activities, which include direct or allocated expenses for rent, maintenance of facilities and utilities, (5)&#160;licensing and license maintenance fees incurred under license agreements where no alternative future use exists, and (6)&#160;costs related to compliance with regulatory requirements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the Consolidated Balance Sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. The Company accrues expenses based upon estimates of percentage of work completed and the contract milestones remaining. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for leases in accordance with ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;). The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of the contract. The Company&#8217;s operating and finance lease assets are included <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">in&#160;right-of-use</div></div> assets, net, and the current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> portions of the finance and operating lease liabilities are included in&#160;lease liabilities,&#160;and&#160;lease liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current,&#160;respectively,</div> on the balance sheets. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Right-of-use</div></div> assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Right-of-use</div></div> assets are based on the corresponding lease liability adjusted for (i)&#160;payments made at or before the commencement date, (ii)&#160;initial direct costs incurred, and (iii)&#160;tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. For finance leases, right of use assets are amortized on a straight-line basis over the shorter of the lease term or the estimated useful life of the leased assets. The Company accounts for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components as a single lease component for operating leases. The discount rate used to calculate the present value of the Company&#8217;s lease liabilities is based on either an explicit rate stipulated in the contract for finance leases or the incremental borrowing rate based on the information available at the lease commencement date. The Company&#8217;s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determines the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated. The Company has elected the practical expedient to not recognize leases with a lease term of twelve months or less on the balance sheet (&#8220;short-term leases&#8221;) and will recognize lease payments for such short-term leases as an expense on a straight-line basis. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Simple Agreements for Future Equity </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE instruments do not represent legal form debt (i.e., no creditor rights), but allow for redemption based upon certain triggering events that are outside of the control of the Company. The Company accounts for the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE instruments as a liability at fair value on a recurring basis. Triggering events include an equity financing, public listing transaction, change of control or dissolution. Changes in the liability&#8217;s fair value are recognized in the Company&#8217;s statements of operations and comprehensive loss. The SAFE liabilities were adjusted to fair value upon the closing of the Merger and all SAFE instruments were converted to common stock of AVROBIO pursuant to the Merger Agreement. The SAFEs were redeemed for common stock shares upon closing of the Merger. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recorded all shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company&#8217;s control, such as a merger, acquisition, or sale of all or substantially all of the Company&#8217;s assets (each, a &#8220;deemed liquidation event&#8221;), the convertible preferred stock became redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of convertible preferred stock was not probable of occurring. All outstanding shares of convertible preferred stock were converted to common stock shares upon the closing of the Merger. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prior to being publicly traded, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent to the Merger, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Select Market on the date of grant. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company utilizes the Black-Scholes-Merton (&#8220;BSM&#8221;) option pricing model to determine the estimated fair value of options granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees,</div> including directors. In addition to the fair value of the Company&#8217;s common stock, the BSM mode requires the input of several assumptions. These assumptions include: </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Term&#8212;The expected life represents the period of time that the stock options are expected to be outstanding. Because the Company does not have substantial historical exercise behavior, it determines the expected term in accordance with the simplified method, which is an average of the contractual term of the stock option and its vesting period. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Volatility&#8212;The estimated volatility is determined by evaluating the average historical volatility of a peer group of companies for the period preceding the stock option grant for a term that is approximately equal to the stock options&#8217; expected term. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-Free Interest Rate&#8212;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury&#160;issues with a term that is equal to the stock options&#8217; expected term at the grant date. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Dividend&#8212;The expected dividend yield is assumed to be zero as the Company has not declared or paid dividends to date and does not anticipate declaring dividends for the foreseeable future. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units (RSUs) are measured and recognized over the vesting period and are based on the quoted market price of the Company&#8217;s stock on the grant date. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">All stock-based compensation expense is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss, on the basis of the respective employee and nonemployee&#8217;s role within the Company. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic&#160;740,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Taxes</div></div>&#160;(&#8220;ASC 740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determined deferred tax assets and liabilities on the basis of the differences between the consolidated financial statements and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">income,&#160;tax-planning&#160;strategies,</div> and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company records uncertain tax positions in accordance with ASC 740 on the basis of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;two-step&#160;process</div> in which (1)&#160;the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">the&#160;more-likely-than-not&#160;recognition</div> threshold, the Company recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Basic and diluted net loss per common share is presented in conformity with ASC 260,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Earning Per Share,</div></div>&#160;for all periods presented. In accordance with this guidance, basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period. Basic net loss and diluted net loss per share are calculated without consideration of potentially dilutive securities. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Related Party Transactions </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies ASC 850,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Related Party Disclosure</div></div>s, for the identification of related parties and disclosure of related party transactions. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. The comprehensive loss for the Company equals its net loss plus changes in foreign currency translation for all periods presented. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the FASB under its ASCs or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (Topic 740) (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09&#8221;),</div> which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> are effective for fiscal years beginning after December&#160;15, 2024, and early adoption is permitted. The Company is currently evaluating the impact of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on its consolidated financial statements. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2024-03</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</div></div> (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">220-40)</div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03&#8221;),</div> which requires disaggregated disclosure of certain income statement captions within the footnotes to the financial statements. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> are effective for fiscal years beginning after December&#160;15, 2026, and early adoption is permitted. The Company is currently evaluating the impact of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on its consolidated financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Merger</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. MERGER </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As described in Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Nature of the Business</div></div>, the Company completed its Merger with AVROBIO on June&#160;20, 2024. The Merger was accounted for as a reverse recapitalization in accordance with GAAP with Legacy Tectonic as the accounting acquirer of AVROBIO. At the effective time of the Merger, substantially all the assets of AVROBIO consisted of cash and cash equivalents, as well as other nominal assets. Under such reverse recapitalization accounting, the assets and liabilities of AVROBIO were recorded at their fair value at the effective time of the Merger, which approximated book value due to the short-term nature. No goodwill or intangible assets were recognized. Consequently, the consolidated financial statements of the Company reflect the historical operations of Legacy Tectonic for accounting purposes together with the issuance of shares to the former shareholders of AVROBIO, the legal acquirer, and a recapitalization of the equity of Legacy Tectonic, the accounting acquirer. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock of Legacy Tectonic. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As part of the recapitalization, Legacy Tectonic recognized the assets and liabilities listed below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">85,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,988</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(5,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">78,156</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company incurred transaction costs of $9.3&#160;million which was recorded as a reduction to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Consolidated Balance Sheet. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_MergerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_MergerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. FAIR VALUE MEASUREMENTS </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following tables present information about financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 62%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">139,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">139,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">139,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">139,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds are included in cash and cash equivalents on the Company&#8217;s Consolidated Balance Sheets and are classified within Level&#160;1 of the fair value hierarchy because they are valued using quoted market prices. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">There were no&#160;transfers between the Level&#160;1, Level&#160;2 or Level&#160;3 categories during the years ended December&#160;31, 2024 and 2023. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">SAFE Liabilities </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">From October through December 2023, Legacy Tectonic entered into multiple SAFE agreements with certain existing investors and received proceeds of $34.1&#160;million. Prior to redemption, the SAFE liabilities were valued using a probability weighted scenario analysis and discount rates derived by application of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">build-up</div> method to reflect the cost of equity. The valuation model required a variety of inputs, including the probability of occurrence of events that would trigger conversion or redemption of the SAFEs, the expected timing of such events, and a discount rate. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon the closing of the Merger, the principal balance of the SAFE instruments was automatically redeemed for 2,752,216&#160;shares of Legacy Tectonic common stock at the conversion price of $12.40&#160;per share immediately prior to the Merger closing. As such the valuation inputs utilized to adjust the SAFE liability to fair value upon the closing of the Merger was $12.40. At closing, shares of Legacy Tectonic common stock issued pursuant to the redemption of Legacy Tectonic SAFEs were converted into 1,470,839&#160;shares of AVROBIO common stock based on the Exchange Ratio, pursuant to the Merger Agreement. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table presents activity for the SAFE liabilities that were measured at fair value using significant unobservable Level&#160;3 inputs during the years ended December&#160;31, 2024 and 2023 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 77%;"></td>
<td style="width: 19%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">SAFE&#160;Liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of January&#160;1, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Initial fair value recognition</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">31,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on issuance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(34,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. PROPERTY AND EQUIPMENT, NET </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net is comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,590</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Office equipment, furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,978</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(2,745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation expense was $1.2&#160;million and $1.0&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and is primarily attributable to research and development activities. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities is comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued compensation and related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,787</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued professional fees and other expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,071</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. STOCKHOLDERS&#8217; EQUITY </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, the Company&#8217;s amended and restated certificate of incorporation authorized the Company to issue up to&#160;11,947,558&#160;shares of $0.0001&#160;par value common stock, of which,&#160;2,634,246&#160;shares were issued and outstanding. Voting, dividend and liquidation rights of the holders of common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock. Holders of common stock were entitled to one vote for each share of common stock; however, the holders of the common stock were </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">not entitled to vote on any amendment to the amended and restated certificate of incorporation that related solely to the terms of one or more outstanding series of preferred stock. The Company had included in issued and outstanding common stock shares of restricted common stock granted by the Company. As of December&#160;31, 2023, there were&#160;2,634,246&#160;common shares issued and outstanding, of which&#160;2,598,752&#160;relate to shares of unrestricted common stock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company amended and restated its certificate of incorporation, effective June&#160;20, 2024, in connection with the Merger. The Company is authorized to issue 150,000,000 shares of common stock at a par value of $0.0001. Holders of voting common stock are entitled to one vote per share. In addition, holders of voting common stock are entitled to receive dividends, if and when declared by the Company&#8217;s Board of Directors. As of December&#160;31, 2024, no dividends had been declared. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company reserved common stock for future issuance as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,647,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,626,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,002,535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">18,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFEs (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,519,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity awards available for future issuance under the 2019 Equity Incentive Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity awards available for future issuance under the 2024 Equity Incentive Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">976,082</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares reserved for purchase under the 2024 Employee Stock Purchase Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">147,343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,775,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,213,717</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to the conversion upon the closing of the Merger, Legacy Tectonic issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;A-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-2,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-3</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-4</div> convertible preferred stock (the &#8220;Convertible Preferred Stock&#8221;). Upon the closing of the Merger, all outstanding shares of the Convertible Preferred Stock were converted into&#160;3,647,675&#160;shares of common stock.&#160;No&#160;shares of Convertible Preferred Stock are authorized for issuance as of December&#160;31, 2024. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Subsequent to the Merger, the Company authorized the issuance of 10,000,000 shares of undesignated preferred stock, however no such shares were issued or outstanding as of December&#160;31, 2024. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Changes in Capital Structure </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon the closing of the Merger, all outstanding shares of convertible preferred stock were converted into an aggregate of&#160;3,647,675&#160;shares of the Company&#8217;s common stock and $80.6&#160;million of mezzanine equity was reclassified to common stock and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. As of December&#160;31, 2024, there were&#160;no&#160;shares of convertible preferred stock issued or outstanding. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon the closing of the Merger, the principal balance of the SAFE instruments was automatically redeemed for 2,752,216 shares of Legacy Tectonic common stock at the conversion price of $12.40 per share immediately </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">prior to the Merger closing. At closing, shares of Legacy Tectonic common stock issued pursuant to the redemption of Legacy Tectonic SAFEs were converted into 1,470,839 shares of common stock based on the Exchange Ratio, pursuant to the Merger Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Concurrently with the closing of the Merger, on June&#160;20, 2024, certain investors completed the purchase of shares of Legacy Tectonic common stock pursuant to the Subscription Agreement at a price of $12.40 per share for an aggregate purchase price of $96.6&#160;million. The shares of Legacy Tectonic common stock that were issued pursuant to the Subscription Agreement were converted into 4,163,606 shares of common stock upon the closing of the Merger based on the exchange ratio, pursuant to the Merger Agreement. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. EQUITY INCENTIVE PLANS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2019 Equity Incentive Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Legacy Tectonic 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) provides employees, consultants and advisors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> members of the Board of Directors with the opportunity to receive grants of stock options, stock awards and equity awards. Following the effectiveness of the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) as described below, no further grants will be made under the 2019 Plan; however, any outstanding equity awards granted under the 2019 Plan will continue to be governed by the terms of the 2019 Plan. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2024 Equity Incentive Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On June&#160;20, 2024, the Company adopted the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) which became effective upon completion of the Merger. The 2024 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, consultants, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> directors of the Company. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The 2024 Plan initially provided for the issuance of up to 1,938,799&#160;shares of common stock (the &#8220;Initial Share Reserve&#8221;). Subject to any other adjustments as defined in the 2024 Plan, such aggregate number of shares of common stock will automatically increase on January 1st of each year for a period of ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to 5% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase; provided, however that the Board of Directors may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of common stock. The maximum number of shares of common stock that may be issued under the 2024 Plan pursuant to the exercise of incentive stock options shall not exceed three times the Initial Share Reserve. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2024 Employee Stock Purchase Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;20, 2024, the Company adopted the 2024 Employee Stock Purchase Plan (the &#8220;2024 ESPP&#8221;), which became effective upon completion of the Merger. The maximum number of shares of common stock that may be issued under the 2024 ESPP will not exceed 147,343&#160;shares (the &#8220;Initial ESPP Share Reserve&#8221;), plus the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to the lesser of (x) 1% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase and (y)&#160;a number of shares equal to three times the Initial ESPP Share Reserve. Notwithstanding the foregoing, the Board of Directors may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. No offering periods under the 2024 ESPP had been initiated as of December&#160;31, 2024. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The equity activity below reflects the reverse stock split and retroactive application of the exchange ratio as discussed in Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Nature of Business</div></div>. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the stock option activity under the 2019 Plan and 2024 Plan during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 52%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,002,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">982,980</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">18.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(335,894</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options forfeited and expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(115,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,534,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">51,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and exercisable as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">364,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">15,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,534,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">51,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the stock option activity for the options that were assumed from AVROBIO upon the Merger closing during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 53%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options assumed from AVROBIO upon Merger closing</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">365,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">89.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(52,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">14.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,344</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options forfeited and expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(220,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">136.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">92,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">22.69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and exercisable as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">92,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">22.69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">92,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">22.69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the years ended December&#160;31, 2024 and 2023, the Company granted options with a weighted-average grant-date fair value of $14.90&#160;and $4.04&#160;per share, respectively. The fair value of options that vested during the years ended December&#160;31, 2024 and 2023 was $1.6&#160;million and $1.1&#160;million, respectively. As of December&#160;31, 2024, the total unrecognized stock-based compensation expense for stock options was $13.3&#160;million, which is expected to be recognized over a weighted-average period of 3.3 years. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The table below discloses assumptions for the fair value of options granted: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 61%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value per share of underlying common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">16.09&#160;-&#160;$51.28</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2.50&#160;-&#160;$4.21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">6.00&#160;-&#160;6.25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">5.81&#160;-&#160;6.04</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">100.0%&#160;-&#160;104.0%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">93.4%&#160;-&#160;111.2%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">4.10%&#160;-&#160;4.26%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3.64%&#160;-&#160;4.90%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units (RSUs) are granted to certain employees. The value of an RSU award is based on the Company&#8217;s stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest. Activity with respect to the Company&#8217;s restricted stock units during the year ended December&#160;31, 2024 was as follows (in thousands, except share, contractual term, and per share data): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 55%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;Date<br/> Fair Value<br/> per Unit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">26,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(725</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">34.51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2024, the total unrecognized stock-based compensation expense for RSUs was $1.1&#160;million, which is expected to be recognized over a weighted average period of&#160;3.2 years. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Common Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Legacy Tectonic granted restricted common stock to founders, employees and consultants. The purchase price of the restricted common stock is the estimated fair value on the grant date and the restricted stock is subject to various vesting schedules. Unvested restricted common stock is subject to repurchase rights held by the Company at the original issuance price in the event the restricted common stockholders&#8217; service to the Company is terminated either voluntarily or involuntarily. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes restricted common stock activity during the year ended December&#160;31, 2024: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 75%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock awards as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">18,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Early exercise of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,859</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(25,827</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock awards as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted-average grant date fair value and the weighted average value of the vested restricted common stock for the years ended December&#160;31, 2024 and 2023 were immaterial. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table is a summary of stock-based compensation expense by function recognized (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">705</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">416</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Modification of Certain Stock Options </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2024, the Company entered into a separation agreement with the Company&#8217;s Chief Operating Officer (the &#8220;Former Executive&#8221;). As part of the termination of employment, the Former Executive will serve as an advisor to the Company through March&#160;31, 2025 (&#8220;Consulting Period&#8221;) on an as needed basis. Pursuant to the separation agreement, certain modifications to the Former Executive&#8217;s vested and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-vested</div> stock option awards were executed including continued vesting of options during the Consulting Period and the extension of the post-termination exercise period of certain stock option awards. The services performed during the Consulting Period do not qualify as substantive services under ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div>; therefore, the continued vesting of these awards represents a modification to the original award. During the year ended December&#160;31, 2024, the Company recorded stock compensation expense of $0.4&#160;million for the modification of the stock options of the Former Executive. This amount is included in general and administrative expenses on the consolidated statement of operations and comprehensive loss. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. NET LOSS PER SHARE </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 66%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(57,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(42,823</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average common shares outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,490,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,268,512</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(6.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(33.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,647,674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,626,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,002,535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock units and common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">18,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFEs (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,519,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,652,453</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,188,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. LEASES </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2020, Legacy Tectonic executed a facilities lease agreement to occupy 18,768 square feet of office and laboratory space, that was subsequently amended on April 21, 2022. The lease requires the Company to pay fixed base rent, which is included in the measurement of the lease, as well as its proportionate share of the facilities operating expenses which are treated as variable lease costs based on the Company&#8217;s election to combine lease and associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components and are excluded from the measurement of the lease. The lease expires on January 31, 2026, and contains a <div style="-sec-ix-hidden:hidden136075767;display:inline;">five</div>-year renewal option exercisable by the Company which is not included in the measurement of the lease. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Legacy Tectonic has also entered into various financing leases for laboratory equipment used in research and development activities. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of lease expense and other information are as follows (dollars in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Finance lease amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">488</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,608</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Short-term lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">545</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Variable lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">911</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 73%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average remaining lease terms (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Future commitments due under these lease agreements as of&#160;December 31, 2024&#160;are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">552</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,948</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total undiscounted cash flows</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">959</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(83</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(184</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,427</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">876</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LicenseAgreementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. LICENSE AGREEMENTS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Harvard Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2020, Legacy Tectonic entered into an agreement with the President and Fellows of Harvard College (&#8220;Harvard&#8221;), for an option fee in the low five digits, whereby Harvard granted Legacy Tectonic an exclusive option to negotiate a worldwide, exclusive, royalty-bearing license under Harvard&#8217;s interest in the patent rights covering certain technology that was developed by Harvard. In October 2021, Legacy Tectonic exercised the option and on February&#160;10, 2022, entered into a license agreement (&#8220;License Agreement&#8221;) with Harvard to conduct research and development activities using certain materials, technology and patent rights owned by Harvard, with the intent to develop, obtain regulatory approval for, and commercialize products. The License Agreement will remain in effect until the expiration of the last valid claim within the patent rights covering a product developed under the License Agreement or the termination of the License Agreement. As consideration for the License Agreement, the Company paid Harvard a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> license fee of $170,000&#160;and issued 227,486&#160;shares of common stock with a fair market value of $0.4&#160;million. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is responsible for payment of (1)&#160;annual maintenance fees ranging from the low five digits to the low six digits during the term of the License Agreement (through the first commercial sale of a royalty-bearing product); (2) royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from products that utilize the license technology (&#8220;Licensed Products&#8221;) and royalty payments as a percentage in the low single digits of the annual net sales that the Company generates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">from&#160;know-how&#160;enabled</div> product <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">licenses&#160;(&#8220;Know-How&#160;Enabled</div> Products&#8221;) and (3)&#160;a percentage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">between&#160;10-20%&#160;of</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">all&#160;non-royalty&#160;income</div> received by the Company under sublicenses, strategic partnerships <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">and&#160;know-how&#160;enabled</div> product licenses that utilize the license technology. Subsequent to the first commercial sale of a royalty-bearing product, annual maintenance fees will increase to a low six digits for the remainder of the term of the License Agreement. The royalty term from sales of Licensed Products will terminate on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">a&#160;country-by-country&#160;and&#160;product-by-product&#160;basis</div></div></div></div> on the earlier of (i)&#160;the expiration of the patent rights covering the product, expected to be no earlier than May 2041, and (ii)&#160;the termination of the License Agreement. The royalty term from sales <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">of&#160;Know-How&#160;Enabled</div> Products will terminate on the earlier of (i)&#160;ten years after the first commercial sale of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first&#160;Know-How&#160;Enabled</div> Product and (ii)&#160;twelve years after the first commercial sale of the first Licensed Product.&#160;The Company incurred expense of $0.4&#160;million and $0.2&#160;million related to the License Agreement during the years ended December&#160;31, 2024 and 2023, respectively. No&#160;amounts were due to Harvard related to the License Agreement as of December&#160;31, 2024 and 2023, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. COMMITMENTS AND CONTINGENCIES </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Commitments </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company enters into contractual agreements with various suppliers in the normal course of its business. All contracts are terminable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would only be obligated for the products or services that the Company had received through the time of termination. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is also party to commitments, which are described elsewhere in these consolidated financial statements: Lease commitments, as described in Note 10,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Leases, </div></div>and&#160;royalty and maintenance based commitments, as described in Note 11,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;License Agreements.</div></div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with the Merger, the Company and its designated rights agent entered into a contingent value rights agreement (the &#8220;CVR Agreement&#8221;). Pursuant to the CVR Agreement, each holder of AVROBIO common stock immediately prior to the closing received a contractual contingent value right (&#8220;CVR&#8221;) subject to and in accordance with the terms and conditions of the CVR Agreement, representing the contractual right to receive a pro rata portion of any net proceeds, if any, resulting from a disposition of certain AVROBIO intellectual property (including a license of AVROBIO&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-closing</div> assets as defined in the CVR Agreement) after the closing and prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">18-month</div> anniversary of the closing, received within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-year</div> period following the closing; provided that no contingent payment will be payable to any holder of the CVRs until such time as the then-outstanding and undistributed proceeds exceeds $0.4&#160;million in the aggregate. The Company believes that any receipt of payments resulting from the disposition of AVROBIO&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-closing</div> assets described in the CVR Agreement are highly susceptible to factors outside the Company&#8217;s influence that are not expected to be resolved within the timeline outlined in the CVR Agreement, if at all. In particular, these amounts are primarily influenced by the actions and judgments of third parties and the buyers of such assets and are based on the buyers of such assets progressing the specific platform and intellectual property and early stage of research and development programs. If the Company were to record a receivable for such contingent payments, it would also record a corresponding liability. As of December&#160;31, 2024, no receivables or liabilities were recorded on the Consolidated Balance Sheet relating to such contingent payments. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. There are no matters pending that the Company currently believes are reasonably possible or probable of having a material impact to the Company&#8217;s financial position, results of operations, or statements of cash flows. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the normal course of operations, the Company may become involved in various legal proceedings. As of December&#160;31, 2024 and 2023, the Company has not recorded accruals for probable losses related to any existing or pending litigation as the Company&#8217;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#8217;s consolidated financial statements. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">13. INCOME TAXES </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company did<div style="display:inline;">&#160;no</div>t record a federal or state income tax provision or benefit for the years ended December&#160;31, 2024&#160;and&#160;2023, as it has been incurring net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense consists of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">13,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">11,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">741</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">16,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">14,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(16,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(14,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company had an effective tax rate of&#160;0% for the years ended December&#160;31, 2024&#160;and&#160;2023. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 81%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal statutory income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign rate differential</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Permanent differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock liability fair value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(29.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(34.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024&#160;and&#160;2023, were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 68%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">109,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">11,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">13,946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">660</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Capitalized research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">40,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">14,595</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accruals&#160;&amp; other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">863</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">171,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">32,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(170,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(30,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(485</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Right of use asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(608</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(729</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,939</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets (liability)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferred Tax Assets and Valuation Allowance </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December&#160;31, 2024 and 2023, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December&#160;31, 2024 and 2023. The Company&#8217;s valuation allowance increased during the year by $140.0&#160;million for the year ended December&#160;31, 2024 due primarily to the generation of net operating losses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">NOL Carryforwards </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on AVROBIO&#8217;s value immediately prior to the ownership change multiplied by the long-term tax exempt rate which is published monthly. Subsequent ownership changes may further affect the limitation in future years. The Company has not yet conducted a Section&#160;382 study to assess whether the Reverse Merger resulted in an ownership change under Section&#160;382 that could limit the ability to use the net operating loss carryforwards of AVROBIO and Tectonic.&#160;Nor has the Company completed a Section&#160;382 study to assess whether an ownership change or changes has/have occurred related to Tectonic Therapeutic&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-merger</div> activity. However, the Reverse Merger is expected to result in an ownership change for AVROBIO. Therefore, the Company does not </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">expect to be able to utilize a material portion, if any, of the historic net operating losses and tax credit carryforwards from AVROBIO. The impact of this would not materially impact the financial statements, given the full valuation allowance. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2024, the Company has net operating loss carryforwards for federal and state tax reporting purposes of $399.3&#160;million and $71.9&#160;million, respectively. Net operating loss carryforwards generated after December&#160;31, 2017 for federal tax reporting purposes of $399.3&#160;million have an indefinite life. Net operating loss carryforwards for state purposes of $71.9&#160;million, which begin to expire in 2040. As of December&#160;31, 2024, the Company also has federal and state research and development tax credits of $10.5&#160;million and $4.4&#160;million, which being to expire in 2040 and 2035, respectively. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Tax Cuts and Jobs Act (TCJA) resulted in significant changes to the treatment of research and development expenditures under Section&#160;174. For tax years beginning after December&#160;31, 2021, taxpayers are required to capitalize and amortize all research and development expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;D activities must be amortized over five years and costs for foreign research and development activities must be amortized over 15 years&#8212;both using a midyear convention. During the year ended December&#160;31, 2024, the Company capitalized $40.3&#160;million of research and development expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Uncertain Tax Position </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluates its uncertain tax positions under ASC&#160;740&#160;which requires that realization of an uncertain income tax position be recognized. The benefit to be recorded is the amount most likely to be realized assuming a review by tax authorities having all relevant information and applying current conventions. The Company concluded that there are no uncertain tax positions in any of the periods presented. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The earliest tax years that remain subject to examination by jurisdiction is 2020 for both federal and state. However, to the extent the Company utilizes net operating losses from years prior to 2020, the statute remains open to the extent of the net operating losses or other credits are utilized. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">14. RELATED PARTY TRANSACTIONS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scientific Advisory Board Member </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">One of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-founders</div> and former director is a member of the Company&#8217;s Scientific Advisory Board (&#8220;SAB&#8221;) and meets the criteria of a related party. For each of the years ended December&#160;31, 2024 and 2023, the Company incurred expense of $0.1&#160;million for advisory services provided. There were no&#160;amounts due to this related party as of December&#160;31, 2024 or 2023. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">License Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Harvard meets the criteria of a related party resulting from the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-founders&#8217;</div> employment as professors in the Harvard Department of Molecular Pharmacology. Core intellectual property utilized by the Company is licensed from Harvard under the License Agreement described in Note 11, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">License Agreements</div></div>. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company incurred expense of $0.4&#160;million and $0.2&#160;million related to the License Agreement during the years ended December&#160;31, 2024 and 2023, respectively. No amounts were due to Harvard related to the License Agreement as of December&#160;31, 2024 and 2023. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Adimab Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">One member of the Company&#8217;s Board of Directors also services on the board of Adimab, LLC (&#8220;Adimab&#8221;), an antibody discovery company. In May 2023, Legacy Tectonic entered into a discovery agreement with Adimab </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">whereby Legacy Tectonic and Adimab collaborated on human antibody discovery in accordance with an agreed upon research program. The Company incurred expense of $0.2&#160;million during each of the years ended December&#160;31, 2024 and 2023. The Company terminated the agreement with Adimab in July 2024. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">SAFE Agreements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From October through December 2023, Legacy Tectonic entered into multiple SAFE agreements with certain existing investors and received proceeds of $34.1&#160;million. All investors were considered related parties of the Company. The SAFE agreements had no maturity date, bore no interest, and were redeemable by Legacy Tectonic upon the occurrence of a triggering event, including the Merger which qualified as a public listing transaction under the SAFE agreements. The SAFEs were redeemed for shares of Legacy Tectonic common stock in connection with the closing of the Merger. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAbstract', window );"><strong>Defined Contribution Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">15. EMPLOYEE BENEFIT PLAN </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has a 401(k) retirement plan (the &#8220;Plan&#8221;) that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company&#8217;s funding policy is to contribute 3% (&#8220;Nonelective Contribution&#8221;) of employees&#8217; eligible pay to the Plan. As defined by the Plan, highly compensated employees are not eligible to receive the Nonelective Contribution. The Company contributed $0.2&#160;million to the Plan in each of the years ended December&#160;31, 2024 and 2023. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment information</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">16. SEGMENT INFORMATION </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We operate in&#160;one&#160;operating segment, and therefore&#160;one&#160;reportable segment, focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer as chief operating decision maker (&#8220;CODM&#8221;) in evaluating financial performance and deciding how to allocate resources on a consolidated basis. The significant expense categories outlined below align with the segment-level information that is regularly provided to the CODM. When evaluating the Company&#8217;s financial performance, the CODM reviews one measure of profitability, net loss, and makes decisions using this information. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No segment asset information is provided below as the CODM is focused on how expenses impact ending cash by period and overall cash runway. Any review of segment assets, which would focus on cash and cash equivalents, would be at the same level as the consolidated balance sheet. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table presents the segment net loss and significant segment expenses for the years ended December&#160;31, 2024, and 2023 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee-related expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development employee-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">11,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative employee-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5,553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">External research and development expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Research and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> expenses</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Clinical and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">15,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7,202</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Chemistry, manufacturing, and control expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,947</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Non employee-related general and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,988</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other segment items<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">1</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5,134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">774</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">57,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">42,823</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; text-align: left; vertical-align: top;"><div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">1</div>&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other segment expenses include stock-based compensation, depreciation and amortization, changes in the fair value of the SAFE liabilities, loss on the issuance of SAFEs, interest income, and interest expense. </div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">17. SUBSEQUENT EVENTS </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In February 2025, the Company entered into a securities purchase agreement pursuant to which the Company issued an aggregate of 3,689,465 shares of common stock, at a price of $50.00 per share to fund investors and $54.14 per share to individual investors that are either an officer or director of the Company, in exchange for aggregate consideration of approximately $185.0&#160;million.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying consolidated financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP, as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock', window );">Reverse Stock Split and Exchange Ratio</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reverse Stock Split and Exchange Ratio </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon the closing of the Merger, each outstanding share of Legacy Tectonic&#8217;s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO&#8217;s common stock based on the Exchange Ratio of 0.53, after giving effect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">1-for-12</div></div> reverse stock split of AVROBIO common stock that was effected on June&#160;20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include those related to the valuation of stock-based awards, income taxes, the fair value determination of the SAFEs and certain research and development accruals. Management&#8217;s estimates are based on historical experience and various other assumptions that it believes are reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The operations of each of the Company&#8217;s entities are measured using the currency of the primary economic environment in which the subsidiary operates (&#8220;functional currency&#8221;). Assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">period-end</div> exchange rates. Expenses are translated at the average exchange rate in effect during each fiscal month during the year. The effects of foreign currency translation adjustments are included as a component of Accumulated other comprehensive income (loss) in the Consolidated Balance Sheets. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer, who reviews financial information on a consolidated basis for the purpose of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. See Note 16, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information</div></div> for additional information regarding the Company&#8217;s segment information. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash, Cash Equivalents, and Restricted Cash </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of cash on deposit with banks denominated in U.S. dollars and investment in money market funds. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $0.6&#160;million as collateral in connection with a letter of credit issued with the corporate headquarters and lab space lease agreement entered into on November&#160;19, 2020. The Company may not access these funds until after the expiration of the lease term on January 31, 2026. The Company has classified the certificate of deposits collateralizing the letter of credits issued as a security deposit as restricted cash in the noncurrent asset section of the Consolidated Balance Sheets. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk <div style="white-space: nowrap;display:inline;">and&#160;Off-Balance&#160;Sheet</div> Risk </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in accredited financial institutions in </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">excess of governmental insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have a high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of each asset, generally <div style="-sec-ix-hidden:hidden136075766;display:inline;">three</div> to five years. Leasehold improvements are amortized over the shorter of the assets&#8217; expected useful life or the <div style="-sec-ix-hidden:hidden136075759;display:inline;">remaining lease term</div>. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Construction-in-progress</div></div> reflects amounts incurred for property and equipment for use in the research and development process and have not yet been placed in service and are not depreciated or amortized. Expenditures for major renewals and improvements that extend the useful life of the asset are capitalized as part of the asset. Expenditures for repairs and maintenance are expensed as incurred. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying amount of the asset is not recoverable, an impairment will be recognized and measured as the amount by which the carrying amount of the asset exceeds its fair value. No impairment was identified during the years ended December&#160;31, 2024 and 2023. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;1</div></div></div></div>&#8212;Unadjusted quoted prices in active markets for identical, unrestricted assets or liabilities that are accessible at the measurement date; </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;2</div></div></div></div>&#8212;Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar asset or liabilities in markets that are not active or valuations with significant inputs other than quoted prices that are observable, either directly or indirectly; and, </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;3</div></div></div></div>&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments are categorized in their entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire fair value measurement. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of costs incurred for research activities, including discovery efforts and the development of the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Company&#8217;s programs and platform and include (1)&#160;expenses incurred in connection with research and the preclinical and clinical development of the Company&#8217;s programs and product candidates, including agreements with third parties and contract research organizations (&#8220;CROs&#8221;), (2) costs related to manufacturing material for preclinical studies and clinical trials, including fees paid to contract development and manufacturing organizations (&#8220;CDMOs&#8221;), (3) employee-related expenses, including salaries and bonuses, related benefits and stock-based compensation expense, for employees engaged in research and development functions (4)&#160;facilities, depreciation and other expenses related to research and development activities, which include direct or allocated expenses for rent, maintenance of facilities and utilities, (5)&#160;licensing and license maintenance fees incurred under license agreements where no alternative future use exists, and (6)&#160;costs related to compliance with regulatory requirements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the Consolidated Balance Sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. The Company accrues expenses based upon estimates of percentage of work completed and the contract milestones remaining. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for leases in accordance with ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;). The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of the contract. The Company&#8217;s operating and finance lease assets are included <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">in&#160;right-of-use</div></div> assets, net, and the current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> portions of the finance and operating lease liabilities are included in&#160;lease liabilities,&#160;and&#160;lease liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current,&#160;respectively,</div> on the balance sheets. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Right-of-use</div></div> assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Right-of-use</div></div> assets are based on the corresponding lease liability adjusted for (i)&#160;payments made at or before the commencement date, (ii)&#160;initial direct costs incurred, and (iii)&#160;tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. For finance leases, right of use assets are amortized on a straight-line basis over the shorter of the lease term or the estimated useful life of the leased assets. The Company accounts for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components as a single lease component for operating leases. The discount rate used to calculate the present value of the Company&#8217;s lease liabilities is based on either an explicit rate stipulated in the contract for finance leases or the incremental borrowing rate based on the information available at the lease commencement date. The Company&#8217;s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determines the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated. The Company has elected the practical expedient to not recognize leases with a lease term of twelve months or less on the balance sheet (&#8220;short-term leases&#8221;) and will recognize lease payments for such short-term leases as an expense on a straight-line basis. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock', window );">Simple Agreements for Future Equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Simple Agreements for Future Equity </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE instruments do not represent legal form debt (i.e., no creditor rights), but allow for redemption based upon certain triggering events that are outside of the control of the Company. The Company accounts for the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE instruments as a liability at fair value on a recurring basis. Triggering events include an equity financing, public listing transaction, change of control or dissolution. Changes in the liability&#8217;s fair value are recognized in the Company&#8217;s statements of operations and comprehensive loss. The SAFE liabilities were adjusted to fair value upon the closing of the Merger and all SAFE instruments were converted to common stock of AVROBIO pursuant to the Merger Agreement. The SAFEs were redeemed for common stock shares upon closing of the Merger. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recorded all shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company&#8217;s control, such as a merger, acquisition, or sale of all or substantially all of the Company&#8217;s assets (each, a &#8220;deemed liquidation event&#8221;), the convertible preferred stock became redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of convertible preferred stock was not probable of occurring. All outstanding shares of convertible preferred stock were converted to common stock shares upon the closing of the Merger. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prior to being publicly traded, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent to the Merger, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Select Market on the date of grant. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company utilizes the Black-Scholes-Merton (&#8220;BSM&#8221;) option pricing model to determine the estimated fair value of options granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees,</div> including directors. In addition to the fair value of the Company&#8217;s common stock, the BSM mode requires the input of several assumptions. These assumptions include: </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Term&#8212;The expected life represents the period of time that the stock options are expected to be outstanding. Because the Company does not have substantial historical exercise behavior, it determines the expected term in accordance with the simplified method, which is an average of the contractual term of the stock option and its vesting period. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Volatility&#8212;The estimated volatility is determined by evaluating the average historical volatility of a peer group of companies for the period preceding the stock option grant for a term that is approximately equal to the stock options&#8217; expected term. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-Free Interest Rate&#8212;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury&#160;issues with a term that is equal to the stock options&#8217; expected term at the grant date. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected Dividend&#8212;The expected dividend yield is assumed to be zero as the Company has not declared or paid dividends to date and does not anticipate declaring dividends for the foreseeable future. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units (RSUs) are measured and recognized over the vesting period and are based on the quoted market price of the Company&#8217;s stock on the grant date. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">All stock-based compensation expense is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss, on the basis of the respective employee and nonemployee&#8217;s role within the Company. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic&#160;740,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Taxes</div></div>&#160;(&#8220;ASC 740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determined deferred tax assets and liabilities on the basis of the differences between the consolidated financial statements and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">income,&#160;tax-planning&#160;strategies,</div> and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company records uncertain tax positions in accordance with ASC 740 on the basis of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;two-step&#160;process</div> in which (1)&#160;the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">the&#160;more-likely-than-not&#160;recognition</div> threshold, the Company recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Basic and diluted net loss per common share is presented in conformity with ASC 260,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Earning Per Share,</div></div>&#160;for all periods presented. In accordance with this guidance, basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period. Basic net loss and diluted net loss per share are calculated without consideration of potentially dilutive securities. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_RelatedPartyTransactionsPolicyTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Related Party Transactions </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies ASC 850,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Related Party Disclosure</div></div>s, for the identification of related parties and disclosure of related party transactions. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. The comprehensive loss for the Company equals its net loss plus changes in foreign currency translation for all periods presented. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the FASB under its ASCs or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (Topic 740) (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09&#8221;),</div> which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> are effective for fiscal years beginning after December&#160;15, 2024, and early adoption is permitted. The Company is currently evaluating the impact of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on its consolidated financial statements. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2024-03</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</div></div> (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">220-40)</div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03&#8221;),</div> which requires disaggregated disclosure of certain income statement captions within the footnotes to the financial statements. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> are effective for fiscal years beginning after December&#160;15, 2026, and early adoption is permitted. The Company is currently evaluating the impact of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on its consolidated financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_RelatedPartyTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_RelatedPartyTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split and Exchange Ratio [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_SimpleAgreementsForFutureEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Simple Agreements for Future Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_SimpleAgreementsForFutureEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481288/505-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of the Recognized Assets and Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As part of the recapitalization, Legacy Tectonic recognized the assets and liabilities listed below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">85,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,988</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(5,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">78,156</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following tables present information about financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 62%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">139,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">139,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">139,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">139,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFE liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Activity for the Safe Liabilities that were Measured at Fair Value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table presents activity for the SAFE liabilities that were measured at fair value using significant unobservable Level&#160;3 inputs during the years ended December&#160;31, 2024 and 2023 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 77%;"></td>
<td style="width: 19%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">SAFE&#160;Liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of January&#160;1, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Initial fair value recognition</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">31,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on issuance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(34,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment Net</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net is comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Laboratory equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,590</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Office equipment, furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,978</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(2,745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities is comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued compensation and related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,787</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued professional fees and other expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,071</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company reserved common stock for future issuance as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,647,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,626,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,002,535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">18,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFEs (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,519,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity awards available for future issuance under the 2019 Equity Incentive Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity awards available for future issuance under the 2024 Equity Incentive Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">976,082</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares reserved for purchase under the 2024 Employee Stock Purchase Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">147,343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,775,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,213,717</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense and Other Information</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of lease expense and other information are as follows (dollars in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Finance lease amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">488</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,608</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Short-term lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">545</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Variable lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">911</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 73%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average remaining lease terms (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Finance leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Commitments Due Under These Lease Agreements</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Future commitments due under these lease agreements as of&#160;December 31, 2024&#160;are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">552</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,948</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total undiscounted cash flows</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">959</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(83</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(184</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,427</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">876</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of The Stock Option Activity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the stock option activity under the 2019 Plan and 2024 Plan during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 52%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,002,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">982,980</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">18.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(335,894</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options forfeited and expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(115,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,534,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">51,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and exercisable as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">364,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">15,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,534,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">51,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the stock option activity for the options that were assumed from AVROBIO upon the Merger closing during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 53%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options assumed from AVROBIO upon Merger closing</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">365,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">89.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(52,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">14.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,344</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options forfeited and expired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(220,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">136.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">92,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">22.69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and exercisable as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">92,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">22.69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options vested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">92,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">22.69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Values of the Options Granted</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The table below discloses assumptions for the fair value of options granted: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 61%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value per share of underlying common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">16.09&#160;-&#160;$51.28</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2.50&#160;-&#160;$4.21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">6.00&#160;-&#160;6.25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">5.81&#160;-&#160;6.04</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">100.0%&#160;-&#160;104.0%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">93.4%&#160;-&#160;111.2%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">4.10%&#160;-&#160;4.26%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3.64%&#160;-&#160;4.90%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text">Activity with respect to the Company&#8217;s restricted stock units during the year ended December&#160;31, 2024 was as follows (in thousands, except share, contractual term, and per share data):<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 55%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares<br/> Underlying<br/> Outstanding<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;Date<br/> Fair Value<br/> per Unit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">26,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted stock units forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(725</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">34.51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested and expected to vest as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes restricted common stock activity during the year ended December&#160;31, 2024: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 75%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock awards as of January&#160;1, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">18,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Early exercise of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,859</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(25,827</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock awards as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table is a summary of stock-based compensation expense by function recognized (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">705</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">416</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 66%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(57,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(42,823</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average common shares outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,490,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,268,512</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(6.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(33.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,647,674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,626,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,002,535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock units and common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">18,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SAFEs (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,519,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,652,453</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,188,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">ScheduleOfComponentsOfIncomeTaxExpenseBenefit</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense consists of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred expense (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">13,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">11,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">741</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">16,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">14,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(16,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(14,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">ScheduleOfEffectiveIncomeTaxRateReconciliation</a></td>
<td class="text">The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 81%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal statutory income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign rate differential</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Permanent differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock liability fair value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(29.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(34.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">ScheduleOfDeferredTaxAssetsAndLiabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024&#160;and&#160;2023, were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 68%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">109,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">11,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">13,946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">660</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Capitalized research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">40,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">14,595</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accruals&#160;&amp; other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">863</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">171,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">32,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(170,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(30,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(485</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Right of use asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(608</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(729</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1,939</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets (liability)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment net loss and significant segment expenses</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table presents the segment net loss and significant segment expenses for the years ended December&#160;31, 2024, and 2023 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee-related expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development employee-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">11,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative employee-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5,553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">External research and development expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Research and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> expenses</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Clinical and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">15,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7,202</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Chemistry, manufacturing, and control expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,947</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Non employee-related general and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,988</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other segment items<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">1</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5,134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">774</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">57,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">42,823</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 20, 2024</div></th>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_NatureOfOperationsLineItems', window );"><strong>Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,586<span></span>
</td>
<td class="nump">$ 90,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,982<span></span>
</td>
<td class="nump">42,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ProceedsReceivedPursuantToAgreement', window );">Proceeds received pursuant to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,239<span></span>
</td>
<td class="nump">$ 28,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_AvorbioCommonStockMember', window );">Avorbio Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_NatureOfOperationsLineItems', window );"><strong>Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization', window );">Stock issued during the period shares new issues converted pursuant to reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,163,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tecx_AvroAvrobioCommonStockMember', window );">AVRO Avrobio Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_NatureOfOperationsLineItems', window );"><strong>Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ConversionOfStockSharesPercentage', window );">Conversion of stock shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization', window );">Stock issued during the period shares reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,956,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization', window );">Stock shares issued during the period subject to reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AgreementAxis=tecx_SubscriptionAgreementMember', window );">Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_NatureOfOperationsLineItems', window );"><strong>Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,790,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share</a></td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 96,600<span></span>
</td>
<td class="nump">$ 96,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AgreementAxis=tecx_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | Avorbio Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_NatureOfOperationsLineItems', window );"><strong>Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization', window );">Stock issued during the period shares new issues converted pursuant to reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,163,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ConversionOfStockSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of stock shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ConversionOfStockSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_NatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_NatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ProceedsReceivedPursuantToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds received pursuant to agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ProceedsReceivedPursuantToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period shares new issues converted pursuant to reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period shares reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock shares issued during the period subject to reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_AvorbioCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_AvorbioCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tecx_AvroAvrobioCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tecx_AvroAvrobioCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AgreementAxis=tecx_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AgreementAxis=tecx_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Basis of Presentation - (Additional Information) (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 20, 2024</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash maintain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Useful Life, Lease Term [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger - (Additional Information) (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Reduction to additional paid-in capital</a></td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_MergerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_MergerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger - Summary Of The Company Obtain The Assets And Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 85,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(5,405)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 78,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed accured expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - (Additional Information) (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 20, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ProceedsFromSimpleAgreementForFutureEquity', window );">Proceeds from the issuance of SAFEs</a></td>
<td class="nump">$ 34,100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 34,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">1,407,753<span></span>
</td>
<td class="nump">14,856,309<span></span>
</td>
<td class="nump">1,407,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, price per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_FairValueInputAmountTransferInBetweenLevels', window );">Fair value input amount transfer in between levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=tecx_SimpleAgreementsForFutureEquityMember', window );">Simple Agreements for Future Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,752,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,752,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=tecx_SimpleAgreementsForFutureEquityMember', window );">Simple Agreements for Future Equity [Member] | AVROBIO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_FairValueInputAmountTransferInBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value input amount transfer in between levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_FairValueInputAmountTransferInBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ProceedsFromSimpleAgreementForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from simple agreement for future equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ProceedsFromSimpleAgreementForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=tecx_SimpleAgreementsForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=tecx_SimpleAgreementsForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_TypeOfCommonStockAxis=tecx_AvrobioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_TypeOfCommonStockAxis=tecx_AvrobioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 139,610<span></span>
</td>
<td class="nump">$ 27,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">SAFE Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">139,610<span></span>
</td>
<td class="nump">27,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">139,610<span></span>
</td>
<td class="nump">27,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | SAFE Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">139,610<span></span>
</td>
<td class="nump">27,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | SAFE Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | SAFE Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tecx_SAFELiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tecx_SAFELiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity for the Safe Liabilities that were Measured at Fair Value (Detail) - SAFE Liabilities [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Opening Balance</a></td>
<td class="nump">$ 30,515<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition', window );">Initial fair value recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Loss on issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Fair value adjustments</a></td>
<td class="nump">3,610<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Redemption</a></td>
<td class="num">(34,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis initial recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tecx_SAFELiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tecx_SAFELiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">$ 4,896<span></span>
</td>
<td class="nump">$ 4,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(2,745)<span></span>
</td>
<td class="num">(1,856)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,151<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">4,590<span></span>
</td>
<td class="nump">4,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office equipment, furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Additional Information) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_DepreciationAndAmortizationExpense', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_DepreciationAndAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and amortization expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_DepreciationAndAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AccruedCompensationAndRelatedExpenses', window );">Accrued compensation and related expenses</a></td>
<td class="nump">$ 3,585<span></span>
</td>
<td class="nump">$ 2,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">3,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees and other expenses</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,850<span></span>
</td>
<td class="nump">$ 8,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AccruedCompensationAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and related expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AccruedCompensationAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - (Additional Information) (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tecx_AvrobioIncMember', window );">AVROBIO, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement', window );">Period after closing with which assets may be disposed to pay the amount as per agreement</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid', window );">Threshold period of receipt of consideration on disposal of assets based on which amount as per agreement shall be paid</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Business combination, contingent consideration, liability, current</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AgreementAxis=tecx_CvrAgreementMember', window );">CVR Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount', window );">Business combination, acquired receivables, gross contractual amount</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized', window );">Liability recorded</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after closing with which assets may be disposed to pay the amount as per agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of receipt of consideration on disposal of assets based on which amount as per agreement shall be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tecx_AvrobioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tecx_AvrobioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AgreementAxis=tecx_CvrAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AgreementAxis=tecx_CvrAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - ft&#178;<br></strong></div></th>
<th class="th"><div>Nov. 19, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember', window );">Operating Lease for Office and Laboratory Spaces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_OperatingLeaseDateOfExpiry', window );">Operating lease date of expiry</a></td>
<td class="text">Apr. 21,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_OperatingLeaseDateOfExpiryRevised', window );">Operating lease date of expiry revised</a></td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_OperatingLeaseDateOfExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease date of expiry.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_OperatingLeaseDateOfExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_OperatingLeaseDateOfExpiryRevised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease date of expiry revised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_OperatingLeaseDateOfExpiryRevised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense and Other Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease amortization of right-of-use assets</a></td>
<td class="nump">$ 448<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest of finance lease liabilities</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_FinanceLeaseCostAndExpense', window );">Finance lease expense</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Operating lease expense</a></td>
<td class="nump">1,608<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total lease expense</a></td>
<td class="nump">$ 3,619<span></span>
</td>
<td class="nump">$ 3,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_FinanceLeaseCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Cost and Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_FinanceLeaseCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Information About the Company's Leases (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract', window );"><strong>Weighted-average remaining lease terms (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">1 year 21 days<span></span>
</td>
<td class="text">2 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">2 years 3 months 3 days<span></span>
</td>
<td class="text">3 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">8.49%<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">9.76%<span></span>
</td>
<td class="nump">9.62%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease terms in years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Commitments Due Under These Lease Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">2,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">$ 1,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability Non-current</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance Lease Liability Non-current</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">$ 876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">2,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">3,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_TotalLeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LeaseLiabilityCurrent', window );">Lease Liability Current</a></td>
<td class="nump">2,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LeaseLiabilityNoncurrent', window );">Lease Liability Noncurrent</a></td>
<td class="nump">$ 519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Payments Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Payments Due Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Payments Due Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Payments Due Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Undiscounted Excess Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_TotalLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_TotalLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 20, 2024</div></th>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Reclassification of euity upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,856,309<span></span>
</td>
<td class="nump">1,407,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,856,309<span></span>
</td>
<td class="nump">1,407,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of voting common stock are entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends, per share, declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=tecx_SimpleAgreementsForFutureEquityMember', window );">SAFE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">2,752,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,752,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AgreementAxis=tecx_SubscriptionAgreementMember', window );">Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share</a></td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 96,600<span></span>
</td>
<td class="nump">$ 96,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AgreementAxis=tecx_AvrobioMember', window );">AVROBIO [Member] | SAFE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_AvorbioCommonStockMember', window );">Avorbio Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization', window );">Stock issued during the period shares new issues converted pursuant to reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,163,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_AvorbioCommonStockMember', window );">Avorbio Common Stock [Member] | Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization', window );">Stock issued during the period shares new issues converted pursuant to reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,163,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity', window );">Common stock issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,647,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Reclassification of euity upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance', window );">Convertible preferred stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,947,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,634,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,634,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of common stock were entitled to one vote for each share of common stock<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_RestrictedCommonStockMember', window );">Restricted Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,634,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,634,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_UnrestrictedCommonStockMember', window );">Unrestricted Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,598,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issuable on conversion into permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period shares new issues converted pursuant to reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=tecx_SimpleAgreementsForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=tecx_SimpleAgreementsForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AgreementAxis=tecx_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AgreementAxis=tecx_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AgreementAxis=tecx_AvrobioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AgreementAxis=tecx_AvrobioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_AvorbioCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_AvorbioCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_RestrictedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_RestrictedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_UnrestrictedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_UnrestrictedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">2,775,878<span></span>
</td>
<td class="nump">6,213,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">1,626,841<span></span>
</td>
<td class="nump">1,002,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">25,612<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,647,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_SimpleAgreementsForFutureEquityMember', window );">SAFEs (as converted to common stock) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,519,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">976,082<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">147,343<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_SimpleAgreementsForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_SimpleAgreementsForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share based compensation by share based award equity instruments other than options unvested and outstanding unrecognized compensation</a></td>
<td class="nump">$ 13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">2,775,878<span></span>
</td>
<td class="nump">6,213,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock Compensation Expense</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share based compensation by share based award equity instruments other than options unvested and outstanding unrecognized compensation</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">25,612<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tecx_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options Granted, Weighted-average grant-date fair value</a></td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="nump">$ 4.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">1,938,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription', window );">Common stock capital shares reserved for future issuance term description</a></td>
<td class="text">such aggregate number of shares of common stock will automatically increase on January 1st of each year for a period of ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to 5% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase; provided<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">147,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription', window );">Common stock capital shares reserved for future issuance term description</a></td>
<td class="text">the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to the lesser of (x) 1% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase and (y)&#160;a number of shares equal to three times the Initial ESPP Share Reserve<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares reserved for future issuance term description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tecx_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tecx_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of the Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Options assumed from AVROBIO upon Merger closing</a></td>
<td class="nump">365,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised, Number of Shares</a></td>
<td class="num">(52,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options Forfeited and expired, Number of Shares</a></td>
<td class="num">(220,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Closing Balance, Number of shares</a></td>
<td class="nump">92,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, Number of Shares</a></td>
<td class="nump">92,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest as of December 31, 2024</a></td>
<td class="nump">92,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options Exercised, Weighted- Average Exercise Price</a></td>
<td class="nump">$ 14.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options Forfeited and expired, Weighted- Average Exercise Price</a></td>
<td class="nump">136.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Options assumed from AVROBIO upon Merger closing</a></td>
<td class="nump">89.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Closing Balance, Weighted- Average Exercise Price</a></td>
<td class="nump">22.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, Weighted- Average Exercise Price</a></td>
<td class="nump">22.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted- Average Exercise Price</a></td>
<td class="nump">$ 22.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years) Unvested and expected to vest as of December 31, 2024</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercised, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending Balance, Aggregate Intrinsic Value</a></td>
<td class="nump">2,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">2,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2024</a></td>
<td class="nump">$ 2,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember', window );">2019 and 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of January 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted, Number of Shares</a></td>
<td class="nump">982,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised, Number of Shares</a></td>
<td class="num">(335,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options Forfeited and expired, Number of Shares</a></td>
<td class="num">(115,210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Closing Balance, Number of shares</a></td>
<td class="nump">1,534,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, Number of Shares</a></td>
<td class="nump">364,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest as of December 31, 2024</a></td>
<td class="nump">1,534,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Opening Balance, Weighted- Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options Granted, Weighted- Average Exercise Price</a></td>
<td class="nump">$ 18.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options Exercised, Weighted- Average Exercise Price</a></td>
<td class="nump">2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options Forfeited and expired, Weighted- Average Exercise Price</a></td>
<td class="nump">8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Closing Balance, Weighted- Average Exercise Price</a></td>
<td class="nump">12.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, Weighted- Average Exercise Price</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted- Average Exercise Price</a></td>
<td class="nump">$ 12.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years) Unvested and expected to vest as of December 31, 2024</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Opening Balance, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercised, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending Balance, Aggregate Intrinsic Value</a></td>
<td class="nump">51,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">15,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2024</a></td>
<td class="nump">$ 51,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Fair Values of the Options Granted (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility ,Minimum</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">93.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility ,Maximum</a></td>
<td class="nump">104.00%<span></span>
</td>
<td class="nump">111.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value per share of underlying common stock</a></td>
<td class="nump">$ 51.28<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.26%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value per share of underlying common stock</a></td>
<td class="nump">$ 16.09<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Restricted Stock Units (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years) Unvested and expected to vest as of December 31, 2024</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2024 | $</a></td>
<td class="nump">$ 2,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards as of January 1, 2024 | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted | shares</a></td>
<td class="nump">26,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited | shares</a></td>
<td class="num">(725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards as of December 31, 2024 | shares</a></td>
<td class="nump">25,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding as of January 1, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Restricted stock units granted</a></td>
<td class="nump">44.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Restricted stock units forfeited</a></td>
<td class="nump">34.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding as of December 31, 2024</a></td>
<td class="nump">44.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested and expected to vest as of December 31, 2024</a></td>
<td class="nump">$ 44.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years) Unvested and expected to vest as of December 31, 2024</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding as of January 1, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding as of December 31, 2024</a></td>
<td class="nump">$ 1,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2024 | $</a></td>
<td class="nump">$ 1,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Equity Instruments Other Than Options Unvested And Expected To Vest Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Restricted Stock Activity (Detail) - Unvested Restricted Common Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards as of January 1, 2024</a></td>
<td class="nump">18,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Early exercise of options</a></td>
<td class="nump">6,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(25,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards as of December 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 3,491<span></span>
</td>
<td class="nump">$ 1,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 1,182<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements (Additional Information) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,856,309<span></span>
</td>
<td class="nump">1,407,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,364<span></span>
</td>
<td class="nump">$ 36,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tecx_HarvardAgreementMember', window );">Harvard Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">227,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_LicenseAgreementsPaymentsDescription', window );">License Agreements Payments Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(1)&#160;annual maintenance fees ranging from the low five digits to the low six digits during the term of the License Agreement (through the first commercial sale of a royalty-bearing product); (2) royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from products that utilize the license technology (&#8220;Licensed Products&#8221;) and royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from&#160;know-how&#160;enabled product licenses&#160;(&#8220;Know-How&#160;Enabled Products&#8221;) and (3)&#160;a percentage between&#160;10-20%&#160;of all&#160;non-royalty&#160;income received by the Company under sublicenses, strategic partnerships and&#160;know-how&#160;enabled product licenses that utilize the license technology<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period Value</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Amount Due to Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_UpfrontLicenseFees', window );">One-time license fee</a></td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_LicenseAgreementsPaymentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreements Payments Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_LicenseAgreementsPaymentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_UpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_UpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tecx_HarvardAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tecx_HarvardAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate continuing operations</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current federal tax expense benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current state and local tax expense benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance deferred tax asset change in amount</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred tax assets operating loss carryforwards not subject to expiration</a></td>
<td class="nump">399,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred tax assets operating loss carryforwards domestic</a></td>
<td class="nump">399,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets operating loss carryforwards state and local</a></td>
<td class="nump">$ 71,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AmortizationPeriodForeignRDCosts', window );">Amortization period foreign R&amp;D costs</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_AmortizationPeriodRDActivities', window );">Amortization period R&amp;D activities</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Deferred tax liabilities deferred expense capitalized research and development costs</a></td>
<td class="nump">$ 40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=tecx_ExpirationThrough2040Member', window );">Expiration Through 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets operating loss carryforwards state and local</a></td>
<td class="nump">71,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Country [Member] | Expiration Through 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred tax assets tax credit carryforwards research</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=tecx_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current federal tax expense benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current state and local tax expense benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Expiration Through 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred tax assets tax credit carryforwards research</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AmortizationPeriodForeignRDCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>AmortizationPeriodForeignR&amp;DCosts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AmortizationPeriodForeignRDCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_AmortizationPeriodRDActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>AmortizationPeriodR&amp;DActivities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_AmortizationPeriodRDActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=tecx_ExpirationThrough2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=tecx_ExpirationThrough2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=tecx_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=tecx_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=tecx_ExpirationThrough2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=tecx_ExpirationThrough2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Components of Income Tax Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current federal tax expense benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current state and local tax expense benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit), Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred Federal Income Tax Expense Benefit</a></td>
<td class="nump">13,004<span></span>
</td>
<td class="nump">11,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred State And Local Income Tax Expense Benefit</a></td>
<td class="nump">3,181<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred Foreign Income Tax Expense Benefit</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit), Total</a></td>
<td class="nump">16,926<span></span>
</td>
<td class="nump">14,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense', window );">Less change in valuation allowance</a></td>
<td class="num">(16,926)<span></span>
</td>
<td class="num">(14,568)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance for deferred tax asset related to income tax expense acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479172/805-740-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference', window );">Permanent differences</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_Effectiveincometaxratereconciliationchangeinstock1', window );">Equity-based compensation</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_PreferredStockLiabilityFairValueAdjustment', window );">Preferred stock liability fair value adjustment</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Less: change in valuation allowance</a></td>
<td class="num">(29.20%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent difference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_Effectiveincometaxratereconciliationchangeinstock1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effectiveincometaxratereconciliationchangeinstock1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_Effectiveincometaxratereconciliationchangeinstock1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_PreferredStockLiabilityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock liability fair value adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_PreferredStockLiabilityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Deferred tax assets and liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 109,392<span></span>
</td>
<td class="nump">$ 11,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research credits</a></td>
<td class="nump">13,946<span></span>
</td>
<td class="nump">4,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">660<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts', window );">Capitalized research and development expenses</a></td>
<td class="nump">40,742<span></span>
</td>
<td class="nump">14,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accruals and other</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">3,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross, Total</a></td>
<td class="nump">171,270<span></span>
</td>
<td class="nump">32,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(170,177)<span></span>
</td>
<td class="num">(30,228)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets, Net of Valuation Allowance, Total</a></td>
<td class="nump">1,093<span></span>
</td>
<td class="nump">1,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(485)<span></span>
</td>
<td class="num">(1,210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use asset</a></td>
<td class="num">(608)<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,093)<span></span>
</td>
<td class="num">(1,939)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets, Net, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized start up and organizational costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Depreciation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net Income (Loss) Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss, basic</a></td>
<td class="num">$ (57,982)<span></span>
</td>
<td class="num">$ (42,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss, diluted</a></td>
<td class="num">$ (57,982)<span></span>
</td>
<td class="num">$ (42,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_WeightedAverageCommonShareOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">8,490,171<span></span>
</td>
<td class="nump">1,268,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_WeightedAverageCommonShareOutstandingDiluted', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">8,490,171<span></span>
</td>
<td class="nump">1,268,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (6.83)<span></span>
</td>
<td class="num">$ (33.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (6.83)<span></span>
</td>
<td class="num">$ (33.76)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_WeightedAverageCommonShareOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average common share outstanding basic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_WeightedAverageCommonShareOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_WeightedAverageCommonShareOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average common share outstanding diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_WeightedAverageCommonShareOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">1,652,453<span></span>
</td>
<td class="nump">6,188,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,647,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">1,626,841<span></span>
</td>
<td class="nump">1,002,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">25,612<span></span>
</td>
<td class="nump">18,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tecx_SimpleAgreementForFutureEquityMember', window );">Simple Agreement For Future Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,519,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tecx_SimpleAgreementForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tecx_SimpleAgreementForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions  - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,364<span></span>
</td>
<td class="nump">$ 36,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ProceedsFromSimpleAgreementForFutureEquity', window );">Proceeds from the issuance of SAFEs</a></td>
<td class="nump">$ 34,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=tecx_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Amount Due to Related Party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=tecx_AdimabAgreementMember', window );">Adimab Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tecx_MemberOfTheScientificAdvisoryBoardMember', window );">Member of the Scientific Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Amount Due to Related Party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tecx_MemberOfTheScientificAdvisoryBoardMember', window );">Member of the Scientific Advisory Board [Member] | Advisory Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ProceedsFromSimpleAgreementForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from simple agreement for future equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ProceedsFromSimpleAgreementForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tecx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tecx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tecx_AdimabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tecx_AdimabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tecx_MemberOfTheScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tecx_MemberOfTheScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tecx_AdvisoryServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tecx_AdvisoryServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - Retirement Plan Name, Other [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan employee mathing contribution percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contribution by company</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=us-gaap_RetirementPlanNameOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=us-gaap_RetirementPlanNameOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Additional Information) (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of segment net loss and significant segment expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (57,982)<span></span>
</td>
<td class="num">$ (42,823)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_Non-ControllableExpenses', window );">Non-controllable expenses</a></td>
<td class="nump">8,733<span></span>
</td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">5,134<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">57,982<span></span>
</td>
<td class="nump">42,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Total employee-related expenses</a></td>
<td class="nump">11,135<span></span>
</td>
<td class="nump">10,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Total employee-related expenses</a></td>
<td class="nump">5,553<span></span>
</td>
<td class="nump">3,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Research and Pre-clinical Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ExternalResearchAndDevelopmentLiability', window );">Total external research and development expenses</a></td>
<td class="nump">8,477<span></span>
</td>
<td class="nump">8,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Clinical and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ExternalResearchAndDevelopmentLiability', window );">Total external research and development expenses</a></td>
<td class="nump">15,380<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Chemistry, Manufacturing, and Control Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tecx_ExternalResearchAndDevelopmentLiability', window );">Total external research and development expenses</a></td>
<td class="nump">$ 3,570<span></span>
</td>
<td class="nump">$ 8,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_ExternalResearchAndDevelopmentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>External Research and Development Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_ExternalResearchAndDevelopmentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tecx_Non-ControllableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-controllable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tecx_Non-ControllableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tecx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=tecx_ResearchAndPre-ClinicalExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=tecx_ResearchAndPre-ClinicalExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=tecx_ClinicalAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=tecx_ClinicalAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=tecx_ChemistryManufacturingAndControlExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=tecx_ChemistryManufacturingAndControlExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Additional Information) (Detail) - Subsequent Event [Member]<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate consideration | $</a></td>
<td class="nump">$ 185.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued under securities purchase agreement | shares</a></td>
<td class="nump">3,689,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Fund Investors [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Individual Investors [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 54.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tecx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tecx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tecx_FundInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tecx_FundInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tecx_IndividualInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tecx_IndividualInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !J)>EI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !J)>EI03>2_\0   "L"   1
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M9"SB(P^F@>'ZE7OC'W\(>OY/"'"W!.YBZA7P8I?5]@@>/C\/$(C+$N(259D
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M[5Z YTNE[*'@/E">*([_ 5!+ P04    "  :B7I:+Y1([8P&  #S&P  &
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MW>&.)G+IU5X@?W]D3+R<M&^T'M_"OOT_4$L#!!0    ( !J)>EH@79EKFP(
M (T&   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULI55-<],P$/TK&L-
M.\/4CO,%Q?%,D[8#AS*9AL*!X:#8FU@3?;B2G+3_GI7LF$ 3'R"'>%?:??OV
M65HG.Z4WI@"PY$EP:29!86UY&88F*T!0<Z%*D+BS4EI0BZY>AZ;40'.?)'@8
M1]$H%)3)($W\VERGB:HL9Q+FFIA*"*J?I\#5;A+T@OW"/5L7UBV$:5+2-2S
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MLH.Y/ LFX;Q%38$5S(>[KU^\^)9OXG,E8);Y$8+84E@<3C6TF:K%:D*_PC(
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M7_J8&T$/^F.9#16"UOIRCU&)F1*0OV\I%:\WZ@7=]U:KOP!02P,$%     @
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M.P=Z7BIE7PXN0?_A6_P+4$L#!!0    ( !J)>EH\%%F/W@(  %X&   9
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MH-Y%K^. JKI9M3"R*#O(1AKJ1^4TI0< E36@\T1*<UA8!\V3,OX+4$L#!!0
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M<T9A>"(!/%\I6%#K RIHO]I=_0U02P,$%     @ &HEZ6B5;Y1D0#   6"4
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M5TQ/9<-KG,FEJIC!H5K-=*,XRZQ15<X\QXEF%1/U>'%AO]VKQ85L32EJ?J]
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M7-$"G,^E-,. -M@^FQ?_ U!+ P04    "  :B7I:1G/0F-\$  #5"P  &0
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M8(?L 9 ;RA%-2N#Y#YLO,&49LH].<$(&$O1<"<-#YM'MH5\Y>@$1!4))+LI
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M=I.S!/^'ITD'/ $6*,5XE.P]@EP<I8ODM#L9G(IDU#TY/>O\K9P3Z5R6-TK
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MV>S\Y>7\FE]=O'RDZ,'AE5^V.+9+%GV)BXAPV/%=I,@@A*N*_L7U[R[G5P'
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MY'=1;&<\HSC%!(2V;!TL9LJ7A=E7/BLNX:S[WY+N5'2D)M@K5%E,S8>$"Y!
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ME%=8;,5&0';?=(3C4CIGB]#O24HMB]A;H/B2=+J.B>/6@3JA$"TU!BD4'Q6
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M1 Z1=NK;C19M/VG70N/<[I<%/I0@C0*>;X30^XTA&)_>Q7]02P,$%     @
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M5D2)X6GWG!Y=]'&\'7"?BXE>:A-<R4#*']CYG)UV/20D"I$:1.#P\R#>BZ)
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MOEF_Y;-BAT6.[_=) !+^ZR&PR70A[?M]AE+N!VY(GQT8.P@["YV(8BD28%Z
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MH*P![M=2FFEB#YA?TLT_4$L#!!0    ( !J)>EJY9$M1.@8  !0N   9
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M)CS+!^COIVFJWM[DS]Q5SUB._@=02P,$%     @ &HEZ6I7O_]!1 P  YPD
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULK59M;],P$/XKIX 02&-Y
M:[L7VDCKQL2D34PK@P^(#VYR;0R)'6RG'?^>L].%=FW#B_C2QN>[Q\]SYY<;
M+J7ZIG-$ P]E(?3(RXVI3GU?ISF63!_*"@7-S*0JF:&AFONZ4L@R%U06?A0$
M []D7'C)T-EN53*4M2FXP%L%NBY+IGZ,L9#+D1=ZCX8[/L^--?C)L&)SG*"Y
MKVX5C?P6)>,E"LVE (6SD7<6GIZ?6'_G\)'C4J]]@U4RE?*;'5QE(R^PA+#
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MTM [[SYSZL1060>:GTEI'@=V@;:W2WX"4$L#!!0    ( !J)>EJ1T3(VK0,
M (T1   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+5878^;.!3]*Q9;
MK5II.F ^\C&;1-IF=K4C3;=1I]U]J/;!@4MB%3"U33+]]VL# R'QT$E%7A(;
M[CV<>WQPKC/;,_Y5; $D>DR33,RMK93YC6V+< LI$=<LATS=B1E/B513OK%%
MSH%$95*:V*[CC.R4T,Q:S,IK*[Z8L4(F-(,51Z)(4\*_OX.$[><6MIXN?*2;
MK=07[,4L)QMX /DY7W$ULQN4B*:0"<HRQ"&>6[_CFR4>ZX0RXA\*>W$P1KJ4
M-6-?]>0NFEN.9@0)A%)#$/6U@R4DB492/+[5H%;S3)UX.'Y"_[,L7A6S)@*6
M+/F71G([MR86BB F12(_LOU?4!<4:+R0):+\1/LZUK%06 C)TCI9,4AI5GV3
MQUJ(@P3L/Y/@U@GN2Q.\.L$K"ZV8E67=$DD6,\[VB.MHA:8'I39EMJJ&9GH9
M'R17=ZG*DXL55X[@\CLB683^^%;07*V1O$)_*P>]10_5XB(6(W-@&??Z%B2A
MR1N5\/GA%KU^]0:]0C1#G[:L$"I<S&RIJ.H'VF%-ZUU%RWV&UBV$U\C#5\AU
M7-^0OGQYNM=-MY5 C4INHY);XGD_4.D*K1*BJNYJ\.5>A:,[":GXSU1JA>V;
ML?5[>B-R$L+<4B^B +X#:_'K+WCD_&8J?""PC@Q>(X/7A]Z:)6]4@$:%#6?"
MN-(59E!BZEUEM_ GT]',WAV690B:CB=-4(>NW]#U>^G>@Q W:J,(B[1(B(1(
MO=]*E9 2O8.8J%9XHP,6;]VQ'QQQ-43A23 RDPT:LL'+M.VH>H4RD":FP0D'
M%P?XB.AID(==U\QSU/ <]8M*UHP3R=2NT*[]E_>0KH$;W=\+=Z[[!P+K5#YN
M*A]?<!,8#RG#0& =&2:-#),+; *3$ROZP=0Y\JLI"#MFOTX;NM->NA_BF(9P
M^$;%!<^H+#B4W&/ZJ,>BU\.]CSAW\08"ZZB!G?;WWKF@BVOP@908"JTKQ4'K
M@R_@Y!JTL_5.CG=>0Y#O!&8GX[8+P;V_[HLERX3D1=4 JP8KYVRCA.GW;C_F
MV4MVB?X#MPT(]B[IWM[VYFPI!D+K2M$V-[B_N_E)]YXV+\>[L"'$>Z83PVUW
M@_O;FWM09ZTM2R)TERK;[D#3_(%Q>Q'/7JV!T+KUMUT3'EW2N(,V44.A=:5H
MVRC<VY[\K''')R<$][@Q[X^IZ-H'9V7]1\5[PC<T$RB!6"4YUV.5S:NS?S61
M+"^/SVLFU6&\'&Z!1,!U@+H?,R:?)OI$WOP#L_@?4$L#!!0    ( !J)>EJ,
M92$]> (  -L%   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;*U4RV[;
M,!#\%4(-B@1(33V<M$AE 7ZT: XIC 1I#T4/M+2VB%"D0M)VTJ_ODI15)W#2
M'GJ1N-3N<&;$W7RK])VI 2QY:(0THZBVMKV@U)0U-,P,5 L2ORR5;IC%4*^H
M:36PRA<U@J9Q?$X;QF54Y'YOKHM<K:W@$N::F'73,/TX :&VHRB)=AO7?%5;
MMT&+O&4KN %[V\XU1K1'J7@#TG EB8;E*!HG%].AR_<)WSALS=Z:."4+I>Y<
M<%F-HM@1 @&E=0@,7QN8@A ."&G<=YA1?Z0KW%_OT#][[:AEP0Q,E?C.*UN/
MH@\1J6#)UL)>J^T7Z/2<.;Q2">.?9-OEQA$IU\:JIBM&!@V7X<T>.A_V"I+S
M%PK2KB!]7C!\H2#K"C(O-##SLF;,LB+7:DNTRT8TM_#>^&I4PZ7[BS=6XU>.
M=;:8:[P0VCX2)BORZ7[-6_Q%]I1\Q0MT/*XJ[LQF@ES*<&,P.B'',[",BQ/R
MCMS>S,CQT0DY(ER2*RX$)IB<6J3F#J!E1V,2:*0OT$A2<J6DK0WY)"NHG@)0
MU-0+2W?")NFKB#,H!R1+3DD:I\,#A*;_7IZ]0B?K?<X\7O87GT_)7#!IG]I-
M?HP7QFJ\TC\/61>0AX>179M?F):5,(JPCPWH#43%VS?)>?SQD.S_!/;$A&%O
MPO U=#0504O.0@.C ZQ1VO)?80,><#09..1 @$UBC^L&TZ9(!FE.-_O*0M+9
M?DZ?$>C2O3YI0*_\^#"D5&MIP\WJ=\.$FN"$\IW\;!\GU]@W+/T#$\;>%=,K
M+@T1L$3(>/ >^>@P2D)@5>N[<:$L]K9?UCA]0;L$_+Y4RNX"=T _SXO?4$L#
M!!0    ( !J)>EH*83PJPP(  )P'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;*U576_3,!3]*U:8T)!@^4ZCD4;:6A!((*IU@P?$@YO<--:<.-AN
MN_U[;"<+69M51>(E\<<])^?<7%\G.\;O10D@T4-%:S&U2BF;2]L660D5%A>L
M@5KM%(Q76*HI7]NBX8!S ZJH[3E.9%>8U%::F+4%3Q.VD934L.!(;*H*\\=K
MH&PWM5SK:>&&K$NI%^PT:? :EB#OF@57,[MGR4D%M2"L1AR*J77E7LXB'6\"
MOA/8B<$8:2<KQN[UY',^M1PM""AD4C-@]=K"#"C51$K&[X[3ZC^I@</Q$_M'
MXUUY66$!,T9_D%R64RNV4 X%WE!YPW:?H/,3:KZ,46&>:-?%.A;*-D*RJ@,K
M!16IVS=^Z/(P +C!"P"O WBG OP.X!NCK3)C:XXE3A/.=HCK:,6F!R8W!JW<
MD%K_Q:7D:I<HG$ROLHQO($<?'E1="! (USGZ)DO@:+;A'&J)OA"\(I1(HG;?
MH67[NQ$KT#]BS^<@,:%O%,G=<H[.S]Z@,T1J=%NRC5!0D=A2.=*Z[*Q3?]VJ
M]UY0/X?L OGN6^0Y7C "GYT.]Y_#;97'/IE>GTS/\/DO\"WP(U[1+A$F.Y@*
M]/-J)217]?IKS&#+&(PSZC-\*1J<P=12AU0 WX*5OG[E1L[[,;O_B>R9>;\W
M[Q]C[RLI8Y4N!]R>4I4(#A1+M0%=F8QEH:4.#;5N/-O4#^,PL;=#=X=!7AQ&
M?= SU4&O.CA)M<X'YEEI%.>P5>VMJ70%'U/=4D=#09-XLJ?Z,,CWW&!<==BK
M#D]2W7!6@- =%5-40%=YS!S!8\+# TUN,(GWA!\&><[$'1<>]<*CH\)OF51*
M<2<?AHVC59UUC8/^;1QC!J*#4IC$H;-GX# H=H-] _:@=^I[ZROF:U(+1*%0
M,.=BHO"\O0O:B62-::<K)E5S-L-279_ =8#:+QB33Q/=H?L+.?T#4$L#!!0
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MGWGG'LE@R=:%>9#;6VCTC"Q?*@OMWF1;VXZG'DG7VLBR 6,$)1?UE[TT>>@
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M$1P1GC=0]S>,R=>3?/>RVJU>_ =02P,$%     @ &HEZ6F 9VV/>"   0U(
M !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULQ9QK;^,V%H;_"N$M=EM@
M-K;N3C8QD(0L.L4..D@VW0_%?E D.A9&%Y>BG;;8'[^DI)BB+5-BYP1;8!I;
M%A]*[Y'(\Y*4KE\K]J7>4,K1;T5>UC>S#>?;J_F\3C:TB.N+:DM+\<NZ8D7,
MQ5?V,J^WC,9I4ZC(Y^YB$<Z+."MGJ^MFVV>VNJYV/,]*^IFA>E<4,?O]CN;5
MZ\W,F;UM>,A>-EQNF*^NM_$+?:3\:?N9B6_S R7-"EK6654B1M<WLUOGB@2>
M+-#L\7-&7^O>9R1/Y;FJOL@O'].;V4(>$<UIPB4B%G_V])[FN22)X_BU@\X.
M=<J"_<]O].^;DQ<G\QS7]+[*_YVE?',S6\Y02M?Q+N</U>L/M#NA0/*2*J^;
M_Z/7;M_%#"6[FE=%5U@<09&5[=_XMTZ(7@''/U/ [0JX4PMX70'OJ$ 8G2G@
M=P7\HP)GSR'H"C2G/F_/O1$.QSQ>7;/J%3&YMZ#)#XWZ36FA5U;*"^61,_%K
M)LKQU2.ODB^;*D\IJ_^&R*^[C/^._HYNTS23@8QS]+%L+T<9UF\QY7&6?R?V
M>'K$Z-MOOD/?H#FJ-S&C-<I*]%1FO/X@-HK/_]I4NSHNT_IZSL61ROKF27=4
MN#TJ]\Q1.2[Z5)5\4R-2IC35 7-QBH?S=-_.\\XU$G_<E1?(77P0_UQ_X(#N
M1XK'HKAWOC@V%\<T$<6=L\7)].*>00SO$'2OX7EG>/=Y7->H6J,F^NB7?XK?
MT4=.B_H_ P=WU\+\89ALR:[J;9S0FYEHJFK*]G2V^NM?G'#QCR&=(6$8$D:
M8%I$_$-$?!-]]4 3&9-LG27MG2:"0YM[<;<5WY*JW(L;5/PP%!\CVC8^D##<
MPH(&)KNL_6JY"-WH>K[O"P]4I29\<! ^, I_7Q6%$+B6-\('%._XIF+9'\=-
M3JNSD62K,R0,M["PI[,3+-K_CK2>LJ<F9'@0,K00<ALSM(_S'1W2T0BRU1$2
MAEM8U%-G<2&4<8Y$'-U-4S Z*!A9*)C5]6[X,C12;.6#A.'H].+RET'H+2Z/
M!!S:<1%%@3>LX/*@X-)"09$6UUSD'UGY,B2C$64K(R0,+Z?*.+2C0<;+@XR7
M%C+N*RX41$QFW$.IW)T19BLD) R;3_.'-NN576UWCDGOQ)%(:1$M><9SFB)>
MH4KD2&(_BK:4M1GOQ5 6 70"6N"<A<KF%Q:A2[-]EE*1@7]0!RVVRER##;<M
M9KQM,$%IN*/ULXGCW@VJ0EW]GI=RC.H_WGY/T"^?:/%,V6 F;2YO+2\D#8/2
M"!1-CX2K(N%".IR.!A472!H&I1$HFAX793P=HXNRR1([DKRE5??F7OCZ+7]O
MKM!:[$F5$JA*=165673,;G%JIMAA^@F"&P6NZX3'(H*ZOJG5$JAJ=1F5]7/,
MWN]Q]UPG+-LVAOOVA5%:B [?W("#>D!0&@:E$2B:'AOE)IT0M $']92@- Q*
M(U T/2[*HSIFD_H8YU2&I<V1FZ8';5F6]-+BP?A$TQKS2;MA\S%:*PI$TQ55
MGM4QF];/K$HH36NT9E6!^(8VJL9ETNC<MR2#PBY/DN++,#P>]KF?MALV'ZJU
ML$ T75CE8AVSO[O]^>&GNX\_'=IS]%\TGJ"#FEE0&@:E$2B:/ANCC*J[@&S?
M75!?"DK#H#0"1=/CHBRL:[:P4U-+,\8Z(*!.MJ/IXV+18ND=CY]!5:MKK4RJ
M:S1;J]M]Q9ZS"G6:=W>"H74R\ZQ%![6IH#0"1=,CHVRJ"SI!ZH+.D(+2,"B-
M0-'TN"CCZYJ-[Z/*.E.4[I@<M)49D\@]LRI]6X=0TM=VG[J;..5B[^V.R:R*
MRZ%<1N5L*A5_DWB;\3C/_FAF70=C"SJ["DK#[JG1]IW0"Q?'1ANJ6CULRFB[
M9J-M;.AD6F9OQ,TU6H<%U(B#T@@438^=,N(NJ!%W08TX* V#T@@438^+,N+N
MB!'_/S2%H#//H#3LGDXIGVD*W\/MN\KMNV-NGZXI8R(*$](]T"EJ4!H&I1$H
MFAX4-5+@7H*V<:"#!* T#$HC4#1]E:(:)/"FSV:WHV+/.9VR(L[,M5ZR"#I<
MT-'Z+947^E$8!4<M%52UNOAJ), SCP1\U9)$,]LZ *## QWM:%7BR4HYJ$IU
M^=7@@&<>'+AON^M,7O&JTYBVM,F,ME8?=)R@H_4O_Q/EW\/\>[W%T6-SU$KY
MK:Y\;X$H6E?L,%(_& 389=.PZZ:]\2"\A]/WE-/WQJ:X#9?_^6%),]5:=%"W
M[IVZ]1/1W\.G>\JG>Y,60X]GIF:.M<R@[AN41J!H>D24^_9 W;<'ZKY!:1B4
M1J!H>ER4^_9LUFJ;'QLPHZR# FJ;06G$&UC7[5SZ41 LAU<D>\HW>S9+NXT+
MQ\PD:[U!;3,HC72TJ0\B>,H0>S8KP W=+:@3!J5A4!KI:-J:MM#S73\<UMI7
M)M>W6;(]DMF;6=;/>H$:6U :\4]MLEEP96Q]FRGNT<<;S#1KR4&M+"B-C.C6
M>UY">U#BE9Y[4D):)!HGFW8TVKR<20^FLLF^V28_E2FMLY<RE@/;-H.K9JYU
M6$$],BB-0-'T""D[[8/.I?N@MAF4AD%I!(JFQZ7WQ/%7..RQ;@C49H/2L#]N
MLZ$JU)57-ML?L]E_:FS#3+46'=1T^Z?/%9^(_AY.VE=.VC<_G_Q :\ZR1'83
MDX<YS$AKQ4'M-"B-0-'TX"@[[4>@?02HHP:E85 :@:+I<5&NV[=QW8:F"=1R
M@](P*(WXI\]<FVV)\MR^C><>ZX!!C3<H#8/2B&]IO -EO .S\7XJV9_H$\Q0
M6^5!:1B41J!H>GB430\<R#XA +7IH#0,2B-0-#TNRG$'7S$Q/?("'5#/#4K#
MP>F\M'/F%3KOX:<#Y:<#FT>H1_H),\M:<5 W#4HCP>F4MAM<+J/ />HGYKV7
MY164O31O*93+(W<E;]\G=]C:O@D1.U>D>6'@T?9;Y^JV>2_@7&':URM^BME+
M5M8HIVN!7%Q$POJP]HV%[1=>;9M7\CU7G%=%\W%#XY0RN8/X?5U5_.V+K.#P
MWLC5_P!02P,$%     @ &HEZ6CER/=2%!   "!P  !D   !X;"]W;W)K<VAE
M971S+W-H965T-3,N>&ULQ5EK;]LV%/TKA 9L+;!%(O5T9AMHG08+L&)&O&P?
MBGV@93H6(HDN2=G-?OU(2='#EIEXH-$OMA[W'O+<>TP<D^,]94]\0X@ W[(T
MYQ-K(\3VVK9YO"$9YE=T2W+Y9DU9AH6\98\VWS*"5V52EMK(<0([PTEN3<?E
MLSF;CFDATB0G<P9XD668/7\D*=U/+&B]/+A/'C="/;"GXRU^) LB'K9S)N_L
M!F659"3G"<T!(^N)]0%>SU"H$LJ(OQ*RYYUKH*@L*7U2-W>KB>6H&9&4Q$)!
M8/FU(S.2I@I)SN-K#6HU8ZK$[O4+^FU)7I)98DYF-/T[68G-Q(HLL")K7*3B
MGNY_(S4A7^'%-.7E)]C7L8X%XH(+FM7)<@99DE??^%M=B$X"]$XDH#H!O37!
MK1/<DF@ULY+6#19X.F9T#YB*EFCJHJQ-F2W9)+EJXT(P^3:1>6*Z$#1^VM!T
M11C_"7SZ6B3B&?P"%E57 5V#&<TR6>\R$-P33MB.K( 4$+@M1,$(N..\P'E,
MP+L;(G"2OI?Y?(,9X6-;R"FJ@>RXGL[':CKHQ'1N2'P%7/@S0 [R!M)G;T]W
M^^FV+$Q3'=14!Y5X[@F\68HY5T6HV'_Y7;X'=X)D_)\A;A68-PRF?I#7?(MC
M,K'D+ZZLHS7]\0<8.+\.,34$UN/M-KQ='?KT3RIP6C=1T<>%V%"6_"L;'U=R
MX&5!6%<.ZTH.22V'H0)5HP;EJ&J!V4U1&/I1&(WM79?[<5R H!O"L(GKT?(:
M6IZ65M7%/[9J >% 4# O6+R1BT!?Y%\^DVQ)V&"+M0.<VV)#8+U:^$TM?)/2
M]DWR-@36XQTTO(/O(NW@2+(P0$'DP0-I#\0Y#O)=?UC:84,KU-)ZR'>$"SE=
MN4(+EL3J\LVBUD*?VUQ#8+TJ1$T5(I.BCDSR-@36XSUJ>(^^BZA'1V)U#N1\
M' &C41 -BQDZK2MQM(0Z*JY:^9 G@FM%K$<\MYNFT/K\.ZX,FA1RC6:*NR&T
M/O?6<T&MM;F8F.MA>^[##R Z4/1 F'-"SJV=@GH_-:-R>68B6:8$S.7_%,)8
MHVRMIK6P9_?5$%J_"*WY@IY131NU6J;0^MQ;LP6UGN9RFO9?7:$'0MS "X/P
MA.. K9.">BNU^'#[B8-WF$L.I;[EO*6I[A)ZKY>W%O_L%AM"ZU>C-6 P-"IO
MHZ;+%%J?>VN[H-;=7$[>T>OR/@Z!/ARY+CPA[]930;VI0@X<O>R(W,D)YFK#
M"<Q3G.M%K44]N[&&T/K;'ZT/0X[1#1"C'LP46I][Z\&0UN=<3-3UL#I1#X0@
M'SDG;#7J;&?IK97:5?L?DM:CGMW62^QLH=:+(=>HI(U:,%-H?>ZM!4/Z#;"+
M2=H[TNLH#)SHT%L/Q)WPUJBU5DAOK2I-9]N4/A-2-[79UWM=VD8WMDRA]4O1
M&C(4&)6V4?ME"JW/O;5?2+\!=C%IA\?^P@M=SSV4]G'<H;3MSC&-.B/[C-EC
MDG.0DK7,<:Y"J1Y6'3M5-X)NRY.;)16"9N7EAN 582I OE]3*EYNU&%0<_@W
M_0]02P,$%     @ &HEZ6DB35"X_!@  @QX  !D   !X;"]W;W)K<VAE971S
M+W-H965T-30N>&ULU5E;;]LV%/XK!UXW)(!CF_(U:6(@<=,MPX(9"=H^%'M@
MI&-;J"2J)&7'^_4[%&7)%UEI F?97FR)Y+E].CS\2)XOA/RF9H@:'L,@4A>U
MF=;Q6;.IW!F&7#5$C!'U3(0,N:97.6VJ6"+W4J$P:#JM5J\9<C^J#<_3MK$<
MGHM$!WZ$8PDJ"4,NEU<8B,5%C=56#7?^=*9-0W-X'O,IWJ/^%(\EO35S+9X?
M8J1\$8'$R47MDIV-G(X12$=\]G&AUI[!A/(@Q#?S<N-=U%K&(PS0U48%I[\Y
MCC (C";RXWNFM);;-(+KSROM']/@*9@'KG D@B^^IV<7M4$-/)SP)-!W8O$;
M9@%UC3Y7!"K]A44VME4#-U%:A)DP>1#ZD?WGCQD0/R+@9 +.E@#K[!%H9P+M
M-%#K61K6!Z[Y\%R*!4@SFK29AQ2;5)JB\2/S&>^UI%Z?Y/3P^GOBZR7<1"Y&
M!E 8!SQ2< *7GN<;H'E G39=#.Q''U!S/SBF$9_N/\#1NV-X!TU0,RY1@1_!
MI\C7JDZ-]'SK!P$)J?.F)E>-P::;N75EW7+VN,4<N!61GBFXCCST-A4T*<8\
M4&<5Z)53J?$#N@UHLSHX+:=3XM#HQ\7;%>ZT<]S;J;[V'GWW!K"3*TI #\9\
M21-#PZ64/)JB>:[#]2/-5-/+(P]&//8U#_R_T:O#92@2&OWU#U()-QI#]5<9
MP-9^I]R^J0YG*N8N7M1H^BN4<ZP-?_F)]5KOR\ YD+(-J#HY5)TJ[1:J=*YZ
MX(K0P&)S\6%I\R[KXPLN/4";T'ZDM$P,E J$GJ$$/>,1B-A(*DBB.2J=H4O5
M36EZ\*,I=4ATQ30R4&]8*X/8^LU:J>.F8,Z'K-V@])BO8U<9W0NQZ^;8=9_&
M[L3B$V=IQM?3+!(Y$@:^.L6L-+5J6-(:4F!1AQBE+SR@4K!JW@=+M4MMTLRE
M@C:$=H:S 7A\658D1I6:7@A=+X>N]P/0V1DZ6D^[M6EJ4K!T)ELL_[395H?/
M%F(JB>,4Q3I\Y+Z$SSQ(L S!7DEB-7I;>54ZB.6#-H+NYT'W*X.F0.FK "T[
M[C?*!5MV5M4]P]CFP"31"4T]7ZF$T^)1%H4UU5OSS^GWNX/^8"N0W7$]A[7[
MK%\>RR"/95#] 4T0FY\N*ZIES@YVT6PU.EN>5AI\83Z>YN&<5H9S1SDD?=?D
MD8TL76GAZRV&#RA+EX!*A<]= @ZD;"-VUBIH2NN-U\O,@0.A=2AMFW"ML3KV
M/UTS,\?WEJT,OLKP7@J?4\#G_/>6S2=\6JV;3KYN.GO7S6I5+X6OX+:LD@\>
M=A7);&TL(]T><[8S9G=8JWS]8 7Q9-7,TVFQ4RC=(566W6JMSZXDK\$?64$@
M6?>M"^^!6%X&UVMP1E:01E;-&C/*![\20MJ \"4]2$#OA,]1\BG"U/2<>%PC
M3 P)G.\C@:R,X'4:I]N);X<-UD9U&JW.GMPOB""K9H)FF_R2W*_4^NR/>2!M
MFQ@4!)(-WCKW#\0H,[A>@Y^R@J"R:H9ZV+)_NE//V6E[T#_=R?_7(*9.04R=
M2B:W$?1S8@:-,@0/E2O]>!\E>,*V2MP9\.E4XM24DR@QTQ+$9&6?GMQU]Q9^
M$ !/M#"'>2X/ L/Y7(F4X$"#?N=1PN42&%$9$D5.V@WG2-WG*R9#/1JCC(P8
M]1BYA@46"BRZ]JRLFTX-M$31G!^:5S(:)*;EN$2DW:F;C3+5&6[G$+%3@E0+
MZ/Z<&I\1=L*@_&2\!NL2ONJAP9ZPI"ZU4DE4"F(*4!I+*; K:-Y3NYC[.\>0
MV;'A:Q!]IR#Z3C71MV4ZC .Q1,PVAN-$NC/S39^LUM7*GUM^#J5M$XJ"M#O.
M&U=KYT"T.H/K-4BZ4Y!TYU\DZ<XN^V:=?KNS?19:[=-+8RX(O5--Z%^W6%?;
M-D7FR8I%&VZST\2M*LT]JC[/*M%);.K8&Q5J$VJ 2ME0CQZ/@;U-Z4[ECY;'
MUFN^:W;-94GU4_LA-1J=-V:?3EW7]^.Q/>*%.YL@I5/YH'NTYMIU7HARFMYR
MFD]((-L+K[S5WJ1>L;-1>N&XU7[)SB[3>\5FH<9>S]YR.?5IFQ+@A%2V&GW:
M-4E[XVE?M(C32\,'H2D1T\<9<@^E&4#]$R'TZL48R.^=A_\ 4$L#!!0    (
M !J)>EH@23V$&@<  .<N   9    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM
M;,6::W/B-A2&_XJ&[G1V9Q*P)-LQ:<(,D+1-I^EFDKU,9Z<?%"/ L[ZPDLCE
MWU>^!!G;"".@_9+8QCHZ[Y$M/WZMB^>$?>=S2@5XB<*87W;F0BS.>SWNSVE$
M>#=9T%C^,DU81(3<9;,>7S!*)EFC*.PARW)[$0GBSN B.W;'!A?)4H1!3.\8
MX,LH(NQU1,/D^;(#.V\'[H/97*0'>H.+!9G1!RH^+^Z8W.NMHDR"B,8\2&+
MZ/2R,X3G8]M-&V1G? GH,R]M@U3*8Y)\3W=N)I<=*\V(AM07:0@B_SW1,0W#
M-)+,XT<1M+/J,VU8WGZ+_FLF7HIY))R.D_!K,!'SRX[7 1,Z)<M0W"?/O]-"
MD)/&\Y.09W_!<W&NU0'^DHLD*AK+#*(@SO^3EZ(0I0;(WM  %0U0M8&SH0$N
M&N!,:)Y9)NN*"#*X8,DS8.G9,EJZD=4F:RW5!'$ZC ^"R5\#V4X,KG\L _$*
M;F*?QFE!P5U(8@Y.P4,^KB"9 C&GX$$D_G?P<9'5?IC6/FWV_HH*$H0?Y/F?
M'Z[ ^W<?P#O0 WQ.&.4@B,'G.!#\1!Z4VY_FR9*3>,(O>D)FGO;?\XLL1WF6
M:$.6$(';)!9S#J[C"9VL!^A)R2O=Z$WW"&DC7E&_"S \ <A"=D-"X_;-L28=
MO!H&G,7#&^(]I!4['<GK<0+&221O4D[R4C-&XAF5-XX CZ^@?-X=><T.#Y\)
MFX!O?\J0X$;0B/_35."\?[NY_W2R..<+XM/+CIP-.&5/M#/X^2?H6K\T%>=
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M,J$L/4'^/DT2\;:3=K!:VS[X%U!+ P04    "  :B7I:=)B- Q@$   J$
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MG*QQAUCM[KE#SBKJLY^\_\_^@^C.J^C.K6M2)8VH%T?FB\,,NRSSYD^69D9
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M*&N WU=2FL/&$K2_L.0/4$L#!!0    ( !J)>EK//"8P1@,   (,   9
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;,5676_:,!3]*U963:W4-E\0H ,D
M/KJMTCHA6+>':@\FN1"KB9W:!LI^_6PGI$ !M1)57\!V[CV^Y]R;Z#07C#^(
M&$"BIS2AHF7%4F97MBW"&%(L+ED&5#V9,)YBJ;9\:HN, XY,4IK8GN,$=HH)
MM=I-<S;@[2:;R810&' D9FF*^;(+"5NT+-=:'0S)-);ZP&XW,SR%$<B[;,#5
MSBY1(I("%811Q&'2LCKN5<]U=(*)^$U@(=;62%,9,_:@-S=1RW)T19! *#4$
M5G]SZ$&2:"15QV,!:I5WZL3U]0K]JR&OR(RQ@!Y+_I!(QBVK;J$()GB6R"%;
M?(>"4%7CA2P1YA<MBEC'0N%,2)86R:J"E-#\'S\50JPEN,&>!*](\+83*GL2
M_"+!-T3SR@RM/I:XW>1L@;B.5FAZ8;0QV8H-H;J-(\G54Z+R9/OZ<4;D$MW0
M$*@6% T23 6Z0*.\KXA-T$BR\ %UE5@1ZK%439# I@?73WH-: A3S"-"IXA(
M@:[3+&%+ ($PC=!/1J$\..V#Q"0Y4_AWHSXZ/3E#)XA0]"MF,Z&B1=.6BI0N
MS0X+ MV<@+>'@.NA6T9EK.ZE$42; +92HY3$6TG2]0XB]B&\1+Y[CCS'J^PH
MJ/?Z=/] .7[9(=_@^7OP1C'F<)&K/\!+]0I)U.$<TRGH]?FJ"Y&1NX<S(G%"
M_D%TCCHIFZGH^Q\*$MU(2,7?70+G]U=VWZ^_(U<BPR&T+/6A$,#G8+4_?W(#
MY\LN<8X$MB%5I92J<@C]U5+M$B%'KAID_>V;M_U*PVW:\W5R+X-<UWL.VBBZ
M6A9=/5CT-Z# <6*ZAR/UBA,A.3;OXOTMI&/@.YMV$/2M33L2V ;_H.0??/!\
M!\>4ZDA@&U+52JEJ[S;?.7*P-KJ>[S2VYOME4,VI[A[O>EES_6#-0Z4"YF%L
MNA?!7!F'S!1^:+@/0KZU8T<"VV#?*-DW/GBX&\>4ZDA@&U*YSK,5<=YMO OH
MS4]SW=N:[QU1%3?8&G![S4VEP*?&9 H4ZG;D+J(\S8UL5QM9[<:VSI7![1A;
M9S_#Y.[X%O,I438K@8F"="YKJB*>&\Y\(UEF/-N82>4 S3)6)AVX#E#/)XS)
MU49?4-K^]G]02P,$%     @ &HEZ6GD7PHT;!0  (10  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C N>&ULO5AK;]LV%/TKA-L5-M!$+\=V$L> $Z5HL!8+
MDK7[,.P#+5U;1"12(ZDXWJ_?I5ZQ8E6K 6% $/-U#^\YY+TB.=\*^:0B $U>
MDIBKJT&D=7IA62J((*'J5*3 L6<M9$(U5N7&4JD$&N9&26RYMCVQ$LKX8#'/
MV^[E8BXR'3,.]Y*H+$FHW%U#++97 V=0-3RP3:1-@[68IW0#CZ"_I?<2:U:-
M$K($N&*"$PGKJ\'2N? =SQCD([XSV*J],C%45D(\F<I=>#6PC4<00Z -!,6?
M9[B!.#9(Z,??)>B@GM,8[I<K]$\Y>22SH@IN1/P'"W5T-9@-2 AKFL7Z06P_
M0TGHS. %(E;Y?[(MQDYQ<) I+9+2&#U(&"]^Z4LIQ)Z!,_Z!@5L:N&\,9O8/
M#+S2P/O9&<:EP3A7IJ"2Z^!331=S*;9$FM&(9@JYF+DUTF?<K/NCEMC+T$XO
MOK  %Q$(W4@ 7$^MR' 9ALPL"HW)'2^V%M9&9.B#IBP>D1/R[=$GP_<C\IXP
M3GZ/1*8H#]7<TNB2 ;:"<OJ;8GKW!],[+ODJN(X4N>4AA$T "[G4A-R*T+7;
MB?@)5J?$L3\2UW;=-H>ZS7T(3HGGY.;C%G/_Y\V]#C9>O3Q>CN?]Q_(LJ^4A
M?W[!(>1.0Z+^:O'ONL ;M^.9+'*A4AK U0#3A +Y#(/%AW?.Q+YLTZI/,+\G
ML(:.XUK'<1?ZXD8D"689#*?@Z2-A2F5O-UNA7B?*L>H58),<S.3?YX4SGIU-
M//M\;CWO*],VT)Y.S[QZ7(/T64WZK)/T [I(91"1)0^)#\^8Y--\#]V^I&97
MM0G0B7BL  78V1ZOL>--QF_8'X[R)N>323OW2<U]TLG],Y7/5(;[@?,5DA7(
MUJ#IQ#J6=9]@?D]@#0VGM8;3GI//M$\=^P3S>P)KZ#BK=9SUDGQF!VG =:?C
MV:09+S>=DQVK2T]@#5W.:UW..W4YV%^*W--=4?!!!9*EYN#1)E4G\+$;K=O+
MH3,J3"GG&1Z)S&%: Z<\ +(&4$12OF%\0]92)$1'0/ L3=9XFB4AVS#DHD7=
MK-A+U1IFTEB9'@TR(6*=EP^#;J@C*;)-E'>OF52:!+BC0 8,W5$T!F-+B10[
M&NO=R0J3OD%.I0BS0(\NR= =5;TDK12F^$=21,$:GO#-0>[52[Z):_=+QTKZ
M'.\B9DZD%5&=]^#^3BG?D0UPD%1C5RY%.7\Y,-,L9O] ,4?)44,0<1&+S8X,
M/[R;N:Y]6=(/R7UIG;<[ER.</_S_210K_\3%]B02VZ*&:[^*T<.27\5&%;T5
MD5^-S>?*YK:T:64U]*H=MD]E!7H+P(L>QSYQ[5^*LEGL."[*7/"34I2B@7'<
M&X WL@!P!X9DM6NPR_"4;6Y]J\KICYB6#-T-"U!5J9&\BEBJC&/'D/^916[+
M/ST%<B/_./;KY<?NC.U'DY+)79Z1B5\$Y#U()D+RG<99ZPFIA&R<:FS[38[N
MGO?8)-T76E.EO2NBT_LYLAORV Q=HG5J[I>#&M_/O4%-\NXK>;>3_#(1&5+U
M,S!Y_ %B#!:,8PR5MOU\W8UV-&_W@/<!ZZXA3<ZOETZG\RZV^(W#B6;):PSC
M=ZZ5K'<PMS.U[<-HZ/4>V1=:(8ZU]W:"W]1-_@:E\ N+JUZ\.M2MQ3O7C7GG
M,F\O;]J7SL4R?_6Q7F&*Q[.O5.(!09$8U@AIGTY1,%F\1Q45+=+\A68EM!9)
M7HR 8J8V [!_+82N*F:"^E5P\2]02P,$%     @ &HEZ6AW$?W<K!0  4!P
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M+,6I1X6O41W0FSU[$L3]%VT1^$]@?\1CT,1CT(7NXE%0'"YMJ?*T36L%,'0
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M+W=O<FMS:&5E=',O<VAE970V."YX;6RM55UOVC 4_2M65DVMU)$/:#=U$*E
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ME[I8LFR9B0/Y)=9EYG NA^01,UHS_EU$ !(]ITDFQD8DY>+2-$4004K%!5M
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MLS7BN;5"RR^*VA3>*ILXR]OX*+EZ&RL_.7F$N6J*1+=928F\M.?H4;$E7":
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ME(9&1;?,:#A'92_0]Y649K>Q"MIQ?_8W4$L#!!0    ( !J)>EH0L:TM20,
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  :B7I:SZCPYFH%  #3+@  #P
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MFS^.'Y]E9YO^+9^-_YH\?P%02P$"% ,4    "  :B7I:1L=-2)4   #-
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M !J)>EI03>2_\0   "L"   1              "  <,   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( !J)>EJ97)PC$ 8  )PG   3
M  "  >,!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ &HEZ6J V
M!K>+!   710  !@              ("!) @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( !J)>EHOE$CMC 8  /,;   8
M  " @>4,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  :
MB7I:G]7QOE8#  #@#   &               @(&G$P  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ &HEZ6I#,N73"!   8A(  !@
M         ("!,Q<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( !J)>EK?C(K%1P@  )$]   8              " @2L<  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  :B7I:(%V9:YL"  "-!@
M&               @(&H)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ &HEZ6I!'[7@7"   >R4  !@              ("!>2<  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !J)>EHTIM>)3@(
M #8%   8              " @<8O  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    "  :B7I:T8[5B,P)  !N&@  &               @(%*
M,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ &HEZ6G@G
M/K)C%P  4$$  !D              ("!3#P  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    "  :B7I:(9R,7/0"   X!@  &0
M    @('F4P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M !J)>EH_]?\?[ 4  -X.   9              " @1%7  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ &HEZ6B>!40M2 P  ! <  !D
M             ("!-%T  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    "  :B7I:/!19C]X"  !>!@  &0              @(&]8   >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !J)>EHSA.61& <
M ,$3   9              " @=)C  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ &HEZ6B5;Y1D0#   6"4  !D              ("!
M(6L  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  :B7I:
M\?-D),0#   K"   &0              @(%H=P  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( !J)>EI0U+^Y(@4  $(+   9
M      " @6-[  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ &HEZ6D9ST)C?!   U0L  !D              ("!O(   'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  :B7I:_Z[GNP4&   V#@
M&0              @('2A0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( !J)>EK0*0<KF@L  (L>   9              " @0Z,  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ &HEZ6M0[\TR>
M!   & L  !D              ("!WY<  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    "  :B7I:KJ[P$#<#   E!P  &0
M@(&TG   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !J)
M>EI;KRA_K 4  ,4,   9              " @2*@  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ &HEZ6GH<HY7? @  (@8  !D
M         ("!!:8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    "  :B7I:D.^%+,<8   U3@  &0              @($;J0  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !J)>EK,E_<>M (  -(%
M   9              " @1G"  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ &HEZ6L,(0H?Z P  P@H  !D              ("!!,4
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  :B7I:APB?
ME.("   G!@  &0              @($UR0  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( !J)>EKD"?5WOP(  $ &   9
M  " @4[,  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M&HEZ6BXA&GD^ P  A@<  !D              ("!1,\  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    "  :B7I: :SPR3,$  #4"0  &0
M            @(&YT@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( !J)>EK"#YVRD08  %03   9              " @2/7  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ &HEZ6MS4MZKN P
M^ @  !D              ("!Z]T  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    "  :B7I:W;LW%%D%   G#0  &0              @($0
MX@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( !J)>EJ'
M)5V0/0,  %4'   9              " @:#G  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ &HEZ6KED2U$Z!@  %"X  !D
M     ("!%.L  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !J)>EHI>;SI4 4  &\I   9              "
M@7<  0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ &HEZ
M6I7O_]!1 P  YPD  !D              ("!_@4! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    "  :B7I:D=$R-JT#  "-$0  &0
M        @(&&"0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( !J)>EJ,92$]> (  -L%   9              " @6H- 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ &HEZ6@IA/"K# @  G <
M !D              ("!&1 ! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    "  :B7I:0V39^F\#  #E"0  &0              @($3$P$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !J)>EJ)V4PG
MU0(  ! *   9              " @;D6 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ &HEZ6J<IFL)! P  Q@D  !D
M ("!Q1D! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  :
MB7I:%BE27K("  "3"   &0              @($]'0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !J)>EH_<M=\9 0  +D6   9
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M970U-2YX;6Q02P$"% ,4    "  :B7I:=)B- Q@$   J$   &0
M    @(%90 $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M !J)>EHJ',ZI:@0  (,2   9              " @:A$ 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ &HEZ6O='7I[) @  S@8  !D
M             ("!24D! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    "  :B7I:SSPF,$8#   "#   &0              @(%)3 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !J)>EIY%\*-&P4
M "$4   9              " @<9/ 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ &HEZ6AW$?W<K!0  4!P  !D              ("!
M&%4! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  :B7I:
M*GL;C%P#  "&"P  &0              @(%Z6@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( !J)>EK,*^K;DP,  &,+   9
M      " @0U> 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ &HEZ6N)&WXT5!   Q0T  !D              ("!UV$! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  :B7I:B WO;B<#  !]"0
M&0              @($C9@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( !J)>EH?/_;U\P,  ,02   9              " @8%I 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ &HEZ6I1_#V4P
M!   "A<  !D              ("!JVT! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    "  :B7I:ILYH1+4"  #R!@  &0
M@($2<@$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( !J)
M>EK 2$F.. (  #8%   9              " @?YT 0!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ &HEZ6F=&;+JR!   =!@  !D
M         ("!;7<! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4
M    "  :B7I:XL+ AT8#  #Z"P  &0              @(%6? $ >&PO=V]R
M:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( !J)>EH0L:TM20,  ,P4
M   -              "  =-_ 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !/ $\ H!4  &.. 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>180</ContextCount>
  <ElementCount>366</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/Merger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - License agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/LicenseAgreements</Role>
      <ShortName>License agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.aw.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Merger (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/MergerTables</Role>
      <ShortName>Merger (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/Merger</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/EquityIncentivePlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/NetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aw.com/role/SegmentInformation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies and Basis of Presentation - (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Merger - (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/MergerAdditionalInformationDetail</Role>
      <ShortName>Merger - (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Merger - Summary Of The Company Obtain The Assets And Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail</Role>
      <ShortName>Merger - Summary Of The Company Obtain The Assets And Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Fair Value Measurements - (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aw.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Fair Value Measurements - Summary of Activity for the Safe Liabilities that were Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Activity for the Safe Liabilities that were Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Property and Equipment, Net (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aw.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Commitments and Contingencies - (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aw.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Leases - Schedule of Components of Lease Expense and Other Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense and Other Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Leases - Schedule of Information About the Company's Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail</Role>
      <ShortName>Leases - Schedule of Information About the Company's Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Leases - Schedule of Future Commitments Due Under These Lease Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail</Role>
      <ShortName>Leases - Schedule of Future Commitments Due Under These Lease Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Equity Incentive Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Equity Incentive Plans - Summary of the Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail</Role>
      <ShortName>Equity Incentive Plans - Summary of the Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Equity Incentive Plans - Summary of Fair Values of the Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail</Role>
      <ShortName>Equity Incentive Plans - Summary of Fair Values of the Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Units (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail</Role>
      <ShortName>Equity Incentive Plans - Summary of Restricted Stock Units (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail</Role>
      <ShortName>Equity Incentive Plans - Summary of Restricted Stock Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Equity Incentive Plans - Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail</Role>
      <ShortName>Equity Incentive Plans - Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - License agreements (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License agreements (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aw.com/role/LicenseAgreements</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Income Taxes - Schedule Of Components of Income Tax Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail</Role>
      <ShortName>Income Taxes - Schedule Of Components of Income Tax Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - INCOME TAXES - Schedule of Deferred tax assets and liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>INCOME TAXES - Schedule of Deferred tax assets and liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Related Party Transactions  - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions  - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Segment Information (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aw.com/role/SegmentInformationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Segment Information - Schedule of segment net loss and significant segment expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail</Role>
      <ShortName>Segment Information - Schedule of segment net loss and significant segment expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d863285ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Subsequent Events (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aw.com/role/SubsequentEvents</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="d863285ds1.htm">d863285ds1.htm</File>
    <File>tecx-20241231.xsd</File>
    <File>tecx-20241231_cal.xml</File>
    <File>tecx-20241231_def.xml</File>
    <File>tecx-20241231_lab.xml</File>
    <File>tecx-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g863285g01v82.jpg</File>
    <File>g863285g02v02.jpg</File>
    <File>g863285g09v09.jpg</File>
    <File>g863285g93v93.jpg</File>
    <File>g863285g96v96.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="616">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d863285ds1.htm": {
   "nsprefix": "tecx",
   "nsuri": "http://www.aw.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "d863285ds1.htm"
     ]
    },
    "schema": {
     "local": [
      "tecx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tecx-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tecx-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tecx-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tecx-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 296,
   "keyCustom": 70,
   "axisStandard": 26,
   "axisCustom": 2,
   "memberStandard": 30,
   "memberCustom": 32,
   "hidden": {
    "total": 7,
    "http://fasb.org/us-gaap/2024": 3,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 180,
   "entityCount": 1,
   "segmentCount": 71,
   "elementCount": 595,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 616,
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://www.aw.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.aw.com/role/ConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
     "longName": "1005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical",
     "longName": "1006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "tecx:TransactionCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "tecx:TransactionCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "1007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.aw.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
     "longName": "1008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "tecx:OfferingCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "tecx:OfferingCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.aw.com/role/NatureOfBusiness",
     "longName": "1009 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.aw.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.aw.com/role/Merger",
     "longName": "1011 - Disclosure - Merger",
     "shortName": "Merger",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.aw.com/role/FairValueMeasurements",
     "longName": "1012 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.aw.com/role/PropertyAndEquipmentNet",
     "longName": "1013 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "1014 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.aw.com/role/StockholdersEquity",
     "longName": "1015 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.aw.com/role/EquityIncentivePlans",
     "longName": "1016 - Disclosure - Equity Incentive Plans",
     "shortName": "Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.aw.com/role/NetLossPerShare",
     "longName": "1017 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.aw.com/role/Leases",
     "longName": "1018 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.aw.com/role/LicenseAgreements",
     "longName": "1019 - Disclosure - License agreements",
     "shortName": "License agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "tecx:LicenseAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "tecx:LicenseAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.aw.com/role/CommitmentsAndContingencies",
     "longName": "1020 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.aw.com/role/IncomeTaxes",
     "longName": "1021 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.aw.com/role/RelatedPartyTransactions",
     "longName": "1022 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.aw.com/role/EmployeeBenefitPlan",
     "longName": "1023 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.aw.com/role/SegmentInformation",
     "longName": "1024 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.aw.com/role/SubsequentEvents",
     "longName": "1025 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1026 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.aw.com/role/MergerTables",
     "longName": "1027 - Disclosure - Merger (Tables)",
     "shortName": "Merger (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.aw.com/role/FairValueMeasurementsTables",
     "longName": "1028 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.aw.com/role/PropertyAndEquipmentNetTables",
     "longName": "1029 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "1030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.aw.com/role/StockholdersEquityTables",
     "longName": "1031 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.aw.com/role/LeasesTables",
     "longName": "1032 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.aw.com/role/EquityIncentivePlansTables",
     "longName": "1033 - Disclosure - Equity Incentive Plans (Tables)",
     "shortName": "Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.aw.com/role/NetLossPerShareTables",
     "longName": "1034 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.aw.com/role/IncomeTaxesTables",
     "longName": "1035 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.aw.com/role/SegmentInformationTables",
     "longName": "1036 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
     "longName": "1037 - Disclosure - Nature of Business - Additional Information (Detail)",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P02_01_2025To02_28_2025",
      "name": "tecx:ProceedsReceivedPursuantToAgreement",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail",
     "longName": "1038 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - (Additional Information) (Detail)",
     "shortName": "Summary of Significant Accounting Policies and Basis of Presentation - (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P06_20_2024To06_20_2024",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "tecx:ReverseStockSplitAndExchangeRatioPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_20_2024To06_20_2024",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "tecx:ReverseStockSplitAndExchangeRatioPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.aw.com/role/MergerAdditionalInformationDetail",
     "longName": "1039 - Disclosure - Merger - (Additional Information) (Detail)",
     "shortName": "Merger - (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail",
     "longName": "1040 - Disclosure - Merger - Summary Of The Company Obtain The Assets And Liabilities (Detail)",
     "shortName": "Merger - Summary Of The Company Obtain The Assets And Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "longName": "1041 - Disclosure - Fair Value Measurements - (Additional Information) (Detail)",
     "shortName": "Fair Value Measurements - (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P10_01_2023To12_31_2023",
      "name": "tecx:ProceedsFromSimpleAgreementForFutureEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "tecx:FairValueInputAmountTransferInBetweenLevels",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
     "longName": "1042 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail",
     "longName": "1043 - Disclosure - Fair Value Measurements - Summary of Activity for the Safe Liabilities that were Measured at Fair Value (Detail)",
     "shortName": "Fair Value Measurements - Summary of Activity for the Safe Liabilities that were Measured at Fair Value (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
     "longName": "1044 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Detail)",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.aw.com/role/PropertyAndEquipmentNetAdditionalInformationDetail",
     "longName": "1045 - Disclosure - Property and Equipment, Net (Additional Information) (Detail)",
     "shortName": "Property and Equipment, Net (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "tecx:DepreciationAndAmortizationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "tecx:DepreciationAndAmortizationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "longName": "1046 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "tecx:AccruedCompensationAndRelatedExpenses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "tecx:AccruedCompensationAndRelatedExpenses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "1047 - Disclosure - Commitments and Contingencies - (Additional Information) (Detail)",
     "shortName": "Commitments and Contingencies - (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "tecx:PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "tecx:PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.aw.com/role/LeasesAdditionalInformationDetail",
     "longName": "1048 - Disclosure - Leases - Additional Information (Detail)",
     "shortName": "Leases - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail",
     "longName": "1049 - Disclosure - Leases - Schedule of Components of Lease Expense and Other Information (Detail)",
     "shortName": "Leases - Schedule of Components of Lease Expense and Other Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail",
     "longName": "1050 - Disclosure - Leases - Schedule of Information About the Company's Leases (Detail)",
     "shortName": "Leases - Schedule of Information About the Company's Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail",
     "longName": "1051 - Disclosure - Leases - Schedule of Future Commitments Due Under These Lease Agreements (Detail)",
     "shortName": "Leases - Schedule of Future Commitments Due Under These Lease Agreements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail",
     "longName": "1052 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfUnits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail",
     "longName": "1053 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
     "longName": "1054 - Disclosure - Equity Incentive Plans - Additional Information (Detail)",
     "shortName": "Equity Incentive Plans - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail",
     "longName": "1055 - Disclosure - Equity Incentive Plans - Summary of the Stock Option Activity (Detail)",
     "shortName": "Equity Incentive Plans - Summary of the Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail",
     "longName": "1056 - Disclosure - Equity Incentive Plans - Summary of Fair Values of the Options Granted (Detail)",
     "shortName": "Equity Incentive Plans - Summary of Fair Values of the Options Granted (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
     "longName": "1057 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Units (Detail)",
     "shortName": "Equity Incentive Plans - Summary of Restricted Stock Units (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail",
     "longName": "1058 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Activity (Detail)",
     "shortName": "Equity Incentive Plans - Summary of Restricted Stock Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail",
     "longName": "1059 - Disclosure - Equity Incentive Plans - Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees (Detail)",
     "shortName": "Equity Incentive Plans - Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
     "longName": "1060 - Disclosure - License agreements (Additional Information) (Detail)",
     "shortName": "License agreements (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "tecx:LicenseAgreementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "1061 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail",
     "longName": "1062 - Disclosure - Income Taxes - Schedule Of Components of Income Tax Expense (Detail)",
     "shortName": "Income Taxes - Schedule Of Components of Income Tax Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail",
     "longName": "1063 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail",
     "longName": "1064 - Disclosure - INCOME TAXES - Schedule of Deferred tax assets and liabilities (Detail)",
     "shortName": "INCOME TAXES - Schedule of Deferred tax assets and liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail",
     "longName": "1065 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Detail)",
     "shortName": "Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail",
     "longName": "1066 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)",
     "shortName": "Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "longName": "1067 - Disclosure - Related Party Transactions  - Additional Information (Detail)",
     "shortName": "Related Party Transactions  - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis",
      "name": "us-gaap:OtherSundryLiabilitiesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail",
     "longName": "1068 - Disclosure - Employee Benefit Plan - Additional Information (Detail)",
     "shortName": "Employee Benefit Plan - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.aw.com/role/SegmentInformationAdditionalInformationDetail",
     "longName": "1069 - Disclosure - Segment Information (Additional Information) (Detail)",
     "shortName": "Segment Information (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail",
     "longName": "1070 - Disclosure - Segment Information - Schedule of segment net loss and significant segment expenses (Detail)",
     "shortName": "Segment Information - Schedule of segment net loss and significant segment expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis",
      "name": "tecx:Non-ControllableExpenses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail",
     "longName": "1071 - Disclosure - Subsequent Events (Additional Information) (Detail)",
     "shortName": "Subsequent Events (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "P02_01_2025To02_28_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P02_01_2025To02_28_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d863285ds1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64",
      "r67",
      "r1011"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r837"
     ]
    },
    "tecx_AccruedCompensationAndRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AccruedCompensationAndRelatedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and related expenses",
        "terseLabel": "Accrued compensation and related expenses",
        "documentation": "Accrued compensation and related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees and other expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "tecx_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued research and development expenses",
        "terseLabel": "Accrued research and development expenses",
        "documentation": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r142",
      "r645"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r79",
      "r148",
      "r640",
      "r680",
      "r681"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r11",
      "r20",
      "r521",
      "r524",
      "r582",
      "r676",
      "r677",
      "r879",
      "r880",
      "r881",
      "r890",
      "r891",
      "r892",
      "r894"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r837",
      "r1088"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r890",
      "r891",
      "r892",
      "r894",
      "r1024",
      "r1091"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AdimabAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AdimabAgreementMember",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adimab Agreement [Member]",
        "terseLabel": "Adimab Agreement [Member]",
        "documentation": "Adimab Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AdjustedBalanceBeginningOfPeriodShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AdjustedBalanceBeginningOfPeriodShare",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Balance Beginning Of Period Share",
        "verboseLabel": "Adjusted balance, beginning of period (in shares)",
        "documentation": "Adjusted balance beginning of period share."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AdjustedBalanceBeginningOfPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AdjustedBalanceBeginningOfPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Balance Beginning Of Period Value",
        "verboseLabel": "Adjusted balance, beginning of period",
        "documentation": "Adjusted balance beginning of period value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/MergerAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Reduction to additional paid-in capital",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r428"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Net of offering costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r99"
     ]
    },
    "tecx_AdvisoryServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AdvisoryServicesAgreementMember",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Services Agreement [Member]",
        "terseLabel": "Advisory Services Agreement [Member]",
        "documentation": "Advisory services agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AgreementAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Axis]",
        "documentation": "Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AgreementDomain",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]",
        "documentation": "Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r463"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AmortizationPeriodForeignRDCosts": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AmortizationPeriodForeignRDCosts",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AmortizationPeriodForeignR&amp;DCosts",
        "terseLabel": "Amortization period foreign R&amp;D costs",
        "documentation": "AmortizationPeriodForeignR&amp;DCosts"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AmortizationPeriodRDActivities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AmortizationPeriodRDActivities",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AmortizationPeriodR&amp;DActivities",
        "terseLabel": "Amortization period R&amp;D activities",
        "documentation": "AmortizationPeriodR&amp;DActivities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r118",
      "r144",
      "r168",
      "r208",
      "r216",
      "r241",
      "r245",
      "r287",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r514",
      "r518",
      "r554",
      "r633",
      "r731",
      "r803",
      "r804",
      "r837",
      "r855",
      "r917",
      "r918",
      "r1043"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r149",
      "r168",
      "r287",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r514",
      "r518",
      "r554",
      "r837",
      "r917",
      "r918",
      "r1043"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r826"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AtTheMarketFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AtTheMarketFacilityMember",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At the Market Facility [Member]",
        "terseLabel": "At the Market Facility [Member]",
        "documentation": "At the market facility member."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AvorbioCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AvorbioCommonStockMember",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avorbio Common Stock [Member]",
        "terseLabel": "Avorbio Common Stock [Member]",
        "documentation": "Avorbio common stock."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AvroAvrobioCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AvroAvrobioCommonStockMember",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AVRO Avrobio Common Stock [Member]",
        "verboseLabel": "AVRO Avrobio Common Stock [Member]",
        "documentation": "AVRO Avrobio common stock."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AvrobioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AvrobioIncMember",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AVROBIO, Inc [Member]",
        "terseLabel": "AVROBIO, Inc. [Member]",
        "documentation": "AVROBIO, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_AvrobioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "AvrobioMember",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AVROBIO [Member]",
        "terseLabel": "AVROBIO [Member]",
        "documentation": "AVROBIO."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AwardTypeAxis",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.aw.com/role/MergerAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.aw.com/role/MergerAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r311",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquiredReceivablesGrossContractualAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Acquired Receivables, Gross Contractual Amount",
        "terseLabel": "Business combination, acquired receivables, gross contractual amount",
        "documentation": "For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Business combination, contingent consideration, liability, current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r107"
     ]
    },
    "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized",
        "verboseLabel": "Liability recorded",
        "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "tecx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accured Expenses And Other Current Liabilities",
        "negatedLabel": "Accrued expenses and other current liabilities",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed accured expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "verboseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/MergerSummaryOfTheCompanyObtainTheAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash maintain",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r636",
      "r706",
      "r726",
      "r837",
      "r855",
      "r876"
     ]
    },
    "tecx_CashAcquiredInConnectionWithTheMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "CashAcquiredInConnectionWithTheMerger",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash acquired in connection with the Merger",
        "terseLabel": "Cash acquired in connection with the Merger, net of transaction costs of $9,300",
        "documentation": "Cash acquired in connection with the Merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets",
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r140",
      "r790"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r108"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash and cash equivalents and restricted cash as of beginning of period",
        "periodEndLabel": "Cash and cash equivalents and restricted cash as of end of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r86",
      "r165"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract]",
        "verboseLabel": "Components of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r86"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosure of\u00a0non-cash\u00a0financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid for Amounts included in the Measurement of Lease Liabilities [Abstract]",
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ChangeInFairValueOfSafeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ChangeInFairValueOfSafeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Of SAFE Liabilities",
        "terseLabel": "Change in fair value of SAFE liabilities",
        "negatedLabel": "Change in fair value of SAFE liabilities",
        "documentation": "Change in fair value of SAFE liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ChemistryManufacturingAndControlExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ChemistryManufacturingAndControlExpensesMember",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chemistry, Manufacturing, and Control Expenses [Member]",
        "documentation": "Chemistry, manufacturing, and control expenses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/CoverPage",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r145",
      "r146",
      "r147",
      "r168",
      "r192",
      "r193",
      "r200",
      "r202",
      "r210",
      "r211",
      "r287",
      "r323",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r338",
      "r339",
      "r342",
      "r345",
      "r352",
      "r554",
      "r685",
      "r686",
      "r687",
      "r688",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r707",
      "r718",
      "r740",
      "r763",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r859",
      "r886",
      "r895"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r210",
      "r338",
      "r339",
      "r340",
      "r342",
      "r345",
      "r350",
      "r352",
      "r685",
      "r686",
      "r687",
      "r688",
      "r815",
      "r859",
      "r886"
     ]
    },
    "tecx_ClinicalAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ClinicalAndDevelopmentExpensesMember",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical and Development Expenses [Member]",
        "documentation": "Clinical and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r112",
      "r635",
      "r717"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r315",
      "r316",
      "r785",
      "r910",
      "r912"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Total shares of authorized common stock reserved for future issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "tecx_CommonStockCapitalSharesReservedForFutureIssuanceTermDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceTermDescription",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Capital Shares Reserved For Future Issuance Term Description",
        "terseLabel": "Common stock capital shares reserved for future issuance term description",
        "documentation": "Common stock capital shares reserved for future issuance term description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends, per share, declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r847",
      "r849",
      "r850",
      "r851",
      "r852",
      "r890",
      "r891",
      "r894",
      "r1024",
      "r1087",
      "r1091"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock, price per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r718"
     ]
    },
    "tecx_CommonStockSharesIssuableOnConversionIntoPermanentEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "CommonStockSharesIssuableOnConversionIntoPermanentEquity",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Issuable On Conversion Into Permanent Equity",
        "terseLabel": "Common stock issuable upon conversion",
        "documentation": "Common stock shares issuable on conversion into permanent equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued",
        "verboseLabel": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r718",
      "r737",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 14,856,309 and 1,407,753 shares issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r638",
      "r837"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r103"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r125"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r172",
      "r208",
      "r218",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r803",
      "r804",
      "r917",
      "r918"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r172",
      "r208",
      "r218",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r803",
      "r804",
      "r917",
      "r918"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r794"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ContributionFromRelatedPartyInvestorsRelatedToSAFEs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ContributionFromRelatedPartyInvestorsRelatedToSAFEs",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution from related party investors related to SAFEs",
        "terseLabel": "Contribution from related party investors related to SAFEs",
        "documentation": "Contribution from related party investors related to SAFEs"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ConversionOfConvertiblePreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ConversionOfConvertiblePreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Convertible Preferred Stock To Common Stock",
        "negatedLabel": "Conversion of Convertible Preferred Stock to Common Stock",
        "documentation": "Conversion of convertible preferred stock\u00a0 to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ConversionOfSimpleAgreementsForFutureEquityToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ConversionOfSimpleAgreementsForFutureEquityToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Simple Agreements For Future Equity To Common Stock",
        "negatedLabel": "Conversion of SAFEs to Common Stock",
        "documentation": "Conversion of simple agreements for future equity\u00a0 to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ConversionOfStockSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ConversionOfStockSharesPercentage",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock Shares Percentage",
        "verboseLabel": "Conversion of stock shares percentage",
        "documentation": "Conversion of stock shares percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r342",
      "r849",
      "r850",
      "r851",
      "r852"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Reserved for Future Issuance",
        "terseLabel": "Convertible preferred stock authorized for issuance",
        "documentation": "Aggregate number of nonredeemable convertible preferred shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total lease expense",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r334",
      "r340",
      "r588",
      "r609",
      "r632",
      "r791",
      "r793"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current federal tax expense benefit",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r888",
      "r1019"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r888"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current state and local tax expense benefit",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r888",
      "r1019"
     ]
    },
    "tecx_CvrAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "CvrAgreementMember",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CVR Agreement [Member]",
        "terseLabel": "CVR Agreement [Member]",
        "documentation": "CVR Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "verboseLabel": "Merger transaction costs included in accounts payable and accrued expenses",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r877"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Federal Income Tax Expense Benefit",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Foreign Income Tax Expense Benefit",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r1018"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r131",
      "r888"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred State And Local Income Tax Expense Benefit",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r1018",
      "r1019"
     ]
    },
    "tecx_DeferredTaxAssetsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "DeferredTaxAssetsAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Amortization",
        "terseLabel": "Amortization",
        "documentation": "Deferred Tax Assets Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Capitalized Start Up And Organizational Costs",
        "terseLabel": "Capitalized research and development expenses",
        "documentation": "Deferred tax assets capitalized start up and organizational costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred Tax Assets, Gross, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Research credits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "tecx_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability",
        "documentation": "Deferred Tax Assets Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred Tax Assets, Net, Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Net of Valuation Allowance, Total",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Deferred tax assets operating loss carryforwards domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Deferred tax assets operating loss carryforwards not subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred tax assets operating loss carryforwards state and local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred tax assets tax credit carryforwards research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Accruals and other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "Deferred tax liabilities deferred expense capitalized research and development costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "tecx_DeferredTaxLiabilitiesDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Depreciation",
        "negatedLabel": "Depreciation",
        "documentation": "Deferred Tax Liabilities Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "Right of use asset",
        "documentation": "Deferred Tax Liabilities Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax, Business Combination or Joint Venture Formation, Valuation Allowance, Available to Reduce Income Tax Expense",
        "negatedLabel": "Less change in valuation allowance",
        "documentation": "Amount of valuation allowance for deferred tax asset related to income tax expense acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Contribution by company",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r377",
      "r413",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "us-gaap_DefinedContributionPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined contribution plan employee mathing contribution percentage",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416"
     ]
    },
    "tecx_DepreciationAndAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "DepreciationAndAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation And Amortization Expense",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "Depreciation and amortization expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r208",
      "r221",
      "r245",
      "r803",
      "r804"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r430",
      "r458",
      "r459",
      "r461",
      "r822"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Domestic Country [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "verboseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r189",
      "r192",
      "r200",
      "r201",
      "r202",
      "r207",
      "r508",
      "r511",
      "r529",
      "r530",
      "r629",
      "r651",
      "r795"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "verboseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r192",
      "r200",
      "r201",
      "r202",
      "r207",
      "r508",
      "r511",
      "r529",
      "r530",
      "r629",
      "r651",
      "r795"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r204"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r203",
      "r205",
      "r206"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate continuing operations",
        "totalLabel": "Effective Income Tax Rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r823"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r471",
      "r496",
      "r823"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Less: change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r823",
      "r889",
      "r1012"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r475",
      "r823",
      "r889",
      "r1012"
     ]
    },
    "tecx_EffectiveIncomeTaxRateReconciliationPermanentDifference": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifference",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Permanent Difference",
        "terseLabel": "Permanent differences",
        "documentation": "Effective income tax rate reconciliation permanent difference."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r823",
      "r889",
      "r1012"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r823"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r478",
      "r889",
      "r1012"
     ]
    },
    "tecx_Effectiveincometaxratereconciliationchangeinstock1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "Effectiveincometaxratereconciliationchangeinstock1",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effectiveincometaxratereconciliationchangeinstock1",
        "terseLabel": "Equity-based compensation",
        "documentation": "Effectiveincometaxratereconciliationchangeinstock1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Stock Compensation Expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities",
        "terseLabel": "Total employee-related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r1053"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share based compensation by share based award equity instruments other than options unvested and outstanding unrecognized compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options to Purchase Common Stock [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical",
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r135",
      "r153",
      "r154",
      "r155",
      "r173",
      "r174",
      "r175",
      "r177",
      "r182",
      "r184",
      "r186",
      "r209",
      "r288",
      "r289",
      "r308",
      "r353",
      "r494",
      "r495",
      "r505",
      "r506",
      "r507",
      "r509",
      "r510",
      "r511",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r565",
      "r582",
      "r649",
      "r676",
      "r677",
      "r678",
      "r695",
      "r763"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r504",
      "r861",
      "r862",
      "r863",
      "r1020",
      "r1021",
      "r1022",
      "r1023"
     ]
    },
    "tecx_ExpirationThrough2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ExpirationThrough2035Member",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Through2035 [Member]",
        "terseLabel": "Expiration Through 2035 [Member]",
        "documentation": "Expiration Through2035 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ExpirationThrough2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ExpirationThrough2040Member",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Through2040 [Member]",
        "terseLabel": "Expiration Through 2040 [Member]",
        "documentation": "Expiration Through2040 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ExternalResearchAndDevelopmentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ExternalResearchAndDevelopmentLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External Research and Development Liability",
        "terseLabel": "Total external research and development expenses",
        "documentation": "External Research and Development Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r546",
      "r826"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r546",
      "r826"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r1026",
      "r1027",
      "r1034"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r547",
      "r827"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r547",
      "r827"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r545",
      "r546",
      "r548",
      "r596",
      "r597",
      "r598",
      "r813",
      "r814",
      "r817",
      "r818",
      "r819",
      "r826",
      "r829"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail",
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r547"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r536",
      "r826",
      "r1029",
      "r1036"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r543",
      "r544",
      "r545",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r627",
      "r826",
      "r830"
     ]
    },
    "tecx_FairValueInputAmountTransferInBetweenLevels": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "FairValueInputAmountTransferInBetweenLevels",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Input Amount Transfer In Between Levels",
        "verboseLabel": "Fair value input amount transfer in between levels",
        "documentation": "Fair value input amount transfer in between levels."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r377",
      "r382",
      "r533",
      "r546",
      "r596",
      "r817",
      "r818",
      "r819",
      "r826"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r377",
      "r382",
      "r533",
      "r534",
      "r546",
      "r597",
      "r813",
      "r814",
      "r817",
      "r818",
      "r819",
      "r826"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r533",
      "r534",
      "r535",
      "r536",
      "r546",
      "r598",
      "r813",
      "r814",
      "r817",
      "r818",
      "r819",
      "r826",
      "r829"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail",
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r547"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r547"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Summary of Activity for the Safe Liabilities that were Measured at Fair Value",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r542",
      "r547"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r536",
      "r826",
      "r1029",
      "r1036"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Initial Recognition",
        "terseLabel": "Initial fair value recognition",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis initial recognition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Loss on issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r547"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Fair value adjustments",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1035"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "verboseLabel": "Redemption",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1035"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodStartLabel": "Opening Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r547"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r545",
      "r546",
      "r548",
      "r596",
      "r597",
      "r598",
      "r813",
      "r814",
      "r817",
      "r818",
      "r819",
      "r826",
      "r829"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1036"
     ]
    },
    "tecx_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "FederalMember",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "documentation": "Federal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_FinanceLeaseCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "FinanceLeaseCostAndExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Cost and Expense",
        "totalLabel": "Finance lease expense",
        "documentation": "Finance Lease Cost and Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail": {
       "parentTag": "tecx_FinanceLeaseCostAndExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest of finance lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r572",
      "r836"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      },
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets",
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets",
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liability, non-current",
        "verboseLabel": "Finance Lease Liability Non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Total",
        "totalLabel": "Total undiscounted cash flows",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Repayment of finance lease obligations",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r575"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance right-of-use assets, net",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail": {
       "parentTag": "tecx_FinanceLeaseCostAndExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "verboseLabel": "Finance lease amortization of right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r572",
      "r836"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r836"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r836"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r336",
      "r350",
      "r526",
      "r553",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r650",
      "r810",
      "r826",
      "r827",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r838",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r904",
      "r905",
      "r906",
      "r907",
      "r1025",
      "r1028",
      "r1029",
      "r1030",
      "r1033",
      "r1036"
     ]
    },
    "tecx_ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction And Translation Adjustment Net Of Tax Other Comprehensive Income Loss",
        "terseLabel": "Foreign currency translation adjustment",
        "documentation": "Foreign currency transaction and translation adjustment net of tax other comprehensive income loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "tecx_FundInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "FundInvestorsMember",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fund Investors [Member]",
        "terseLabel": "Fund Investors [Member]",
        "documentation": "Fund Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office equipment, furniture and fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r743"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail",
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "tecx_HarvardAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "HarvardAgreementMember",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Harvard Agreement [Member]",
        "terseLabel": "Harvard Agreement [Member]",
        "documentation": "Harvard Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r93"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail",
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r312",
      "r538",
      "r542",
      "r547",
      "r673",
      "r675",
      "r748",
      "r788",
      "r828",
      "r1058"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail",
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r538",
      "r542",
      "r547",
      "r673",
      "r675",
      "r748",
      "r788",
      "r828",
      "r1058"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r471",
      "r472",
      "r482",
      "r490",
      "r823",
      "r1015"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r471",
      "r472",
      "r482",
      "r490",
      "r823",
      "r1015"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r467",
      "r471",
      "r479",
      "r480",
      "r481",
      "r483",
      "r489",
      "r497",
      "r499",
      "r502",
      "r503",
      "r690",
      "r823"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r132",
      "r185",
      "r186",
      "r208",
      "r224",
      "r245",
      "r470",
      "r471",
      "r498",
      "r653",
      "r823"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r468",
      "r469",
      "r483",
      "r484",
      "r488",
      "r492",
      "r684"
     ]
    },
    "tecx_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.aw.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetail",
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r884"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other\u00a0non-current\u00a0assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "tecx_IndividualInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IndividualInvestorsMember",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual Investors [Member]",
        "terseLabel": "Individual Investors [Member]",
        "documentation": "Individual Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_InstallmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "InstallmentAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Installment [Axis]",
        "documentation": "Installment."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_InstallmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "InstallmentDomain",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Installment [Domain]",
        "documentation": "Installment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r883"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r162",
      "r163"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r219",
      "r245",
      "r803",
      "r882"
     ]
    },
    "tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock To Related Party Investors Upon Redemption",
        "verboseLabel": "Issuance of common stock to related party investors upon redemption of the SAFEs (in shares)",
        "documentation": "Issuance of common stock to related party investors upon redemption."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock To Related Party Investors Upon Redemption Value",
        "verboseLabel": "Issuance of common stock to related party investors upon redemption of the SAFEs",
        "documentation": "Issuance of common stock to related party investors upon redemption value."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_IssuanceOfCommonStockUnderSubscriptionAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IssuanceOfCommonStockUnderSubscriptionAgreement",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock Under Subscription Agreement",
        "verboseLabel": "Issuance of common stock under subscription agreement (in shares)",
        "documentation": "Issuance of common stock under subscription agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_IssuanceOfCommonStockUnderSubscriptionAgreementValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IssuanceOfCommonStockUnderSubscriptionAgreementValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock Under Subscription Agreement Value",
        "verboseLabel": "Issuance of common stock under subscription agreement",
        "documentation": "Issuance of common stock under subscription agreement value."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_IssuanceOfCommonStockUponTheMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IssuanceOfCommonStockUponTheMerger",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock Upon The Merger",
        "verboseLabel": "Issuance of common stock upon the merger (in shares)",
        "documentation": "Issuance Of Common Stock Upon The Merger."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_IssuanceOfCommonStockUponTheMergerValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "IssuanceOfCommonStockUponTheMergerValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock Upon The Merger Value",
        "verboseLabel": "Issuance of common stock upon the merger",
        "documentation": "Issuance of common stock upon the merger value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r866"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r866"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense and Other Information",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "tecx_TotalLeaseLiabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability Current",
        "terseLabel": "Lease Liability Current",
        "documentation": "Lease Liability Current"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "tecx_TotalLeaseLiabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability Noncurrent",
        "verboseLabel": "Lease Liability Noncurrent",
        "documentation": "Lease Liability Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability Payments Due",
        "totalLabel": "Total undiscounted cash flows",
        "documentation": "Lease Liability Payments Due"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "tecx_LeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2025",
        "documentation": "Lease Liability Payments Due Next Twelve Months"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "tecx_LeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability Payments Due Year Three",
        "terseLabel": "2027",
        "documentation": "Lease Liability Payments Due Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "tecx_LeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability Payments Due Year Two",
        "terseLabel": "2026",
        "documentation": "Lease Liability Payments Due Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "tecx_LeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Lease Liability Undiscounted Excess Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r579"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r580"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r580"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Commitments Due Under These Lease Agreements",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Total",
        "totalLabel": "Total undiscounted cash flows",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r168",
      "r287",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r515",
      "r518",
      "r519",
      "r554",
      "r716",
      "r796",
      "r855",
      "r917",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r113",
      "r642",
      "r837",
      "r887",
      "r908",
      "r1037"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r139",
      "r168",
      "r287",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r515",
      "r518",
      "r519",
      "r554",
      "r837",
      "r917",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r1026"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LicenseAgreementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LicenseAgreementDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License Agreements",
        "documentation": "License agreement disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LicenseAgreementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LicenseAgreementLineItems",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Line Items]",
        "documentation": "License agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement [Member]",
        "documentation": "License agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements [Abstract]",
        "documentation": "License agreements."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_LicenseAgreementsPaymentsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LicenseAgreementsPaymentsDescription",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements Payments Description",
        "terseLabel": "License Agreements Payments Description",
        "documentation": "License Agreements Payments Description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.aw.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r322",
      "r464",
      "r682",
      "r812",
      "r913",
      "r914"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r322",
      "r464",
      "r682",
      "r812",
      "r913",
      "r914"
     ]
    },
    "tecx_LossOnIssuanceOfSAFEs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "LossOnIssuanceOfSAFEs",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 9.0
      },
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss On Issuance Of SAFEs",
        "negatedLabel": "Loss on issuance of SAFEs",
        "terseLabel": "Loss on issuance of SAFEs",
        "documentation": "Loss On Issuance Of SAFEs"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r420",
      "r464",
      "r536",
      "r625",
      "r672",
      "r674",
      "r682",
      "r708",
      "r709",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r786",
      "r787",
      "r809",
      "r815",
      "r821",
      "r829",
      "r830",
      "r834",
      "r835",
      "r840",
      "r919",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "tecx_MemberOfTheScientificAdvisoryBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "MemberOfTheScientificAdvisoryBoardMember",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of the Scientific Advisory Board [Member]",
        "terseLabel": "Member of the Scientific Advisory Board [Member]",
        "documentation": "Member of the scientific advisory board."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_MergerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "MergerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_MergerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "MergerLineItems",
     "presentation": [
      "http://www.aw.com/role/MergerAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_MergerTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "MergerTable",
     "presentation": [
      "http://www.aw.com/role/MergerAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r420",
      "r464",
      "r536",
      "r625",
      "r672",
      "r674",
      "r682",
      "r708",
      "r709",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r786",
      "r787",
      "r809",
      "r815",
      "r821",
      "r829",
      "r830",
      "r834",
      "r840",
      "r919",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r133"
     ]
    },
    "tecx_NatureOfOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "NatureOfOperationsLineItems",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations [Line Items]",
        "documentation": "Nature of operations."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_NatureOfOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "NatureOfOperationsTable",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations [Table]",
        "documentation": "Nature of operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "definitionGuidance": "Net income (loss)",
        "negatedLabel": "Net Loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r88",
      "r114",
      "r137",
      "r150",
      "r151",
      "r155",
      "r168",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r198",
      "r287",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r508",
      "r511",
      "r530",
      "r554",
      "r648",
      "r739",
      "r761",
      "r762",
      "r853",
      "r917"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss, basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r178",
      "r179",
      "r180",
      "r181",
      "r189",
      "r190",
      "r199",
      "r202",
      "r511"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted, Total",
        "terseLabel": "Net loss, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r191",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r202"
     ]
    },
    "tecx_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "verboseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "documentation": "New accounting pronouncements not yet adopted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_Non-ControllableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "Non-ControllableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controllable Expenses",
        "terseLabel": "Non-controllable expenses",
        "documentation": "Non-controllable Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Lease Expense",
        "verboseLabel": "Non-cash\u00a0lease expense",
        "documentation": "Non cash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income, net:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r898"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r808",
      "r898"
     ]
    },
    "tecx_OfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "OfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Cost",
        "terseLabel": "Offering Cost",
        "documentation": "Offering cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses",
        "terseLabel": "Operating lease expense",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r797",
      "r897",
      "r899",
      "r900",
      "r901",
      "r902"
     ]
    },
    "tecx_OperatingLeaseDateOfExpiry": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "OperatingLeaseDateOfExpiry",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Date Of Expiry",
        "terseLabel": "Operating lease date of expiry",
        "documentation": "Operating lease date of expiry."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_OperatingLeaseDateOfExpiryRevised": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "OperatingLeaseDateOfExpiryRevised",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Date of Expiry Revised",
        "terseLabel": "Operating lease date of expiry revised",
        "documentation": "Operating lease date of expiry revised."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_OperatingLeaseForOfficeAndLaboratorySpacesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "OperatingLeaseForOfficeAndLaboratorySpacesMember",
     "presentation": [
      "http://www.aw.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease for Office and Laboratory Spaces [Member]",
        "terseLabel": "Operating Lease for Office and Laboratory Spaces [Member]",
        "documentation": "Operating lease for office and laboratory spaces."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets",
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets",
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, non-current",
        "verboseLabel": "Operating lease liability Non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r836"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r836"
     ]
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Leases [Text Block]",
        "verboseLabel": "Leases",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r246",
      "r803",
      "r804"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r649"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTax",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTotalLabel": "Comprehensive loss",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r153",
      "r156",
      "r470",
      "r500",
      "r501",
      "r557",
      "r560",
      "r562",
      "r628",
      "r649"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income",
        "terseLabel": "Other income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r741",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Amount Due to Related Party",
        "verboseLabel": "Amount Due to Related Party",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r64"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, equipment and improvements",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "tecx_PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period After Closing With Which Assets May Be Disposed To Pay The Amount As Per Agreement",
        "terseLabel": "Period after closing with which assets may be disposed to pay the amount as per agreement",
        "documentation": "Period after closing with which assets may be disposed to pay the amount as per agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "tecx_PreferredStockLiabilityFairValueAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "PreferredStockLiabilityFairValueAdjustment",
     "calculation": {
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock liability fair value adjustment",
        "terseLabel": "Preferred stock liability fair value adjustment",
        "documentation": "Preferred stock liability fair value adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r849",
      "r850",
      "r851",
      "r852",
      "r1087",
      "r1091"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r718"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r338"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r718",
      "r737",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, 10,000,000 shares and no shares authorized as of December 31, 2024 and 31, 2023, respectively; no shares issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r637",
      "r837"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "tecx_ProceedsFromSimpleAgreementForFutureEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ProceedsFromSimpleAgreementForFutureEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Simple Agreement For Future Equity",
        "terseLabel": "Proceeds from the issuance of SAFEs",
        "documentation": "Proceeds from simple agreement for future equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16"
     ]
    },
    "tecx_ProceedsFromSubscriptionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ProceedsFromSubscriptionAgreement",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Subscription Agreement",
        "terseLabel": "Proceeds from the Subscription Agreement, net of offering costs of $2,000",
        "documentation": "Proceeds from subscription agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_ProceedsReceivedPursuantToAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ProceedsReceivedPursuantToAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds Received Pursuant To Agreement",
        "verboseLabel": "Proceeds received pursuant to agreement",
        "documentation": "Proceeds received pursuant to agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r626",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r789",
      "r816",
      "r839",
      "r840",
      "r841",
      "r843",
      "r844",
      "r915",
      "r916",
      "r920",
      "r1055",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r626",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r789",
      "r816",
      "r839",
      "r840",
      "r841",
      "r843",
      "r844",
      "r915",
      "r916",
      "r920",
      "r1055",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "terseLabel": "Professional fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r803",
      "r853",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r150",
      "r151",
      "r160",
      "r168",
      "r176",
      "r182",
      "r185",
      "r186",
      "r287",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r508",
      "r511",
      "r513",
      "r516",
      "r517",
      "r530",
      "r554",
      "r630",
      "r647",
      "r694",
      "r739",
      "r761",
      "r762",
      "r824",
      "r825",
      "r854",
      "r881",
      "r917"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r579"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r126",
      "r129",
      "r130"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property plant and equipment gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r141",
      "r646"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 21.0
      },
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets",
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r579",
      "r631",
      "r646",
      "r837"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r126",
      "r129",
      "r644"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r579"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "tecx_PurchaseEquipmentOfFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "PurchaseEquipmentOfFinanceLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Equipment of Finance Leases",
        "terseLabel": "Purchase of equipment through finance leases",
        "documentation": "Purchase Equipment of Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail",
      "http://www.aw.com/role/LeasesAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r375",
      "r420",
      "r453",
      "r454",
      "r455",
      "r464",
      "r536",
      "r599",
      "r608",
      "r625",
      "r672",
      "r674",
      "r682",
      "r708",
      "r709",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r786",
      "r787",
      "r809",
      "r815",
      "r821",
      "r829",
      "r830",
      "r834",
      "r835",
      "r840",
      "r847",
      "r911",
      "r919",
      "r1029",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail",
      "http://www.aw.com/role/LeasesAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r375",
      "r420",
      "r453",
      "r454",
      "r455",
      "r464",
      "r536",
      "r599",
      "r608",
      "r625",
      "r672",
      "r674",
      "r682",
      "r708",
      "r709",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r786",
      "r787",
      "r809",
      "r815",
      "r821",
      "r829",
      "r830",
      "r834",
      "r835",
      "r840",
      "r847",
      "r911",
      "r919",
      "r1029",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r400",
      "r586",
      "r587",
      "r634",
      "r643",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r736",
      "r738",
      "r770"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r587",
      "r1042"
     ]
    },
    "tecx_RelatedPartyTransactionByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "RelatedPartyTransactionByRelatedPartyAxis",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction By Related Party [Axis]",
        "documentation": "Related party transaction by related party."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_RelatedPartyTransactionByRelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "RelatedPartyTransactionByRelatedPartyDomain",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction By Related Party [Domain]",
        "documentation": "Related party transaction by related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r744",
      "r745",
      "r748"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r400",
      "r586",
      "r587",
      "r634",
      "r643",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r736",
      "r738",
      "r770",
      "r1042"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r584",
      "r585",
      "r587",
      "r589",
      "r691",
      "r692",
      "r693",
      "r746",
      "r747",
      "r748",
      "r767",
      "r769"
     ]
    },
    "tecx_RelatedPartyTransactionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "RelatedPartyTransactionsPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Policy Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "Related Party Transactions [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r334",
      "r340",
      "r588",
      "r609",
      "r632",
      "r792",
      "r793"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development",
        "terseLabel": "Research And Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r788",
      "r803",
      "r1051"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail",
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "tecx_ResearchAndPre-ClinicalExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ResearchAndPre-ClinicalExpensesMember",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Pre-clinical Expenses [Member]",
        "documentation": "Research and Pre-clinical Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r876",
      "r885",
      "r1052",
      "r1054"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r877",
      "r885"
     ]
    },
    "tecx_RestrictedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "RestrictedCommonStockMember",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Common Stock [Member]",
        "documentation": "Restricted Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail",
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Common Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Retained earnings (accumulated deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r99",
      "r641",
      "r679",
      "r681",
      "r689",
      "r719",
      "r837"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r173",
      "r174",
      "r175",
      "r177",
      "r182",
      "r184",
      "r186",
      "r288",
      "r289",
      "r308",
      "r494",
      "r495",
      "r505",
      "r506",
      "r507",
      "r509",
      "r510",
      "r511",
      "r520",
      "r522",
      "r523",
      "r525",
      "r528",
      "r564",
      "r565",
      "r676",
      "r678",
      "r695",
      "r1091"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r821",
      "r865",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r821",
      "r865",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_RetirementPlanNameOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameOtherMember",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name, Other [Member]",
        "documentation": "Retirement plan not separately disclosed by name classified as other."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationAxis",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Sponsor Location [Axis]",
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r981",
      "r982",
      "r983"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationDomain",
     "presentation": [
      "http://www.aw.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Sponsor Location [Domain]",
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r981",
      "r982",
      "r983"
     ]
    },
    "tecx_ReverseStockSplitAndExchangeRatioPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ReverseStockSplitAndExchangeRatioPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split and Exchange Ratio [Policy Text Block]",
        "terseLabel": "Reverse Stock Split and Exchange Ratio",
        "documentation": "Reverse Stock Split and Exchange Ratio [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_SAFELiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "SAFELiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SAFE Liabilities Current",
        "terseLabel": "SAFE liabilities",
        "documentation": "Safe liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_SAFELiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "SAFELiabilitiesMember",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfActivityForTheSafeLiabilitiesThatWereMeasuredAtFairValueDetail",
      "http://www.aw.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SAFE Liabilities [Member]",
        "terseLabel": "SAFE Liabilities [Member]",
        "documentation": "Safe Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Aggregate consideration",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued under securities purchase agreement",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock issue price per share",
        "verboseLabel": "Shares issued price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r425",
      "r860",
      "r893"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Diluted Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.aw.com/role/MergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "verboseLabel": "Summary of the Recognized Assets and Liabilities",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "ScheduleOfComponentsOfIncomeTaxExpenseBenefit",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "ScheduleOfDeferredTaxAssetsAndLiabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Earnings Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "ScheduleOfEffectiveIncomeTaxRateReconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r823",
      "r1012"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfStockBasedCompensationExpenseRegardingItsEmployeesAndNonemployeesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r504",
      "r861",
      "r862",
      "r863",
      "r1020",
      "r1021",
      "r1022",
      "r1023"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.aw.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r579"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/Merger"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "verboseLabel": "Merger",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r744",
      "r745",
      "r748"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment net loss and significant segment expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of The Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r102"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Values of the Options Granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]",
        "documentation": "Information by financial instrument subject to mandatory redemption."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r12",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r95",
      "r97",
      "r98",
      "r99",
      "r145",
      "r146",
      "r147",
      "r210",
      "r338",
      "r339",
      "r340",
      "r342",
      "r345",
      "r350",
      "r352",
      "r685",
      "r686",
      "r687",
      "r688",
      "r815",
      "r859",
      "r886"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Summary of Common Stock Reserved for Future Issuance",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r72",
      "r73",
      "r97",
      "r98",
      "r99"
     ]
    },
    "tecx_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r208",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r252",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r313",
      "r314",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r800",
      "r803",
      "r804",
      "r811",
      "r842",
      "r1055",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentOperatingActivitiesDomain",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Domain]",
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r208",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r228",
      "r230",
      "r231",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r252",
      "r798",
      "r801",
      "r802",
      "r803",
      "r805",
      "r807",
      "r808"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r248",
      "r251",
      "r799",
      "r800",
      "r806"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted stock units forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Restricted stock units forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Restricted stock units granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding as of January 1, 2024",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding as of December 31, 2024",
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Unvested restricted stock awards as of January 1, 2024",
        "periodEndLabel": "Unvested restricted stock awards as of December 31, 2024",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding as of January 1, 2024",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding as of December 31, 2024",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Fair value per share of underlying common stock",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility ,Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility ,Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Early exercise of options",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options Forfeited and expired, Number of Shares",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options Forfeited and expired, Weighted- Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Granted, Number of Shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options Granted, Weighted-average grant-date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period",
        "verboseLabel": "Options assumed from AVROBIO upon Merger closing",
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodStartLabel": "Opening Balance, Aggregate Intrinsic Value",
        "periodEndLabel": "Ending Balance, Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Outstanding as of January 1, 2024",
        "periodEndLabel": "Closing Balance, Number of shares",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Opening Balance, Weighted- Average Exercise Price",
        "periodEndLabel": "Closing Balance, Weighted- Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options vested and exercisable, Number of Shares",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable, Weighted- Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2024",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest as of December 31, 2024",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, Weighted- Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "tecx_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Equity Instruments Other Than Options Unvested And Expected To Vest Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Unvested and expected to vest as of December 31, 2024",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Equity Instruments Other Than Options Unvested And Expected To Vest Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockActivityDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options Exercised, Weighted- Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options Granted, Weighted- Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options assumed from AVROBIO upon Merger closing",
        "documentation": "Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfFairValuesOfTheOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options Exercised, Aggregate Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and exercisable, Weighted-Average Remaining Contractual Term (Years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfRestrictedStockUnitsDetail",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years) Unvested and expected to vest as of December 31, 2024",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain",
     "presentation": [
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]",
        "documentation": "Identifying description of each financial instrument that embodies an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur. Examples are preferred stock or trust preferred securities, each of which has redemption rights beyond the control of the issuer on a specified date or upon an event that is certain to occur."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r12"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease expense",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r836"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r166"
     ]
    },
    "tecx_SimpleAgreementForFutureEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "SimpleAgreementForFutureEquityMember",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Simple Agreement For Future Equity [Member]",
        "terseLabel": "Simple Agreement For Future Equity [Member]",
        "documentation": "Simple agreement for future equity."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_SimpleAgreementsForFutureEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "SimpleAgreementsForFutureEquityMember",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Simple Agreements for Future Equity [Member]",
        "verboseLabel": "SAFE [Member]",
        "terseLabel": "SAFEs (as converted to common stock) [Member]",
        "documentation": "Simple agreements for future equity."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_SimpleAgreementsForFutureEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "SimpleAgreementsForFutureEquityPolicyTextBlock",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Simple Agreements for Future Equity [Policy Text Block]",
        "terseLabel": "Simple Agreements for Future Equity",
        "documentation": "Simple Agreements for Future Equity [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.aw.com/role/SegmentInformationScheduleOfSegmentNetLossAndSignificantSegmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r136",
      "r208",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r252",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r313",
      "r314",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r800",
      "r803",
      "r804",
      "r811",
      "r842",
      "r1055",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/CoverPage",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r145",
      "r146",
      "r147",
      "r168",
      "r192",
      "r193",
      "r200",
      "r202",
      "r210",
      "r211",
      "r287",
      "r323",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r338",
      "r339",
      "r342",
      "r345",
      "r352",
      "r554",
      "r685",
      "r686",
      "r687",
      "r688",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r707",
      "r718",
      "r740",
      "r763",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r859",
      "r886",
      "r895"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical",
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail",
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r76",
      "r77",
      "r135",
      "r153",
      "r154",
      "r155",
      "r173",
      "r174",
      "r175",
      "r177",
      "r182",
      "r184",
      "r186",
      "r209",
      "r288",
      "r289",
      "r308",
      "r353",
      "r494",
      "r495",
      "r505",
      "r506",
      "r507",
      "r509",
      "r510",
      "r511",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r565",
      "r582",
      "r649",
      "r676",
      "r677",
      "r678",
      "r695",
      "r763"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical",
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r209",
      "r565",
      "r626",
      "r683",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r727",
      "r728",
      "r729",
      "r730",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r738",
      "r742",
      "r743",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r763",
      "r848"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Axis]",
        "documentation": "Information by continuing and discontinuing operations."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r425",
      "r860",
      "r864",
      "r893"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical",
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r209",
      "r253",
      "r565",
      "r626",
      "r683",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r727",
      "r728",
      "r729",
      "r730",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r738",
      "r742",
      "r743",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r763",
      "r848"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "verboseLabel": "Conversion of convertible preferred stock into common stock in connection with the Merger (in shares)",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r41",
      "r72",
      "r73",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued during the period shares new issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72",
      "r73",
      "r99",
      "r685",
      "r763",
      "r780"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Retroactive application of reverse recapitalization",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Options Exercised, Number of Shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72",
      "r73",
      "r99",
      "r439"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of convertible preferred stock into common stock in connection with the Merger",
        "verboseLabel": "Reclassification of euity upon conversion",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r76",
      "r77",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock Issued During Period Value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72",
      "r73",
      "r99",
      "r695",
      "r763",
      "r780",
      "r854"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72",
      "r73",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r76",
      "r77",
      "r99"
     ]
    },
    "tecx_StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during the period shares new issues converted pursuant to reverse recapitalization",
        "terseLabel": "Stock issued during the period shares new issues converted pursuant to reverse recapitalization",
        "documentation": "Stock issued during the period shares new issues converted pursuant to reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_StockIssuedDuringThePeriodSharesReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "StockIssuedDuringThePeriodSharesReverseRecapitalization",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During The Period Shares Reverse Recapitalization",
        "terseLabel": "Stock issued during the period shares reverse recapitalization",
        "documentation": "Stock issued during the period shares reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Shares Issued During The Period Subject To Reverse Recapitalization",
        "verboseLabel": "Stock shares issued during the period subject to reverse recapitalization",
        "documentation": "Stock shares issued during the period subject to reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited",
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r76",
      "r77",
      "r90",
      "r720",
      "r737",
      "r764",
      "r765",
      "r837",
      "r855",
      "r887",
      "r908",
      "r1037",
      "r1091"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity (Deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "verboseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r167",
      "r337",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r353",
      "r527",
      "r766",
      "r768",
      "r784"
     ]
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r70",
      "r71"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "tecx_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://www.aw.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement [Member]",
        "verboseLabel": "Subscription Agreement [Member]",
        "documentation": "Subscription agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r591"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r591"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r591"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r591"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r591"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.aw.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r592"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "verboseLabel": "Convertible preferred stock (Series A-1, A-2, A-3 and A-4), $0.0001 par value; no shares authorized, issued or outstanding as of December 31, 2024; 3,647,675 shares authorized as of December 31, 2023; 3,647,675 shares issued and outstanding as of December 31, 2023; aggregate liquidation preference of $87,459 as of December 31, 2023",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r462",
      "r639"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible Preferred stock, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r38"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible Preferred stock, authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible Preferred stock, issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Convertible Preferred stock, outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "tecx_ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold Period Of Receipt Of Consideration On Disposal Of Assets Based On Which Amount As Per Agreement Shall Be Paid",
        "terseLabel": "Threshold period of receipt of consideration on disposal of assets based on which amount as per agreement shall be paid",
        "documentation": "Threshold period of receipt of consideration on disposal of assets based on which amount as per agreement shall be paid."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r1041"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_TotalLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "TotalLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetailAlternate1": {
       "parentTag": "tecx_LeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfFutureCommitmentsDueUnderTheseLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Lease Liabilities",
        "totalLabel": "Total lease liabilities",
        "documentation": "Total Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_TransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "TransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.aw.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical",
      "http://www.aw.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Costs",
        "documentation": "Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r336",
      "r350",
      "r526",
      "r553",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r650",
      "r826",
      "r827",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r838",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r904",
      "r905",
      "r906",
      "r907",
      "r1025",
      "r1028",
      "r1029",
      "r1030",
      "r1033",
      "r1036"
     ]
    },
    "tecx_TwoThousandAndNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "TwoThousandAndNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan [Member]",
        "documentation": "Two Thousand And Nineteen Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty Four Employee Stock Purchase Plan [Member]",
        "terseLabel": "2024 Employee Stock Purchase Plan [Member]",
        "documentation": "2024 employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_TwoThousandAndTwentyFourEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "TwoThousandAndTwentyFourEquityIncentivePlanMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansAdditionalInformationDetail",
      "http://www.aw.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty Four Equity Incentive Plan [Member]",
        "terseLabel": "2024 Equity Incentive Plan [Member]",
        "documentation": "2024 Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_TwoThousandNineteenAndTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "TwoThousandNineteenAndTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.aw.com/role/EquityIncentivePlansSummaryOfTheStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Nineteen And Two Thousand Twenty Four [Member]",
        "terseLabel": "2019 and 2024 [Member]",
        "documentation": "Two Thousand Nineteen And Two Thousand Twenty Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.aw.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail",
      "http://www.aw.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "tecx_TypeOfCommonStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "TypeOfCommonStockAxis",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Common Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_TypeOfCommonStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "TypeOfCommonStockDomain",
     "presentation": [
      "http://www.aw.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Common Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated Preferred Stock [Member]",
        "documentation": "Undesignated preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_UnrestrictedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "UnrestrictedCommonStockMember",
     "presentation": [
      "http://www.aw.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tecx_UpfrontLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "UpfrontLicenseFees",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/LicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront License Fees",
        "terseLabel": "One-time license fee",
        "documentation": "Represents the amount of the upfront license fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.aw.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r123",
      "r124",
      "r127",
      "r128"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.aw.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance deferred tax asset change in amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfComponentsOfLeaseExpenseAndOtherInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r836"
     ]
    },
    "tecx_WeightedAverageCommonShareOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "WeightedAverageCommonShareOutstandingBasic",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Share Outstanding Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "documentation": "Weighted average common share outstanding basic."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_WeightedAverageCommonShareOutstandingDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "WeightedAverageCommonShareOutstandingDiluted",
     "presentation": [
      "http://www.aw.com/role/NetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Share Outstanding Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "documentation": "Weighted average common share outstanding diluted."
       }
      }
     },
     "auth_ref": []
    },
    "tecx_WeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "WeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r202"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.aw.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r202"
     ]
    },
    "tecx_WeightedAverageRemainingLeaseTermsInYearsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aw.com/20241231",
     "localname": "WeightedAverageRemainingLeaseTermsInYearsAbstract",
     "presentation": [
      "http://www.aw.com/role/LeasesScheduleOfInformationAboutTheCompanysLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Lease Terms in Years [Abstract]",
        "terseLabel": "Weighted-average remaining lease terms (in years)",
        "documentation": "Weighted average remaining lease terms in years."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481288/505-10-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481679/480-10-45-2A"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "740",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479172/805-740-25-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-70/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-30/tableOfContent"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001193125-25-064163-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-064163-xbrl.zip
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MSTM[=;LO3T*]>$F01O5N\0=02P,$%     @ &HEZ6D$'.,XH @    4  !$
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M>R8").)"C++T$E\FDJJN;:^]^R!B_\K'D'[3]5G]MPCGHA_-?K7G']]1G&;
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M]V#J]+SH]41 <>M0OJ881+F.=5-*0J[ AS<:)/V][_O])6;T/#\9\Y8(+S<
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MRV,/3(X+3QIAB3H[T><(">( "*2?9N,[(@8)&HE(*Y C57"#MK87O[BO52-
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MZM<HX5L0:H!(9G:,8 LC;/$+"A(L(-1F19ECH C-+S*J!*H $/A2H;+4#S?
M!(A((UX)K .0N21Q3%85JXKQ -XM,M;%^!T^E%=23B85;SWN=^MVL9&EW3>\
MBYM7J3(C2%LUSA)?)1]&J1)$I.7LWW7+\>3/4(F#'5J!JKU"I4]+X=]B;1"F
M.<GA1Z@/022%J!'Q2-_I_QDU"-NY.,%FL6V[AHM9C#^RR%X3]!\OUF^DZ F"
M]FR*AJ&-T!PMD#%J5N@/\<;YM_?_=WAPX5V<8-/%T\^'V$>KY7W8QVZ77QH[
M#]=/IGEA#2;Z;1?6(*5/SPX_'W\Y_KI_]H=W>G9R?@IS_W;NU:9AWK%K3FGJ
MH4TY)#/(YMT'N>EG;QNTQS] OT1#$"19\.M:?V]WJ[.WT]_L7&YV-OX:]=<\
M/RY^7?M\\O%DK:ICVAL[FYWM/= SROVRL?5Z=[L#GZ RK&^2K9P;FK76#VO[
MMH?5M+1O(Y076ZW=O=>M[=T=CUK$YRH/$B3$.2C?[]./DR9ZFZ.X05%;+[%-
MM]V-&X\<)U*QO&#[-U$"D.7E_7.3_I\T3="_,_'V.;6_M1:9#GVK$[1-P.V?
M;BE7I/[0.H,$+56CD1 ?J5Q5EN:H*. T4:!KI'(T(J68]GH3&:O=<55SXN$K
MM1E)!"UN[%/49@(44Q(M8=Y&OP_Z4R:Z&MK*-6T%3%LT? LLSLR[].-2>/_:
MW*"T?- [_#35K4YO[W07#OJA_?]-4.*I2G#$/6)K@3=9YK VKK-R#9VVR1+R
MJFI^$/7ES?E0IR4H!,R%W(<M9QO%AU?VO9+MA&DOVO!.RJSZFK0W_UH"U.M
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M.I5ZD8L$:V,)SRFSERGB@L1"!T,F!BEDBV4]")HU(=P_'.DZTEV@*U0)2;]
MB'WVV62"XFPPB@2=MBHVL=039&^.&=QQ2]G;M9":R;FJ^%85NE&:U=RLTV,.
MIA/4E,Q,[ AVRQZ@RRE-.E"-.+UCJQ+V ;)9080D""<1(YQ/4%(Q 1>LH2"*
MTX 2;_W"VWZ]Z>V# 8H)2;]ABL\Y=0_I( C);^AU+M*KI.5]\?/<#P8EHD3E
MWF9G^U7'Z.%"Q&(T0'P7V6$17O%B:^OUSS?7X>SN[JYO;74V-U3M#4Y>]_R3
M..,P'/;^0Q=?FD1!<;T!E$.!7]GJT^J *JM1S.;C_R'N.5)@Q(!H#-Z46F^B
M2JN);G4$\5MM(1BD)'DX#E9]38LA( QZ#;^30&GHC:W**_U<.ED;^H"=-"B/
M&$N2R!OUU<]#_V_9 91":>,AD)]*_;TX//A=(_(\E:*)75<TX8HFGG/1Q/&0
M^AX6JKWH>\'M.,ZQ P3(@3.!71;PLX?NQJ7JRN7$,CTQV8E+-YW%@%-/-21%
M.:9;RNX'A<[KX0[.JIT)MPO2":><2.!CX8.$%2JQ&J[247O:1)2;7L58=9.1
MB1>RR[[A/1@#SE-0I]3%U#;AN8J]R80?B)C*]&Y4C4F:K"-&>XQ%,KG2CZ@)
MJ L.5FS^JX/5\)6Z;@3VP\GI/DN$IE\INI2W$PF0U(MP80JQB)08!?V2A/NN
M7@JTXJJO!1:KOU;"1-,6($X=1L3)>ZQRJ_2;*&N_=N.YI^UZ-3GO']NN^P>6
MLYI:MR9LG89NT+K=T!4E[& ^$&6"4P!7H1M4/?G2EC>-6FGSKE1=TQ"EDLYX
ML%PXW,:YB<^>3O'F*V>'.#OD^=HA32QQ\>G0.SDZ.CP[_OIQD<!-*^J%JKEP
M@%0:'5!;>S_-<N5,'+CU$9UWYZ>JHECOW!IR!%%Z,N,5H4F^NY"7:$)2E641
M+>\X"5!&S^5.="=YWR<I,1Y(*I-I=$ZFT0GI9]U0\5RBN9Q;:"[UT_\VDC"<
M?K^?B;[L0SZ!WX1&MF6$.=)X=*11%I@#3N6%-1)H[[5V=SNMW5>=*:?M<?/;
M*MI39\_ /3E26$E2^,:9-Z<*/*QV[K($B&[,S>>>5N5)$SI4!2"F?M50%VE"
MDIDUB&RZ&5%AW$AA%P64F, %/1IZ1UTS9 [V#%BT*8NR@'$FW*R.E%>4E*6'
M^YS]VG4+!OW;[NQ6]>S(*D&6/Z4H=OWPILD$XGC='F<N$55S='!9$18=^0Q"
M9D?3N7:)_G')!8")Z*<%X\_P$XZF5I:F;#2;.D7]80)T&74AM. 0K9\IK[,"
MS)D,NS%L&?EWR\E.!:D)_05 FAS+EG@^"-T3RLXG[%2CGIV:A.NY(#=0VCP^
MQ%MM'W;TMG G;(\A+"H06:)<MZEDWA:V#5#;>!/>YFE,:*C>!X1NB[J$ORK]
MKVK7NP(60&_!5CGH5F]O[SU,2UP9HH;Y6C"VJ64OW\$J]L2U;#]:P4IRZ$@N
M)^<..3GMUJO7.ZW=[;UII(B$2\10CF340O=L(FECT3)KS1&'#0E)F;UY2/>P
M<.1$_5N#L=Q^O='>E D&*+PZF^W7Q"= [-O>X=\EEH,=)^@!1.,<!4#^UJ6D
M.?)?!/EOM5M[K]L_3ONWIOKMS8V]32NM9O\_9R?OCT^D=Q1X8*^9]!WE.\I?
MC.#?VVQM[[V:G_0Q&T_E0U:)7V'U(OH8_;A,HL+):$>IBS)1.MM@HNR\GD:K
MNETH7JID7@'1+T(@V(;%-'OB+=D;CEP=N2Z 7#M@3[_>W%T(L0Y'<3J&RS$'
M6G0;EM,9*>A/(?%ESR6^W%OBRX/F<WA1"&M, VY3]>?VVKNSX_-_>T?[!Q<G
M9^?W[K*YR?ET3/XV!:/*>7JJA9*$EI/(W!O>>W;741(;)7EJT&VJR"K'M0%:
MU"U#.LYTZT;&Y0;EI,'HZ&72;XA7C&YZJ>2&=*$=^-R5*!M[7]."6J-@*VB8
M]5&:7<&?ZY_3]#M'[V6O!@/;;94@&->C]D:2'3B"=?0P]XXFEW.?TV+@8;=<
MV?::BR4)Z _6S9VLN=#''T4ACHBYM[R180G6XYCS!O4FUG#.)W9@PSNN@5S(
M!PDV TOQL9<0[&E!&88U2*-*04_+ZT4)2-^(ZCX3/H"6%T=@*80*KLSJH6EC
MRDXD2#95YEE$PI78(>$="E/SP1]CGU)NM)OI:HVQR9UD!,3?$#<W% SW@1MX
M-1#<RD:Y@UOV&5*S$.J.KDB*TR=K;EG<5I4:7:M+86!VU:7>;)7N\V&:@F,S
M<[P$)&G!WLE,%*DI..0WFQ&FN(9+#08?>B+.Q15U89Z<&NR^=C-C;^&9_*)1
M[1NR5B707 6A?J1*OV2+&%Y @@ 54UZA\EZQ!MF>VM0?X*C4Z9XREW6_7YZ0
M&LT 8W1%'(E+(<LYHZ$B:9E!B_B4FLP9NJ)6[#\!WG)#:ZHE5:UQ0X8S22JP
M&JP_.M)$<9KFD6Y0?^#G QA,)1BL4O._.5#E:0EW!Y8G07I77/F':#NFBS*J
MY?6R$H,Q56=LUX9W/KD)N#)T"%/=I]Q+%'+4GR(OE(C%CD)@'/-.I%G?3Z+_
M<M<+O"=@IKZ47W(R+549JCZOPP$T@+UTRRC6<K 9I EST7MI'('00TV" !?P
M?*5R-*& 5^9'U+9+H:'+=UYR9 ^[:6>:BU'.<YNB2T&2"5ZBLEIR45%'JCN4
M*8/PJ:@"Q( '^K0O,CZ%JK,1MNS_RD3PE4/3+#5N,H>D/)41M28I&2:'^INC
M4/11W\"T"J )[T5O[A @3^I6 < OND88?]!^]3;'6*"*HN+T]^&E8^Q&CB$T
M+5@.E&JG9\Z,/C_1&WAC'/%5^^<-'"@7?Y<DE0U9)BE6=^#38#)9A\+^,P;2
M0B0Y+#ZA3,B*!<+G+T)N>)5;[6SE#5&AYL'.7D8*(\]&JD/3!X2"S\6>!':L
M85\8G&+@(SE@^9#(&H05Q:/U/WJ-==2*I>Q::NK EI5]#6A$9#@IK2KX8@J?
MGP9K0'JVRK]U.Z_,J S"XTCZ*7O>IYACIK\;3JT7L0-F4B9;\MB'*2%V9AHV
M"^0CV7<=13:BVZ")\D$$ H.\LMUJNV7X"/[8:C%B)S(ML:,2VMQ>=*]>(40M
M0[<[&WN5CUM6[AI"B>S3SYO?W-)G3?U8RV')VX;E;T%4<,AM>V]CM]:A\P9E
M8Q^?W+&>ZD*?XGD*VEXFUVI/%,:@X]_P>-BOCNCTRJ(4*<<-852:.O1X3'C/
M]R;@4YH-USS'F)@Q(<!;A.D%@U#]'.NB6>C""F= 3N+^TP=0EL/.8%T]%9K[
M+ \T.U .D]Y+"X<9P=+D;OF(X2=<9H#S8][!CVED %WMIC(FVU52B*\K5:8_
MR*FPM:D10!*:+@#F,6K*;E\[N4J3Y]+X[F:&)WYW,2C'# MA!BUHD1K](2:/
M,YS\%+;P45='"@,2<?&+J%=I!-/$$F6N[A<V7+'51P:U'1@ICJP=62^$K,DS
M#3_%TFQT2&;IV(^+L<9!@FO/F'U\?/^[L3 > PZ,-JR*X@EZ*8[A1B,[[>IN
MXBY#P)'QHL@X(A=V"\UCANT-;X:/-^X:1XB.$!="B)+\++Q0](#9$2;\VH*Y
MR\=Y(89L#&L;PT*[,V:P_I!![M@-:)O>MOW1JF'V-G>64FWB)Z:<DS])86Q(
MGZEC$L<DBV&2'(\ZR@=44IFW9-"4'.-#]($BF_1Z?I3I2Z(N]4!G<N8;#S2#
M[3;WSV$/E6Z;@]X<V9-4O[#:! JU1!).CBE;DV" #@;\*XTH($<^I K<^U0.
M>91).*]=$L[])>$X\?=LQ)\IVDOO=J'B= \5L"2YX])7'7DNSH15W>-0E\JN
M<=A63C=S(#A:K&?,32!% B-0.IIMMH+:IA"<"ON#<D4 :"H5@"=0_7.T^EKE
M6-5MUV" D(I)'Q_EEI+JY=I+806$S-.WQ&A>3@UHJE)S.(D,+ZI6-!*C,RV9
MEZ!<)*FT>LB0P2:9U%M3QJFJCPW+7+<^YX@;ML#D_+>J!:,M(CHO.Y:G$M;4
MFS:\"XSQ4W0I$W^74::ZLG>%%1/FS+Z, #0QPUGN.IE4VO5ITX%ICEOI]RN)
MH!H(YIZC+3EKHJ*(1%T@%X#A ,(.KU)*M0L\)8'(Z\P+E1KYX<N)JL[^667-
M?$N(,BD94MW$)&$1Q6>T%#8=3:E_Q7I$0[,I9Z0ROY;]2XIE,C3!7<W5'!:7
M]\8\'!)+7JR;1^7AD:--XYMRAW Z1LZ%(];-..M095):OFMX38NH2N80A*D&
M8.>A.%6E$!J[D],X\PJ-82M68"P!(H3 L!$5*AA0-IOB!4IHH*1.>DOS]ZTI
M[?ERX .?]:FY0]L_1 O>5S":,:^8(4>[?AY)#&P42_)*,8MG93NT4%@!@3JB
M*.4[\9T;GXW@@RBKMS?$'""A,H"0-MB'-3L.+J_LVM%50:8G5ZL53;=3(^X[
M?'UHB,8BMWKB",*XPZR'F"D]M1,P'3L)I(:T!*O_\/1@3#69)(P* M2E5L9&
M>$I):"4N-?785@W M3(L$YG_D.C8?*O2[D@J.(6GW%(JU<RJ3#C[4^,_( _A
M6VY(X21\$[J@]NQ<(2LOD':-6PNV5*?-ED*?S20BF_Q9/TNO0+;*L72>@:(R
MBW+K3,_\,\HB9'1^L<G_P$H7?H'\BK)O.$$EG#Q63JI,U-)E"QUU!;=17&3Z
MER>XHHM&2[/O5EK=3*I?3G;K'&FC##>%#&$3KT5VO9++*DFBA9RYK3+ZIO>,
M1X.ML7E\,U-M>$=&WDD]0]E]B4 5CW%'E9QXA2GG.&%,NL0^X&D6**. :!G3
MDZC''5J):.@E2!P6<K8]A:J2-DQ;%58/D;\*QAIG"JF</O;:B@GG*% ZO#O"
M)K.RO8/&!R/K055SU4J_*"F4['U4(R/*RL]4S6S]RW0(PZ!!R\GT*H?>'OM\
M_^@PMQ.W*GQK9UJ1Y$T2B49#)I2=0F=;;.3* LGEHYYLR- ZI0*T=I=FQ/_H
M3'2+A\EQMA4AN(FZ,]K8%ST) /[ITT5SRE8';H4M:9-%A*#D#80?XZ6C+ :I
M:B?_$L8Y_OH!Q#)Z%A&+@B\*%?/2DC**ZEH5#:!?T; >TPAR:LH8F"^F@J=E
M*S^KU3=SL<T$BH9X,[=8X#)#-G6K[\ERA=GJTJ3R3:;O-00"&G(LU<#33-@6
M>V\G/+0;WGX0I%1O)/-CC< SHN9FT==$L/((ZVF?32W6*]95181Q^T_9?0AS
MJK&6AG=-9\R2B MO$'#3I)I*8E*%)?KN-B7^\B"X[C?GC_ZKO=W>Z%334_%<
ML":#^ G_0.4+5,F7C'W@2R+E*V'*553BHFF3,'4$ ^I8HOD4"89^1*+@S<;\
M>5,Z@**XQTAKL4 D_78'+,FD&.0&%8GUI31T) D1RK;/30(:JIET\5%3-11]
M0&M#2">\/C":OP]R>2@Q0+3Y1CU=Y=7Y*DN19V3'6"8T:E];VQJF5U//D*=@
M(V<2%=^N!V(.OW_:.9+4K&=JKIET&M0Z5XIU^Z:ON<*R27'GAL0B;/E:#@.7
MM.J\EW?P7C(J(U :E544**IU])O\3VP3S^F"TO:)9+N:1&]L"8TF$Q"X[- "
M<B$-&/@Q2/.BXA+#D:S;(WVO/!RLM7U3S] T:W)D5*>L+I<AVSF@F,D 3,N"
M" T=!R.@M"&ZTBA)!O[#_]+.U, 'N>1RLQQ'+HXC+3XTN;,Z[9#];#+S4"<<
M2HM.ZI>0.[1_)Q,,/P<5W(^4K2=QFPUZA@R96;F&;$1^\K-+/PLMW\ODD\3#
M8&ZCQP9>\+2"^NU-%]5W47TGYI8BY@S:JPG<)3!$<W59K2@@D,VRY$W2Z5]'
MF(LC3"'QIBQ72YK)&!)\=6,6"EB>Z\K05'DHL^SFKABGY+%,<V$ZPB%T,Q>7
M$CN01I:%K:JJ5QG:..A4*]OQAN.-A?$&7[LD\! Y?3 0IC'*K30"A:!#(3?I
M3,10-KJ:=#'TA&=91VF,3I@:IIGWFND8P#' $AF@QRTML/ <:7=D!Z]5FH*Z
MSPET8 3F<7(DA*(GV)'O]^%9RG;L8?Q J+"?=#7$?C3,V5>O^FS,D4[MJ-Q1
M^6VIG.A6)"IVRJ'2B,'\M ^ _(3-M8HZ @O_R- _!Y(?;?MY?NL(V1'R(GUI
MBMKJ<MND*$X+'#='C'6^J70>7]5SG&I^:(&OK+VF$@>BFP;G[RC@Q+JQ/S.$
M[1C&,<S"&$9ED%$RSHB38TWU1*!K,BG[SS+:'14Z*ERLE<TV!,=")#F:D*2Y
M%*[G ;6:+ M. @BGYD\Y"G44NE@*1>VNRG,YCZY:H3M9D!OX(TX-5OE\5@6N
M;6-,%#>HJ%V3K<*Y;Y1-P_"_F/HR2,F;.%&=:TR(W"K5=;SA>&-AO&$C/E'*
M>T[YG80DJX$",Z1F$9%G(P1;."BXU$2!\Z8(/-Z;C'13AV&%\TDYE3-R._&M
MQ"4B=&6?CLH7"*'#U2\!@ITJ+PF5,4EJ:TQX?O@*R]^H7 P+PF3E")<^1@6F
M7,' (L-@%QM27.R2A%:RDXVGC"S74&NE<S;]1-:=J<H&"FPU9"^K-%:3UYDF
M:F<I9843CCEUU8_C#>];4D2Q?(DIK['28-7F8\6$E!^ZXBY5A0H<0\"D6OLV
MWJJJ7:[;DX5\)DW<'D(E+.-(":&OJQQU'S>WB^G/*I&.(6*H_)&:':MR'-7<
ME>J=NI6)RZQ;^J[B,L,"7P2Z!LT?X+Y$.*.\)7UL9'UD5')J/')\BL8\0>>S
M;9W8/[C_7-F3IHJ_&L%,),3JI.26)X(T257K#,FAND6%O0$Z?Q9Q JOGK="I
ML39+UF!3^6P*9/>%A[Q,P?[B6;*[!G>2M%)?I*,4;3MU3=8S0J^^+LN< .OL
MP9$5& 8NKC"U\0S1N7T:X-OW#'M-J#);?/Y+%(; %8>8PJT94]7"!::-A:F&
MPX)*6>]B;:_/$-D:4UURKDG]YZ8A(5 H$BIOOH*(KO"J,3"Q"*;&N/:(6OO/
MKAG@;AU^0_E6FC5' VMM0"HUH79]08.AC7:VGI0IB"BH"4UXZ2>$M&KJ_DSY
M*(E"[-T7B=G,\C"U<V<2--]B(%W?066$F+@*[!^7*EI;+QEL248:ZY:%M=*N
M%I>DV67OF8BC!#Y J8J3S=7 S?KP(0K76'OD)4+,PW=D)**4;ZD"KJI2,94W
M:@E2E<Q0"0VZ@ 7];/%.\;QUI.*QTHZ5$J*)VZ0MKRO)U*H>_T9U06,V:XR6
M"JS7E)@L>Y?@JK+*]_96Q89WD<HFL047=G'>RX385U0[43V(MV^I/K-*/2#M
ML=TKBG(3KN!(X9H^(N JI.AZ'H%-^]HJ(09!T:4B6BS5]#Y8[8ID)CJ6P\A^
M2'+/-#PH%3%B[2FL_@-.DI0$K\$F!+RV* G;DN-2X,(.L<D64/P^A+R%W\/'
MI+:D<E=\JW!R+?%/ DXWI_(#12+(%CZ6MH7PGDCW7,=9?.=:,]5=B;/S8>]J
M4@9W7S^N#L\N)6]12R>?02BB2\SL8R-S%-,5AI<@2Y:DBZ*BN$C@M @1@A4U
M!Q6;82M9#$D!_3BSD-LN"_G^LI!O=;(_I(BX$/-&>3<!9C/#]J>T*J-$I@EV
MV]BM*FUU6:/&*W@J52W>R&(M-45UQX*I"8*EG],(HWG#]]@L@WF9^)XEK:X/
ME-?)GG\)FR#-M')F/6N3Z=-LC=IU$](>)2'4;)9.PQ'U3(_2J>6KUEK-UC8
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M /L_33$TPA4]% K1A2[KT7*>S/#&9J&&PZC;@HCCV8@M]NV#*N<)6E#G&=P
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M/4',*\(+?J<V%N\$TX%[;)"V/^UIIH0>#LV4LJN*?#OL-*EWCIHZ] AE!UI
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M:(.#/OQH,"2['=  ZC=!R$^PQ;I2Q^RO KK\R2N9D+NIQV..;-7BE!5Q"!S
M?A RZLB';UH[GCG]%:K^1??ERL0O9R]WM?KKF5>"YS>&*Q<?<>*IB%]P_M%D
MQX9W)FR=K'; '&LA%2?M"2*4[MNN9YS,] KMYJEMZ4@C397@.#Q(/UH+Z5QD
MDSL=%#!;<O-[=L>D;E)N=;Z.KG93;GN"63MY<?'E\,P88;&R6;B5X#ME(V*T
MGFRY!>EZ^,\:FQ)LW5R]H#6O1<;"]N.VJ?NPNYNJD"TGFXH^,MQ$8M/!#01?
M7',DQM<G IWD1 +9@ 8\/*T4CHR6PIE?RT-_^,"E1S0Z=2UR&A<+]^2U6:*8
M"X6D)#S2LWX"/2!>)C,JW)0=]GEXY!P&>2+6 9DBQL?I[.-X/MA-N% X!77=
M?W>U^F%PM/P!1\OOLU7PUBMBL>R9U)OJI#2UM'W6'YMZ4 W%'K'S<E>V]'!%
M[16LP.7@F!!&VRK8WV<L5/6G!3GZ\9"C'U"H*G>B$*M[A@(0B#-Z>F?C(?%*
M0D[L-A$ID.WVQTS4"FB[A7R%22]VY>Y$D8Q24\12PS"$$<?'I_3PH!+G=[5Z
ME8?S#IL>2A/Y#B3S31J11!^J!QHT#3%[[A[J 0L3SYPC*3"$:])3AFN42GDF
M>A>.(4;]F?K&ZSZ<:YC$#%%K<^2,%BRD2!%QIJI"1!G2Y5+<6UAL^C'(.-!
M_5#]H.RZGG.C_HA9=?TA27KX;N@I>'S-;IF*%J\1GH1[Z4IFX<A/FBG@DGK
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M,NZ,YA?')8Q8N+#@-QW3G'BO_-JO0;R*VG+P_DT;PO5. + 5HPP%]XYP>D=
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M=-I9!57QJE=A,]G9H8>":[L;?C62<L?#!TYJC64R?,[Z?(<*EO2[_>%/3T%
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M%Q\M@K*><_[N_A2)0_<&-ND-]]'#]<4V1Q#0._._3EV.WHXI;0R)HG@PG1=
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M(5S5F[765N9N7SCSZ,0;\M/1\RSXW]-AA!ZFYJ30-5=4EIPC\Z,"CQU\K.(
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MY5]E5YSL.FMB$<"5@U@9ZX\B61-(3L+OPO67>L..O,K\N?CU%%FJ+A/%3."
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M<16_F +K.2%LR<VT6C0Y!>WH2WQ,S<!X^K^+@QQ>-/[3SJ_3SJU3X/IX."D
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M ]V/@_0RG:NN3Z9*FMNTU%-9;JIB'@U(NU-E285E,.G0+.EW+ RR8L)N5_P
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M<=KF0%"U>_CB!!&39XX[<;,0M[PV%1J0C7O7>-A,SW ?9^!/FBBQU;,)'-%
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M[#%L,4<07\<9IPN!G%I&(R:#F,V=YCN66BX!V[!2H*=<5V+A 5"FD)TB7FD
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MM7DFR26"(M1X(-")R_G1&.F](E +$&G9LF!02P<[4GWJNIV!M'GV<[ &\#M
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MHR3285YP\TA"AI!+"6)B'26G-LU;2)H3!",!#/#S4$6+:Z6I.I](C6"VDKQ
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M3@ X7=8]%[]VO=_ DA2V-'1HR#U<'BY"?U:/(P6@6["[&+K06,-X1AT:$C4
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MDY >&\77MT:VC_ !V'^(L7AW$Q"7[$ S-F"@IL"!3$>N?#JYCHG&,1K#.%>
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M,X1AQ)5R@10?KI#Z[(-WK)"31!,@M"(F10:?IRQA*?#I&.FE. T)# ,WTIR
M^'+6.@-]5<H6MF).2*U\H(>)K81QM?=A=. 5!QK(UXWL&X<FF=8NM4BV['2K
M3'$!:/FHZHR"AZP^(*7M#+:;[S([-"F],&4F)O,OA3(O:5#@,' Q MI%82=
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M8;'1=:?#?"3ML^[59Y$E<,1L(*Z,/D![*34T7$7(PY3G:2DAJEAJ#/JEDI<
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M<72[E)TX&8XD680Z4]LV38>56SR,8L&IR'HL)K$Q*/>FLZ_8@9C8RL54O];
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M0HXQ\'"0-VN5GEKIR0I!\@:?;37G>FDLHCJAMGAP"-226C@WTT<N^V<!FT]
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M=)9SA&4-7\%+'DBK4+XR6U<_-]A0LW M-+TDC=]VC,=!REN2*I@,D5!_G5R
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MMQAUU-3\2]Y7[ ;#K8(H,TNQ5.=CG&?,DTQQ3E6@233W6_)B38.CP?)Y7'&
M*/.8L>:[2")3S=@$=E_-'Z+I!&:K:%];17Z%,G,R;O7O?@Z_];-\C5%.RD^
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MW=])YVT2]<W 1!])^0O] ]DF#76)L'"2.CH$@5?HY"0)956QF(!S!J2XV=\
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MQJ]TFXHJJC1QJHY>&?>SH6W//LV&7-RE&95S22W^?'KR45)2[DV(3XMQ5/%
M%3*H'OL,^@[AJT%-@-;$*5&/4),&R -(?!Y)8M(Q]4=1)U?&CN&!@#O5&F*
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MI;E!%D#N=C8\)UWC\AXPZ7&&"X2$^OSU0DKX+'JHD4EQI(%K7,YVS7)JJT
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MF+&BW7IVZ]FMY]>SGO_8&#;\Y]6&I(\+?[&]P\/> "[<AWQ'99G'_8H1R?#
M**T!R,TR@ /-<[9&=FX[6 J2\-=C;_O%O:U',*S:YKH,IT%#\?\8743YL CI
M90JDU^%.LV$\@J- 7\Q&P0!.1J0/#[(9_IX7KS!P:J)T8)J(>@+A#ZL!/2*F
MU\.'RDE4!ME@4.4XU6&5XR*OM4#;P3I9U'K1PM'&A#-=2ZJH<&')-@J?># R
M\#_P=Z3$S?(R>&_R,6@7F]B !3Z/2^7*;3PEJH9Q&0:)&;>?:?L6[P59E<,.
MFSR238;_'\Q ?\4#7I9TOH$:B ^4NWDF]0S?!^]2&(L)X3OE)8,Y7#(6WQ5_
M<545N:H<@X&!N/IOHC@/_H@2V& X0V?';UX'O\91'S-3\=*:C#6&?[/J'Y!3
M&DKB#27)B@+'" KLL'YFN) &!&V49U,YU5,0KPK_PX4Q9=L30:!&./USFO[5
M#CK7E[2O26MA2K  @G0W[/+'W%1*6Z"CSP]E\'!Y#^/SG_A__P:3@=^T'A<,
M^#3&@;_R@EA] WK+_! E%]&\0&L$7O"W?TRL@R89VA?T?S].^-3LS;Y(X4=O
M9^>['P<)K#H:-!,L@/G'Y*#%N\/YMA0?1<$D-Z/_^>;_@.H'Z:$;%C;]!#X)
MDR[^\?<(9CDY^(FF"+/5)[<!:[T_\^".M@_BVD+BD?S1/YY4UJ._(7_W!ZWT
MN=K.WNF9?X<3-$4I>FE#1]N.(N91N+NP/\>C_?S^;!-GFK5?;X.HX'(^^L'\
MIXI!4: \\7WCRO?P=7SE;>#6^36&@0T11T!U@]$,]SOX: JX(P>DP:^ZOW=;
M"7@FXX)U<T/?C"R>Q6@3HBV!/Y#!& 87)IA$YR28;  6<.;)T,2;A&T.N";P
M-D*3^T\V3 <E"A!]I_:%FA'?_+:5;E2>A3&DMT95"?<6BAB,)!J>D]V*'T+X
M1P*&T4!M-?U'HP84YV.K4:6=NG4BT-@%>4Z'\1!,L_KXR>SUO]PL,,5_7Q+%
M9^/Z DYN_1AE:6K8Q+Z(RPG^FTQN6 8LP2S9^O1G5Y1@$LJ:V5^"\Q0EO&0X
M2-H<&9,LV;J3#G$(,&@> XT)RVUK!N::PPEQ\?#!\""6H](D"<RVHBGAAH-T
MXQ-'&>BS4$=T'M-7+EE,'8C.UUF[V\&Q4S\DK[3DJ4%+VRWH0#0!&CD5"E_M
M(?"]20Q+!=^>1O,@ZY/K1/:3]PS4>3!^&,+0]&$L<0K2" .G)4R2J)_9Q\'9
M!D&G3<US-"ZGI"EQ]&06BSJZ5$'>2;0 !'R8!6E6JLB OJ<##DY"$,UP,XR5
M$MYD^G.*3J/L$*.S$*EU;E*X*VB=5+ *N!3X(-'W<+%-<[E9RN ; ]BEPMFI
M^%WR7;.4 CNH $#T1H8U#WJR[/S&15&1)ECX<#:%OV7Y'*=HQ%7FRXBES;UB
M.LW$.]X&&R!X8_IY%<$7X3(\(#DJ0($'Q01NT4(5B?^M &>6@^@5!I:23>@9
M[.H$#WHTS@U;VQC+^#)@!P.E=YRCX6[GCA9\[^B@=LV32,,?VJ]VT<G@+??V
M>]N[=0/A\GN:O<T(?/EIQ;[HT(!FCDL>QOY1PY78#EZ2+8(1!4_)]"N0;(.S
M2"(4=A"LB"4\Z)LD!JDHG/K$483M8P'9_FPX .2M(;QL0B,ME]DVL".@$$8X
M<GPG'.FI,34O&,Y=CF_+Y=SAPL/SP*0N2A*)%,Y0T-L-8#?+B2>!OF#AOS$"
M@-EM6BPY\*0#X1?\:(8DPE]C7J3C-*W(XF#/' 0+F6QK9L!BG@<;_FW](M?^
M959>X%PN/6$<&BHG<1& (0DV7&GPM1',9"I1']H,5&QTO''!^J F\RP=\Z&X
MP(E6"0;()E%5Z,:QQLRM[51D&1Q_?%J*7^&+\@&R*YR@L+U)LHM-.NQPP\$(
MR(5F"9_@>$!;5-,IJAG5*#C6$8W5W_;B<NL>-PV-]A^:B_^8Z"&.+#O$\\/K
ML4,\WWM([!"/OSKT*V=E>$(;^+1Y!1[2C&_"*/#X!>Y2A7E9/?GAZG+RAUU&
MWKMVT<UUD]1W4W>#Z1@R0JI"C%AK0KM$U2TB$=='FJV+I7IV\"+<N5GAS&WU
MW[N#R>WOA(='-T)0WG5?O=ZZ*N>!"GR<GJ/C=,\"?VU5:IM.'MR(8/B.1?[&
MT]M]?FL=->](Z)^6^N<P+">>;&3S49V(WO->^+SW$/I=W]$$]_;"Y_NW59W>
MW00_O1Z-,-.3C5R$%H/; ?],D<BEP=2'?QR>W8@3Y8%?#[W;(M=_NNCYQUL@
M=@?R]E6NX].S>VZO" _M'IN6?S8T_-/WFD!;DK%"J$X>#S 9A']_T&YQK[<;
M[C^_?SZ)>_&*GX>]%S>RA"[W#Y[*'?"8*RH>UBWPF%=RK=J49:G:.P5A?K"Q
MQF,'BM],SO;5%?#.X>J(*=4)?'OP8KO70%2<K/5-!\:DC[:CEO#7 DBCO[1A
MNQ@7A6_ VH(@A6O/(L</CIJU0.3IB/<C> 9OB$5AY![T8>,$'=G9WJL]*0QF
M$4A_E"28Z1[!%S&NL!(%D6;I%E^LC(2 L>1C><>+)M:ET0EB8$'\A"%T2/8E
M>/<P6%IW(S#%L,8RQ?"9:0;3^F_M8[PB9$C(;Q9+2U:N(D^&MC0:#/+*KU92
M8 #CF 0T9V;1G!$H,O^3CQ\>-0[_>8?#ER<_-!S^?>G5O;7UZOY. QE_5WJ5
M4<37T*W[N\U2MNOJUIT&*.\.5.MNL\[@:U&M85#&4T(KCX)SD$Q0M*I6&1GG
M_LRC<&KW6KBW.ZYHT3S6HS*F+)@MI!.T,C7'&F"G:0W@4[Y=-$/@C")*,8;3
M/ ]]N5:H+IT BTW'IZ#33P?_X6WQ&YN8>51;[.WLJC03[V[O>:^ADL+%^B1\
M9@U'_6*_60JY@"P7.#=L/N)\2U5P9U6_&.0QP66#8\5NA\&WSP^;)C)(9>W%
M)'>]YHNYFK@!;S=?3#Z("QZ(7Y:]':R=AKM*7>9>X\J3=>.*T(&!Z7(!Z7[#
M29$3T1B]#XU&A7\]#7BWR-\W%1>??/3!WYLY'ZZ2"&]Z:\MS6=32:B"R"M)Q
M5M]TN?('51+E2)U0,&([!<U8&6V>UUZDE(U"]\D,2W+@B93D:E02X0>9'<!\
M%F0^#8)*0N!C8$F'2RPACY87/P W94N=4?#I7_L'] ;MRO<NM<4U81"/<$Y2
M>-/^>GI"*%_'N6 -BL"HN:JFS4B[N+PB#2LZ\%2"_-1-CUJG02FAXN*6T(V/
M:A^J$>P4GTI:?:Q:0F8+?)@<-Q DJE1 ''Y1P38U'[3X32QRP#(=V=T9J(FX
MSPS)>#PS?""6(KC*HRR'(_FFRG$IP)8RK7/W2Z*H0 V,I@S-,)@H2Z!G3K70
M"!P/!EF.6XW7::W8"EXAVU> -BTC'I[WOI$<SB5B+U)*4N15=[TCP<#5J%+E
M"LDCU*):H' Q,2D- 2M5<JI]*+F>#6L=8"U8"BZHPJ%OF-9BR$9^$I%5 %)#
MI\,D:.]1!<5EE7^VH@Z^(M5V+7(T@A>ML!/OJL2KIGEBMJ"6IK+!",[&A@X0
M;0;7QY0M5X 7@*A=JK4"J+4N5A(;PQM:%6U^F,^YP:/FW:9?@DQQB>/*&I_R
MPB3G1NI\MH,/E=LQ6]_B/83&!:Z)2:GJ:8HJ!H\WG"V/??R2LHO#ZU9=R)-N
MI^FF+:9P@8S%.HY&G<=:F<)&+H0??_#=)1QY](F][YIY&%B<9O "'W*TNWNX
M]"F]MJ>LG01H?>-5@_%7V82%E]&9&8!\AZQ!3&&#""+CI)'9^J*+S':W#=<M
MP?TQL'D "ONW1/T[8>V$]8K"&F>HW__K@C5I1=6(S?KZ91=E)Y6=5-Z:5)*6
MM)$[8I*H2F)/ 7',S1A+F[$"/#?G,3Q99'3!-^ADLI/)6Y%)E*Y(7#..,6-M
MO%>@WD)#@6H4)=B .]^/BE@845(P-L_!ER,_!SV73D@[(;U=Q=E(:Y"3!^+:
M)+:IQS569I<*F*O9JF::7?(Y#IL!AO88DFOWY/AJFJ0_Z(7F636>K,7^TYV=
M[NS<A8(W!>Y\+-&4:12G%/6J4P"UZ'(*<D9PO)*D$\U.-&]-K4>#"7+N*.$9
M/ @D-$L-TTTQ<:_D;5C!>CI2N&'*/!YC9,]BBIC;")_.3%8>HY'R",WE:36Y
M]S^&T6=$KR -6-9)?"?QMR;QFD[)'&T;)@@RT,IC3=GD)I[VJQRA)AC83\NX
M3!I_<0FR6@Q-["0^ LNDFY5Y.E\JUX\3A'?4@?#N#X37::VO2FMYT7TSBW)*
M'X_ JI0@%K@]F$BCS-<L(@47S6:)4/I3LI@M3?V"23&3>3G7)DE<(7'9D=$$
M;,M'+3W]((GB+O#02?X=W]<#RKKBW;PRN("ZE*U0#2\L@WMP<,,,)BE<*N/8
M=&+<B?$=*' &/( F;:!_?*I?A",X4(C**FCR3B0[D;Q]D6R%;25S\&BBH6#P
M+_-6.MGK9._:LF<#HF2+YC4^>6IAA6!'C_&9T6@S5Z%1 W]Z&5Q%?Q) C+^[
M)'WP(SV^$^Y.N&])N*?1(,\,2'(VC0?@:IW'>98R=M&AG>-TE#A,3*R]7'+N
M);%2&N\<"?H.OQ:/YN126L3P$K/9:T2Q;O<)3%M3%GN+.J5-R:5EU&9\SL5;
M5:J-Z#33R 'GZ#,\D^"53'<-!QSOJ,24QG*2(V-YO>^ X#KQ.<BA#8./4.$H
MADZ@G#X6N05*3N%KCIDWNQ;4(.G+ROXP\">-$D(>8U;:!WHF7U$1$H!!I][O
MI6V"#2$*&K9OP$7/XW-MW,5:TP,#>OM%:WAA6SDXD'??'P&6"IQ'<<*-5&"=
MW'I[N:@5F&Y79H"14ZPY3&N@;ENC0M '7@1<.=LD(.O_Q058V*IC"#N$^]CZ
M!%U+F(0;-SRVHFP:XBIFI9].8\ O3>%W&&3"T'J41YH>2DZHQ1+@85HA\O'I
MNKAN4VJ@>1Z<<53M*2&B-0T=X6KW$3$N93/:(F0T,CEW!EG9*H1ZG)@Q:!F8
M28QOTQ+&MA8BV\&KV@-Y(W6U6![C]#Q#T+.7BR&!D58% 4)*X>OP:X2[EW)K
M*[>-!I2\C">>U@#KZ+!J@G+[/')<[JB0WD"-#C8X;QS.9[GMF^#M@ONH#!**
MA 7#&,N>TN$&\/)<8< U!8A"][;7+Y98O6LPH25]7P17'^=#KN01.</-HAX.
M?+;B%*0'9 QK:TG.)7J'V@PVQ(]KA*[+#_=@@?&8:,IXXD;;GZPU4H*< ED
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M]MPL&M+FY6<T;=S +!@1FZ+V:%? +$"LJRV"0V.!;(MXD@T+K@F55!<T+[Q
M:P7%7$TF=<*J">OW<7_N1OF8FR(?];H ]^,/<"\L0\M6!_$0YI@-C@[W=H\.
M_M_1-S^]_/WLW6^OS\[NW5Y>K7,7BC3%!T&OQ4,W:MC\0CL(<X.O-)J*$2Q^
M[_$?'S^\?/<AA%MWL*V^+J@L^?,G>%.6@IG\"4SF:&:J,A[P9T/K&$OO,*LC
M^F: ;W&]+PF#IW\5J@LVH'XUXV@P#_0MI($81W>!]?V.!P-=VWZ<V3+LN;KG
ML)R#2E2X9,315DDSO/Y_/CWYN 4>,BP%O3"F"NX!!4Y8J9+)(25I(T.I4P..
MPPRTERL>+PSC%=$(&/AJE( RK/YS'KBKW*1J:<;)I)G]JFTZNO*V7'JIWZE\
M'1>V_R^Y9B]UV\Y8Y-B)N\CR8:$B(G$<*P_RZPO3_ T(2?-75>%+44/F]$^4
M/67N!KMCL('+19.S393-\0)C6/X<@Q7'@!&;5EAV=&ZR13>SNSZ<(^@%/K"I
MD)B>NZTUSYVBEZE;6DL75#H?LD/HU9<F3I7)O(S[&7'<<$EW-JP2Y9J1/A;D
M2ORLW]L:9-4L(2P,XL,Q'&!1WW#:BSKLVXT*ZS/<\<=W81F*?1]]%ZRBPK,#
ML6X'+22D3B M"O*7PHJ/24V1!27S1(0/D;F";)7H;GKK-8/G$Q(9GP@?_/GU
MAU?F'T75DL%Z?@!;UIYG.=H_V@43"+[V4^C4?A1/*=/ 46E7^*IC55+.3-L]
MKMPITI@+"I/5%Y64^TN'!4Q\^V@)##P;W4!:(!*0@ UNQJ_Y<-<JG8+;HVH1
M^0G DAUA<8E3J2HRFH$DRSW#B!_JU)2Z:U)Y,<5%Z6LIB+,;+/-[8*;%$C"A
MES]EU@!1\A@<4X\UB4?<BQ1)4X<8);0 -_S3_<?/6"X95,KR#@L/:K!*2(E5
MJ3V 8*^/HH%$G)-$0>G(AE"0QZS%2(J^AV'E$7X4.QL'Z(542>S)"L8UJU0H
MD.$DE!=X&/C9$@^-<Y^=2RN0W "E[!ME#@0.Z\S)SR=AF%0P09&PN8>RZ2<9
MY\3( PF#<5*!/T9@S CT8UQ,0\0WI<4TYIH6'5EJJEQ=GAB'3FMR;L!CP0 %
MC4YN:2(U.-K9D4%@S #6(QUD- ):\U!@WX/,!HJ;3+KU&4P(+9#$JA+A\I2%
MP-6=@Z1.N19L,B_D6+$I4>99PMH*?80ATFZ,K,LG?T_87&)I@"?#G"IFP;'(
M! 0L\9Z/T811:H:]G>](18#;IL19P3"OQH5J#3&/"GOE#Y*H$.#N.4:7??0N
MJQ?Z?NB0L123P;2%V_K0$Q%]@?,Y$_P-!=M3SJB@5QV,0.QQAGA3TWF(N4TS
M=YKVJH@B=J$QRA./;<088W-)@0^JCX6+5YP[+3) SRWB4B%=K#_<'<' 1PD4
MN 1+P<+3F*ZD='7U:*EXULP@ /==R9 :PASSWQB+AFH[0?%62!HX:6 ,)',;
MF&3=H-I9JET*P\80;@QLZPAC%<Q_0(>7T7BI7K!SC9(S%,WFCG#=Z)7U^5!I
M43YDH@'4OE-05_1:7RT;C(F@^:[F<SEWJ6W6K=OH6]+19U@MS!VT3!EOP>V!
MJ"!V8V#9I(6TQV,685D(H>CK)X9/1NCL"+J3C5$<>S^V\*)1E?(+(C3VZ*]#
M2I33\N,7!9R(AQVI)!:VU1;VN+HT70Y^F\R $.FRD_QTZ\JT^R<U5T1/(A]O
M>[N/LRCA,.Y,2(Z)>".;85"P2JD8:0,PHY)4'9WCFJU4BY&ID;&^Z8<ETK08
M%*]>9@;2"J&#614V@H9[B\6VL$=XKSF(^!>Z1>3^IO,N!XAM_B^X"X.)F6+K
M][FGL.)TPIDD.K82SR;AS<TTLR2!_&%51=Y%"-_C0XJ7)9ULN*\,P<1!SC!-
M6+=)6&S%U/(6C&N\\RP:&@6PB4-<.9B)3.F"0<5"Q&4-T1M;FU?\;L#?:K-_
MJ009V\.;Z8QD!.6# OPX-:X\\ S7!6,4;QUGO-Z_X'^B[&5<<B!U.@,#5/(Q
MM)LRS9 <SU&<P\VIC#,@@'/JC)[$( G(G6G0%!90)#^1/R!:G9#>69F!RTM;
MF]<\#:YA>QOEYPB#?B\F-(+(T9"P^0W+W$0Y8KQ<F>U3:Q3$#![JB>,"'C(4
MG)7F3\TSTB2[S$<&F?6\J=8GB=0^5F/2[:[ZFIXC3'[BJ"Q=!#3RT*0IJEA2
M=?0H>[MY8J$VZ) \#;[;:;X<(.?8AGO%( )W%L?)6DCL"[R!Z77<3Y32@:27
M&U<#?5P^C-G\5/-B=+CE:I2QPPFGFVS@&G_$5$DSY6IHF-0$92=FXMA8U8Q*
MB)ULR^#97+OQ86]NM0Q/)!V\318_V5!G%ZN>#9%8P*Z[4#VQ!OVO=:3$I<%%
MBN)<RR2EH*JH]:G$VZ(F+_S O!JPSGW$R87=+KGP^),+\&QU_WQ.=<T=TI4M
M)(>L%<FCL9[\@F3;@^WK14M4IKZINQ*=#<6!_LS1!1NAH57=/E^FU4/'-*=.
M$B7Y0! X<G1N4E5ADF/<0"[:KQ?&.9W&,^1L-0@:9:;5>PZ6?JIATP5(3D!/
M>$ 1?#;S&M2)>090K?D!-]=MUS7@U8GIWRY!O).=<R7(>]M3=J[_D%5?:]-\
M?X/3'T_AZL\'__/-F%-NXYT7YSLOMO^:C;\! Z3\GV]^_?#SAV_J&N!P>_?P
M\/ Y: '57-M[A_N[H!904]V_1'[ZUP[\W_[!)DA>Z&P2.T6@PP@#6V2&3E0!
M?\!?4G/SU6C$-P-J0?8E5J Q^,[D.-F(@$83XW.I)37!QW^].>U9;<8>#YEE
MXE^+HIG (0 +(@SD#=O!1_Y!!N>Y;GKE:SQ'+ NV.M#-(]^.0E5X18%KQ4;T
M!7@1*;'A"BD3A^9LX&!N7XY/K68:EQPJ#A1_@R")N82!8BRI-<A.?!X5H#ZE
M)X9$Y90#N9"X'A)1HSE3)3!1-'WA2QSW@]%K/20;^X.<^?<&2" 94>$35D$R
MJ@2!I$-U>_6S&**?$HP# ]]?YF.9<UJ5.><H;?&S%U\8&>)0U)6FP)C,""^-
MK1%<1YD$<?A6@.4RR3G\!F-JMCAY% UBPB'BTY-84RF4T8WZ8&Z?#7 0<:'Q
MO<E\AHJL('M?"3<*I&Z)_P,W$\5?O)M(MT6OT6DD!.[UP(%UE05J0EE:S5G0
M6F9VS6T.XG?4OV65$E0G]%=(OQD%Y['F1>S+7'#N&L?&AD:\=%'HI<*]T(5\
MTY9BT=H6$ZQJA^^.MC:3</!BI:A![.AFDPA.UL"&X23FZ $C.;=$_,M29)Y1
MLP8N)EYFT?MV4TC+MY"OJ<4)**T>>6Q!ZLM2_!#.\3DE-R3,4&,35UDC)NV6
MN)1+ZWDNV,]4OK/K'6Z0<#A'"$'T:K5/W]I2;1%14,ZE\!I,#/*+C*(X07P4
M.3@45\[1^S9"H1V\R268J,]\^V;V^HU];$.]KY3-T[=;](!015.65MU).28X
M7-Y"Q;^"W:$ZJ/T,.MGE%7,G7@Z\/9PT55UV#JAK\FUB0-?-4Y#"@<=2[RDC
MN]YD&:N>M>J8_$O5HO _18DU-,%P7KBHK_KA)7?^H*)Y83JGZX,DS2EMO&E<
M;DMV36&U.'9*.R7,N$$9"XW',1(0FX..JD2G*)% 4KN$^T-1'U!IF7(S*,QD
M.SAI<@!BEDHXG[@1"):_<XK!+C@UI"AF,>T6%KOBP1V%=30.\EJA'^&SOR/T
MN5;:SIS?#%AQO!4R4"L"2S/'CE.20-669\F&$UPW&<<_01]?[#?UF)WZO<ZI
M?Q)./5=O-CM.@+%CC(*4"/+\ADDBI)04?U60R24Q2I3P5WIFPJ#IPWYTPG^L
MP@]O1@/_5-Y]8KM=R#LL2?7U#ZL%[-UBN/ JYWO)XBK:Z]X1%G+!G[[EEEJ@
M)TNXX:D \ZVH?UF]0N+>A/#) I10N27T,M6K^]>WKWP@4BSMNKA4#.XMN.]2
M1*NAC;<%MQ\F[%-&HRE"6RB&.5&%1B.#5$:9M@9PJ6Q)4B?8,68-H_75\99"
M =0V8!R.0A/7-2V\JC4P=]%\,3G9_?TY=1?B=MEZ2>N]C&S%XGR WU!4IG$U
MV[LW%)^)F;?TKO2^OOB]!1>,$.G4ABI)G'U'<38^H\2\!"O^WP7G ,U??.Z5
MEZ.1GL3T0 O<R56_9;/*ZV1'MJ-FL.NI[\CU6E&CBLFDJ_$8RT_8;2[%6K'X
M#LRN&>P(44XRYQ+K\%1TE>!+V.7(0,*2!C [9$%(WI'&,X_9TZI96C1-A>T4
MBQM"!8BQ(D,6=Y6^[_G+E^VHC^4!D0>)=N 6UH'"C^H?;FOLK+VAV[JC;[@!
M!'(VAL+595.QU >/>(U\R' TJ$KV^>6L-YP LI&52#S2R&U&_'<2>F%<1MT?
M],,8H(&I<O'<2IHS=KW\L/5ZADC^3(%E6WMY)1O4\I624%L;-!!:,=_(U\I-
MBQ!96)^K[\%+,\_6(1M9\'LNVM _7O\CAB=RW(?.?'T.?9.:44PA&B>LV@%E
MB5>XE@O(,23/ 1RI [ARCL[KA+GFSDGT?3W4>/1??)<<\@4..,I0B( 2VT7L
M4?HE%><E_@[B_CD>8@FA/?%2V(3N&(*LN7F=:((6_;P1-IPSY(\F5)6M:<3B
MIHH8^5Q3-2V<8B:RX)1XT7L1GP*?]8,A3B',.T$(E2N"U-C(9_"X<-YV>WZQ
MWKO_,7%[W<>LK>#GA?&B1W&DL"9=%#2@D&7T0G>8!T/)H)&0U>=PQ5$X]=F[
M/[YG5VB(#/$!-L6CX"#.=&=[;SK^^V<ZVGL!_R@<:*"[HM30$V2(9R=VB"V/
MZAWL3.DYASOPPW9P^HN%I&%!/O,09-29+2.51><./L45I$Z[K=/XI+>_M;NC
M<CX$IPC>]XHJ2+.4+UU:H S!.O@:L%&+:12,,'RLT_EXZN(JN)(82E=6#R+9
MI-$.,E*^"$M'S-HLH38)9@8*L<1K&VY<_-PV+_$;C<+:#Y_^\G<8F90("H=(
MD&=]Y*34>N0M._#7T^@+\_H)S9[B/1PBET;EDH0CX3Y@B=UE^=@.7CK**PZA
M-U[$[Z"K/Y/N-7L[.R !P=D)]>V<P[,NC/G,H9#FW_;E;X1*&4S@$:E%_='*
MUX9S)0/*Z?J,4; "-\VT\-?O5N:46%&:"&$1%*4N)9(DTRZ">6P2NO93)'*
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M#C,U;$DG0EL" \"9ALW'OU2@@WV\#<;8(,I*W8N"SE/06)N%,=5N&<Q*ZDW
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MJV6_M*X<;1[+0N?[0]$PFI4.AN'BJPT40YS6[N>V$G';$*Q9"*XLL&X$28;
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M:"\RVW!L1EH7;><X'U3::^-4PX6P>%G>+'YGO"0&AF1.'%34(Z+1>A!W1TQ
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M%M7-D<ZB4U\8_B5+9:7ARJ###IT5'Z:".!@9U:I4?GC:4A!4]"05<B0P%>.
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M+V@:;KT<8Q".F6Z(TK*&BT*47K/U7-Q3_4#*UK4 ZUP9;CKYN\@G$R)#$&L
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M8"72"_SC2"0^+45PK+AR>E;.5H@&1(/!+$PM0.9[(R)VQI6&G8L@ZF0_>T)
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MJO =,\\E..&1D< $4V.Y!M3BA2^?M$!#^+;_H 3@AGRZOH#%: G53@/OS.*
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M=9Q/8O\57^'B/$E55T%L:JR*)>S* V?2(0NO2PT58=])/#D>/0V XH3(0B7
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MW2!@,_^E<=G]@Y:"-YO+7F;^&&RA/S&9,;[&M..7J WL=5\$G?YC2=?2ATD
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M,HU4B#;5. :/7YBX1!-HRGUIU 8:,C-$SDNM87^OXWQ4AR!C<S_KA*#<#(.
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M)7O;<M1HL<R+K3\$LH6%N*Q@Y EOV]QX=<G%B]Q*LCW_@H5%6C,W&9*5CTR
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MOLJ&0'N65:S'UXE+M_1Y5:LAJ.(%Y*/X3*@RC3*43&(JG <K<3JMB^,.=KJ
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MXYI]AL>Q%HGB OAOS,/P67V?HG\!_A Y^]V?E%,D!<T:?2X$(:0*YFH_@@!
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M4D+N<4Q=0PUX@O ZY# F>T@B<0H$R&<(D,\%/Q)^8>#S/$579S_K8,XT/<9
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M$6%3V@X9SPB'%*3#4-Q_.C])$I<OSTY;SW5+CP]%C]J18S7A+?MU)CG"T"O
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MA;CK"'CF#ZGG^SL$&^.T:DH-$B.?FM+HT<?8=P%AVV"K4X:$QP)])^5I@!K
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MAK\5_\.VXC[V2' ZJXP$C]DC%0KPEIF$4J!77Y M?UQA;<TEX?<\@:8M*4V
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M;<%0EC8&U C19.'?U\24&&$0^R:C<8X> 5J=.%\67 ::#T\U'G/=U?=@RMZ
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MHT]8O\?*/]AO5 PP#3(+=D9!R)FD\HS@C03 $[Q$?@GG@2U]Z7;>X %0YO(
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M&:O:21T*;;9YJ_QF/3KC>,PS.2-[EO_NCVB=PBH^9YN$/KH0M@<_%\D\*&6
MO-)>@ V%X_Q]J[FU3J?/_^R-8!#:C2(*>#MV^ZTH06'1@.$<VTQ*S[6>/I&@
MWT7!GIGM<WK+O2) WPI)Y4QY@<PL&RL+WME""N38QJXHL0MI-=N_[.3DC;!N
M7DWBO ^<W_DA%A:$"3"6T4MP7IE>>#-0WD5]Y7/IUFI8/+H&,^FLS9XT]QK-
M7RI(8.#)8UB@BS&(WO#>"7V%AO3GR<DG(_=EFFV17Q<% %X"_N]+"*'10J#[
M@HZ=JR?)FMEN%?296?V6U-MFJU5?@YG4]^KMI7+IYJM4Q:%7-N*!&!=^$(W
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MO_W?5!>G6V!5DCK<E0QL-A &^)+I"WQPX)$;6D1Y&Z6Q]2\_0.P9[E@T8].
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MG,:R0[AJ5?\<]H1A)&-._)A;AN>F]SQV+OK5 MPM?)<2%K]SQHDU)-7LLL6
MOFLOD%,\AEJ)':B5O$C2F*GYI<0.?_I<V;.9$$W[%423&'F%$$T?0#^U-U _
M&:U]NE<KTPV3.!C<44/4LL[P**G2U=64L???,;QUY*#_@<E[*L*E/J?'9)3K
M-ZFR=HSF4N:3F87^E9B#R<K"O[7)7R5W)SU9]OO%"/E7A$G(+E=MKEY,W\@'
MI:H4+7E!H%!L3BJ:@E?L&>>N?6N<^4/;18$M!A#>FNS&"[_GW\IVX\H91,>-
M=C:EB]*^?8E>+9W1-ZE;U*SPM?PH2C.E5DNUJM9WV>;&T=1X&[UCE%])^VSP
M/6//L0)LH(XQ@S!*NY_84CFW]V;9U&F>N?ULMO>-:_O.&EL2G/9_-TWC"KX\
M#BS0ON' -XU^SSAHU6O-RBSG^NNU%WN4*L6UYG:4J6 %N3"VX&OX?Z@W"4?R
M2+%&-@3"[<=53VS)*0-8O(7!^F0H#H<XD0A)AGJH3YN:7@:_I[Z01"L+^$SC
MQ!OL31$>,Q:K&/8JLN]MC__>VP-SX0[<!R%+0F5.BM'$8\5#XE;-F.[G)]@Z
M*TPB7=1^/)2]RB]CX)84-E$1P%B].=QM"D B)28?02. F8NA+#,[ZY(],&?,
MEI6!VBC>F9PD3>292WWALP2AW!!)&25'#1LSPF9/,"IV.'<\T"#+6\9L+P?C
M@M1'/5G+S!N;W(4-3BHFT/Z09RF\BZO(&H.<'HK+EH-:HQ*B7!&_]D+T.DW>
MT9T5J4N),+[YEST0NAJ.'^C$@J,+[%NP-@.+0MQA!"3/HA5^14RA6$18& IL
M@#7TM@5<!#3JX2V.[?H/.]328>3#,P_AIR3"D@,IT,JX=,/ON'^AK"^,LH=&
MHVVV#QHE]N9O6O@E]XH3+P1RI^C]M!>>9-_8[)K[76GA_J8':N9\A7%R4O 6
M^#3SHKI9:W:T]]PO_)J2]V1?U#2;'6U!ZCU^'!C]P ]#D@(E;_FSZ!U_9M[0
M,FLM;2GWI3MV/AJ%=PB8RG<=?O%NG9_D=ZN];W8[#?T=I2_9[GW;25Z0&[WW
M;?H&D:]S/^78C]ORRCPW];8:&X<Q,PX+D+=IX ;RG[1T>6;B;W_B?VG]- ^:
M;<JS2;-@=I/,@TY+78&I1W7B1T 08[MHP%P. @]-+%UBRDAU/FMAF04E@3^*
M0JK@(XD8VH7L9 I%35KC6SF%61(2+!!D? E*^3]XA-K6I;EB^^O%#G-$?AL+
MYSW/)LIS?^9R^.?:E($\<9[%LX35/6N.;23#Y\Z0ME3:3/_PP[O8,OZ!J3,3
M9V C#*/C@FGS!0.U]M,H#H%0?[<\S[HSCN"SV/-,X](!,S(8&I]AH0'%+?ZT
M@M@SSO9@.7!NCFF<.0/?A25\=:SXWYA^PJDYUWO&'\[8-+[A"+9K?-TS3AT<
ML@_FUJUQ&H/#>&G]R[E';,@+4(&N%I"]O@-=*P*_\,-+'R@5+^W_$8#U=C0,
MG($!.WQE.1&,\L-Q7<<:&U?V$T;^< *4_'H%3X#0 ZNPYX&%]H!K_X8XE/Y/
M-#'Q>IC?<+EG_+""P&9S[9L5_,31?]AW :C@;5@=FJ'.O<U7VGD._B;C^2*1
M(76R%A@'G@,N>"[JG_M(4<+ "FUQZJ9BT!)YP=:L)7PH&E9_X:Q1B]E>"HHB
MND4OC240#:@R!=@;! = AOIU5P_-Z\!&=IZ/G"GX0<;V+"&24/CT72I?K3EE
MJ6HCRLZ:?!-*I9'^ _H)LWT(H2LR_H.M+46Y#3@'S,\!KHHM%XU(! /W!C+<
M!W:EA\D9\-_!K_X\R%2F<4YX&VBRCBE*^!\+?) 87$NC@47IQ9&=>KUR2ACV
M9^V=DE0>0AUL^<ZL>TX%BH0Z.019/;*-JX&#=):UY5+?*5,(R;1KMFJM66_J
M=/9I0#4>?)!$B5.#TZ#PM<'!6<I0DUE220*/A>X]NU#PSA)TI[WB+\BTP&B#
M?D%;H(E+1_U'#,K'0X7!CY"U9;O.XQ[J&_%9D+OT#4L'E3-:/+C0!6OZAP6R
MQKN-5!<Q\[G9H(9(! 4J8S7Y3S_X"?_\IP&,6&]5HH QAS9*% A4HED<6@+)
MM)=\H?S4TX2-<U\JT1#:P3WAL!$-:V;!.$F3+GEG\6W-#8=7IAO"1=.=3TUS
MMEZ)CL87X+WVK8_<K/-?RS@:WUC!P )2]8T^W1U+M=ILM8O4JDA%F:Y;-S.A
MH%LE%%0)!<LHC:EMFM05,$^SI&XYXI82L?1(8BM]]F^,7C0 A2_- ?3IT:G_
MBO%%%88NLCW2;TMN2*2'P%GDY:4UQ;/E\IJB(0IL*AJ"?2QR?,@SDK?U 8O6
MIV+W]0X^I.T<:JEDOU(A@U(NV9O[_)TDKZ% PY3H%LUU>]ZT9]\R96Z89ES]
MBVM72IW+90'@,WQO5EEJ]8TKJ.O.)S/FP0A3X@.>Z.$3B011MZ#'8)G\,TYY
M05K1!7'KYZ]Z2W$L6,NP>":LK,_M*U5+;)_]<X>33_AWXMY?8UI:J9PF.$4A
M,829"HP4&%^I"UVQE)(4GP626)-Y:"&F<<:&)(8M&G1Q_ZW5K*$@_:D*^>J-
M!7VWZ"[GNQFZV]:HKI4EUM9&"0,&P9HE#*8"DB59?MI3B2"0GR:Q#2T_+_ME
M-E5OX@?1R'<=7W?H]/<4C/\["!:Z -7,FW[O]^S0&9F2&P9Y2'[X]2(]ZZ\7
MV=$*C!!XYY[QA^UY=G0'8LH9C1P/F3C,U'LIK0I?P\B:Z!0_4AH_"6)/&R ;
M!P<!175_PJI1T72LNS.I@-&7$3!1>8C.ARGMGNS/.).1'\G]6*4YHL5R+R/@
M:2(K(BH4:8YPHOTP#BCF[/F<% :_<UWZUPWE7H91$&-\'\\(Q.#8"3&MB?,C
MLGN'4T1A*J2D>.=N8+N$VJZ$I L,@6.2%!5G6GA]@((Y,:+DL**Z3[MVS!B&
MUB"*9=X2E\CJQMVV0R/OY"1[BO%$&%Y^=H3'/@GP/J0WM@,0,2&KP"L_AK>#
MJC:.L6J5%B!C!EC7?07V/6RT]>39QF?W'K6M""4T,4+_S0$Y8AK'I_#O>K.*
MS$ODMLV2ZW,9>46H=DK*J2\UHPYL*]A[&V80AK,JCY+!GU].F#!0-OG/3B\
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MQI=,XXA(;[)Q2JD$J'7@@XEK(W"'NMW6:\:W,_?H>EQX)\,<928VPB+]HD;
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MV@NMH2XIX%F$$8T9L90O4N(\GE^K7=^^V4GR]? ^HF* B@%6%1167>=D7#@
M8<ZY,Q(3JR+'BAQ?41X30IL CR[ N$Z*%O5.'4#(ONH?D\ M6P2 -+&]4$!8
M5+1:T>KK!4.2EIPR'(*D1B#%V!I/*Q6423..EU;OW8/];7=GNY'2\)R)@45
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MN*L&\"KN/&9=#W%#A]JG.SP%_O$VSYT=2]5=B46G0OH$FX@S1>6XG ?F33O
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MO8W-7\2SM)UQR-ZO#O&:[7" I3QW/L(E8 5SJI>(I)X":JFJ23-5/!6@\3R
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M*CIS^[+9F?3=*CUW3=-S7RIA!0@^LFCB^%JNPH&=F3MIEFL4DL7X/ <VBP)
M_-*,+ZY466'5E4K)Q>&1T^( I?\M)JF@':;%51.TVY2>Y<] K- JU;2X^DED
M9)))A@BE8WN*=E? 11FK*K=S/"N"K&51CB\([8QF&;B4SQK+CCG\*S4ILKI<
MWZ(,6F&6YM:']>?I[130*;Q1.&,INU+OGV>5VF%RD"Z3RON"0Y7->P<$P"4
M9;3438(JI2)>?<^8$(0"8)G+V_NDBK'3U]W39Y$RW$=V($WUC.TK*KSXP<5?
MPD5@= AI39HV + 4-=%7G%-,)K!$DAN1F4/OUW9_YVWR<!-<;!T5I=S83"/.
M%O!IZ@#L<<I^E>D/(J96]'-L^T)M<!A9PF=^=+@GCD2DVS..+-B]*1F5=%#!
M/57R@:6!@IK<V@&!$I'_E@8G8,85;0,+W"DZ.02*$):]SY5X5,T<$'3>4U)P
MJ-:9=18(NII;IQ?U8>77$Z"V*FN5AATY[J,TQI,X#4>0O4 ]7)-D;N5!R2PL
M=+"#?#*6X$>TZR:V)[/<LUF*@2UJ_0F"EMQ2;/"9 (YDO<X<<,<382$)806N
M1.!8 M"8"J83>U]#NZ$I6MRIC!/H/>'_*K# 3*%OSF5(C5<VW74Z-BK:?N*I
M/M!& =_EE8)@%=H>BE@(('?'FR$?BNHX1!V%0+_07ZT:_A7B[*<@]AO;ULYV
MO;Y3'(<PMAVL55<M[F$VOH;J4K@70)H)S+L KF 6UJ>(F;+H<PDH&RK<5I&?
M9&M$$DV*77<81T?).S,M[8 T,20@]2Q#7C,M8Z,Y6?XB\L32_"2V5$T4%Y?(
M529\]:HIA'E5M#$(J(=5,TL]L (<[(Q'IXR&/-.N 8>EW%[I[)KZ&16K!R"G
M80+9.K5PP!3R1H$*I#6L:$,8W[C.0-&<*E)*O8&Z.7(J;6(-:>=J*L&@A?YT
M"J+.CI*\<H"X@@\(?YYCFNIT02:#_(WN*,.,D\S&$WB10 ,H" 'X 1L"2<MM
MD]1*&.TFJ1>9X&9I($=8V:(L<!V"9RJ\00@W3_K%IJ)HUWK@^R&,7C-F@=P3
M<3AF7O1*#'B$NF'6!$+Y%PP9#IV!['^)P2-ACO".D36'#@Q0C8?6C81"(S ?
MT@?4Z#:)^<FHNL)2*)B'[)WA$VH867U.1+APU#$D_6J)KL$@_!(%(8^RD3KB
MY'># DWLZ("_HC45(PJ)OG*K/_H?HFT*(7PP!E9)F%PJ+<1SV87?\ETUK5&F
M8UXJ+ KCFR;=CV1N!@K8!+,5G2[I>2?V&,EN-L<$"A*]%/F+J7": 2X0PM"H
MEE'!+)VD X,ZZ3X( Y@"P0-_HEZ6=[6<2-%UB=.5L^9W,EC/TR+KPFV1!:LA
M;&DX>E)QAV?JHJDN.]+/V*-N* I@5;JH67.+SREM*]_[[KV<8(%A(+'U)!J3
MQ-%S^-9" HMK'X.J=T)E.*V%<E6\@JD?0[XXDKM63I)BY7.LN&RE?!5'-2(9
M:6QRY2YM?('"29]![GJQ-&JQV?'G@RK^_![CSQGNFYEY%=-M#R*[TG[=X+TF
M6&H$NX]VCB5O:Q:];$.<+(K/V>K6+>D.IMF"G@B]C:DW/"S-\6(_#A$,6CW$
MD$ZDD*P S  T5#^!URC@VR*%KY!"$"AW&VF'@-D)6+  _V!(9G>ZGFV $&N%
M<B 5<E3A#[[Z?=%]97X+V=3?=F:M7(F_U*Q?Y1 ][H+&/3S%E]+9O!3#(R4E
MPEEK@,:153L8HTV7 06\U.=VB?P#8EU"V9GBITG B T+<8@W4U0+L@#&_U-K
MQVW4OK""H6P. BHZYK23EP.,,(CPKC_:166? 19QG;$324@R;3JR?[WP#77,
MP$)"*]6'9(?+E"*T/LE*$H#&S%P;K<+:M4J%K:D*6S+"T?[6X>G1U]ZI\:UW
M?7UT>?4F(=I[F.)08%SG_&B.9I;;CHD[/<%6G:)]&WHU,16@]GW?!2EW>GIA
MTGO_Z0<_D[]-,^H;K;<YD^[6X='_7!Q=7K_-:23W@DJMD2U_#=OM>R!'X2&0
MR78,[ID)ONY@C_IXCHPO]H#R>5B*->NFT:@U6B21X2]-UKC2W<2FOA0UP>MQ
M;.XIPU-#%3^^T&XUM;;%X,>(MAU?;-?'K$[C_UCCR6_&M0^*S>:3)ISDH3VQ
M:2/T2(M0!J*DF&"3G&!,0,*T7JE%'=GV2>0J%6X+ 6!J\TY?X+"=0*VC9/H]
MOLNX=;AM'\4-!)PR1=;M1VQ*&\HR5#$_BDGBJI.KKPU5,_5*S7Q(-=.H@3N%
M@)#&/\^_&_W>F7%\<O;%^'9^B?B7Q^>7H'W> E?O!W?US=R]:'8B<'M1I"L5
M8&2$:;UNG"[\T @U19:?Y\78NOO?L87-S5WN"""M4]&:C2YS'Y]2TD7A^^NF
MJW)$KX[ZG$T:H%CF_C*R90%^AWX@!K_0X7BP;T(G$LV,T3>DSS$3:$2X:Z$.
MI)Z9$2\PF4 R0[-DBH0)C+%%7'UZBNGI8V?EAX<]<+/V;OW[-XFPB1M\S,55
M\=(1)6&/##CEX)9<0BU_ 3=-;J>8?R148_2X![8+]R7OT:&+=HYXYS!GGZ-Z
M;?</U>7HOQ7%/&><_U;C] 6M+3Q*=_</.0:I(7G?)!)H&,V<Q^36K=@=2S4'
MT;VLU*5HO;EM4:)]O;T]W"EF*[QR1O\R3*(JF'V"(6"^F.-:Y(<<A1'5<8V1
M11D0KFC-H<<GY"0IMBX8'RA2P+'+X^4FDK94]!8'49#D8A(-:)1Z\@I2- /#
MB7/U'4\'N[F(;M)DM:A?<:Y:+H%+9R0R(G"3Q8Q"V:N& @CKD =_G;'&Y05J
M\:4F][;DJ9?E8!NRX3H35%I>8(ZB+WL5<[<'!:N9%D'>E# -G_(H=MVR.<AF
MSC?X#KT).<Z"? N3H6Q$_LT-F*(/>\8YB4+942%,-QO#GV/$1JD1Z=3H6=H!
M9Q7RZWD'R#"\<VZ<*)P5_]+?/8WNIN[-5:*!I"FNG::(A92<[XW(#\4(H)H)
MZ]@QD)XC6<62*/2<[AYJMY_B3,7%>IB>NDSJ%V,GD/9.Q$\!"_S3CS$Y%0L'
MZ"/M3@^Y-ID7=3'@#$ZZ%;4C6^#Q3_3K###J[7N+B"**U!OX$HLO_['*<?*4
M/%]"UDEA.E"1:JXJ6#M-3]0,X TNYD?&$ZR-JRY<YZ?-$>5_QQC,5AM'A3T6
M)>AZW"F<'\"<P:3B'EUUV+G)'6;*BB-(P$V%:,W!E<ZSQ!?Z(5,<V97[1*V#
MFM$+8!^!,'\ 1:U\ E<Q*KI&O;;Z5_] [1SY#YYI?.L9M49KO['Z2?2BR/MD
M?+$\QW:-4W]PA[WJ5CZ+[6;S8&>V-=;I=':;S49-FF0KG^<1^!3N)]75Y?^E
M#=^-CDTT2F(3[SXRH<<=\-;.M9X^@87EV3"(\_CISK:&=L!_=8:@5NBO\/T9
M*(, I"AFU_U]*PYW;RUK\NF"&M!&3Q<N:,R>-SP"[WF"6N-[:(/!=>J,;(X.
M\&#U9J>VW][O=+;(H(.#N<1)7_3"<Z_>^*M9_PMCB']]<SQG'(^_<;U@$%VB
MF]![=&!?+YK__-NOJ1F]>()?$AO@?'0-%ML1)N]0YZ$C#P<EU5ZPC/;!]&6<
MHM;$V[23,6IZ-K)X47&(LRN=W.>GZZ>)6/%=%$T^_?KKR IO]OS@]E>QLE_Q
M%?\[605._'Q$K^17++1-I^CWV.?<Y=.[I6$N;<]^L%P<N.@,]XL67_^K?H"+
MK\%)M?,G]6N:K!*/ZO!OKN/]_!0.[NRQ!>,9C_3O"';A[ULA]G\".N+/F,Y!
M%#WNXA;4&\WZWF,X!(ZAX?4Q?]4(FME<_E$0F#-8./Q6%)HS.#9GZ(]3=,[(
M!^/49UK(;FO62U,"S/@__X[]Z+>,'.,/==%GU'7QB'+**)"7]%EZ KF0GA0$
MC@=;;!<]_;RI@8T-J]L5:!@XE4?81)[H8_ZMUT?]Z_.SDSZVE;GL71Q]OS[I
M4[<:--42,9V<93;P6-]:P1YW-GJ/3\Z^'/T/MN[!MC_GIR?8O><+!FA[9_V3
MWJEQ=0T??#LZH^NHPCW/Z20C9;HO2H?Z$ NN15H/F@87J"\S,%D*J 0\MT#-
MF=XGN%E@OM G(HC;1UTNO]EUQF %L [%$@&2%Z3.TP0W!=9$G*08#]MR6I,0
M/I9_@Z4BALQA'KK%.&C_\AL9"[EO&C"!#%2+P4<A?Y#^DU!0=*B:N6??Q<GG
M@6VXWSW/O0P\1L[($(>5$,M>F\A% Z%Y^3#9P6!_T;+^^U9CJMPH>YDX+_[G
M+AMX1G![LUTS#?S?3O8121S:88MOZ.V?")]^F&&2!7EB,1ET :>69O-7V>@$
M5N=9!,7L\#***E"Y(DQB[)(YOV2-F[8"Z(VXY[O"\@=Q$8PM=Y5GW1-7Z<?J
M:EL+_5FB8B:YLO\G7=ESNKF\ZR_3!8O.^\4#++3PD@R% O4V)_67R9,9/#,W
MQ64$^CJ.5S'WPLR].ALOB0:,'$_F&6$=5I(B0\+ #U18FJ\*C3T.%*R,)?2P
ME\%QKW*EK^MF<KC*57/QN"G'KN")1??Y>+>QH-J<N=Z*KS:,KQI;AWW?(\.-
MKMX^6RYEA5S=V;:,NU7L-"<[M2MV^N#LU,RPTU4J*54$*&7F/]^_]_WQ)+#O
M,&1[;^/%'A;*;)_Z8;A3L=]"[->IV.^#LU]K*OO!5[35&&&[H$![0,]0YS%/
M_$V4#PG+$ES'$;;<JRS+!7EQO^+%#\Z+[>F\:(5WQK'K/X05:RW(6MV*M3XX
M:W6V#L_\B($N4SQ6%!NMN&LA[CI8"G=)>'Y]ODFZS&]CZU'2F[AFG'9?V7WQ
M=67W56XK%TH*F"U&GKFBE7#A\6Z]Z#XYMPWZ&@JRKHR2M"N#\ZZ2@T\2KU(W
MLE(F8>*5H=W8U=M-TY!_[,!71%H&T19&N]\L9003'/0@;I5#,H/0+H\NSB^O
MC?-C S,=+H[@C[-KX_+HZ\G5]='ET1?CXOOGTY.^T>OWS[^?79^<?36.3RZ_
MS9/L\#Q.+,IK?E-6%"!^!,^10;8R/ON(Z(#5O03EBHT;IM<"S[5ASZ?%>G>C
MB?%\XGBJL,<NOGE=&N$MD*>TDLU0"#OB'IJ+-#1DQ(%NB=V(.'I(<?19%>F(
M8!7?@.GL<-7)-@XNP%7Z_ :!IK(S;_FZJ 6AR:1FEJZ3]],AR4$J&.GZ(4.>
MJK#)1(5-0A4V"0O")D,.FW#)Y0!]O1'Z>N:4BGK)PW+2'EFXVYA$Q'! KBBM
M"1A=S&(80[%+107O<LL(XPZK''VF9]Z<PA+Y"2(C>Y$QLIP *U1%>8\JS9-U
M/MDA5(][454C#FT1K $!&QJ[?#!8/Y4Y'/PHV<NIX 020AE+];FS25*A+SJ:
M([;@K>W!&[#NCV&X$U2>[YZCG'::3X]R8"VCDIG3Q<1G*W3X;*3T_# 2\IHJ
MZ4JA)R0NKH_)Z8CJ]Y3A%G6;#W,"$YGK^\[C(/LKAQQ?^Q&9->0VIRD]E1VN
M<$8W%N%]L6 @F<XH[SA3JP1W0T?F4)6>%_RHY/A>\I-S$)LAX=RS7;*=8JH=
M8_NBWSO_O,-5J('6?8=!AW5(D"QZKRYC2MK ?]^[VC-&]A 9/(=3*P6.AAS,
M.*7X1:" 2HO0,O$)5?O<5W##:DA:U)Q28L--T1]8BND-XP'!FRHZ*CL1;$0V
M!$)0NRJVZIJ*II-ODR8<7%I,/:D(-IH;V?')X:N0%+CJ5P?SPUXK ;V:*UR3
MQL!3N%.B""A5A^<J'TF:"P]C*H\$+>P3'O4H@(EPA;*BQU!T24BH&0TG$R-I
ML)S IBIXZC(S%"VC<%4$@\.K$NJ/0.FQUA +-0+?-1#43EL!U_(3SDPO5)7:
MR3D0:&V6L<1VP;L$YKS%G?#PG?.^S[B)(UIC 1RM$$L,A9.53 K:T$/)52+]
M%EDV41G\%6T5W%4A$SW1L46\_F-PX[G.@ +E2-"6 "X?V,,XX+ IHF^%LA5)
M^#,L)7UY2D6,,X,M3)UILU.@'A:DUX8:.@5.14 X:0^KY=B/L)$(W&]2HP$C
MPD+F&[0X3,/&6FQD>L8UE#7\UCAI+X!H\&#3QQJ8=-&R6.F*K23$D60"]Y8;
M"TA=X?_DK<H8-2MY!LZM1\@2L(TP4V=,QB3U6KEYTK2\J>.Y9%Z!Q(\FN+#,
M4]"]Q9/_@=A;KF/?"PFJ"691L4Y5X GVJ;+8-!^A,G.G,UL?K8$![#QE8AK?
M&&S@0]FZU+.&]H"UE@!<($# &.%=(@FU04I(?BV1NQ5(AZC*V05!X?C#1 66
MJFMA%S 01/(J/\A:D*FO):X$#4]M(B)L$\EF&PRX71?@LNR B]Y,JN>3+COH
M>;$FEI@2,:'0ND#HVH88G+'0A;E$]JQ#_N<  7K!*"#9)B"NG'ON\,-P%X_&
MO^+AK>#QZSM]=4(DE)S'T+?9(K%<[KE&D" /V,HWX7>IH8O%?&3]M#WN)D-]
MIEBR"^L"AC91GFGS$;*K9$)$$[(=$N'6VF"\$)PO3R:4LRD9 $65IPO@_ GY
M"2[PDPBI;+!($_5%XBIVX2O4XN&<R +?IZ#09# (8J'!0.M,+&?(II@U()5M
M6P%L+#<@O(>CG @5!A_ 3L4C1&ZAKBX(D.@A'A.9=HW?C$L)\,*WMPWZ36<J
M\\QSZ;0:L;K2,RA4+X96ZOYQ-$TOE)S-T3FD'2"=*41CIL(#@8T^ K;4S9-U
M&35/(V;V>9Q@N(L>UU,!:_C!K>4Y_Q$1A&T9Q[X\#Y,@MJ?QU!PENM65]QM<
M>3>J*^_GHR0L@1)2N5%X9EM%1T-_&NL!%?&.V&&Z="P1>5^^G6NW4$?*!>8X
M$<M3<)MCNM.RJ#<O8NX1B!\AR=T[-@&0I;H!J#::Z3@P_ !]7&RRBJU<Q6/J
M=ISQW%"5Q*(_'/<6]JG/FP@Y@0\28AMK5V!$BH\+QDR:TH+>B;E-E0"2!',9
M(RJBW: 5!!@J%H;[46[9CD=8E!P/D]$*=!.X6QZ%[U"#,;:@U&)R^_:,"^N)
M326**Z1&&_AAE-E@?2RI!9.Q/D*8[ =L$HH0QB^44-T<GM0)-.)F6K<44)2M
M[VS5VSE]UB+(Q62+FI[HA^B?W:9"3T:&S?!5JJN+BXR&KY#N7N+5IH)&ZL)!
M=NX0H.73 DU%;53L6Q'YMKBF5+U7\T.=2* 5 RUAY,@>RA9IR,G4-H?Z#I=%
M&T5,2]Z!R="3C (G$U1!X-11%!_#!OMS*R'TW_T'EH^%OL0/(,N>0,Q5M][\
MQ(=Q+5285R=7F7_!\9_Y70:ET/+:4<EA#B*GL#5-E/FH03&.3@B;,YV!SHN=
M@<ZK. ,O1NM9'VP>.<<Y4_G%5!"\IRRU6SS2_*7(ELPF4\.NTTA@*75*AZH7
M( +)'\[,+I_VWC(SF7^S[/*#=2HV^&'3E9+@T:&-%SBL]\8"-#D)MO+E9,BW
MDYKU(+Y_5=F1!5!;2EI])58JL5*)E:6$D@BZ/+10B"C980UD5_*\=ZD9T@N$
M*),VR)0,D?@D*8/C4R5+/I LJ==F"Y-&)4PV2)@<"5]:)3 &_B3 7N9Z3M78
MCN[\(6>BI", X-8(*4+1LCG\['RXHS)'*A%2B9#-%2'7B8\C6ZEXG$H^1+\E
M!MM$Y:93EJA+!3Y#*[)8I(APT3S"0P;>1?<5+7M-===)S"'5RE[5YSSX 785
MC1YL.Y7<K@I"2L+].#7.:A6-9&X<U]7BYEK[8/7Z2JQ58JT2:YLKUBZ4PS/P
M@\"_\;D; H@>O#_!V@URMZ0$2>[Z5'T-=A/$Y#(L7+'M),M7^E7I>YZBY/7^
MY;FZ^C%%#AHWGZ+@KVC7GA%9LFI0RE,6BBR8A^*&"::E)&SRM0Q& 65@5G_J
MXI&FGEP^+EFZK?-URZK3YU3-E"B/^&8'MZ!L2M+@ZD0PS2H-KDJ#6S -;B[:
MH5*)?\2>S7JF4>/JVW227")M+/ =B5I)5O;^O#S_?'(NZK1E7H?X-,GLN":7
MDW_&20K( C:CD=/]=V"33,7\ VM"Q_T?U?HQ6RM&E7M?>[V+I'1,JR?.U%U8
M [H<#ZA&E^?U$?,8R!P7E2.)B6WE95'YZ2XK3T&[4.5;%4[Q*9NH.E!5HTFE
M2GHM$ICK7FBQ,S&=NO+Y#F,?*T*C:8D/*O>'40!X)Y(LATR!3M8"6&A]+UC;
M<JA\ 1V\4DU0)3.\-)F!4V^8EH00J#(2WIM36UT=OC.?]CD9"1FFUS2**5A>
MP/5H"0P%*7B%BDRI_S*-EFA;[0E4NNY"ZJQ"#GPG>>/'N\VJC&*Q"H)*BU5:
M[-UI,3MU;3V7T[39NJ:RB2MI4DF3Y=O$@0UF+-\MWRM +UV,E :',,/?=0T_
MCA0*$F(8P#<$KEH._2B^90A(GP+1H2F@P\(H< :1!(BL)$TE:2I)L\F21N2M
M $.#>1*+7)<\SK*\PAW;-EHAB$?U: ]B^AT'VU*!70P]B]L9%!L4:DL5N:8A
MNL NB@-;I,<$\8#^E1%O*J:G!Z@+W'J0:0,WI@K8%5T);_A%RZ_AK\87V_41
M+TBTA+#&D]^,:S\>P/Z?GEXL(Q*_;G[\9Q\4FF<:WX LK<%=',+/PX^P\&^8
M?9^Z.VU_A&5+N&],5N%R\2*_35Z=A0[>WL+>-&9<2U5QN#>+P[6J.-SSD3S>
MH&''YL&=5%U-RA*NC_K7YV<G?>/Z]Z/+WL71]^N3OFF<G/6S%I@ZQG3CF,8J
M&L<L<*&]AEO</S^[.C\]^=*[/OIB?.Z=]L[Z1\;5[T='UU<S<@"J+2W9TFU*
MI/#C$/P.<FBP10)'/R2RK_@75@;LS)-J(6;3>+'^YR'>/F3!<^:0!0O)]0EB
M% 4-NO5?4)^61";*6N'Q#_)_OG"(YS=>)//O97T7#7'>";WMM8GB%FSX-WV8
M[&!P1$!7WM^W.E-%>MG+Q)'S/W<U^PD\$_S?3O8125\:O8AO1/H6-<;)\-E+
M4[FFRK)<,YA<#.*5#N\C4]=T@^$=4Q>F-B^+H%YSF.JDL//3^K'^C(Z^QHTU
M^'D;^+$WU'>]46N91J/9A3_:[9T9$J(DR%XU_=6+'4(;._<N3AW/[-H[]](R
MMM.&CK>P6%OS]2PTWANU^Z[8?K8/S^X2W7Q%X:>*_RO^WR3^KXR#U4@); &J
M^JIBS=F]Y>)=^@KE17'7^_^:FG)!H?1RD[YXR+\YCY\\WSL.1.: 9XUAV#C<
MO;6LR2?<BIXWQ/\<)?O0B_I6$"!DQY^6&]M;E.H/$[FT1W_?NNB%YUZ]\5>S
M_A?Z2EM&[#G\#79G_.O[U9<M8V@/'#CA\.];NTUP3V"R\$[X&Z<G_'W+>8P^
M>?%X=^A'N^+9+8I8.X_WNXUZH][9.JRWZF:C>?"W7],+F-_,+]Z/Q<YI83GW
M7LZUN9QSW0>WK6ON=Y9YK)5YMJZ"]R*#%Z^E+@U2EMN;"^(Y$N"6P+5B?P3$
M/_#O.>X-^[+"M'T#6=S=.FR;G7KW74CBC3S8)0GC Q#&9KW>7KDL%B*$,A+>
MT'E9E #+LEQ*I;&(DW(JS.210Z29*.ML^?SR)*6/L\(E"Y5WL$/O?X55'/_]
M6(S7?H1]O"OC</+IC<W 1@U=\H[9;>]7AN#R#W$Y)E^COG78K)G=;JOROS^@
M-+T(_(F-+4<)G^K?L2,Z[WIV]$&%JMR1"]?R(O#+CN2FG-EO(6,;Y)&UZY6$
M7?F)+DG@-D'@FO#?392W'\[&/2;T2]M(E3D4;/]+H.J*QLO]@/ABUQ_MQJ&=
M*M-@"S@EL3^,K!:G<XKM(R]Q^//1]] FB^H-1'5KZ_"@_CYNIS;J.)<DI]O@
MW9BMYC)]F\HNGBV!SR>VP%Q?=QG\X<2O.IHU$< =M)4;S67>7KQW$?SL(UV2
M$,;L +.SF<D!'\Y8?IL0QA>)H>2/X"^JO^D'#5_(W>CC'BQ'!H^<1WNX^Q\[
M\-.\VF5XH7KCMQRWPN?U@]:2=O0]RN&YCW%)<O=@ZW!#I6XE3U\H3R\3O#G,
MAOV@<C39!<R8//.]P5M=LS5K6X?M;G7%MMJS7(Y<;=:7?9:5-;O9TI?2 #]V
M6H.6"?FF<K>Q=5AO=RJYN[J#7)+0Q1NW95Z@5BFMZY3L]_Y76*6T5C10^=*;
M8,UQLNJ:6',K+SEDU?\&EEL++;>&>5!['U=!:WAP2[+4VF"I'9C-@]5''C^B
MM=8$/3;T8P0K?*^J>BV6N-[VVEILT0=88A6E>S]VW:ECW3BN$SG8LZ>O=?2Y
M4!U]KJB3#Z;5T]_N?!?(4?7TP!SDZ,G8_F*/G($3[52X1!4NT2;A$E42Y)5P
MR=Q$DE3@9)40V"@A4!D;JT$NY4:D(1S$$R++?\! DMB!"]Z -ZMX;G:V#@_V
MW\>5X 8<XI*"3/M;AZU:E=OV045I$-M3X<8T@^S-!>T;(1+P)FD^[ML)W.[6
MX;[9;=?>A<C=H.-<DN@]V#KLFO76ZI,Q*FMW4T3T5>_XZ ,+X<@>/'["/5B5
M^"VIYFC5JFJ.MSK,Y0C?%B/]M-\ W;$R?=]>KB9UU"Z6=BH1^_3!!&QQI:MD
MT*<W,W5;A/33.'@?*2N;=J9+$KE-Q)!HMI8)E%S9NYLMER7"4"65LQ P:R"3
M6UN'K6X%Z;/Z\UR2/&[#>>Y7Z.8?)4G^_:]PO5,+UV&'WO\**_][$^R\-&[Y
MQPUP2LM@':Z76MA4K&YVZM7]TJH.<DF&'=WIF]UNY6EO@@0NC46:KP[R"*2P
M*X3N!Q6T)4&QMX16:'5![C:7B8#]WH7NBPYU23+X (.=G5;52&(](,LKT?HV
MT:VW%*SMVM9AL\(*>YLC78Y8;=>W#KM+S3FN8I;K%,UY_RNL8I85#51^]7N+
M;%8132T0]@:6'Z(5-LQZH[JM7OH)+LG0:VX=MIIFJ[;Z&&9EZU5ZOK+U*AK8
M8%NOLN)>"DCAC\=.A&TQN2H2U1_\SO8&H V-[3,_LHUZXV, U<PP$[2MZGG#
MOKY1BQM^CZ'SR7-<H,@@MM,&00LF\FQ3X.,B:"SG](J-OBFGUU[5Z57^\VM)
M7AW):Z*0O$)"\MJ^L@.4A*]]B]+;K9NBC>#K#]U8WM!-V?L0=,7KC][:D3/_
MK^G<?&V/)WY@!4^,J'9A!>?!561%]O!/RXWM"SNXNK,">ZI<_DL[=P7@1JAM
MW^SQC1W$(;Z*1D6QT7>M,#P?T0.]1R<L$ Q_3>S@+_'BQ"\\.3M6CF%M <>P
M,TNDO<(F--=]$_:W#FM[M5JMJ'8\\P%(M,"XQY7_9BRT<339L!='=WX ,F:X
M2JH)Z=WS[=1N: ]PMQ[ T@]M+[U1W06IA1=]$H;QAB[XX%D+/H^C, +A!?)H
M$U?=J>$%_&Q>R#,'S\"P%)6;AD.';_B!X2>[8EBAX8^,+_: ULGF7[,.6A]V
MY;>4S)_:6C?_Y;)8\K5EV")G-55X=;#TVNRT]LU.8?5)XE+E3V?:,32?)=]F
ML_KZ;F1CF;R^OLMN3J>?$A87;$T81_/Q-1"4=7L;V+>P0K"180N'%FTR6\,V
MYA7!;_]K.G\S/2]R3*?)JR[4FU9LKKP\@M]I8:J&V6KG[V#*-IW_@@OZ<-=E
M&1+H6T'P!.39&R-*7"^* N<FCA I[MH'@W;5^">==H5_LIY'O9S;MPXX6=V:
MV6EL9'/&=Q2#>2/4J3DPVBM\YBJZ7.$S5[(C*SN2G@\4*39G^&1I:W6AD-/R
M'(S]K<-ZS:S5Z/_E,0.,]2YI<3FU_FJ1DFYAI&0Q3[M%:Y=>DFG +R<V#'1O
MNT^SG/"B/9DCW+:T_9@9+WO>A)=V@/NUYTQXWOC>TF9=7^*LE[?7C6>&%5\Q
M",&\EN>S#YI6FB83NM!9J2>\WZP\X;<ZS.?[NF6'V5KA85;N[KJ:K)@# [0I
M[-495^S\,!'LLZ[7EWTUO-^>)^7G!2LHXL+774%G&9?;VJK7P\O8WU_@H%;F
M.TR?,B(5M,L]HU=Q*Q9W*7+[M&1_8OH>S70H<M-=A7$^=<Y=\"GJ+;/;[IC-
MPEXPN?N;F:[O,\YD>73;G>E]//=,ECAG+&$R6[5]<[_=K!R,E=FD&B4LT;N8
M>O+@8E1H,*LYP5=W*;KOPJ7X<+'RWG#HX!E9[JNG[TXL9PBK%AE- VOB1);[
MX<1JLL$7L!\G7I_WX0VD*_A'C>Z!V6POL^_2>Y>QSSC.Y60J=,%9;)L'^U4'
MPX\8N>D-!O$X=C%^(1L7^N-)8-_9L,_WMN%X\&_;V';],%QEL=Y:L6JR1^>X
M17U]ATYH@TYA>\[LZ'QT;3V^@43>WSJL<!JFC;N]LA->3$B','?X;(&CQ@#2
MJ^O=G<HD?I<2?<BI9N]6;L]@ZTL[LF!3AD=6X,'6A=K6B"2\UY/5BW,RXINV
MNF:[^^I@?#L?27:_[)"7+*X/:J"9:V:G]NHHMK-%=H7"4R&P5"@\%0U4*#P?
MUQAD+,6PH!K!%M4(PD3\J+Z]7JC!!1JK=]\/ZF@)ULS]I<(ROWM#<+&C7+;A
MU]@Z[+;,3G.IQGUE^*V32GS_*ZP,OXH&JNOS]V8>:E#;)FK,4LPR3',JMR7?
MW(+\KS?$=^YYP[4P);%#?+MA'M26V95X=:;D1AWI<N[G#UI;A\T#LWFP^@OZ
MCVA(-D'%#OT8Q=][M2+68HGK;4JNQ19]@"7F9!#\@< MJ=<-7-L*/L%"[GX;
M6X]R:K@@!0Z5-?+$3@W TK.#C&":;9;J>UEOE&SFF]EL=[9A#3!+Q_(0]0:.
M*,("D0 ^]@P'%GP;@%$WL8((,]:C.SNTC;[OD=] M\+<D\R!AQ2>5;AGI,XG
MNS*>;W=>L[=@;[017DX^RSON!5:TDM,^WFVG3Z9D&U(DBVY&=@WXF>9NW=A@
M?Z"[Y3Y83V'"2'?* GAPAM$=SKKVRV^&% =-G*WFD-7;3=.0?X#L8%8UB%<1
MBF3Z0:4W5;RPN]=VX)3TQ]%[4BL*>"96'/D9]XH^*O#XIE''Z[M\*2>S1K93
MV0%2IO2'W*0"=GI@$KL!:SO/!F\D:H_ZU^=G)WWC^O>CR][%T??KD[YIG)SU
M]XIX$J>(=OO(\;J=9J/;_@OM_:5O<6>CM[A_?G9U?GKRI7=]],6XNH;_?#LZ
MN[XRSH^-\PO8].L3>,#HG7TQ^N??+BZ/?C\ZNSKY\\@X/;^Z*CN$:L^G[_FV
MXX%9X,>AY0U#T[ ?!_8DXO(W"O%,[$#\"^P%:V?&-NNS:;S80. A7FPA@&V)
M9B2<N^M.K"%6\%'M(/Y;C$K_SI-*&('A).=,[Q-2E&UG_D1T;^VC(E16-7CN
MM^1>PYR,E/9<T!X1XX&:=:U)"!_+O[$;'J2< _&B_>XO6:]:?-/ZI31"(GZ0
M__.%0SP_+-Q]03J C$*(\T[H;:]-%+=@0&KZ,-G!X(B KKR_;W6FRORREXDC
MYW_J$>_$+4L_(NE+HQ?Q#;W]$U\3O,QO6TR6_1,L/^,([)YAODKV.>[M/.?X
MD0FM\5$)#8/GRR*HUQRF.BD=AWI]6+^Z>ER'J\=SL#(M;)4%]N?$]D([K/!P
M*SS<C<+#K63 "V7 I1V"T3BX(Z]S:-_;KC_!:/3'RR20.]'SAE^2?3ABR9BY
M<Z[5_ZIQ"L&UO^QT@O;68:MN-CNO7K[R,;()GG6L3>U8EY12T-DZ;';,@\XR
M\XTK VVSA?-7V[/Q(A%ELS4<.YX31FBQW=MO+I[?IE1 ; CP<B^U'6\OI1%M
MO6-V*CR6U9_N"H1U=^MPW^QTEPEH5J5_K5.&]?M?X7HG?ZW##KW_%58%I)M@
M!7*%@)\+UGU0&U!%+859$+ZAU7>P==CNFK7Z^\CT7_/S7+J=UZS5M@Y;+;/3
MZE:&W@=1@>]_A96A5]% %11\/^8@HB :H\ ?2Y/0]]ZO*3@#;T+9#@E Y.M;
M@XL"3S1K]669A1\*56Z!PWV^:;CXX3:692.N! &T$K\O39HAA&;&9#8-SXZJ
MG)DJ9V:C<F8J.VTU935WEG>+Z.W&R')$?S>L!KWJ'1_I>!\?S7:+[,'C)]Z<
M$^\8MH;ZVYR/KJR1K4$_K(,=U]PZ;)J=>E&/N,J,FQ'>>^$QKR#8U\+>9"#K
M-C$!IY+.K^%% [%BJSG+&RC)_'[%\10VQ<TX]T[$5@"/XD8L]UJEN/-8L]8N
M[SQ67:G,IUL7.LT5R-G.UN$2I&S5+^/]".,3+,.RPTBXU1],!,MXUXEW#WN
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M.Y9')/?VB3+:L=2.Y2'PL:9,.2BSW.9+FB4&#]X"5Y#.]DF3GBN*](Z!,QC
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M<8NV-5N5LWK/;&R^=-!!J8@=K7F]F#5O5\X:;;/5:NBP]Y$$! ]_ACKLK7E
MQSB.VPIE\$MY[,]_'(P94E!X OO.-VMFMWX8MN?AK'=!KD9W"ZZ&-CNE0FZ
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M6F*]_Y@*PP3/C47'LS!>1O"++-@[7A2"B>-BBS_A$\%5.6Q8Z_P6(,DP0R!
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M<.%?;(8F8H#QI[')/1]'.7]%G))+!CH8C8@WBF/P%(Y@/-;@/9)390T&#EX
M XM+QYX:8#4.(J"+C3[]@ YF$W\M@J'X*0S4"UA?\#(Z&TU!A)2G@ZH'<6"/
MY@!4; C", S40 JP G,#/"K<M)L_]=F)Q'\)AYVZ((JO@.H\C,1/+(AZGD_'
M(CXLVMA4PNK *1BUCBTT.F$!RUS,)Y\>$UX4 M9:(8VP]$SX#NXA,U\N+Z8
M^Q8P&JQ&Y#-3A,LE>92U3PZWX7'6HS.FTK]'%UE0-GA\,*!NJ]\O;KZR!09;
MI_7+?+H;YJAFWI+<TCT%)4BU(9K=NC#;#+@T1!,9!4RR:V"O*5Q/S((^!7AW
MC[ I/3IE\&DEZ41/W$CK/>0ANX4[**GTS'?B(^)!;#R$&4:(PXAC(R9_=L)F
MB?1!3Y.#2S#G:HS:+\*\*R =$&06/YB+C>11+L:W2%@$<DP$M,'#0RYADN.@
M><FD[BV$!,;/Y%^BAR8?+@>0[#N8V;.#Z76GQL4S ]T]E%?GR1<"%B9D 7$3
MX@)%4E$AW- U\2'H@*5!6?1NCFL)TQL:3VK!N#*&X%[';P_ 40K26$J/P$%<
MF2"$P7UV?,^5 %*09 X((>[$H+I)] RN-<)]0HNC'7$M6>CP-:.7@A<U 9$8
M$=?2]7F(5E46:##D4BOFFP.">X#1<23F.1?.QAT+O,BW2V7-W#LH+_"?*8?L
MJ4P[LJ@B$=57P5- ^ .U [C3@3AV=3&F1&I$5IP(.$]Y<?:#T#=3AEL0=L](
MWD\:D'L6TD 28@I?&^*/?-^N(K5(!8NGT:/%=0(#F;5%TEM+[DN<3RB']W9@
M[)J%5R[L#?8-[MA(.GDJKK5VQ<].$QL:GLZ' U,!+B+5)F:V5HKU!V?6JIPU
MZZ?=-V8V)/G/C!FP2V"@O3LPOH+NP/B5""[71' 9B8#C-I&[D#<%> 6^'ED#
MBIC:=C0AK/V CL9LCJ!Y@W)WC"NW"\MW8:\$_>0I7_E#/M1UZH-D1/10L_M6
M"%0 =O,IE]XY*"%$Y4@.-U;V/1A,(') 6L4U)@EF:HE*9HX()6</,Q?B@O)^
M]";P&#0!*.?;%!7HI:,BC\:N7..2/?IXQH!S:*6E7  *1(DDXBQ2443NK%A&
M@ *02YLXAF[%)QF.@BI$/GSR8>O@""EVOH1S>)E"<=V=@%HDP=PXY)C=AG6Q
M#5L/'OQ=[]+?;_%/^UV!<P0Z=.>+PJ>81J !,?;]R/& U[ D1JUM&KO5Q1B0
M!V,5UPAMO'1_^GEN!KWAA2QE,:%<0&.4\X8*!I;ZG%2<,!)!]SS*!"D8B>N2
M8R^4F3CCSU5G*(IL/W+H(M#IUE."M2=CC*PS&-1PR)TXWW("X:WAY(_.4>L'
MF;R'Q>H_=MYBSXHR/>,,H'D+@:S[XJ(2(-?BB,$ZX8.ET8.K$)8'9"&Z'Z"_
M1@ZC-WE#8 ]RYV>F0*^-D3OYGZ$SQJD./'7.L6$&+Y+A'F0WEA-TP-^&D9N5
M_]FMQ5M4\LEF>UF^K5=%;[],1[]^>&[Y/A;]^,,:1WD'M^]4K2N+QBXU=#R=
M+P.SCD;]GFSV1S;&51/9?F%.*$*Z]8NIF7CP0[0X&#_&BI>(A!*!16-538?$
M(=5^#F&?&Z#\PE' ATGF/ XD5MBX/Y)**K9:2241CL&B2BJYAQ*+4=C)INO'
M212W\#Z85X!A]B_CU<OMKYUAW50SK.O59C$9UH7YO%N1PO53X_[']^_]N__#
M%.O[J]^OKRZOSOO7#T;__/SFQ_7#U?7OQNW-MZOSJXM[HW_]U?C2O[^ZQXMO
M[R[N+ZX?^@]7-]?KIME_09#4S3##%#/^[\<80UWR;B%+?ABIX;0$* AN40>Z
M(3__*D]LHR3EJ-X4D#PE^9$Q%\V"J>5S^QGN0S7DA +?ADELIT8?E"GY1(P'
M;H04YC6O$'6/Z1<VU8M^BAR>5 >K-&$"S4#WXA_X.#+:AQYI!AZ!2?83IM.Y
M \L'Y^7<&Y ,IO6-,R_OSQ/\%3P@]\X?4W[TD]ST([Y)P#&2XENY3_CBP7_B
M^R_[]U^2K,.E!_K+A$=2_0MFM&&146OMF9;8JLRX39(W><NA9!VTY!BM8$W)
M$O%J7FF<H"VM;4N8>G&6+\7N^^,Q+_\I<UL?K3'*!Q$P29+!58G$\"C:M<)8
M)B4+]L8&U*"HDO!5&A15JQ:.BFJN@1EJ[B$JJKD6*JJI45&KD'0=*%WS9V.K
M&*HE)0SGR%VJHH;K+T-CK65H+DBBIJ#V7+YTWQU(H"WA;#=L>36K&EBW&%@G
M$L)Y/T=:#E+[:>1SB6RPHZU/,8]'7S$'*56L $]?DIV7U+"@!]:R6ZT->TNF
M;,1_OU5RXEU)*]WJ@HH3Y2X5D11=4 3[41596,>__A&PF^%%$,+JARMWSULL
MUXL)PAV(1_V#YRC&U"Z1"-^=&\WC:'$)JU6\ZMQXFSS\"]0#6=AT$^LOV*4Q
MR:E2(]9X$!N)@Q"%!!M)9"W6@U+0NT' 0G[KV(G1MF:VDP_98D]T#IQ[@TQR
M4@YEWIZN&4,D\D8F>\L9 \H\4ZZCPE>4A1:<&LK1C $2=)+"PA/0:S&!DB"&
M1S7!.,Q&"/MG:QS%2T="Z(0K1^L%0X*DNKT)W&R](L$(.&8Y/MT'A&"8P(\A
M"Z5D:8(+D5C-): RVX] OZG'<K'&5F8$ZQ.K[)&#6<5T?HO$\QT*SN*3GRT?
MJ^\9'I:RG.<11SGQLPB@:P6>2]%;#CNAY71\.YJ@@+<QC'-.JH%8-CT<,#X\
M?Y 48^(K91 P%?/EX;L9O(YH1\7G3HT^Q^@",:(QX5ZB,5##&6*,6!S\X0+%
M[_E S/42/'/@F',ZO@2K7PDW@5] 'T6BP8;=@I8.R"Y1'V)9#+DN)5(?*,B5
M0VJ43&3S#W//Q:D.HR.VP@3V482&3A1("6;+"8K[.3QM9L!^<+T)L*N*J%;W
M3*I6H@1ARP.)8>3:$@XA7I"<3_3S)38,8"BHK@9HL4!C@!C8N2?B 0X.!':#
M^BU.-!3[1GHC/T[O3XV!-QXC I)/?N,),"163I@[$&:P:JVBB+B0^B,S0*&I
M++!'L6IRZC:29EQA"JU#:SUTT,/@> 15'2'"4YC*=%.*J#&!PD2HI I)X;CB
M3JM4G=*6%6O(?E>0GUQNX\\^&PGLCE _GQ H_%D*VU1#F2\\L&[<CQA3 1!K
MB,M[]H2#O9-ZMY#C[78QJ8@'(AK%$AA720_%$DG'I%ALP,<I^!I?"V89Y^R8
MK[G)B6DC0# 0?8CD>@2W48BY@)O+O$HYN)I,,1N5%I)TDFP-< ];SIC,%(0.
ML<1B>YQQ83MRV% *;Q@B1@(P^D"&LQ]+S_.;K]^3RNKTJWHU>KU/8/()U"2!
M+='?]<11M+ J61 (PY0&"ALOA3V+-02^#6= "%\:('ME=D3Y"QY"I7AI(8SB
M/#OL)5A  RH>E#*Q><$>B3X7E6&1X&(^\W1 "SP>>/(:90I\<F*NROSG<'58
M75W:Y[0B@AWH =QK";+0[!6G$/LI<P06#U\T.W .&"L- 'A^&Z>B. 1^2U"-
MZE(G[)=G<4A"*W>\2]3G8QOOXD!,_N]<%7Q4 W2*B9D?B 9 DIL&-=!4*&^*
M6N=QH(PN*(]FV'G:+(D6AVI'8G1R!.L[GH$)C$EQH@:7*(K#JZD;X#O#--#0
MP^8YHN]"./)!B' H*F9V<LPRMR'!'24!&R=B(.J>S4%AT01?#+Q5DH#F,+0T
M SH$D.V4/<R^!:E($&D8]J/E_H7I N@\Q/B(E/G-R\3+V9)^ U$]PT7[BX4$
MR%V247G0T/T4LV I(;18.+<0L;DK% 6$79/%$!XYQA\/#$1B\;,P$ZQTZ59X
MPJFZ/SE4&HV>P(CAS"*R1TLC]9X<$D7XP)_"0!%?_)4 ZGGX\]K/6@^%<+40
M_'FWAJ<I*^1SV<B3(5;5SRL\:HGU(V8'MYD2FZF\55)93S0%8,:(68-_1Y8?
M,L'C8 @:Y%(2@%Q-BB)K4[JF'J8$/2O[L-:C?5A-6S24P>!1' XW/(<WTEX1
MR0K\F(A:+[Q.'3\5Y^,#P  @OFZIUOV&EU[$3_@*4YL[%EN@3=750?/IA(04
M/OYD8,U.T#D%]SB]4.!IB3)WAI _[:R1,&_9Q5N#!VLQ=LF!F"3\A#A2%]?Y
M6QHKV04-Y(J2ORMRV6:Q2)O?0=*Q=>-"BSP"C?>J)%_)\7T/0A.1$7QML"C,
M.<T"_RH([-^MIPVCGC:,EAA&ZO)P*"<7&[A ZS<  BG"1<+-<'@B>(A_08PD
M#'7^[",WLRX5GQ2+NHC2Z'B8$*>S@;$%HA$U:$:IV7/+)J0]EBZ2-H^2N"MM
MG[PTHU.#UR/$4X_Q+)U2*Y5GD,@HWN:%WI8ZE,)9.&$DCX5T7;U]@)#6UH&0
M+D7(K0PJ[:Z!#^S&I?;6!+^M!UQM[2%PM;76#-L[!:[N+92UO1:1.^N_0S#X
M(E&PW[(&&_(&I)R2:D]<4=")'GF#F2AHHF70&EZ8& OJ98'BF3N,IP0(BT(7
M4D?*EI"\1L@SY5PIQ_T#JCHEB\>X' $1)V@0RL"#7_ F\191/XJK:H[E<K$V
M7A2@>ZMJYD<V\V3Q/;+O4K^"6>[9#MG?Y*XEF>$4I.#18W&V/G*F'TO(O17E
MO+#['P%Z@;X$G-CLT51C[Y)MMYQ&)8JJ$817+D&)C./4 %D\0*J@%LK38-L+
M0A'62Q7;P>((CHBG?U4^43D\:VR+"Y.S?3"$+5RK$R2/,6'AR!L8*#QXF$"@
M5_ .-HS&U-$UAA.04VLJ/0=58IV LWOBO)Z,G $0[%?^'RZ$.^WV_+I0S%*X
M*TF![S5WT@\:Y3<8Y-*"!C^_6Z_.))KP^MR!'][A:3HOQJU$*' *OPXB_\7S
M!T$V*@&;;(C'7U0Q:3X>03$2A!7+_KC).:,UP7/IOYE"YV"$4#)?!@8X7DV<
MEH@*8-DU\.?0O<LHWNK-4]QGZ&Q06;(X]B-KN^P<-8RQ$2J\"<P+>PY;*C_Y
MP.\9%#$UJ@IB"%Y<<@W#DM/\C80_47C4%<',!6@V*D D:GW$2FO&0I%N/+9L
M'K@.F/_LR%-'GU\6;T1<9#]9<8'P /T3(3(2AS*Q_H1_?=A#+]981+Y5CB']
M2M5/N!;+;,287>C=<=EZ'JW"1C:IBW+>CW!/1X0CR?ED+C^F])F$,]*S)&F/
MKE8.95/X+)01;Z 95N(R16PW"!5(*MY,%@E!!B1.5&!X%@AJ 4"<4,7-.,:>
M,G\LREQ'H"'NUB>,K>.I#I;)<JC)F/?D<O9Z=]3P:H)L@!.\\;_2+*SQS?";
MYSY]PZI:'(^U84.EUM:&RF)#)5D1RLR!E3BAI9#8N/)8++L_"!,P&@'7&".M
MQD0KOB]EVZO<,%V^FC!).#K)&F"%6JH.Q9XY*,@7-6,Y EX%&F-]<G[4$)<B
MLD6Q):&I")X=21,JB$]N'CD4&6%^5%KW(?]6:VZ** ?P <K=6$W70=7!R^AQ
M..9$JH/(1;R2:#6ME""-C0U*R4*1D\@DU)I$)*0 .EI<W#GJF890,U?#1=-.
M%-;\D!$>D**Y*,>42#BNIB1$5?:(Y@]_G"G(TZ5OEC2AHG0Q_OWTC4PQVG?)
MKCP?P5Y8.45G^0EF(S[!;,Q;H&XTR;5 6W$&Z48&O%91TG<-&,3]M3=WX#K?
MFT;E +0\$EQ>!L>Z8J72CT#O82!4(.T[Y[G$7=^P+JP7DY9](+H0E\&@=3"4
MA= Z4-6!'&W(@FQ6#\*[<T^^A/2,P>2B_R]E6U(V"Y>\O(&M;(9&\A.=*\OA
M64<(%!]2E5<)U)\9GZA1O!/R1\9 [RFO8,.KS4_0<K8&SQ8U@L=$'PGN$:YM
M_*KDN;Q^.V;J^..96G8%AAJ^H%LFGA%W\"1-S=\^21B'4KX(X81*V%2IY> 9
M/W^*2)U2[R/B@+,NJ",3IC@*E"<TS24JY0V)TU=XH4@DGD"=,V<:I:6 3"5
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M=@!56@-DT^V^$ZI46Z]K="W;-GH?P$JU]=HXUQH:KO0N,J_7IKG6? =XI7O
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M@.VXYA4FR\YW^@JES<J^W3E!^96"\"(&#=??(-'Y;SN0 O7*6:/6VT<1H$V
M[3@^LM;!U)HAOQ^L//BT=8&@_B"H?,N)O -!T*B<U<Q>M[MI4?!9FP/[L<M]
M/#]>8@XH88MCDP&$H-ND .AC4STFC8! 6@'S<F$'@J!9.6N9S6IK^X) \"_P
MY_+]_-&(R48YM+(0<KM0%(CH$P]T3E\-"MB3\5(U#?S?YU6$P\?QW,<S0VV0
M'HZJPJQ[&4T7,G;G^FA?HE&_B^/%7*4$A-V!NFE5SCI=L]9J;]T'/49UTP!A
M// B/+<Y5'U3BBG.<5]<=7U)SE<IJ["G<&PN.0,#-9V6]T?'<]%_+!=9_;A
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MV?*4Z34LGQF.:X^C 1O 'X:-->0M=\#_4(K)&V!FAR-FG'N3J>7.R"7N_!;
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MI_-+%M4BA6;OEX5P)W%'^M_W@]J['ZBY(3$\8K$29CEM$;NL"0U;_ICLPX#
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MAI1R%Z6I)!-9$L/J_9X@TP<L^'Q=#DLB.Z6IYW?ZBN9->2"C((J8TZP0/YS
M"N&9_+PGW7\Q8\B*22,7B)V+0\I!HTM(!0<.!T<]6ZW5WI RSRU<GQP<TX!K
MYA1A"]"4)YL(["QZ3YRZR,T\_^W/FZC&J0C6;KHQ?\2KE>.__<*A/6"V/<7"
M4>>1'![XMW@J=X4LR#:PZ+QHS?0^(:IX=S7^C<C.O485)^J[9DU CT-> &O2
MA##LU+:G:/$XT)]L<^K#U_(3[];HI;K'B?<TX#USS1?%+\V?EC;8%#<L_GL6
MC]B]96_[%0,L9,M,070QT5<:1/9;ME9=_9CYAP&A '$[/)5YN66X[&6"\/B?
MR6[$<?? ]"52^4]0K?A%R$5JX?RZ]H+;">AOTO'P2]][U^5.')]_QKXAGCV#
M=_*_$U7)X@LN]G9IUJC0?1QT_XM^9,.K%-((FP=;0P_@"[SBB"NX$8'%(RZ!
M:C?4R5$GY[1.SAV;F):#$N!X:[B.%? CK@(#9_R5;_Z-P:.=!K:KPWR<P]R3
MF4Y')*#/0,6H* ^.N ;J-)$7X19^!(B:F[<ZM66AN5Y&1+Q^H5/QLKV!/<]#
MIS(FD7Z8+=2U]3!A6QA-">!R$VQ5ODLMF7$A)T)3YD7T;9R$<>A,%P,S=JO5
M6KG>7NP(=[K36/YQPA0E=56A+TISAVR.@]/9?LO']7JI:U1T_8PH+6<&MB2N
M@=CHKZ>V_M;4%ID("3T=E>7:LD"(D0B$&/NAP/F>=</00Z=_FI(:6.-:6TR
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M>E;Z6/$FSN2KGM6Q-,UH5FIJYN )/$]!255C%&J:ROGO4/&QPIR7HN]*0>E
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M.JS6GE4TFC.3.A.IP3'"A3?<Z;!JSZ:_$:Y?;9!*7$<XW=2\7&U@-"),-+?
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M$)1L/PD2V<HVWY%$.CF32$[]/?;$PO7V$AZ^;4KP8NT/STT6O'YKY3#[<58
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M!]DLL_V JN*J3*<V=MYIE@VCI09AG@A][6GJ3VXR:Z=N1FVLO*A7FHO5<*=
MAN<T>NQ<#FM>NK7RHYVE;@2,:L2L<]:.WAQ+?'V2H#U-#:E9ZK;B+E+[DDMO
ME7ZT;P(+ =WGJ1RU2EVC7FED]7I4RE'!GG<2)_6PRM$ESBF'W?) ^MF.*2_"
M#A4'*\QY*?JN%)3V_CP5 "BJD;N8+))=U76VQN[1PX?KTT6*8^&V2]U:H]S4
M3]/Y>CDAZ5?EBA3.J.V0QS^C-\OI$EW.W&S/G:0%>25DQ1R!1>GEB1QO3+2N
MY>5$V:3S= =;PE8ZBXVG3Y5HSI%3;9X\DR-;VDD8=K"-;EEO+\ZN5UZ2_?L0
MC.F+-G1#K'4_5S=)(;:H_"2%.3%%WY6"TNGX253*P$&\*;\+K8:ZV+!HZ)9+
MW8:4?T7Y5]:HE#7E7]F=I@(V>-F)H-;2DCS6/6<8#5!R_X"OSLK/TC&4GZ40
M?I8_LHEM>_?+AN/S<G*_U)7[Y4C"<6,ZBNKI#^R&2?*JJW@JBK$%LVHH[XOR
MOIS;%I7WI3 GINB[4E#*Q_OR2[+7=K*O["NZ;>^S272J]VR2FQW+Y]%;X=4H
M4\O@P U,&Y0 CPW<1P?>) HJKG@/Z$%"N2&GB>,SU -XGV;L)OR/U7K2C6@Y
M?<^\)VO LM6FR!] NHG_@&M*_G[M^L$W-_@W TU%+I/T&Z%,'58G:D0Z47,+
MG:B)&O=B[C?'"9""#7^54>\9C+$%=])!U0>Q%Z/'A>.DF=JS,#,TD]L9V #/
M<N'GD> 2JZR@W+#"2T,^N9[X"J\[KJ6#6??Q>+ZH2S5>Z%?2S:I5#_[U/?B!
M "9PR'DK_DMOPO\%[+/!3'N D^HZ<,ADR_U$I_8!AQ<O4H.S/'*I'3XV6Y?-
M^,DA#2?$#^T 2X1Y\_QIZ W&<"1EIWW>77_9DX%CX,_P*W >_'6$[3%%@W\G
M;LS/6_7C"^>>%CW&#_O_$4WHGTPXS"%OQX\YB+[HN0\KC)SI*Q:4>)+'HNV0
M+>YK8V8/M?XLV>A>,P/ZTX5++ >D$@X',)V!!('%]\&>@)16 6,,)P@@+/KF
M:S[G<7-=]0EBS)O B_!^9J%;$>=;ATX V[9GL QX8^*+RI:=[=?UK#]KQ0,I
MF \9H-D$U ??#R>P0GBFOY1J3#D/89NA!C^OYN)J+$#V6(!F^S!C 5I+QP+H
M#=5.7_45W:SA.8>+5&Y%UW/59%-%^E=%^A?T&YIPY*O.FX4,]2]T8#MXB+\-
M-GJ[W&FV#QZX4.56QV<;-Z8':C][8=[ \LGB<CD-*Z:P4XCSAD,2E=T=\GP.
M?O@[I6ZSW&YT3O'L*\7B(!R"!^W/EAT<K;?0'Z+<Y!6-A0[,+EK5*J4#MFM[
M;[GX=BW#N,0LAR+TJ3C_'2I%]13$T(;VK4IF+YJ%>Q"IE=U4O%4]Y$P));<*
ME;IV 5M<H+X\<H7F PJO"B>U]Q)-6A"4<X&!5P05M]C10<0>,GCV,K##(>M^
MNJKQG [YQ5PNP@+.7Q.Z-7ZTMAA.;OQHI]>Z['"17C$/7S9):4Y]!JP=-2?[
MV9SY,5$FMYZQV^UWN,WX=>-'9VZ'XXC1R_A1M?K3>TV>?0,1F_!+Z VCK,E_
M@%'P4ZC1,:1<O]6[6TWR:?(4ZVE7&A;0>_)R5.XB^'M\H3R<FM+^Z*O2+B#M
M; 52O9I?>L"*D[S)>:%_:8#>R<#^2- \6JZ%S :\DMF B6R?1"J03/Q92!X4
MF4(\R6A-:@^F?\K$#']E9@:]#R,[\$*/:=8$<Y,\R[15XMUFB7=D)%R13:(E
M[1;M1J3B+LW 6UD#)_*X;D<;Y8'V;-L=T*?;T7RF)^: ^G@4/\ U?V[DN2MI
M# R7*1Y*#\N9I(T"A&/4\CNU1<L=S,J0LL!T%VE2,SR,:S.Q^S-M%#K<WDVD
M"+^A5#DW].'\^6]5?M1.^5&MYH'RHZK+\J,Z6Z9'[>$1EYQAU;S4#"N<M<VA
M<H/"G']<D.C%R[8Z?9*[V*0^X7&D_S3>HUH@/D:NR'R(3>'R +@T#H-+E4UQ
MVF&L7YD#QJ=-1J(YG%B.!?8FZ+=/[.@QJH.WDQ V%AMFFV#"W-LL,T+ M><,
M>RFHBH<D8TZ?'3 KV'T ;\;8UA=AY^75&:)5-4K=6MFHYIEDI6AE):T8"5HQ
M"DTK]5*W5=W[R"Z5X7 "HN&.^6"3#,8D&X;LB=GN%(GNZ(+A.,D+^Y0.$K1P
MY#_&@"W">1==@\ZIO]XIDDM:0!277)JE;EUOJA93%Y*:>/X[/ BC.@,XG?\.
ME9=C9U76*)HJ2VUSED;RCJ[0GICU.A=)SD.OP(9!Y7KG-,?TG@624QIH/DAN
MDZU1RQ/)2GTL5(+P!6SQ%!3(0@#J K:X.A\^V?/[==GP*E5/7/[5'5HCBSL]
M,'?K&FC+M&2G/%$K5*".>9\=[;?0GFEQ*U#9&8TBUJ"G6D[@8CX:FYH>WY;Y
MZ#'R[FC/5C!.WB2:K?G:]=AB(]@NPUN<1^UV!$!AGO8&+\:K:M7WGP A\-7-
M"QN$&&R@K_7W;RM:SP=[Q0MD(JILT"9 RCOFX?OY@N>? ZNR;>KWQK $SH0%
M#Y\L']-5T[W?@C&8/8]C[2MZME(IJPWMC5CD-6_(AWO@J8YRE=A/#Q_M:PYC
MF/L*6KWE5[3OH8?MZ@+YLBRXE;6!((M)@EQ\>4L68 BJB<DUJ03K#!UD6S('
M5G#UE*AK%TF^O/6%+"BD]%U&RR+"P-1\A$R4WQ[U"(R[9B1[N"T ,\I$!EH'
M55 @&+^8NGYPE41\U) C:G : 3%CJ;QYHNCYY^,]J!/" E>N9N@"^ +MKQ#.
M]FB&N/7#/C;B)[**GD:M&[7>_;76TL% /B[#22K4HK"/\YKK)?;E>]R\1P4E
M_/QD8@]^ %@+O'MLZL&?3H")J4F2E10;]6JD&RK:QRWZ]J6Y#J:O>L.HDC4S
MW166MV&[X0_,82,K\'O.$A-D+P;F+IV 6]5.J5NMU%=W HZ2["=S8H4X2X+L
M??GE/._ @X#YQ!,W!)X$G_BII>.K/2Y-O9"P]F7;4&Q,BNXPDU<9"_<^/^?,
M$_R+=S"= +&,\33#8VS73[37S2I06MZ<V/1P7HH/9Y-P][KT\N4E.+)<I%5+
M)J'K]?;>7$6'47,.XL;J5+1O-P_:E]O[>^W[S9UV_\_>W4V6.K-AX<$<CN%\
M6@.,,5DVBI@'5%7W55:@-RZ\K,!GP+^!H0B5#0]J&$0<!=67 0^T<^"#7A/0
M^47IJ5'E>;JBH Q,8L"F@?@-;XVO!$9AJI*#8I<<-)O+2@[:KR\YV/81EYS_
M?=$E!]I-MG)8O'SATR>TBTU.W[7EC<+7T?!E%(\!7&0HO7!9H614F & ]X!A
M\ST'X(K^/ 4EE19>7 8@#--SS)I9TWP5MLXS;+_ _GM/IF63B\3E\YCN$W-O
MA ME_QDT/NP"OMO<TTE-6/:T*W(0%6%/>JG;:)4[F6GJ^36"502^,8'OGCVT
M/3'4#D3@A]P33IJOE=NUK.G-JM/QA:2/7, 65;:4H@65<']^1L)'YKB4/*+\
M!(43C47?E?(3G 4+^-=\-TS9OY*ZJ&MN&&!N%[J+RXOA[Z,[%PY;-!RPP<O/
M$F ]#B]AG2"T;F-8O<:QL*>I*WK]]=O8W9.PKTTT2MUVN=ZIEN%S[D;6Q52_
M[XV05QK;^Z*!9LZ$?)!-M+"*JM9LEQMZ_NXPY2PHJO5T 5M4S@)%"\I9<'Z6
MPK>%5-<B6@2'C\;,YV>_,JCX \#[@QZ45#IJ2:5C^T!%>UWP)3/)O%!;P)FS
ME?9A(RV*>+<,KN6!^=K:T/A6Q'N4+>BEKF%46EDMN%2<\$)TH0O8HE+]%2T<
MNJN"FC%8C!F#QIH9@TF,;S5A,%E[NNF0N%;MAWYJDP5IS=OLL*8F"ZX':9QV
MMJ[.M@?/)2O6>F+W;!!Z5F Q_X9#8/C)<R?7<37H8EGNODIP#8QY7-(\OK@$
M-Q%LC.*/(VWJ!K!UR[3MF2;QH_D1@F3##5&Q/P(\997NKBC8E?T#>-,,^(7W
M<<!V)6Q@ACY+=/& ZR;:LQO:0VULPCKZC&&+DYAR5#EOH<MYET\0,UY?SKOM
M(RZYRE*5\ZIR7E4>JLIY%;Y4.:^*O:VCI&O7(:BAJ@;JZ8AY7M3^ZXWIH\6!
MO\-W@9N:0/WVZ &Y(\WU>)TQUZ-68)M.B1DR-D$M.H&E[Q))5+>4'/[QRI5]
MF&4_(&MXR!:Y2R/KA0VO_LL\-QVX,&AF(3;,RVC")D86JIR[PE#F_$":,Z#,
ME7&U.C:@;]9;Y69KL4M@WDET*GW]^()1-@L&L3<-O<'8]%E*_BGQE[?XDVU$
MB9UP=)PX4Z'A:LU:L]RNG]-DBS.DQ+2X.S]*;"(E5JNU<L,XR>&>RCH\B!#\
MW1%-SX'H L\:!)%MB&09M1Q60O& -J%$Q#EHV:U2M]8H-S,+5Y0T+ P)+DPC
M/2,2Q"%4[7*GV3Y%,:@$W"L%W'WOTXVO')U'%FKW%BC8K"<'M'QRO4]A$'KL
MYJ_0"F;%9S#+?)P=Y>,\):),B[E3)\I54L^HHOW7T#MEPU#C%R]EHO'Y[_ 4
MR@2* *?SWZ'R0IV/DD[3NY46GK,6GI>JH5/0HU$KUQM9-;9*_RT,.1RB78U1
M*W6;9;W=+C>JAW>Y7*+F68B:O0O8XBGHGH4 U 5L<?,2U97E;QL4K:ZJ0(L&
M0']AIL_\V]$7YONN]]'R![;KA_D/]6RWDO5G]7I+#?5<?*M>K6A?;GKW-_=9
MDSQS*M=;.9+\F_M$WBT-L Z'YPM[- <S[0%PZSI 9-$(:E,;P19M7BQG(XTE
MAI,'KN8.!N%TIJW1:,"NNAW=,=.^H<&VWST<:1O,YDBRY]\ZNO[#J"(I5G^D
M2?N3Z_$1YSUG^,4$;H!]AV?WJ!WX24<=77P-C\6EA*;]P+Q)II?MKU'P>DW'
MH,A2*R.RI/E_A50?R!@?XDN+IVBZ'2U?(^T&YS.;@?8LIF&SOT( KCW3 (94
MZ0/PS.0!U,$P#:6/ %U0"5^FEC</78"LWB'(PH&//N\=RDG0X2SCJPE<-<8%
M7PW-V14.J[YB3AJ*]5*W-_4L6ZOQB=6U>1;*AXUS\O, /A96=Z8&S;M@P<\T
M<M)C7RF\#*? @PXY&,\/9:9QS_ LX(YRQ'(@'U_&F>3/S+;QOYC^, 5:=3U$
M*6Q&U'R*&Q(GPY50C,<Z\U?CY0&0/YTE7WLR/8M*)OE>!JX/K\#U#N48:+&C
M:"*]Y+<B9-4'AB+/(<Z4!F8_L.CI><RKIQ>)<?58$NLZ?$0YOCFS;G896),(
M9$B=?.[U+F1]QYXL?Z')4(&INU'J_F:"Z(?C+B:R-^?INRRR;)S M'#*=PJ9
M5SX;7%F@&EA#D L_\_]PZ=MJMA81-P*[D>.,UH,G@3V;MIACCJS=&U@^46%_
MECI%T6EQW&#C$Q,-'\])C*7*G8M0=CXO*\=PKD&$N!I5F1' X*SB27=#'UB2
M8SKX7 XMF@^=E #(S:8$U-#GP,8"<M-#WH&=\=@3LUU^ 4J6)^(WE;0:L4I!
M%+3L!WL=]5UO-//K,U XC#^(C@""_0'U1YP,>3TA"A1XT*8LAW,(/&@TLML7
M'0I\[<T0"\P]7TM.^%8#O$^UXK_S^HK_;1]QR878%UWQSZ%"9?_\HZK]5[7D
M^9&<R%NB_S3>HR(@/D8)3:HOP,GBTC@,+E4\?E_Q^$]D0$1&_P2=$?^-.E/M
MV^I?][R%&R@ >N6.KD+I*1#^ M/W6> ?,9B?0S_DU6Y.@2FRN.[P\;>CWWW6
M0SCT$FC;_W#=C=V58+35ZWF&9!6.5^-X]_FR&^.X!3ANJTJ'2TRB^DP.*)_\
M<Z.4V+ MLR]\U1>:9)4\N!).-]Q_<T2&C)5)U=89,>230>X!.'$'D-M0J?>7
MDHY\_CL\A?2G(L#I_'>H3/WST1K3#@81T[HP+9%R#I):!$9,>\[PZ!IBO5KJ
M-AIY]F]1B#V*=EC72]VFT5%V^@5RW"@KZ:)Y[D(*,QY-/SZ;_A&Y;HT*FG*M
M7E'(/1;GQ:3=<KUZDCT_E4Y\F)XQ8]<+KN".B6+1..<(P8%9L)$*=43>7 >-
MN*XTXL/A]  LN5'JMNI*&;Y$5OM'NB3BLAFM!$81^&RSU.WHJH?QP5!Z #;;
M C;;SIHCK2)2Y^BE/_\=JHB4H@05D3HWE9":015,'SQXIF&!O*%M&I2CYVF?
M*70>3@OL(#H;+=6:Z6)ZU5S %D]!$RP$H"Y@B\M;,VW7>$E58Q>L&MM85HVM
M5U4YMBK'WHF/J'+LTR"YBRWA+?8H=H4I-81=^;364]*_:!EL>&4"\  7FL<F
MIN7$28"8;.)K;RQ'PZY=_B%'$NW9SB[Z\[;F@ 7?SU;/4XD01>40<UG!9U^H
MNTE#8\DU>YQIWDF>23]B\I*>U4,VX0Y/.$6QC^+/P]!#]IIRB#9P4E*ENM"5
M\2C>[4O'F;$ASG10MRK53GXX4PK7:;/35%G;A3+39.'385AI#8_E8H-;Q4H/
MCK%-&:E1ZAJ5FG&"C%2QR'W;I'#% *<':2#.#YER<4X&EC) CV2 *KU*F:E'
M*&S,$M4?!1^]PV$GS$/7]QKE*IWG,PT]EDSTJ4=Y/E>US1-]&O52MUW9?UG-
M3^>HCAT S0OI7'M"<P/17-M[1=Q/2H<[ 79\66;N!OW?BLF*L9BJTMI[Z<TE
ML>+](3DO1MQ")#=KN3/B7Y9-&MQ'>EM[4\:X-+NMO9?DM@6N/Y='\(H!,UOL
MZ" \'.E>S-+J?KJJ\<84\HNYB8'S7IK$;W-C)HDTE\YL7#[9L3>=,F<87_M#
M3Z]P67XHB<9YJ+))2OCW&1PF%/[VLSGS8U),;CAC7N;:G66L>9L=UN9V.([T
MG"B_$!,,I<@W$)T)$U-O&&5-_O,6?J*SI]'A(XMW]>Y6$_I<3W:^GG:E80&5
M)R]'_22"O\<7RG,Z4PH,?57:!:2UK4!JY#<?:L7QC:DI#>*%H9O4./]D0&^L
M\1KCT%?&TK;*%]'R>?;5#'"&^&RO \#(N#P"@H^C8X< 01H!-K&""<T &X8,
M=(@A\W 0GA]-9Y"C47V<_.6.TNFA<OQ?G7\]/Q],S05[?29Z>P?*VR43O=F9
M?\\67E3QC,;R?/.='WTJ]RD07"H(CIO"GCDB9UGV[:N%S<:F5#I_F7*:,POJ
M)2?6B-M>(7?=V!N5[UCT76R^'HW27%,\L<<\:I6POC26DX)VWWO7U0ZVAB\[
M.RY50<IQJ$8XXA3-*)K9&&/4TD/5QJ@85A8I@4W<.'KDZN =058Z;;Z;,_(C
M? S9-UC&PS.SG]A7@/-XOG/(ZO#57CJ&-#J H[+1R;-SW-FC.QF^*B::FS1K
M8N_AJTM ,HV9*#)JL5RBW,EU]J?*$2FP?&T>7;X>)VE@4R&+?1T>GMTCG$P<
M-6&<$],]?G9(L1",!19-0R$X%]%Z/+362]UZ)\\Q!,JJ/7FIVU)2=[W4'7ML
M?@[;GL[OR'IAPZO_,L]-']T&PJ5=TVOO%XXO?*]WZCE!_7P1OI'TS0_1*QEU
M$QAUGK.>SAO#&XC?(^&UE3->50_;(O5W/_\=GD('VR+ Z?QWJ"A!4<(!IUHH
M2^^5EAZ?5P'FM"A#8D-M8/IC;82)O<H$7&D"'D%Q;&,LI%%3PWWSMOJ.@-M.
MJ=MIG-.@DB)9>X?'9ZN*LTKJ[9;RLRKINT3ZHJ3Y6;,FTQ %KX6I=,P/SE;L
MOGF%W/T]H:+<O S@TMX$_SK"P=9+7;VZ]^FB;\^04Z]!>*80+A"B:Z5N>^_1
MSPO"<X9(+A!V#3C&[;U[8=^N%<_*#:M<+LKYIBA!4<+QX73^.U1NV%,P!)-C
M@VVA*UD%Z(EV\%*#)=;?$=3#.KI:Z[4\W3=GC\U, ^\(N,0VD_OO8'<)F"03
MCKA3"HG6PA3H0Z"QB1Y5HYIG0K+RJ&XE2(VB"5+N415-=[2IZR%]'%V,%J$!
M<,1_KSEPCG!^6RA2:[EFGE\&9C/EZO'PVBYUZVT5N=QCY/)XN*1ZZ=;^_:+*
M+5I0!\'Y[U YPQ0E*$I0E*#<HJ?F%OVB'*)+C+AOKC,XEH[8KIY;W7\Q'*-'
MQ:E>ZAJYYBJ>+4XSS+>C8K)6ZC;T/*UQ9;])3<8 36;HAM@^_%R5M4)L\13T
M]D( Z@*VJ&A!T<)2*^Z79>.E5HZNV6#@5-8($R[XK0%S?-:3XS-PGI?M^J&W
MKWDEK:IA[,W^2@T]:B_!\\$[L.]D&^IZ1?OR^?KFV_V-UOOU[N;FZ\VWA_NY
MD5/#K DDKP==,R_(T>?HV&P]C"O[<58 )W^P>/D_3>_)](9:1+M9P,L>:+:G
M:3G+X?C9T7X+[9D&1P/XRA?V: YFV@,;!*X#YX^:3O.*&5<SG7AXC?9L!6.<
M:Z-]]QBZ8N KTQEJGQB?5...-+GK:]>VV2/3WF _G5KUO?B>_M+?ORVCPHW/
M=J>DZX\8TVC,#=/@2=K(>L*9XX]6X)=!8X;5]&?1HQ\]DRIIYY<-3Z-96C[>
M+)X+&W#8HQM89L T4WMV/7OX# LOQY>6-<^=F78PN^H#GZ+QQ9SIB#$^B97K
MK?=^5$<DUSN%1^-@="1$'W@1" 1\R #D@HF7L,'8<6WW<097FP!"TP<CY(G9
M[A3V$&^KH@%2;F$K. \(\*)GX.6%>0/+A]OPO6*'"'_XSR?6]T+3FW&6K5=I
MGE"M/(?+:&LQ2B6"!*>-R56BBB-= A^> NQV& Y@Q\P'@ W&M 2Q)7HDFD1/
MY%#2 ,()6("%!< !ZZN<! O>G@:B^^RD8%.."0^A#Q?",L0;RYK;IX=[[#&T
MS<#UX(G3J><^F38269F>CQ.:$'AP5/\+*/-<W(%?T1[@D0L[A[?9-CQO@H^%
M_V.C$:  R"&P;%H$>YE:'A_1!21/1&L"0< ;+7B5;5H36O!J C'E,A+D$ V.
MREB4RW\ "$XL)_7RA6LK6@]?1-Y2L<Z1N^2Y9?KZVIU,36<&:X4=2%R;J;[]
MF1-2MF2A+B@O ? P,6I-4B.>?MC+/U9X 'Z?CCS@=6+YG]A"AE2U]D.OHJRO
M/;CQYQ]B+]%VO])(D=!'/]'#;,IN1ST/^,DC_=A[L?Q\O 98#=.JEJO5:D9C
M,3RQ2*26[X= !*M]6X"IB>O<!Z#YW(]-.(.?Z:X,3\@^H>#3JY* J$9PJ&X!
M!TS[K+7*]?9BNB"' W\14L. -@K4!SOEY]_41J;EH43[D]%I"U>1C008@8H#
MZ6.()^\[G#]W^ ?>#I*4?CD6,34B(#:W &*CU*U6%E,(. !!4;#AKXJ6KVZ1
MFC"75BX>$OS$\E%,3)$5H2V#7&C*R\81<YOK_7Y4; YZO&>1Z-M(\=\%9PGC
MH X$^T9_*\\HF#>VAF(!.#H-UP;.!3N$VY&C X>:9*DP**WDU[[U(K\=$C5&
M3'TI-]?>!&//#1^Y !Q9'HB:6)YI/M /WFLNZ#%"OH#5^*;V5OXJX4^#"$$&
M\:'(YF-*_T*I;4?+%PL3VW?@[.$[?:[/)*7'(W-0WL!/! HI9OF%(4A/%+[T
M#K''A!8PIX<,0<7D=T=Z"++(@VYBW](/@<(IZ4]XPM78?>9_ 2W!X1@*H2BU
M@GV_7<#<Y^^4X/Y_N))_RI7<I%:2B8$WACP-2;#O>[%]%CPSYDAM]JI6%;.N
MW5%B3.L^WVC:-G\#,*0K06;\"\N!TR95%H\-&)QLTDZ35,,U-S_L2S"787%(
M1H_ V*:F%P!1^6-KNG^J J1L3E1R=9L<R7DO3T6[#_L^^RL4"OANW*BL+6.C
MI'4#L#T*2W-S)<TQI1++57,$N#C5*_DGU_(EYZ!+B3WQ\P]W+; <OA2I:3.T
MK_:-M77/V_J&W!=@<KJBZG(/T#J[$A\C!99_$'C&"\1'_GW?]"U_F0L$04R6
ME>G9%L?K&TLPFFR+:XE513])2H.[P'!C9+7V&>PL>CZ0OZ-]-=$#4M>YB?C&
M2KYP,S-K%6'MW7820X,WX=@9!+P4NLS19O #R-%1((S/I:<:?]R[5,27;;RU
M>531\)3M-L!_G#_T%?[ E/+*P\Q#HB/$_'ICXT[X1'K.\&/L$;GA]^>FL.9A
M9#0W,#((&7E Q$A Q"@*1%H(D<6\G#1$/&:;@N-D*_,)K9]3+0-!-EP<=HK^
MNSH!&&%0)C,*A\ #"&>5-3Z"6WBZ=P\JB3=+E)1MDO5^.'_)E<\&".]GUQOZ
MS$F#NKTV;VO7'>9 33OML%/J?G,SLDBRG4/4Q 6X.O,8#9@'ZI).NK4$9V8/
MTUU#7T(VS\7Y%B(@VTTS7CIL?I<AP1F!RWE?APC)RBF:KW!W;+&C@X3G/EW5
M&AO%DU(^&TQ G=\$FZ12;/L,*!A3;.UG<^;'$=IQE(XD1XA6JS^]UV0DVL#E
M)@HO]0:0E/SG+?Q$,6"-@L XZWLUIN:T4_["=J5A 9J2EV->;;0CCZ_$# -W
M+O&6OBIE1YF3;E4K()\"2*IKBF4_,F< 7"6'F#/.B,DA<+H%E18QY%RK:->W
M7[]^?N"QYMZWC_#WMX?/WWZ]^7;]^6:KZ/-^(J5I.FK]=/2@<H),UT#C,('D
M(_7S2"CIQ#%\'M_$0XF2$]T+4833Y\$#$):6&_J:'TZG: 3YTE7($0?WAAY7
M\='3T,? )?/]BM:S[>BY8&)XD6D(MDDY>O1,>#B>+!_$-CJ]'T$XDZ(7&Y(5
M[3,Z1N339% #Y:XU H[T!*J@ZW$ISRW6R((;IL-TSVYH8]C7GN%5;A_8(2D!
MTD$2>5[A;Y]Y3Z 49'@ZQ^8P]F<E?<P8HB-K*;GV0Q#:YE$%4+U<\JO->$@Z
M.A:8+V!A4!I5)0H6]-&"LWU&>00"ZX!IC(]BF0P''&6,DZ48P!?TI)\U7B"1
M>CA%[^53X5G?7#"O]6KYN&R!ZT)\^'DYA:G(+2/=%*CQ)5UO?1.-X WVJ!=C
MC_/ZK5])^9'V*A:6YG 54"XD%)9"2(;/#IXPAW'K+<K?^,J\1^:EN1G%O@,B
M.E#KZ#P*MQ[HI6#!S.6P#.1>90PXNC@1,&.:"'!<_W&WF--2T;X#MP_-V)&=
MNJRL,1-8R!B4(^XMZ_UQ=_OA\VTZ)FU-)FR(B47 A:<@7#SY+-06D?5'O-5,
M2:;L]4<!,%A)%'#QP_Y_,/6$\K#H+)J# 9B3='(CF"*;]D6:BS.T I) PMDU
MMR^/33%MAQ; UYI8&%\'O$LLG*>H:)X9F++7![GV 648/X/?!HP-@6%8]"79
MD*$=1*%04T,Z!5C(.V4>D 0G<B';9OSM\+@I0W[^QG(&=CCD.3(R+!$C(4K$
MVK<C$B!S)5 GF(GI^XS'&(<,) 3GA@M0?9MP/$K44TY3DB;V[KY?&CKGZ0T]
M7-(U7\V_@%#^A4*Q1_OY:LX^L(^$&39\<+^;,Y"MO$]LSX>[HXUMYJ_L/7EN
MWW(_.X.D)^6.NR6^HX1^\$S'YPX-_\,L^0MWK\S[3(:A!Z<L&*<\)ATLBVO/
M>R2NZ$*)+L<!JO5\4,<D^0M\E..S*!*S]I_;M!PC. ?-1V;"47,[NL/%3(/;
MT74R1^O6X4@Q[=L1Q]0'E,VW#L==!H+NQZ9M?V#?36L^_^>0N$(W9AI5U,)[
M 55XG0Q'$B#@89@W&K$BCJOW7(\>DDX*&NMJ1^ 'H:B#+.D+5362A4$*O%MU
M_]@#I/;O-.S42EUGT6F8%"@RN8;B/WV,DLW04.$"9):0:(*+^2*KT0]!WI':
M;_I<IHR9<^6& :C#SE!R-!ID$X!>2 WU)?_'5%KZ[YI(0 :J>H._0@M$.QV(
M)URI_ZOGXB615-J@@?6/ZR=OSIW[<'/]?]%7N84$.L8F01(A,\S'1[0* \;#
MAE+YZ3.P1I^D>8;?>)P[():B-)<YR8K/FY.M1Y..*5-A03B2'38&Q0*4)#_T
M!VP:6((@1P M%^QPI#(XI4F5,)%L/0(-";4=#AX/[?5@/K +T''M!'.7-BPN
M'1]O+Y7=7'>!!]LV)6"C16D-0MOD*BIF2@O?.[X:)#KHNJ FQ^N*$D$$)Z!S
M\I]P^,CQ1B?-\H;\P8S_C)?WPQGZ(.!W.GI2TX!?\47<*!-1V^Q+X?3!)GQ?
M<L_(BP!H"Y" A<:8I6'A+Q@+GJ&U^TC*U=)D;GJ/.?')>9'R00@W!9"K2\G"
M7G2(R0]!BUUD3:@N!L*!049\=#_\A^<*#GD2OF#7E,R\-()1WEX^) )&/<]"
M 'Z",Y6RH#C3 :[D/CI@^61EU^Z7_>PD#NK9XB#& _E_$OT=.,XXP&/ZNDXZ
M0CZ8-AD7]V/& AY<(@ISE^+SB)FF1XJ]$ =&68FZ/?PW;<U.3/2L@?4DK9T$
MS)*X$ S-\J.D11<]AJB\9OLB$W45:1$"-J$7(F^)#TU\ H&2R$'Z# (=3YY%
MK*//M0)<PB@,0H_Q' <P'D-/IF(!8YV80R98%EQ)STM=-S =SG]-WT6/Z$QC
M/D $*:FBW8,QCQP)K6S)$7E",!?ZO(B#^Q@9A8;$RO@.)*>,GBA8,>T=%LQE
M0;0_6A7QPCDOIV@58"=$K>FEU@QBE*<G8W:RA T '[#(C5!9MX*SA,Q![#.8
M$U:Q$U$*9FD2$P-SIT(3!1:(V(D<C60:1V,!C^YI/<ZI^KS$&Y^$VOPQZS/,
MS(3C\\3%/YPCZ>:W0=6RI8H*[_=7BY%$(#SM(?=)WXA8)ATU8-D\DUW2"JA%
MF%.9",539 +X/C%/O)1)J1:@JYYR9_Q,(@*0FCSW@-X>'9!A1-F+M,\]V^BD
MP9PX)$!<4>JH4_+T_#&%']*<9.@ROF%Q5&*E-&LS5.GD"UE.+&_QJ$0R)KW+
MM<[WN5,PGXBP*I3[F?)U'\R7?05N164S&_9 *..C[IG-_9H_=*-9;36:G58J
MO(N^"E52O!#?-4"'_'9]^_5&>^C]W]IP[J4$,(?6,+F(97DNJXO"N(R[Q^/3
M<X9?7- EX0"(++L/S&$C:T-W7NH9OX6@GPPM>F72#Q(=L5X8C%W/RM'GT5B7
M"O:JO:<3#8NV]^:&>__$T,FU*\;%W4?:8RNG/:8Q>]P]MC,-M9V^0"X9Q#;S
MB.\KTB<U7JRB!>9+G(Z O_8YM*(,@?6YIW-I_5PY HW$XHI)GZ$]01G2J M@
M0$BH06"M#&@A;"JR'D#9&0Z%0DQ*'L.BYQ&CY&I<JO!IR-*K(?=RX66N;- G
MGXZJSRBT;73QC^ N]+^8%$@3:A6ZE,F$32M8L?;/C2#4<B:NAX4O?V($CRH"
M\,O(@) @D\80J$]8+3-<KJ"KG,AC"E5D(]358<@P/Y)7&,LO5JN3R=_F6MG0
M05ZJ]"U7#7M35)/C:W_HZ17FD:29W'!&3YZU.\M8\S8[K,WM<,\YHVMV=ZR4
MTBU!6ML*I'.]B?:I$Z\XOC$UI4&\6+;URP8\IC"@-[8"?7U-QO#]8,R&H<TP
MBCN9N@Y:K;>C2*M(:RD/:&OO*WU8UQM'(8LC^84BA4:685%G$S^NZ8[#R&_(
MD^J&/J@M_MN?-Q'4*4?8;I*:/^+5HOIOOU!W-3@VMCU%A<EYI.8:^+=X*F^[
ML7#20/7SHC73^\3!X2WE^#?"#WJ-##=J-@=J[2/%!&%-FCB:K>;V%"0>!]S<
M-J<^?"T_\7:E7JIEGGQ/[:?Y[J/B%US LKYZ_(;%?U_YB-V[E+=?T:1<=FL5
MZ([)K=(@@MNR5>_JQ\P_#% $9.50Q'N%AKCL90+E_,_DT*VX66'Z$JD$).A%
M_")2)<DC^+INAMOYP?X-"H9V@S;0+WWO77?1$-JE\^,FR+QD:JM=*K6A4,^+
MH!2^<L&743P&<)&#$ LW.D,X)2.5](UP%KW]^8 S-/;<X[WHSU-04K-T)$-H
M%(TAB ##Y4W0V4<(:N>>FR/KA0VO_LL\-QEP:5>K"--V3:^]S\C-;>N=>DXC
M+!6&EP3@]HYA_8 85LK::?-F"NL?G3,?9Y;Q_C)#]GZ$:V?,I$\0V?GR:^/H
M_/H2)V@581;H^>_P%&8F%0%.Y[]#-?<V0Q\TBJ8//K@!EA@4P857+!-O2?+"
M<=3#^AFKAR>"X'Q5PL;154)EPI]*O.6CS!96 9>BFRQ%WY4*N)R%4^]B RZ2
M%0H '$5G6]$4I5UM8JE?N5I=[(NB%+8#87D_BMM*++=P1FRY5FWEB&6EM9TV
MC[[DP(L\P"EG?/&8=;O4-<IZ6S\C7GVZ^#X V^X@OHUFGOA6.G-1^?$GUX.%
M.!?.D044"L>+]6JIVZHK3GQ</.?J\]2/G[:DPN J^*G"X(H23CX,?IXV?*MH
M.N/'9)\6$72Y< 6R>)ICK=35F^6.Z'FBE,>#XSA_RUTW ,?U<J/95J;[!0;
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MBZ>+XFB)Z=2>R1F;<MH&CMH( ]>;\3,BQL'1S"W>FE^\P/1%;VH?6U'O8>8
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MW1'&1 A7\PDG!-1XG^@! @):#O/][OH3?]W=1YP"]XI]X];2FVX!:V\L;)9
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M.4GG)QPP,( ;*X91TL[+:U^<+7:R[:XUAIBPLW8,.:4IBW<RX/HU9N=D*@A
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M?$9OE9SZ<^UZ4U=8F%_,Y[(FQL%__/7Z"_IBQJX'KX3=:(/$E3Q1AO8^TZS
MCW)@^+9%<@S\\6@"6PV2:<*:Z5D^*IIN&%#F"RW4+VM^B _"VZ>>"^P374]^
M*CMQ1GZVB3ED?)7 M@/8QE"XWN@'4YN:7C!#%QS\['.D\ 3F0<"]</2DL?F$
MOC;O"6['U!QXL$CMMV?T/2[1Q'W'Z3U>E/5#^94)@%0T=!X*D,#;T<LW<.'
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M,BD3Q&^M7&\VRT:KEB"9N8U%>79RA5?Z_!K+DAP3;XO?43=:Y5I[JS?4%J#
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M>"M&7/.Y-^ E@3T .OB:V^].!AH05@)^G"AXN<B!:DU =:W69?>=HRX=J!9
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M.IF8(SY[BYRUK]$XH!V8^7B^8>4HKQ517JTZ /X=R$D#Q<O > (B&Y'YZ N
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M^EMCNC<](;V/,5$OJ&I:<!>JVX"=3K70!3%/2JVD('!,BFR#-R@42E(=[,/
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M(Y]@57<O0)9Z\@A1H:C34[,**.&!D7R1%TH%<R(6R3@BV7 RK+BS16<P6\L
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MT9/1 XD:2>&N0-:$TO9JS<M2:33@T >]16-5R_*ABB>FQRL1V"WS$EPIAZT
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MYY\;&+HVAZ%#=D:23I2U=AR8_01&QW7M_W8@^:.GK,BN'<%ZJ).M9QQ@:G+
M:Z#Z T/&'WXU VD+)OIV:+2E)KI.%$V0 XLF'4=V_Z%Q8)E)1Y_WAX-&.\_0
M[8)&)T+& ?*,CB/SWT;&'QT8VEWAQ-#IEC/^Q^'D +=F_.%7,[2[P@G:V9C&
M :YT'7 XZ;@YY,_&--JS$SVR\SD3;2>"Q@&F)QW#P7_[49..R/YC0L.P>X,P
MTHDBR@%BH^/6G__Z!N&.(>T/!PYD%SC:0XJA$V'C )/7 \;& 8:4CN4?&#3V
M]C[4GUUL+V'?[P/]?=\EW5[8[I>:.D12+NVHPGZ]ZA3^N5+G>M5I_?;"SIO5
M,-2)IE5G?E/5'_YME[^ A?$@*G[+P.^""M38;#0:=9T#%.A!4/R6@=\%%(8V
M4*!HYP!%9Z)EG1D4^G9/8>@<H- ?!,5O&?A=0(&T@P+N'*#H3,E]IP9%9R*:
MG>F^8V<&A;8S$<W.]"QX9P:%IC,13<U!4/R6@=]GH:(S$<W.= NZ,X.B4_',
M@Y#X#0._"R1TOV?L^ /?(S"+3"8K_37O$M0?3^ETK_7Z7S^>\F=_KU?[C5GD
MKX>,CINX#@)CKS[C+_=>\@-^/\^?_+WD'=\#V(F T=E? _A'A\:.E[%TPF?G
M#_AE+ >?G>]0L5\ 0]]9<=%Q/_#_ A9:^$!@H?V]$OW_%UG=K_YU[7W\ >UA
M@JI"B(5T.46)._YX/&&U-W),4B1%N;']/6K#P%](=?MY<5:JE!(906(*]:&L
MGPU8[:W=U+);U-+SU&^,T>]V'"SD8"$'"SE8R,%"#A9RL) _5"'=AHVH"2IA
MHJ1&BD\/[U?M-Z+UI[<;+ U=#SN\Z^&'=>UZ>-<CCNAZ9+<3NG4[ZJAN)QUW
M_#$GG'S2*:><?%*O7KU/']"W=Y_^I_7JU3BDL?_9YPP:/.C4ODU0TT!HP,!!
M ]N,=#GBB".Z'=FM1[=N/0;V[M5[X'X?/_VSH?N1#=4N"P_MTJ_AD.Y=#NW>
MY:=_-YS6T*7AD$.[=.G2L.OH>L2AAQU^R)%M5T,G-'0Y])!#U'H?=>SA1QZJ
M"K5)JZWI?L2)9\*F'GZR>/'U)YW<+WS'K#=Z]M*8 ]*DV4N.[*_5&Y)BZ6\W
M_'W.LSH$O?'.LP984O]:\]E6:S!]EVJU=Y<=Q^XR#SVDBVI5O6;HWG#((5T.
M.>PPM0J'']Y^K<LAW0\]\<S#8)._1S]-\?  >;'6?/T=LT[ZK&O_Y+-OB+/_
MM6;K3ZL:CE%KIPIV;QC1\.T]W4\X?,)#]W=KJ;X9?O6T$R#ZH[,$-M'B]&\J
M7KWY+>]58^[;MNR&XQ<LA;[Q?33LU8^^O%_LS87O :Z<'-T6V;CZLXGYOS5?
M?NW56SY_S7PW_'%DN_7>2>Y[GCS[ZUL]D9?/:>TS8.B6$Z^Y[8$K)S8JZ.V.
MQ 3-3PUW<R,?7]G3>M+B=YB[3I@SVY'_J2$P6YA^S8.1KK,=_P0^L2\=;K',
M'C%E]<(E2NCU8RZWB,N?<"RY>N-M3_F^&%C9..?D4=\_.7/Y"=ZMB&5=];YK
M72]* X1E*ZMW-Z^'YXVY8MJPU[X^8>"UO6Y>OG3=*OZ5RLA+>_JN_NJ$(^ZY
M8.R6)5U[]%_]LG/PH%L?F3^]B=Z.O38\_<":"] C=.,;3&^9UDYK^O;&:[L^
MU3SAJZ.9Y$O5TIE/L",'>Q<_?=L'Y]SQ_=!S(SU.6S'KH=0E4];<W+C^2&)4
M_*X^/;=>.WG*F?D'A\JQ/I..^GX]O^7%^[=,_F""-'K,R\KVWD]:5G\X-W;S
MM!'P>]U7GS%QT)W:+TJ;D)?/>'KTHA].[G_T6N"" 8\_/GNE_LEJJX$[GU\O
MC"Z?_0 ='KKZ,.NHEN[=&ZS6+MU/.,QZ[GY^]=]VX56#'IEZ\YLO]ADP:M[L
M::?]V&?>XO431WP5&#QC[3W3)]]YQUHTR8Q]MXK\@W9]\^.$;C,'??!-YO8Q
M0T.GGCCBVS5'I!P;AK[]RHR)@[9\TT\^>_FB6[7_-^K,\R9NF?W>K+-F3SEY
MA,;YTM+KMXY\Y8TGX3=;P DML8$S4M/OOO*Z9T]9EN9.[3KQHF>806ONGCYA
MVA3]<X?AQZ1Z:XX]5#AZ\(?K/_QQ?/%9TSASOR%]CKSBHJ4+WIGQX/;Y4[[=
M\'%PZ9S1&ZX]]_2S-IW.7G7QUAN/ ^^]_X;+!ZT9IYVR\M2!IWZX:5O_?O*U
MXH/2ABM7GU>\ZG@"G3_PM--;IZ^6O>N_6'>[O#'P2=/PUJN_* \(IQ+\B5W.
MNF8QNU[8EOJX[QO/C5QXWZ>O7K^U&6_&WF?>[M7K8_+CHS#5:;RS=.':.=].
M>P[ZYRGY-S9^.V7E%?$U35.G.TS-[^(/K>KSNOW'OX5'WWGK85_/[>6KS=_0
M-'S8;0L>$E8.N7M]GV7__K++<^..>?+Z^P8<5CJQQ'/?_-1PPLJ'YC?_VS]Z
MR)+6D:,>6M;[;5.?;XPC[OCQCM%HX*<&QY7<Z^\,//W#)U,?C.AFV,J,K([-
M-[W[MM]TWBDW3*E\/._>Y<8KWNUV)_1E?LS56[]8_O%7\Y:OO*U/_R=:-.=?
MZ< ^^,XTHN<XXOMSOLB\GKWFS%</O_N$RM_0.R\6@8FS9IY]_$GVV9.5:[NM
M6/;A%2L?F/S]X@T#;Y^XR#?ED^]6;HX@JQ;EG]PVYF-BZ;)M\8_%5XY;MGC(
MML7W-5^X8 &R'JB^C@2:>\X_9\#0E=?=?OKDVY$57\U9-6UH4RO[\*>9Q_"G
MUJUY&![Y],4S/@6/E2>L_N+8Q+)K9TTU#MTM^\QQMS;%N<=67/#Y\/L+.Z5\
M<HU])?+I/W*Y%]YB7GKGDJ\W/?;-_7._NG7SF 65Q/DKSGMW<>[6L8L6CDG.
M'7=H\-TQO3_O^>3&WE-F;>\M5L]LW5FX3[B\\9(>\?[S @O/@H>_]G_I6S*/
MK'OV_[ZZZ?(%S_'?=GWHJ?GO.;E[3EK^;7;&C&?/<O0H)XYZ;Q;M/5;VWS?C
MWO7TRUMULY[ML6Z:W=&CZYQIGU^7W7#6P[Y2[(7A6XYE[>E)UW4A3IG^77F)
M_>Q>([N7\E<7EYUZW8J&RJ)S'-#':Z-G'NO(# <^]H'*J(7+OQG=\YQ+1YVQ
M>LKKCW:]X/,K%C_2\\7Q^*-=/??.60;?MNG&AX:_/3QGNEP:/7[S"=#RX./K
MHC?=V'3NJ_.^T JGR]-N;+S]*/*CM?!+J<<_GCH-U_8>^\]7FMY%'COEP8?'
M(L+3Z*RDX\C-7RJ/&3/O?WZL<VC7#]YRW7!_YO2-,QZ][ND-ETX%SAK_Z>4W
MQ2;-X8M/7I"Z>?L9W:)W#G&*S[QUV]M/#?M70NR]ZE[H\M?>?;KYM+$G#S@\
M<>=KS_-?O-3GK4].\Z\Y:N#*N-M/Y"Q7R?WTN77/:)?<^>[.OHW-90?,WI(R
MN+KEYO0B+\\N?*STWN1QINS.08GV6S/RKMG!IVXY:NM*YO/1%XX=/N.#V4O7
MS_]Q^]C0VSL';-JVSU;<//.]<Y?-C'UWZM))\RXYY(/>H\X[?-2CTM)_#GIG
M^1,N^SO/#M4,[^9]-*\?6[[C!LT*FP];>21XPB.&V#4K/[Q3B3P_[<N9W.57
M/+IZ\,7=,W,G%4Z^?N/IP]T][P_WJ$XW]'_LRJW7W'3L,0^5+_+:\W^#'SYS
M4Y_YK[F.\D]_>VRZW[0WPF==.&C;8^.?R'PRZL$N=SG!5TY>$!VRA3*M._6H
MXO%_[WOU5X6&SPN1>\[NOO#-ZX]\?_;(A?;%@[LNF#;;-"#_8''E%GS8I-6<
MC9M_WL(OESP^>+G:K KK>GU]=6ZA%NFI^VS9N2]]=$_ZD04LLDDHC3(^V^W4
M*W74^(=/&/'L1R/Y&8M>FGQS[B(E_L3$#Y8\X!E:F[]QT4GSE]::QSWD..0S
M;=.RH?=DOCS]L +>?<JV4N]U1VSX<-QA\YZXX=.>$Q8%Q?NNV6;QW3]F>>'%
M)XZ=^LU#EQ;2LQ['WCGCA8O6/W':LT<4NPVZY]J7-F_XDOMV<W#"XY. <_SY
M$T>.RP]_?D+O^8-&(L->/3[U]A.7/?)TZ8W6ELII,WM]]_=+5YU3^7SN=<6O
M%]YU6^7+'WJ]\+B]K=*G:8\[ G*T+,?0%NVU_:;,^=(RBV^]<V%TU<C1^ #K
MDC?AA]D/FI9U>:WI[5LV!GM:/YJS[:K,-PM&O*HD)_Q]QM6SB]?<N=U_6G4B
M YW_*/? W=/^\>;X7MNLQSPFOG=[XJ;!OBU7]=T<Z?_-).6MF^^\9W!JR&W)
M5<V*\SE\B/;1$U;&5EQ4O?IY=O";<ZZ>>5+_*5V/_^*R;VKS@JN:RLB7#[]Y
M[[WDV,5GW+'$^^SR62-O?6KFM"W1;FZJ_\</]>RNAH$UK8[TB*]>?^"!AV[A
MI"7&OY_T6'G>^>=?FA\>W_S%0&18]"E@+=/WK,NGO=UE\=3K=%L:SL_<_OV+
M0.Z%NQ8@S&4S\X\/GG?NVTVQ$V\ZXZY'*H>/AL8_4+&Y2E]LNF+F&5,V%Z[K
MMFAT>L@W_J=F4V^)P>^-5\Y$)QPZ8/JL2;VN?N_4;6->>WSJ4T].[O;]J>.!
M.^ WX]ES^S=EUW1_HC*WW_VC"A<]\$CZU:?7*#->U34OK[SWM&GI-Z^N^>35
M$R_=/A)Z%^._LFV;T&-\<6J>FGR#LFE$Y;.;YAAN9EY*391I[?O5[7=.NWS"
MC.G%1[=>H#M%Z1,Z_N7<5^,^[_^H??6]"]:]$[K$5JN1WP_PO'3J _'0X=8/
MKYEW_:RG+CESQ929LXBO5DR_?VQIP?R<?&J7OC?_<\S6]Q[L^=F,$4-.<BY\
MU=#\]F&V4Y<,J<X3%FQ:.&#M@J?F;>./O6#ZV++SG6J%OOO&^8-7 V>]^'3Y
M*X/S]L'??._\SOWZ/Y9DO_YJ\5K?JO!GT5>N^'KQNLP;W>"[3XOZ+GNPY/WH
M%/9#)J\[:W-IWK;U?197>WIOO6#2Z*?:Y4=&1O=*#EU=F_'O2?,G]RN-77?3
MC;=\<!?SQ;3GEDT$9.VU0Z:]<>6GYK=X]^IOV1]>;(D-2C>SM\^]\;;-B^\=
M\ODG9^88-0RV-C_WR,K-QD6X[YPSCTY4W(.,QM6CNJP_;&MPYIGG92']B=2$
MYT?V3,_:5IQUK\&^\+.[BQN&BL,VM!Y]Y3]>@=XZ\]8>HRY*]5ZAN?F9_SNV
M[W&^V*<CERWN_]TI2Q>==,&'J\XTW75UM^>?#']ZY0+]J1NJ/WQWT49B]8F+
MSW\J.7_18WCHH;NZ_$O8<+H#_;[7H_S*9_YQW(T+GS.X7FU<^W4V?_'SUS\$
M+WUTR[%?+QFZXLV&:.7T.4MC^9.V?WOV#UO.?.R%L:N?>^'NA\>?NNBJQ3-'
M#+FP<L$SS4,N[/;^@D' HNL+/][\4\.%S\Q:$G[HML\VSB.?7]U(ER.?WWI%
MG]'=O[8\\N'897^?%0DZXL[ANLW++Z=;#'.GWIT>QWYL3HR^_9;;RF=?X;V\
M\/SGEWQP>?63T.M#GWUOVK9W%ERR>LYVU]3[^UIZ.%-+#G_YI:'/'+GRS/Y3
MMSYQW=A+;OSLL<E(T]7DC2\(5TR@7)J66[X?=[,LRV"W_L%1'_]X]"UC<N.O
M_?[<VZ?V70>L&0GZDJCRW:6V/DN.G?!P=W)>T_9O/OC;'4O@-9\6#VVL;#EL
MQH"".'/)H\[N_M:!17#JQA\G^V9/V_7M@34OK!^PUK<.3(=\$TYS;U!&W#-I
MTP/_NOP<D\UWS*7&K<\O/Q&]3A/[>^##3>^<M>Y5_W%+!RS;ON#H6+\B=R.?
MA_K?LO*F"^_NOFK>E"-GOV"[;+18.N+2Z(O>N=W[.+.GKWGAT2$72L?PE1/N
M&GO!T<#(F:M>N*S?&\,>O-6Q/'5&7&^ OAS_1-_ >T-&5N'%S3]<F>PW</*1
M[<G/16T4MXL]?G^F9>P-/89-![O=ECMYZGG/COC;@F7'IU4>ICG_X[N^\47_
M]3@_[=_"M@O6G/]3@W#M>Y.GC';[URVQ$,FFH?/0BY>?;KWDNT4;#S=G-T[(
M:T>=>?MG$R?/N*1U7'+<N=.;_G[[Z]3JY\:Y-_]#U_!Z0Y^&(Z^X,S;X ^_D
MV">?W33_V.QG$XX8?T1Q2'&9\&GC=N!TFVX&T.^-'S:^:+<WOK%\5,,7-R[@
M[[XZ'3V9GGC9EFOGO9^@7U[[T<!W/T[ZH!?G_M!\Z"R>26T;*_\PLO7)4&G+
MV&M>_5?YTQ&'+WMHT:RK \.'7. KC'@@LR*W-#QI2[)YZ[@)BP][_T68ON:<
M#Q>FYCT;/_/>OV_==NJ'0__Q[?'\N&-[I(R;D7N/7JO9>%7?EX)/C[[\G,S7
M!JE4Y1<-ZGK1A2=FOOGDQP=ZN&\^X3QF=/DQQX]?7OSTR-XCCGMVX1?CCQOW
MSLL3G2_]:]35 Q_KB7X^Y,:?!8 ;-EYR^JT/-LT>DWYYW='BY8ZI<W3"B-N&
M]W_,_NC*;VQSOG^W[_JG2J>-RGBV. >9WQ@[.+CEJA_?2/YPU%-<-'%/Z\9G
M-O<"7[]U^7-7G_%HP7#'3<?>]=W]5WTYY-L[PN]) Y9]MFKFXR^^<^Z,ZY=B
M1YSPRD5'/+9R.V!_XX=EMF\GCR-F7#C_;,/1,Z>9AXT_=_O$1];<_N#9/4O&
M&Y?KXU/TLQW)9[=_6WGTJ'NN]L%KQZRY9?$#_[<I0,UD;YST-G/V5<U>[.;M
MZUXY]TQNQEQ^9>S^T-]..++Q(M/[_I./N]1ZKK]WWY\:Y(]:-@L7+#EUV#^_
MF'_N<.M#]WSNF?3ZZD\&#7IPZ_R! R33DI<M$V<LTFA6/BFN^V'Q>5='B4\O
M>_^N3RYK?2HYY/">K]6V//2X,_%"[N71SI=O>^&0]Y<^6G[8\\F8CQ</ 6WW
M6ON^4"[<,N/I6][]]];5(]?G"M.KLUQ/;=NXXL-5SRQ:_);O_/G(-_J'MWV^
MO<>B;=JG"U.[GW?ZLJ?IZ=]FQO;8J?C<X*\6W77>I-Q/#> (<OAN5?#%%V[=
M8(WN$EL\[Z.__=0PYC7SVVX<V[#IN&NF.X=J5VX,/KRKC),3SUTI.&_6+PWG
M[KWQ[:[^*X[ZM$LS,.Z0N[<OC\2&VE><;Q.^\IW4^XI!8S97M_U[V](O\JO>
M6#+VI$D>].+'5PT^'\FQY#5OZ%[I_U:?,]8_4EXW]Z[F<OZ0T[HPAYW^C\M,
M']SPXJ/S'C[OAYM#2XVKWIXW[);;OSP/7"MO6!-8M;KOG3\U'/O9$^N>,SK'
M_'W=EF6]>DT0KGMDU?F:6;>,NG_5T1?W2=*?O?OT.4_^;6H_8.USIQ'$M6>=
MOP6X\O:>D^.SA[]EM5E>([XJ;HE,>W_LL,FOAKM_:^]ZNW/PUZ'(B+>G+\+X
M'Q.3JJV/1.]_?(Q_>_^K;KOIS7[]KDSN]G7$UI\:KNCQ^5W?WW,^0'VTR7'\
M><(5=WW]2??3P/$?SGO\YM!D;+E(?7O+>G'QL DW1#[JF1_ 7=?OGO-KSO6]
M+CSI@I=KGTUZ9<B/ W^XT==UW)5??[9E-#;CO#-.E"^[_;F^LQ_,]UU;NFJ(
M]XGY?P]<K[WSS>-7O--E\;#Q+:_,>GGPRK<^O'KJV?0+%=_Y:&1-@1XU9^7,
M[B.:[M5_=?U-N0>_./7*6RV(O<^\)Z^_?LG)2S_9]-)W4_N:5M[\T:NC70\O
MX:^96KMOW+O_'-EST1KW<<J=R59HV.D;AQ]QP:R7=&OZW])OZ8H37[=9$E],
MO>*SI9=U/6ON_!EO;/KNQR)^TT=IR_QMFT<KUQ@6OM3WB-D8]?VW%S5LR=6T
M&WO5RDT/7$8-?WI";O[*D<<.:VH>^X[8T&SO\=SC#P8/N_8QS[:O9Z_K=_UE
M#]%CYZQ9>''HG8G/]_;=?\WE(XYX;'SF9B9][$>O;)8_W11M/6ZA+I9X?=7@
M[@^N+4^_9>'+-[ZSX:Z;!:?)QG_5_=9;5W+5[MVQ&9:5(_Y]S.TM]_T87/;9
M?6//^?KB21O"?5]6GNXY1]K>?_RDK[I=MN2R =X>2YK./O,N$GIM^VOH(5MG
M;1J>*FSN.:[9._"1-Y)#K<N_N^2H:[Y+;/WL+N&=-4MF353&K)]M";Q]RZS4
M_"7OSI2^_.+$HP:MYQ\99EI[/-QGPKOGM;;<='+VZ?G1)9?XV;%SFH\%+_M@
MZL*QIZ]>'KI\$O[Z*>,O6YD^<=W<&VX[8>SSS\V][/.)&U]^99Z;'N6Z9>G3
M ])KCS&>NR4PAG &3IW;?VM\Q=QA\V]JW7P/N^Z+K[OV?GS^E/CYUVW\?$IJ
MV9PS5UP_^H=3-Z[*=7O^W:W-@>B&AT\Z?-6JB2-.WW#54R._VK*)7//-=#JX
M==@C9\]OG77;\$OO&WA60ZCKMDD7W#HQ7>$W):;$OI_V[H61Q0\M:_(W[7+J
MMXU^53,[W/6FU/A_]/WW+3\J/S7<_USZ_K?/'7&E]OLO?VH(3WAI]*)/,K#2
M'?^H>M@B-[')-W[5QG77O#/3W>^MQ)JY-_)CIOU8;G@FR13Q;U^*AD^A0O!S
MA]W-C[UT8LO"6R'[:^>O>-/;Y=4FX?"[TZ:U]^']WK>,__2+FX:.RKQSR\>G
M/OC\M?\<]F1UX[33WUFYXCCK]NM/>V+5N\.NVAJX73IO^U4G;\0_2<Y?-N@K
MVT\-V5D77/KNXX/>__+.>4\=\T2^[^K0>3,RR[KUF+Z@];O73D)TKX SYC[Q
M2D,?M^:E]ROI"RE\Y@Z1H[,7F8[( MTGWY+0?W"_[N6WS;7[@7O^-M1FO2CZ
M^MSPS'.XZX7^#U2K+;/#X$0I?UY^WJWO'@,R[#R+K_NR\[UKXZ^-,"PWL(E'
MGRO-O;;KOWO=,6SK-\UCG9?]U/#HDB,7SXO$OOSF'RZC3J;' #==67@3K:P8
M,.XU\XN)<X_E5PQ_H91 ;_S_&C.O<#88A@WG?>U2I5;MUJC6^JJ"$*-:I6*5
MA"!2M4N,$J-*42K4WB.(][7%JI40BM+:.Z7$CCVB-:+I]/<__:_OX#][3IZ#
MY^R^K\<&OML!BB?.!V0=!IZXLST6#>O=0'S9NCFM-JVU_V.SG*B!7AZ[(SHF
MJE?]62&1#S'A&K1E\<1WQ#E5PHE$>K*=LLMG?X2S0&'7)@T?D,X*=%CP2RP7
M!8#>E;&D.F;WYT-48TI"A%4BW"I[2N6K B07''8FQ+';LXNBOS631P1/TDNZ
M-J$VPWN#S,?"7#XSU\H*Q^V2AZ5319Y6Y'HJKPJ2QQE[QF(#@VE!!W*MCHI/
MP^[EZ7L*1X-BO3.\RDCI \SD))* Q6NP8Q$J,@CW_D@.=5+G=]@\5Q<D/*U$
MH 7UGI!MY6[-"K4NFV)C:6RH>VU/#VWMW)?LB D<2)[/EX.[M69_[^N\III_
MVK9?6?)HO*=#W67:F(F46"&\#>N;9CL'5#+.?I7[_ X A[\:>%_4,-[:39IP
MWEHZO8[@+'K2@1IF'=QS&92DB';D E;-KOZ%L];)IOU B:O?Z'\FL28&1\,8
MJ3\O]+JB!L3AM%-^^W. 8NWZU+=2HRW)]XP8H]Q4=/V4Z9YZ<9?5(%JD6UZU
MH\.);A98Z1'#.U?M?S][L=F.9U/-J#?1=YE0>"(>/E(9O[,#S']Y/ZBNM*^$
M97(_7/V!+K]1PQQ,3Y]1T+._U9<KG24@D\=<+&B1U%>LIP':?10AQ_RLT$RM
M_9 1*:H7=\0[PH;ZU<$GSN,\$43#;=H,%05)AT>O$QY\99K5" FLX7UX97S"
M^J6*MY"HC7=YV#?[D*=^PTFGD7?K1U6?5W3/5Q_RQPVEA9I.H,0T6NC_*7JW
ME<,(>%[Z4])O75M,$*<:]U/S]P3^]^]*,UX44L&9L("O\3)_2.[?=?S(BEH,
ME\JHU=W?/5,?V%07R>&NAVA/E)<_&DZ:]%$D>CL%=\&21D2HR'/ ;2.//>[/
M<&R]#S;5&11BCNR52J4.^8LYYRZ_YP_(K!MYIC^B1&GW$9?GR\D.\JCAUA/T
M$LRF^Z;/?9%WY/B2RAJ3.Z$+S129IW]&7*AJHQ;Z^W5,+GAY*IGA:^?9 6G!
MFRW[WE8H9L;,UR>B866$ 3^MQ9I_=6V/S>U"C5(@O-2LY6RA[Q('W9RX&ZBL
M=3/[$_39H:F-5KQ456IF58*FRPK^+(Z;6L) \,PB5<RO$6$$7A;FEXV"P#@>
M$PP9MS1L6Y<JA9WA&RAF?F-A\&TZ$M]LLICH5[#S.[;K_5>IA:WO>O_Z-?J6
ME#?Q)_\G0*G+K_2[X _!,1UMX-0>])Z8Z82.+45$=8]32MF.PAX?U6=M8@&7
ME(,S0P>.W1X_/50P% .[19M;B>J0-'Y60&])6NU)T9JSHH2Y,#WQB7%WI:ZJ
M+=R'4(K9?8!_AY]L,KL@=-_N.PEF'ZZ.6%?4=]EH&4+[795\3W)9^G<1:NR:
M0X;:\Z3$?(RO^XES:1OI&F^5>]<_FGLTL*K]C( 0@4JQO5;^>E;NKBFYL'5!
M+OM-*/+BV@>/][ R4I:M;/W#3./^PQ5?W/93FBA<OI3;3M[U-LR.-JU-4WZA
MRJ'3KHR7ES,0:7Z4@,G W!Z6M[TY%Z&H@N%>)? *<<=2GY1B-8R WAD:?JC^
MQV?_>1(U8&%Q$?@\:W* 4W7"1AV3].V84TH*T&G!A7Z_4YF<84BC/1N5^$#C
M88FN2,%6M<Q ^]3K#RU?S@>Y-Y< )D4 3P 7HY@-[@C6!9$2.O]"&IE9L:X!
MS2)KE<KNH'<.@K$WF;."AT5"4I,%P")A/4AF@PZ.AP8&+&$5G=I^5VQGH<WV
M^$73TFLM_1%73IGFFG90E]6_QI:6Y7^;7>B)7?V,UI7NP" 3GJV*37\"Z OS
M/,-SGP.,X*5<(>+C*Z+%GM5RUH6<',<E.M+/#G9MXG!:>G=5CTT<S<N_)YJ/
MH<LZ$8\;B,.R%?FDL:=KXY=4Q.XN6BJ-_AG8UM9]B>R,$##K*@-JKH/*I+W]
M1 OU3H)1+8G5Y!;_&M@$+A#^HIB=^NW@JP.ULBHS+;\>+)TEACVL%SX18RB]
M57.J5B3.-9Q-[JSBTS0/W<<A_D3=I..)6H$9<K_ J%%\52GE=D(M,%CM''"*
M^[#4DWL%^#+*RT?#"FG-Q,RG3=,[WA '@RFAGRKABHF'H;#0]4B7X E+H[):
MIJ$904+M16-V4>?\4I<X_96/#RQ?7'X7WN0\W&%F)M.;_FZQ74DK"6V4\27$
M9VGZTMV$552K.6! =1+)X::ZLDJ_%R7\[39W<CO]<E<*,P^[9DQ;[!KUV8/.
MQN$B^&&'I&,TH^SH2SO(3@F"_*Z[(U]@89L%13B_(>M]IFN:6*8S5&+>!*<7
M>T"*U[F,C#&*S?!9'@?MO)():04&,!+:(^]G>";?Z9/H\5[HC6M9PB/+C=3K
MQKH*;%LO<Q\S)="=DT-79,(7F[JEMD; ]T'A:S^OF8D=S-14Z_+>DGZBS'3]
M# !&0YGO7Z<M* B46[''MP76'7W:5&7_G?L+,FC=I?6SPDER^AQ0;<<Y$O,I
M<^57.AWTN6?M'+ ;^?5V4?."KX;/52H6(II$^ Y5"3)]\YNW![376HD)+7K+
M65X=\"YO=LQ0>2;H;*0@R5VK<C^GL(>>4]CO8+.5>@Z0/*K<+Z 7=@-3&;3H
MKL"(3M30E1O4(R$=QV^6]&VL':AAMRPGCGMDHZ,KV,]3Y!?"V-*G:7[+32?H
MPS?AI7, 1_YF<8.?OD-BA7AM\X)[N[V*C_?7"\'"#D/;EUSG?:3A>H]0@CD[
MGO.O%37 M<K8J5^X2EAZ34M:L _5XJ A)%$BM8X0JBQ6R->B:@^BUOH'5D8)
M@\\!)NUJ)C)TFZ4%:R+0!3.5R"HNM-5158WH,B.0 G]D%/C0/W7^I32KUSF^
M9VS2RFV? 02)=1@ZZ7]QPYT#$@Y:Z'3;#$(.Z)%+;&/[AXFA^5S0/M>X:PHX
MJVM$7 'H9_7] H?2Z?'TF,+C],U#0.L"6OO'#WC1I=]7%\X!$,<M3:A%(NAF
M]PA])7W[",X9!_R"/RFKNSY=[3/S@HLQSG4/H=.UXAQ6[2D;\@.)<E!;][LE
MO#W14>I+Y_MP!DE2\GHQO)1P>+WI,GGPXT>V@/8T;K/3#?U%PNEKN-(CU1;;
M&N7+"[4G PV*Z=W0K&#?.>0<ZW)0_P#!5/IQ7RO7OQ^Q-/4:Y^MHZ?Y)D_B)
MJ[?9?!U@;9CR>I-*FSW"3BJ\;W5M]:[%S-L;E7\D5-6/L?%:'=0YTVT(_ KQ
M+*O %Z4]0'(F/E >3&-?;;1T4OA ^23>OQ9_^!#IGF0L>BV-< ,MC,E)_@4.
M8^PX4[EC?=Z+#4B;_>(GC21ZD]<&%38:*E\GO0JH1?>@Q5AG-[NU?S#DE31O
M1^:= ^3W/[=O9X[$8+HD]'"0O16((QIJR(C&[WO51G]9.XPE0+D^+]6RAH).
M#Z0;#>LNSZX/8RE['1MG':8!>=6[U>6\[3W^_C2Q'^BEC)4II$SVQ[R$76EQ
M?KA7;MY+T:#PNK>'?WJW6!(OPI[Y-//U##;PDS7;3<"EG_P,)[F-=$<3<-7#
M(/(2>&OO1\3 O\Y]B7*\('E_\I <?*^,LD^<S)BO%VCSN#)M)U^?2K+?IX1R
MN 6WI&M[O,&!FVBBA+H#I"/<HHQ+R8S%=(H\ZCC\?B#M$SU%(=VWI!?&H":L
M.+>2\'B];JT*^5S--%ZB[_0E[B^"X^G;;AVB3N!8RX]EKBFH#7!!B]_G,10T
M1<[/37:&M!2D4B(,JH(AAR]O91"M*HU)D;]D["%X7"KSXM[-ZQD<<\(U,KY*
M3W^L&_9J"0GQ0<W04T@UT^P9RR$!)KE,RW- G';>J%ZAV,FCP(9XGY1W=!B,
MG@:#S7BQWA:**XR)24Q!8/1]9Z-I/*ZL'HL8R7- 'FQ$5G-,#F7Q$^<K<KDO
MAHM2<1R\:W(.\-A*4/(KZPML36FH*6J]E6PK&^'?EZX'>&KK:TWWGJ;7O\Z&
MJB>?^H;]<TDK1=.XA1@<QA:P,O7BA:SA)0+Y'90KFZ<O*UUMM1UGN:P1.T"*
M0"A)JH3@8120_^YGOB[/HT*C>")9MZA=E'2W<]'.O]7IAU@OCK1*==1%N"3Y
M2V06WYUJ7Q/=Q*:W,B)^H>O:^E<=60RPHWD>1*<Y,+PPXAS@?[0EU@V+>\:D
M7YES1Y5+#N%Y$*K7!(OC7Q<-P@Y^'WZ.]VI?!$0+0L1<94Z?KF,W6B!V$G#K
MD0@(2;S_Q'D@6AO(9X4X*.KPK#R%=&?HZ\N0+:%#UI>N/610=J5&Q8W<6MPU
M-FR":CQQSVO<%.EISW0,&EL_)VK3.80WYPBY7>"R<&%\ICZOD.FK__+-HU5D
M,U)Y*'+$1>$Z_AB7N%Z7-E!@+-G G*A?,_?M;,GQ^92YU MQM#C4LX@R?RE&
M(0*A60A*^<WR2%UTAN7[\O "\I[[RX7C9?+H6D_Y[R']2*+QO<"7S7=HI3%Y
M$5"+OZLYQ_G>DW3:=+?C\+*X*)_;AJK7.J>;XW>7/C80'$NO;7T8"7P!2*CM
MQ3XFVK2F4=F360P/[:)(<I*(%SI>P\1/TPZ/^1Y:WX-R,(ZT0<_YR]DDW%Q
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MR."<FOUL4I18C_+]?<YYOX#7OCD,CRRN=K.Z8(?Y: YDEG66M*R53:JR=O.
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MILJC?VZ/7@6J^5+<*H;^P>4<ZL9,UY"6^)Q-3+?"6(8UXQG**?>8<1,0J;*
M83!?SHT1=)%E?.-O\1 Y.\2MF>7K@=#GYA[3C:J0MM;M3!]KS<B]*_%O+2TS
M"*DRY3=(IKO3\%T%WF1[2#6S1Y(%Y@\SW0]\ M0/;AN75U';'P;W<5:DG:+
MBF]O)%P>I.Z!A3"RL@&+C6_ZV1J=QN"3EJUTZ7- ND:NG-/:?$9&R0W"\@')
MV#M:2EG\OPSZ?T>F\_G_ 5!+ P04    "  :B7I:51WKKJ=4   \[0  $0
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MI,#P$L.Q]4U_$PFN*/7MTJ5C_4^.6D%)<G\Y?%'(-9>2) $J1^4I5A*5/H2
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MM&1.:T0<8P%/$I!%&UI5<%<(Q&F5.:$ FJ^@7AM58H+*]X(M#[@3*&BA&%4
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M$D3=M1HFTCFW&<E4+ %;B63B18=>-@%.A2FX<QI.H^)=@$S3YKR*XRIT &,
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M,VXAHS+C5)QV MX74X+>BLHN:BLIH&I)&>&PIFS%(PI!B@8,?F58H(KB]N-
MKL*EL;Q 9$,LI-)')$]%UGM+41",PAD=K:U8"9OD"M561>6JU8G#R@PIQ9(I
MPF7C4;^2Y^5L6MH-9&*XXJG4*;4W3?@3VGC<%7 ::8;*69/58E72B625M&(Q
MF+$G'8(GVFP0#\6#V5P55U,!KY)?"XPIH 0 UN+.^&4[E0ZG?1E=)B<P)0\@
MNW/9-$A'//:LPP&J@:0O&.3*)N5;V5!PL]I:'Y:J:#F2,<IV':-W*3R9(B(
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MEDEA9K_$VB/.$.!0,1HK0T62.%B DPZ'+H"G=!4(QE F64C92AEO. ^EK>F
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M+3< _,E@H6X*)^HF7,"M#!<MN?T1 J.E^I&O?_ZY@0$W.0P8^3&2M**LM>7
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M9./G)R/Y(CQCSZ7+/X,73:5-T[O,_4:S_)FWSQXZ_^-K)DY?]K?N)\V:=>'
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MEVRO]VS(D-IY4:J->N2 (>YX8XX.M7%SSA5^NW0Z7D:?%\!F4R)7>'AG.)J
ML H[KM&'&0!DY3]-SBRN+6\.Y</C7.^ ^0=MG9'9:)7*R(L74,>A[B[9#7J[
M!W16M'9,Y)_JK_'_G,3[7VW9/4!E.2&?8W[E^&?_WF%U; \Z!!I*,LMTA^#6
M.^,B7"\)UF+F?1LUR2T9'7_J6NMX=]IR6?;69D?;PA(73T1TN5JU5GP(P=<M
MF=R7/3S.MUOW,X@>!PANP<*TJU'U/-/2T!PF;TKHT@1*;[YR4$/%"[AYWE=]
MR9$JRMY@/QWW9-T0\0;:>%TM?<E-I-<UC>=\&U#2^N'3"9&Q:C@L"%S];=MO
M^Y;8^ER6:6MT7MMI@/8;P#./^1+>\%)%DBG4J/\V,): Y7;2N^!G4=&0O4CS
M1"[Y]0:+ YMU;Z>D]<,XU))[#'3/"CZ<!LG[,SS +;(YII>=)=DX$W#NV\N<
MN^9CO7T/U,S4%M20YST#YC&1IYQ<^7EWOT1GPP]F]@96NGMLK]P<%H'[ELJV
M5Y9$W(?"6\WNA_@=/*!*Q 5O4<Z#\L,0[),E9HF>_BN&WG";W7";,K7'D'TR
M*6%F$[>Z-*WV>ZU#I*L8KR]5*<])TE47KQN7E3^GO'X$"Y\!.R3;,7/Q5FQ3
M7<1>I#^3* L,0 6#Z^92"@'(R#Q.3=-\__*!>15SZF]-9BZ I6IBMRD2HZ_>
M!16=L.E\A2+ZU?6H]F4,0(,B21//QOH-I%JQB4N:KW9F&-QF6WT=UH_QD8+V
M'FZ2+DB,PYF9*"BNJ\;?^C6<ZUKY9PZS$\[:<:C)GZ-Q>4C[E^<I'8BTD.#G
MN*!4#9E)*M.,)+)4^':@[:V9V9+H*$^K?'^-< E@+66C,N7J .%!\=:3',5L
M?+:ZX=B_@!,B02'[(:)K)OJ*:48?B9;"_I[Q\[S*["/OWJ'1GIBD'U5.=55(
MO0H>$#KU5&VYS_YT80V]5QKQT MQI:JXO":FN*SZB7S:>] R & =,'.'&='"
M[?924$%K6>XOW>FG,DN)K^X:5M'+>WXC*, -EW&5S+9'MB=W%4T\(T7Y2FO@
MD=:TRE<>W5)[2$#BX?F8GH#Z:I><VJ#'57DMOB6!LW2A9/]!P]*.YDD-U-GK
MC1^2<I$XS.5<IXHX #:Q_N*77>3.>Z#FV.Z4V]'K#T_+1GM2C4,*]HR3%T$Z
MG7G[M/Y9$N?JXE!*]97)58Y?$PS7CG:I ,>$_?QCKI1AQGGI_93ZGH.- N\^
ME7.'DK<I3CT@9$\#8O7]TL%):JK<RC%6XR,O*ZB)/M=>G6KL./ G ZM:?H-:
M0P%33,=-H5\7+EQM>K)T2ZPD'C A4ORT?Q=?!]N%CFRIO.$"L7\K1&?,.]&H
MAG>+H:<9EYE$44F81Q6AE^/[)O2Y[-8U9$KDNX2::V&/]\9A$JXU+[O715+J
M(RS7*O2&@826#SNSP@M$")HQ >\D]%^7R7-"@O^F]?\@<UZB=%9(W*AFYP+1
M#<L'T+K.W]V#!:*%X'C69Y^'<>LGE"3_Z]\W<M??/-ZB]'MYU1YYK?HM:AQR
MADSZ0K@WPJ6\X:QH!M^A<&.%^',Y)R(7SV9%6$F7B.=Q2#;[(T/09:RLJO&U
M[[\73C "%:@P^I:!&U_B]AY]%2X/?MHY%94<_X9[_.8]H6JYLER9\5HGU1CA
M^R8=*#M@XF?*O+%54^VO_9P;%\B<3\B?HD#&; *Q$O<_YUE\O;-,S-*V5+2O
M+8W!97A8O:/*@+Y(A_.W?_S)G!<G1ZQF&2.R8O(_3>7SWPH<>ITPV[+-W-3J
MH\*KX74I/!;",7HE1:H'7 I7&0"X!TI%*BU,U>V/S-(4?Z+Q] -$@#>1!/[X
M7"4MDJ'(Q[[&4)1[=!8P^5[K<D5/20Q#<EGVRX44TQ8!OA!Z].HB4>[I/7[#
M.'NE;(8!SFN*"=W??0["-,ROL'T_/GI=)[#AR)OX+?:(WWP3=?_+I565YN8D
MO+&A<?J:MX>OP,_?:D$M$Q^D' )!QR,P>S5NUIH7;T7>_[Q[U&B+\G06P5 O
M7NR\Q:DH,^X)QF("@E<_6-'(J*H;%;21.Y?=^@P=&<JQ^[6E:L-F0^G6(?M;
M1Z^T3<7_K:^EYNY%U75EM95ER$=5OMUZM,UU6,7K1)'^L7QLAF]Z*=BCJ+BF
MJKJT#"F95%*KF#*W-S;W%#_^T 9J8&IN"&@F=5AQ=X2S]>1N,<.Y%?NJ4D*:
MQZM-NVC1ER3Q;E(2\\;F+('W=C)+THN(PEC.FV4?<SW06&/.8K8G@+[V0.K;
M[QG@(GV3 (MO8@'ZZ,^]SKWY_D3LB7+J]8> $2T>"_[KTQ:K!;WLZ<RLN!C4
ME.Z@%2//10T%F92..%>%'S#QUD>;F$KWL7# QG@&-?Q%HXW;8J6CD3=E$D;6
M'6GY+A<;$\.T6-HZUIHIUV1H9VT]]MY%7PVX+OW>S]?TT2 XD7@CQ/^-"<TG
M@2U;W+YX="8K2RYA :G7(^SB1%^##\J5O6(V-DJ!6A5&/BQVS$<\7ZI21KU,
MU[1_-&I\'*+6KA0N IW<ETUP1G(FL99[3_N&UQ^""'RW$M,_]34ILYJUE@@R
MR#&GAWWZ#9LIAI5V\JR<!YIZVN0HV\68.W,Z,PY LDN&4J5WAJQOCVWE$9LF
M:U%Z,T-0#DCW/&.+RQH\LZ7FP,";GY).GN!U6Q<4TS1/W@4MY>['XA**.%HH
MW:O]:XMJFC8_H\FIHW9?-'58=DRM"CU%?;#HJ7>H/1=]02 9TJ"C.ZBKW?UX
MLO<!J-FGD,<Y1]G@#A ,</P!"1:-: _.?W. "/":#!ASQEC6!LF/Z8N/A]IK
MZ(:NI$NY&$!9<BRVC,N2)W2_&F;>?,77YHH]J"7;/$F"H#Y9[CXR>IKI31LN
MBL-E8/!Y^[_2/H.N\*BK\?US@$2?;@O$K-ETE0%$IJ!<N9TP/ Y:4$V[G%:\
MW-AG-(V[]1:H^NZ!H1A1]).03,;_2IG_B^<XDQ3=[;K4]AA966&X//<F-['2
MCM3"_:JM-NW)C#$U3'< TD&+N22M6ZR9E% ):$+VKB3=F5F#.$A'Q]L,F)D_
M5@I.+."8R\S;KWE,JI,)7:9"C6R/XX1D(1"GVI(!B4? 3/6@'%81!_EJ?:A@
M\D[*-B''K;\NY5("<(*'H"OZ(10<8A]$$DAQ=<XI97]@"; !.VSW8NM@*.4;
M'W]+JU4=7U;NQ$;OBNXN;X(T[CR%Z'!19W/T9=*T=7J*_I]O3_^-T7^G_@-0
M2P,$%     @ &HEZ6MD'9BSH70( %1X# !$   !G.#8S,C@U9S Y=C Y+FIP
M9Y2[R=+SRK4E=BMJ=D=^A!.G(BKL@"7TG2RI B"('B!Z@)BA)_H>!##S<WG@
MU_#0'M70CW"-[^-_I"/=(]4U(_@U1.9&YLZ=:Z^U$_RW_^O?_N]_^9]D7N+_
MY3_]IW_YS__]/__W?_F7?_M__G?YM2S#'T"PFW\?I7V<_3[I6W"/!A#^/03^
MRQ__VSY$29TM/\59479_^OG__3_^SY]_*M,__>SC&J0-M^Q5BN>4V:?N)&>=
MT.G/_^W/__K'_0][.[39$OVTMTTW_V'_T\_?QO]P_?WU,?CS3]]-EOI//S-?
M%WX*-..G6S]E/Q&_AWZ70!#R$TG_'B8P'*;_UY\0"(% B (1_'<P^0<<^P,$
M_?3C]?.?__7Z^<<IS?]@<?R/VUW__>GG'_-ZO]^_?Z._[Z<"A&F:!B$$1)#?
M72U^-Q_=$NV_Z^;_\C'RBQTNFY.I'):R[W[Z^C^*^W7YT\\__^M/OWI];C2D
M^?Z7._V-![^N7"Y$P=_J=LW\MWO]XO=_T$F0VN*?=RS LBU^L_OP*Y_\_4C_
MX4#3Y"]]AG5JOKV8)F#69&W6+?/5#_Y'8W6,_\%0%W#X[9'."U>V_[SO[!Q#
M!E[-LFZ^ENE:P=^TPW?+?\0.WW?+;UKX<OG_R-^_U:]LFG5>IFCII]_N_JL&
M_VR]->V?W[UM_X$#K>P?+/;?3MS*YGZ=DNQJ_@\\>-_^0Q[\Q=!]R[Y<^>>_
MVOKCUT;X V,XBG>W_@Q? ?-[Z/<( J/T3\;4?[W3-?G::K]#D3^"?]/X5T8N
M7_SA-F71DG'7^\\7'N"_@]#?(;@#PU]X@&&_@\@+%?X(_EW+W[+13T[?-W_^
MX([TUY7X"<%_#_WT/_MEE_;O^7_YE:T?/?[.F-:G97[\@P'AOQ[0KUK^O8T+
M#--HB?Y#5G[=]N_L.*^UC;NH;.8__\TZ?@,:TRQ_^^DO%YKR&^"&:)JSKW7\
MT\^_+.3/_Z[#CSM]0= ?WF6ZO/Z,X,3WP'[UT3_K],K*XK7\&<:@O_;Z\=D_
MZY;W4QLM?Y:-N_#7?C\^_&?]RC8JLC^#= 5B#&/:=2A;!<,RQ9U5F?O,,!Q(
MFLSL"J\M%>@S$NBWQ&FKQC"863<Z T#,]XMEKO9?KSOS7__+SOQOC/G5^7J9
M# L"&,/5?!TC<L,(SJ=##L:,=%TLS#O+N'>V<'FVJ 76?,JW=R&P1:%R3*_<
MWKWR;9!C&8UCWE]ODV,PX\Y0#X[5')XUG?O^CH5]3L2=RO_R?M]%]IWH' ,]
MKSL\A9=K\5;_?>W;X-\T_O_Y!JEKHF;!5-=TF??=^DR9D2S&U*QK:G<FDKXF
M*3)?LS/OS%]?)L^\)>%RBWACZFMZU[5"XOZ^W0\?,K=KMI=?$NEF]NIU^7;=
M@&,*\W9]=GGD,M1IUV)I%LLPO&1)N^G=A3MR+Y/GW=4&X<7N_FZ6!OMMT%W$
ME[:')76SCF*[-^9I.?6H'$_4N.FNV=7$X]1?J1N*#@>MDB3WFGQ[%>%+OEPW
MVI"WZ)["3@<&&O=O@_##@<+ YYO(A_<T:&@_1%Y#U"YS[./;$[7@M$NQ+!C(
M7(2!''W<7\](+*56*;%#KWK@5N.VUPS9LPV_#8YQ)R-9ARO5H/CM0)3#.*[S
M%!%;;UW^O:8O<:QYA8OYO-^N@(B_?/:Z<^SM;FONG7<M_245X5Z$]^/;8!^+
M;UX3+<S6;[PGE\EV/V7.XHI79+N'7SY)]<:BAJUG\KW84[=^%]]3EJN0%\JT
M3GD7I<;'^3Z*X=L@!!CG2[;K17-<W+":].E[0QSP<!; 5A.V:1_YPQ0+\!HC
M_Z/I?QL$N$;V_08OPW98DRXD\GI\U$,4=:/2CB-Q+-,(;&!T!1KW%1'WKQ#C
M*(9VL?$=4+LN4"B:#42:1I^P@1&(F6EKB0\%WKB8#0?,7#KMT-5;E362+S^]
M9^RRO;:]CY*)J0V9[=MN4\MVDL)PRN%^'#Z_):<Q?!:EZV:8*6]HDF[$4-:^
M[64J@C]M:ES6=&_>#V$!(2 @?6,T]6H*<)"HHL!M6Q9'7RO'"M!!Q *?H2ON
M?1ML[( 49;_0\MWRV(&2J5!XW,6<-I+E"-G)K_*VFL1&//#8/M"FF? -><Q!
MLR26"52A08S%,5U.G^O]VV#0")$%'MW@OZ9*%06+'!';M)F]1=?\/"#05ZL#
M'QI4S8)T$.#S%N/DPPN?_HK#]YFJ*]MF%I[P) S]+,JM1VYX9)425@'=:A'U
M$^GR#HLS;(L""_9.AEY?ZZ19BKN0-.?+H5?(W(&@4O)0ZZ3<WJ2U<0>1BY\X
M!*,!:TW Z<!'#SQ)W=!J3[\',#C=![TZGEY'JS!? &H;O2$M@YG,'*-RD[&
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M;_P0X./S0NOK/F"[L:#"D#7 XBM(\!I<79JE5:ZM;:'@UQ@:)CU^=?%7'47
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MXC6T;URT))M.<%Q:!XB.%$1U@[DT]RB 2GY=FW/0@;.<]N;\])V/U@/PC'F
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MC/6#*Z57\?X^ G[2.3'Q])6J8V5N!*4K;/8 I'N<4A/VSJSX<3/Q%[O$ >>
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MA?\\!"6V_#G-*:XKLEI:$LE>%.>Z^V 5]P ;6AE@"MAXP[UY0JM)2S#ENVG
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M.(/,?X<S[+?^<0WY;4'Z\Y+SZU*D88FP_<KD9^O1OWS)ZK0WK?]KIY2$D=9
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M*"DICQX^2GOT*.TE1CK&2W_[VGT%H#E,_H'2@)SL N  #1DY#=GN6P +@ Q
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M5JBB&MEK?A+Y $\<Y(?C2YGN<IPPZN0^E1(Q'O:0$W2.4M,*@ ^,3N0Q>4>
MQL_,R'*GI/&D"<QTM.AR0<:ZIXO(-@_Z8K%TF>/KWL8O'Y3K=?4BF+3[T@-^
M(0(_7^,=RA&]^IK98>F-\!@7NB&@K"A\M+6D%5,1;SI:L"V;FJ6O/"!A(D^\
MOG&.5?L."\#FS7O1=#7M65$%:4U]?(+ >(X1=[+,L-),]=BF1ZZH(]?=YU&=
MK2[RE0YSD_%Y0[PB4Q8\N4V<<L&?KS.P]?;@K=T*4W'6,&&F_(OW"@?2U]22
M3:V0\.T4:VJLH5>H+WGD\IS)+#HM$J^BP*Y-FZ.P*%]G=$\/ZP^S\]--[?5(
M&F&FQCX=^:6Q+IX=",%S6/?;.-XKM^7B#)^,,9EIH?8_KVYXK#CM"5DM\L4C
MZ<\<-E\49:I@YS3\)=$=9@GS9I>>G].#*L6]LY\4%LC7=_9\K Z+!$"L*E(K
M*N[,L.NNV.$Z(K/ZN1=%DSX:LWA&?3X4_73RHLJ.&!6Y#8 FB. 0@'[TK!]?
M]YY23(S77,F+//(DON:H'F!'*<\'\3XV+NU9"GEK:F)&2$[>VGB1[V>93G@R
M_-/5\:U0+*HPE5=$=++D$D^2KZC9 ?#SB@=NHLK048&*PYJZ+,\V/^\",J"0
M#^@9.0,UKX(JY_%X]3;=!JUJ96DR/@\'^8NRTOV3C_3%"&5SS?Y=G7JE;O'E
M+P,B4*W$D!QZ88@-E]BRM%X(%2J2K^J(^M'B[NGBRD<1!]4*\OOG<,Z/-78!
M9$((OT?P<Z_7",ICT>>AA@6ST; RZBE$9V&:#VJ%*!]B=TC[]!.. R?BAJ]*
ML!R=GSN737\*.>)=HQC7=MM[Y;5FZN*U%Q8*<GT^O3"):TC4M:MUV(A78H!(
MOQIF2K5Y>)IV"!016%2G;$(AC^O0$F61L@WTO^)RV=3&!L+FR3)WQ*0G\36]
MT(ITW)I(;BP8^S*UO+6WH.$"C6Y%9*3?6P\U *6]C8-'&;RDC33L\K-"&U+X
M)D6]'93/1X^P/SS?,WW>6<\W<LT"KN9<8ZDG&D+/3Z#!I7>#Z%.RC>YI"&O5
MT,;9TA]AE,;;$X.(K[BN,"KJH!\P$ IF?3JMHI9HBNKTV8+HSY'U0-C6%H=*
M6:R>(CN+\8S-9S-LM_C\COE,I_:/A8F*!+D?7+^N_>RW->[7.=S@3'JPJ$O-
MY4Y1HY[:R:2$I-N/.\DCZ[N%Z<#QY&(M-W+=G/,O03Y>P*P<?I"CL3<1XAM
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M9G6X$:S5,\/SP]"S_3WDQ^Z%B_B_"F Y6RU0Y1 K"^\MS[A%?&/_AH_J;F?
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M6K$9]Z(^G0U>SO.ODI.?$OD^ZB0I?;RT+[:D;R(^U7;>&VXE>B2*MIK: 9I
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MEURN8>!G.Y7ORLI2VG)R'V<J'[_'_HK3<3T_\=7G5_#B6I'XZ,IZSH*+M?+
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MW.I VI@VB#9\Z&!$Q/V5Q^MJK<R"#H_RM\WYUI_P#/:6\QG4USN<;>Y[7\A
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M3^"D5U4C=@$=K4O< 0DL6]B62VNK$^-M?2]4CPD5G13\N,#+U7_F/5TII9=
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MJR?7,YPMVH"=494))^EG5%HC\Y39'@6)?/)L8O_FC#H"\09< 9Y;;>V,)1H
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MV8\K.6NXQ<?4(]IB&5\T:#^@@S_YF@$'$F0GB B?4]3G@C#-2495KI_;84B
MS,(2AEO-[/S()Q"+S'GR6U<A09G#LW)\W3%W+#[K.')MHU#;)*G44?O72\E:
MD?."46?8OMH3WL**D2:Q]NW^U'GX\A_J.*<I\RB/^+]UI"9CQ!-L(&KSZUH.
M.1-<5L-Z>#%FT2DN3Y,D*? K"7=+RR6]\5,/IJ&U0B@'Y2_H_-\LMOS&N/>
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MF*IV14'5HYI7W)J9T")."50F:E5#U5CPNI-3^,]CU3?-8H<IUJR<\KY>\\"
M4!BX*Y&ISLNV>9;J3EYL]H%ZYV\?GZ?O95J:EX-O+F&91<>,_7#Z9:C%_JK/
M@51,$X<W5$GS<3/J'M#R!_O,P\Q&8F_+<ZLZE4_[PY2AN*V XNYT?_%76M#F
M;AS'RJMEQ\81*TEC20HB5(:4G8MKNS%</J:50_G&;H?1Y5OS^<+&>.^<,JE-
M=H7'Q>G*7HDZGN8MXY5+/M]2*7(<'BR4YQ26Y'W2ALC#DT&QU,YA*G\>\B/1
M2]]4\^6EJJ%X C>89J6L_M0OI)%I *:?HK6UDU<%*2P-@!T)F^E18G5":;^5
M"K"S\'[2H=8!!1I)> =$)(?DH[3C75<U=*X IE> J=5IBE@).R0!YFDP+;JL
M-<O/X"FERBVN/DADW9A-(L@Z'9R-T1<FC[O7*)1-/AI_RO*KCB.:/KXI\M"Q
M":6E'1\ISYCJ8TEQ!3B]O7H!@^XD[9I8"9Z&+2)JQZ:WV7RVO$N*"MQLOCZE
M%!$E;4RH2H^5)BG!^"TR"]AX(SJ7;/\G7EU7_A^-FZL "KGHD9/WI=ZQ'HLN
M8_,)[Y)75EX:),_YN1["<:=)%5*-='\=R^ '\F@Y3+[4WE3"J)YUK^^H-B59
M*%P\O@*T>LRDU\ZXXM'M6XP)8"N.EN?<?,^^OBRCZI<""-Q-YT@'&F<?EE6.
ML%5.^A_H$:7S4N!#OWCA$N]NDI??P#C\[<6CHEY;_#CN7]?UB+)'-VVDM96%
M6G]'9Z\M3_OT>,;_*'/Y15YZBFGZ>]9>V9<1W_"Y(DY=OLI%ET"+O\=\%#N_
MUMDBPWY\&HDOYY3]E9.N2WBNO]1GVBD55K^!HF@PKM#A-N1%Q*4FN'JJONU?
M)'P-R:\](:1> 5[E_FG'<Z%=R0M0" 38OX;YEWOM0Q\RMZ%AZ).U1K-[HZ<'
MZZ[>M9J6Q1L;GW]C1UK"&^JBTRG?*- .XS=^>6)*XU-+5&\K*JG1+,/73S]>
M 6A+"E-$/215T=7\>46E9</,J$BMSY1T-U\>3A*O<UQKEI>V<;>XY3;JFE>A
M/Y-JW3#::/U6@TKZ<97[Z;9H,SO^] D*UJ:W]4//)XX^ >=[:21)?AA_!7C?
MUA@<W=25H%2F?07 .BKXYA\E%XW5R@T@4S39C?E'K!\A88,DR@+E &!NIW?0
MF99I@UK@L'%-^VD"K[>82G*U'&#[G3J 1X9UN=7CT'A914WQ0?N][_!4I7]A
M]K/_,GH\X&#>X]NF,*E11J6CV0RNZ+I68<O'&8*<C-TM7CJRB^GDC*%3#5/'
M6:A+?8RPUV?=_LEGK[O8E3F7%=@3U*L=ZFK;(O8S^O-7N:%R!@XEF)Q[W$JZ
MS'O\JF$1;*HH\,;<]:9A]5?Y82!KQVAG'=EF(_CCHJQ SVD@<M\ED(WCM>PU
M%L4O*C(/SILD9T5$=C"]!"O-W17T\H4$]Q)I06,T=_=?/Q3U7*P!>PYC+[7*
ME$94+N^:7P$ZW;]I8!IX()6L6X[$O*31$3E;+.UJ]M!VB$3Z"M=7Y@V'S5/Y
M^/80#"?SX9ND"@]($+7<?&]%8]6 F.?XT Y2*],00QU--\$N4JZ@FN;VW]AY
MRZBXMFY;M+()D$" ")! (4EP" 1W"<$A0/#@(6A1N#L)V4"".\&*0&&%%%:X
M!7>IP@O7PMWUDIV]S_V^?<Y][?UX[;5S;ML_:&VRUAB]]]'GG&O-M>:"RRVL
M76U7%G*H)KB2:8/80W13'$CW\$V[Y'&U3,A'KA* 1:? ZJ0':?,B0S3(R?3V
M,?X/\S P^9-WJ#M^PAACFJ\,MQ=<9C,,LCZ'5!5= X2W0I+BB!;;57W5'19"
M:2[ )=< _<"+5]6I<2R]Z%+E*<1A]!L#,$/.^R_#O+=Z<)(?ZCC&VTS]L-7;
MM1SPZ)MQA.;;?*NJ&]KG?#]XEXS5CO\RV(,.JIAU&E5(9B<D.B='XHVM2"DA
M,9<3BA3)SH3??G"N$1V=QRJ=C.3-TVA$D@?)!M,ZV73[% M];1?7E';PUWM/
MZ.,__-K*]GV6$=G1IF\G&*YR*,98G1B@:YTJ.\6J>2K= Q]C2]0\?/21G$B6
MZL+&@%\UN8%E-@PN9\];_WD8JJ7HG1C'?Z$MI3T;,\@=939NP>9:2FL\5)6W
M"KS(TVM(_WS!6[#4J4BI&;B8&]Y<\)@L+Y5E*2XJD1+VR?$+&8CFM, 259NY
MNFF8SQ/KO<S*X)(=8!W0#IRC:RRPL.@35.(Z*50*@9*7@.-IDK?F2WE3D6HG
MGQVN >YB%XQQGLI9B]E+S(4J4KUX'DE@D G@S$RS,WF!@O<5M=^PWA=-2X('
MH(*R:2?OTQU%E;E[B9!4"S^=D0AQ&M=T/O]ZQNR=7%GSY<S E/>^?%PN!CTA
M<\W?PR)JSZ2&Y7@ZDP*?0#>^!/<X_7_U =W_M&99_TNM]6G( #QOL'6WZW2"
M>/B>#3* DW*5,#\"QX-KI)PS2W;\A4V8)L]NI5&O70=-CG^.G+1<F0./L[&L
M T\FPB ;Q:ZI-Y]58VCJ.:.SEJ"0"3X*F^>*X B]9.&LVG/NW"2@B-:S.NK2
ML2,<BI(U!OB6(=CK8B_B5JI70TI!:]*R2HZWG,2*?\?FUOMFT26@2^OA$R53
M\2FYVG9L[_4V,ZP&)K;=TQ0:FQ\JUT$53[CT?->KM-PH:_7- $KY*0T$[4*.
MXS97TWGD# ]5ER"VD^Q("XUL:PPH_GP+F@/(TUL;=C;]FAABEW=;4B_T7UZ/
M4+3R+*%3X[Y:"T,U!"&]BBHL1NFQDT-/0_:-VEWFV5W"*<+\*H0$V >VWWMR
M7V(E2HN3/;T:]AXBUVG/D9#:&I;360[AV6O#1PM^K@SW:$_HI/]B=&#U!FOC
M1+)&=#/_I7H>$YW9PLXU .'X%CQM*:J'@,1D\];XA&1\69-;NVT6]77YM?&X
M )N-4F=?'[]-O^;F:;HUYQ@B%#+Z=G85QF0<])I0>L"B3T2["]Z<957MG:%M
MK>XDU4SHQ ' $.E6IK;D5;?*]]F_[2@.36GZM^_+_G-'WZQLR)[T*; D8K@%
M]IM&_'R*)W"Q=K!!ME"I-^H762V=D)%J#[D/X0QD+ACC252U@IJ%B !L75?+
MNP*O"CW0%J](\PIKB )7'M'>21@8NNGE0L^S*4!H+?GC\V791K;!@XS5FET!
M>8+N!Y#G^Q,K<Q5(*05YJF=?:U[</%7;KSM^9=AE&:@U?_O?8<3_T_RG^4_S
MG^8_S>=-[K*CGZ6JIPDJ1T[>16PE)8V/CU\#U#%"AL5.F?(:)FG8+GW.EDTQ
M>LL;D4G/41#OI&.GB^UKP ^(]\2?K3K="KG5K=I^^GVDQ[D8C7,ZZL]SEV54
M/L!CYQFA:X UGTWTX)1[O+O%E'YJ9,T#D)@8P7GU=LHUH!S:W^VSE?JSE?0'
M3ML>LKI&C,8E'67@D_073-*Q_2\8EY\PH0M09Q<?Z2VI#*_+BJV%>M<K=+B8
M]7GE'WA96R@/ST+.;4KJO-(]/@_69YC=!E?*_8:C(?<+VZEVK^U+Q-29C++S
M,E] ^/#X*;"1-'S_9*8F['3FW%+XZD\XFTN:[.I]MAGHX0W/KA2T]AK MS7Q
MBZCWO'P;\I-H&R5X0[1Y(%C#Y?X<6>\[<6QU<7R)V+^:J;$YW3X'U1R$0=9[
MK(=^G4]= OQY_.HMP7FYC^<5VHK\IP[>-4K]A%JD1</>)]NI"J\;A&L (^DE
M6DSDIF!>@C^$3$CDE?*ELY)<O54\1_S!GKITN[]&Z2=<D=9/U\9E\K9LU758
M+KXG'8-F?J;*G(J7;@W6W_ D$?A 5FI,J0JKZB(M4O=^MYW*OJ$IHUZZ,_,G
MQ.CJ5L#H3P0G'9J+-.UCTS\17E=L=?]$L.(Y\TPK0_9OV?ZN0WV1EO ? 1)<
M_SL@?5.]]#QIB33@1K_+Y;AKO^^$RM7;C?.2/P3_(<+Z9\0JJ?]-1,#/B&O
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MA&_26/_P6^'O?E?_]-NA4$>@]"_$CFJ5ZH M69PYE?"C2(UK0*R:[Z55^#6
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M."<W%@BQL!A<1*JT6$D*6)P^YU);9T"CM'^ 9_C=:0EFW_,3C<&CI3.5>ZE
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M576*B+LC/,Y@Z\*V&-^J-12WMQ6/#VG95=SYXS5!<= 0@G=@%N.F++@G6!&
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MMNQ<9N WO8*48^Y3>NS:_YI4$1WW%46"3X%7\[YA$H/FJD_L S>1_]E/8'Y
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M0DQ0PMJ&Q3@A86WD:3LEPJOU8W-&7-43F73TR))<S'RXAH8\P\","%Q(FU_
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M7EFCU1"@O?P:==%[MPZC9S]%,2&T'<]417@@BY^=CA@8QHV+[8@DR[)&B9'
MM0*X8C;4G",&M(9'Q.CN,M=A[9=E)SH+&^$Q7<JOUO5Z8?-!5F4*MA8:U'8+
M^&-I"\A@-H;2/3RQ25QYY7""4Q3^F' @"=.A1E1UIM%QT*P9IG(+0#PY^%G-
MYJ(&KY:P5$4R=/7,5HQ=S*FK>&1F(49?QM5AT(RHP%[A"F,Z'R><R=E1K_1>
M^B'M1*TXB>0:I$]%TA7$XP14FQ4?XNS)G)529'%/U*L_2[(&.CP<4.?7^39@
M.@G$(G(SF*#]6.+IOD\Y)#UG_"7"UMU_=\LA[=B3A24ZIB"BE,M3@&:U<N<>
M@>N:;^\ T(['1<D%8O+!9+R_T+O,E'+>Z< I^)?^$;8\A*2:&A6S?%-O '94
M<YQ0.E'5Y=>E040&O&5!6[I9@+\>59QXSF- &5-W,3F624STML3%#6D7!F K
M3K$E?J6V3D)=F(A%G.T++NJZH#4VXOOUL],#K'F&WJ(K^AI@$SEMVUPD>L,J
M__U1XV'?L\=@^#0AL;"SH14D:QP2HV"570?<<35RY*?_/#XR\.QE3= K3N?'
M@R0&0-Y/P-Y-.HWR"N#.Q]HQ?,IW[^-X&* ^XI=J,^T8OTK7>OAU56\!K\?T
MYD R[*HCWK0$7>MT$_-\-J%#V.A&H=$XQ+PU4:6!-W"%Y^1N^_Z:XM&$@)>6
M^W%/^1IC*F().0\>-'"D31 Y,"5275 1$,G"I"=#)"79:5QY$?<?#U43:%US
M!@X=3QQKWYQRH <"&L? #I3VI94JCE55D4H6":,"4EH+Q)(I-6_H< -.^,'Z
ME(SE75\[SN&\C00^&9H@%7\4XK/6F Y_IZ*4Q'L2SL[K:_R+)IVQ_9&. >W.
MG]EHMRK@"YY%8_5%)<G(BW(&4!.NSH,'_\F!&=DCQ>Y,/UAC24P,EUNJ,X!&
MB0UI/G$+:#=1N-DMN 40]7:8_/P8NW9PDHVTE3!/VUC:4K#[X=<F.D%(?VT2
M8>WM$>;VZV(87?GDQ>#Q7T%;H0\$F#ZC:(?^"A[M0D''OYR'>I8]EOV9:&'@
M*?FQE+98ZHAP3_T)4%0O>)5RML;\T5O#&//I&XE*2"EN/V^CF+_M#I#DLXW/
MP@?5"&O^_[_*G)QE-T^VYPN"O68N^D0G\+(^2ADFZ'R;,]68]#6=.>+84V>Q
M;RQW/$_T+,.62YNMBP%?=_E[RUCM^'KV5S2*92).&^M7#6=KR!YYEF66G]&>
MK! E(7?F> :/#T/[T*=[R38^\SJJLW6AS=.>$_$"IA/5?GVBH[W4W."I)JNT
MK?>:@CZ;5+< EW\H*#NS5? _2D^3*[/B<4948WW8%L>>\1\17[DRR\[^8>7E
M&B.L_WLX[/^+,B77I4YW%2B7(\Y"K"QUD>_\N@6<Y'F6_2%'%Y01H6OD]8_K
M;'A7+]1_+/18U2W QJ7-$77H$Z(B.G&/WO%DC/]FZ9B-TB+Y_7YWSV,O82@6
MV\3:2MV2D<-G5<>2PISX0(G[QFU[V Y$U'UEN16*W>5,29'/:B+\*=^=B+G<
M-<9D@SY821N>?,7,_5M\!JA0%,H$Y,0O8)?:W2*,]A:G?"NY15QNT&W(MM_+
MQ=6_F7:.):N1^8]/>(&>Y&1L\)TALF_@,WV*UXRW *7\QH0GQQ/-^T/376NG
M-FLWK)>&?DWK(U&LRUM*H@9F9C(+]'"6+%ZEYX/#+4_?$#=\^F:UBYC9VDX8
M*$7J-,%SO[P[=0]N_\/SP2;[)EMA#3^NM1^2 IMOM:Q!I8L%KHF6N.%<S='I
M8I2V79Z<%&6,#1(Y'/GF<A)T9NJ(G"@Z0\VPF6EK7=T[.R$&8-20:)@"O:)'
M$0*U,5Q":-]@H'C.OF%>[F,FS9E?*2G1>3/\5O,.@UH[%'7I&AOLG)R). B\
MEP8F UV4-$HN3QW-;+=*JTUU3AA1WO3[-F@;BU6G,=\V@-N9"^7&1J<><Q^M
M">V0MH*)0VE><9Z'F,N.W%-&X2_+#[H.3$U?LX%L=SV5P'8;&]FP&3%"]W(B
MM&\GU;VK]1&?$.8!^:[UNC[3Q5IAX\.QC2)*]\J)*+E!Y0SLM/B3EP.X_#%-
MQ""TL*.G4^LI=^$(Z:&NJ:WMKG1>V:2BW1RC/<Y]&1D5^ 2N#02U%/-+C*):
M54F*.+CQQS08M.2O:B5:F]<[<B;?Y6/5_%YH:]V0C \522OC'P2[!$-'#>W3
MX:&/T^<[*?@L4F?>[70QPA;KE$L6T:K[9W[BKZ7C&>- +F=7_H3X1.*D$+!5
M[XJF&%_U?3-JJTC:JG:J'9A9@].@IP?A1=+WOGR;.I$%#FEO5A9G1@^QY_HU
MM>U\_%_V!N\OO<,XI4E2G%GYUJ&@3M8Y8V13[!;2&5FXE.+(Z*82;!+<^+[L
M<<\6S;T82?TW)6&Z!B9ZG)4>HU6^'J\G)ZW;TA 3Z0R<$-X=8()R%,59R.$O
M[^08(3')68&AV:LH@>(1)P1P)TDH0[1@JPI.J4W"RZ$.:@6GQ.W@YG#3A13
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MO@2J&&ZQ6$2/MDM4ZOMOE0[V[[R6GJ;3^(2]T@/Q\_$=F>Z0Q0OB=X[MC K
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MNC,&W4IA;_=4R]9%L0 X!Z,-L'*1"AWCDH:LJ84O[O8YB512_+STMI:M X[
MA9C+",SB3'"OJA30?:ER"_2F,!<6X/V^WRW'_H,%1UNU+V!NR["<39\M2J(D
MMP ZI6P3"2-^BU"<5J%[+.3TTP6TA4NWTC%:H0%KQCU:]M3ERA6J=SUW$Z>"
M3SJ-5L*#%AP<=%Z9#CR&14I1S[^)EGQ#0\-7V^[8-8X!!!45\*,0(P<Z&JH$
M2@[\)K(?L<83HU?:,38>U*2+?N]R/_U6:RCG9UXY?CR^9I>77B<!$39)W7GP
MR6VK=U]_;LNNC.\DUHW/,<_90\P]-CSY/JZP+:WPAC"3(Y]U68;8C;R);9,Q
MXCP)Q"^.AI>=2VD3L-$7V<=W0O5@O:[$2]0XJXE+$"&.U5*86?E5ZA27+F^?
MG+Y#J-*B7[ZU#5_C;)*AZ%.K-S[!QL;<+HIL+*7.NJ]G(C8W-F28/[N'B4Z,
M1MN$81\D&1IG2-F]XTE((&]!:>L)2"[\1-6#2@==WOD;GJ7V:,;#0(87;AQV
M'2:"'INF:L51+4X"/FCV!+<B]/I2:)9UK,H+9N*8S"8HR:O.A9"C,8<,-1 G
M^V)R3IX@ON?XF#I!E G[Z5<JQ;G0:,>%AO0$IV9PY&7?<QX-=&%1/LC^Q'TL
M,TZ9>"G)<DE<J-/+V=2'T\00.U147)<)^WLD1=)H51G]$H88!._I?-HO8;S"
MWWO+R.8:\*.ZYM:KOB$.1!UX)5U_R>'41Y^&D# Q_7VK?)QW(!-\!6IO*<O2
M1_M5(-2&\OA;7(MOHG#A"1,D&PXWB@(%%R[8$ZZ:@\7)]WNHAW8WOQ>-%[)Q
M5K$GY+$I*[&64=/]L4%U>&9/FS<?1OAF;UJ\J,A59^D)F6-_7?NFL)?H=?3W
M$_\:H#O.A^*J?M:B6;;3O)@8DC8K6TRAA6B;<DRV@3YQ,;ZK;!,C=6IZBW:M
MQ*]O'$2>"W<=,&9T ,$G'"=5OJI569'A(U,$T0#<X W:?%S:TG.&>H*AHA-L
MM;SZIA4S,C$/+?Y2[Y#<S*FG&#5Q/P#3N2)J/&J39YYR:7(LZ'.(L8H'&<<X
MDB,_SWJZ?)[W'>Y#I7D =8_8O89-ZF*F*J/MJC.*J9W6(?<O#X9>'PHLGP@&
M&Z6_1SD7CES '438&NCF[(OY.0F]2_/7&O]P0V (=3I[N6.?-6WA1S52@TSL
M*C3;!@44(JE>8B11MAD#78V:@Z:_";O.1]"PB?U*SF<AJ]2!2TKA3^GPKZ"&
M9'OXHB<OFLW;)",/9S9!1;7W(Y5%'J]G'^P*%RS[=GK'-7,QW@+.R1D*^1UT
M;Z:<,DNR,Z'L?GX#O)E@]"HO9&=7>%YHA;BL4.0U: [CRX%S7 9=U.EYOX43
MV.GC]@D7?G2\!=QS%>*A[31OX>B6"G"+('H,2,=D9QA!,JCUT=Y @C4?>[Z3
M#3R'[=$L/#&O'RIMP6C]V64@8WK?UAE7E/G]"<?D=(YNPPNE?/>&%$)[!^XJ
M9#L?(0;,!V!2]-:NQWA-K2_*6M!VC"**R1ZIUQ>BRR1;XPZ-679+8[!U/QB\
M029NI7P=!Y*/!M:T$7!'E\!"0=FV3A^^E8"#PVD9;$FZ]O7P_0W9_6S9'03@
MI]-/!B6_/Q4./\:;[N+OQPS%Z+Q7:5SF-H' 2Z<DXQ?B#,4+I7S,S$S)"%-_
MJ,0,N>[CHH EE PCV9^7>2G\_=B[\,/=D;>Z] >V/R^U!'TI9,,/^7T;TP>V
M9P](^:3OVC6-'%+I<"W\$";IT$]LL"(V6(B4= *>CE9X)!5>^!=)&<T'?@M[
M?V\P.G/#U?MVRK@@BE69F(Z"YFV_!/?9W8IET=9=_(9%B<.O+F [V>Q?0-[B
MWIWZ^?(E!;6"B_"+=(?G42592<'JZ^871ZK:AGQJ627?6EEK=3K%Z',/191,
MOQ]4;]#^FAQ\9="4OV:4?2XH4'YT75.;!A6>= QTY*EVL>6<?$J^]%AO4Y2L
M+#(S;D1#NX,=@]#-0)SP8/)2>*.3 @BTQOIV )I#EK@69RXZX6*-U\^NUI7#
MV0),YQ.SY!6H'9:3Q-[A?MG-:#7@DZ,^P2[7-]RM-F"Q3BQ/+UK+ZD])2_NR
MN/".P ?*NV646-<%+B\+0E3-J8CK/%Y=@;U8$\1EP)UJ]"LZGDDL6YX*T2V#
M E&?O-?:"1!"CU!Z2WER<NPN"/V% ='4E4REGOJ\LIF:0[O.BA&=KSU]3*O"
MT^B6/DNO1'E_MX'O E^]'MX_2_BX 5-_YE/B0E3ZF-9HP:BQ+F 0W6,W99]-
MIA6&V__,<2HXE%B-QS6^+F!(2453506<%9K^Y:UM,@%P$K<$HQ'L^)&8Y"KP
MZCS./(F._:KYVIO*PDB=,/7S>L$23%")>F$*K,A4:[ZT*[$"WX1?L-1J(-I>
M/UD:PG'#BE.I4">U%%L9H)[=&6SI7I\;3R!BRK^B$G&SJO[,P#1@\04$2&?V
M6JKA;H2D54P,J?-[(&!90$AH^P8],2?FNU.?1-,$U4G#6T"2FXIL0=EN<]>W
MO.,/]3X4\6\LP7 SAM#.U=0P)TPQXKV?50J,DCT#21>"OY\/[NWX^5OU]P-0
MUBV@(ZWPB$!=R"WMVO>LW*,N"#;UFG7G^,?HJ_OT0@94/]1I6RT41[+U.)D&
M\M&=QP[D.I8I?G$FNW;D(VTFQ^]J6C4K+=P?/X,)AQUS;("P=3,W=_FH4O1
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MNNKF3XG)Q<+*T)"*5K++US[DK7LDAV+/B 4T(CVY<AG[Y*H6WV$2::Z*3 C
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ME/B.27T1(5K_WG!CC7E[:?Y%,7XD']F94<GMGDM)C=4EC"Z4D2Z83^'5PP(
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M_X04K(G:$6;O\NP:WOWP9P"T0]),@,X75X12<Q5J\VZ1Q+CR[QH,(-]RXY;
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MIZ:VX=!'J[5W=C?<^H2/D$F6%C7\#8-YE@7%8)>CO- D3#<7N<M@?.\M<]4
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MTM[VBXR_J)<\/;QE;U;G,-9'@3A77O>FWU&:>%LZM0K-LG3T_J$A;CH[;;?
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MB]'ZI8^(J"Y1(PD:U]'8GA9;+<N/39_B6&$/R.N\"+583DQ5?N<@TP\?F@$
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M.(HDUNA3V!66#?4 KQVB=MYVA5>&]E_;%X\.2BH@V:I)DK*U#\*E2<2!@P(
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MLKVB/F:/S'6'7UK,_C!7'7Z7]FUG '5)U6XH>Z1G+U1M%6^]DLF+LVZDFVG
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M8MUB_#?B1?A)P\=[*/U=EXR#H$H\^O5Y=QCW=>$,^RG%;PYGYPJ%T7#'6FA
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MOA!P[U"RR 4G9C)^\+Y(1J^*LJN;;@:>HF=7SR6(DS6<GL24U)P^M@PUFX[
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MLY#F5B IW/JD 9]"VG6^Q1T.R[P%T)]R0G)O 6V>6 WM'?+RT@[Y>7Z9N8U
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M0M(N>J8-,<PJT2MPED&??EN4B!#?C1VL*@VY>!V>C^L<.CM"P<#/;V*I&M1
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M]_$K*ZHWX_0T@QA&OA:4"533]7%)%B\FH0<ZV07Z#,C/=*'[E1]Y*-R#&UG
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MKJ[:*BG-)2?6\M3/7[+RF!,[\@=A>/MAR>F8JDHY\59:M#KBVX[H*(<U[S7
MGQWC[JO.5R;/2_+4+LI34[LI]&B5SKH2C[81WZI9/@U';O*_<E>KGG+.+LI.
M]6SCL]3TH*[G\5D-H G9?GEQZEO6D/^5PT33CS(W/_:S_(T9:15'V=*+29Z/
MP[*7WT7%WVD^T2E\4*W'O)@9Q/WFN0=ON_4JAC .SLGRXX,?S[&CB'CU///+
MZR7'5(:.R-X^_^ (^RZUY/]R&<!C1T]_QU/+/1LM0O:- '7J.ZNHFDE:"PMP
MDL@LZ9RLESPZ^O[[^H_P6CCP,2X-?W-4V :T.G7!O;*S-T9::;X'C'['1,Q<
M>.J%ZA2"9HO*/.15'W1^P\"_<N$3!]!K:=T+A'S?^<B8RRU,$VVGS__963&P
MGAY&N;J]$D9AU$XSXK<".V%)2LH,BO-'E[0M+\U8LODFL818AUP#.)?2EY]P
MH*KSAV[*\"B+TSHTGUO.*3'#DD5?-DY7C#HNC%3B;ZKJ%D41N#&">I )O2J6
MKGL8#JSC#F3>TT \CK.O+UH;']XG$;AK@UM<(IUCP<*GJ3J[ +$N+4G"Y[7P
M"'?O("NKQ?X$(.<QTK%Z@F^5Q1TWSD0-UXF]%R27$$A5B](.!$EB'[PR;USS
M>3\/]L$%YLN4<X>*B65E$T]:2=-X>AH&6-O 'PXTA0$J]TZPG:)6:T?%K$;L
M(.1*[7+2H#BW4;:O;"TT\:@X$QU0P==?.>Q%YAV#=4>F8DV6VTC]B\6<3:RC
M>8UM:==FYZ$B9'W?C2ED:?VO 5QJ2EDI6?A")+&H:^^X*\!)C0/R1]]"[@R]
M[_@LN&/8/4W*U]E</K?+H;.8OF\1RSE"R#:," /V#<Z"-RWH]S5/(,TZK1Y0
MMR]O)\-6VZH.8-JG$DUL2XV^I<,[K\P"2K8ROWIP?F>P>!LFH20@$GO_KE8@
M0&(:\I@3?ZR&+"8L]\0QR%=9 ^/5VS0'G]B4+/?)P<@MNKZ):X#?G6BN'0=[
MD#<+\ DEICJ)M,.!>-**TO]JSTRCH?#_/3X:2[(D4AB#S$AD)V:,D7[6(23&
MTI0E.V,=NQ3Z)6D,1I9DSS;63(PM6S)C][-FW\/894VIVX/[[#[]GWM_]YR>
MO<]Y/?F>S_DL[^]Y,ZEQJXZ#[$A903<4Y!RJA.#[397]>8MU]Z=#2HET&T,#
M8^->D^@,J?=Z&+*@<KH*D,X\%S>Y#A31CAYP*ZZ/PDR=7'O+:W;7'/'[,%;G
MUXH'LB-V/W9@DWP_CZ\6KXER=:M))0T\S2#J>(<?YOZ'8\%_B=RA85^D!,OH
MH!X@%KCF/V&CSA@Q;[T?;>P&C7!]IMH59=<.*U<.4;M"S*/VO/A!M]KX(<XN
MB1EC1Q%A;PLNEKUB+4A)3QATLMC$+JTX^"OY,1UI:6#6/>Z,3*VZYQ--I/E]
M7I1!G&7XH'BOZ3JT'T73QQ]2^*A,:7"O9WGZ?2)Y>?N'8)#7005S=KTQ!W72
MM29^HFL%]EJO(^HJ>]T8'='"/YVXAJXKC5Q'\<C*<*O(I*59":SH3R<^Q3O8
MSFVU:(1)2)GM^YRE.Q5%L^9EX2)F3DOQ%_ ANJ#Z^I0^Y U/O!:5;.2DJJDE
M.KE_VYD0@CO^.5<9BIQ8P7CF%V>7D(J*215B\75O;CO*C N]IFYK.,/[]!;(
MY_0G7DZO+;+SJ&=.>L5K+ JM],HHS&=&U8AXSACK \?6.:1>E4<Y]XK_Y!M4
MUH5Y*"C(:7K+L;;,XK?8ML$%:0@\.F&S>K=%8J)E6T..6V>;=N3/%#/K[E1E
MX^):[,4KE1N:3WI]W$E@KBYS1W'0XW<7!Y+BZ:XR"G>,UHL>/Q(U9E%04M;D
M##NS Q-N*T'\(RP9<ZZXT73^/(\FBNE*C 3?<HAQ:,3CS25/=Y4YOPH/<":!
M4*X:XW((OBC$27U:5SHQ<?,%K)/^\3B(7M9@,=C-EIN?\XS<>_=(2<G#(8*F
MQO +L+O(O7;.I6XKX%SR69*A_<M4EAW;1;5 GF:?UJD[PO="P5"0M$MHCL,6
MR4%&I)(,;_^TTSF#XA=G/(E25S<R.:ZN^DL_?'0XR%1L$H1-Q#:[>-*X@P@9
MWTPYLPN3]>P]D)9$7T9IOZ"5,'#N/105L! VWF$BE)>='"60VO.W/JUKU)8%
MJ[@.6YIC&#7B$GJQ*3>,TH8.&7V3<%2H;O\%L&K/+T14MF3RV5RUO#8.9N-S
M.D-T[NNY&9IY6I:[]6&S8:8HK^E<R;O\F&3S%@F0V;<E:1?;)R.,SI"U!J3E
M#[2)FR1+2FWCQK-W @F*47SV?<#G1GMMD"<Z=R[[>7?K=?*OF9\+Z2SQQ]CC
MS32-#77[#$!]P&G(NYYP8P#MY*A",&799&8;S<M<H'_.R"GCXTU4 @Q?M\3S
MLX%Y(X/F"YPU+"!)6'E='!K1%F/WC(%KMOK8 2XU0!A#I%?[-BK*T)')!07!
M&=*:M_<7DLTIAH-R'O9PQB4/H8Q3N'Y#.M>,C>"(0BM83*(HE6O&I9K&\&F7
M$=L G""1F@?;>8W5.G/\_+Q*S]PB/P %)32+[$QY!V:+U8<D$0=1@M52_DAX
M?K<U$M;)XCA9WS(?YUL.XI52#1I/H\?R/T^%-@^.4>73_67%BI=<RBY6'91G
MEB_R0MPD-;WO3^&)*!&?#N +&BFLV%^Z22#0: @ZH)!47>'G<9* @/ET"GH'
M<GPG++%,D-MUS2>6._M4VB0F]4]3[)V4-VU5 K9+T5?;=&S,4"D/R\H\M$(Q
M^>-\_/3YVKGPO[Z!VA&>:./DW*"<O$+[O-@>$&-'&+<\_;(GQ'E4Q8MM&[EU
M+D!MN-64%9OP"3C&/)0'\^3TH1%..\YG.&7DE*APAF:.E[D+'%8?<XR=Y-?.
MZ2@.?=<_&;'*+2Y\EL3+*YO&CU'"I7!0&NL $;&9C'A[ENN?P?>=8D<464RI
M+0L_0SG&.,2A^_:^Y/IYL8"W%&U]R8<1[U!HD<!<J%V;Y=E^%'2[=?_.Y7-O
ME'A-!WK5WC?N3P9U_VSZAV$24^LY)S_2YKLWL?\%3 D)MB5FUY^=YM&<C=?,
MJ,(UE)[_ME01V_2=)6+(L ]MEO9-S!\A2&5AKA%W\ *$,V\N)6WY+P.L(3&Y
M]OSVCLMO)Y:[=\-UK<]"V>>\KK'63%S)3@L<ZH7%6#V _UV+O;$%]_EM!(C>
M**'\_5)*&]K&P/RH:]PU[?"]XYA0LF+61MPO />'KS9%8W.ZL&-#C;R5-&::
MJE&'EV"608 &->PYK^D,:87 4IVHA#(1DY]P^<FQ,3DQ,5L;PO*DDD$;&4G(
M:D_O3"JKH:XN@![=HAK4]^?>]+IW\$!Z]SYIG'TKH<RA-/62(+@ !GO,SQ!L
MUSS08]/+>I\ZE)9]&B]PW$K5,3;ZX<P/B&_RJR<0<V'68\5IXNQR+#1"4"U/
MU/8LF6%B%>S"6C3T"BTD8$W?0T-]:Y]OVR]R<. "?4 <B+VA48L)<C\OQA5?
M?4/]@K$L4G"^=]*=8A!D[\S(+8]_+!GM-9PXU 85M:BWG);#,U3Q#44N-@/\
M!;=7N_9<)\9%!V/K+)HLGE<>.+M\Z<43EV-/#6EU#+Z[6&9*&FDK8<^4>CQV
M?^/4ERVN9D"H??&YT9"F)R%&8NUO]A<[\=:<DS;X%0A8,*S1,3A[F,OD+HW7
MH$32R8.K##<+ J:W)7XX T#$W9D*K#!I])C:?/5JF-PQT6&(BD^.$+0'=8C#
MN]]LJ]WA;;4O*"CSUY9*;!$6]$'Q"*]^D+.KFX[7F*[%[U<@JAIY7OP4*%+\
MV.MN*237R2H#]>S[:BP$YK-.K7B5B*89 XBF5Q)*$[*QM>_7;5?"$>_;$.0/
M)FL3_%?R7E<=-)V_NTR!W]:T3>&63]^>0U$#19!W!_LQP6^3@X*+W2[K'7+O
M;/FW-TA[T]A9;L996B>XYZ^4<\/SM\H9WGL(27.,<X U^8^25@J:!X<=2QT6
M'H?M;_Y=Y5'7"ZB-/6YA>:%>CDB)W/._41]<4:,>=)54["%H=%+.N1(@J',>
M (R;"S]ZR2$;26%I<@5*Q$IYX:*&?1*>OH^HG>/X$2B97VG2T?GF!1_T[8ZP
M]MC8RR<C:XCCDTA*>\".>_5,0<Y0TRQ8ZZ)A:S<D&.A*$_?NB66,(U?L5TL7
M^6O>Z^2S2TP+&*,:,72L\UUAV$V;O)C\?+*N$P-<D+]\8R:YDP^QVQ#8\):M
MTZ207IA=8U+O^NFB;.PN<S(^]6?!Z.8QC<E,90V%T;\GQDDBA4D92O/+.(T.
M+![HM-542!OE%F32D YGRF'"H."Z,6IB2FUE?G;&$B+[A,PEK$M/4]DK4QC>
M\RKAS8E89$]Q=TEH0/3;<.*O)S5%"C"8]+ X!6>H/:-!:Q=_:IRW->^*U45I
MK14Y>=PFFC1=*_"V-S+8?5K["U Z^WBN\3+B0*SQ0/J5_B\ 4RS9R-Y%5+EV
MOF[V0SJX33RPDF'O]P28LO8Y$:S<,!9]E3.)#IYR.K?XIE3LT$NGXBI^=L3L
MER\#G!&A/[/MJ)OCP(9S-Y#SHR\-G".O2-__JI"9)N[)F;3"P3(R&/9R'L-&
M=\WVT/[VCWG'(<%75[XL,6C"W5('YLPWVQ8"G$0[%6:6$W(JDEDE+%=?]\(
MEAN.A8'GM;Q;I]O#L*,=TI>.5^FWHRXY.V.7MN&6(]*=(R%IVQ>3JLOR"4%T
MB7$>HW[X^]><H_(-$!\D4^@;#%IZ&<1[0W-JS2V@%V.N,0F?&HT=XPQ@%0>%
M3W_8 D[R1F9>[64W':;$6($A=,TWO<3%%$Z0)92HX_-A7[::.K66/)):O&9'
M#()'O)?@B O>GV!A\5I<8^/_8'.U>MA-W[Q?*G[P#CE7/#&%=KT[W"G$5U.O
MWVK5^DV289OQI-2!XJB!J>)R9&:Q!% OOAGWTEOA+(*J$A+/+XV^B X8=W&C
MY$=:XN]Z@+<8;;?7S1]H.Q$-D+?]/)(+*$$8W3YX+Z>#D<A-0<!T8D,P;(VO
M5OE([V25]' %ZD>L!QSB:SS*9+P7,\9:16S!4Q:#\WXQ,61BTH"AU CFT1@>
MF)&0F)X0Y\6QRAKS&0B&_MU!S[JLV >++7B_40,$5GB?=DT+O<IV1.1PFVVH
M1M\1GK_YS5Z]'.9SX#U=]TC-4^:(C:^F4\FD"?4EX_D 0M[Q63DPD"XXZUN'
M>I2/3:C&IYFC[DI@( )LM]]\A6U3.?6F:_?Q(J+E[;IF7:/-Z2[%!1Z00W!L
M*G5T^2#L85,5)56B9+DT=@\W^*F#\" A:M-V9Y$N;$&RDJR6ODUQ7<G/R900
M*]F1=.9N2_'8N!R&];PR4]8:2BK??^7=X':O+F<G 5@0__SL$B[\P@H<Y@.$
MP,0)B^'7'J?[X2,ERM&R49GV)JSC7JJ=JJP!<CXI/J#?7=98K>SB)NFR!D8:
MN$E0VAS<J?>%8[,#O6&"\@2\K)@UZ6T!;[D_TGY<YT@A\+?/5<94$W$M.V#X
M5&XA^I\A2FDGK\5/@:NWY_@X+3>V02=R3YP4$^*1APW:2,K8FD"@00^XN70C
MH0H%.TKZ4D.OE^0O^O+L@&F_:OGUL_Z%?EW"5FSRSII%GH;5U2$S7!OD:G*N
MKOJUG!7!^2I^$"4-9KN]&._;5'WI''RN_ 75;CXN]FNSE\P^4%-#'-%X@:9F
M?*]!%"C0>&]=LECH)-"L_89:4.YOET!F!:K-^>S71&30 CF^6=!)XVBM$[=1
M!<LO3I_*( />$)8=&S\-*T)FQ,Y@JPG: BFMA"=><PCU9E.I@2K!QPX2U[M2
ML5*1(737]?6'1(J1[\/!GD0\._=4; M'UTXTFQ79E*(/MR4&N4D\E",[P2[#
MG_-S3C BH,#FQQ;4&L,!]*3;ZA>_UFK">=(K&(Z8T 8E@*+F(V*G>.E<EWX!
M+MX2TU(<:;I7)X(PP7W"OCN("@=E62M<O'/O2DY1QOZ>$23-PLA.!L2P-;.@
MXAP\&ZEW<#U&1"I%7[6X5QL;BH'Z^94FFRH:W-37<-?A-!Z1G27$-^U:%LV7
MY!>]3+>G?PH';/;+2N/2MX@H%WA7O>@9ZJFBSD]O?K?@FI&8?UIVHPRJJ_2F
M,U8J8*L?]SKM<?:7QB I+1EF721GHL9FQ3P[P0EV:CO;2GO\A2AZ9JP;# &+
MM$VS)S$7?5Q0AO>LJ"D$;K?"NE*L2(9B75D*S%."1T9SVWJ;2DIS^YX )E\M
MIO+B=MT[791:O0%3_6L9[S:P6LHU*B7KPF/E2KO*9ZUX6*5=6J!+Q0/_G@3F
M/QOG/"1$?979)A'+PUM6YAB /;%Q\#%7F98^E72O'\RR1>'')I3\LI0VZ(LM
M!1BM]UT->W\N)ZJ3QMVT&LVF/3%X\C*?J8^HHT".1T:0SV @8'S58M#<6<3I
MLR!W+'HD247RLYDFAZ.A<,1? FQO@"BQOKZ%!108&&XE*:*6'"/O56TR4*5T
M+N@-U_C\*OY))^::!V] PS.J@=^KK8+RU&%XXAGVNUS :-HH"V QL-HF@8&
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MX,+:V" %$?_<C3X\S&N5"1:VHKV@U>2$)3!$F[B&G-A<[)A89=]7^JK%&IU
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MF=EORWTB1[N%&!0P1"NPO3+='MH:$%=*!-4/<-;:(UG!!6=("UI3RZP,,Q2
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M$LV?-H->7(RC(0'XH:0JO1IT:6DK;<\^@R)*)6SD[@A06OD22@-!H@ Q_B2
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MG%4?:QJO%TO3S(YA+:?&(CL8A5P-SM9''-FUVZ/.;&NJ\U)!.Z^:!:>9UER
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M;6)'A*7/J?"2<&7HSP/5,%W)UHK.D8 )I-B9+)BPE.)0SNGKQ)Y\6B#]%&D
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M6<KGP6_2')4&DQL]O3DI:T4F-Q^0"Y(19KL(KRML'OI4:7/I46O5B0#;\42
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MR[GM"6#B4HW,,)G6],JJZ2=4\[R^D3+X1?P4I)?O<OQQNR3(N=C,P6XZC+)
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M"6PV2\^+4S^RM4W>L1\8=;?Y_#VT^\MM)88WXFZ9*.4X&GTN>H8%T33)400
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MVQ?RIV/FS:U';HJ>H0E:(B=<([6*[X- 07GE; _+.\2HKSHCS82\)&RPS5G
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M'^RQZF"-6ODCK4I_2&Q3TMX]E;_A?R*@, +]^GC$[0Y'W7IXZ&X'>,4K?2[
M*0,"Z09=>H'3,!*6CL83-,#BP^ [>.,E8^L"?4G\W_^/B_[7MF_S+]4/7]RK
M0KK<H%$&SP<J+\SV:] AUOXTPIG=V2'.*Y[TM?8&W A3DF,% KF)C+LONMD-
MWVT'GN<+BH]16;HE!00+AR.=SJJBJ_)@85*.K-<[*A]\ :G,O;M=!*SLG750
M[-W+$ZHL&__-W$5B>WN_[ [;NE$O]$*^<NK05E>CHRAU_:MU 1ZU?_4L2-SB
MRA[,]KU5?_[YIZV[-U*<BC*X";O0C/06JSE'<\32ZD5!P99?G/48U&R\4[[D
MG+')8ND9=G^QW-Z_@-JBVB+JMIM0[#\"J@_^^_S^_\_^_8=9//[0ANL<7#$I
M(:F4E-28L;."E0MQDZ3FY!1NDJ;D=.+MO,Q]%&3W0":#X/AFG":-.-[83PX:
MR =HSE7L9QW]&[.E]E#-,*D,;F[:_-B_VM:R"C!2UP%9)O\655E]A;OV_'*
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M<@!O""^]=?=I,0R*<O]@O*"C]A\_&H4("%Q ENQ&4DII0.''X2\%A878#G#
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MMFO-R>B[XE9B.JP>AQ.V@@:+A.-#RUHGO%SVF@3$ ^PDT/-O"U_(P00FY>B
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M1%#J95OY,RK3LQWWF,G50_EK!JV/<TNZ(=V07);P4]UW<JEASR:$:^B Y,D
MRD_[)]*-19W+9J1):KSN/7,UZ **O18>6H)C$DGO6G#\(<6;2CL5UI.N_O!)
M^CF>C2B] +?8S8Z@-NY%#2,WUK#D\MZ7WN/HJ(PLM3P$T8Y9%)Z10:H$L^7*
MZ)XQ06:W'%>[*96,FIU7'GPX\UD](QC(1<MOQ1>YP,SU'RD(RV>LJ-PH[DDP
M,JKH8?<@%5I8&=N6%%F+,E^PGJC=%&I@RY677KK@T@8<M2.S%YF*%H'!#_0@
MWW4;/7E5]SW: E5HRHO'5SCI/V)6L.YZ[;97 _/ENE6BA;$ BSSN5M.YG>.B
MI,1;*-Z?"K3LSMZKBY8=R@D.;O*D4.)CN^T7!-S4/WZONM18;U(12 -6,F<6
M2'WMT!#&N1V_DIP"Z:AJ-^8V@:@<-:3NF$Q]5JPD8# =L-E/3UV2%,'>EW$6
MFA-I]3-WYCL5-$11D+.-(/,]?'5,;JW9]-SXMNS\.=W@X)+N@0PTZNJ4#*Q]
M)]HH+;-\MNHBEN2.2]#Z^OJU.^:QY90?Z+LFL"P(&8HO$C9ND(AS&NXUGZO6
MN95<H0G^.&F'8[_;6!+^)%;T9R8L]1'*"!L6-U?K_DS$L2;68.7G['FQ*L1<
M@P-+=!/\[&6@!Q_L_2=L/IKM=:M;N\)]5F*=XZM<#.52=X_:,5<%,&S>#HR=
M@'["8T-N=>W&S'(J\#'2_,D24WF*29=^0[O,O%G":CA^$H3JJ@9-R\Z+R$O&
M=4'TZYMQ8Q9J7/;:H'SE6E[!B".L>E$3=,"J>OIZX_Z:(JE<Q50$6-0/T],"
MIZ_']N2U*^]!?;RV73>X3+U/Y9N:+L>[QR;,#YL.='B2Q#L<.]5D7J#D[SWJ
MVH*0;7>L0\O:":\6")#HJ]MN>F=L@!/Y3BRTN YD8B,J4DH'[ER](H %?BDN
M-G+5Z'DG83O]"-$)4E5$5L,+CG5>.)UVMD%V>Z2\Z[*= ZM S)9+1/E6?;)L
M.<(*G>_C&F0@/)QV!EO-9@[.MHU4$<9*5OD%SA$(-TB]H-E6S8=D[!!O[DDR
M#-;!R NH&<!<KL"K43_3 3MD;$!5T^[)#R?%QIUB.4;T3$UBS?M*TK+!/LFR
M;NB4V$ 9&/(+#<?*/"_[E!]PS/L@)GWS_S/W@(<ABA$\#BN*,]_]<I=1<S!B
MT[>8=.G@]Y*#BQ%U (#B"CJ@B!#P)F )UZQ;]0_'?+K,?.>46JNYSA>>,?,.
MP)$QA4__%&I.JHTWICW$VO$G2!7&*. ;D);(1UZY>=U$-U:_;5R04(ZAJ7!\
MOJHH3$J,9>W*:4EL:!A?%S..*Q,3Z['@LE,N$2_GB+ E6T<\W%?BZ0GO2ZCP
M)%21=JNYJHF85E;YGIGIE'-ZT>^3B$AQB>>#XYWS/S;=A]XNU:$,L8N!H+TH
MJ;-!=;'/8K] [DY-K!3,"WV6*I?*S'1-'I\V(+*>7_=1O4$'.+!L65B*HOQ2
MQ'._W"B0KQ][ S5V_$!LJX(6+\E,OV^Y3>:);SK6R7,-=3YM Q'3SWWT5F'1
M&8<M+):*]KB=+M/6Q"THFVQKXS^3Y1NY7-5*V-&(R;#ELT=J\26.)O?+P)B_
MW(=Q$-Q4P"P=^\P8.J#'':45WRX!4ET01X\.^4S<3K;-+BV_2OVZJ;T$4;R,
M?W2F,KM^G?2!?'7"[AIV0OE3JFQ'@(!RM[!,2Y9_QWGJA&G-HPL):C>X^2CR
MFG@;3U,=OX**W>6I.A[5"J,S^5\-"9LV;9'^Q""+L/74-!T][=3QUBC'>C.9
MX514V/A(C)&:*2>0=QE=D=)0$<T=IS('[6"9*M2[I3X>#B_D?M?<#[29OU[4
MW%MGMJ9W6?2L:G4RHM2DISJTB2>7OV!@':;2RIM/Z?#R=6VO1GH?*S1=(/#K
M60@&5B3C@H93.8+6B^[Y$6%JXC,/-FY SJ[&@[7XDZ$=_"B;W%J(1$X&"::E
M/T1=L(P/:Y<QP2;14@NPE,&&;:&>G@IFN4EC'Z%"9)6*\2K3U=#Q 7?NOC/Y
M0AKFSQ=:C-Z0(-MX7)B2A5C>5,->]\.N7\ ]6AUUNA$O,X!\(Q-+\1*4=\P+
MM\Z!7DZN>Z??C*QV2!9FLJ#6>[]?6P&<Y,O[QXTIL:TZ1X7]7^R]=UQ36[<V
MBKT NI'>U$TG%*6)H=DHT@U)B$" 39?00P]@1R%($*1(Z &2D$ 0)$!H*DHQ
M2"<@O?<F4BW@!<3]ON]^S]GW?O><<^_]?K^[_F",-9XYGCG&7&O-N>;,3$A^
M1]FZ[U!W9J:\]H]]Y<:WR=Q"XQJ&*A$<@R479I9]AVP4XVH8:^.N-#,;B&UY
M;8JVZS<7F'.E)ISPL(IOE93;=6%F='O\=779O==O"%Z^O$>/WOFS,P]_\8]A
M'OVW S[3]FB_4GDD9GNFF__[Y1MG[U]G"E0_?77G63VTS7-TYFPJ;F?*>E1D
M9]S_;6\-N)WGO[@8C'>IM(#>JKSIRG4K)ZMBP#[(-L0D7XF9)]&[+SP4N8%%
M)R[%KZY'FME5?)RF>/;,SE,9;OCXLGCEZBEHHU_'S;Y)G_*CF/ZI.HYCOPW<
M%3S*<>1B$<+2D#175+(I%E^3$4-;$A4%"V!"5.U-I9-'5!^42A64\,"](*.M
MK_>W#7MEE:PK^QE\C,<[ME='M'T1;.DPIL'FM&1?[RQO.+F4MO4[JY(&%9P(
MDV?XK@^$>I_.]5,+-J^X7,[4$FC$2 B1L2"<NL_'*RGK+W'+WH<X'EW>A<8)
MX7R$5L98-WZNG; JQ%7J>[>I (I7;SW".$L6+[@9S=DT:^/92INYG;)92=T*
M)+>BE^\C/[^K*Q?DA=1SOGF0\O7Q:*3"[YA[/FUM-,>@N,"5-*F'FE.U<M]"
M#E?Z,A)0ITVE^9Q;6M:+1UG:O<,P9F [ 6+*12.)%+W#7UD$+5:/([YRM=5=
M+G-S'J :H_(U8I9Z(HV>! _V3LDKKO.91T1:LB@HK4(B[?"V=\"W_2;;B QX
M0,'H_NWWM@-:XW>@ECY6"2$+W8*LFJ#K]6./,J+H"W ' 8RQ#DO(D,?E2>40
M8_(<U@:+QO4[T2RZ#R 09_'!3S_4,]B@YI0^3+4L+#.];K8)3)H/3NOUQ6 Q
M:%+OS36=#U#ME6A2^<MAI8]T*<^<J H>7X>SC'/K/=]./[&(=%V1+0/F3=A@
M4F:ZLY$!YPO*UX'T"H4THXO<97J&6NI5P%5-OQE$(@^ZJ"@2N:P_XLV@HZL4
M-;]UL'Q2) ]DE.M2,MO73HP@KGB$^-I3Y50TM6!NX>'4QFI29APJ@&]1G*_Y
MIDND@OK (^R;XW4W-DZE0A*5I4#DY6C8&=5WZ6_)#[ ?:9JD#B[!JT4^GKU4
MUL<H4Q#4T11 %5R&,SP.F9*<R(+,;XP%TA IUKE%R=STF[F_%<,J\^YK?X@8
MHEG4U).?C&[SX)_>ZO&//4ADG&CGB^^;5?K!Y+YQLU#D!4,Y*I3CN<'*N4.:
M5LR=:(^SNX_K_\SRV:&:JH1R0.*12QRRJ&%*@@2Z2O9H=JD1\^NB#YJ+>CA'
M.=;[B]DD-\7WZFY0J9MD:BF,1!J&G5%NL7/C&J=UB+!U7..@?,E+0+H/QXV$
MY3 Z?41J":WZFXCXDL5)_L4?3.R:U!],.(M9<L*#M75%Z]S%Y%?>H)!;*/,4
MI7)_"5+8NIC"ET"LFV%#_"R>MC[BM6$W8^NJ4';!4*!^@'^TB?%-/LQ$'G6[
M67VFG#8$L3-/2A,B'"94O ?=O+7@&Q<+X607-50!4-MPKL^80Z=&DKU&@1+M
M<!H;5*[N<=W87#[8O:-1R?C$I9-)O+8O&P*)P1SM5]^;]_?:0PT(F4>SJ72T
M?HA/QTLI2Q']4-/\ W9C6^)O2/9H4[*]O8<+ME(/_;#+(J-L%DL'9L>(1C=0
M&S6M)/J65OE']3EOXDEV ]@7DRF05B()2^A'(SON%33\@7\,$<7KA?N5(RYH
M4Q7B#):N#MXP&WHY()05W*;+_KR+5M^A(P8%WP^I11>52.(1S_O9P[^423(L
M2$2\>'"MW5CU 8_*:03_U?8JTK#0%2&2K'!# L^4\9*,DE&R0ZH* AW8+R/=
M\(2F)@)W6AQR\M9"]4&5=)9&J]0^6G29T11K%+Z7NJ>)5=6+!,OK=0)MHXZN
MV]UW2L?[F,_H.V@\BK*%Z.@#"K6\;S*BZ96(Q+IYI2#?R&?F)$J<B:X@"X#X
M#B'VA?OB-_9L-4>8#[05 C:8<%2XM"C&Y=L!QY-(3S2-A$>__7$/2S.SX,1B
M9[77J^*A/1.5[#[N=(*>#V%_;O'%O#44ZEOF>/\-8O1;+C:07#(I/Y/8WD]Q
M]/=\\OW\X$#>B)R:$\]R Q,KNL2H$+VD9:C8["OC",RYV=',J3F2^B3C&;%U
M13%!!84BIRD+-%HF(H23%[G#V3/1&XVQ4QY&_I[)7H_*J)UV_!NU=CY%Z:ZM
MSO$JI*G*ENE;4V# %!8]S<U;[>N@\L%^)5:6JD&)<:;5ZGWLY&63#R.2DPG&
M.N&LOLX4,"]Y=&VD*05:-LGQ7>,[S^M]&2W__'1P2@Z':"Z]9?:_OMH3!E8V
MY$1,X,R_] Y7RITZ!T9U+:H4H9P[^M'"C]/>-^1VU&([^E(UK"^@6B\W^++X
M+"U!1B9#Q'US O:MQ8(XP!SMU6?8++TMP5"X_=D8EN<[0^X!XHGTLWN5:>W\
MN;H]=;YY^<\ M/Y^,.9._XRR>O#>AHD)]C1=XK<K(DQJJ5&_[PS$^[=Y#OK^
M9@S:&XEW7J+E4?[+I#2&\Y,]Y19OR]]P\WR[,[E^LLMCX5P#\Y_:T<GO><C@
M>1?=*V#W_)#B;ZZH!BT( RY$D>^R0XN!+A*T51K!US]'!)0@5 S/T%.*+[HK
MJ.?H>+J ;(E(X 7 JA-23""%^0E.LMR:-^>64@=,2NF +%?X+1.^>BZ_VLVY
MH#A*E/\AO],5G"!.E8W?\UU857W'#YA,ET"Z)U[VN'&J=TFO(C5?&HQ!()&1
MD4W5LA=)I-M-0KP1R9S6 NXG.V!0?<47<O%E?'SAB3<H=2OYICJ/@=XM%2#V
M=[8T\5+&#,40$;,,,Y/NH(+;1>83EPS6"I#]3;:X2>;0I=%PHVY71J<1A*I4
M$Q_F7L1M'RI)ML]UU=6K%?K!I)T'@=E%70-CV% ;0,#+&4,9PKG.ANR$9&2G
ML;K:BXZZK>A7/&^AP1S#FP[-'$,55U_TW<M32HM^OGKPLRGPUB@YL=4?DMQ&
MQ: HPOTOU52\VE#1OK*9+1WK06ZR!,=LTKVX6,9YV#5!@-2+B0*AR>+E 'B
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M9'9P=9-%[URH-U.%+OB'L]=R%N[._W;B99)+X-_$]UOK7K/TPC\JSIL6X%A
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M_VW!\V()7\7)U(FGYF_NO7Q/#69R >YZ*[AK:]D,U[2S6[2^M,_I#[G2QZ+
M=\DO9\O443(K95%F@3T_[]K;J!'YQN?H+KL'[S:+I44C_Z0\0=RPK;<%"TTU
MJB.ZB(JF7J9/ E?I7W43#0C4J4.5/]C^9Z>^U,W+D/P.ZZPG+[?=I3/UC,W*
M(OMCH,"JPH94\KD1EBSVR)71D&;@I;FIUIC&\G()1*]92ZRZIG'I!V;F(C0T
ME;,ZHZ2&_J7@K+RNI>L,:/+5H.:&F$%*$P^2 BJ^<S@J5^+>=IV7W BS?W[C
MQM4%8H1>7YG<5/)[+TQ#^"K?0.S2VS>28JC2//'D<!!HN:R5X/[>[/AI)$=?
M-'80731F4WJOFB7;&.RZ[*+FY2E\0G_JP&&C-T=H*NA>7]<+TH^[@KBZ8'[,
MB'G50M6F:Y&[>"5AWL,%K%P^B *!",&$"B?NB(,S#J9IY7[ERR^';-V'^$\U
MP@PF@JAEAK?-$M'WKDDN#4!Y<.J@^OEG>=FQFH2B:"WZ,*&PDE9E\LS +T2C
M\=P0GBW[)[='$!73@/<(UD7<\1"4(=B)O,(^W%D.91W;;-FEV7RU;BIYU1*/
MK,ZR",R97AA02=+HV7MQRD(@MCZR;L9LC\?3DV)-"#^WD)1O*]3CL.Q"$ 6'
M;<,R/XEY-7YR-@[^01%E/SL(\GYLB?T9,=]O*-JYF\B'VI(9:1L.'>:]^%./
MA]1^1(%,G? #LJ=[;2L[WJ.H.$\)1/^BCU0G"S#7%W.%O_Y E<Y?Q/<?\GOZ
MO]EO_SY^/OV3T6\<5G_%/_\#R[/_2_6I?SX;6=WB^+N:W_\0^7]H_%^E]_Y-
M/$.*OG/<&_W.<9^DH)7T7_F&Q^2C;S5?7_6Q=6.^<RPC![]RG.R(N/MWFY\"
MS?W*@$1G<U.=MY#.M46DY,.%]Q,/=.KW)=;I^1L0>(ZN8!KN$2YJY1C<X.N
MD\W5KV'[(M!,Q-#5S+NNM4BCU5HMT'/-!%IW"HB";&\ZB<$/I&Q@A$V:,Z<8
MB=BI@P/!Y5J\7'9#^8YF/XD2;G@^6'/PXRL7XHW=ZX?$O-'L]9I-!'H4,.0O
MH;;EM]3H'PTT["KYSDS;3:OP['<A^9HCI^B5%NKM9E'50ZN6-GUZI/6[P?F$
MD($DK%D*0(-=6:A?,W.K'A8(-^VP-E9!U"A5Q&XE]NU:O:\1!5B"&<C"3Z[C
M-75+E0-V"O)(!8;!/94W&O4LFDL.WI:X<I"9-^!=QZXS(% BB)+JQYFRCCJ[
M D"&YN^1<JF%5Q)3,@V5')-:TI4/O\V*[S=XELHX[ =>M6D?_/(\^20G)N43
MFNWX(;#2-B[+8;%-+='#$69.Q@3 !@XR-W%++HNAL>2NSOP8\ 015\-L_S@1
MVT=#6A#CD[25WX%^R\A&0J \"RG-\A'^I3 T!<''?S[7:OH+U-6:^G@MGOX6
M"SH8XE,Z8@Q?Y$+DMV[:+ 0^+2Q^-2,W@G6]&G0DE/L9%^Q6%K\G'XLP+//*
MK0OA+WH7FU/B+?600#2^UES=G9@B%%>ZM*8N?'WI_N/ J?8(>][>\E"]^L;H
M[-%<.LPTDN J#T_1'!85FUA=;DGO2T9]_O9!Q4;=4/>K""1Q>D$T]T.^?7V5
M4'$WV\OK-Y)!A^![*E:I-,LA"W/]&VO8@IR7TA)2:Z;[%N)TM0L:NVRXP[ZV
M,7WTMC,1;LXG2H%VQX, 16?CVJG!AW01VZ^J4W%;EU<';V84^#5/>4W@L8&!
M(\H&E9NI:M0- I4G-IS;U#M&;HRS/&B4_<#C\7TL;<@ R$0X!/'7G3]$-\L(
MP1F5PRT"Q _>? CAC$;.KF3DAN(#)<2'Z3L>3P,K?CGNUYGPVO0FM#,S"VY^
MYZBP !H%9%^9:V1.)W_G2 S1-F^U,3I80SN\9T)[4RI.6Z2+CD#EP9W\^IM
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MZ_5^S.#M1V/AG3&1FZ>U(?+.$&>[L$ISB)[X-I01.$P7=PWS7^M+083)T$Z
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MK5O.S4\E/*=U;]"1T31DI\_OMYCTVR_*Z>.+)776-P@6#U)!/Y:\OMFQA-X
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M^X&:"0-)ITXNZMO0$+HZ2L.!TY:.I=Z:?&,9S;>U?:W'V8LEN$7!@&DYGQ0
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M2% @EFG'?*S/J2ZN'"%9^AKCGT;C$6^R(Z4M' >+PKXP2 T##>L98ND4U5U
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MW>'R8DE=SNL(:V0B;^"-FH.6NEUGNX_4ZPF5*$XZYQVU"\=(.@WCC6VS,W0
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MO=S?8]9@2+:F,8N[_;UDI''B')F:28';*S>-@5FJI;^W"!=W*#F>607:$^G
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MT.O6TO+:5S@'RT;5RAYFX[2Q41R'PC@76 +3+ICL+E![H[+&*I-YR^%4OU\
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MC>:129N?+%G3,VJ5E?W$+,D1K;R CK[-$;@29M7H;)S5/%S,_63CI/!^>Q7
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M!N'FWPRBD,[2'Z/BXT.NM-%]Y/6;0Y)4V!\4+<%0SV/&&>:1Z^+"A0B>F<=
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M#93F-YFTJNY/;$1?4@ 1Z?] '0R.#^3NG=L:=^K\U!XQTV+I^U7,.ZXR.)!
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MT?\(VEK_$5MD/NBR\4QP*PS*ZV6>IKY<PH?9JO"GK_!=-(D^WU]Q*;;X[E@
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M74^9G]75W?U;9N:ARFQHU(_7>Q?9]T4&%KW"Y;P\%ZWBHL';FYU.$RD/1(9
MF3H0P&L?G ..Z1J8AV$+6?PA+[ZI/_/,T_\WE?W_WG)^X_,RH>-V=$ GY&9<
M1AH6%KF(WP4RQ]BOKWBQD?#@ =,I7FAY^)K\X,I6^II\ZM@;(,S2".+[K&;<
M> 6!:3R.CM;)CB%HLM3BG5(";)UYQBH\*1Q;M.9J7P&YU8BX=;K1>3"'@_VM
MSEXGQ,.',WUH4FO<>!X)K,#<D$OZ%*VIT%D[=B68+ _R=CB:)/#ENY_X[Z]8
M8.I1T0G/<3EU2K[A3RIK1X9N$M7K$6#RB0.O)2C[D1US8/NV;[IB.#;:F'!$
M=*:NZ1KQW-Y+AB*BK;1F5SWV#:5LTCNOI!;N=*+8;>H!VT(TR(?.(&=6Y7P,
MD)[Z;H@>YQ\_B#*3A'<-^+X\/HUO;9XD$7K4<DPW )XZJ61>>XA_X4S?YXM6
MM=L?K_>_Y,D"1PY.*L\NL^L&^N'M!RI41"*&VC#9C!9?!6H;U>AIDDF'Z#!^
M&;1-2>GT'1E^!K.C=^Y[1=0LSR4SN\#U#9D#1+ HM 1[[Z$63:BODJI_']5>
M6?2J"4E]L/LWP3]G0EQA8"QGR)J'J(0'+OJ?%_:5X;=M>&"1XX*W$*X%953P
M$'^"XQ*T-2+)&17)CP'ZYUE"R)=*T,,NAZ/K9V:^$PS]W1%V[#>D.C1%?<]Z
MEQ4^-)&URR0USTT$-WJNEMWWG;O@?JY9B4A(&662'JZNZ3?@9J*31J#3F6UA
M*QN!#,*%M3$?C)S>@P'&_J;OAC\[1EP)9H^.9&32DG(\ :O:C"GQF\01WNKX
M5MP(PO+V+H' +,D[$;/ 6* ):S<N_0BFL)C*!WPEWE,>,QOA>Y$Z6G3!2MO9
M/-/1;2)X1ESEL;_R"M -/IG*O])DRJ+)I1^#"G8-U.OJ1:X2L )[FY>>YG]:
MI$"UIRNS-Q%.>@/^X:DOI*1,?TZOG61IATQB\G<C_ZH9M\>QXTK=*QSGK]Z6
MV49&Y@E7#]EI]T>J\Q"]-\"NTHZ*^I;VQ6,V[=,KH'"BJSQS<#3CJYCLTJ-F
MD4YHZUZ+1X'+FZZSCKL1A=JJF*#S?0V0:(N T!H8)T#";2"BDD"\T _J[I;R
MZJ=+:B97F^'"7W]OE12[3"?%SJ9*3Z9C&PQ2A^E,Q"9Q0P'ZUAJ!18036G3(
MD.COLL>/IJ+A,,'DE+.BT=,V)U8'=N1NAZW&/\;O(;4[I*D7>IKT&9U HA.0
M^8?K+_+END\=4A,><#0S.(U#_?ILD_/CDJC*W[N6*VU]SNP=QZZO;U"7H4\%
MW1G&\,2[':V >?VV"UV3A");\\"21LAO% _F>^2OL1T*2H7&,HQ$GY9+\!CD
M%_=G$V^OM&1B)7BJS)R7*]WK=5W2Q=4@9@[O(ZQT"X%;>; @_N*7@3E=)]X$
M-DS!&P"S7HL)ZWRC'E&H)ZMI%?U_;.KW';KGEV7'O+)[-?6D6N76.[UNCV6*
M=N]X_FM5EN'!0-.ID:J[EJG'K*]^I9RC]T$I^5/GQ0MK6SOG]?/LF"6U_=6I
M4[=;63;?RE+/E3<]8WG.+[/CQ;V5UXY6+_'K28U:M8.Y>F+HFJ)E1IU33CVT
M^VKJY9NXW^]@[>KMN[AC5C_TN!GXKG?5VQ7?S3D??/T0&J-7$/?Z5->L7.4B
M[U*;SU=/<AWF5N@\7Z2]1^;ABKV2Y^\DZ9?=U+.*FNU]\\'<"586+Y^MG";N
M<F-AGM'*G8(Q3UT.*57\>,"[\_+)NQN=;I5;L1][ON;%L[=9BY9)]SPMGAJS
MG(_5<Y5BDZ3:K#!WD8QUU7>>N&2I>ZWZ*K67N7IZX/W72Q>O?/8HU5;&ZT3,
MJA<7!4///GQ8.+'*^+/=899M*Y,OF9K=7)$R?\Z:KGNWV@ZL^KDRZDO(Q)-]
M4[+GW;V;-?.\@)5)T2:/F<JQ#VP%HU8?UMC+OO9D2\PR\07/OS\/U2Y5R=D>
M8N61F*N[3^SRSN1DN2-WM0MFA-YYZB=3P^(O-35OV_-MN[(Z<C_MFW0Q+>+E
MHXC0L$J9KA5'?D5XW.J:_SGY&-OWG6;O3N6^/!&N9*ZUHO.Q27>HS133,B^I
M4U7+;VOJ]GI,GE$\ZU=+2-;JB<)-BP-%!6_\/'UMCM*V^\KK.[,C7JU\*Q"P
M=4I/"M],F>?:$U_O[PY\ZY*EM-OBSBJV3UPE&XQFS=)0=,T)-)2X$GI.4)@C
M9*!KJ%% "F!^?O]4WM5?UK$_VJK;GYIG_95=]\?9]OCI!5^J]^[SD[NW+W_%
M?LW=X2_>EC^2?"<_Y>[J+V6[/_)\E]=KO/OVDW75SWV+_BQ[&[]XZ_V.]!UU
MP67K+]YZ?\3X3LTN]O+M)]Z^?O:K^]/LK75]U^L4YSW\Z7MKOWOV?H'SA9]>
MR-Z[K[Q]_>Q7^M@M+Z^NZ1NU>M3J4:M'K1ZU>M3J4:M'K1ZU>M3J4:M'K1ZU
MFJ96KY3\,'/KSK?Y1V_=T^[_^N8[\],7]M>-OT[^WN0WK\];?/6S#PQ64@X#
MW6VE$Y![\)\AYOPU_WLL\J]G_CKY^Z!JXO^; %!+ P04    "  :B7I:7(F=
M6>"7 @ R8P, $0   &<X-C,R.#5G.39V.38N:G!GK+S)LNO*N2:FBHJHP1WY
M$4Z<BG#8 4OH.UE2!0BB[WL0,[0D^KZC'\T#OX:']JB&?H1KK,4MZ4A7TE79
MQ0AR<P&9/S+_]OLRD_M?_\]__;]^]3_(O,3_ZC_\AU_]Q__Z'__KKW[UK__W
M__:?7LLR_!8$N_DW<=8G^6_2O@6/> #AWT#@KW[W7XXA3NM\^2G)GV7W^Y__
MG__]__CYIS+[_<\!KD':P.:O4GQ/N?/6W?1=IW3V\W_YP[_\[OCMT0YMOL0_
M'6W3S;\]?O_SM_#?7M^_+H,___3=9*E__S/S=>.G4#-_8OLI_XGX#?3K%(*0
MGTCZ-S"!X3#]O_R$0 @$0A2(X+^&R=_BV&\AZ*<?KY__\"_7Y^^FK/BM?>=_
M/.[ZZ_<__YC7ON^_V='?]-,3A&F:!B$$1)!?7RU^/9_=$A^_[N;__!'R1SGW
M?$ZG<EC*OOOIZ^\XZ=?E]S___"\__>+U>="0%<>?GO07&ORZ<ZD0!?]6MVOF
M?[O7'_7^=SH)4OO\QQV?8-D^_V;WX1<Z^>N1_MV!9NF?^@SKU'QK,4O!O,G;
MO%OFJQ_\]\;JFO_.4!=P^-LCG9=[V?[COK-[#CEX-<N[^3+39<&_*8?OEG]&
M#M]WR]^4\*7R?T_??ZM?V33KO$SQTD]_N_LO&OPC>VO:/WYZV_X=!=KYWS'V
M7T[<SN=^G=+\:OYW-,AM_Y0&_RB(V_(O5?[AS[)^]Q4(OV5,5_$Y^P_PY3"_
M@7Z#(#!*_V1._=<[6].O4/LUBOP._(O&OQ!RZ>*W[)3'2WZ_WG^X\@'^:PC]
M-8*[,'(E@]]"]*\A\OKR._"O6OXM&?WD]GWSAT_>D?YLB9\0_#?03_]34'99
MO\__\R]D_>CQ5\*T/BN+\V\/"(9_.:!?M/QK&5<RS.(E_J>D_++M7\EQ7VN;
M=''9S'_X"SM^)S2F6?[RZA]O-.5W@AOB:<Z_[/C[G_]HR)__38<?3_I*0;_=
MRVQY_0'!B>^!_>+2/^KTRLOG:_D#C$%_[O7CVC_J5O13&R]_D$U.^'._'Q?_
M4;^RC9_Y'T"Z C&&L9PZDNTG<V.>W$UEN)EA[B!I,;,GO+9,H-^Q0._275LU
MAL&LNM$9 &*^7S?F:O_UXIC_\3\?S/_*6%^=KY?%W$  8^XU7R>(W#""^^E0
M@ DC73>?%G=C/.[V]/C;LQ9NUD-F]Z=P>S[5.],K[-XKWP+O-T:[,_O7V[HS
MF,DQE'&_:2Y_LUSNV!/AF%/QH(H_O7=.O.VI?F>@Q_6$A_#R;-[NO^]]"_R+
MQO^-;Y"Z)FH]F>J:+K-S]F?*C&0SEF9?4^.86/J:I,A\S<[BF#^_+)[9)>%2
MB\@R]36]Z]Y3NO]UNQ\Z9-AKMI=>4HFU>O6ZS5X/N#-/B[VN71JY!'7:92S-
MOC$,+]G28?F<P"%<F3XX3QN$U^T(#JLT;]\"O45\:4=44JQ]/C>NL=ZV6X_*
M^4!-5O>LKB:,M_[*O$AT[] J27*OR>SK&;WD2W6C _F+[BNWZ<1 D_L6"!LN
M%(4!W\0!?&1A0P<1\AKB=IF3 -\>J UG78;EX4 6(@P4J,&]'K%82JU28J=>
M]0!;XX[?#/FCC;X%CDDG(WF'*]6@!.U E,,XKO,4$UMO7_J]IB_=;];E+M:#
M8R^'2+YT]N+N-Y9S-(_C/5M_2<_H>$;<^2VP3\2=UT0;<W26]^4RW;BW?+?O
MSU?L>&=0/DB5O:&FH^<R]SPRK]Z?WU.6JX@7RJS.> ^E1N.]G\_A6R $F.^7
M[-2+YGJX:3?9(_"').3A/(3M)FJS/@Z&*1'@-4'^O>E_"P3NC1P$#5Y&[;"F
M7404]6C40QQWH]*.(W$NTPAL8'PYVOW+([@O%[M3#.UAXW&G3MJ@WBC0$ F/
M9Q^!,XN[WA0[9(QT^FK'BDN@1DWWH3<!N\RX9&9G+\URC^Q]1>.[+W"2X'.4
M'GJ:S./CT4C0<YO.^,S:;X$9M_C:'(=<71VPU '\LH+(0IV&RDM,E^! 00H2
M]VR;204*&P;=(GRQA+5#&%$ZF0GPKQM/YXSOA(KP+3"$,SA>G(U)K=R[8[JX
MH23XK%-'H6#"!2(.V.)-[D$8,(X<@\KXJ)\KQHL#\CX%(%"4."PW/0S&M?LX
M-F >/C)J:>^ITP0<#MOG62: VG@%JBK40"M'FR9!9R!8"#<B1PG;R()PX,@Z
M,B_VQ[L/;@P@C7HWO+X%'LY3%M>-- ^G%FK1'#H<)]PL7*8>?NNCT3F(!M&3
MGBXQCTU$',+<RR7>>NJFCQK,P$T6PVF#]C*0GI\ISPEPB*-['A!)'63H%!J]
MR'(6KCWQRFUYT$E=C>U)3)S=MC;CQOFTC.7J?(Z#*#'CY#_:F\;:Z*U6OP5:
M0!N8'4) A$X"1S?3R1-BR3FS:R=C8#BC(+Z215U4#_PI*_AC-FX%NI\:DZTA
M#\;]4JT5D0%%V\;QMT J3?U#SEWAC9MF'M 0%QAP)I<;/,8IU:[L=%Y%X6D^
M,1B9ZU0VWX^GXR>R":25N%YS8S)2";'(F>)/+ O6Z]7<11KR:WN-*@E;8?9.
M^?I\HX1E@T9#@4Y0)=WB74"@GVDE#$^MZW91"V<X3AI9KA!)<NQ0T<C? M/T
ME1ZKR)):44[TU(BZ*E@Q#BZ!I$K;FX/>[]>(-J+7+ZH3(_"J^!MDZ-J&OF);
M>?EUE[VBEWLEP ?P+=!E.+;2FUSP;"D\"<0D V\:*IC$<PI NDY!MHQ?Z&#5
M><[&D04<\9@+H\#N(S$D#EEZ2&WF-9:O,OZW0&QSL>EFW"I[!-/G$^GC!,]!
MO4>!:AMK&MGGS%^GE@P4VI_R'*I73F%]J%VB^U'Y%2\2-W<^>];WSNY;8-7#
M:'8^>0&90$8^>SU7$7>BLU6-:0@JL1F7U?PV\ ZQ2)L?]8<T*[!;;P.U7@G;
M#F1*30H2;%=2_&2;3 /Q\[:0++!@Q:2?X'Z+RS4SFTUMH3L<4'761/TP C5D
M#E1?OE782Y(H.1Z)B!$2[:1F G:8KI?KXUL@V359X0MY<*3QY123@MJ>75HR
MD05+9#SB3>S$E1$P/,P%<&=1*H6 08AO$=AB8*><FQ['+BT>05I[WP+/24VF
M2/"G ,4TB'.!'GJMMGY>^9LW;L.S38N[A8_JDN'F"S2")"1#D)NI9AFXU*X[
M3!W>P&!P%P,SOP42#[64.[IX>H#2B76,X28[72RY[+?Q0.E[T461&Z-I?!4<
M%F_6H8.\4*=CE%^;B7Y$QUT74Y3?E>V^?POT!=\Z.6^RJ^!='L(TO1';=F,9
MW!EZ@Y9XYM+@'G9 ?: BH2E3K$I#)><<T!^Y-,\H;UG8W89#+'U]_)"8 -@@
M["L#@^_ZE2'479O+D-_DFWD7>?-A2]#L5K"_!F6L=\^'C_4&\H:EV[F+C+E[
M8NF.^PR^QS7[A!ZUO..%(()LT45Y5/9WD,:"WJTO11T>@7?.HX"RI<8;PW">
M<W?!%=#%B\7='@[H)W>*7FR8!>A (<KY,V4>T/4 64D'E>CK7XQ,ZD?T:!^J
ME$2O]^@;8%5C'<N8+Z"BQ_MAAK0<D*XSZ>JYP<=#>J54*9CC[?;^%'K+8?.P
MT)30C&8[N(6/D>3__!%(8.N/8EL>T-N5376#GZC7#@'D0VI^AT&:SRKB*"@F
M#>WJDP]5.)4<L^B362J=7%T?YX+3 XJ_P$Z."6=TB'MVI=J2Q=JZ71>CNVGE
M^2X-O; <Y$)CAO#4"GE-A/X3*?Q;:EX'1X'+H[2'L (UE,*WH*[,QH1Y2WO@
MMX&F!3&+PBI0L>%^T+9W!WKW<%8PN6&""F17S2W-= @^@/,:2GL5I&'A5I(5
M^,QIEB1&(82<!^QVDQ6YKG/^A!+7WD]6>B]G$CT]K&)3PU@+]0V*N\<AXP#$
M(OXM<+][FUU?Z 1>B%[4,WT[ !)8!*[JWE$,E*:'>\-5A/);-1';(E[8Q[_2
MM@P:,0X1E).<J)Z@MWF(U/Q;8(Q !.G8ZM.VUB?3 ;-TX*<C'U>V JH[9DAB
M!Y,P5I[/F,1!V*0VW8%C.UHD&$""W(%GU=D;#<\D5OH6.&4].<B@/Z6<"$L-
M-O=@A [^OG.[\:")1)?Y&TZ >OD&YJ @E%6W: -9HBFY"KE#U@8%4<M$0,F4
M?"+E)11.M<IK.19H#A:JR1Y=3@#F%IQ/<+\W"8C79WR,>1L$=;#V#E&D6PPO
MR24,S[N+'4$]^^9:Z;2.CQ\&(F*$I*^_@?!ER7I0E9=+AZ'Y%LU&/(<T]#*8
MST+W75U7Q%@D4,YWK%VE0TW?SYYZ^F%J+5;R3#Y&"1X[-A2/<X:X\LIW?EUT
M8H+4#_?<4K<MTV!-%"Q/>^R>3Y<06E#K(7D^8$LSETSK,,, 1P 6.8^D/H S
M3XNWM)GZTL5$-WA44,7/T;G &-SHG&IO4'0W*,=I'C +!DA=3?(9]UAU<%IK
M,-6<'1<^(YJ;"H':ITBUOPRT_X:/_D2R3DTM5+L27/-.TFVD/B5 &G(3OMG
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MXI'!_G7/QO*7;N+I9\KJO#%,MBVJ*2);ISWUY8TJQ36U3:2.#0B :[J*C15
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M0[1M:X2@M42LM<63D?G^E12E3:D))/+F:D51@K/+A@S0.@'QH1>V0W#H8-_
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M :ZIF4AN8X91*/M9/WRN\L6ZOHK$ZRH2L==R#_T*07=!^3IWN>'^($#@42)
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MBV,G,.IZ6?WX=1<Z8:59B@E+Y22HUQ6"ANFI!Q@D[.V!<SZTMAN)(9A56G*
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M4+QZ]GB4S!^0]N45M=^/S4P)*$_7/T-Y>DJ)0Z4D][\"U75#VN-X3=!_A)*
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MRX3AY3?\NP!/4Z\-.9=9:*]S=Y0YYBQ6D!RM[3EM!43>0CZW5]2X[?%JEK^
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M()8L7R8\6-W1U,SJ&=W-5 !"\"? ;WE'E-.*PEY9.>/+-O('U:MJ%LX<@2.
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M533<X(,$S<.=<H[6<[Y.JFPV%23?[JS )<1^5NVI?G+<OO7LQ9W0+Z&A_\.
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MM_DR_BP?<0,HE+XH,[7"H->XM*X;V7&-? =NEV.8@/'TJZF7N8O-@1_&+D3
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MOG>@AQ/\+I\[B?QI!\-NH7HV/9^1M/*"VW$^2LS[6P2NP\-I1I^\^'VV@V\
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MHZZSB]^\6U"7D.&%#D^)\X-\*363_<K7"U8-!N4"SKK*S\.]"G(LC.DZ1#L
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M5\NJE!=/[M";GOON8UT4@.39,X,&)UXH1@TUAZ]H[3S(+NP50N%Q#,UK57*
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M&G(#7NP&V,XU<=P POTU<=<SOWRU;P!4C\/^KHLD['+\=UYWW,"0LUWTZ1]
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MXK4,TM$[,F>,^X)=/S2<V">4F8BUSA#)H!:H4+]&]<CD2J>FK*KN//VG6H&
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MJ[ONIO+/GC'[X"@*N88N]2Z*T=Y'+0VT!"P''E7(I$TTOD^DQ?R<?"!49.=
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M599=P)@'[KC7EM3;;3\^M?RX/""9.[;Q5I1<Q_)34HYXR8^.XL\5<TC,DQN
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MUX*2EV0AGML99RYB)_7G/-%..(U+-5.O^E;19IS.2-7?L33@,(XG7NJ>U!L
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ML?^CZQ<>TH^^=5>_U@$-/BZ9?\C]KT6(F$H$#0<5E6:A$T!OK\&XIY.0+&+
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MPF>3H1WR&!HJ69K4^H?\5KV.7,7B.Q# /9FP*T6TT7:0LARW"S]?8&5&'DG
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M,Z[$5D#M]3B,099[$OP0ZS?6QD,5&9+=F,-U5SB(U'ZY\MXT(5(91HY:X*K
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MJ3"9ZO1$E6UE.49!"L(C:L>9ID7G*9]L,7<,G'^W8#M#):N^(95)!4S"O'=
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MD))F(B%-$+F%#P_H]VUVL1XDU'/U&JVZ0E*Z'@WMAM^'[&9FL/WI7$,B3&:
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MZ=L%#K<\Y#T-^H]0<!D!<^]Y/*\<.=1P_'([ZO*F-JTU;W\/P)W:&?S,YC>
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ML?:R!ZNNK;\!YXE\OP%YMW\:]RIW)-WH+)((9YQ/S]NJS/;(BYE.?C=C$UO
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MO-\G_>;3F52?VOB&BXQ;L1V?"RF*/3SX$2>_R/[L7I"O3BNKF3Y"VY!<NK\
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M!XO5<RMR/5(&9V'XXR0"%Z?R P0)X>H:!8>CIZNO1H:-FE2^T%$4_^+!/[@
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M\N1^7 B_8Y1?C+-D%5XV?/$;&>*G9)WWI$/UL'/)Y]K\^9B11A;UN:'Z<38
M/ZB+.RV]OB1 O\()#,G.SW]>WL'DA75Y7,2D(Q(!F*^K]TCR (:!EK5<%*=]
M"!B&XSI$B:JY@<T]YP3U(>:-MTC=$^!BV'W/<K9N#10US+,Q*&)$6S@Z!R6D
M4=N1P@]'%;,C!XQ?3<*VT*=D0MC,"(V$X 4RW7650)NQ;(0)!N]$FU#6W>VZ
MBG]$0\N@Q:,9D$WL!UYEE9?O!_TPO_[*5"_;)L*B8$W,*"NE]*'3V]X\!59+
MRY5=F+:%KVTZ_WC@Z3'HO:*/E;[5:N8(OC],6WD?[6O-HCFC?LHZ9V&A-]1_
M99,[C4O8N3BH9)/)8BHJ) HB_4%*XVG7+8AT/%?HVW5*9OF:A,[+@ WY;Q-"
MXRI0>08&E_B_C[AB#GP],WP!*%)9#BY?_+V2].O%B<CDB^"(Z'],KA0\ZH^+
MUHDRM-*SDH.[N9Z(4%JZ+BITW,NY[Y^AQ@OE$/M:9;C%KV_Y70,A;FPX4AKC
MPA,3*PKT224HL8@6/<O\.ET1VHX22H923$CT%42T;\9X4?4EOBXW%X9ZQ^:[
M'J@//3+7TP/>HR-/$G\QHQ":6$$KWF>>AZUF(Y>Y],W)+^)WB<F^"O+Y:=1J
ME8?HBN3 J%JVSC.:C ?Z?0UK,Y[YSE<_N_86MYTVHU[.',.1%X!&$[N#_:C3
MW)QRGV("XLC#1QD,68X=E,"^G9F1KYUD:R("?\P[C$]O*WH]K/J>+;B07Y(3
M&3]2Y@GP8:C7U61KUY-H@PT(+H=J+-^T3=">@K+O=SJ52'3PA-MOE/XX^X L
M'[IN"(W"3(LB^M$;;EC)9OGB]SMPE_YUJ-*GZQ+!E/<]DT8Q3MEFCO:0[3 A
M2 %2H3I[H1,'6(R3U>(*P0L+R8AV/!EP0G?_<!UI@N;@X'N8YY9R.I_"W18C
MN5U702"2CE=:D1Z_:VAQ-&3S;-HX,#<DOW]X,ALMOJ*\Z>%Z3$_'5WN$LQ\^
MI&7^6/W5V/'7AE7[S.-^)#\74GV5ZLURT_Z2NCI3E39B1\-QP[A.XZFA%6_N
M[?(RGT.[+04Q+]_@JQX#C.-C=6(5)U8O[)F[IVVKG)Z$S&["1R1V1,AO=+9<
M78UQ4V+E5+LKQ9I>P!C9/>!0*'.,$>J0<R<\Z-(.D,/0W??/=$D]VV*[ "AC
MS[LG!ML[7]KJ2\O*2LL4 X.!(>-*]K_KU%\/0'_O%W\5?%9$K)75<&X\Y!FX
MQ."MI&ABI[<F21<QLES3$3#7?G_$Z7W]]*>Z*=S64:P8%A<Y!*+SY6'C0AB.
MZ'\_',.X?)CZ[EZ0#8U"X11LG W*^=V_^C7W-35QD_6$&>:6^;VX5,JMFSD^
MX'!$5_N^OW>G*Z->M 3GSZ_3EW.81AAL5"RL:'^2DN-#J:44+D:<!;PZB@9[
MC.TYKCDYB53(L.PIW!B6=6]/+O-]BY*K1?R^:MW"BO+K;J@4ML=6*6!*OOO9
M:8LZY-R4-)26B $!-4!I7OQ(J9";QSEC\'@SD=RCTNE; 1&:4Y%6R-4XN,(V
M5?&$.UF_ZM*U[MJR+=RF)$1(U-!\L= 1B=-:CMV&T0\SA#&B-&CJ6/M]]TUN
M0S])5Q &LK$H=N\K"\[QX=O2  #; 2!YXZWRE(^C8IR.B@L#!7I9_4P[J)^_
M7OUG1#:4B^&GR5+%S-KVH4A1E5&'X9/]1W8QRUBJ/W:/]OB4_,R&],@6\Y0$
M)U^W NG+F-09M^_OI,QGZW-AF-M,TOIMUY<ZI]BI\OE>OG3@7:1%[(?DA8#3
M1@=X)?"..='9\7T4O3U3=/02B=$5_F/K+NE/.UY&<<"K%5[DH9P<6^TR^_CZ
MYQ3F:P8^FE<5/B\DX.\T3KO,R+B)!+H$5#^*MJ23&FUB8O$>\1&%9=*6G*HQ
M997<;8?NB2=7F5R62X,T2:^RDJ?=R&E=<2\%H2PRU"V<I(/ %'Q Z?V1;];:
MTBZT* 7VJ["WX< E#X5%%/[X_BL<P8(NI&QND0]"G8EZU+>,O32;9J,2^#E^
M ,<_0E>EY[BVO?VVEFCAQ"-]VKZCW3S].X@X&P@BN6E,"!ZVIV55#-<T?-AJ
M25>GGM$2\RE"%2%Z^5%O]J/H?GXLNW\!X*N6=3L.8K'YO6%/C%;#570=DM/S
M#^&-[/$C[J0&*5.GE%\<.9>&M&,./<G0&1V]3\(^>^=^'G;[HUP&B0YO:^V*
MX$,8[Q Y*X&6ZGYU38[:KB.L5@HHWIK?OJ%.(>:K4@GN0_G0>Y5=HZJQBER3
M@I%2R;'CLF4U)2?H"9(L@IQYM3"C@B)U%K-U[Q-%M=8C)O WU/4)#@7:&_<5
MO.*N2WHN#K 9?&#R887_XCVQX%=9>>FFIZ<5_E+'@XR?]6BQ/QY8U97N%TH/
M<0HH//;P80$K&[I]).2Q+:4[MJKV[P;2CK/(HWQIZ)]D-_9()Z:*?)FY)2*>
M;&6P-1("7&636&]R/"K.M,***>(WM/4+LNWX,$A5$=FJ>LWU= 5%!WHJLC8V
MH%_1QTQH5.JX?XF)3WM/6Y:'LOS[>51,[%H7J9_J5IL]3*KOI4>7Z50L"BSH
MH)BA,VXZ8J+?W:+$6XBRU^V0EZ.C]QBX<=__JY%)-#(:75M,9)(]$'>S/_3K
MV#'>LE;S'O.^.TE;DC5.^S@>TT7BBVR.@;V->&Z39JE%1A[,E+Y!#L>_+$NG
MW&YCXEBT"6!G?4"M#UR]4N*L=_#"YM?5^T3_.IQZZP5 EOG^8,*O\<)8VS)5
MG5-N+"I/M5M@9M!JPX/LI-"ZYZJR1<;S6].(I)]-03L0/R=ES.2124+Z\5F#
MBA#%-P_YM<*7'&E634NGA-F"PC$?1=VES)'BG+R -_GQHZ6-&NWR:.G+XE8Q
M#LJO*C']0H1VNP'="\!&7_[W[8YO>16MTU8*I'7Z4$$N=W=E)WI'] 3O5']T
M,UK*>$365(,'LPJ8S:*G(X^)8?*8_(C*:LLIF*^I9A$*;\1]YF4<KE]:0K*1
MD1$R*T/3]ZPK1&40654J%M3Z";FOP1R6O_;BR%D0?KL)M]Y%KGR&I3(U]E0H
ML\QJ4E37+:$Q.<-<$=T#5-SQ8SYQ7*\"@\MDVK*^YQWUAQ:5ZK<\DE'SR$MN
M(LXF(D6I H #C*W'!4%!#O5$1%AB#:0X#HT>54 [*#I.60(AS9_JDHF@W5J7
M&T.^]=\/BXVK)DZY*T>K2CS7LZ$\HDK%%#-Z9"L'!1*$R+7H*:*(QX85E<%L
M0BYZ9>RKI'Q%\-K>7,*;\4Y$B=+SK,BSGH<-2)2@DQ@GXU+L<@FQAXKNFZ0O
M<I2_0EN-=/)J>-1DVB@N;-Q$*.\>YFX2S9?M"C>O7;WG Y5!4TQ9!_X$1=TR
M(BQ^UX(4:G1^\'A8W<S'0JXF'A\X"T\F::!8+,V+SV#/'"WJF*0$L 4ET@=X
M$60B4H0JH.*'1N1BF\MRR7&D0_TL@NY#8=7T+5YF?*:Q0N!013R:<RQVF[]9
MQ4UQPIFO%Q:MK<4F*M]YX&Y1]-*./YMT1[3L[\D/3?1_^6ML[?)?'<,=3I.Z
M!O^.-[T9Q:.4%6A!J"%CX\@T"PHE3PAR%!2EH]/!6Z'3?L=]^)%%RT&$F_+F
MYYEMW?!/,YS\6+:EJE<H0CQ)7H@W*@KW_N'<L!!'R"8RETL$\5TA[&"HND8I
M+O/[=[;9S0X9%S]1F[2QI/>2[!()*PLUZR9#4BD'?H=0_]X^;'\@QA3V/4U8
M[TS\ H!?QH_EC2O"]*V/U)3[T6,3\U@;UK&NIWVKKC5U_%3A,A7Y>6A?,I)@
M!OBNNTT 9G&]1^L:]'%;\8?!R.A9>\6":=.B]U."(A7A%P 6[WQG6K+6SED5
MXM"&T*);#C(L+!UU*>)3;.D7O^ F8Z@(XFA:';D%X8"X9&%G<G>;Q?Q6/$8/
M/VY><S!I]LP?J1PRYUW;IK._XWV\OB)YB<1K>[F:K:]8?-UR93SY O!BI/C>
MRY87Z,^^$MM>+VQFAE=*^^5GN3VX:=(0B]3&&\1'SXN&"%5U?)8)?9R:: T5
M?IEAH)+?-J\';]K9Z 5 ;6*;$>JE4<SC8OM1(H GW_U#90UKUV)"VE&ZDY2C
M(MVU'FG]]4)C7N,0]U5FRG8?.:MT_H'0'H-[_BM*KTH4APK\P5F*'7K2)=VN
M\,JIA\AK4.KEG.=1+_#J&S5I'JLDLS$PA\>7\9FV]$4])MJ MY&!?,-M V]]
M%XOV5-HD/FV&M&$%H<MY4=>^#3K)B?M\G-)<;79PDG!'Y)D5TUX VGH?@]_7
M7+K.3_'3;\YVSJ.?1?/S7&2U&:+X/H4]\85..CYL@A]?BT2DM]**TO@MZAOX
M*I]N*)O_NE.[?CZ66UQ!^PBB+&(DEIBER$ _$E,O_?[G$A=(894+D5(B'9AX
M)H09L:.ESPZPY@!Z##^_[AF@NZ>P9>YM(1SJ0H%#-;YM(!B)QC3R:X[C';[0
M#LII7?H4O W2(@MI-1ER?EU[ <#*%R],7 "\+@#:+\?K/"\ E&UGB_=#-UZ(
M!E3?VW6V+I'Z\0P/>TUG%:BQ6U0[,D K&B9(2N,@-VK>E]^GI>WZU:-N# W_
M+EC"_O:)09>>ZLW08NP?L!QW,C$OP))\'!7_Y\%JV)JYUPAGBW"TN;[F'3%@
MNWD,KBHFJQ&JK08N@1ANG-AZK:]@,>(=JP7-_13U&B]62@O !PS*P,J*'PD,
MCDL;$]MYB(51F<8\^4GE*Z[KL6_>;"IT7&JZKK%S;2.P6L.[PN2ICK9-?DR[
MI4(U*"Y_SXA(D2T,W\I:%5Z)>";,<SNUWOPJ8#OF:$]!)72R'*>LYYQ;^]6
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MYH-MTRTI=5GLT:E60^$&Q.+#T?@+ "K+ EU1/0Q!S9.ZEV6*L^Z,)@D6WV.
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M*8"*P3D,?5;C*?Q-5))C0AL.7B-9@ A%'=&?A*3A9!RMWNEK-/3U[LBD2L1
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M2[V9Q%<;3$]OJF:T'3DY@WZRIS-I\, 27R]12*S'2L]T))OET?(#1MRP*."
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M6 ^([XZ0@#T^0U[W<\02SUC$KLE8ZBA,.((8#$"<X'+1F6(+'Q"%E[K'? "
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M^G8G25\!R2#IJ#G[\-/EF^[Z25*=S$'<";,2T1BQT]'JO.K2C-D3[X&7&S\
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MF,N$#VDKLSQB6T!TW<EY1HIUX*][>L]*PJ9&_4J^Q7O*Z$.P1).;'(.0'+T
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M#9'ZVQ,S>DAKWX\$CNL:N26%2):492A8YQ?<[:)/@NF.]RI:_.:H%AEF.Z
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M2L -9RNWLNUK#5QHDWZ"SA;M2^$R\YV2T5[V"J\/"O97V.&2-2%ESOCLAXK
MY2T=]X:1UBF^AR6^2UQO60?V!D7#.KQ5Z>CK@1!?*]#7S1FH0VY1,=+T14*T
MXEO2*)G<5K$$"B=@MD:Q_>2'^?QI+5 O]%W(>?I@4)$3Z8PP?^LA"T0*\)1!
M.*#Q?,BQ?N;\^:6+\V,7(*W68N/(B7O['.W(T%T*V3M9;&'F%T^E*J;V:J_=
M="ZA *H4!OP!-.B(]EROX6NVKZ6^KVLL7RPQRK=JC;QE)*V2,+'HU0I5#J#A
MX>'2<"TS7+B/\< _-5+O;<)BFP4,04[.*%F$_U)/_X._>VM74MO%$\.QIF?C
M8]$K6\L5B0?Q_A[BA>5M')\6OQ\SG&L=C._=MX#&W(A3PJ-B1T8;/Y<6Q,4]
M(<K9"J]PX!X&%6"K7=1_,_LUNP1>SE[O0600AL5'JA^SC"S:W?:K#CB@0Y=[
MZK'PZQ'AVKT//U?[.[L7,?L5;OK-6#%[#NX_6\'38O5/!(MK%VKE0C;TS+>V
M3]E^R[#J<+S-H;W&U/UH743(>R0Y.<FSQI?9*T^&!?ZX+)30SF"V]J& ==?]
M&*&Z3G&G:S#AU;$CG<OO@(\99O)%<+R^ -9U6+]J5'5Q)6XWE&6DU;W6,<*'
M4"#QJD00->E@+ RK0%&F"E2/])AJX'N ^(D&L.<#-AEFTC*.ZR$7X@W!$Z/?
MV:DUIU?ZONK>Y[G&-3R3477[7'I-&,"V(2QZD\+/L2<O)D^+ >B,-[KQWKR-
MD![;<1RV=-?T"UKJTD+=6,EJ=2+UWE3A%X-9#WI<4CLU/5?<)H=SN[G)8J"V
M;$_W$,TM_M5QW_JVCZ:*XG946/$C(?TT1$(2BS+K4 */O.V4<<BQLDG=6ZAT
M48^>Z^2/#^>EF%4B-5)$X:XM6]5)!(V0_SM$9*;#5JZE ./W -_?W<]']'9)
MFKEE.<+:44D& _'$_;0!]$S9089XM7AKM]E;?L4H:/=QJ)SLY?B B=W_@T#T
M/QN_^I^L?P":@N__*2E2D+#Y7[L8GEK&.^251^2>]YTV=-U7&9DMDV:4B9;B
MH.")%V-DV6YX_'BCK#RU2K^UG3,)? A]UL.OM8= !C:G+7A,@K.!%KIA*8>R
M7D7%6^F*.K;$ML'CQ3<I_*F^84@M08&3P*1=-GYF4R*\@D'/OJ%=]@&)^S-?
M6A,#ZAKG.$6/:>)@T4;Y]CZL'&9&J-;]QFJ5P4+Q;IZ#(A[C8,1:-_1[3.GJ
M[=-W M%Y""<B6[]K8E.FN0@MQDC,'N@6J2T?M'>ID?*<>Y 3Q=CQ(%:4TU^V
MR]+(OLS89!_EK7$*_"KJ'!_T.G?QDZ@?6@$0?S534K)78WA>IF4T^[YZ2\#0
M=3\0U8TQW\0LOZ&0\5^4FBU8=&1>5V8H4_P@;A136]VII)2E7Y5P\I8SXO P
M,BZQ:R@U36YYP+B8IT&^&IDW^"/[RV/_8/=73!Q#:),-0JD9=]ZOV&FXS,'0
M/M.476F"MM>P\"!7+C&2J7L/K"-^9.-6;U@W7;0#BIB&)]WJ/)<S=#5 P R^
MR[R-\FKU^:1*"AZRHN)'1R1-<B?4 I_RJ+FXB3)KK_3C\MG>+'=+':_Y8)M,
M2T\&E()Q!CB)@(>^O^+\@]A';X".D_O8CMN>N4*ZC(O/_-SR&X2_&X!;;.DN
M.MF/%L<VVIB!!<49JY]!%D=NOZ;:+@D+'74QXPO<"P.Q][%:O]36591'+/1$
MA+[+K)"KSBRRL:8!/%6!P9Y@&O];&7[3J\;\V5I0G'QID>CG+[E%#?O*_:?B
M39\I,K1[8+5;I4$6^ U?.V_5$3):;#HL&1EZ4Q#<UVAWEJ)<-<Y2/0Z;0:#R
M"/22&O;45)T0J5),K!:FA),\N;E#Z#9X)5K6DP(XBNN<=?/:9F7 ]VE.]/AB
ML-&$5B^8&\6E&JVMHD_R!BF:H4E_6\,HM4X"_].(%Z,9]TX6-\C5!69RXDG@
M(21@O>J<B;JUU%DS:!\MKG8\IX?^!\O6A>;Y<;=9+E&7NE<8#G\RB91NT9E1
MMJ?^ALTXW48<BXJQ/BE('-681&"D6J9H+/@R+*GRN<AWQ,O6U\/J^D.Z<0M2
MWL<KL0?,V1R1Y&<_I/C\9$0D]$SAPS.0':,Q+E<Q;G+5E2RJB(9+G;]1]\59
M*G4]JR<!=NFG-5K_>LG4T[4UK)/)9!*6Q-XJ&7J<5/2@HGYWS-&HQ/VX<U)?
M 0AV_P$4Z/ "H+&[64>DT;J^6A[Y3H4EC7.GXM5!S1K/4,JRR,ZV#B6F3C\*
M7!?G<6L@.S:%G)RQZ$+=8&X+Q@2G]BPN0/HJZ-+9'J[1]'1>^4M&WD'(-2SZ
MOJ\N-Y[=VIYE7;;;O2N>1 46^\X,5&%:(N#B>^T+=B<?W&6UN,GSR5]]Z+DT
M-O##RZ&\DU3[25U"FR=2DH32V7G@J>J&M7CZDS=L?_DAOL&KX[/!#K]O5M)1
M#PC.\%*)2&=V72841"IH:[<P>,B\$GM7ZCI)O1,Y9IHP-#9^9U+-O20&MU?L
MF0RB]MP^E@D"AIEC3K6JZQ6N=)E7]BET,] :D>%^_I\NCA=7<.3:,8045(W6
MR/QCT@P&1>T3=WEZ#PH:YY,[.^O%C$U37#$5;34QC]WOX/EB,NX;V'BV6?M*
M*@!5 &P!X^UZIK/!.+7GV]N7M\_%B7)41/I\"C!-VV+@J#0/2M<%I%58%^E!
MD RZ2FD9&2)ZT,+)$B(.A/.IK 6[P>R^WSE/RR(R1G2W?D9CW3\2Q/\ 1I P
MXUOS2$'P2A,>?+A>*,"2UU/"NX$:\"DJ0UQ[41B_/*0J^^SX2#&/PAY"G.D=
M-YC95E0,J.\;-AJS#IWT:@-\!RP>RBI0C%;L6.[.1!:/H_KT]&M\B;"2&&EC
MVVL.'5\GU64@&W1O)V/+E&H,3/?3=N)0$575<]@?^U&*YI)R=M:+A^#5! UM
M)^FF0<R,1,FXF.\F_X+JL>(SEVWIQQ^=>) L*\UXBH=7?E[+==P?)KTMQ1G:
MM:W<(L;>Y'NHOKI[DM@_R$X'#)NAD:$M9B#&*EZ(8^"OD=BKF(]&+-LO]X%B
MM(ML\W.O&G>Y?"6B)W52U"KSF(MPD'>&WI*;)Q5/B*_DFBHHV.T?FHL;I<Y<
MYR[ ;U/SO,X/*!7X VC5N.%N:_VP_/HT1<:.Q]T >Q,)_0JN\1.&VG-U4<7@
MNNZ'V.(V %T6F+3#D<RV[%;[JW%&C9]\0(?&,<-S*5"*\"]31#4M6\ %7\70
MYGM+_(0T,J.A;K+E5J S!<G3%_WR"C/$?<#IXL?VF:X?*PY_ ,>2OP?,Y*#4
MY6\0$AY_ *)OYL9KQM\=07]C77ZV)!3B#,QX>7G"*ZJE53(H/[3YZH2#:;1D
MU38(^?!U['B@^,3.MTY6\PG3[4PM<7KJ )30HNJCY\^\#G5>W@_<O%!JQG[:
M^K@!"+K0]D=_G!9YXV\EKT\#A0%IOI/^ 4 4^_\ VA\E?>J=#"PV<F8)U-B#
M@I[4X',3#725)S-L;?&7YDL=MM](1PM\OY3MS\BW:WC5CHT,T>.HPCIMEI>:
MDQ-&PJXL:R9[E((+T"/5%]Y+2X:*"-D?254MNDE"KNNS:5322SH(V5_W4AYF
MUE(;EXF%@$"7%:SZY<3A[M+'MK2P?MN:KH+NZW/2$:*S ^+[)>,SEF/L!<%&
MR<YV5=$EDI9;F:R#HJ,;K',J#\/0+2TY*8VD]L=V"/&7*T,=%7M?Y(IM4U?!
MMZ\VB%(;OSETR/:?V[K>K0M)7EB+74O2C:R]B";CF^^!9^.)-65 SI/ZR!YZ
MK@J81&^T23"/MX^)PBF#<.TT$S':/,MR>-(L'[ 1-KC/:-D^WR-A7/R!C8U,
MT+EM59&8@'9,MC2OI#^O3'F=7%(04R$A$=?_J!2E"LR>'B+_?$V%/1@Y-(G"
MG-WZ ,1')\JO!931?Y*VUO2*C=MHN':S4X4J=@,UB>]TRCQ"C9J-"KF/N+/+
M9KWXP9Z<N&<D5]?E%,P2,G[.."LX,A$Y6\;^S.Z).]O&4UE)3PJ:&KR,/KYA
MX52[= S5.V*;B"R+E0Q9TM#GL-)J.(N_64%<&#*Z 7QM7[VT("Q:1'UW/VYQ
M+('6DM9F$GD^(\Z(J9FK@*"[/,OKQ9<1R CE6F9V@$_W$R\>TE"VSSNV_%3=
M_SH9_D=#T_MF9^7W@Q:MW["<@M>G9_]53DE'N.U?9U5*X_JWT2@3-=!=H1J.
M,HX;B*"![Y$X ]^F"WSS'T#1T#E+F5$V0F^V(@6.;3;LWG;.$'H5"]B;)$6\
MMK>9I:KZ5E/6FKCG'&0R$?XZ<<$#T-C?/^'#%+ 'U<ZN[Y3R>_X+_:5U[*J9
MYU!8Q8W[O!0K_6W<E]_@6$]1?4JS,W7TT^J!#)GW'\#CIWDU+3HBPC-\A6$#
M3]R@?9EH#@$'^LK!D!B0CK%]Y=;F EF$X&;&1^4-&@J$-\4K63G*.W&)S.VI
M7M(,T75W,H5G3 BX]4EX80QR!6_!FM=ME[XNY/\6(3OTJ,Y[XA@".L\N@52<
M\2AR\'($[93R=@OX1+6S?@;?^RYU3((NS*09V5R;'!R[%N&Y]/"=P0'5O; D
M2:^^2-E+9)FK,D@0!4E6[2RX6.9ILMA,P[?5E;TSCHP"RFPX)>GC@9_WUK/0
M<YXG%8R]B.2U:UN/T>Q=X]VC)MXW-KO]?D],3)Z>4<(!Z%,E%2O36+TQ-3H[
MI#&<//QF9T"JP31Y1%F]T5")QZ>Z6UOM>)9@VSP:*4&.$O0S.-5E5;6-3=7"
M$]G-?HC8CM1&3DVQN^_6=@7*.Z](*L<^YG]K[TJCV5S;=5HV=@VMC5)3!U/5
M4$/,E-9,C3$454.H(6*,N:JTQA(UQ=!*"6+N%D(,K:*:F(D08U2JQ*S:T);2
MT[V_;Z]SOG7V.G_.C_.ML_RY_KS7_5S/^S[W_8SOLV[KF3R#L:TT7A71N)G1
MF-2^X(X;-(7/W KAA1-<Z=? TDJVIP72_* BJ@ $3=#T:_"53]4</P#;V;>V
M#J5LT[]I94UDOMES/1C^+)M]^^9@Y"METJP/UD*-<'!D15=I]T\K3T5^L?RV
MR]YOOEJ96*@H#<^DZ'#HL &C5*5R44MFH:4\P(2#IV_A?FG2T8(<K+=)/9Q3
M=L^FO73MZW8-BL<5#85L!8H.0S#$ +5.I"9.-SP&\G.)N13*;N:WH\X[.=Y1
M:;"3I)3$?M?0B@(Q%BHW4RNP.!V)C9(X6S%EN%?DL+]R,-_</7[ <D2JT78^
M'SV!6TYLTGYL,7F@W!HHV+M7K/:A:1XS'7,-_7H$AE@'F:\ZDO.G.G4HWD(=
MGH%C>XD^![^(8;+;[H* \-Q%Q@_9A)DF+C4:1V[3,HGKMB&E?,_GV_K+V"K[
M[YX!$S1*@<V-P\:Y,K]:Z4*3%^G3"]];,N'SK*,<(;?&:$_(<5G&G2="B-\;
M/G^]VJ<=Z6V6<C_DJLO*R-&ZW>&=^U./=C1\PNU_%4AQ>UJZ2']=YD-=>]^<
M2%2:N/88GCQ@*'8[USQLW?%C)QEW3G1AY[VJ9+D\]V C]:JC]U"=9D.3>A:S
M74,=\:$EGF_F\Y%=UJ\,C:K"G=BC<1D&&ZCLB!].48GSAI"3E.%NT+9'@/"H
M8L;8J<5:Y;CK[B1N'-^G_>JO3F)B&DD)28#P9XJ]7I-]EAO1-O4.EZO9Q9H7
M04&5X@YK7G,<2//),^;,KH( N[W:HW.YD^-CN 7L_H 75#BKH5UW7K(N/62M
M+(D='-GBP7N")M/;7>KWZ=91 *I^NC3?>>W9GFU+]W(J]+TNDL:9ENAZXEEV
MAOJ,787-M4F#M3%V4(E;'@-#+(.FEIIEVTQ;D(695[-FPQ(L*"%#D)IV>E5L
M5R7O64*-H=9P6T[:CI;\T7[QZI8=-?"YU=S:.0MW[$-=?]GWPCO=QOSJ??@%
M@N65MQ5*GCA+3>5D6P.:W,!YF,[*OMW)$R&_+BS\*MAN5S=CB\F"0$70VHU3
MBW#E>JX'P9^$"/@W.O3GZM-8_)5-$$L))#J59/[5=)H>9;]%33\\B\NX^]&Z
M42T?;+Y'D9^)K?T!&.O%BL\*!?%_&F%L.J!OSR&0LAGLC_*V=LY]A!N$O,$$
M-*'"-J@<+TF?3<+=_6Z*$9[TE.60OU>D'?&NLY?^G/>6T>O,\-] 0K#10RYN
M+9;,'FH=0^04?<EF<3P*X?S<N";!6?'.K[E8H6'U:\G:L/B-;:^"X1A3"=]!
M_YI1GN!;[RC0TDJ_=F*$60Y0:)-TY*K2UC9C:)U4^N+!/:1'N-$[IJ*/G,\_
M%Q@1*I*M26KYG]ZHYQ5]YM1$M29V$]7A[*"*XE928VE(B@>&"YF^F#]2GR%_
M"O9$[<G95U/.:/0DBJ%Z:H7BH%'-1V [TTW&GK^S%0/1=EFY')I@)DBZ+5$&
MW @!I#_8]GCX ^#94C#[7,7WSN?RLWA/OYKRBKH4S#BF 3_9K#,6$0#\P#4;
M?V+W"A,E36&5S[OM6F%'=;7R&)Z8E\?0$[="73]E8>$(/5 B\8S4MG0X6DD6
MC1F-<A@!@!P-06_&FG:9QC?@KP8BVYW6UZ3P8#1$EU42M>'O3,]0V+9<P$0;
MR&LVT.JJG)\&]'OZO"3:^&@E6>A]B7T/1J]\N/!)H8_*]@W7:QDMQ;#L!0I<
M]GT]Y8LEC8]@S9[?N7-Q1:3VJJ>@O\@%.?:Q15K$M02KZ<'W#ST*.PIK^7PE
MGUM.B\0R ]O$L2>U+B04?"?*DSA Z;OYW]N]V)YGA][.P+E("AJGGG//+:U_
MJ7I^@358QJ%^5@\A).04^GOZSA>'U3=!5-A-GR["<UF1H02-1DHQ"**>NG(1
MA<BD=ZH&O%35*EO49&98/ER/"DGM,?T]$0LRQ^(<?.LT7 +)&E;(31[1< :C
M\YK<)#,BIM:'XCI\^M)"9)"4K[=6,<DW=:TF5%]@\XO)O3P=VG82(# P4/7A
M('BF,OIB\P!ZKR0<2\8VF"]'N\O^  QZ1QN)X&3.[?W>KM9L9M]L>H@OJFBI
MNN*+*SNOEZ?5J7*M(<:T2!PLW/!YQ7&7$%G0[Q)@MU:(FY*X%W*-Q#8,!:%\
MP@T$G:AG-+O>'9I@[.>K[EQLZQ),KY]>A&%:\ X4KE:TLH*<CBC@O>* +-\'
MVR6;*[$'BV0VM#!/=3]5FI(UP8G #?-Q['S.G&H;"E*47]YULH"BB9HTX7=;
M5N,J[6'P,K=QKC8SW;#L-J^*N$1CTZ*N6D!L;BF[\,.$X$:*Y(OQ&**1!SN'
M=+28&W@Q<'D2N/.+S^:SY/6][*KM\&^E\"AF;=C-!77-%IQF5"%YD=R,R/;+
M(DW>]DPGAN/+QN7A?(%I2K5N(I6(>@WA4."R)_"J\D'LR_'7.89?93-VEV,9
M'WM:QKI7_ "8O0XFO[Z<\='Y_/K@T:]G^XN/WEH</;V_!/FV5!W+_P/@'8ZZ
MM$+_\Q_-O[)$/+;.<9DN6#\@0XF^6WKZ0R5_LT/%Z.RUE[??L03?:]H($1Y=
M5G6-5V#9<.#YYSGVNA#?#=TR^@97<X3?V>1E".ZIR.5%#F:LT-R2:1L?14H,
MYJ=0?X: 2,,*1V@Y=.[)]MCHSV%W"U=5"VG>.+N;3"M9J((L#:&"0*FV2>_F
M&0<1J-V^NGCO]0AT B8)C C7&5%HS&3D&U.'W6Y?D+;K<G[UFO1%2N5+>PC\
M?JA$4'%9JU6?<1 ZL1IQ/>FM(L/,MI&4V!G=]*ONT!(R>GKS_0R-63T?A"N5
MP.+X1HJN %_%HU5%JC SRQYLG#W3DB*!Z1U2P:JGY4 LQ:G5)(1)RX7$ZB%H
M(1_3);B)G1H&CH]7C4) V7ED.@JP=.Y1$ BW\I;-+5WX@:KT(YL;DSYF6B[V
M8K:AJ9,@T,6!I<+<C.@6<(J(&.R^GH_+X4SC/>[8_MK+Q9W8Z3I$F-& 64=6
M0M:9.S/>3GQ!@BF=YYQQ J$\P\^+6ZU(MEW/Z"$]TP+(N3,W^O7U;*\5-9#&
MADPMO'#Z9BJ[&(7<=/#/6>V)A^LF,FH>Q:O1B4-0]*JC@X2N"3X ^YF9(?FS
MI(VE+L@'JFWRI:/PK6_"B \X#9:);2US?1C7FT"F"*$=%Y979^4"U1@MWSZG
M@BH?+NI =+P!' ".<BY[M)]2KG]U38.31'70 !J1I:*)''NO4$ZT^@A@8@9P
M"] 3"^\E;).:PS6?Y?%?3I$@M558,<K8Y9(F0L[YUBH7E%\X^>WR8@A<+>BB
MD5,=/6SF?CS%V,*8*;Q-5<0/.N(/(%@Z&#W R-K-"#R[))#+H^1QX8,"2KQW
M;I]%2N:,'FFU74@+.#Z^!_&S^<QFRB5YB]RWK\-VWO' L$(ZYV9!3A@$JB'N
M_R$]-3?M= "X7C7#)%>?T1EGX5 74E"'>!PJV.-?(+E:()"\,:!CG9R:7"BC
MXE'2:AR(PEJ")HV,8_0"E7Y7HU%/(*669 LP8V_M>920%&Y;KZB2] K7WY[1
MNOD6UZU7BE-*2&'JS*UT92=/Q?FQ275^.[DG!BRJ@BTO@#-WNDRM9PJ=A*KY
M$XNHTK#,ILZ]>":;[@LR'&L#/&^6N$(\\=&A9AT0UP<ISP@]7QZ\:2?$:9[&
M!"00YW)^ *QX6[@8Y6OW()Y(7H)W<7DI7/<EU8++X66TN=J+FN:B1N<UM\JV
M&6^(5]*C8 N&.\OP"$:XB2T/9ZXRJ[X9GG__J3-W4STN6.T=@^G4?*=1KZ!%
M$TRW'$A7.AGAIYQ/8XXPZE=]$[<YK(#.O/XX&$><6_E0UFK=96LJ04J]R]PT
M_\3N_ =*]BNBTQ!RSMM=S5.C*A_LLWZQS,WT4NG)2:]F1\<=7YP5D?GPHAD#
M>)Z^%9>;(IM#^C1WL"B3-;-_N'FT$JK(^H^X R;+RRJO"3P38N^'%S8(TDHK
M4QI4KL6?R@AE?VPV6[TFN2K37*ERVE@T2($)*>0!0$_R8K)4P@R:AC8">Z^C
M[IN3-S6BB:?1[=:S4I"2NMRAU)*T>^D^$#4& K,PG#4*U,4#9$LL%-=G X=F
MXD?)V#" VM6TBD25 $-N:#C$\81SM9YK@=XLEI(UZR3CV4&\;FHO&[Z<6%07
MW3B2+ 1)4,ZK'QNSL29-0S$D&XW[WD]O#O6=AB3*V?1?2$7_C/);$O&((6CB
MKW@QN+J=4@,' 2 7 REJ>./=9+(*#:L^)2FH<GO?-\S :$.L6%+41G_4YT"K
M@ZH5P_XB%=E\CY[]EL'Q"RVECT'3WI1>%[?TENP4-+_O\C6,?7N,2B#_;("W
MZ1 ^LGQ)G7<GP!70>NG*WZ?^_2_P5P:Q&]L!>RI'^=9&L$O_FC*85;@C%4$U
MV8<D 'EL1O!T$%Z8X/K!0Y@YM5=/Z.[E07$N 3;]]H1'$1HM>/FI^E5I<K^&
M4QVV>=^H;HL#4E7 I><A[(KC4[-FB6>:**5OHDLKFJ=EZ"3F &8"PW6?369!
M+9.[U4C^MDC)-13<6]0'LIA9,A2HV<6<[UP9?XI4!MQ$!2DU] 6@\X46OBYX
MRV@5+R95F:,NR$ Q-6;;)C[)?KC'FG41E9F'FJ">/:86FD3W_-[)9I/+IY2_
MN3>Y%'NHU(3*P&YJ#/KM)&TAB<@[Y:*IR0?ZB.F[R00?W!BQ_@%+_(7!1430
M4)@S%,8;=6>YC4@B@[:9Z2%X80JU=V&WMN=Z%Q%#S)_#Y_=29$3BA/*M$(<J
M=W$VS:C$24/&04;YC>23G9&)7XN_U9=G,L:0!R#M])C=9J(]+')N*U] =BMR
M,4(PF)7AD^+-V"U*WH+[D>VUU-,/7%V#G7GH-KA3QCZ056H5.L=MQZ1SKR6R
M:Z&!TRK%#V?E6#EM[%<6GY7[W."R")OW[B\)PGGU!$??Q4:GI]8N8[#XH@?;
M7^=:OWVK>O1'>GAG?A'35)H=NS9D*T^(IMWZM.?SL'Q:S6\7O@*\ 0#  N 6
MK+DF1B;&-E2)!ZC4=&N5YN%Z[7;PO&;_D![G)$2L89LH4/2+$@BEECXFQROW
M ] =F6&]C7-:V<RAC/B7)R+8\OQO=!*S!S^N?ZXMN^X<EDPZ_7L,!'M8/Z&Y
MK:Y[<ZYE#\G77]]4DL[N?:+8%2!W<C]9"?][TYW=LW7$W4"')719DYUZ5(H$
M4GJKZ!V*_[W%I6;U2_'*-#>LLX=?GJGM+W[I?)!JR>F+#/6\)UOL?&9E_ ()
M3EXX&P7.=@'/<O ;9O!U0>82$Q3J2H6YPY7BQ%,U2LW>%_E2U21O+>,U^%DZ
M=V65^.^^!;')VSC(9+UEH:1G61LLUX<!.=^,EQ,9;>V*&B:ZV'C"HF$?N^6Y
M@ZTQ0VFQW3^M1/>#^ZQ,V97T"V=E@-H3>OMV:FF'9PR8JTQ0+ 78B=0H[ZJ*
MAEG1BB0M08OR-$P![<'/9^&.&\WMYC\ 4758&Z<? (O68K_H^:)1A3).1L%"
M0[,!J?(\B^EW4G!3BOXYT3U:J+5RAN/L_4ILUWV,J1,*A9;X 3AM2I+//7<!
MEL[PT'%8MVEZ$2Y@QMV%*#KKS%FU*O;0U,>!W2;]DCI15TP4-KSVY%77RPQ!
M%5&J/\N,(Q[;TO* R4*1=CM3[E_.^Y@]M7=WCIZXB!^U68QI1QU8'-Z++>/M
M>_TBFYXQ7Y&_\)];6)?WU\6JJ2JF+GXEU7E\[PJ9M*8V^DY=YS9.1E;.:+ C
M4\-&#'UQI,%WI:(V@^"DXKA</+5BX\L5.)+J6U+U-,]8FCWD59FDWLT;T!?R
M2;; ,Z0;4SXH.%^A'-E@E)RAP\K3'!WBG_AAAM\M4 0VSD(P,I"GMWY::"3*
MM23RR%2_,P6)F?UT1=O??G.1 I_8DFB:^^F)-RZ)%+=)2DJNO)<?TQ64S^-%
MX$=';YL;T[/:B58\LLC&H1#><U!8P MF+8T2G_M1\*"1X7(K[BY.SE''G\,)
MZQ&B]M6YS=%Q?6=+,7"!]:BCPI9KAOJT4=FD(D*FXFP^S@T\:64]^69T$G0=
MQ!'2"G3;'/$_U:N/WLF1&R,#@J7M:H^JSB\T5F_F*.4,5M2@T$BDIK^^M%F(
M4US<SW;_!9'JSN5GF"7H$PU0.ZMAJ5UM^%6ZI@A%@<6K^@.!$U8&X?E]8 [V
M:WZ?''KS'T*CW(2<P-A)(P)Y9L57&)^H1 )A/@"# 9D#*0MM3'GU#)GN32>U
MC[*TNVY><F?/W9"%?ZA0BJ]]<SZ49?^B[,K\W'!XR#12U7FENEZ6'!WZ7MP0
M5E)1 ^9P%$_3@'UK[/,8 UTW-.^/,@+',[$IJ\[PDS/D6%NYNY*']>/"&F=?
M[&#R3/A]F^664-YOOE@\U41$793GZG>&?=0W8[B(3LG4Y:. ^?XQUEW&^3P5
MJ$[7K0.*NV]^6F2-:,?CY9]K*\FE)!O76MSBY+3+GZ!SA_/IV9\RB:I\B'LH
MD:95O+< OV>2\1U!^@%P<^S@^/D:J/S$NQ@M-Y*AJ87^SXJI7JJ(*Z# Q9F4
M6M54&9(4ZFNDE0MG2D'VT++"D+17.\ \,"(BB%!DC'(M[/ETKQ,O)S_ >FK2
M&^?8YK]G2;*&#<]GEZ0I1GS[V)C)RSGQ, @[NV6>/D&WV3V=L:)N<')Y_[1<
M>^7E*BA]LZ*D(K&0:8>SIY-\<+)7[X]O0#0VMC B-"/XJ)!YCT"PSGS0^]OW
M:$WA*)1LJ87#FK],BXWCRE(=WR6O[K$-N*'J<CGG'[Y$?!%6!7[M.V 3ML8*
MLVJX@LPQ$S.]=X'A 15^;KY_"E@K3](CQ(C7 _=UG"O+[+D04A4\V-EA/3U'
MV)]QR%W.NW<WZFCW;/GEUXV*DU]J9U$3<\F/G_Y=%CPVXU4AT1<1@>><8[JW
M!://1DFU@=@XJ.%PK90YV1T"Q@O57M8CIY$PK[HG$=A.$'Z+3&F[J<O0XKR8
MX1[.^C)HPV'EZ3'AF/!_1)#M,J&>R(CP:%=S\$:ORG5N\48L3A7]Y<G_SC4_
M)OQ;$-Z7AHA"'G=U]7_=5U';"OOZ/KC1RFS,+>[/SN]/:VFZ/2P_D?F/,GK^
M=*]&HHIQLNN?99C_T5$^UN(Z)OQ_(#@\D2-PW3(/;$5E*XHSZEGI_<UMEF,X
MAF,XAF,XAF,XAF,XAO\=7%^\^GPS<FD\EJ7GV]$DTMGP8YIC">\$%=1("Y*A
M-!W%-M'RK+Z+<-$.[D2&GN^6]WUDSJ,A:!H.C?WO9EP)YH3?*+,N?W&O_=/X
M;*4>%83IP85-_L6U^*?QVVI.59N-8Z%CH6.A8Z%CH6.A8Z%CH6.A8Z%CH7\#
M(4Y.:.;_?)OZ&/Z V!_3_P%02P,$%     @ &HEZ6G,)AMCI%@  ._@  !$
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MK>"CZXJ7M:I?B>DE>7)/G'46PJV("/1K?->CI<6>*U"0V>_OR:>SX-W%MS-
M]NKC6;&W<XW D._=%])PMDCS2#*'K^DZXN.5"*S(F-)</*=RCODSQO0KK,Q^
M7[D;30CJ;M+(9HSW.TD4X]Y!E]J+CV)W]9$&,W'#OL NI1IF;U++OEAZ+0ZE
M(E_-^:;A^.J*[YSZSGK))5XS[,9H82V#SLFXLE)[312I0T=G&>+Q<W'ZI;.
M4H6@DX6]%\.D)B7=)6G%^,3K%(BY2W%9FIAV@K5^]4>?G%=1TEUJP!/;3["R
M"'&+I%0A4-_O,=1M8-S%(-* ]6H*%>!M;01=4W<?=I"&MD700*(<SSDX*'X
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MN*CJM=(+JJGH@K/[R[$+;E)!I+,_OK(TM!@_\[FX$BBY<PTZ@-C,RF9[IA&
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MOO3LSG:C<+/)-BLY(7 %T&POW%B:#="Q/*\:?O N]NS2^@%ZH?B'@'LP,37
M61OM*KQ*CE=%/UC7:N_E-Y+_MDE0%$+ZE%D[WHS8,E:9M^!(F)>@Q"[[5WNA
MO9UG["8D6D&2K',3BC^#0WMJZSU)_MZZM[218Q("G.P)HYCYU=5:7 JE@NA>
M2]-5=#I.35C97S%T@#PSWMF07K*^A;-BZF_Z[Q#R_L:S8F(0*3H%Q<U]HG/*
MT!QTK>FKG$\'3+I;$,.?_@]02P,$%     @ &HEZ6F[I+[@W0@  .3\$ !4
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M%S1')%Z2O?AG?>25ZPFGQ:<$3S\MVGR*)I.?M'!RG&!+'Q;U?ATR6&RT-N3
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MED"UHVNO2]9S( @8W_S"J\OXRRDB+SA]^8UDWXLQ=8]'J5P W!Z XJ1_@I!
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MR63BK+_&MDU=^?P/%!<TO==<KBW&!>#^#-R-!=P:</A5R6[1=_:GQD4J5@,
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M!/"<%#4-@)_6TH<?A@]1^H($#NN-OP.V$'+BS"2Q(4T.'&=IW3I<%_K<MEK
M<NWHFJWT/G-8)N!IG51GF=:VN>K;?]R$O1T\\*M@\]?H#4_+J931&VV ;"^F
M0*YR[C*80ZNSN%85:X$Y2M;6VX#2>*GDI<O:75I#"$ 5[AUG\R?XK")^2Z,W
M0'7CENILLS0&&T+@JA@F?%098Z31&Z ZLJ!J!X)I"\10GML@0\AO[D2>O@\!
MW0I6=7SHUE%U@Z(<T>"$Z^F,9*]5039E*KND%T#T6K]7>WKQA:A$%D0T[6Y(
MR6U6U.))UC$.#]0\LR<1I>E0P 6O,>PM[0B-T(81K1OE8X5!%:CU6F.TG6S6
M"()X\%<(YEN.1N7D!H]DQCB-WH#5Z\L2[:2E#3"(R%X-:B_0*M/R;O2$R/22
M6M1S6I/T,BVG"R= .Y'K?6-X^-EKU0KGBF'"AB "BP=YC@HX$428L"2#<41>
MI.$[_ Z R.L+%>T$*\,41/0Q.[M=OLUPI3\748%D)Q]><T 3YNE52T)B1(K0
M8H>NQJI$O,OJ,=479'X_7K/AH97*1-6HTLHPM28@##=6*7$U&"[L3?7A4QF6
M$\U@&5@\4/PX1JBXH5^@/)8;%$5=@!.^"\?LRH4[]>4(0BB>S*-0:4$2=P)@
MCNXZVH9 .<_UY50'%$*-9 >2"L7$9U]D'7@#30ZJ&E7\V",=LK.K[ABPE_C+
M(-'8UQH"DKL>'1Z5KN!DS<+#OL(YKB25[3&,<*L5:>P20"/#;G#T3.M18Y0O
MR$WNT@<4EX2&GT*#VRPERQ]9&)GLA.;D.\/#@VZW.!O4JZ*\K'UC>+CO)B9
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M0&FC>* %#S,03\E&R45)0+^K%.K?HTF)UACN1M] %'*OL\$XP-!@;$I2*;=
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MJ0I.EW:9\[<*'3[9"\H;9$> 7"W9A=WG<.&3/4=A6LW"A1D_Y7RO$][G<&$
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MBJBZ5(IR41*<OE0F/)9X=XN^L[](4\-T^@->+]7A6IAG]&$%\2*0U([>U+<
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M-0V!!DK<!<YIPF:I5QQ0?Q 0Q%'G3X/R:%.E_LJZ48UTD^TBS? UYC)_;=-
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M(_/F\DAN3&^Z)3]01(>TI4L,"T'0QZP0 2 8O<-YD<4A6<BI<ZR97P5<Y5T
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M@;IATH3\,U]_CHV*;8K[N0"<A(/!H8NCJ6E'@$5:^@$JU2Q(P:2: IAS>I>
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M>#7?0,U'RKKU5668B)W+VD6 RR\1$\YN@WPPY(M+39R+%-2:+Z,_ [._C/+
M9/0+XNR78'?$31"SR?9=W0TRGY^:_D$Z/](<L?:MT'Y?=O$F<S'(?V<P$<Z
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MC.YGEA)("6DYY$N!%*FGQFX&/1E:/5^4Q-S\>8H-1TZ,MAS:*\%[_(G]2>3
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M#3CA!"\'N3C10Z[;!@IR/<H&$\K_[A)R$RD$@YQHCCN0$TTPU"V >$MT]OI
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M+UIS@>M$;IOM \[VEY\+G.3437"9'/=E.I!INF7Z#;\TT%@R&CU=*11UA>C
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MG9J2B-/=N:EEZ\+@-;0@2LP*E>1\$9L[.W'7,GEI9+*2B..$=W8&^KWP3L]
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M^XABK]51[>.^PU'GBX[@,,IM/]SGNY>2WCURC2Q-CD^_S^)J S,:?)3QCMW
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M;X5H@90U 4F=^K,\JI'P63QSE46FL@K6V". [<@IEK:D+F9J/7H^,^>N,3.
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M-FM%4\""' ZA)6R!U5D+G*>3YYE,V3ZU=I.NSXMBY<N?R'M"B[N_&I?$!$V
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M#<@G_=8J:5T:W=U"P:D]T?NGIML*%,>'_:;4$HZH561>7>>0#TV:(N=/0UV
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MM9X-ED\],*A!SP+ZG@ALLZ,0QJW]P9,T 9Q>K)-Z."R%+=O:F'R-J3E9TD8
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M6)&'@KWJOP7T@P7[+C<[0EHE3P,PY(OBC9C8)%6)S]*1N5D4DN9)0V:1D3<
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MHQ^$;<(&84CS8)86I2!-/@7ZO8XN+ERN1V?P53#%C.K5U%U;ZODAM->/>B/
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M!KS&*X!&1TQ\;KD1C=5!'V5GP4_<<)G?V,!?X3SX7_\_4$L! A0#%     @
M&HEZ6OFDXA?? @  8@P  !$              ( !     &0X-C,R.#5D97@R
M,3$N:'1M4$L! A0#%     @ &HEZ6D$'.,XH @    4  !$
M ( !#@,  &0X-C,R.#5D97@R,S$N:'1M4$L! A0#%     @ &HEZ6L,W-)2-
M"0  BR$  !               ( !904  &0X-C,R.#5D97@U,2YH=&U02P$"
M% ,4    "  :B7I:5Y%N3<<'  #?3@  &               @ $@#P  9#@V
M,S(X-61E>&9I;&EN9V9E97,N:'1M4$L! A0#%     @ &HEZ6L#P-9B>/P0
MH?@D  X              ( !'1<  &0X-C,R.#5D<S$N:'1M4$L! A0#%
M  @ &HEZ6GO?#)6D5   >>\  !$              ( !YU8$ &<X-C,R.#5G
M,#%V.#(N:G!G4$L! A0#%     @ &HEZ6E4=ZZZG5   /.T  !$
M     ( !NJL$ &<X-C,R.#5G,#)V,#(N:G!G4$L! A0#%     @ &HEZ6MD'
M9BSH70( %1X# !$              ( !D  % &<X-C,R.#5G,#EV,#DN:G!G
M4$L! A0#%     @ &HEZ6D<H2<34"0( H;<" !$              ( !IUX'
M &<X-C,R.#5G.3-V.3,N:G!G4$L! A0#%     @ &HEZ6ER)G5G@EP( ,F,#
M !$              ( !JF@) &<X-C,R.#5G.39V.38N:G!G4$L! A0#%
M  @ &HEZ6G,)AMCI%@  ._@  !$              ( !N0 , '1E8W@M,C R
M-#$R,S$N>'-D4$L! A0#%     @ &HEZ6B\;4F9]$0  OPH! !4
M     ( !T1<, '1E8W@M,C R-#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( !J)
M>EINZ2^X-T(  #D_!  5              "  8$I# !T96-X+3(P,C0Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    "  :B7I:30UF@XR#  ";]0< %0
M    @ 'K:PP =&5C>"TR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @ &HEZ
M6I5,*BT28@  9HP& !4              ( !JN\, '1E8W@M,C R-#$R,S%?
=<')E+GAM;%!+!08     #P / ,0#  #O40T    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>d863285ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:tecx="http://www.aw.com/20241231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tecx-20241231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P06_20_2024To06_20_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="PAsOn11_19_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="P02_01_2025To02_28_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndPre-ClinicalExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ResearchAndPre-ClinicalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ClinicalAndDevelopmentExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ClinicalAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ChemistryManufacturingAndControlExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:MemberOfTheScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AvrobioMemberTECXTypeOfCommonStockAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tecx:TypeOfCommonStockAxis">tecx:AvrobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_UnrestrictedCommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:UnrestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_UndesignatedPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:AvrobioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandNineteenAndTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CvrAgreementMemberTECXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:CvrAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AvrobioMemberTECXAgreementAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:AvrobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ExpirationThrough2040MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tecx:ExpirationThrough2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ExpirationThrough2040MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tecx:ExpirationThrough2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ExpirationThrough2035MemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tecx:ExpirationThrough2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SimpleAgreementsForFutureEquityMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:TwoThousandAndTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndPre-ClinicalExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ResearchAndPre-ClinicalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ClinicalAndDevelopmentExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ClinicalAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ChemistryManufacturingAndControlExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tecx:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:MemberOfTheScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_HarvardAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RestrictedCommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:RestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_UnrestrictedCommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:UnrestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SimpleAgreementForFutureEquityMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tecx:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdvisoryServicesAgreementMemberusgaapRelatedPartyTransactionAxis_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:AdvisoryServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:MemberOfTheScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdimabAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:AdimabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FederalMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tecx:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">us-gaap:RetirementPlanNameOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_HarvardAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandNineteenAndTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AtTheMarketFacilityMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tecx:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SimpleAgreementForFutureEquityMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tecx:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AdvisoryServicesAgreementMemberusgaapRelatedPartyTransactionAxis_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:AdvisoryServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:MemberOfTheScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AdimabAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:AdimabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">us-gaap:RetirementPlanNameOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tecx:AvroAvrobioCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandNineteenAndTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_FederalMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tecx:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tecx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tecx:AvrobioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AvorbioCommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:AvorbioCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandAndTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AvorbioCommonStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberTECXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tecx:AvorbioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_30_2024To01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-30</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <context id="PAsOn01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="P02_01_2025To02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2025To02_28_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="P06_20_2024To06_20_2024_SubscriptionAgreementMemberTECXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="PAsOn06_20_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tecx:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="PAsOn06_20_2024_SubscriptionAgreementMemberTECXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tecx:AgreementAxis">tecx:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tecx:OperatingLeaseForOfficeAndLaboratorySpacesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="P02_10_2022To02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="PAsOn02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:HarvardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_FundInvestorsMembersrtTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tecx:FundInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_IndividualInvestorsMembersrtTitleOfIndividualAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tecx:IndividualInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tecx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="P11_19_2020To11_19_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tecx:OperatingLeaseForOfficeAndLaboratorySpacesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tecx:SAFELiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tecx:TwoThousandNineteenAndTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Segment">
        <measure>tecx:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2024To12_31_2024" id="ixv-19785">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2024To12_31_2024" id="ixv-19786">0001681087</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden136075533">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2024To12_31_2024" id="hidden136075532">MA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="P01_01_2024To12_31_2024" id="ixv-21189">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2024To12_31_2024" id="ixv-21190">Tectonic Therapeutic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2024To12_31_2024" id="ixv-21191">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2024To12_31_2024" id="ixv-21192">2836</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2024To12_31_2024" id="ixv-21193">81-0710585</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2024To12_31_2024" id="ixv-21194">490 Arsenal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2024To12_31_2024" id="ixv-21195">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2024To12_31_2024" id="ixv-21196">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2024To12_31_2024" id="ixv-21197">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2024To12_31_2024" id="ixv-21198">339</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2024To12_31_2024" id="ixv-21199">666-3320</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-21200">Daniel Lochner</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-21201">490 Arsenal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-21202">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-21203">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-21204">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-21205">339</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-21206">666-3320</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2024To12_31_2024" id="ixv-234">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2024To12_31_2024" id="ixv-21207">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2024To12_31_2024" id="ixv-21208">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis"
      id="hidden136075766">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="hidden136075759">http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="PAsOn11_19_2020" id="hidden136075767">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21216"
      unitRef="Unit_USD">141239000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21217"
      unitRef="Unit_USD">28769000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21218"
      unitRef="Unit_USD">5618000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21219"
      unitRef="Unit_USD">2115000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21220"
      unitRef="Unit_USD">146857000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21221"
      unitRef="Unit_USD">30884000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21222"
      unitRef="Unit_USD">2151000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21223"
      unitRef="Unit_USD">3122000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21224"
      unitRef="Unit_USD">919000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21225"
      unitRef="Unit_USD">1437000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21226"
      unitRef="Unit_USD">2235000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21227"
      unitRef="Unit_USD">2669000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21228"
      unitRef="Unit_USD">0</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21229"
      unitRef="Unit_USD">669000</us-gaap:DeferredCosts>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21230"
      unitRef="Unit_USD">587000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21231"
      unitRef="Unit_USD">587000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21232"
      unitRef="Unit_USD">156000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21233"
      unitRef="Unit_USD">31000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21234"
      unitRef="Unit_USD">152905000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21235"
      unitRef="Unit_USD">39399000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21236"
      unitRef="Unit_USD">976000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21237"
      unitRef="Unit_USD">409000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21238"
      unitRef="Unit_USD">7850000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21239"
      unitRef="Unit_USD">8141000</us-gaap:AccruedLiabilitiesCurrent>
    <tecx:SAFELiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21240"
      unitRef="Unit_USD">0</tecx:SAFELiabilitiesCurrent>
    <tecx:SAFELiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21241"
      unitRef="Unit_USD">30515000</tecx:SAFELiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21242"
      unitRef="Unit_USD">2295000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21243"
      unitRef="Unit_USD">1348000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21244"
      unitRef="Unit_USD">489000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21245"
      unitRef="Unit_USD">475000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21246"
      unitRef="Unit_USD">11610000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21247"
      unitRef="Unit_USD">40888000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21248"
      unitRef="Unit_USD">132000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21249"
      unitRef="Unit_USD">1644000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21250"
      unitRef="Unit_USD">387000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21251"
      unitRef="Unit_USD">876000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21252"
      unitRef="Unit_USD">12129000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21253"
      unitRef="Unit_USD">43408000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2024"
      id="ixv-21254"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-21255"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21256"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21257"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21258"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21259"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21260"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21261"
      unitRef="Unit_shares">3647675</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21262"
      unitRef="Unit_shares">3647675</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21263"
      unitRef="Unit_shares">3647675</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-21264"
      unitRef="Unit_USD">87459000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21265"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21266"
      unitRef="Unit_USD">80627000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21267"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21268"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21269"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21270"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21271"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21272"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21273"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21274"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21275"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21276"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21277"
      unitRef="Unit_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21278"
      unitRef="Unit_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21279"
      unitRef="Unit_shares">14856309</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21280"
      unitRef="Unit_shares">14856309</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21281"
      unitRef="Unit_shares">1407753</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21282"
      unitRef="Unit_shares">1407753</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21283"
      unitRef="Unit_USD">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21284"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21285"
      unitRef="Unit_USD">289351000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21286"
      unitRef="Unit_USD">5979000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21287"
      unitRef="Unit_USD">9000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21288"
      unitRef="Unit_USD">-11000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21289"
      unitRef="Unit_USD">-148586000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21290"
      unitRef="Unit_USD">-90604000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21291"
      unitRef="Unit_USD">140776000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21292"
      unitRef="Unit_USD">-84636000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21293"
      unitRef="Unit_USD">152905000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21294"
      unitRef="Unit_USD">39399000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21295"
      unitRef="Unit_USD">41364000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21296"
      unitRef="Unit_USD">36966000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21297"
      unitRef="Unit_USD">16651000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21298"
      unitRef="Unit_USD">7682000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21299"
      unitRef="Unit_USD">58015000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21300"
      unitRef="Unit_USD">44648000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21301"
      unitRef="Unit_USD">-58015000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21302"
      unitRef="Unit_USD">-44648000</us-gaap:OperatingIncomeLoss>
    <tecx:ChangeInFairValueOfSafeLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21303"
      unitRef="Unit_USD">-3610000</tecx:ChangeInFairValueOfSafeLiabilities>
    <tecx:ChangeInFairValueOfSafeLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21304"
      unitRef="Unit_USD">1255000</tecx:ChangeInFairValueOfSafeLiabilities>
    <tecx:LossOnIssuanceOfSAFEs
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21305"
      unitRef="Unit_USD">0</tecx:LossOnIssuanceOfSAFEs>
    <tecx:LossOnIssuanceOfSAFEs
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21306"
      unitRef="Unit_USD">255000</tecx:LossOnIssuanceOfSAFEs>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21307"
      unitRef="Unit_USD">4261000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21308"
      unitRef="Unit_USD">581000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21309"
      unitRef="Unit_USD">107000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21310"
      unitRef="Unit_USD">152000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21311"
      unitRef="Unit_USD">-511000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21312"
      unitRef="Unit_USD">396000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21313"
      unitRef="Unit_USD">33000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21314"
      unitRef="Unit_USD">1825000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21315"
      unitRef="Unit_USD">-57982000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21316"
      unitRef="Unit_USD">-42823000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21317"
      unitRef="Unit_USD">9000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21318"
      unitRef="Unit_USD">-11000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21319"
      unitRef="Unit_USD">57973000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21320"
      unitRef="Unit_USD">42834000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21321"
      unitRef="Unit_USD_per_Share">-6.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21322"
      unitRef="Unit_USD_per_Share">-6.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-21323"
      unitRef="Unit_USD_per_Share">-33.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-21324"
      unitRef="Unit_USD_per_Share">-33.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21325"
      unitRef="Unit_shares">8490171</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21326"
      unitRef="Unit_shares">8490171</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-21327"
      unitRef="Unit_shares">1268512</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-21328"
      unitRef="Unit_shares">1268512</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21329"
      unitRef="Unit_shares">6825483</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21330"
      unitRef="Unit_USD">80627000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21331"
      unitRef="Unit_shares">2525771</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21332"
      unitRef="Unit_USD">2127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21333"
      unitRef="Unit_USD">-47781000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-21334"
      unitRef="Unit_USD">-45654000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21335"
      unitRef="Unit_shares">-3177808</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21336"
      unitRef="Unit_shares">-1175989</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <tecx:AdjustedBalanceBeginningOfPeriodShare
      contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21337"
      unitRef="Unit_shares">3647675</tecx:AdjustedBalanceBeginningOfPeriodShare>
    <tecx:AdjustedBalanceBeginningOfPeriodValue
      contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21338"
      unitRef="Unit_USD">80627000</tecx:AdjustedBalanceBeginningOfPeriodValue>
    <tecx:AdjustedBalanceBeginningOfPeriodShare
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21339"
      unitRef="Unit_shares">1349782</tecx:AdjustedBalanceBeginningOfPeriodShare>
    <tecx:AdjustedBalanceBeginningOfPeriodValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21340"
      unitRef="Unit_USD">2127000</tecx:AdjustedBalanceBeginningOfPeriodValue>
    <tecx:AdjustedBalanceBeginningOfPeriodValue
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21341"
      unitRef="Unit_USD">-47781000</tecx:AdjustedBalanceBeginningOfPeriodValue>
    <tecx:AdjustedBalanceBeginningOfPeriodValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21342"
      unitRef="Unit_USD">-45654000</tecx:AdjustedBalanceBeginningOfPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21343"
      unitRef="Unit_shares">57971</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21344"
      unitRef="Unit_USD">121000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21345"
      unitRef="Unit_USD">121000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21346"
      unitRef="Unit_USD">1121000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21347"
      unitRef="Unit_USD">1121000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tecx:ContributionFromRelatedPartyInvestorsRelatedToSAFEs
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21348"
      unitRef="Unit_USD">2610000</tecx:ContributionFromRelatedPartyInvestorsRelatedToSAFEs>
    <tecx:ContributionFromRelatedPartyInvestorsRelatedToSAFEs
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21349"
      unitRef="Unit_USD">2610000</tecx:ContributionFromRelatedPartyInvestorsRelatedToSAFEs>
    <tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss
      contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21350"
      unitRef="Unit_USD">-11000</tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss>
    <tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21351"
      unitRef="Unit_USD">-11000</tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21352"
      unitRef="Unit_USD">-42823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21353"
      unitRef="Unit_USD">-42823000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21354"
      unitRef="Unit_shares">3647675</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21355"
      unitRef="Unit_USD">80627000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21356"
      unitRef="Unit_shares">1407753</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21357"
      unitRef="Unit_USD">5979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21358"
      unitRef="Unit_USD">-11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21359"
      unitRef="Unit_USD">-90604000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21360"
      unitRef="Unit_USD">-84636000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21361"
      unitRef="Unit_shares">-3647675</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21362"
      unitRef="Unit_USD">-80627000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21363"
      unitRef="Unit_shares">3647675</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21364"
      unitRef="Unit_USD">80627000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21365"
      unitRef="Unit_USD">80627000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21366"
      unitRef="Unit_shares">388727</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21367"
      unitRef="Unit_USD">1624000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21368"
      unitRef="Unit_USD">1624000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21369"
      unitRef="Unit_USD">15000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21370"
      unitRef="Unit_USD">15000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21371"
      unitRef="Unit_USD">3491000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21372"
      unitRef="Unit_USD">3491000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21373"
      unitRef="Unit_shares">1470839</tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemption>
    <tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21374"
      unitRef="Unit_USD">34125000</tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue>
    <tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21375"
      unitRef="Unit_USD">34125000</tecx:IssuanceOfCommonStockToRelatedPartyInvestorsUponRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="P01_01_2024To12_31_2024_AtTheMarketFacilityMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-21376"
      unitRef="Unit_USD">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <tecx:IssuanceOfCommonStockUnderSubscriptionAgreement
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21377"
      unitRef="Unit_shares">4163606</tecx:IssuanceOfCommonStockUnderSubscriptionAgreement>
    <tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21378"
      unitRef="Unit_USD">1000</tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue>
    <tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21379"
      unitRef="Unit_USD">94600000</tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue>
    <tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21380"
      unitRef="Unit_USD">94601000</tecx:IssuanceOfCommonStockUnderSubscriptionAgreementValue>
    <tecx:TransactionCosts
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21381"
      unitRef="Unit_USD">9300</tecx:TransactionCosts>
    <tecx:IssuanceOfCommonStockUponTheMerger
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21382"
      unitRef="Unit_shares">3777709</tecx:IssuanceOfCommonStockUponTheMerger>
    <tecx:IssuanceOfCommonStockUponTheMergerValue
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21383"
      unitRef="Unit_USD">1000</tecx:IssuanceOfCommonStockUponTheMergerValue>
    <tecx:IssuanceOfCommonStockUponTheMergerValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21384"
      unitRef="Unit_USD">68890000</tecx:IssuanceOfCommonStockUponTheMergerValue>
    <tecx:IssuanceOfCommonStockUponTheMergerValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21385"
      unitRef="Unit_USD">68891000</tecx:IssuanceOfCommonStockUponTheMergerValue>
    <tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss
      contextRef="P01_01_2024To12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21386"
      unitRef="Unit_USD">20000</tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss>
    <tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21387"
      unitRef="Unit_USD">20000</tecx:ForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxOtherComprehensiveIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21388"
      unitRef="Unit_USD">-57982000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21389"
      unitRef="Unit_USD">-57982000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21390"
      unitRef="Unit_shares">14856309</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21391"
      unitRef="Unit_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21392"
      unitRef="Unit_USD">289351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21393"
      unitRef="Unit_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-21394"
      unitRef="Unit_USD">-148586000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21395"
      unitRef="Unit_USD">140776000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21396"
      unitRef="Unit_USD">-57982000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21397"
      unitRef="Unit_USD">-42823000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21398"
      unitRef="Unit_USD">1645000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21399"
      unitRef="Unit_USD">1478000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21400"
      unitRef="Unit_USD">3491000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21401"
      unitRef="Unit_USD">1121000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21402"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21403"
      unitRef="Unit_USD">-9000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <tecx:LossOnIssuanceOfSAFEs
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21404"
      unitRef="Unit_USD">0</tecx:LossOnIssuanceOfSAFEs>
    <tecx:LossOnIssuanceOfSAFEs
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21405"
      unitRef="Unit_USD">255000</tecx:LossOnIssuanceOfSAFEs>
    <tecx:NonCashLeaseExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21406"
      unitRef="Unit_USD">434000</tecx:NonCashLeaseExpense>
    <tecx:NonCashLeaseExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21407"
      unitRef="Unit_USD">1118000</tecx:NonCashLeaseExpense>
    <tecx:ChangeInFairValueOfSafeLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21408"
      unitRef="Unit_USD">-3610000</tecx:ChangeInFairValueOfSafeLiabilities>
    <tecx:ChangeInFairValueOfSafeLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21409"
      unitRef="Unit_USD">1255000</tecx:ChangeInFairValueOfSafeLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21410"
      unitRef="Unit_USD">3194000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21411"
      unitRef="Unit_USD">1019000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21412"
      unitRef="Unit_USD">-544000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21413"
      unitRef="Unit_USD">5000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21414"
      unitRef="Unit_USD">-1421000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21415"
      unitRef="Unit_USD">-165000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21416"
      unitRef="Unit_USD">-5642000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21417"
      unitRef="Unit_USD">1611000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21418"
      unitRef="Unit_USD">-565000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21419"
      unitRef="Unit_USD">-950000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21420"
      unitRef="Unit_USD">-56000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21421"
      unitRef="Unit_USD">-59080000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21422"
      unitRef="Unit_USD">-40681000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21423"
      unitRef="Unit_USD">156000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21424"
      unitRef="Unit_USD">279000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21425"
      unitRef="Unit_USD">-156000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21426"
      unitRef="Unit_USD">-279000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <tecx:ProceedsFromSimpleAgreementForFutureEquity
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21427"
      unitRef="Unit_USD">0</tecx:ProceedsFromSimpleAgreementForFutureEquity>
    <tecx:ProceedsFromSimpleAgreementForFutureEquity
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21428"
      unitRef="Unit_USD">34125000</tecx:ProceedsFromSimpleAgreementForFutureEquity>
    <tecx:OfferingCost
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21429"
      unitRef="Unit_USD">2000000</tecx:OfferingCost>
    <tecx:ProceedsFromSubscriptionAgreement
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21430"
      unitRef="Unit_USD">94600000</tecx:ProceedsFromSubscriptionAgreement>
    <tecx:ProceedsFromSubscriptionAgreement
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21431"
      unitRef="Unit_USD">0</tecx:ProceedsFromSubscriptionAgreement>
    <tecx:TransactionCosts
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21432"
      unitRef="Unit_USD">9300000</tecx:TransactionCosts>
    <tecx:CashAcquiredInConnectionWithTheMerger
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21433"
      unitRef="Unit_USD">75965000</tecx:CashAcquiredInConnectionWithTheMerger>
    <tecx:CashAcquiredInConnectionWithTheMerger
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21434"
      unitRef="Unit_USD">0</tecx:CashAcquiredInConnectionWithTheMerger>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21435"
      unitRef="Unit_USD">1624000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21436"
      unitRef="Unit_USD">121000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21437"
      unitRef="Unit_USD">475000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21438"
      unitRef="Unit_USD">499000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21439"
      unitRef="Unit_USD">171714000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21440"
      unitRef="Unit_USD">33747000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21441"
      unitRef="Unit_USD">-8000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21442"
      unitRef="Unit_USD">16000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21443"
      unitRef="Unit_USD">112470000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21444"
      unitRef="Unit_USD">-7197000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21445"
      unitRef="Unit_USD">29356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-21446"
      unitRef="Unit_USD">36553000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21447"
      unitRef="Unit_USD">141826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21448"
      unitRef="Unit_USD">29356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21449"
      unitRef="Unit_USD">141239000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21450"
      unitRef="Unit_USD">28769000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21451"
      unitRef="Unit_USD">587000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21452"
      unitRef="Unit_USD">587000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21453"
      unitRef="Unit_USD">141826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21454"
      unitRef="Unit_USD">29356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <tecx:ConversionOfSimpleAgreementsForFutureEquityToCommonStock
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21455"
      unitRef="Unit_USD">-34125000</tecx:ConversionOfSimpleAgreementsForFutureEquityToCommonStock>
    <tecx:ConversionOfSimpleAgreementsForFutureEquityToCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21456"
      unitRef="Unit_USD">0</tecx:ConversionOfSimpleAgreementsForFutureEquityToCommonStock>
    <tecx:ConversionOfConvertiblePreferredStockToCommonStock
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21457"
      unitRef="Unit_USD">-80627000</tecx:ConversionOfConvertiblePreferredStockToCommonStock>
    <tecx:ConversionOfConvertiblePreferredStockToCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21458"
      unitRef="Unit_USD">0</tecx:ConversionOfConvertiblePreferredStockToCommonStock>
    <tecx:PurchaseEquipmentOfFinanceLeases
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21459"
      unitRef="Unit_USD">0</tecx:PurchaseEquipmentOfFinanceLeases>
    <tecx:PurchaseEquipmentOfFinanceLeases
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21460"
      unitRef="Unit_USD">234000</tecx:PurchaseEquipmentOfFinanceLeases>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21461"
      unitRef="Unit_USD">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21462"
      unitRef="Unit_USD">669000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21463"
      unitRef="Unit_USD">107000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21464"
      unitRef="Unit_USD">152000</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations contextRef="P01_01_2024To12_31_2024" id="ixv-13146">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1. NATURE OF BUSINESS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Description of the Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Tectonic Therapeutic, Inc. (formerly AVROBIO, Inc.) (the &#x201c;Company&#x201d; or &#x201c;Tectonic&#x201d;) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;G-protein&lt;/div&gt; coupled receptors (&#x201c;GPCRs&#x201d;). The Company focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Merger and &lt;div style="white-space: nowrap;display:inline;"&gt;Pre-Merger&lt;/div&gt; Financing Transaction not &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On June&#160;20, 2024, the Company completed its previously announced merger transaction in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of January&#160;30, 2024 (the &#x201c;Merger Agreement&#x201d;) with AVROBIO, Inc. (&#x201c;AVROBIO&#x201d;), pursuant to which Alpine Merger Subsidiary, Inc., a wholly owned subsidiary of AVROBIO, merged with and into the entity formerly known as Tectonic Therapeutic, Inc., now known as Tectonic Operating Company, Inc. (&#x201c;Legacy Tectonic&#x201d;), with Legacy Tectonic continuing as a wholly owned subsidiary of the surviving corporation of AVROBIO (the &#x201c;Merger&#x201d;). The Merger was accounted for as a reverse recapitalization in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;), with AVROBIO treated as the acquired company for financial reporting purposes, and Legacy Tectonic treated as the accounting acquirer. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon the closing of the Merger, each outstanding share of Legacy Tectonic&#x2019;s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO&#x2019;s common stock based on an exchange ratio of 0.53 (the &#x201c;Exchange Ratio&#x201d;), as defined in the Merger Agreement, after giving effect to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;1-for-12&lt;/div&gt;&lt;/div&gt; reverse stock split of AVROBIO common stock that was effected on June&#160;20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Each outstanding and unexercised option to purchase shares of Legacy Tectonic&#x2019;s common stock immediately prior to closing was assumed by AVROBIO and was converted into an option to purchase shares of AVROBIO common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio. Legacy Tectonic&#x2019;s restricted common stock, outstanding and unvested immediately prior to the closing, was assumed by AVROBIO in the Merger. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Legacy Tectonic stockholders received 10,956,614 shares of AVROBIO common stock in connection with the Merger, including 11,447 shares of AVROBIO restricted common stock subject to vesting terms, based on the number of shares of Legacy Tectonic common stock outstanding immediately prior to the Merger, including restricted stock, the number of shares of common stock issued to investors participating in the Subscription Agreements (as defined below) and Simple Agreements for Future Equity (&#x201c;SAFEs&#x201d;), and Legacy Tectonic convertible preferred stock outstanding immediately prior to the Merger, which was converted into shares of Legacy Tectonic common stock on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis immediately prior to the closing of the Merger. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Concurrently with the closing of the Merger, certain investors of Legacy Tectonic completed the purchase of 7,790,889 shares of Legacy Tectonic common stock pursuant to the Subscription Agreement dated January&#160;30, 2024 (the &#x201c;Subscription Agreement&#x201d;) at a purchase price of $12.40 per share for an aggregate purchase price of $96.6&#160;million. Shares of Legacy Tectonic common stock issued pursuant to the Subscription Agreements were converted into 4,163,606 shares of AVROBIO common stock at the closing of the Merger based on the Exchange Ratio, pursuant to the Merger Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-clinical&lt;/div&gt; and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance reporting capabilities. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s proprietary GEODe&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;&#x2122;&lt;/div&gt; platform is currently in development. There can be no assurance that current and future research and development activities will be successfully completed, that adequate protection for owned intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Capital Resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Since inception, the Company has incurred recurring losses and negative cash flows from operations and expects such losses to continue in the future as it conducts research and development activities and continues to develop its product candidates. The Company generated net losses of $58.0&#160;million and $42.8&#160;million for the years ended December&#160;31, 2024 and 2023, respectively and had an accumulated deficit of $148.6&#160;million as of December&#160;31, 2024. The Company has financed its operations primarily through the sale and issuance of common stock, convertible preferred stock, convertible promissory notes, SAFEs and the Merger. In February 2025, the Company sold shares of its common stock under a securities purchase agreement in exchange for gross proceeds of $185&#160;million, as described in Note 16, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;. The Company has devoted substantially all of its financial resources and efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As the Company continues to develop its proprietary platform and potential product candidates, it will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. It may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital to fund its operations. The Company had cash and cash equivalents of $141.2&#160;million as of December&#160;31, 2024. Management believes that the Company&#x2019;s current cash and cash equivalents will be sufficient to fund its planned operations for at least 12 months&#160;from the issuance date of these consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <tecx:ConversionOfStockSharesPercentage
      contextRef="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      id="ixv-21465"
      unitRef="Unit_pure">0.0053</tecx:ConversionOfStockSharesPercentage>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis"
      id="ixv-21466">1-for-12</us-gaap:StockholdersEquityReverseStockSplit>
    <tecx:StockIssuedDuringThePeriodSharesReverseRecapitalization
      contextRef="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21467"
      unitRef="Unit_shares">10956614</tecx:StockIssuedDuringThePeriodSharesReverseRecapitalization>
    <tecx:StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization
      contextRef="P01_01_2024To12_31_2024_AvroAvrobioCommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-21468"
      unitRef="Unit_shares">11447</tecx:StockSharesIssuedDuringThePeriodSubjectToReverseRecapitalization>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_30_2024To01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis"
      decimals="0"
      id="ixv-21469"
      unitRef="Unit_shares">7790889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis"
      decimals="2"
      id="ixv-21470"
      unitRef="Unit_USD_per_Share">12.4</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_30_2024To01_30_2024_SubscriptionAgreementMemberTECXAgreementAxis"
      decimals="-5"
      id="ixv-21471"
      unitRef="Unit_USD">96600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <tecx:StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization
      contextRef="P01_01_2024To12_31_2024_AvorbioCommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21472"
      unitRef="Unit_shares">4163606</tecx:StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-21474"
      unitRef="Unit_USD">-58000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-21475"
      unitRef="Unit_USD">-42800000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-21476"
      unitRef="Unit_USD">-148600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <tecx:ProceedsReceivedPursuantToAgreement
      contextRef="P02_01_2025To02_28_2025"
      decimals="-6"
      id="ixv-21477"
      unitRef="Unit_USD">185000000</tecx:ProceedsReceivedPursuantToAgreement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-21478"
      unitRef="Unit_USD">141200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13204">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The accompanying consolidated financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP, as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reverse Stock Split and Exchange Ratio &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon the closing of the Merger, each outstanding share of Legacy Tectonic&#x2019;s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO&#x2019;s common stock based on the Exchange Ratio of 0.53, after giving effect to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;1-for-12&lt;/div&gt;&lt;/div&gt; reverse stock split of AVROBIO common stock that was effected on June&#160;20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include those related to the valuation of stock-based awards, income taxes, the fair value determination of the SAFEs and certain research and development accruals. Management&#x2019;s estimates are based on historical experience and various other assumptions that it believes are reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign Currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The operations of each of the Company&#x2019;s entities are measured using the currency of the primary economic environment in which the subsidiary operates (&#x201c;functional currency&#x201d;). Assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars using &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;period-end&lt;/div&gt; exchange rates. Expenses are translated at the average exchange rate in effect during each fiscal month during the year. The effects of foreign currency translation adjustments are included as a component of Accumulated other comprehensive income (loss) in the Consolidated Balance Sheets. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM is its chief executive officer, who reviews financial information on a consolidated basis for the purpose of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. See Note 16, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information&lt;/div&gt;&lt;/div&gt; for additional information regarding the Company&#x2019;s segment information. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash, Cash Equivalents, and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of cash on deposit with banks denominated in U.S. dollars and investment in money market funds. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $0.6&#160;million as collateral in connection with a letter of credit issued with the corporate headquarters and lab space lease agreement entered into on November&#160;19, 2020. The Company may not access these funds until after the expiration of the lease term on January 31, 2026. The Company has classified the certificate of deposits collateralizing the letter of credits issued as a security deposit as restricted cash in the noncurrent asset section of the Consolidated Balance Sheets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentrations of Credit Risk &lt;div style="white-space: nowrap;display:inline;"&gt;and&#160;Off-Balance&#160;Sheet&lt;/div&gt; Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in accredited financial institutions in &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;excess of governmental insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have a high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of each asset, generally &lt;div style="-sec-ix-hidden:hidden136075766;display:inline;"&gt;three&lt;/div&gt; to five years. Leasehold improvements are amortized over the shorter of the assets&#x2019; expected useful life or the &lt;div style="-sec-ix-hidden:hidden136075759;display:inline;"&gt;remaining lease term&lt;/div&gt;. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;Construction-in-progress&lt;/div&gt;&lt;/div&gt; reflects amounts incurred for property and equipment for use in the research and development process and have not yet been placed in service and are not depreciated or amortized. Expenditures for major renewals and improvements that extend the useful life of the asset are capitalized as part of the asset. Expenditures for repairs and maintenance are expensed as incurred. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying amount of the asset is not recoverable, an impairment will be recognized and measured as the amount by which the carrying amount of the asset exceeds its fair value. No impairment was identified during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;Unadjusted quoted prices in active markets for identical, unrestricted assets or liabilities that are accessible at the measurement date; &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar asset or liabilities in markets that are not active or valuations with significant inputs other than quoted prices that are observable, either directly or indirectly; and, &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Financial instruments are categorized in their entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of costs incurred for research activities, including discovery efforts and the development of the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Company&#x2019;s programs and platform and include (1)&#160;expenses incurred in connection with research and the preclinical and clinical development of the Company&#x2019;s programs and product candidates, including agreements with third parties and contract research organizations (&#x201c;CROs&#x201d;), (2) costs related to manufacturing material for preclinical studies and clinical trials, including fees paid to contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;), (3) employee-related expenses, including salaries and bonuses, related benefits and stock-based compensation expense, for employees engaged in research and development functions (4)&#160;facilities, depreciation and other expenses related to research and development activities, which include direct or allocated expenses for rent, maintenance of facilities and utilities, (5)&#160;licensing and license maintenance fees incurred under license agreements where no alternative future use exists, and (6)&#160;costs related to compliance with regulatory requirements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the Consolidated Balance Sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. The Company accrues expenses based upon estimates of percentage of work completed and the contract milestones remaining. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for leases in accordance with ASC Topic 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of the contract. The Company&#x2019;s operating and finance lease assets are included &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;in&#160;right-of-use&lt;/div&gt;&lt;/div&gt; assets, net, and the current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt; portions of the finance and operating lease liabilities are included in&#160;lease liabilities,&#160;and&#160;lease liabilities, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current,&#160;respectively,&lt;/div&gt; on the balance sheets. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are based on the corresponding lease liability adjusted for (i)&#160;payments made at or before the commencement date, (ii)&#160;initial direct costs incurred, and (iii)&#160;tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. For finance leases, right of use assets are amortized on a straight-line basis over the shorter of the lease term or the estimated useful life of the leased assets. The Company accounts for lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-lease&lt;/div&gt; components as a single lease component for operating leases. The discount rate used to calculate the present value of the Company&#x2019;s lease liabilities is based on either an explicit rate stipulated in the contract for finance leases or the incremental borrowing rate based on the information available at the lease commencement date. The Company&#x2019;s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determines the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated. The Company has elected the practical expedient to not recognize leases with a lease term of twelve months or less on the balance sheet (&#x201c;short-term leases&#x201d;) and will recognize lease payments for such short-term leases as an expense on a straight-line basis. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Simple Agreements for Future Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFE instruments do not represent legal form debt (i.e., no creditor rights), but allow for redemption based upon certain triggering events that are outside of the control of the Company. The Company accounts for the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFE instruments as a liability at fair value on a recurring basis. Triggering events include an equity financing, public listing transaction, change of control or dissolution. Changes in the liability&#x2019;s fair value are recognized in the Company&#x2019;s statements of operations and comprehensive loss. The SAFE liabilities were adjusted to fair value upon the closing of the Merger and all SAFE instruments were converted to common stock of AVROBIO pursuant to the Merger Agreement. The SAFEs were redeemed for common stock shares upon closing of the Merger. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company recorded all shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company&#x2019;s control, such as a merger, acquisition, or sale of all or substantially all of the Company&#x2019;s assets (each, a &#x201c;deemed liquidation event&#x201d;), the convertible preferred stock became redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of convertible preferred stock was not probable of occurring. All outstanding shares of convertible preferred stock were converted to common stock shares upon the closing of the Merger. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Prior to being publicly traded, the fair value of the Company&#x2019;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#x2019;s common stock and the general and industry-specific economic outlook. Subsequent to the Merger, the fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Select Market on the date of grant. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company utilizes the Black-Scholes-Merton (&#x201c;BSM&#x201d;) option pricing model to determine the estimated fair value of options granted to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employees,&lt;/div&gt; including directors. In addition to the fair value of the Company&#x2019;s common stock, the BSM mode requires the input of several assumptions. These assumptions include: &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected Term&#x2014;The expected life represents the period of time that the stock options are expected to be outstanding. Because the Company does not have substantial historical exercise behavior, it determines the expected term in accordance with the simplified method, which is an average of the contractual term of the stock option and its vesting period. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected Volatility&#x2014;The estimated volatility is determined by evaluating the average historical volatility of a peer group of companies for the period preceding the stock option grant for a term that is approximately equal to the stock options&#x2019; expected term. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Risk-Free Interest Rate&#x2014;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury&#160;issues with a term that is equal to the stock options&#x2019; expected term at the grant date. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected Dividend&#x2014;The expected dividend yield is assumed to be zero as the Company has not declared or paid dividends to date and does not anticipate declaring dividends for the foreseeable future. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted stock units (RSUs) are measured and recognized over the vesting period and are based on the quoted market price of the Company&#x2019;s stock on the grant date. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;All stock-based compensation expense is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss, on the basis of the respective employee and nonemployee&#x2019;s role within the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic&#160;740,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Income Taxes&lt;/div&gt;&lt;/div&gt;&#160;(&#x201c;ASC 740&#x201d;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determined deferred tax assets and liabilities on the basis of the differences between the consolidated financial statements and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;income,&#160;tax-planning&#160;strategies,&lt;/div&gt; and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company records uncertain tax positions in accordance with ASC 740 on the basis of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;two-step&#160;process&lt;/div&gt; in which (1)&#160;the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;the&#160;more-likely-than-not&#160;recognition&lt;/div&gt; threshold, the Company recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Basic and diluted net loss per common share is presented in conformity with ASC 260,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Earning Per Share,&lt;/div&gt;&lt;/div&gt;&#160;for all periods presented. In accordance with this guidance, basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period. Basic net loss and diluted net loss per share are calculated without consideration of potentially dilutive securities. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company applies ASC 850,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Related Party Disclosure&lt;/div&gt;&lt;/div&gt;s, for the identification of related parties and disclosure of related party transactions. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. The comprehensive loss for the Company equals its net loss plus changes in foreign currency translation for all periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the FASB under its ASCs or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (Topic 740) (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&#x201d;),&lt;/div&gt; which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09,&lt;/div&gt; public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; are effective for fiscal years beginning after December&#160;15, 2024, and early adoption is permitted. The Company is currently evaluating the impact of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; on its consolidated financial statements. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2024-03&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/div&gt;&lt;/div&gt; (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;220-40)&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03&#x201d;),&lt;/div&gt; which requires disaggregated disclosure of certain income statement captions within the footnotes to the financial statements. The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03&lt;/div&gt; are effective for fiscal years beginning after December&#160;15, 2026, and early adoption is permitted. The Company is currently evaluating the impact of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; on its consolidated financial statements. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13208">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The accompanying consolidated financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP, as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13215">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <tecx:ReverseStockSplitAndExchangeRatioPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13240">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reverse Stock Split and Exchange Ratio &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon the closing of the Merger, each outstanding share of Legacy Tectonic&#x2019;s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO&#x2019;s common stock based on the Exchange Ratio of 0.53, after giving effect to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;1-for-12&lt;/div&gt;&lt;/div&gt; reverse stock split of AVROBIO common stock that was effected on June&#160;20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock. &lt;/div&gt;</tecx:ReverseStockSplitAndExchangeRatioPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P06_20_2024To06_20_2024"
      decimals="2"
      id="ixv-21480"
      unitRef="Unit_pure">0.53</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:UseOfEstimates contextRef="P01_01_2024To12_31_2024" id="ixv-13248">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include those related to the valuation of stock-based awards, income taxes, the fair value determination of the SAFEs and certain research and development accruals. Management&#x2019;s estimates are based on historical experience and various other assumptions that it believes are reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13255">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign Currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The operations of each of the Company&#x2019;s entities are measured using the currency of the primary economic environment in which the subsidiary operates (&#x201c;functional currency&#x201d;). Assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars using &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;period-end&lt;/div&gt; exchange rates. Expenses are translated at the average exchange rate in effect during each fiscal month during the year. The effects of foreign currency translation adjustments are included as a component of Accumulated other comprehensive income (loss) in the Consolidated Balance Sheets. &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13262">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM is its chief executive officer, who reviews financial information on a consolidated basis for the purpose of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. See Note 16, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information&lt;/div&gt;&lt;/div&gt; for additional information regarding the Company&#x2019;s segment information. &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2024To12_31_2024" id="ixv-13270">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash, Cash Equivalents, and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of cash on deposit with banks denominated in U.S. dollars and investment in money market funds. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $0.6&#160;million as collateral in connection with a letter of credit issued with the corporate headquarters and lab space lease agreement entered into on November&#160;19, 2020. The Company may not access these funds until after the expiration of the lease term on January 31, 2026. The Company has classified the certificate of deposits collateralizing the letter of credits issued as a security deposit as restricted cash in the noncurrent asset section of the Consolidated Balance Sheets. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:Cash
      contextRef="PAsOn11_19_2020"
      decimals="-5"
      id="ixv-21481"
      unitRef="Unit_USD">600000</us-gaap:Cash>
    <us-gaap:LeaseExpirationDate1 contextRef="P01_01_2024To12_31_2024" id="ixv-21482">2026-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2024To12_31_2024" id="ixv-13279">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentrations of Credit Risk &lt;div style="white-space: nowrap;display:inline;"&gt;and&#160;Off-Balance&#160;Sheet&lt;/div&gt; Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in accredited financial institutions in &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;excess of governmental insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have a high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13304">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of each asset, generally &lt;div style="-sec-ix-hidden:hidden136075766;display:inline;"&gt;three&lt;/div&gt; to five years. Leasehold improvements are amortized over the shorter of the assets&#x2019; expected useful life or the &lt;div style="-sec-ix-hidden:hidden136075759;display:inline;"&gt;remaining lease term&lt;/div&gt;. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;Construction-in-progress&lt;/div&gt;&lt;/div&gt; reflects amounts incurred for property and equipment for use in the research and development process and have not yet been placed in service and are not depreciated or amortized. Expenditures for major renewals and improvements that extend the useful life of the asset are capitalized as part of the asset. Expenditures for repairs and maintenance are expensed as incurred. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis"
      id="ixv-21484">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13316">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying amount of the asset is not recoverable, an impairment will be recognized and measured as the amount by which the carrying amount of the asset exceeds its fair value. No impairment was identified during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21485"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21486"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13323">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;Unadjusted quoted prices in active markets for identical, unrestricted assets or liabilities that are accessible at the measurement date; &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar asset or liabilities in markets that are not active or valuations with significant inputs other than quoted prices that are observable, either directly or indirectly; and, &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Financial instruments are categorized in their entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire fair value measurement. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2024To12_31_2024" id="ixv-13359">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of costs incurred for research activities, including discovery efforts and the development of the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Company&#x2019;s programs and platform and include (1)&#160;expenses incurred in connection with research and the preclinical and clinical development of the Company&#x2019;s programs and product candidates, including agreements with third parties and contract research organizations (&#x201c;CROs&#x201d;), (2) costs related to manufacturing material for preclinical studies and clinical trials, including fees paid to contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;), (3) employee-related expenses, including salaries and bonuses, related benefits and stock-based compensation expense, for employees engaged in research and development functions (4)&#160;facilities, depreciation and other expenses related to research and development activities, which include direct or allocated expenses for rent, maintenance of facilities and utilities, (5)&#160;licensing and license maintenance fees incurred under license agreements where no alternative future use exists, and (6)&#160;costs related to compliance with regulatory requirements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the Consolidated Balance Sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. The Company accrues expenses based upon estimates of percentage of work completed and the contract milestones remaining. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. &lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13391">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for leases in accordance with ASC Topic 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of the contract. The Company&#x2019;s operating and finance lease assets are included &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;in&#160;right-of-use&lt;/div&gt;&lt;/div&gt; assets, net, and the current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt; portions of the finance and operating lease liabilities are included in&#160;lease liabilities,&#160;and&#160;lease liabilities, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current,&#160;respectively,&lt;/div&gt; on the balance sheets. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are based on the corresponding lease liability adjusted for (i)&#160;payments made at or before the commencement date, (ii)&#160;initial direct costs incurred, and (iii)&#160;tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. For finance leases, right of use assets are amortized on a straight-line basis over the shorter of the lease term or the estimated useful life of the leased assets. The Company accounts for lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-lease&lt;/div&gt; components as a single lease component for operating leases. The discount rate used to calculate the present value of the Company&#x2019;s lease liabilities is based on either an explicit rate stipulated in the contract for finance leases or the incremental borrowing rate based on the information available at the lease commencement date. The Company&#x2019;s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determines the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated. The Company has elected the practical expedient to not recognize leases with a lease term of twelve months or less on the balance sheet (&#x201c;short-term leases&#x201d;) and will recognize lease payments for such short-term leases as an expense on a straight-line basis. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <tecx:SimpleAgreementsForFutureEquityPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13408">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Simple Agreements for Future Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFE instruments do not represent legal form debt (i.e., no creditor rights), but allow for redemption based upon certain triggering events that are outside of the control of the Company. The Company accounts for the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFE instruments as a liability at fair value on a recurring basis. Triggering events include an equity financing, public listing transaction, change of control or dissolution. Changes in the liability&#x2019;s fair value are recognized in the Company&#x2019;s statements of operations and comprehensive loss. The SAFE liabilities were adjusted to fair value upon the closing of the Merger and all SAFE instruments were converted to common stock of AVROBIO pursuant to the Merger Agreement. The SAFEs were redeemed for common stock shares upon closing of the Merger. &lt;/div&gt;&lt;/div&gt;</tecx:SimpleAgreementsForFutureEquityPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="P01_01_2024To12_31_2024" id="ixv-13432">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company recorded all shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company&#x2019;s control, such as a merger, acquisition, or sale of all or substantially all of the Company&#x2019;s assets (each, a &#x201c;deemed liquidation event&#x201d;), the convertible preferred stock became redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of convertible preferred stock was not probable of occurring. All outstanding shares of convertible preferred stock were converted to common stock shares upon the closing of the Merger. &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13439">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Prior to being publicly traded, the fair value of the Company&#x2019;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#x2019;s common stock and the general and industry-specific economic outlook. Subsequent to the Merger, the fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Select Market on the date of grant. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company utilizes the Black-Scholes-Merton (&#x201c;BSM&#x201d;) option pricing model to determine the estimated fair value of options granted to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employees,&lt;/div&gt; including directors. In addition to the fair value of the Company&#x2019;s common stock, the BSM mode requires the input of several assumptions. These assumptions include: &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected Term&#x2014;The expected life represents the period of time that the stock options are expected to be outstanding. Because the Company does not have substantial historical exercise behavior, it determines the expected term in accordance with the simplified method, which is an average of the contractual term of the stock option and its vesting period. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected Volatility&#x2014;The estimated volatility is determined by evaluating the average historical volatility of a peer group of companies for the period preceding the stock option grant for a term that is approximately equal to the stock options&#x2019; expected term. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Risk-Free Interest Rate&#x2014;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury&#160;issues with a term that is equal to the stock options&#x2019; expected term at the grant date. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected Dividend&#x2014;The expected dividend yield is assumed to be zero as the Company has not declared or paid dividends to date and does not anticipate declaring dividends for the foreseeable future. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted stock units (RSUs) are measured and recognized over the vesting period and are based on the quoted market price of the Company&#x2019;s stock on the grant date. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;All stock-based compensation expense is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss, on the basis of the respective employee and nonemployee&#x2019;s role within the Company. &lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13517">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic&#160;740,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Income Taxes&lt;/div&gt;&lt;/div&gt;&#160;(&#x201c;ASC 740&#x201d;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determined deferred tax assets and liabilities on the basis of the differences between the consolidated financial statements and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;income,&#160;tax-planning&#160;strategies,&lt;/div&gt; and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company records uncertain tax positions in accordance with ASC 740 on the basis of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;two-step&#160;process&lt;/div&gt; in which (1)&#160;the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;the&#160;more-likely-than-not&#160;recognition&lt;/div&gt; threshold, the Company recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13530">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Basic and diluted net loss per common share is presented in conformity with ASC 260,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Earning Per Share,&lt;/div&gt;&lt;/div&gt;&#160;for all periods presented. In accordance with this guidance, basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period. Basic net loss and diluted net loss per share are calculated without consideration of potentially dilutive securities. &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <tecx:RelatedPartyTransactionsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13538">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company applies ASC 850,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Related Party Disclosure&lt;/div&gt;&lt;/div&gt;s, for the identification of related parties and disclosure of related party transactions. &lt;/div&gt;</tecx:RelatedPartyTransactionsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13546">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. The comprehensive loss for the Company equals its net loss plus changes in foreign currency translation for all periods presented. &lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13553">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the FASB under its ASCs or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <tecx:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13573">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (Topic 740) (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&#x201d;),&lt;/div&gt; which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09,&lt;/div&gt; public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; are effective for fiscal years beginning after December&#160;15, 2024, and early adoption is permitted. The Company is currently evaluating the impact of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; on its consolidated financial statements. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2024-03&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/div&gt;&lt;/div&gt; (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;220-40)&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03&#x201d;),&lt;/div&gt; which requires disaggregated disclosure of certain income statement captions within the footnotes to the financial statements. The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03&lt;/div&gt; are effective for fiscal years beginning after December&#160;15, 2026, and early adoption is permitted. The Company is currently evaluating the impact of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; on its consolidated financial statements. &lt;/div&gt;</tecx:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13594">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;3. MERGER &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As described in Note 1, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Nature of the Business&lt;/div&gt;&lt;/div&gt;, the Company completed its Merger with AVROBIO on June&#160;20, 2024. The Merger was accounted for as a reverse recapitalization in accordance with GAAP with Legacy Tectonic as the accounting acquirer of AVROBIO. At the effective time of the Merger, substantially all the assets of AVROBIO consisted of cash and cash equivalents, as well as other nominal assets. Under such reverse recapitalization accounting, the assets and liabilities of AVROBIO were recorded at their fair value at the effective time of the Merger, which approximated book value due to the short-term nature. No goodwill or intangible assets were recognized. Consequently, the consolidated financial statements of the Company reflect the historical operations of Legacy Tectonic for accounting purposes together with the issuance of shares to the former shareholders of AVROBIO, the legal acquirer, and a recapitalization of the equity of Legacy Tectonic, the accounting acquirer. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock of Legacy Tectonic. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As part of the recapitalization, Legacy Tectonic recognized the assets and liabilities listed below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;85,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Prepaid expenses and other current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;319&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(5,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;78,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company incurred transaction costs of $9.3&#160;million which was recorded as a reduction to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Consolidated Balance Sheet. &lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13601">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As part of the recapitalization, Legacy Tectonic recognized the assets and liabilities listed below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;85,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Prepaid expenses and other current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;319&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(5,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;78,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21491"
      unitRef="Unit_USD">85230000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21492"
      unitRef="Unit_USD">319000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21493"
      unitRef="Unit_USD">1988000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <tecx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21494"
      unitRef="Unit_USD">5405000</tecx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccuredExpensesAndOtherCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21495"
      unitRef="Unit_USD">78156000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-21496"
      unitRef="Unit_USD">9300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13688">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;4. FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following tables present information about financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 62%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;139,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;139,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;139,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;139,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 63%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;27,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;27,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;27,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;27,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFE liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds are included in cash and cash equivalents on the Company&#x2019;s Consolidated Balance Sheets and are classified within Level&#160;1 of the fair value hierarchy because they are valued using quoted market prices. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;There were no&#160;transfers between the Level&#160;1, Level&#160;2 or Level&#160;3 categories during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SAFE Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;From October through December 2023, Legacy Tectonic entered into multiple SAFE agreements with certain existing investors and received proceeds of $34.1&#160;million. Prior to redemption, the SAFE liabilities were valued using a probability weighted scenario analysis and discount rates derived by application of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;build-up&lt;/div&gt; method to reflect the cost of equity. The valuation model required a variety of inputs, including the probability of occurrence of events that would trigger conversion or redemption of the SAFEs, the expected timing of such events, and a discount rate. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon the closing of the Merger, the principal balance of the SAFE instruments was automatically redeemed for 2,752,216&#160;shares of Legacy Tectonic common stock at the conversion price of $12.40&#160;per share immediately prior to the Merger closing. As such the valuation inputs utilized to adjust the SAFE liability to fair value upon the closing of the Merger was $12.40. At closing, shares of Legacy Tectonic common stock issued pursuant to the redemption of Legacy Tectonic SAFEs were converted into 1,470,839&#160;shares of AVROBIO common stock based on the Exchange Ratio, pursuant to the Merger Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table presents activity for the SAFE liabilities that were measured at fair value using significant unobservable Level&#160;3 inputs during the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;/td&gt;
&lt;td style="width: 19%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SAFE&#160;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of January&#160;1, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Initial fair value recognition&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;31,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Loss on issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(34,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13692">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following tables present information about financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 62%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;139,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;139,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;139,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;139,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 63%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;27,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;27,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;27,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;27,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFE liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-21497"
      unitRef="Unit_USD">139610000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-21498"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-21499"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2024_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-21500"
      unitRef="Unit_USD">139610000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21501"
      unitRef="Unit_USD">139610000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21502"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21503"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21504"
      unitRef="Unit_USD">139610000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-21505"
      unitRef="Unit_USD">27278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-21506"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-21507"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-21508"
      unitRef="Unit_USD">27278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21509"
      unitRef="Unit_USD">27278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21510"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21511"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21512"
      unitRef="Unit_USD">27278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21513"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21514"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21515"
      unitRef="Unit_USD">30515000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21516"
      unitRef="Unit_USD">30515000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21517"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21518"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21519"
      unitRef="Unit_USD">30515000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-21520"
      unitRef="Unit_USD">30515000</us-gaap:LiabilitiesFairValueDisclosure>
    <tecx:FairValueInputAmountTransferInBetweenLevels
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21521"
      unitRef="Unit_USD">0</tecx:FairValueInputAmountTransferInBetweenLevels>
    <tecx:FairValueInputAmountTransferInBetweenLevels
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21522"
      unitRef="Unit_USD">0</tecx:FairValueInputAmountTransferInBetweenLevels>
    <tecx:ProceedsFromSimpleAgreementForFutureEquity
      contextRef="P10_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-21523"
      unitRef="Unit_USD">34100000</tecx:ProceedsFromSimpleAgreementForFutureEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      id="ixv-21524"
      unitRef="Unit_shares">2752216</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      id="ixv-21525"
      unitRef="Unit_USD_per_Share">12.4</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024_AvrobioMemberTECXTypeOfCommonStockAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      id="ixv-21526"
      unitRef="Unit_USD_per_Share">12.4</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024_AvrobioMemberTECXTypeOfCommonStockAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      id="ixv-21527"
      unitRef="Unit_shares">1470839</us-gaap:CommonStockSharesIssued>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14246">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table presents activity for the SAFE liabilities that were measured at fair value using significant unobservable Level&#160;3 inputs during the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;/td&gt;
&lt;td style="width: 19%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SAFE&#160;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of January&#160;1, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Initial fair value recognition&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;31,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Loss on issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(34,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21529"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <tecx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition
      contextRef="P01_01_2023To12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21530"
      unitRef="Unit_USD">31515000</tecx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialRecognition>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21531"
      unitRef="Unit_USD">255000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2023To12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21532"
      unitRef="Unit_USD">-1255000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21533"
      unitRef="Unit_USD">30515000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2024To12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21534"
      unitRef="Unit_USD">3610000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="P01_01_2024To12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21535"
      unitRef="Unit_USD">-34125000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2024_SAFELiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-21536"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14360">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;5. PROPERTY AND EQUIPMENT, NET &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and equipment, net is comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,590&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Office equipment, furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(2,745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Depreciation expense was $1.2&#160;million and $1.0&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and is primarily attributable to research and development activities. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14364">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and equipment, net is comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,590&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Office equipment, furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(2,745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-21537"
      unitRef="Unit_USD">4590000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-21538"
      unitRef="Unit_USD">4510000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-21539"
      unitRef="Unit_USD">281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-21540"
      unitRef="Unit_USD">405000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-21541"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-21542"
      unitRef="Unit_USD">38000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-21543"
      unitRef="Unit_USD">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-21544"
      unitRef="Unit_USD">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21545"
      unitRef="Unit_USD">4896000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21546"
      unitRef="Unit_USD">4978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21547"
      unitRef="Unit_USD">2745000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21548"
      unitRef="Unit_USD">1856000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21549"
      unitRef="Unit_USD">2151000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21550"
      unitRef="Unit_USD">3122000</us-gaap:PropertyPlantAndEquipmentNet>
    <tecx:DepreciationAndAmortizationExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-21551"
      unitRef="Unit_USD">1200000</tecx:DepreciationAndAmortizationExpense>
    <tecx:DepreciationAndAmortizationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-21552"
      unitRef="Unit_USD">1000000</tecx:DepreciationAndAmortizationExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14538">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities is comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 78%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued compensation and related expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,585&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,787&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued professional fees and other expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,071&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14542">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities is comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 78%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued compensation and related expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,585&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,787&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued professional fees and other expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,071&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <tecx:AccruedCompensationAndRelatedExpenses
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21553"
      unitRef="Unit_USD">3585000</tecx:AccruedCompensationAndRelatedExpenses>
    <tecx:AccruedCompensationAndRelatedExpenses
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21554"
      unitRef="Unit_USD">2856000</tecx:AccruedCompensationAndRelatedExpenses>
    <tecx:AccruedResearchAndDevelopmentExpenses
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21555"
      unitRef="Unit_USD">2787000</tecx:AccruedResearchAndDevelopmentExpenses>
    <tecx:AccruedResearchAndDevelopmentExpenses
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21556"
      unitRef="Unit_USD">3214000</tecx:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21557"
      unitRef="Unit_USD">1478000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21558"
      unitRef="Unit_USD">2071000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21559"
      unitRef="Unit_USD">7850000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21560"
      unitRef="Unit_USD">8141000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14662">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;7. STOCKHOLDERS&#x2019; EQUITY &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023, the Company&#x2019;s amended and restated certificate of incorporation authorized the Company to issue up to&#160;11,947,558&#160;shares of $0.0001&#160;par value common stock, of which,&#160;2,634,246&#160;shares were issued and outstanding. Voting, dividend and liquidation rights of the holders of common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock. Holders of common stock were entitled to one vote for each share of common stock; however, the holders of the common stock were &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;not entitled to vote on any amendment to the amended and restated certificate of incorporation that related solely to the terms of one or more outstanding series of preferred stock. The Company had included in issued and outstanding common stock shares of restricted common stock granted by the Company. As of December&#160;31, 2023, there were&#160;2,634,246&#160;common shares issued and outstanding, of which&#160;2,598,752&#160;relate to shares of unrestricted common stock. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company amended and restated its certificate of incorporation, effective June&#160;20, 2024, in connection with the Merger. The Company is authorized to issue 150,000,000 shares of common stock at a par value of $0.0001. Holders of voting common stock are entitled to one vote per share. In addition, holders of voting common stock are entitled to receive dividends, if and when declared by the Company&#x2019;s Board of Directors. As of December&#160;31, 2024, no dividends had been declared. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company reserved common stock for future issuance as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible preferred stock (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,647,675&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,626,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,002,535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;18,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFEs (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,519,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity awards available for future issuance under the 2019 Equity Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,208&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity awards available for future issuance under the 2024 Equity Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;976,082&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Shares reserved for purchase under the 2024 Employee Stock Purchase Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;147,343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,775,878&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,213,717&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Prior to the conversion upon the closing of the Merger, Legacy Tectonic issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Series&#160;A-1,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-2,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-3&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-4&lt;/div&gt; convertible preferred stock (the &#x201c;Convertible Preferred Stock&#x201d;). Upon the closing of the Merger, all outstanding shares of the Convertible Preferred Stock were converted into&#160;3,647,675&#160;shares of common stock.&#160;No&#160;shares of Convertible Preferred Stock are authorized for issuance as of December&#160;31, 2024. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Subsequent to the Merger, the Company authorized the issuance of 10,000,000 shares of undesignated preferred stock, however no such shares were issued or outstanding as of December&#160;31, 2024. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Changes in Capital Structure &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon the closing of the Merger, all outstanding shares of convertible preferred stock were converted into an aggregate of&#160;3,647,675&#160;shares of the Company&#x2019;s common stock and $80.6&#160;million of mezzanine equity was reclassified to common stock and additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital. As of December&#160;31, 2024, there were&#160;no&#160;shares of convertible preferred stock issued or outstanding. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon the closing of the Merger, the principal balance of the SAFE instruments was automatically redeemed for 2,752,216 shares of Legacy Tectonic common stock at the conversion price of $12.40 per share immediately &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;prior to the Merger closing. At closing, shares of Legacy Tectonic common stock issued pursuant to the redemption of Legacy Tectonic SAFEs were converted into 1,470,839 shares of common stock based on the Exchange Ratio, pursuant to the Merger Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Concurrently with the closing of the Merger, on June&#160;20, 2024, certain investors completed the purchase of shares of Legacy Tectonic common stock pursuant to the Subscription Agreement at a price of $12.40 per share for an aggregate purchase price of $96.6&#160;million. The shares of Legacy Tectonic common stock that were issued pursuant to the Subscription Agreement were converted into 4,163,606 shares of common stock upon the closing of the Merger based on the exchange ratio, pursuant to the Merger Agreement. &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21561"
      unitRef="Unit_shares">11947558</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21562"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21563"
      unitRef="Unit_shares">2634246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21564"
      unitRef="Unit_shares">2634246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockVotingRights
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-21565">Holders of common stock were entitled to one vote for each share of common stock</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_RestrictedCommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21567"
      unitRef="Unit_shares">2634246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_RestrictedCommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21568"
      unitRef="Unit_shares">2634246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_UnrestrictedCommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21569"
      unitRef="Unit_shares">2598752</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21570"
      unitRef="Unit_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="4"
      id="ixv-21571"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="P01_01_2024To12_31_2024" id="ixv-21572">Holders of voting common stock are entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21573"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14694">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company reserved common stock for future issuance as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible preferred stock (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,647,675&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,626,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,002,535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;18,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFEs (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,519,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity awards available for future issuance under the 2019 Equity Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,208&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity awards available for future issuance under the 2024 Equity Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;976,082&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Shares reserved for purchase under the 2024 Employee Stock Purchase Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;147,343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,775,878&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,213,717&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21574"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21575"
      unitRef="Unit_shares">3647675</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-21576"
      unitRef="Unit_shares">1626841</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-21577"
      unitRef="Unit_shares">1002535</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-21578"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-21579"
      unitRef="Unit_shares">18968</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-21580"
      unitRef="Unit_shares">25612</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-21581"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_SimpleAgreementsForFutureEquityMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21582"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_SimpleAgreementsForFutureEquityMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21583"
      unitRef="Unit_shares">1519331</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21584"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21585"
      unitRef="Unit_shares">25208</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21586"
      unitRef="Unit_shares">976082</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21587"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21588"
      unitRef="Unit_shares">147343</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21589"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-21590"
      unitRef="Unit_shares">2775878</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21591"
      unitRef="Unit_shares">6213717</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tecx:CommonStockSharesIssuableOnConversionIntoPermanentEquity
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21592"
      unitRef="Unit_shares">3647675</tecx:CommonStockSharesIssuableOnConversionIntoPermanentEquity>
    <us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21593"
      unitRef="Unit_shares">0</us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2024_UnrestrictedCommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21594"
      unitRef="Unit_shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2024_UndesignatedPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21595"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2024_UndesignatedPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21596"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <tecx:CommonStockSharesIssuableOnConversionIntoPermanentEquity
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21597"
      unitRef="Unit_shares">3647675</tecx:CommonStockSharesIssuableOnConversionIntoPermanentEquity>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-21598"
      unitRef="Unit_USD">80600000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21599"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-21600"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_20_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"
      decimals="INF"
      id="ixv-21601"
      unitRef="Unit_shares">2752216</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn06_20_2024_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      id="ixv-21602"
      unitRef="Unit_USD_per_Share">12.4</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024_AvrobioMemberTECXAgreementAxis_SimpleAgreementsForFutureEquityMemberusgaapFinancialInstrumentAxis"
      decimals="INF"
      id="ixv-21604"
      unitRef="Unit_shares">1470839</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn06_20_2024_SubscriptionAgreementMemberTECXAgreementAxis"
      decimals="2"
      id="ixv-21605"
      unitRef="Unit_USD_per_Share">12.4</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P06_20_2024To06_20_2024_SubscriptionAgreementMemberTECXAgreementAxis"
      decimals="-5"
      id="ixv-21606"
      unitRef="Unit_USD">96600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <tecx:StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization
      contextRef="P01_01_2024To12_31_2024_AvorbioCommonStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberTECXAgreementAxis"
      decimals="INF"
      id="ixv-21607"
      unitRef="Unit_shares">4163606</tecx:StockIssuedDuringThePeriodSharesNewIssuesConvertedPursuantToReverseRecapitalization>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14912">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;8. EQUITY INCENTIVE PLANS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2019 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Legacy Tectonic 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) provides employees, consultants and advisors and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employee&lt;/div&gt; members of the Board of Directors with the opportunity to receive grants of stock options, stock awards and equity awards. Following the effectiveness of the 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;) as described below, no further grants will be made under the 2019 Plan; however, any outstanding equity awards granted under the 2019 Plan will continue to be governed by the terms of the 2019 Plan. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2024 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On June&#160;20, 2024, the Company adopted the 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;) which became effective upon completion of the Merger. The 2024 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, consultants, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employee&lt;/div&gt; directors of the Company. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The 2024 Plan initially provided for the issuance of up to 1,938,799&#160;shares of common stock (the &#x201c;Initial Share Reserve&#x201d;). Subject to any other adjustments as defined in the 2024 Plan, such aggregate number of shares of common stock will automatically increase on January 1st of each year for a period of ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to 5% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase; provided, however that the Board of Directors may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of common stock. The maximum number of shares of common stock that may be issued under the 2024 Plan pursuant to the exercise of incentive stock options shall not exceed three times the Initial Share Reserve. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2024 Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On June&#160;20, 2024, the Company adopted the 2024 Employee Stock Purchase Plan (the &#x201c;2024 ESPP&#x201d;), which became effective upon completion of the Merger. The maximum number of shares of common stock that may be issued under the 2024 ESPP will not exceed 147,343&#160;shares (the &#x201c;Initial ESPP Share Reserve&#x201d;), plus the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to the lesser of (x) 1% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase and (y)&#160;a number of shares equal to three times the Initial ESPP Share Reserve. Notwithstanding the foregoing, the Board of Directors may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. No offering periods under the 2024 ESPP had been initiated as of December&#160;31, 2024. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The equity activity below reflects the reverse stock split and retroactive application of the exchange ratio as discussed in Note 1, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Nature of Business&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes the stock option activity under the 2019 Plan and 2024 Plan during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 52%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Underlying&lt;br/&gt; Outstanding&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of January&#160;1, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,002,485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;982,980&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;18.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(335,894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5,585&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options forfeited and expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(115,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,534,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;12.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;51,805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options vested and exercisable as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;364,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;15,809&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options vested and expected to vest as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,534,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;12.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;51,805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes the stock option activity for the options that were assumed from AVROBIO upon the Merger closing during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Underlying&lt;br/&gt; Outstanding&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options assumed from AVROBIO upon Merger closing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;365,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;89.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(52,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;14.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options forfeited and expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(220,115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;136.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;92,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;22.69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options vested and exercisable as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;92,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;22.69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options vested and expected to vest as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;92,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;22.69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the years ended December&#160;31, 2024 and 2023, the Company granted options with a weighted-average grant-date fair value of $14.90&#160;and $4.04&#160;per share, respectively. The fair value of options that vested during the years ended December&#160;31, 2024 and 2023 was $1.6&#160;million and $1.1&#160;million, respectively. As of December&#160;31, 2024, the total unrecognized stock-based compensation expense for stock options was $13.3&#160;million, which is expected to be recognized over a weighted-average period of 3.3 years. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The table below discloses assumptions for the fair value of options granted: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 61%;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value per share of underlying common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;16.09&#160;-&#160;$51.28&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2.50&#160;-&#160;$4.21&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;6.00&#160;-&#160;6.25&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;5.81&#160;-&#160;6.04&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;100.0%&#160;-&#160;104.0%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;93.4%&#160;-&#160;111.2%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;4.10%&#160;-&#160;4.26%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3.64%&#160;-&#160;4.90%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted stock units (RSUs) are granted to certain employees. The value of an RSU award is based on the Company&#x2019;s stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest. Activity with respect to the Company&#x2019;s restricted stock units during the year ended December&#160;31, 2024 was as follows (in thousands, except share, contractual term, and per share data): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding RSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Underlying&lt;br/&gt; Outstanding&lt;br/&gt; Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&#160;Date&lt;br/&gt; Fair Value&lt;br/&gt; per Unit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of January&#160;1, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted stock units granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;26,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted stock units forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(725&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;34.51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested and expected to vest as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2024, the total unrecognized stock-based compensation expense for RSUs was $1.1&#160;million, which is expected to be recognized over a weighted average period of&#160;3.2 years. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Legacy Tectonic granted restricted common stock to founders, employees and consultants. The purchase price of the restricted common stock is the estimated fair value on the grant date and the restricted stock is subject to various vesting schedules. Unvested restricted common stock is subject to repurchase rights held by the Company at the original issuance price in the event the restricted common stockholders&#x2019; service to the Company is terminated either voluntarily or involuntarily. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes restricted common stock activity during the year ended December&#160;31, 2024: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 75%;"&gt;&lt;/td&gt;
&lt;td style="width: 15%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted stock awards as of January&#160;1, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;18,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Early exercise of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,859&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(25,827&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted stock awards as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The weighted-average grant date fair value and the weighted average value of the vested restricted common stock for the years ended December&#160;31, 2024 and 2023 were immaterial. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table is a summary of stock-based compensation expense by function recognized (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;705&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;416&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total stock-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,121&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Modification of Certain Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In July 2024, the Company entered into a separation agreement with the Company&#x2019;s Chief Operating Officer (the &#x201c;Former Executive&#x201d;). As part of the termination of employment, the Former Executive will serve as an advisor to the Company through March&#160;31, 2025 (&#x201c;Consulting Period&#x201d;) on an as needed basis. Pursuant to the separation agreement, certain modifications to the Former Executive&#x2019;s vested and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-vested&lt;/div&gt; stock option awards were executed including continued vesting of options during the Consulting Period and the extension of the post-termination exercise period of certain stock option awards. The services performed during the Consulting Period do not qualify as substantive services under ASC 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt;; therefore, the continued vesting of these awards represents a modification to the original award. During the year ended December&#160;31, 2024, the Company recorded stock compensation expense of $0.4&#160;million for the modification of the stock options of the Former Executive. This amount is included in general and administrative expenses on the consolidated statement of operations and comprehensive loss. &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21608"
      unitRef="Unit_shares">1938799</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tecx:CommonStockCapitalSharesReservedForFutureIssuanceTermDescription
      contextRef="P01_01_2024To12_31_2024_TwoThousandAndTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-21609">such aggregate number of shares of common stock will automatically increase on January 1st of each year for a period of ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to 5% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase; provided</tecx:CommonStockCapitalSharesReservedForFutureIssuanceTermDescription>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21610"
      unitRef="Unit_shares">147343</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tecx:CommonStockCapitalSharesReservedForFutureIssuanceTermDescription
      contextRef="P01_01_2024To12_31_2024_TwoThousandAndTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      id="ixv-21611">the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years commencing on January&#160;1, 2025 and ending on (and including) January&#160;1, 2034, in an amount equal to the lesser of (x) 1% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase and (y)&#160;a number of shares equal to three times the Initial ESPP Share Reserve</tecx:CommonStockCapitalSharesReservedForFutureIssuanceTermDescription>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14961">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes the stock option activity under the 2019 Plan and 2024 Plan during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 52%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Underlying&lt;br/&gt; Outstanding&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of January&#160;1, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,002,485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;982,980&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;18.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(335,894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5,585&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options forfeited and expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(115,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,534,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;12.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;51,805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options vested and exercisable as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;364,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;15,809&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options vested and expected to vest as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,534,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;12.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;51,805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes the stock option activity for the options that were assumed from AVROBIO upon the Merger closing during the year ended December&#160;31, 2024 (in thousands except share, contractual term and per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Underlying&lt;br/&gt; Outstanding&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options assumed from AVROBIO upon Merger closing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;365,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;89.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(52,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;14.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options forfeited and expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(220,115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;136.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;92,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;22.69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options vested and exercisable as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;92,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;22.69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options vested and expected to vest as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;92,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;22.69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21613"
      unitRef="Unit_shares">1002485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21614"
      unitRef="Unit_USD_per_Share">3.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      id="ixv-21615">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2022_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-21616"
      unitRef="Unit_USD">2276000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21617"
      unitRef="Unit_shares">982980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21618"
      unitRef="Unit_USD_per_Share">18.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21619"
      unitRef="Unit_shares">335894</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21620"
      unitRef="Unit_USD_per_Share">2.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-21621"
      unitRef="Unit_USD">5585000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21622"
      unitRef="Unit_shares">115210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21623"
      unitRef="Unit_USD_per_Share">8.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21624"
      unitRef="Unit_shares">1534361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21625"
      unitRef="Unit_USD_per_Share">12.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      id="ixv-21626">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-21627"
      unitRef="Unit_USD">51805000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21628"
      unitRef="Unit_shares">364472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21629"
      unitRef="Unit_USD_per_Share">2.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      id="ixv-21630">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-21631"
      unitRef="Unit_USD">15809000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21632"
      unitRef="Unit_shares">1534361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21633"
      unitRef="Unit_USD_per_Share">12.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2024To12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      id="ixv-21634">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn12_31_2024_TwoThousandNineteenAndTwoThousandTwentyFourMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-21635"
      unitRef="Unit_USD">51805000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21636"
      unitRef="Unit_shares">365428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21637"
      unitRef="Unit_USD_per_Share">89.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21638"
      unitRef="Unit_shares">52833</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21639"
      unitRef="Unit_USD_per_Share">14.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21640"
      unitRef="Unit_USD">1344000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21641"
      unitRef="Unit_shares">220115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21642"
      unitRef="Unit_USD_per_Share">136.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-21643"
      unitRef="Unit_shares">92480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024"
      decimals="2"
      id="ixv-21644"
      unitRef="Unit_USD_per_Share">22.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2024To12_31_2024" id="ixv-21645">P1Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21646"
      unitRef="Unit_USD">2903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-21647"
      unitRef="Unit_shares">92480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024"
      decimals="2"
      id="ixv-21648"
      unitRef="Unit_USD_per_Share">22.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2024To12_31_2024" id="ixv-21649">P1Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21650"
      unitRef="Unit_USD">2903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-21651"
      unitRef="Unit_shares">92480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024"
      decimals="2"
      id="ixv-21652"
      unitRef="Unit_USD_per_Share">22.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2024To12_31_2024" id="ixv-21653">P1Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21654"
      unitRef="Unit_USD">2903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21655"
      unitRef="Unit_USD_per_Share">14.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndNineteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21656"
      unitRef="Unit_USD_per_Share">4.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-21657"
      unitRef="Unit_USD">1600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-21658"
      unitRef="Unit_USD">1100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-21659"
      unitRef="Unit_USD">13300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2024To12_31_2024" id="ixv-21660">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-15569">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The table below discloses assumptions for the fair value of options granted: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 61%;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value per share of underlying common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;16.09&#160;-&#160;$51.28&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2.50&#160;-&#160;$4.21&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;6.00&#160;-&#160;6.25&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;5.81&#160;-&#160;6.04&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;100.0%&#160;-&#160;104.0%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;93.4%&#160;-&#160;111.2%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;4.10%&#160;-&#160;4.26%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3.64%&#160;-&#160;4.90%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-21662"
      unitRef="Unit_USD_per_Share">16.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis"
      decimals="2"
      id="ixv-21663"
      unitRef="Unit_USD_per_Share">51.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-21664"
      unitRef="Unit_USD_per_Share">2.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis"
      decimals="2"
      id="ixv-21665"
      unitRef="Unit_USD_per_Share">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis"
      id="ixv-21666">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis"
      id="ixv-21667">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis"
      id="ixv-21668">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"
      id="ixv-21669">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21670"
      unitRef="Unit_pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21671"
      unitRef="Unit_pure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21672"
      unitRef="Unit_pure">0.934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21673"
      unitRef="Unit_pure">1.112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis"
      decimals="4"
      id="ixv-21674"
      unitRef="Unit_pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis"
      decimals="4"
      id="ixv-21675"
      unitRef="Unit_pure">0.0426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis"
      decimals="4"
      id="ixv-21676"
      unitRef="Unit_pure">0.0364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"
      decimals="4"
      id="ixv-21677"
      unitRef="Unit_pure">0.049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21678"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-21679"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-21680">Activity with respect to the Company&#x2019;s restricted stock units during the year ended December&#160;31, 2024 was as follows (in thousands, except share, contractual term, and per share data):&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding RSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Underlying&lt;br/&gt; Outstanding&lt;br/&gt; Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&#160;Date&lt;br/&gt; Fair Value&lt;br/&gt; per Unit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of January&#160;1, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted stock units granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;26,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted stock units forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(725&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;34.51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested and expected to vest as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes restricted common stock activity during the year ended December&#160;31, 2024: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 75%;"&gt;&lt;/td&gt;
&lt;td style="width: 15%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted stock awards as of January&#160;1, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;18,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Early exercise of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,859&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(25,827&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted stock awards as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21681"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21682"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21683"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21684"
      unitRef="Unit_shares">26337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-21685"
      unitRef="Unit_USD_per_Share">44.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21686"
      unitRef="Unit_shares">725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-21687"
      unitRef="Unit_USD_per_Share">34.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21688"
      unitRef="Unit_shares">25612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-21689"
      unitRef="Unit_USD_per_Share">44.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-21690">P1Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21691"
      unitRef="Unit_USD_per_Share">1183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21692"
      unitRef="Unit_shares">25612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <tecx:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-21693"
      unitRef="Unit_USD_per_Share">44.9</tecx:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-21694">P1Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-21695"
      unitRef="Unit_USD">1183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-21696"
      unitRef="Unit_USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-21697">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21698"
      unitRef="Unit_shares">18968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21699"
      unitRef="Unit_shares">6859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21700"
      unitRef="Unit_shares">25827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-21701"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-16032">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table is a summary of stock-based compensation expense by function recognized (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;705&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;416&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total stock-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,121&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-21703"
      unitRef="Unit_USD">2309000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-21704"
      unitRef="Unit_USD">705000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-21705"
      unitRef="Unit_USD">1182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-21706"
      unitRef="Unit_USD">416000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21707"
      unitRef="Unit_USD">3491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21708"
      unitRef="Unit_USD">1121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-21709"
      unitRef="Unit_USD">400000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-16148">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9. NET LOSS PER SHARE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(57,982&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(42,823&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,490,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,268,512&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss per share, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(6.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(33.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible preferred stock (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,647,674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,626,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,002,535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted stock units and common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;18,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFEs (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,519,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,652,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,188,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-16152">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(57,982&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(42,823&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,490,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,268,512&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss per share, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(6.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(33.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21710"
      unitRef="Unit_USD">-57982000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21711"
      unitRef="Unit_USD">-57982000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21712"
      unitRef="Unit_USD">-42823000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21713"
      unitRef="Unit_USD">-42823000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <tecx:WeightedAverageCommonShareOutstandingDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21714"
      unitRef="Unit_shares">8490171</tecx:WeightedAverageCommonShareOutstandingDiluted>
    <tecx:WeightedAverageCommonShareOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21715"
      unitRef="Unit_shares">8490171</tecx:WeightedAverageCommonShareOutstandingBasic>
    <tecx:WeightedAverageCommonShareOutstandingDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-21716"
      unitRef="Unit_shares">1268512</tecx:WeightedAverageCommonShareOutstandingDiluted>
    <tecx:WeightedAverageCommonShareOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-21717"
      unitRef="Unit_shares">1268512</tecx:WeightedAverageCommonShareOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21718"
      unitRef="Unit_USD_per_Share">-6.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21719"
      unitRef="Unit_USD_per_Share">-6.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-21720"
      unitRef="Unit_USD_per_Share">-33.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-21721"
      unitRef="Unit_USD_per_Share">-33.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-16315">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible preferred stock (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,647,674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,626,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,002,535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested restricted stock units and common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;18,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;SAFEs (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,519,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,652,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,188,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-21723"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-21724"
      unitRef="Unit_shares">3647674</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-21725"
      unitRef="Unit_shares">1626841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-21726"
      unitRef="Unit_shares">1002535</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-21727"
      unitRef="Unit_shares">25612</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-21728"
      unitRef="Unit_shares">18968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_SimpleAgreementForFutureEquityMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-21729"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_SimpleAgreementForFutureEquityMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-21730"
      unitRef="Unit_shares">1519331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21731"
      unitRef="Unit_shares">1652453</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-21732"
      unitRef="Unit_shares">6188508</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-16447">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;10. LEASES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2020, Legacy Tectonic executed a facilities lease agreement to occupy 18,768 square feet of office and laboratory space, that was subsequently amended on April 21, 2022. The lease requires the Company to pay fixed base rent, which is included in the measurement of the lease, as well as its proportionate share of the facilities operating expenses which are treated as variable lease costs based on the Company&#x2019;s election to combine lease and associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-lease&lt;/div&gt; components and are excluded from the measurement of the lease. The lease expires on January 31, 2026, and contains a &lt;div style="-sec-ix-hidden:hidden136075767;display:inline;"&gt;five&lt;/div&gt;-year renewal option exercisable by the Company which is not included in the measurement of the lease. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Legacy Tectonic has also entered into various financing leases for laboratory equipment used in research and development activities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The components of lease expense and other information are as follows (dollars in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Finance lease amortization of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Interest of finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Finance lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,608&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Short-term lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;545&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Variable lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,578&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 73%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted-average remaining lease terms (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Finance leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Finance leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;9.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;9.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Future commitments due under these lease agreements as of&#160;December 31, 2024&#160;are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 69%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,948&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total undiscounted cash flows&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,427&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="PAsOn11_30_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      id="ixv-21733"
      unitRef="Unit_sqft">18768</us-gaap:AreaOfRealEstateProperty>
    <tecx:OperatingLeaseDateOfExpiry
      contextRef="P11_19_2020To11_19_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis"
      id="ixv-21734">2022-04-21</tecx:OperatingLeaseDateOfExpiry>
    <tecx:OperatingLeaseDateOfExpiryRevised
      contextRef="P11_19_2020To11_19_2020_OperatingLeaseForOfficeAndLaboratorySpacesMemberusgaapLeaseContractualTermAxis"
      id="ixv-21735">2026-01-31</tecx:OperatingLeaseDateOfExpiryRevised>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-16456">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The components of lease expense and other information are as follows (dollars in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Finance lease amortization of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Interest of finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Finance lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,608&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Short-term lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;545&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Variable lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,578&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 73%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 9%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted-average remaining lease terms (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Finance leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Finance leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;9.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;9.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21736"
      unitRef="Unit_USD">448000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21737"
      unitRef="Unit_USD">488000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21738"
      unitRef="Unit_USD">107000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21739"
      unitRef="Unit_USD">151000</us-gaap:FinanceLeaseInterestExpense>
    <tecx:FinanceLeaseCostAndExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21740"
      unitRef="Unit_USD">555000</tecx:FinanceLeaseCostAndExpense>
    <tecx:FinanceLeaseCostAndExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21741"
      unitRef="Unit_USD">639000</tecx:FinanceLeaseCostAndExpense>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21742"
      unitRef="Unit_USD">1608000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21743"
      unitRef="Unit_USD">1404000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21744"
      unitRef="Unit_USD">545000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21745"
      unitRef="Unit_USD">749000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21746"
      unitRef="Unit_USD">911000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21747"
      unitRef="Unit_USD">786000</us-gaap:VariableLeaseCost>
    <us-gaap:CostsAndExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21748"
      unitRef="Unit_USD">3619000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21749"
      unitRef="Unit_USD">3578000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2024" id="ixv-21750">P1Y21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-21751">P2Y1M2D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2024" id="ixv-21752">P2Y3M3D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-21753">P3Y2M23D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2024"
      decimals="4"
      id="ixv-21754"
      unitRef="Unit_pure">0.0849</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-21755"
      unitRef="Unit_pure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2024"
      decimals="4"
      id="ixv-21756"
      unitRef="Unit_pure">0.0976</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-21757"
      unitRef="Unit_pure">0.0962</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-16754">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Future commitments due under these lease agreements as of&#160;December 31, 2024&#160;are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 69%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,948&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total undiscounted cash flows&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,427&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21759"
      unitRef="Unit_USD">2396000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21760"
      unitRef="Unit_USD">552000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <tecx:LeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21761"
      unitRef="Unit_USD">2948000</tecx:LeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21762"
      unitRef="Unit_USD">132000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21763"
      unitRef="Unit_USD">363000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <tecx:LeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21764"
      unitRef="Unit_USD">495000</tecx:LeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21765"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21766"
      unitRef="Unit_USD">44000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <tecx:LeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21767"
      unitRef="Unit_USD">44000</tecx:LeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21768"
      unitRef="Unit_USD">2528000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21769"
      unitRef="Unit_USD">959000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <tecx:LeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21770"
      unitRef="Unit_USD">3487000</tecx:LeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21771"
      unitRef="Unit_USD">101000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21772"
      unitRef="Unit_USD">83000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <tecx:LeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21773"
      unitRef="Unit_USD">184000</tecx:LeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21774"
      unitRef="Unit_USD">2427000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21775"
      unitRef="Unit_USD">876000</us-gaap:FinanceLeaseLiability>
    <tecx:TotalLeaseLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21776"
      unitRef="Unit_USD">3303000</tecx:TotalLeaseLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21777"
      unitRef="Unit_USD">2295000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21778"
      unitRef="Unit_USD">489000</us-gaap:FinanceLeaseLiabilityCurrent>
    <tecx:LeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21779"
      unitRef="Unit_USD">2784000</tecx:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21780"
      unitRef="Unit_USD">132000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21781"
      unitRef="Unit_USD">387000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <tecx:LeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21782"
      unitRef="Unit_USD">519000</tecx:LeaseLiabilityNoncurrent>
    <tecx:LicenseAgreementDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17033">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;11. LICENSE AGREEMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Harvard Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In July 2020, Legacy Tectonic entered into an agreement with the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;), for an option fee in the low five digits, whereby Harvard granted Legacy Tectonic an exclusive option to negotiate a worldwide, exclusive, royalty-bearing license under Harvard&#x2019;s interest in the patent rights covering certain technology that was developed by Harvard. In October 2021, Legacy Tectonic exercised the option and on February&#160;10, 2022, entered into a license agreement (&#x201c;License Agreement&#x201d;) with Harvard to conduct research and development activities using certain materials, technology and patent rights owned by Harvard, with the intent to develop, obtain regulatory approval for, and commercialize products. The License Agreement will remain in effect until the expiration of the last valid claim within the patent rights covering a product developed under the License Agreement or the termination of the License Agreement. As consideration for the License Agreement, the Company paid Harvard a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-time&lt;/div&gt; license fee of $170,000&#160;and issued 227,486&#160;shares of common stock with a fair market value of $0.4&#160;million. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is responsible for payment of (1)&#160;annual maintenance fees ranging from the low five digits to the low six digits during the term of the License Agreement (through the first commercial sale of a royalty-bearing product); (2) royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from products that utilize the license technology (&#x201c;Licensed Products&#x201d;) and royalty payments as a percentage in the low single digits of the annual net sales that the Company generates &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;from&#160;know-how&#160;enabled&lt;/div&gt; product &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;licenses&#160;(&#x201c;Know-How&#160;Enabled&lt;/div&gt; Products&#x201d;) and (3)&#160;a percentage &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;between&#160;10-20%&#160;of&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;all&#160;non-royalty&#160;income&lt;/div&gt; received by the Company under sublicenses, strategic partnerships &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;and&#160;know-how&#160;enabled&lt;/div&gt; product licenses that utilize the license technology. Subsequent to the first commercial sale of a royalty-bearing product, annual maintenance fees will increase to a low six digits for the remainder of the term of the License Agreement. The royalty term from sales of Licensed Products will terminate on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;a&#160;country-by-country&#160;and&#160;product-by-product&#160;basis&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; on the earlier of (i)&#160;the expiration of the patent rights covering the product, expected to be no earlier than May 2041, and (ii)&#160;the termination of the License Agreement. The royalty term from sales &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;of&#160;Know-How&#160;Enabled&lt;/div&gt; Products will terminate on the earlier of (i)&#160;ten years after the first commercial sale of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;first&#160;Know-How&#160;Enabled&lt;/div&gt; Product and (ii)&#160;twelve years after the first commercial sale of the first Licensed Product.&#160;The Company incurred expense of $0.4&#160;million and $0.2&#160;million related to the License Agreement during the years ended December&#160;31, 2024 and 2023, respectively. No&#160;amounts were due to Harvard related to the License Agreement as of December&#160;31, 2024 and 2023, respectively. &lt;/div&gt;</tecx:LicenseAgreementDisclosureTextBlock>
    <tecx:UpfrontLicenseFees
      contextRef="P02_10_2022To02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-21783"
      unitRef="Unit_USD">170000000</tecx:UpfrontLicenseFees>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-21784"
      unitRef="Unit_shares">227486</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_10_2022To02_10_2022_HarvardAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21785"
      unitRef="Unit_USD">400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tecx:LicenseAgreementsPaymentsDescription
      contextRef="P01_01_2024To12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-17044">(1)&#160;annual maintenance fees ranging from the low five digits to the low six digits during the term of the License Agreement (through the first commercial sale of a royalty-bearing product); (2) royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from products that utilize the license technology (&#x201c;Licensed Products&#x201d;) and royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from&#160;know-how&#160;enabled product licenses&#160;(&#x201c;Know-How&#160;Enabled Products&#x201d;) and (3)&#160;a percentage between&#160;10-20%&#160;of all&#160;non-royalty&#160;income received by the Company under sublicenses, strategic partnerships and&#160;know-how&#160;enabled product licenses that utilize the license technology</tecx:LicenseAgreementsPaymentsDescription>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21786"
      unitRef="Unit_USD">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023_HarvardAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21787"
      unitRef="Unit_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2024_HarvardAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-21788"
      unitRef="Unit_USD">0</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2023_HarvardAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-21789"
      unitRef="Unit_USD">0</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17064">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;12. COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 7%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company enters into contractual agreements with various suppliers in the normal course of its business. All contracts are terminable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would only be obligated for the products or services that the Company had received through the time of termination. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is also party to commitments, which are described elsewhere in these consolidated financial statements: Lease commitments, as described in Note 10,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Leases, &lt;/div&gt;&lt;/div&gt;and&#160;royalty and maintenance based commitments, as described in Note 11,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;License Agreements.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In connection with the Merger, the Company and its designated rights agent entered into a contingent value rights agreement (the &#x201c;CVR Agreement&#x201d;). Pursuant to the CVR Agreement, each holder of AVROBIO common stock immediately prior to the closing received a contractual contingent value right (&#x201c;CVR&#x201d;) subject to and in accordance with the terms and conditions of the CVR Agreement, representing the contractual right to receive a pro rata portion of any net proceeds, if any, resulting from a disposition of certain AVROBIO intellectual property (including a license of AVROBIO&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-closing&lt;/div&gt; assets as defined in the CVR Agreement) after the closing and prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;18-month&lt;/div&gt; anniversary of the closing, received within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-year&lt;/div&gt; period following the closing; provided that no contingent payment will be payable to any holder of the CVRs until such time as the then-outstanding and undistributed proceeds exceeds $0.4&#160;million in the aggregate. The Company believes that any receipt of payments resulting from the disposition of AVROBIO&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-closing&lt;/div&gt; assets described in the CVR Agreement are highly susceptible to factors outside the Company&#x2019;s influence that are not expected to be resolved within the timeline outlined in the CVR Agreement, if at all. In particular, these amounts are primarily influenced by the actions and judgments of third parties and the buyers of such assets and are based on the buyers of such assets progressing the specific platform and intellectual property and early stage of research and development programs. If the Company were to record a receivable for such contingent payments, it would also record a corresponding liability. As of December&#160;31, 2024, no receivables or liabilities were recorded on the Consolidated Balance Sheet relating to such contingent payments. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. There are no matters pending that the Company currently believes are reasonably possible or probable of having a material impact to the Company&#x2019;s financial position, results of operations, or statements of cash flows. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In the normal course of operations, the Company may become involved in various legal proceedings. As of December&#160;31, 2024 and 2023, the Company has not recorded accruals for probable losses related to any existing or pending litigation as the Company&#x2019;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tecx:PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement
      contextRef="P01_01_2024To12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-21790">P18M</tecx:PeriodAfterClosingWithWhichAssetsMayBeDisposedToPayTheAmountAsPerAgreement>
    <tecx:ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid
      contextRef="P01_01_2024To12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-21791">P10Y</tecx:ThresholdPeriodOfReceiptOfConsiderationOnDisposalOfAssetsBasedOnWhichAmountAsPerAgreementShallBePaid>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="PAsOn12_31_2024_AvrobioIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      id="ixv-21792"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationAcquiredReceivablesGrossContractualAmount
      contextRef="PAsOn12_31_2024_CvrAgreementMemberTECXAgreementAxis"
      decimals="-5"
      id="ixv-21793"
      unitRef="Unit_USD">400000</us-gaap:BusinessCombinationAcquiredReceivablesGrossContractualAmount>
    <us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
      contextRef="PAsOn12_31_2024_CvrAgreementMemberTECXAgreementAxis"
      decimals="-3"
      id="ixv-21794"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17090">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;13. INCOME TAXES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company did&lt;div style="display:inline;"&gt;&#160;no&lt;/div&gt;t record a federal or state income tax provision or benefit for the years ended December&#160;31, 2024&#160;and&#160;2023, as it has been incurring net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income tax expense consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Current expense (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total current expense (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred expense (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;13,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;11,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;741&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;16,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;14,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(16,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(14,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total income tax expense (benefit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company had an effective tax rate of&#160;0% for the years ended December&#160;31, 2024&#160;and&#160;2023. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 81%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Federal statutory income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;State income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign rate differential&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Permanent differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred stock liability fair value adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(29.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(34.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Effective income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The components of the Company&#x2019;s net deferred tax assets and liabilities as of December&#160;31, 2024&#160;and&#160;2023, were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 68%;"&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;109,392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;11,392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;13,946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;660&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;817&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Capitalized research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;40,742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;14,595&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accruals&#160;&amp;amp; other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;863&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,112&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;171,270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;32,167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;(170,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;(30,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Right of use asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(608&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(729&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets (liability)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Tax Assets and Valuation Allowance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December&#160;31, 2024 and 2023, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December&#160;31, 2024 and 2023. The Company&#x2019;s valuation allowance increased during the year by $140.0&#160;million for the year ended December&#160;31, 2024 due primarily to the generation of net operating losses. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;NOL Carryforwards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on AVROBIO&#x2019;s value immediately prior to the ownership change multiplied by the long-term tax exempt rate which is published monthly. Subsequent ownership changes may further affect the limitation in future years. The Company has not yet conducted a Section&#160;382 study to assess whether the Reverse Merger resulted in an ownership change under Section&#160;382 that could limit the ability to use the net operating loss carryforwards of AVROBIO and Tectonic.&#160;Nor has the Company completed a Section&#160;382 study to assess whether an ownership change or changes has/have occurred related to Tectonic Therapeutic&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-merger&lt;/div&gt; activity. However, the Reverse Merger is expected to result in an ownership change for AVROBIO. Therefore, the Company does not &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;expect to be able to utilize a material portion, if any, of the historic net operating losses and tax credit carryforwards from AVROBIO. The impact of this would not materially impact the financial statements, given the full valuation allowance. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2024, the Company has net operating loss carryforwards for federal and state tax reporting purposes of $399.3&#160;million and $71.9&#160;million, respectively. Net operating loss carryforwards generated after December&#160;31, 2017 for federal tax reporting purposes of $399.3&#160;million have an indefinite life. Net operating loss carryforwards for state purposes of $71.9&#160;million, which begin to expire in 2040. As of December&#160;31, 2024, the Company also has federal and state research and development tax credits of $10.5&#160;million and $4.4&#160;million, which being to expire in 2040 and 2035, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Tax Cuts and Jobs Act (TCJA) resulted in significant changes to the treatment of research and development expenditures under Section&#160;174. For tax years beginning after December&#160;31, 2021, taxpayers are required to capitalize and amortize all research and development expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;amp;D activities must be amortized over five years and costs for foreign research and development activities must be amortized over 15 years&#x2014;both using a midyear convention. During the year ended December&#160;31, 2024, the Company capitalized $40.3&#160;million of research and development expenses. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 7%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Uncertain Tax Position &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company evaluates its uncertain tax positions under ASC&#160;740&#160;which requires that realization of an uncertain income tax position be recognized. The benefit to be recorded is the amount most likely to be realized assuming a review by tax authorities having all relevant information and applying current conventions. The Company concluded that there are no uncertain tax positions in any of the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The earliest tax years that remain subject to examination by jurisdiction is 2020 for both federal and state. However, to the extent the Company utilizes net operating losses from years prior to 2020, the statute remains open to the extent of the net operating losses or other credits are utilized. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-21795"
      unitRef="Unit_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-21796"
      unitRef="Unit_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024_FederalMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-21797"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023_FederalMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-21798"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17115">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income tax expense consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Current expense (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total current expense (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred expense (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;13,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;11,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;741&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;16,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;14,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(16,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(14,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total income tax expense (benefit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21800"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21801"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21802"
      unitRef="Unit_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21803"
      unitRef="Unit_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21804"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21805"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21806"
      unitRef="Unit_USD">13004000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21807"
      unitRef="Unit_USD">11207000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21808"
      unitRef="Unit_USD">3181000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21809"
      unitRef="Unit_USD">3361000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21810"
      unitRef="Unit_USD">741000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21811"
      unitRef="Unit_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21812"
      unitRef="Unit_USD">16926000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21813"
      unitRef="Unit_USD">14568000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21814"
      unitRef="Unit_USD">16926000</us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense>
    <us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21815"
      unitRef="Unit_USD">14568000</us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-21816"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21817"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-21818"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-21819"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-21820">The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 81%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Federal statutory income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;State income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign rate differential&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Permanent differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred stock liability fair value adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(29.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(34.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Effective income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21821"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21822"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21823"
      unitRef="Unit_pure">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21824"
      unitRef="Unit_pure">0.078</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21825"
      unitRef="Unit_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21826"
      unitRef="Unit_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <tecx:EffectiveIncomeTaxRateReconciliationPermanentDifference
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21827"
      unitRef="Unit_pure">0.004</tecx:EffectiveIncomeTaxRateReconciliationPermanentDifference>
    <tecx:EffectiveIncomeTaxRateReconciliationPermanentDifference
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21828"
      unitRef="Unit_pure">0.011</tecx:EffectiveIncomeTaxRateReconciliationPermanentDifference>
    <tecx:Effectiveincometaxratereconciliationchangeinstock1
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21829"
      unitRef="Unit_pure">0.013</tecx:Effectiveincometaxratereconciliationchangeinstock1>
    <tecx:Effectiveincometaxratereconciliationchangeinstock1
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21830"
      unitRef="Unit_pure">-0.004</tecx:Effectiveincometaxratereconciliationchangeinstock1>
    <tecx:PreferredStockLiabilityFairValueAdjustment
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21831"
      unitRef="Unit_pure">-0.013</tecx:PreferredStockLiabilityFairValueAdjustment>
    <tecx:PreferredStockLiabilityFairValueAdjustment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-2"
      id="ixv-21832"
      unitRef="Unit_pure">0</tecx:PreferredStockLiabilityFairValueAdjustment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21833"
      unitRef="Unit_pure">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21834"
      unitRef="Unit_pure">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-21835"
      unitRef="Unit_pure">-0.292</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-21836"
      unitRef="Unit_pure">-0.34</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2024To12_31_2024"
      decimals="-2"
      id="ixv-21837"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="-2"
      id="ixv-21838"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17550">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The components of the Company&#x2019;s net deferred tax assets and liabilities as of December&#160;31, 2024&#160;and&#160;2023, were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 68%;"&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;109,392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;11,392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;13,946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;660&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;817&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Capitalized research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;40,742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;14,595&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accruals&#160;&amp;amp; other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;863&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,112&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;171,270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;32,167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;(170,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;(30,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;1,939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Right of use asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(608&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(729&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1,939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets (liability)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21840"
      unitRef="Unit_USD">109392000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21841"
      unitRef="Unit_USD">11392000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21842"
      unitRef="Unit_USD">13946000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21843"
      unitRef="Unit_USD">4336000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <tecx:DeferredTaxAssetsLeaseLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21844"
      unitRef="Unit_USD">660000</tecx:DeferredTaxAssetsLeaseLiability>
    <tecx:DeferredTaxAssetsLeaseLiability
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21845"
      unitRef="Unit_USD">817000</tecx:DeferredTaxAssetsLeaseLiability>
    <tecx:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21846"
      unitRef="Unit_USD">40742000</tecx:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts>
    <tecx:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21847"
      unitRef="Unit_USD">14595000</tecx:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21848"
      unitRef="Unit_USD">863000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21849"
      unitRef="Unit_USD">1027000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <tecx:DeferredTaxAssetsAmortization
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21850"
      unitRef="Unit_USD">3555000</tecx:DeferredTaxAssetsAmortization>
    <tecx:DeferredTaxAssetsAmortization
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21851"
      unitRef="Unit_USD">0</tecx:DeferredTaxAssetsAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21852"
      unitRef="Unit_USD">2112000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21853"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21854"
      unitRef="Unit_USD">171270000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21855"
      unitRef="Unit_USD">32167000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21856"
      unitRef="Unit_USD">170177000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21857"
      unitRef="Unit_USD">30228000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21858"
      unitRef="Unit_USD">1093000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21859"
      unitRef="Unit_USD">1939000</us-gaap:DeferredTaxAssetsNet>
    <tecx:DeferredTaxLiabilitiesDepreciation
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21860"
      unitRef="Unit_USD">485000</tecx:DeferredTaxLiabilitiesDepreciation>
    <tecx:DeferredTaxLiabilitiesDepreciation
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21861"
      unitRef="Unit_USD">1210000</tecx:DeferredTaxLiabilitiesDepreciation>
    <tecx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21862"
      unitRef="Unit_USD">608000</tecx:DeferredTaxLiabilitiesRightOfUseAssets>
    <tecx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21863"
      unitRef="Unit_USD">729000</tecx:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21864"
      unitRef="Unit_USD">1093000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21865"
      unitRef="Unit_USD">1939000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-21866"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21867"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-21868"
      unitRef="Unit_USD">140000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-21870"
      unitRef="Unit_USD">399300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-21871"
      unitRef="Unit_USD">71900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-21872"
      unitRef="Unit_USD">399300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="PAsOn12_31_2024_ExpirationThrough2040MemberusgaapTaxPeriodAxis"
      decimals="-5"
      id="ixv-21873"
      unitRef="Unit_USD">71900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ExpirationThrough2040MemberusgaapTaxPeriodAxis"
      decimals="-5"
      id="ixv-21874"
      unitRef="Unit_USD">10500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2024_ExpirationThrough2035MemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-21875"
      unitRef="Unit_USD">4400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <tecx:AmortizationPeriodRDActivities contextRef="P01_01_2024To12_31_2024" id="ixv-21876">P5Y</tecx:AmortizationPeriodRDActivities>
    <tecx:AmortizationPeriodForeignRDCosts contextRef="P01_01_2024To12_31_2024" id="ixv-21877">P15Y</tecx:AmortizationPeriodForeignRDCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-21878"
      unitRef="Unit_USD">40300000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17946">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;14. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scientific Advisory Board Member &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;One of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;co-founders&lt;/div&gt; and former director is a member of the Company&#x2019;s Scientific Advisory Board (&#x201c;SAB&#x201d;) and meets the criteria of a related party. For each of the years ended December&#160;31, 2024 and 2023, the Company incurred expense of $0.1&#160;million for advisory services provided. There were no&#160;amounts due to this related party as of December&#160;31, 2024 or 2023. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Harvard meets the criteria of a related party resulting from the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;co-founders&#x2019;&lt;/div&gt; employment as professors in the Harvard Department of Molecular Pharmacology. Core intellectual property utilized by the Company is licensed from Harvard under the License Agreement described in Note 11, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License Agreements&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company incurred expense of $0.4&#160;million and $0.2&#160;million related to the License Agreement during the years ended December&#160;31, 2024 and 2023, respectively. No amounts were due to Harvard related to the License Agreement as of December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Adimab Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;One member of the Company&#x2019;s Board of Directors also services on the board of Adimab, LLC (&#x201c;Adimab&#x201d;), an antibody discovery company. In May 2023, Legacy Tectonic entered into a discovery agreement with Adimab &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;whereby Legacy Tectonic and Adimab collaborated on human antibody discovery in accordance with an agreed upon research program. The Company incurred expense of $0.2&#160;million during each of the years ended December&#160;31, 2024 and 2023. The Company terminated the agreement with Adimab in July 2024. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SAFE Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From October through December 2023, Legacy Tectonic entered into multiple SAFE agreements with certain existing investors and received proceeds of $34.1&#160;million. All investors were considered related parties of the Company. The SAFE agreements had no maturity date, bore no interest, and were redeemable by Legacy Tectonic upon the occurrence of a triggering event, including the Merger which qualified as a public listing transaction under the SAFE agreements. The SAFEs were redeemed for shares of Legacy Tectonic common stock in connection with the closing of the Merger. &lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2023To12_31_2023_AdvisoryServicesAgreementMemberusgaapRelatedPartyTransactionAxis_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-21879"
      unitRef="Unit_USD">100000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2024To12_31_2024_AdvisoryServicesAgreementMemberusgaapRelatedPartyTransactionAxis_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-21880"
      unitRef="Unit_USD">100000</us-gaap:ProfessionalFees>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2024_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      id="ixv-21881"
      unitRef="Unit_USD">0</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2023_MemberOfTheScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      id="ixv-21882"
      unitRef="Unit_USD">0</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-21883"
      unitRef="Unit_USD">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-21884"
      unitRef="Unit_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2024_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      id="ixv-21885"
      unitRef="Unit_USD">0</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      id="ixv-21886"
      unitRef="Unit_USD">0</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2023To12_31_2023_AdimabAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-21888"
      unitRef="Unit_USD">200000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2024To12_31_2024_AdimabAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-21889"
      unitRef="Unit_USD">200000</us-gaap:ProfessionalFees>
    <tecx:ProceedsFromSimpleAgreementForFutureEquity
      contextRef="P10_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-21890"
      unitRef="Unit_USD">34100000</tecx:ProceedsFromSimpleAgreementForFutureEquity>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17993">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;15. EMPLOYEE BENEFIT PLAN &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has a 401(k) retirement plan (the &#x201c;Plan&#x201d;) that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company&#x2019;s funding policy is to contribute 3% (&#x201c;Nonelective Contribution&#x201d;) of employees&#x2019; eligible pay to the Plan. As defined by the Plan, highly compensated employees are not eligible to receive the Nonelective Contribution. The Company contributed $0.2&#160;million to the Plan in each of the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;/div&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="P01_01_2024To12_31_2024_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis"
      decimals="2"
      id="ixv-21891"
      unitRef="Unit_pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P01_01_2023To12_31_2023_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis"
      decimals="-5"
      id="ixv-21892"
      unitRef="Unit_USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P01_01_2024To12_31_2024_RetirementPlanNameOtherMemberusgaapRetirementPlanNameAxis"
      decimals="-5"
      id="ixv-21893"
      unitRef="Unit_USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17999">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;16. SEGMENT INFORMATION &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;We operate in&#160;one&#160;operating segment, and therefore&#160;one&#160;reportable segment, focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer as chief operating decision maker (&#x201c;CODM&#x201d;) in evaluating financial performance and deciding how to allocate resources on a consolidated basis. The significant expense categories outlined below align with the segment-level information that is regularly provided to the CODM. When evaluating the Company&#x2019;s financial performance, the CODM reviews one measure of profitability, net loss, and makes decisions using this information. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No segment asset information is provided below as the CODM is focused on how expenses impact ending cash by period and overall cash runway. Any review of segment assets, which would focus on cash and cash equivalents, would be at the same level as the consolidated balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table presents the segment net loss and significant segment expenses for the years ended December&#160;31, 2024, and 2023 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee-related expenses:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development employee-related expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;11,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative employee-related expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5,553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;External research and development expenses:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Research and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-clinical&lt;/div&gt; expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,477&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Clinical and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;15,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7,202&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Chemistry, manufacturing, and control expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,947&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non employee-related general and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other segment items&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;57,982&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;42,823&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 2%; text-align: left; vertical-align: top;"&gt;&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;1&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other segment expenses include stock-based compensation, depreciation and amortization, changes in the fair value of the SAFE liabilities, loss on the issuance of SAFEs, interest income, and interest expense. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21894"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-21895"
      unitRef="Unit_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-18027">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table presents the segment net loss and significant segment expenses for the years ended December&#160;31, 2024, and 2023 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee-related expenses:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development employee-related expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;11,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative employee-related expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5,553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;External research and development expenses:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Research and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-clinical&lt;/div&gt; expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,477&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Clinical and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;15,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7,202&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Chemistry, manufacturing, and control expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,947&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non employee-related general and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other segment items&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;57,982&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;42,823&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-21897"
      unitRef="Unit_USD">11135000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-21898"
      unitRef="Unit_USD">10351000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21899"
      unitRef="Unit_USD">5553000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21900"
      unitRef="Unit_USD">3240000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <tecx:ExternalResearchAndDevelopmentLiability
      contextRef="PAsOn12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndPre-ClinicalExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-21901"
      unitRef="Unit_USD">8477000</tecx:ExternalResearchAndDevelopmentLiability>
    <tecx:ExternalResearchAndDevelopmentLiability
      contextRef="PAsOn12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis_ResearchAndPre-ClinicalExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-21902"
      unitRef="Unit_USD">8321000</tecx:ExternalResearchAndDevelopmentLiability>
    <tecx:ExternalResearchAndDevelopmentLiability
      contextRef="PAsOn12_31_2024_ClinicalAndDevelopmentExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21903"
      unitRef="Unit_USD">15380000</tecx:ExternalResearchAndDevelopmentLiability>
    <tecx:ExternalResearchAndDevelopmentLiability
      contextRef="PAsOn12_31_2023_ClinicalAndDevelopmentExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21904"
      unitRef="Unit_USD">7202000</tecx:ExternalResearchAndDevelopmentLiability>
    <tecx:ExternalResearchAndDevelopmentLiability
      contextRef="PAsOn12_31_2024_ChemistryManufacturingAndControlExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21905"
      unitRef="Unit_USD">3570000</tecx:ExternalResearchAndDevelopmentLiability>
    <tecx:ExternalResearchAndDevelopmentLiability
      contextRef="PAsOn12_31_2023_ChemistryManufacturingAndControlExpensesMemberusgaapIncomeStatementLocationAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21906"
      unitRef="Unit_USD">8947000</tecx:ExternalResearchAndDevelopmentLiability>
    <tecx:Non-ControllableExpenses
      contextRef="P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21907"
      unitRef="Unit_USD">8733000</tecx:Non-ControllableExpenses>
    <tecx:Non-ControllableExpenses
      contextRef="P01_01_2023To12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21908"
      unitRef="Unit_USD">3988000</tecx:Non-ControllableExpenses>
    <us-gaap:OtherIncome
      contextRef="P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21909"
      unitRef="Unit_USD">5134000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="P01_01_2023To12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21910"
      unitRef="Unit_USD">774000</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21911"
      unitRef="Unit_USD">57982000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      id="ixv-21912"
      unitRef="Unit_USD">42823000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-18233">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;17. SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In February 2025, the Company entered into a securities purchase agreement pursuant to which the Company issued an aggregate of 3,689,465 shares of common stock, at a price of $50.00 per share to fund investors and $54.14 per share to individual investors that are either an officer or director of the Company, in exchange for aggregate consideration of approximately $185.0&#160;million.&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_01_2025To02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-21913"
      unitRef="Unit_shares">3689465</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_FundInvestorsMembersrtTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-21914"
      unitRef="Unit_USD_per_Share">50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_28_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_IndividualInvestorsMembersrtTitleOfIndividualAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-21915"
      unitRef="Unit_USD_per_Share">54.14</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="P02_01_2025To02_28_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-21916"
      unitRef="Unit_USD">185000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
